<SEC-DOCUMENT>0001193125-18-242784.txt : 20180808
<SEC-HEADER>0001193125-18-242784.hdr.sgml : 20180808
<ACCEPTANCE-DATETIME>20180808162317
ACCESSION NUMBER:		0001193125-18-242784
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20180630
FILED AS OF DATE:		20180808
DATE AS OF CHANGE:		20180808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MeiraGTx Holdings plc
		CENTRAL INDEX KEY:			0001735438
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38520
		FILM NUMBER:		181001687

	BUSINESS ADDRESS:	
		STREET 1:		450 EAST 29TH STREET
		STREET 2:		15TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		6464902965

	MAIL ADDRESS:	
		STREET 1:		450 EAST 29TH STREET
		STREET 2:		15TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d570173d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">10-Q</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended June&nbsp;30, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-38520</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MeiraGTx Holdings plc </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cayman Islands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>430 East 29<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Street, 10<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Floor</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10016</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:
<FONT STYLE="white-space:nowrap">(646)&nbsp;490-2965</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days. &nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;&nbsp;&nbsp;(Do not check if a small reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Small&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;31, 2018, the registrant had
27,184,132 shares of Series A ordinary shares, $0.00003881 par value per share, outstanding. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding
product pipeline, anticipated product benefits, goals and strategic priorities, product candidate development, growth expectations or targets and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data, as well as statements that
include the words &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148; &#147;project,&#148; &#147;forecast,&#148; &#147;estimate,&#148; &#147;may,&#148; &#147;should,&#148; &#147;anticipate&#148; and similar statements of a
future or forward-looking nature. These forward-looking statements are based on management&#146;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important
factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important
factors discussed under Item 1A. &#147;Risk Factors&#148; in this Quarterly Report.&nbsp;These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Quarterly
Report. Any such forward-looking statements represent management&#146;s estimates as of the date of this Quarterly Report. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim
any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These
forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Quarterly Report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Presentation of Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2018, in connection with its initial public offering (the &#147;IPO&#148;), MeiraGTx Holdings plc, an exempted company
incorporated under the laws of the Cayman Islands, acquired all of the issued and outstanding ordinary shares of MeiraGTx Limited pursuant to a series of reorganization transactions (the &#147;Reorganization Transactions&#148;). Prior to the
Reorganization Transactions, MeiraGTx Holdings plc had not conducted any operations and had nominal assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the
context otherwise requires, references in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> to &#147;Meira,&#148; &#147;we,&#148; &#147;us&#148;, &#147;our&#148; and &#147;the Company&#148; refer to (i)&nbsp;MeiraGTx Limited
and its subsidiaries prior to the Reorganization Transactions and (ii)&nbsp;MeiraGTx Holdings plc and its subsidiaries upon completion of the Reorganization Transactions, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;I.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx570173_1">FINANCIAL INFORMATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_2">Financial Statements (Unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_3">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_4">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_5">Condensed Consolidated Statements of Convertible Preferred C Shares and Shareholders&#146;
 Equity (Deficit)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_6">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_7">Notes to Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_8">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_9">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_10">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PART&nbsp;II.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#tx570173_11">OTHER INFORMATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_12">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_13">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_14">Unregistered Sales of Equity Securities and Use of Proceeds</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_15">Defaults Upon Senior Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_16">Mine Safety Disclosures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_17">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_18">Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx570173_19">Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx570173_1"></A>PART I&#151;FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_2"></A>Item&nbsp;1. Financial Statements. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx570173_3"></A>CONDENSED CONSOLIDATED BALANCE SHEETS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,<br>2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><U>ASSETS</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT ASSETS:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,060,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,548,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,613,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">311,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">965,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,985,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,475,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,567,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,255,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,676,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,854,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><U>LIABILITIES, CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS&#146; EQUITY (DEFICIT)</U></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT LIABILITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,461,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,055,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,289,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,332,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,442,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,679,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized lease obligation&#151;current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to Kadmon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">861,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Current Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,779,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,401,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,204,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,880,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COMMITMENTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CONVERTIBLE PREFERRED C SHARES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred C Shares 0 and 5,005,935 outstanding at June&nbsp;30, 2018 December&nbsp;31,
2017, respectively (liquidation preference of $52,455,700 at December&nbsp;31, 2017)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,338,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SHAREHOLDERS&#146; EQUITY (DEFICIT):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A Ordinary Shares, $0.00003881 nominal value 27,184,132 issued and outstanding at June&nbsp;30,
2018 8,826,190 issued and 8,714,563 issued and outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital in excess of nominal value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,080,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,080,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(801,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,022,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,808,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,423,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shareholders&#146; Equity (Deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,472,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,365,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES, CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS&#146; EQUITY (DEFICIT)</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,676,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,854,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Notes to Condensed Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx570173_4"></A>CONDESNSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>(unaudited) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Three-Month&nbsp;Period&nbsp;Ended&nbsp;June&nbsp;30,</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Six-Month&nbsp;Period&nbsp;Ended&nbsp;June&nbsp;30,</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,378,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,221,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,500,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,370,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,790,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,363,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,718,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,186,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,168,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,585,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,218,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,557,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,168,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,585,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,218,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,557,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-operating</FONT> income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency (loss) gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,726,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,748,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,184,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,514,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,980,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,178,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,999,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,979,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(345,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(475,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,001,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,523,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45,162,943</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,475,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,980,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,178,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,999,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion on convertible preferred C shares and warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,141,794</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,806,512</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,122,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,209,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,190,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,052,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,611,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,505,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,280,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,545,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Notes to Condensed Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx570173_5"></A>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS&#146; EQUITY (DEFICIT)
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>AS OF JUNE&nbsp;30, 2018 </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>(unaudited) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Convertible Preferred C Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shareholders&#146; Equity (Deficit)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">A Ordinary<BR>Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Amount</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Capital&nbsp;in&nbsp;Excess<BR>of&nbsp;Nominal&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated&nbsp;Other<BR>Comprehensive<BR>Income (Loss)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Accumulated<BR>Deficit</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total<BR>Shareholders&#146;<BR>Equity (Deficit)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,005,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,338,631</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,826,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,080,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,022,477</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,423,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,365,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred C shares in connection with payables</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,356,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred C shares in connection with a license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of convertible preferred C shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,425,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,159,119</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of issuance costs on convertible preferred C shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">761,012</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(761,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(761,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of warrants issued in connection with convertible preferred C shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,045,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,045,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">927,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,720,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,194,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,194,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible preferred C shares into A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,501,432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,520,391</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,501,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,519,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,520,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of A ordinary shares in initial public offering, net of issuance costs of $9,541,530</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,458,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,458,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,856,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,221,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss for the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30,
2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,184,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,080,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(801,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(111,808,028</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108,472,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Notes to Condensed Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx570173_6"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>(unaudited) </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B></B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;Six-Month&nbsp;Period&nbsp;Ended&nbsp;June&nbsp;30,</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,999,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred C shares issued in connection with a license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,633,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,535,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency loss (gain)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(598,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of interest on asset retirement obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,514,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in operating assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(739,977</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in operating liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Due to Kadmon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(861,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,413,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,646,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,748,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(36,425,351<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(10,530,731</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of long-term note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,824,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(1,318,016<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(2,324,514</TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments on capitalized lease obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,720,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs in connection with ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,781,553</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of convertible preferred C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,849,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs in connection with convertible preferred C shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(610,473</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,442,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>131,469,856<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>194,863</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,726,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,660,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of exchange rate changes on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,672,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,921,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,183,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,330,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of non-cash transactions:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed asset acquisition included in accounts payable and accrued expenses at end of
period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">298,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,561,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of convertible preferred C shares in connection with payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,356,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible preferred C shares into ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">120,520,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reclassification of warrant liability upon exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,194,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized lease obligation for equipment purchase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs in connection with sale of ordinary shares in accounts payable and accrued expenses
at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,509,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs in connection with sale of convertible preferred C shares included in accrued
expenses at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See Notes to Condensed Consolidated Financial Statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEIRAGTX HOLDINGS PLC AND SUBSIDIARIES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx570173_7"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Organization and Basis of Presentation: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>The Company </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MeiraGTx Holdings plc, a limited company under the laws of the Cayman Islands, is a clinical-stage biotech company developing novel gene
therapy treatments for a wide range of inherited and acquired disorders for which there are no effective treatments available. The Company is focused on developing therapies for ocular diseases, including rare inherited blindness as well as
Xerostomia following radiation treatment for head and neck cancers and neurodegenerative diseases such as amyothrophic lateral sclerosis (&#147;ALS&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reorganization and Initial Public Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;28, 2018, the Board of Directors of MeiraGTx Limited approved the Reorganization Transactions, effective June&nbsp;7, 2018,
pursuant to which the Board of Directors approved the transfer of the shares held by each of the MeiraGTx Limited&#146;s shareholders for the equivalent class and number of shares issued by Meira Holdings. On June&nbsp;7, 2018, the Company completed
its IPO, selling 5,000,000 Series A ordinary shares (&#147;Ordinary Shares&#148;) at a public offering price of $15.00 per share, and receiving $65.9&nbsp;million in net proceeds, after deducting underwriting discounts and commissions and offering
expenses payable by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Share Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2018 MeiraGTx Limited&#146;s Board of Directors and shareholders approved a 1:3.881 reverse share split. All share information
presented in these financial statements and accompanying footnotes have been retroactively adjusted to reflect the decreased number of shares resulting from this action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in
the United States of America (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification
(&#147;ASC&#148;) and Accounting Standards Update (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interim Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and
with the instructions to&nbsp;Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Article 10 of Regulation <FONT STYLE="white-space:nowrap">S-X.</FONT> Accordingly, they do not include all the information and footnotes required by generally
accepted accounting principles for complete consolidated financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make
the condensed consolidated financial statements not misleading. Operating results for the three-month and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018&nbsp;are not necessarily indicative of the final results
that may be expected for the year ended December&nbsp;31, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements&nbsp;for the year ended December&nbsp;31,
2017 and the notes thereto for the year ended December&nbsp;31, 2017 included in the Company&#146;s final prospectus that forms a part of the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (Reg. <FONT
STYLE="white-space:nowrap">No.&nbsp;333-224914),</FONT> filed with the Securities and Exchange Commission (&#147;SEC&#148;) pursuant to Rule 424(b)(4) on June&nbsp;8, 2018 (the &#147;Prospectus&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any revenues and has not yet achieved profitable operations. There is no assurance that profitable operations, if
ever achieved, could be sustained on a continuing basis. In addition, development activities, clinical and preclinical testing, and commercialization of the Company&#146;s product candidates will require significant additional financing. Management
expects to incur substantial and increasing losses in future periods. The success of the Company is subject to certain risks and uncertainties, including among others, uncertainty of product development; competition in the Company&#146;s field of
use; uncertainty of capital availability; uncertainty in the Company&#146;s ability to enter into agreements with collaborative partners; dependence on third parties; and dependence on key personnel. The Company has not generated positive cash flows
from operations, and there are no assurances that the Company will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, the Company had cash and cash equivalents in the amount of $102,060,551, which consisted of depository accounts. The
Company estimates that its cash and cash equivalents on hand at June&nbsp;30, 2018 will cover its expenses into the second quarter of 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company operates in an industry that is subject to intense competition, government regulation and rapid technological change. The
Company&#146;s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks, including the potential risk of business failure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s limited capital resources and operations to date have been funded primarily with the proceeds from private equity offerings
and the IPO. In the future, the Company may seek to raise additional capital through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources
to enable it to complete the development and potential commercialization of its product candidates. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies and Recent Accounting Pronouncements: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Certain of the Company&#146;s significant accounting policies are described below. All of the Company&#146;s significant accounting policies
are disclosed in the notes to the audited consolidated financial statements as of and for the year ended December&nbsp;31, 2017 included in the Company&#146;s Prospectus.&nbsp;Since the date of such financial statements, there have been no changes
to the Company&#146;s significant accounting policies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying condensed consolidated financial statements include the accounts of Meira Holdings and its wholly owned subsidiaries: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MeiraGTx Limited, a limited company under the laws of England and Wales (&#147;Meira Limited); </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MeiraGTx, LLC, a Delaware corporation (&#147;Meira LLC&#148;); </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">BRI-Alzan, Inc., a Delaware corporation (&#147;BRI-Alzan&#148;); </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MeiraGTx B.V., a Netherlands corporation (&#147;Meira BV&#148;); </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MeiraGTx UK II Limited, (&#147;Meira UK II&#148;), a limited company under the laws of England and Wales; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">MeiraGTx UK Limited (&#147;Meira UK&#148;), a limited company under the laws of England and Wales. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All intercompany balances and transactions between the consolidated companies have been eliminated in consolidation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and
assumptions that are used in the preparation of these consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational
changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially
reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the
preparation of the consolidated financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these
consolidated financial statements, management used significant estimates in the following areas, among others: valuation of A ordinary shares (&#147;Ordinary Shares&#148;) issued prior to the Company&#146;s initial public offering, for the
acquisition of assets, the accounting for research and development costs, warrants, share based compensation, asset retirement obligations and accrued expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction
between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The fair value should be calculated based on assumptions that market participants would use in pricing the asset or
liability, not on assumptions specific to the entity. In addition, the fair value of liabilities should include consideration of <FONT STYLE="white-space:nowrap">non-performance</FONT> risk including our own credit risk. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company follows ASC Topic 820, <I>Fair Value Measurements and Disclosures</I>, or ASC 820, for application to financial assets. In addition
to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used
in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels
are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity
has the ability to access as of the measurement date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: Inputs, other than the quoted prices in active markets, that are observable either directly or
indirectly; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: Unobservable inputs in which there is little or no market data, which require the reporting entity
to develop its own assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The table below represents the values of the Compnay&#146;s financial assets and
liabilities that are required to be measured at fair value on a recurring basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair Value Measurement Using:</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,<BR>2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Observable&nbsp;Inputs<BR>(Level 1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant&nbsp;Other<BR>Observable&nbsp;Inputs<BR>(Level 2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Unobservable<BR>(Level 3)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Fair Value Measurement Using:</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Observable Inputs<BR>(Level 1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant Other<BR>Observable Inputs<BR>(Level 2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Unobservable<BR>(Level 3)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,679,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,679,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The table below represents a rollforward of the assets and liabilities that are required to
be measured at fair value on a recurring basis from December&nbsp;31, 2017 to June&nbsp;30, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Significant<BR>Unobservable&nbsp;Inputs<BR>(Level 3)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,679,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,514,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,194,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The warrants were classified as liabilities because the underlying Preferred Shares had a redemption feature in
the event of a change of control of the Company. On June&nbsp;5, 2018, the warrants were exercised at which time the warrant liability was determined to be $4,194,408, which represented the difference in the market value of the Preferred Shares and
the exercise price of the warrants. This resulted in an increase of the warrant liability in the amount of $2,184,183 and $1,514,775 for the three-month and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018,
respectively. The related warrant liability of $4,194,408 was reclassified as Capital in Excess of Nominal Value at such time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair
values of the warrants at December&nbsp;31, 2017, March&nbsp;31, 2018 and June&nbsp;4, 2018 were estimated using the Black-Scholes valuation model with the following assumptions:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,&nbsp;2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">March&nbsp;31,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;4,&nbsp;2018</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.86</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;months</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;months</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;day</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For the unobservable inputs for the warrants, the expected volatility was determined at each measurement date
by taking an average of the volatility of other publicly-traded peer biotechnology companies. The expected life was determined at each measurement date based upon the Company&#146;s estimate of the time until the Company has a conversion event. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of the Preferred Shares was based upon recent issuances of the Company&#146;s Preferred Shares on or about December&nbsp;31,
2017, March&nbsp;31, 2018 and June&nbsp;5, 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The estimated fair values of the Company&#146;s warrants are not necessarily indicative
of the amounts that would be realized in a current market exchange. The determination of the fair value of the warrants are sensitive to changes in in the assumptions used and a change in those inputs could result in a significantly higher or lower
fair value measurement. If the volatility were to increase or the expected life were to increase, the fair value of the warrant would increase. Conversely, if the volatility were to decrease or the expected life were to decrease, the fair value of
the warrant would decrease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Ordinary Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per Ordinary Share is computed by dividing net loss attributable to the Company&#146;s shareholders by the weighted average
number of shares of the Company&#146;s Ordinary Shares assumed to be outstanding during the period of computation. Diluted net loss per ordinary share is computed similar to basic net loss per share except that the denominator is increased to
include the number of additional Ordinary Shares that would have been outstanding if the potential ordinary shares had been issued at the beginning of the year and if the additional ordinary shares were dilutive (treasury stock method) or the <FONT
STYLE="white-space:nowrap">two-class</FONT> method, whichever is more dilutive. For all periods presented, basic and diluted net loss per Ordinary Share are the same, as any additional Ordinary Share equivalents would be anti-dilutive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Asset Retirement Obligation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting for Asset Retirement Obligations requires legal obligations associated with the retirement of long-lived assets to
be recognized at fair value when incurred and capitalized as part of the related long-lived asset. In the absence of quoted market prices, we estimate the fair value of our asset retirement obligations using Level&nbsp;3 present value techniques, in
which estimates of future cash flows associated with retirement activities are discounted using a credit-adjusted risk-free rate. Asset retirement obligations currently reported as other liabilities on our Consolidated Balance Sheet were measured
during a period of historically low interest rates. The impact on measurements of new asset retirement obligations using different rates in the future may be significant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses estimates to determine the amount of the asset retirement obligations at the end of the lease term and
discounts such asset retirement obligations using an estimated discount rate. Interest on the discounted asset retirement obligation is amortized over the term of the lease using the effective interest method and is recorded as interest expense in
the consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in asset retirement obligations is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;six&nbsp;month&nbsp;period<BR>ended June&nbsp;30, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">For&nbsp;the&nbsp;year&nbsp;ended<BR>December&nbsp;31,&nbsp;2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">221,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in estimate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(75,011</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are charged to expense as incurred. These costs include, but are not limited to, employee-related expenses,
including salaries, benefits and travel of the Company&#146;s research and development personnel; expenses incurred under agreements with contract research organizations and investigative sites that conduct clinical and preclinical studies and
manufacture the drug product for the clinical studies and preclinical activities; acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development; facilities; supplies; rent, insurance, certain legal fees, stock-based
compensation, depreciation and other costs associated with clinical and preclinical activities and regulatory operations. Refundable research and development tax credits received are recorded as an offset to these costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Costs for certain development activities, such as Company funded outside research programs, are recognized based on an evaluation of the
progress to completion of specific tasks with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development expense, as the case may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management has concluded it has a single reporting segment for purposes of reporting financial condition and results of operations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes <FONT STYLE="white-space:nowrap">non-current</FONT> assets by geographical area: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">413,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">436,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United Kingdom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,277,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,942,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,691,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,379,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> Improvements to Nonemployee Share-Based Accounting,
which simplifies the accounting for share-based payments granted to nonemployees for goods and services. The ASU supersedes ASC <FONT STYLE="white-space:nowrap">505-50</FONT> and expands the scope of ASC 718 to include <I>all</I> share-based payment
arrangements related to the acquisition of goods and services from both nonemployees and employees. As a result, most of the guidance in ASC 718 associated with employee share-based payments, including most of its requirements related to
classification and measurement, applies to nonemployee share-based payment arrangements.&nbsp;ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> generally requires an entity to use a modified retrospective transition approach, with a
cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year, for all (1)&nbsp;liability-classified nonemployee awards that have not been settled as of the adoption date and (2)&nbsp;equity-classified nonemployee awards
for which a measurement date has not been established. The guidance is applicable to public business entities for fiscal years beginning after December&nbsp;15, 2019 and interim periods within those years. The Company is currently evaluating the
potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In January 2017, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2017-01,</FONT><I>&nbsp;Business Combinations (Topic 805),
Clarifying the Definition of a Business,</I><I></I>&nbsp;or <FONT STYLE="white-space:nowrap">ASU&nbsp;2017-01</FONT><I>,</I><I></I>&nbsp;that clarifies the definition of a business to assist entities with evaluating whether transactions should be
accounted for as acquisitions (or disposals) of assets or businesses. <FONT STYLE="white-space:nowrap">ASU&nbsp;2017-01</FONT> requires an entity to evaluate if substantially all of the&nbsp;fair value of the gross assets acquired or disposed of is
concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of transferred assets and activities is not a business. <FONT STYLE="white-space:nowrap">ASU&nbsp;2017-01&nbsp;also</FONT> requires a business to
include at least an input and one substantive process that together significantly contribute to the ability to create output and removes the evaluation of whether a market participant could replace missing elements.
<FONT STYLE="white-space:nowrap">ASU&nbsp;2017-01&nbsp;should</FONT> be applied prospectively and is effective for annual periods beginning after December&nbsp;15, 2017 and interim periods within those annual periods. The adoption of ASU <FONT
STYLE="white-space:nowrap">2017-01</FONT> on January&nbsp;1, 2018 did not have a material effect on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In December 2016, the FASB <FONT STYLE="white-space:nowrap">issued&nbsp;ASU&nbsp;No.&nbsp;2016-20,</FONT><I></I><I>&nbsp;Technical Corrections
and Improvements to Topic 606, Revenue from Contracts with Customers,</I><FONT STYLE="white-space:nowrap">&nbsp;or&nbsp;ASU&nbsp;2016-20,&nbsp;that&nbsp;allows</FONT> entities not to disclose variable consideration allocated to performance
obligations related to either: (1)&nbsp;sales&#151;or usage -based royalties on licenses of intellectual property or (2)&nbsp;variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise
to transfer a distinct good or service that forms part of a single performance obligation when certain criteria are <FONT STYLE="white-space:nowrap">met.&nbsp;ASU&nbsp;2016-20&nbsp;also&nbsp;requires</FONT> entities that use any of the new or
previously existing optional exemptions to expand their qualitative disclosures. It also makes 12 additional technical corrections and improvements to the new revenue standard, <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09.</FONT> The amendments
have the same effective date and transition requirements as <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09.</FONT> The adoption of <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-20</FONT> did not have a material effect on its financial position,
results of operations or cash flows. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In November 2016, the Financial Accounting Standards Board, or FASB issued <FONT
STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-18,</FONT><I>&nbsp;Statement of Cash Flows (Topic 230), Restricted Cash</I><I></I>&nbsp;(a consensus of the Emerging Issues Task Force), or
<FONT STYLE="white-space:nowrap">ASU&nbsp;2016-18,&nbsp;which</FONT> changes the presentation of the cash flow statement to include amounts generally described as restricted cash or restricted cash equivalents, together with cash and cash
equivalents, when reconciling
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;beginning-of-period&nbsp;and&nbsp;end-of-period&nbsp;amounts</FONT></FONT></FONT></FONT> shown on the
statement of cash flows. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-18&nbsp;also</FONT> requires additional disclosures concerning the nature of the restrictions on cash and cash equivalents and a reconciliation between amounts of cash, cash
equivalents and restricted cash on the balance sheet and statement of cash flows for each period presented. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-18&nbsp;will</FONT> be applied retrospectively to all periods presented and is effective for
public business entities for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. Prior to adoption, the Company presented changes
in restricted cash as an operating activity in the statement of cash flows. Upon adoption of <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-18</FONT> on January&nbsp;1, 2018,&nbsp;such changes are now reflected in the beginning and ending balances
of cash, cash equivalents and restricted cash for all periods presented. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In October 2016, the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;2016-16,&nbsp;Income</FONT> Taxes (Topic 740):<I>&nbsp;Intra-Entity Transfers of Assets Other than Inventory</I>, or <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-16&nbsp;which</FONT> requires that an
entity recognize the income tax consequences of an intra-entity transfer of assets other than inventory when the transfer occurs. The guidance must be applied using the modified retrospective basis. The Company does not expect the provisions of <FONT
STYLE="white-space:nowrap">ASU&nbsp;2016-16&nbsp;to</FONT> have a material impact on its current financial statements. This update will be effective for the Company at the beginning of fiscal 2019. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2016, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-12</FONT><I>, Revenue from Contracts with Customers (Topic
606), Narrow-Scope Improvements and Practical Expedients</I>, or <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-12,&nbsp;which</FONT> amends guidance in the new revenue standard,
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2014-09</FONT><I></I><I>&nbsp;Revenue from Contracts with Customers (Topic 606)</I>, or <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09,&nbsp;on</FONT> collectability, noncash consideration,
presentation of sales tax and transition. The amendments in <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-12&nbsp;are</FONT> effective for annual reporting periods beginning after December&nbsp;15, 2017 (i.e., January&nbsp;1, 2018), including
interim periods within those reporting periods, which is the same as for <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09,&nbsp;as</FONT> amended by <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2015-14,</FONT> <I>Revenue from Contracts with
Customers (Topic 606): Deferral of the Effective Date</I>, or <FONT STYLE="white-space:nowrap">ASU&nbsp;2015-14</FONT><I>.</I><I></I>&nbsp;In April 2016, the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-10,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606), Identifying </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
<I>Performance Obligations and Licensing</I>, or <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-10</FONT><I>,</I>&nbsp;which clarifies the principle for determining whether a good or service is
&#147;separately identifiable&#148; from other promises in the contract and, therefore, should be accounted for as a separate performance obligation. In that regard, <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-10&nbsp;requires</FONT> that an
entity determine whether its promise is to transfer individual goods or services to the customer, or a combined item (or items) to which the individual goods and services are inputs. In addition, ASU
<FONT STYLE="white-space:nowrap">2016-10&nbsp;categorizes</FONT> intellectual property, or IP, into two categories: &#147;functional&#148; and &#147;symbolic.&#148; Functional IP has significant standalone functionality. All other IP is considered
symbolic IP. Revenue from licenses of functional IP is generally recognized at a point in time, while revenue from licenses of symbolic IP is recognized over time. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-10&nbsp;has</FONT> the same effective
date and transition requirements as <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09,&nbsp;as</FONT> amended by <FONT STYLE="white-space:nowrap">ASU&nbsp;2015-14.&nbsp;In</FONT> March 2016, the FASB issued
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-08,</FONT><I>&nbsp;Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net)</I>, or
<FONT STYLE="white-space:nowrap">ASU&nbsp;2016-08,&nbsp;which</FONT> clarifies the implementation guidance on principal versus agent considerations contained in <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09</FONT><I></I>&nbsp;by specifying that
the determination as to whether an entity that is involved in providing a good or a service to a customer is a principal or an agent is based upon whether the entity controls the good or the service before it is transferred to the customer. <FONT
STYLE="white-space:nowrap">ASU&nbsp;2016-08&nbsp;has</FONT> the same effective date and transition requirements as <FONT STYLE="white-space:nowrap">ASU&nbsp;2014-09,&nbsp;as</FONT> amended by
<FONT STYLE="white-space:nowrap">ASU&nbsp;2015-14.&nbsp;The</FONT> adoption of these ASU&#146;s on January&nbsp;1, 2018 did not have a material effect on the Company&#146;s financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842)</I>. The FASB issued the update to
require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after December&nbsp;15, 2018, including interim periods within such fiscal years. The ASU requires a
modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results
of operations, financial position and cash flows and related disclosures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU
<FONT STYLE="white-space:nowrap">2014-09,</FONT><I>&nbsp;Revenue from Contracts with Customers</I>, or ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> which provides a single, comprehensive revenue recognition model for all contracts with
customers. The core principal of ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> is that an entity should recognize revenue when it transfers control of promised goods or services to customers in an amount that reflects the consideration to
which the entity expects to be entitled in exchange for those goods or services. ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows
arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> is effective for annual periods,
and interim periods within those annual periods, beginning after December&nbsp;15, 2017 for public companies and December&nbsp;15, 2018 for <FONT STYLE="white-space:nowrap">non-public</FONT> companies. The Company is allowed to adopt ASU <FONT
STYLE="white-space:nowrap">2014-09</FONT> either (1)&nbsp;retrospectively to each prior reporting period presented using several practical expedients related to completed contracts and required disclosures, or (2)&nbsp;using a modified retrospective
approach, with the cumulative effect of initially applying ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> recognized as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial
application, including disclosure of the effect of using this method of adoption on the financial statement line items. Because the Company has no contracts with customers, the adoption of ASU <FONT STYLE="white-space:nowrap">2014-09</FONT> on
January&nbsp;1, 2018 did not have a material effect on the Company&#146;s financial position, results of operations or cash flows. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accrued Expenses </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses for the period presented were comprised of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Trial Costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,297,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,859,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation and Benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,386,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,137,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,220,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,289,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,332,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share-Based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2018 and 2016 Equity Incentive Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company maintains the 2018 Incentive Award Plan and 2016 Equity Incentive Plan (together, the &#147;Plans&#148;), under which, the Company
has granted share options to selected officers, employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants. The Company&#146;s board of directors administer the Plans. Options granted under the Plans have a maximum contractual
term of ten years. Options granted to employees and consultants generally vest 25% on the first anniversary date of grant and the balance ratably over the next 36 months. Options granted to directors generally vest on the first anniversary date of
grant. Upon the adoption of the 2018 Incentive Award Plan, the Company ceased issuing awards under the 2016 Equity Incentive Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A
summary of the Company&#146;s share option activity related to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the board of directors and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants as of and for the <FONT
STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Options</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Weighted-<BR>Average&nbsp;Exercise<BR>Price</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate<BR>Instrinsic&nbsp;Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">938,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,420,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">675,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,614,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,884,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life of options outstanding as of December&nbsp;31, 2017
(yrs)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life of options outstanding as of June&nbsp;30, 2018
(yrs)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">265,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life of options exercisable as of December&nbsp;31, 2017
(yrs)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contractual life of options exercisable as of June&nbsp;30, 2018
(yrs)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The total fair value of options vested during the three-month periods ended June&nbsp;30, 2018 and 2017 was
$247,202 and $229,250, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The total fair value of options vested during the <FONT STYLE="white-space:nowrap">six-month</FONT>
periods ended&nbsp;June 30, 2018 and 2017 was $556,349 and $927,915, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017, the Company granted 533,330 and 0 share options, respectively, to employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the board of
directors. No options were granted during the three-month periods ended June&nbsp;30, 2018 and 2017. The grant date fair values of the stock options granted to those groups were estimated using the Black-Scholes option valuation model with the
following ranges of assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.32%&nbsp;-&nbsp;2.40%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">90%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of employee and Board of Directors&#146; options (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.5&nbsp;-&nbsp;6.1</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, the total compensation expense relating to unvested options granted to employees and
<FONT STYLE="white-space:nowrap">non-employee</FONT> members of the board of directors that had not yet been recognized was $2,596,655, which is expected to be realized over a period of 3.5 years. The Company will issue shares upon exercise of
options from Ordinary Shares reserved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30,
2018 and 2017, the Company granted 142,355 and 135,271 share options, respectively to <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants. No options were granted during the three-month period ended June&nbsp;30, 2018. In accordance
with ASC <FONT STYLE="white-space:nowrap">505-50,</FONT> on June&nbsp;30, 2017 and 2018, the Company remeasured the fair value, of all unvested outstanding options that had been granted to <FONT STYLE="white-space:nowrap">non-employee</FONT>
consultants using the Black-Scholes option valuation model with the following ranges of assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.80%&nbsp;-&nbsp;2.84%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.29%&nbsp;-&nbsp;2.31%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">90%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">80%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life of <FONT STYLE="white-space:nowrap">non-employee</FONT> options (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7.7&nbsp;-&nbsp;9.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8.7&nbsp;-&nbsp;9.7</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, the total compensation expense relating to unvested options granted to <FONT
STYLE="white-space:nowrap">non-employee</FONT> consultants that had not yet been recognized was $3,823,995, which is expected to be realized over a period of 3.5 years. The Company will issue shares upon exercise of options from Ordinary Shares
reserved. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant date fair value of options granted to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT>
members of the board of directors and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants during the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017 was $5.63 and $6.13, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2015, in connection with certain service and consulting agreements, certain employees and a consultant were awarded an aggregate of 867,935
restricted Ordinary Shares of the Company. Such shares were subject to forfeiture over a three-year service period. The shares granted to the consultant and employees were valued at $7.72 and $7.76 per share, respectively, and were included in loss
from operations over the requisite service period. As of June&nbsp;30, 2018, all such shares are no longer subject to forfeiture as the three-year service period has been completed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2018, 1,306,348 restricted Ordinary Shares, which represented 5% of the fully-diluted outstanding shares of the Company as of
such date, were issued to certain members of senior management in accordance with their employment agreements. <FONT STYLE="white-space:nowrap">One-third</FONT> of such shares vested immediately, with the balance vesting quarterly over the next
eight quarters beginning three months after the effectiveness of the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed with the SEC on June&nbsp;7, 2018 (the &#147;Registration Statement&#148;). The
shares were valued at $15.00 per share and are included in loss from operations over the requisite service period. Additionally, under the terms of the employment agreements, the Company was required to pay the income taxes incurred by the grantees
in connection with the grant of those restricted shares. Total compensation expense in connection with the issuance of those restricted Ordinary Shares, in the amount of $13,620,866, of which $6,531,750 was share-based, was recorded as general and
administrative expense during the three-month period ended June&nbsp;30, 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A summary of the restricted Ordinary Shares is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Ordinary&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">$ Value</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">865,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued during the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30,
2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,306,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,595,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting during the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30,
2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(541,363</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,397,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,063,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2018, a funding milestone was met under the employment agreements for certain members of senior management. Accordingly, the
employees were issued an aggregate of 550,162 fully vested Ordinary Shares, which represented 3% of the fully-diluted outstanding shares of the Company as of such date. The shares were recorded as share-based compensation in the amount of
$3,096,104. Additionally, under the terms of the employment agreements, the Company was required to pay the income taxes incurred by the grantees in connection with the grant of those shares. Total compensation expense in connection with the
issuance of those Ordinary Shares, in the amount of $6,456,215, of which $3,096,012 was share-based, was recorded as general and administrative expense during the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the three-month and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended
June&nbsp;30, 2018 and 2017 the Company recognized total share-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;periods&nbsp;ended&nbsp;June&nbsp;30,</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,045,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">550,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,318,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,363,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">682,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;periods&nbsp;ended&nbsp;June&nbsp;30,</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,890,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,239,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,743,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,633,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,535,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect to realize any tax benefits from its share option activity or the recognition of
share-based compensation expense because the Company currently has net operating losses and has a full valuation allowance against its deferred tax assets. Accordingly, no amounts related to excess tax benefits have been reported in cash flows from
operations or cash flows from financing activities for the three-month and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ordinary Shares and Convertible Preferred C Shares: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As
discussed in Note 3, on March&nbsp;1, 2018, a funding milestone was met under the employment agreements for certain members of senior management. Accordingly, the employees were issued an aggregate of 550,162 fully vested Ordinary Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s initial public offering, on June&nbsp;7, 2018, the Company issued 5,000,000 Ordinary Shares at an
offering price of $15.00 per share for gross proceeds of $75,000,000, excluding offering costs of $9,541,530. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Also as discussed in Note 3,
on June&nbsp;7, 2018, upon the effectiveness of the Company&#146;s Registration Statement, 1,306,348 restricted Ordinary Shares, which represented 5% of the fully-diluted outstanding shares of the Company as of such date, were issued to certain
members of senior management in accordance with their employment agreements. <FONT STYLE="white-space:nowrap">One-third</FONT> of such shares vested immediately, with the balance vesting quarterly over the next eight quarters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;5, 2018, all of the outstanding warrants to purchase 927,594 Preferred Shares at an exercise price of approximately $10.48 per share were exercised for aggregate cash proceeds of $9,720,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred C Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018, the Company issued 5,425,124 Preferred Shares at
an offering price of approximately $10.48 per share for gross proceeds of $56,849,592, excluding offering costs of $690,473. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Also, during
the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018, the Company issued 129,419 Preferred Shares in lieu of payment of accounts payable in the aggregate amount $1,356,129 to certain vendors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;15, 2018, the Company issued 13,360 Preferred Shares in connection with a license agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2018, upon effectiveness of the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> all
of the 11,501,432 outstanding Preferred Shares were automatically converted into 11,501,432 Ordinary Shares. In connection with the conversion of the Preferred Shares, $664,718 of unaccredited financing costs were fully accreted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company computes net loss per share in accordance with ASC <FONT STYLE="white-space:nowrap">260-10,</FONT> <I>Earnings per Share</I> (see
Note 2). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share is computed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;three-month&nbsp;periods&nbsp;ended&nbsp;June&nbsp;30,</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,980,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,178,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Preferred Shares financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(666,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(475,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,122,626</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,209,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,611,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,505,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;six-month&nbsp;periods&nbsp;ended&nbsp;June&nbsp;30,</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,999,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of Preferred Shares financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(761,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,045,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,190,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,052,266</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares outstanding:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,280,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,545,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following securities are considered to be Ordinary Share equivalents, but were not included in the
computation of diluted net loss per Ordinary Share because to do so would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">A restricted ordinary shares subject to forfeiture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">870,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,614,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,485,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,274,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company did not record a provision for income taxes for the three months and six month ended June&nbsp;30, 2018 and 2017, as the Company
has generated losses for all periods. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates the realizability of its net deferred tax assets based on all
available evidence, both positive and negative. The realization of net deferred tax assets is dependent on the Company&#146;s ability to generate sufficient future taxable income during periods prior to the expiration of tax attributes to fully
utilize these assets. The Company weighed both positive and negative evidence and determined that there is a continued need for a full valuation allowance on its deferred tax assets in the United States and United Kingdom as of June&nbsp;30, 2018.
Should the Company determine that it would be able to realize its remaining deferred tax assets in the foreseeable future, an adjustment to its remaining deferred tax assets would cause a material increase to income in the period such determination
is made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Transition Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective April&nbsp;24, 2015, the Company entered into a three-year transition services agreement (the &#147;TSA&#148;) with Kadmon, whereby
Kadmon would provide office and laboratory facilities as well as certain other personnel support activities to the Company. Under the agreement, the Company was charged for (i)&nbsp;rent based upon the square footage of the office and laboratory
facilities used by the Company (ii)&nbsp;other personnel support activities based upon the hours of the personnel providing the support activities, and (iii)&nbsp;and other direct costs incurred by Kadmon on behalf of the Company, plus a 7%
administrative fee. The TSA terminated on April&nbsp;24, 2018 and the Company is currently leasing office space on a month to month basis from Kadmon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the three-month periods ended June&nbsp;30, 2018 and 2017, the Company incurred the following charges from Kadmon, which are included in
loss from operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">152,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total charges incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017, the
Company incurred the following charges from Kadmon, which are included in loss from operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">275,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">275,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total charges incurred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">282,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">306,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the three-month periods ended June&nbsp;30, 2018 and 2017, the Company made cash payments totaling
$145,887 and $0, respectively, to Kadmon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018
and 2017, the Company made cash payments totaling $1,143,304 and $275,941, respectively, to Kadmon. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The amount due to Kadmon at
June&nbsp;30, 2018 and December&nbsp;31, 2017 is $0 and $861,030, respectively and is disclosed as Due to Kadmon on the Company&#146;s condensed consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective October&nbsp;23, 2016, the Company entered into a four-year master services agreement with UCL Consultants Limited, an entity
affiliated with University College of London (&#147;UCL&#148;), which is a shareholder of the Company. Pursuant to the agreement, UCL Consultants Limited provides <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research and development under
the direction of the Company. In connection with the agreement, the Company issued several work orders during the years ended December&nbsp;31, 2016 and 2017 in the aggregate amounts of &pound;1,161,149 and &pound;241,053, respectively, or
approximately $1,574,000 and $311,000, based upon the average exchange rates during the years ended December&nbsp;31, 2016 and 2017, respectively. Either party may terminate the agreement by giving 30 days written notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total research and development expenses under this agreement for the three-month periods ended June&nbsp;30, 2018 and 2017 were approximately
$183,000 and $114,000, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total research and development expenses under this agreement for the
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017 was approximately $372,000 and $222,000, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Future obligations, under the agreement equal &pound;797,343, or approximately $1,052,791 through October 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The amount due to UCL under the master services agreement at June&nbsp;30, 2018 and December&nbsp;31, 2017 is $374,873 and $775,315,
respectively, and is included in accounts payable and accrued expenses on the condensed consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Manufacturing Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective September&nbsp;1, 2016, the Company entered into a manufacturing and drug supply agreement with UCL. Pursuant to the agreement, UCL
manufactured materials for the Company&#146;s clinical trials under the direction of the Company. Either party could terminate the agreement by giving 30 days written notice. The agreement was terminated in January 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total research and development expenses under this agreement for the three-month periods ended June&nbsp;30, 2018 and 2017 was approximately $0
and $479,494, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total research and development expenses under this agreement for the
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017 was approximately $0 and $1,042,518, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The amount due to UCL under the manufacturing and drug supply agreement at June&nbsp;30, 2018 and December&nbsp;31, 2017 is $374,983 and
$2,466,142, respectively, and is included in accrued expenses in the condensed consolidated balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective March&nbsp;15, 2018, the Company entered into an exclusive worldwide license agreement with UCL Business, PLC (&#147;UCL
Business&#148;), to develop up to eight programs using certain ocular gene therapy technology. Under the terms of the agreement, the Company has agreed to pay UCL Business certain sales milestone payments, if achieved, in the aggregate amount of
&pound;39.8&nbsp;million, or approximately $52.6&nbsp;million using the exchange rate at June&nbsp;30, 2018, and royalties on net sales, as defined upon commercialization. Additionally, the Company is responsible for all patent prosecution and
maintenance costs incurred and has also agreed to pay UCL Business an annual maintenance fee of &pound;50,000, or approximately $66,000, until the first commercial sale of a product. The agreement will terminate upon the later of (i)&nbsp;the last
valid claim in a relevant product (ii)&nbsp;the expiration of regulatory exclusivity to all licensed products, or (iii)&nbsp;the 10<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> anniversary of the first commercial sale of a product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company did not incur any research and development expenses under the agreement during the three-month and
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>December 2016 Lease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective December&nbsp;15, 2016, the Company entered into another <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease with
ARE, expiring on October&nbsp;31, 2032, for laboratory and office facilities in New York. The lease provided for monthly base rent, including rent escalations, property management fees and rent holidays, plus operating expenses during the lease
term. The Company recorded monthly rent expense on a straight-line basis from December&nbsp;15, 2016 through October&nbsp;31, 2032. On October&nbsp;26, 2017, the lease was amended, whereby the lease would terminate on March&nbsp;31, 2018 and only
base rent and management fees in the aggregate amount of $563,507 would be due from November&nbsp;1, 2017 through March&nbsp;31, 2018. Under the amendment, the Company issued a note to ARE in the amount of $1,442,009, removed the balance of the
deferred rent and accrued the future rent payments, all of which were recorded as rent expense at the time of the amendment, in accordance with ASC 420, Exit and Disposal Activities, as the Company had a cease use date as of the date of the
amendment. Tthe balance of deferred lease obligation, representing the difference between cash rent paid and straight-line rent expense, was $0 as of December&nbsp;31, 2017 and June&nbsp;30, 2018,. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total rent expense under this operating lease was $0 and $390,903 for the three-month periods ended June&nbsp;30, 2018 and 2017, respectively.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total rent expense under this operating lease was $0 and $781,806 for the <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended
June&nbsp;30, 2018 and 2017, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;26, 2017, in connection with the amendment to the lease, the Company issued a
promissory note in the amount of $1,442,009 to ARE. The note accrued interest at the rate of 5% per annum and was due on December&nbsp;31, 2018. However, if the Company had sufficient liquidity, as defined in the note, then the note, including
accrued interest, would become due and payable at that time. In accordance with the sufficient liquidity provision, the Company repaid the note, plus accrued interest, in the aggregate amount of $1,472,433 during the three-month period ended
March&nbsp;31, 2018. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded interest expense of $0 and $30,424 for the three-month and
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>July 2016 Lease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Effective July&nbsp;1, 2016, the Company entered into a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease for laboratory
and related office facilities in New York with ARE, an entity that is under common control by an entity that is a minority shareholder of the Company and whose CEO is a director of the Company. The lease provides for monthly base rent and property
management fees, including rent escalations and rent holidays, plus operating expenses during the lease term, which expires on December&nbsp;31, 2021. The Company records monthly rent expense on a straight-line basis from July&nbsp;1, 2016 through
December&nbsp;31, 2021. As of June&nbsp;30, 2018 and December&nbsp;31, 2017, the balance of deferred rent, representing the difference between cash rent paid and straight-line rent expense, was $220,722 and $231,276, respectively. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total rent expense under this operating lease was $121,890 and $121,890 for the three-month periods ended June&nbsp;30, 2018 and 2017,
respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Total rent expense under this operating lease was $243,780 and $243,780 for the
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018 and 2017, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, the
aggregate future minimum rental payments under this lease are $1,927,187. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the signing of this lease, the Company
entered into a standby letter of credit agreement for $122,866, which serves as a security deposit for the premises. The standby letter of credit expires on July&nbsp;7, 2017 and is automatically renewed annually through July&nbsp;7, 2021. This
standby letter of credit is secured with restricted cash in a money market account. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events: </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management has evaluated subsequent events through the date of this filing. Based on our evaluation, the following disclosures have been made:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;27, 2018 two leases for office and laboratory facilities in London, UK expired. Effective July&nbsp;27, 2018, the Company
entered into two new <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases for the same office and laboratory facilities in London. The leases provide for annual base rent in the aggregate amount of approximately $363,000, plus
operating expenses, through May&nbsp;31, 2022, at which time the annual base rent will be revalued based on market rates at that time. The leases expire on May&nbsp;24, 2027. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2. <A NAME="tx570173_8"></A>Management&#146;s Discussion and Analysis of Financial Condition
and Results of Operations. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of financial condition and operating results
together with our financial statements and related notes appearing in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and those included in our final prospectus that forms a part of the Company&#146;s registration
statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-224914),</FONT> filed with the Securities and Exchange Commission (&#147;SEC&#148;) pursuant to Rule 424(b)(4) on June&nbsp;8, 2018
(the &#147;Prospectus&#148;). Some of the information contained in this discussion and analysis or set forth elsewhere in the Quarterly Report, including information with respect to our plans and strategy for our business and related financing,
includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those set forth in the &#147;Risk Factors&#148; section of this Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q,</FONT> our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. For convenience of presentation
some of the numbers have been rounded in the text below. . Unless the context requires otherwise, references in this Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations to the &#147;Company,&#148;
&#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to (i)&nbsp;MeiraGTx Limited and its subsidiaries prior to the Reorganization Transactions and (ii)&nbsp;MeiraGTx Holdings plc and its subsidiaries upon completion of the Reorganization
Transactions, as applicable. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and
research programs. We have core capabilities in viral vector design and optimization, gene therapy manufacturing as well as a potentially transformative gene regulation technology. We have taken a portfolio approach by licensing, acquiring and
developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene
therapy treatments for patients suffering from a range of serious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an exempted company incorporated under the laws of the
Cayman Islands in 2018, and prior to that, we commenced operations as MeiraGTx Limited, a private limited company incorporated under the laws of England and Wales in 2015. Our discussion of our financial condition and results of operations is based
upon our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. Since our formation, we have devoted substantially all of our resources to developing our technology platform,
establishing our viral vector manufacturing facility and developing manufacturing processes, advancing the product candidates in our ophthalmology, salivary gland and neurodegenerative disease programs, building our intellectual property portfolio,
organizing and staffing our company, business planning, raising capital, and providing general and administrative support for these operations. In 2016, we completed the acquisition of assets held by BRI-Alzan, Inc., a Delaware corporation,
including a worldwide license agreement to develop certain preclinical technology for the treatment of ALS. To date, we have financed our operations primarily with cash on hand and proceeds from the sales of our Series C preferred shares
(&#147;Preferred Shares&#148;) and Series A ordinary shares (&#147;Ordinary Shares&#148;). Through June&nbsp;30, 2018, we received gross proceeds of approximately $110.3&nbsp;million from sales of our Preferred Shares. As of June&nbsp;30, 2018, we
had cash and cash equivalents of $102.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage company and have not generated any product revenues to
date. We have four clinical programs and a pipeline of preclinical programs. Since inception, we have incurred significant operating losses. Our net losses for the three months ended June&nbsp;30, 2018 and 2017 were $30.0&nbsp;million and
$7.2&nbsp;million, respectively, and for the six months ended June&nbsp;30, 2018 and 2017 were $46.4&nbsp;million and $14.0&nbsp;million, respectively. As of June&nbsp;30, 2018, we had an accumulated deficit of $111.8&nbsp;million. We do not expect
to generate revenue from sales of any products for several years, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating expenses to increase substantially
in connection with our ongoing development activities related to our product candidates. We anticipate that our expenses will increase due to costs associated with our clinical development program targeting in achromatopsia due to mutations in the
<I>CNGB3</I> or <I>CNGA3</I> gene, inherited retinal dystrophy caused by mutations in <I>RPE65</I>, or <I>RPE65</I>-deficiency, and <FONT STYLE="white-space:nowrap">X-Linked</FONT> retinitis pigmentosa, or XLRP. In addition, we expect to incur
increasing costs associated with our clinical activities for <I>hAQP1</I> for the treatment of radiation-induced xerostomia. We also expect to incur expenses related to research activities in additional therapeutic areas to expand our pipeline,
hiring additional personnel in manufacturing, research, clinical trials, quality and other functional areas, and associated cash and share-based compensation expense, as well as the further development of internal manufacturing capabilities and
capacity and other associated costs including the management of our intellectual property portfolio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these anticipated expenditures, we will require additional capital, which we
may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources to enable us to complete the development and potential
commercialization of our product candidates. Furthermore, we expect to incur additional costs associated with being a public company. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise
capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to secure additional financing may divert the time and attention of our management from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm our product candidate development efforts. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay,
reduce or eliminate certain of our research and development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current cash and cash equivalents, we estimate that
such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2020. We have based these estimates on assumptions that may prove to be wrong, and we may use our available
capital resources sooner than we currently expect. See &#147;&#151;Liquidity and Capital Resources.&#148; Because of the numerous risks and uncertainties associated with the development of our product candidates, any future product candidates, our
platform and technology and because the extent to which we may enter into collaborations with third parties for development of any of our product candidates is unknown, we are unable to estimate the amounts of increased capital outlays and operating
expenses associated with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing, costs and results of our planned clinical trials for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by
third parties against us or any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of further developing our manufacturing facilities in the United Kingdom;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions
where we choose to commercialize our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing and results of our commercialization of our product candidates, if approved for
commercial sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate additional funds may not be available to us on acceptable terms, or at all. To the extent
that we raise additional capital through the sale of equity or convertible securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a
shareholder. Any future debt financing or preferred equity or other financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to
relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
when needed, we may be required to delay, limit, reduce, or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and
market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing
or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain
profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Clinical Development Highlights </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AAV-CNGB3:
Completed the dose escalation phase of the treatment study, with 11 adult patients treated in the three dose escalation cohorts. In addition, three pediatric patients have now been treated in the extension phase of the study. We anticipate
completing dosing of up to eight pediatric patients in the second half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AAV-RPGR: Completed dosing of the second dose escalation cohort, bringing
the total number treated to seven patients. The independent monitoring committee, or IDMC, has recommended moving to the third and highest dose cohort and we anticipate completing dosing in this final adult cohort in the third quarter of 2018. We
expect to initiate dosing in the pediatric extension phase of the study in the fourth quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AAV-RPE65: Completed dosing in the Phase 1/2
clinical study. A total of nine adults were treated in three escalating dose cohorts. Six pediatric patients were treated in the pediatric extension arm of the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AAV-CNGA3: cGMP manufacturing of clinical material is ongoing in our manufacturing facility. We anticipate release at the end of 2018 with the initiation of
the treatment study in early 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Natural History Studies: We continue to enroll patients in the achromatopsia, XLRP and RPE65 long term natural history
studies in Europe and the US, and our long-term follow-up studies in each indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Regulatory Highlights </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Received Positive Opinion for Orphan Drug Designation from EMA for Achromatopsia Treatment:</B> On June 26, 2018, the European Medicines Agency&#146;s (EMA)
Committee for Orphan Medicinal Products issued a positive opinion recommending orphan Medicinal product (orphan drug) designation of MeiraGTx&#146;s AAV-CNGA3 for the treatment of achromatopsia caused by mutations in the <I>CNGA3</I> gene. We
continue to work with the EMA to advance the clinical development of AAV-CNGA3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Received Fast Track Designation from FDA for X-Linked Retinitis
Pigmentosa Treatment:</B> On April 23, 2018, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase
regulator (<I>RPGR</I>) gene. We are currently conducting an open label, Phase 1/2 dose escalation clinical trial of AAV-RPGR in adult and pediatric patients diagnosed with XLRP caused by mutations in the eye-specific form of the <I>RPGR</I> gene
called RPGR open reading frame 15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Granted MIA (IMP) License for UK cGMP Manufacturing Facility:</B> On June 21, 2018, we were granted a
Manufacturer&#146;s Authorization for Investigational Medicinal Products from the UK&#146;s Medicines and Healthcare products Regulatory Agency (MHRA), allowing us to manufacture gene therapy product candidates in our current cGMP compliant
manufacturing facility. Our 29,000 square-foot facility located in central london was designed to operate as a flexible and scalable manufacturing hub, housing two cell production suites and three separate viral vector production suites, offering
production of multiple product candidates in parallel, as well as sequentially at difference scales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Corporate Highlights </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Completed Initial Public Offering:</B> In June 2018, we completed an initial public offering of 5,000,000 ordinary shares of common stock at a public
offering price of $15.00 per share, raising net proceeds of $65.9 million, after underwriting discounts and commissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating
expenses since inception have consisted primarily of general and administrative costs and research and development costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and
Administrative Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and other related costs, including
share-based compensation, for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional
fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and office facility-related expenses, which include direct depreciation costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased
research and development activities. We have also incurred and expect to continue to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and
<FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with Nasdaq and SEC requirements; director and officer insurance costs; and investor and public relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the
development of our product candidates, and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, benefits and travel of our research and development personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred in connection with third-party vendors that conduct clinical and preclinical studies and
manufacture the drug product for the clinical trials and preclinical activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with clinical and preclinical activities including costs related to facilities, supplies, rent,
insurance, certain legal fees, share-based compensation, and depreciation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred with the development and operation of our manufacturing facility. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense research and development costs as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We typically use our employee and infrastructure resources across our development programs. We track outsourced development costs by product
candidate or development program, but we do not allocate personnel costs, license payments made under our licensing arrangements or other internal costs to specific development programs or product candidates. These costs are included in other
research and development expenses in the table below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ened</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Six Months Ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Opthamology program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,303,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">303,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,769,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,766,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,002,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salivary gland program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,367</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">512,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77,253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neurodeneration program</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">457,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">912,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">990,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,315,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">808,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,506,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,282,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,056,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,226,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,136,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,186,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,949,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,790,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,363,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,427,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,718,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,186,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,531,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. We expect that our research and
development expenses will continue to increase substantially for the foreseeable future as we initiate additional preclinical and clinical trials of our existing product candidates and continue to discover and develop additional product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot determine with certainty the duration and costs of future clinical trials of our product candidates or any other product
candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any
product candidate. The duration, costs and timing of clinical trials and development of our existing product candidates or any other product candidate we may develop will depend on a variety of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress, expense and results of clinical trials of our existing product candidates, as well
as of any future clinical trials of other product candidates and other research and development activities that we may conduct; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties in clinical trial design and patient enrollment rates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the actual probability of success for our product candidates, including the safety and efficacy, early clinical
data, competition, manufacturing capability and commercial viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant and changing government regulation and regulatory guidance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and receipt of any marketing approvals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property
rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with respect to the development of a product candidate could
mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another U.S. or foreign regulatory authority were to require us to conduct clinical trials beyond those that we
anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant
additional financial resources and time on the completion of clinical development. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other <FONT STYLE="white-space:nowrap">non-operating</FONT> income (expense) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-operating</FONT> income (expense) includes the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Foreign currency gain </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are presented in U.S. dollars, which is our reporting currency. The financial position and results of
operations of our subsidiaries MeiraGTx UK II and MeiraGTx B.V. are measured using the foreign subsidiaries&#146; local currency as the functional currency. MeiraGTx UK II cash accounts holding U.S. dollars are remeasured based upon the exchange
rate at the date of remeasurement with the resulting gain or loss included in the consolidated statement of operations and comprehensive loss. Expenses of such subsidiaries have been translated into U.S. dollars at average exchange rates prevailing
during the period. Assets and liabilities have been translated at the rates of exchange on the consolidated balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of shareholders&#146;
equity and as other comprehensive loss on the consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in fair value of
warrant liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined that our warrants are classified as liabilities on our balance sheet because the Preferred Shares
underlying the warrants have a redemption feature in the event of a change of control of the Company. The fair values of the warrants are estimated using the Black-Scholes valuation model with certain assumptions regarding risk free interest rate,
expected volatility, expected divided yield and expected life. The Black-Scholes value of the warrants was recorded as a warrant liability and is remeasured quarterly. Any changes in the quarterly valuation of the warrants is charged to operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgements and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management&#146;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial
statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America (&#147;GAAP&#148;). The preparation of these condensed consolidated financial statements requires us to make
estimates and judgements that affect the reporting amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates
and judgements, including those related to warrant liabilities, share-based compensation and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under
the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities that are not readily apparent from our sources. Actual results may differ from these estimates under different
assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Critical accounting policies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s significant accounting policies are disclosed in the audited financial statements for the year ended December&nbsp;31, 2017
included in the Company&#146;s Prospectus and Note 2 to our unaudited condensed consolidated financial statements included elsewhere in the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> There have been no changes to the
Company&#146;s significant accounting policies through June&nbsp;30, 2018 from those discussed in our Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting
Pronouncements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 of the notes to our unaudited condensed consolidated financial statements included elsewhere in the
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for a summary of recently issued and adopted accounting pronouncements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Three Months Ended June&nbsp;30, 2018 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the three months ended June&nbsp;30, 2018 and 2017, respectively </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,378,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,221,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,156,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,790,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,363,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,427,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,168,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,585,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,583,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,168,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,585,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,583,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-operating</FONT> income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency (loss) gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,726,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,176,249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,184,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,184,183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(29,980,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,178,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,802,113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $17.4&nbsp;million for the three months ended June&nbsp;30, 2018, compared to $2.2&nbsp;million for
the three months ended June&nbsp;30, 2017. The increase of $15.2&nbsp;million was primarily due to increases of $7.8&nbsp;million in payroll, $7.2&nbsp;million in stock-based compensation, $0.1&nbsp;million in consultant costs, $0.1&nbsp;million in
legal fees, $0.1&nbsp;million in investor relations costs, $0.1&nbsp;million in insurance costs and $0.2&nbsp;million in travel expenses, which was partially offset by decreases of $0.3&nbsp;million in rent and $0.1&nbsp;million in depreciation
expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the three months ended June&nbsp;30, 2018 were $7.8&nbsp;million, compared to $5.4&nbsp;million for the
three months ended June&nbsp;30, 2017. The increase of $2.4&nbsp;million was primarily due to an increase in costs of $2.3&nbsp;million related to preparation of our manufacturing facility for production, and $0.5&nbsp;million in stock-based
compensation, which was partially offset by a decrease of $0.4&nbsp;million in clinical trial material costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency (Loss)
Gain </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign currency loss was $2.7&nbsp;million for the three months ended June&nbsp;30, 2018 compared to a gain of $.5&nbsp;million
for the three months ended June&nbsp;30, 2017. The increase of $3.2&nbsp;million was primarily due to a strengthening U.S. dollar against the pound sterling during the three months ended June&nbsp;30, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Warrant Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the warrant liability for the three months ended June&nbsp;30, 2018 was due to the revaluation of warrants, which
were issued to certain investors in September and November 2017. On June&nbsp;5, 2018, the warrants were exercised at which time the warrant liability was determined to be $4,194,408, which represented the difference in the market value of the
Preferred Shares and the exercise price of the warrants. As a result of the revaluation, there was an increase of $2.2&nbsp;million in the fair market value of the warrant liability at that time, which resulted in a loss being recorded for the three
months ended June&nbsp;30, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Six Months Ended June&nbsp;30, 2018 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the six months ended June&nbsp;30, 2018 and 2017, respectively </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Six Months Ended June&nbsp;30,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Change</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,500,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,370,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,129,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,718,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,186,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,531,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,218,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,557,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,660,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,218,084</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,557,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,660,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-operating</FONT> income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency (loss) gain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,748,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">598,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,346,874</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,514,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,514,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(46,384,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,999,104</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,385,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $28.5&nbsp;million for the six months ended June&nbsp;30, 2018, compared to $4.4&nbsp;million for the
six months ended June&nbsp;30, 2017. The increase of $24.1&nbsp;million was primarily due to increases of $13.5&nbsp;million in payroll, $10.5&nbsp;million in stock-based compensation, $0.2&nbsp;million in consultant costs, $0.2&nbsp;million in
legal fees, $0.2&nbsp;million in accounting fees, $0.2&nbsp;million in travel expenses, $0.1&nbsp;million in insurance costs and $0.1&nbsp;million in investor relations costs, which was partially offset by decreases of $0.7&nbsp;million in rent and
$0.2&nbsp;million in depreciation expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the six months ended June&nbsp;30, 2018 were $14.7&nbsp;million, compared to $10.2&nbsp;million for the
six months ended June&nbsp;30, 2017. The increase of $4.5&nbsp;million was primarily due to an increase in costs of $4.0&nbsp;million related to preparation of our manufacturing facility for production, $0.5&nbsp;million in stock-based compensation,
$0.2&nbsp;million in license fees and $0.1&nbsp;million in neurodegenerative research, which was partially offset by a decrease of $0.4&nbsp;million in clinical trial material costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency (Loss) Gain </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Foreign currency loss was $1.8&nbsp;million for the six months ended June&nbsp;30, 2018 compared to a gain of $0.6&nbsp;million for the six
months ended June&nbsp;30, 2017. The increase of $2.4&nbsp;million was primarily due to a strengthening U.S. dollar against the pound sterling during the six months ended June&nbsp;30, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Fair Value of Warrant Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The change in fair value of the warrant liability for the six months ended June&nbsp;30, 2018 was due to the revaluation of warrants, which
were issued to certain investors in September and November 2017. On June&nbsp;5, 2018, the warrants were exercised at which time the warrant liability was determined to be $4,194,408, which represented the difference in the market value of the
Preferred Shares and the exercise price of the warrants. As a result of the revaluation, there was an increase of $1.5&nbsp;million in the fair market value of the warrant liability at June&nbsp;30, 2018, which resulted in a gain being recorded for
the six months ended June&nbsp;30, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant operating losses. We have not generated positive cash flows from operations, and there are no
assurances that we will be successful in obtaining an adequate level of financing for the development and commercialization of its product candidates. We expect to incur significant expenses and operating losses for the foreseeable future as we
advance the preclinical and clinical development of our product candidates. We expect that our research and development and general and administrative costs will increase in connection with conducting preclinical studies and clinical trials for our
product candidates, building out internal capacity to have product manufactured to support preclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations.
As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to maintain a <FONT STYLE="white-space:nowrap">stand-by</FONT> letter of credit as a security deposit under a certain lease
with ARE, an entity that is under common control with an entity that is a minority shareholder of the Company and whose CEO is on our board of directors. Our bank requires us to maintain restricted cash balances to serve as collateral for the letter
of credit issued to the landlord by the bank. As of June&nbsp;30, 2018 and December&nbsp;31, 2017, the restricted cash balances for the ARE lease was invested in a commercial money market account. The restricted cash balance for the ARE lease
remains at $123,376 through the end of the lease term in December 2021, plus three months. We had $123,376 of restricted cash included in long-term assets as of June&nbsp;30, 2018 and December&nbsp;31, 2017. We do not currently have any approved
products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of our Ordinary Shares and Preferred Shares. On June&nbsp;7, 2018, upon effectiveness of our registration statement
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-224914),</FONT> as amended, filed in connection with our IPO (the &#147;Registration Statement&#148;), all of the 11,501,432 outstanding
Preferred Shares were automatically converted into 11,501,432 Ordinary Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, we had $102.1&nbsp;million of cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our sources and uses of cash for the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><FONT STYLE="white-space:nowrap">For&nbsp;the&nbsp;six-month&nbsp;periods&nbsp;ended&nbsp;June&nbsp;30,</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36,425,351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,530,731</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,324,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,469,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) in cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">93,726,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,660,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2018, our cash used in operating activities of $36.4&nbsp;million was primarily due to our net loss
of $46.4&nbsp;million as we incurred expenses associated with research activities on our clinical programs and research activities for our other product candidates and incurred general and administrative expenses. The loss included <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges of $17.1&nbsp;million, which consisted of $12.8&nbsp;million of share-based compensation, depreciation of $1.0&nbsp;million, foreign currency loss of $1.8&nbsp;million and a change in the fair value
of a warrant liability of $1.5&nbsp;million. Additionally, current assets, consisting of prepaid expenses and other current assets, decreased by $1.0&nbsp;million and current liabilities, consisting of accounts payable, accrued expenses and due to
affiliate decreased by $8.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2017, our cash used in operating activities of
$10.5&nbsp;million was primarily due to our net loss of $14.0&nbsp;million as we incurred expenses associated with research activities on our clinical programs and research activities for our other product candidates and incurred general and
administrative expenses. The loss included <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $1.3&nbsp;million, which consisted of $1.5&nbsp;million of share-based compensation, depreciation of $0.4&nbsp;million, which was partially offset
by a foreign currency gain of $0.6. Additionally, current assets, consisting of prepaid expenses and other current assets increased by $0.7&nbsp;million, and current liabilities, consisting of accounts payable, accrued expenses, deferred rent and
due to affiliate, increased by $2.9&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the six months ended June&nbsp;30, 2018 of $1.3&nbsp;million consisted of purchases of property and
equipment, primarily for our manufacturing facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the six months ended June&nbsp;30, 2017 of
$2.3&nbsp;million consisted of $4.8&nbsp;million of purchases of property and equipment, primarily for our manufacturing facility, which was partially offset by the issuance of a note-payable of $2.5&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net
cash provided by financing activities was $131.5&nbsp;million for the six months ended June&nbsp;30, 2018, which consisted of net proceeds of $65.9&nbsp;million from the issuance of Ordinary Shares in connection with our initial public offering,
$56.2&nbsp;million from the issuance of Preferred Shares, $9.7&nbsp;million from the exercise of warrants, which was partially offset by the payment of a note in the amount of $1.4&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $0.2&nbsp;million for the six months ended June&nbsp;30, 2017, which represented proceeds from
the issuance of our Preferred Shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating expenses have increased substantially in 2017 and 2018 and are expected to increase substantially in the future in connection
with our ongoing activities, particularly as we advance our clinical activities including <FONT STYLE="white-space:nowrap">scale-up</FONT> of manufacturing processes and additional clinical trials. In addition, we expect to incur additional costs
associated with operating as a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, our expenses will increase as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue the preclinical and clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scale up our manufacturing processes and capabilities to support our preclinical studies and clinical trials of
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">in-license</FONT> or acquire the rights to other products, product candidates or
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional personnel in research, manufacturing and regulatory and clinical development as well as
management personnel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our operational, financial and management systems and increase personnel, including personnel to support
our operations as a public company.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current cash and
cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2020. We have based these estimates on assumptions that may prove to be
wrong, and we could utilize our available capital resources sooner than we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties
associated with research, development and commercialization of gene therapies, it is difficult to estimate with certainty the amount of our working capital requirements. Our future funding requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, costs and results of our preclinical development and initial clinical trials for our gene therapy
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, costs and results of our additional clinical, research and preclinical development programs in gene
therapy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of process development and manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT>
activities associated with our clinical programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other agreements and the financial
terms of such agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of any product candidates that we may derive from our platform technology
or any other product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products,
product candidates or technologies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and protecting our
intellectual property rights and defending against any intellectual property-related claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever,
that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaboration agreements, other third-party funding, strategic alliances,
licensing arrangements and marketing and distribution arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of
equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of ordinary shares. Debt financing and
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise
additional funds through other third-party funding, collaboration agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable rights to our technologies, future revenue
streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or
terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the repayment of the notes payable at December&nbsp;31, 2017, there were no material changes in our commitments during the three
months ended June&nbsp;30, 2018 under contractual obligations as disclosed in our Prospectus outside the course of normal business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not entered into any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements under applicable SEC rules and do not have any holdings in variable interest entities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company Status </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an &#147;emerging growth company,&#148; which we are, to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public
companies until those standards would otherwise apply to private companies. We have elected to take advantage of this extended transition period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_9"></A>Item&nbsp;3. Quantitative and Qualitative Disclosures About Market Risk.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. These risks primarily include foreign currency exchange rate
sensitivities. However, relative to foreign currency exposures as of June&nbsp;30, 2018, a 10% unfavorable movement in foreign currency exchange rates would not expose us to a significant increase in net loss. We had cash and cash equivalents of
$102.1&nbsp;million as of June&nbsp;30, 2018, which consist of <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> bank deposits. Other than accounts payable and accrued expenses incurred in the ordinary course of business, we had no other
debt outstanding as of June&nbsp;30, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_10"></A>Item&nbsp;4. Controls and Procedures. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Limitations on effectiveness of controls and procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is
required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Evaluation of
disclosure controls and procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, with the participation of our Chief Executive Officer and Chief Operating Officer
(principal financial officer), evaluated, as of the end of the period covered by this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> the effectiveness of our disclosure controls and procedures (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e)</FONT> under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)). Based on that evaluation, our Chief Executive Officer and Chief
Operating Officer (principal financial officer) concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&nbsp;30, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_11"></A>PART II&#151;OTHER INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_12"></A>Item&nbsp;1. Legal Proceedings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not subject to any material legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_13"></A>Item&nbsp;1A. Risk Factors. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks described below, together with the
other information included or incorporated by reference in this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> If any of the following risks occur, our business, financial condition, results of operations and future growth
prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline. Other events that we do not currently anticipate or that we currently deem immaterial may also affect our business,
prospects, financial condition and results of operations. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since inception and anticipate that we will incur continued losses for the foreseeable future, and may never achieve
or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage company with limited operating history. We were formed and began operations in
2015. We have never been profitable and do not expect to be profitable in the foreseeable future. We have incurred net losses since inception, including net losses of approximately $46.4&nbsp;million and $14.0&nbsp;million for the six months ended
June&nbsp;30, 2018 and 2017, respectively. As of June&nbsp;30, 2018, we had an accumulated deficit of approximately $111.8&nbsp;million. Since our inception, we have devoted substantially all of our resources to developing our technology platform,
establishing our viral vector manufacturing facility and developing manufacturing processes, advancing the product candidates in our ophthalmology, salivary gland and neurodegenerative disease programs, building our intellectual property portfolio,
organizing and staffing our company, business planning, raising capital, and providing general and administrative support for these operations. We have not yet demonstrated an ability to successfully complete a clinical program, including
large-scale, pivotal clinical trials, obtain marketing approval, manufacture product at a commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product
commercialization. Typically, it takes about six to ten years to develop a new drug from the time it enters Phase 1 clinical trials to when it is approved for treating patients, but in many cases, it may take longer. Consequently, predictions about
our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing genetic medicine products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and additional operating losses for the foreseeable future as we seek to advance product
candidates through preclinical and clinical development, expand our research and development activities, develop new product candidates, complete clinical trials, seek regulatory approval and, if we receive regulatory approval, commercialize our
products. Furthermore, the costs of advancing product candidates into each succeeding clinical phase tend to increase substantially over time. The total costs to advance any of our product candidates to marketing approval in even a single
jurisdiction would be substantial. Because of the numerous risks and uncertainties associated with gene therapy product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to
begin generating revenue from the commercialization of products or achieve or maintain profitability. Our expenses will also increase substantially as we operate as a public company and add clinical, scientific, operational, financial and management
information systems and personnel, including personnel to support our product development and planned future commercialization efforts, as well as to support our transition to a public reporting company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before we generate any revenue from product sales, each of our programs and product candidates will require additional preclinical and/or
clinical development, potential regulatory approval in multiple jurisdictions, manufacturing, building of a commercial organization, substantial investment and significant marketing efforts. Our expenses could increase beyond expectations if we are
required by the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, or other regulatory authorities to perform preclinical studies and clinical trials in addition to those that we currently anticipate. These risks are
further described under &#147;&#151;Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval&#148; and &#147;&#151;Risks Related to Commercialization.&#148; As a result, we expect to continue to incur net
losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our shareholders&#146; equity and working capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to build our business, we expect our financial condition and operating
results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual period as
indications of future operating performance. If we are unable to develop and commercialize one or more of our product candidates either alone or with collaborators, or if revenues from any product candidate that receives marketing approval are
insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. If we are unable to achieve and then maintain profitability, the value of our equity securities will be
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require additional capital to fund our operations, which may not be available on acceptable terms, if at all.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to spend substantial amounts to complete the development of, seek regulatory approvals for and commercialize our product
candidates. We will require additional capital beyond the proceeds of our IPO, which we may raise through equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing
arrangements or other sources to enable us to complete the development and potential commercialization of our product candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. Adequate additional
financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. In addition, attempting to
secure additional financing may divert the time and attention of our management from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and harm our product candidate development efforts. If we are
unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our research and development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed significant amounts of cash since inception. As of June&nbsp;30, 2018, our cash and cash equivalents were
$102.1&nbsp;million. Based on our current cash and cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2020. This estimate is
based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances could cause us to consume capital significantly faster than we currently anticipate, and we may
need to spend more than currently expected because of circumstances beyond our control. Because the length of time and activities associated with successful development of our product candidates is highly uncertain, we are unable to estimate the
actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing, costs and results of our ongoing clinical development for our <I>CNGB3</I> gene therapy
product candidate, <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> for our <I>RPE65</I>-deficiency product candidate, <FONT STYLE="white-space:nowrap">AAV-RPE65,</FONT> for our <FONT STYLE="white-space:nowrap">X-linked</FONT> retinitis pigmentosa
product candidate, <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> for our radiation induced xerostomia product candidate, <FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT> and our continued ongoing natural history studies for inherited retinal
diseases, or IRDs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation of Phase 1/2 clinical trials for our <I>CNGA3</I> gene therapy product candidate, <FONT
STYLE="white-space:nowrap">AAV-CNGA3,</FONT> and for our product candidate for the treatment of xerostomia associated with Sjogren&#146;s syndrome, <FONT STYLE="white-space:nowrap">AAV-AQP1;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing our current research programs, our preclinical development of product candidates from our current
research programs and further developing our gene regulation technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seeking to identify, assess, acquire and/or develop additional research programs and additional product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the preclinical testing and clinical trials for any product candidates we identify and develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing a sales, marketing and distribution infrastructure to commercialize any product candidates for which
we may obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA and other regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of expanding and protecting our intellectual property portfolio, including filing, prosecuting,
defending and enforcing our patent claims and other intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of defending potential intellectual property disputes, including patent infringement actions brought by
third parties against us or any of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of further developing and scaling our manufacturing facility and processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of completion of commercial-scale manufacturing activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of making royalty, milestone or other payments under current and any future <FONT
STYLE="white-space:nowrap">in-license</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire other products and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions
where we choose to commercialize our products; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, progress, timing and results of our commercialization of our product candidates, if approved for
commercial sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that additional funding will be available on acceptable terms, or at all. If we
are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or potentially discontinue
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership
interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common shareholder. Debt financing and preferred equity financing, if available, may involve agreements
that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If
we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our most advanced product
candidates, <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and
<FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT> which are still in development, and if none of them receive regulatory approval or are successfully commercialized, our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have invested a significant portion of our efforts and financial resources in the development of
<FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and
<FONT STYLE="white-space:nowrap">AAV-AQP1.</FONT> Our future success and ability to generate product revenue is substantially dependent on our ability to successfully develop, obtain regulatory approval for and successfully commercialize these
product candidates. We currently have no products that are approved for commercial sale and may never be able to develop marketable products. We expect to invest a meaningful portion of our efforts and expenditures over the next few years in <FONT
STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT>
which will require additional clinical development, management of clinical and manufacturing activities, regulatory approval in multiple jurisdictions, manufacturing sufficient supply, building of a commercial organization, substantial investment
and significant marketing efforts before we can generate any revenues from any commercial sales. Accordingly, our business currently depends heavily on the successful development, regulatory approval and commercialization of <FONT
STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT>
which may never occur. We cannot be certain that <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT>
<FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> or <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> will be successful in clinical trials, receive regulatory approval or be successfully commercialized even if we receive regulatory approval. Even
if we receive approval to market <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> or <FONT
STYLE="white-space:nowrap">AAV-AQP1</FONT> from the FDA, EMA or other regulatory bodies, we cannot be certain that our product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other
commercially available alternatives. Additionally, the research, testing, manufacturing, labeling, approval, sale, marketing and distribution of gene therapy products are and will remain subject to extensive and evolving regulation by the FDA, EMA
and other regulatory authorities. We are not permitted to market <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT>
<FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> or <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> in the United States until they receive approval of a biologics license application, or BLA, from the FDA, and we cannot market them in the
European Union until we receive approval for a Marketing Authorization Application, or MAA, from the EMA, or other required regulatory approval in other countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT>
<FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> are our most advanced product candidates, and
because some of our other product candidates are based on similar technology, if <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT
STYLE="white-space:nowrap">AAV-RPE65</FONT> or <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> show unexpected adverse events or a lack of efficacy in the indications we intend to treat, or if we experience other regulatory or developmental issues,
our development plans and business could be significantly harmed. Further, competitors may be developing products with similar technology and may experience problems with their products that could identify problems that would potentially harm our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to identify additional product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Part of our strategy involves identifying novel product candidates. The process by which we identify product candidates may fail to yield
product candidates for clinical development for a number of reasons, including those discussed in these risk factors and also: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to assemble sufficient resources to acquire or discover additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates we develop may nevertheless be covered by third parties&#146; patents or other
exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other
characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product candidates may not be effective in treating their targeted diseases; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market for a potential product candidate may change so that the continued development of that product
candidate is no longer reasonable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable
cost, or at all; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the regulatory pathway for a potential product candidate is too complex and difficult to navigate successfully or
economically. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may choose to focus our efforts and resources on a potential product candidate that
ultimately proves to be unsuccessful. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases
that may later prove to have greater commercial potential, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain
sole development and commercialization rights. If we are unable to identify additional suitable product candidates for clinical development, this would adversely impact our business strategy and our financial position and share price and could
potentially cause us to cease operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Discovery, Development, Clinical Testing, Manufacturing and Regulatory Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to identify and develop product candidates based on our novel gene therapy platform, which makes it difficult to predict the time and cost of
product candidate development. Very few products that utilize transduction technology have been approved in the United States or in Europe, and there have only been a limited number of clinical trials involving a gene therapy product candidate.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have concentrated a portion of our research and development efforts on our gene therapy platform, which uses both transduction
and gene regulation technology. Our future success depends on the successful development of these novel therapeutic approaches. To date, very few products that utilize gene transfer have been approved in the United States or Europe. There have been
a limited number of clinical trials of gene transduction technologies, with only one product candidate ever approved by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our gene
therapy platform is based on a suite of viral vectors which we can deploy with gene therapy constructs, which relies on the ability of AAV to efficiently transmit a therapeutic gene to certain kinds of cells. The mechanism of action by which these
vectors target particular tissues is still not completely understood. Therefore, it is difficult for us to determine that our vectors will be able to properly deliver gene transfer constructs to enough tissue cells to reach therapeutic levels. We
cannot be certain that our viral vectors will be able to meet safety and efficacy levels needed to be therapeutic in humans or that they will not cause significant adverse events or toxicities. Furthermore, recent work conducted by a third party in <FONT
STYLE="white-space:nowrap">non-human</FONT> primates suggests that intravenous delivery of certain AAV vectors at very high doses may result in severe toxicity. The indications that we target do not use IV administration for viral vector delivery
and do not use doses as high as those tested in these publications, and to date we have not observed the severe toxicities described in these publications with the naturally occurring AAV vectors that we use. However, we cannot be certain that we
will be able to avoid triggering toxicities in our future preclinical studies or clinical trials. Any such results could impact our ability to develop a product candidate. As a result of these factors, it is more difficult for us to predict the time
and cost of product candidate development, and we cannot predict whether the application of our gene therapy platform, or any similar or competitive gene therapy platforms, will result in the identification, development, and regulatory approval of
any product candidates, or that other gene therapy technologies will not be considered better or more attractive. There can be no assurance that any development problems we experience in the future related to our gene therapy platform or any of our
research programs will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays and challenges in utilizing our manufacturing facility and achieving sustainable,
reproducible, and scalable production. Any of these factors may prevent us from completing our preclinical studies or clinical trials or commercializing any product candidates we may develop on a timely or profitable basis, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because our gene regulation technology is still in the research stage, we have not yet been able to assess safety in humans, and
there may be long-term effects from treatment that we cannot predict at this time. Also, animal models may not exist for some of the diseases we expect to pursue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because gene therapy is novel and the regulatory landscape that governs any product candidates we may develop is uncertain and may change, we cannot
predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory requirements that will govern any novel gene therapy product candidates we develop are not entirely clear and may change. Within
the broader genetic medicine field, very few therapeutic products have received marketing authorization from the EMA and FDA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the
regulatory landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes
uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for
Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to
review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Gene therapy clinical
trials conducted at institutions that receive funding for recombinant DNA research from the United States National Institutes of Health, or the NIH, are also subject to review by the NIH Office of Biotechnology Activities&#146; Recombinant DNA
Advisory Committee. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed
the trial and approved its initiation. The same applies in the European Union. The EMA&#146;s Committee for Advanced Therapies, or CAT, is responsible for assessing the quality, safety, and efficacy of advanced-therapy medicinal products.
Advanced-therapy medicinal products include gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. The role of the CAT is to prepare a draft opinion on an application for marketing authorization for a gene therapy
medicinal candidate that is submitted to the EMA. In the European Union, the development and evaluation of a gene therapy product must be considered in the context of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy products and require that we comply with these new guidelines. As
a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any gene therapy product candidate we may develop, but that remains uncertain at this point. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse developments in preclinical studies or clinical trials conducted by others in the field of gene therapy and gene regulation products
may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In
addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity,
novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or
other product candidates. Further, as we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other regulatory bodies may
not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. The prospectively designed natural history studies with the same endpoints as our
corresponding clinical trials may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene
regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the
commercialization of resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory review committees and advisory groups described above and the new guidelines they
promulgate may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval
and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory
and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome. Further, we may encounter
substantial delays in our clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical trials and manufacturing of our product candidates are, and the
manufacturing and marketing of our products, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product
candidates. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe
and effective for use in each target indication. In particular, because our product candidates are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target
indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and subject to uncertainty. We cannot guarantee that any clinical trials
will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process.&nbsp;Even if our future clinical trials are completed as planned, we cannot be certain that their results will support
the safety and effectiveness of our product candidates for their targeted indications. Our future clinical trial results may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret
the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing
application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not completed any clinical trials required for the approval of our product candidates. Although we have already begun Phase
1/2 clinical trials, we may experience delays in conducting any clinical trials and we do not know whether our clinical trials will begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all.
Events that may prevent successful or timely completion of clinical development include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
initiation of clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement with the FDA, EMA or other regulatory authorities as to the design or implementation
of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approval to commence a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reaching an agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can
be subject to extensive negotiation and may vary significantly among different clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining institutional review board, or IRB, approval at each site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recruiting suitable patients to participate in a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and validating the companion diagnostic to be used in a clinical trial, if applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">having patients complete a clinical trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites, contract research organizations, or other third parties deviating from trial protocol or dropping
out of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s good clinical practice, or GCP, requirements, or applicable
regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse
events associated with the product candidate that are viewed to outweigh its potential benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding a sufficient number of clinical trial sites;&nbsp;or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of product candidate for use in clinical trials. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive
marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience changes in regulatory requirements or guidance, or receive feedback from regulatory authorities
that requires us to modify the design of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or
regulators may require us, to conduct additional clinical trials or abandon development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations
to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our investigators might have to suspend or terminate clinical trials of our product candidates for various
reasons, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a finding that the participants are
being exposed to unacceptable health risks; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate and we may not have funds
to cover the costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators may revise the requirements for approving our product candidates, or such requirements may not be as
we anticipate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical
trials in ways they view as advantageous to them but that are suboptimal for us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to conduct
additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or
tests are not positive or are only modestly positive or if there are safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur unplanned costs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval in some countries and not in others; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety
warnings, including boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being
conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA, EMA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the
clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen
safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. For example, our IND for <FONT
STYLE="white-space:nowrap">AAV-RPE65</FONT> was filed in July 2017. On August&nbsp;16, 2017, we received notification from the FDA supporting the use of the described batches of product candidate in the Phase 1/2 clinical trial. However, we received
a recommendation from the FDA on a certain aspect of the manufacturing process for future clinical trials, thus putting our IND for <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> on partial clinical hold. We responded to the FDA on
October&nbsp;2, 2017 and, based on this response, the partial clinical hold was lifted on October&nbsp;17, 2017. As another example, our IND for <FONT STYLE="white-space:nowrap">AAV-CNGB3</FONT> was filed on October&nbsp;31, 2017. We received a
question from the FDA around our injection device compatibility assay, thus putting our <FONT STYLE="white-space:nowrap">AAV-CNGB3</FONT> IND on clinical hold. In the device compatibility assay, the FDA noted a disparity between the target titer for
the intended low dose dilution and the actual titer obtained on polymerase chain reaction, or PCR, analysis. The FDA requested clarification on whether this was an imprecise dilution scheme for the low dose or a PCR assay issue. We submitted our
second response to the FDA on May&nbsp;2, 2018 providing data that identified the issue as a PCR assay artifact and also showing data that we believe supports that this has now been addressed. On May&nbsp;31, 2018 the FDA released the clinical hold
on our IND for <FONT STYLE="white-space:nowrap">AAV-CNGB3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most advanced product candidates,
<FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and
<FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT> will require extensive clinical testing before we are prepared to submit a BLA or MAA for regulatory approval. We cannot predict with any certainty if or when we might complete the clinical
development for our product candidates and submit a BLA or MAA for regulatory approval of any of our product candidates or whether any such BLA or MAA will be approved. We may also seek feedback from the FDA, EMA or other regulatory authorities on
our clinical development program, and the FDA, EMA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we experience delays in the commencement or completion of our clinical trials, or if we
terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate revenues from our product candidates may be delayed. In addition, any delays in our clinical trials could
increase our costs, slow down the development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and results of operations. In
addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The affected populations for our other product candidates may be smaller than we or third parties currently project, which may affect the addressable
markets for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our projections of the number of people who have the diseases we are seeking to treat, as well
as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are estimates based on our knowledge and understanding of these diseases. The total addressable market opportunity for our
product candidates will ultimately depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and
product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used
in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included, or supporting the information, in
this Quarterly Report on Form 10-Q should be viewed with caution. Further, the data and statistical information included, or supporting the information, in this Quarterly Report on Form 10-Q including estimates derived from them, may differ from
information and estimates made by our competitors or from current or future studies conducted by independent sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of such
data involves risks and uncertainties and is subject to change based on various factors. Our estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of the diseases we seek to address. The number of
patients with the diseases we are targeting in the United States, the European Union and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly
difficult to identify or access, all of which would harm our results of operations and our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion of gene therapy and
increased regulatory scrutiny of gene therapy and genetic research may adversely impact public perception of our current and future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our potential therapeutic products involve introducing genetic material into patient&#146;s cells. The clinical and commercial success of our
potential products will depend in part on public acceptance of the use of gene therapy and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene therapy and gene regulation are
unsafe, unethical, or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend
upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which
greater clinical data may be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More restrictive government regulations or negative public opinion would have a negative effect
on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. For example, in 2003, trials using early versions of murine gamma-retroviral
vectors, which integrate with, and thereby alter, the host cell&#146;s DNA, have led to several well-publicized adverse events, including reported cases of leukemia. Although none of our current product candidates utilize murine gamma-retroviral
vectors, our product candidates use a viral delivery system. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation,
unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.
The risk of cancer remains a concern for gene therapy and we cannot assure that it will not occur in any of our planned or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy
products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material. If any such adverse events occur, commercialization of our product candidates or further advancement of our
clinical trials could be halted or delayed, which would have a negative impact on our business and operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even though we have been granted access to the PRIME scheme by the EMA for <FONT
STYLE="white-space:nowrap">AAV-CNGB3</FONT> and the FDA granted Fast Track designation to <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> in the future we may seek and fail to obtain access to the PRIME scheme by the EMA or fast track designation
by the FDA for other of our current or potential future product candidates. We may also seek and fail to obtain breakthrough therapy designation from the FDA for our current or any future product candidates. Such designations or access may also not
lead to faster development or regulatory review or approval, and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of new drugs and
biological products that meet certain criteria. For example, the FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new drugs and biological
products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs, or if the drug has been designated as a qualified
infectious disease product. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. Under Fast Track, the FDA may consider for review sections of the BLA on a rolling basis before
the complete application is submitted if relevant criteria are satisfied, including an agreement with FDA on the proposed schedule for the submission of portions of the BLA, and the payment of applicable user fees before FDA may initiate a review.
Even if Fast Track designation is granted, it may be rescinded if the product no longer meets the qualifying criteria. In April 2018, <FONT STYLE="white-space:nowrap">AAV-RPGR</FONT> was designated a Fast Track program by the FDA for the treatment
of <FONT STYLE="white-space:nowrap">X-linked</FONT> retinitis pigmentosa owing to defects in RPGR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, the Food and Drug
Administration Safety and Innovation Act, or FDASIA, established the breakthrough therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in
combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies
on one or more clinically-significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request that FDA designate a product candidate as a breakthrough therapy at the time of or any time after the
submission of an IND, but ideally before an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> II meeting with FDA. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite
the development and review of the application, which may include but are not limited to holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with,
the sponsor regarding the development of the product candidate to ensure collection of appropriate data needed to support approval; more frequent written correspondence from the FDA about such things as the design of the proposed clinical trials and
use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational commitment involving senior managers; and eligibility for rolling review and priority review. Breakthrough therapy
designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed
schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. Fast Track designation, priority review and breakthrough therapy designation do not change the standards for
approval but may expedite the development or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, the EMA has established the PRIME scheme to expedite the
development and review of product candidates that show a potential to address to a significant extent an unmet medical need, based on early clinical data. In February 2018, <FONT STYLE="white-space:nowrap">AAV-CNGB3</FONT> in the treatment of
achromatopsia associated with defects in CNGB3 was admitted to the PRIME scheme of the EMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast Track designation and designation as a
breakthrough therapy are within the discretion of the FDA. Accordingly, even if we believe one of our other product candidates meets the criteria for Fast Track designation or designation as a breakthrough therapy and we seek such designation, the
FDA may disagree and instead determine not to make such designation for such product candidate. We cannot be sure that our evaluation of our product candidates as qualifying for Fast Track designation or breakthrough therapy designation will meet
the FDA&#146;s expectations. In any event, the receipt of a Fast Track designation or breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared to product candidates
considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if additional product candidates are granted Fast Track designation or one or more of our product candidates qualify as
breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Similarly, access to the PRIME scheme is
at the discretion of the EMA, and we cannot be sure that any additional current or future product candidates will be granted access to the scheme; that participation in the scheme will result in expedited regulatory review or approval of our product
candidates; or that access to the scheme, once granted, will not be revoked. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have received orphan drug designation from the FDA and EMA for
<FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-AIPL1</FONT> and FDA for
<FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> and may seek orphan drug designation for additional product candidates in the future, but any orphan drug designations we have received or may receive in the future may not confer marketing
exclusivity or other expected benefits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is
intended to treat a rare disease or condition, defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation
that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are
intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the
diagnosis, prevention, or treatment of a life-threatening, seriously debilitating, or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary
investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax credits for qualified clinical testing, and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product receives the first FDA approval of that drug for the indication for which it has orphan
designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a
showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the rare disease or condition.
Under the FDA&#146;s regulations, the FDA will deny orphan drug exclusivity to a designated drug upon approval if the FDA has already approved another drug with the same active ingredient for the same indication, unless the drug is demonstrated to
be clinically superior to the previously approved drug. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following approval for the
approved therapeutic indication. This period may be reduced to six years if, at the end of the fifth year, the orphan drug designation criteria are no longer met, including where it is shown that the drug is sufficiently profitable not to justify
maintenance of market exclusivity. In the European Union, a marketing authorization for an orphan designated product will not be granted if a similar drug has been approved in the European Union for the same therapeutic indication, unless the
applicant can establish that its product is safer, more effective or otherwise clinically superior. A similar drug is a product containing a similar active substance or substances as those contained in an already authorized product. Similar active
substance is defined as an identical active substance, or an active substance with the same principal molecular structural features (but not necessarily all of the same molecular features) and which acts via the same mechanism. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained orphan drug designation from the FDA and European Commission for <FONT STYLE="white-space:nowrap">AAV-CNGB3</FONT> for the
treatment of achromatopsia caused by mutations in the <I>CNGB3</I> gene, <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> for the treatment of Leber congenital amaurosis, <FONT STYLE="white-space:nowrap">AAV-RPGR</FONT> for the treatment of
retinitis pigmentosa and <FONT STYLE="white-space:nowrap">AAV-AIPL1</FONT> for the treatment of inherited retina dystrophy due to defects in <I>AIPL1</I> gene, and we obtained orphan drug designation from the FDA for
<FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> for the treatment of grade 2 and grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy. We plan to seek orphan drug designation for other current and future product
candidates. Even with orphan drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products, which could prevent us from
marketing our product candidates if another company is able to obtain orphan drug exclusivity before we do. In addition, exclusive marketing rights in the United States may be unavailable if we seek approval for an indication broader than the
orphan-designated indication or may be lost in the United States if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the drug to meet the needs of patients with
the rare disease or condition following approval. Further, even if we obtain orphan drug exclusivity, that exclusivity may not effectively protect our product candidates from competition because different drugs with different active moieties can be
approved for the same condition. In addition, the FDA and the EMA can subsequently approve products with the same active moiety for the same condition if the FDA or the EMA concludes that the later drug is safer, more effective, or makes a major
contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek
orphan drug designation for other existing and future product candidates, we may never receive such designations. There have been legal challenges to aspects of the FDA&#146;s regulations and policies concerning the exclusivity provisions of the
Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to predict. In 2014, a U.S. district court invalidated the FDA&#146;s denial of orphan exclusivity to
an orphan designated drug, which the FDA had based on its determination that the drug was not proven to be clinically superior to a previously approved &#147;same drug.&#148; In response to the decision, the FDA released a policy statement stating
that the court&#146;s decision is limited to the facts of that particular case and that the FDA will continue to deny orphan drug exclusivity to a designated drug upon approval if the drug is the &#147;same&#148; as a previously approved drug,
unless the drug is demonstrated to be clinically superior to that previously approved drug. Since then, similar legal challenges have been initiated against the FDA for its denial of orphan drug exclusivity to other designated drugs, and in 2017,
Congress amended the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Orphan Drug Act to require a demonstration of clinical superiority upon approval as a condition of receiving orphan drug exclusivity when another &#147;same drug&#148; has already been approved
for the same indication. In the future, there is the potential for additional legal challenges to the FDA&#146;s orphan drug regulations and policies, and it is uncertain how ongoing and future challenges might affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and our contract manufacturer for plasmid are subject to significant regulation with respect to manufacturing our products. Our manufacturing
facilities and the third-party manufacturing facility which we rely on may not continue to meet regulatory requirements and have limited capacity. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have relationships with a limited number of suppliers for the manufacturing of plasmid, a component of our viral vectors and
product candidates. We completed the <FONT STYLE="white-space:nowrap">fit-out</FONT> of our cGMP manufacturing facility in early 2018. However, if we experience slowdowns or problems with our facility and are unable to establish or scale our
internal manufacturing capabilities, we will need to continue to contract with manufacturers that can produce the preclinical, clinical and commercial supply of our products. Each supplier may require licenses to manufacture such components if such
processes are not owned by the supplier or in the public domain and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers
for components our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials in the European Union must be manufactured in accordance with
cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale.
Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.
We or our contract manufacturers must supply all necessary documentation in support of a BLA or MAA on a timely basis. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass
a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory
authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the
activities being conducted. If these facilities do not pass a <FONT STYLE="white-space:nowrap">pre-approval</FONT> plant inspection, FDA approval of the products will not be granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our
third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or
the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the
temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could harm our business. If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA
can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a <FONT STYLE="white-space:nowrap">pre-existing</FONT> approval. As a result, our
business, financial condition and results of operations may be harmed. Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be
qualified through a BLA and/or MAA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve
substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors could cause the
delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to
meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any contamination in our manufacturing process, shortages of raw materials or failure of our plasmid supplier to deliver necessary components could
result in delays in our clinical development or marketing schedules. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the nature of biologics manufacturing, there is a risk
of contamination. Any contamination could adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials required in our
manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived
substances in the manufacture of our product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial
condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical development
activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their
protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The natural history studies may fail to provide us with patients for our clinical trials because patients
enrolled in the natural history studies may not be good candidates for our clinical trials, or may choose to not enroll in our clinical trials. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete
any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. The enrollment of patients depends on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to study sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate being
studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same
therapeutic areas as our product candidates or approved products for the same clinical indications, and this competition may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials
may instead opt to enroll in a trial being conducted by one of our competitors, or chose to be treated using Luxturna, a commercially available product by Spark Therapeutics, Inc. Since the number of qualified clinical investigators is limited, we
expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which may reduce the number of patients who are available for our clinical trials in such clinical trial site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a
harmful effect on our ability to develop our product candidates, or could render further development impossible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause
serious adverse events or undesirable side effects or have other properties which may delay or prevent their regulatory approval, limit the commercial profile of an approved label, or, result in significant negative consequences following marketing
approval, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Serious adverse events or undesirable side effects caused by our product candidates could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other authorities. Results of our clinical trials could reveal a high and
unacceptable severity and prevalence of side effects, toxicities or unexpected characteristics, including death. A risk in any gene therapy product based on viral vectors is the risk of insertional oncogenesis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If unacceptable side effects or deaths arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which
our studies are conducted, DSMB, EMA or CAT could suspend or terminate our clinical trials or the FDA, EMA or other regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted
indications. Undesirable side effects or deaths in clinical trials with our product candidates may cause the FDA or comparable foreign regulatory authorities to place a clinical hold on the associated clinical trials, to require additional studies,
or otherwise to delay or deny </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the
trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to
understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient
injury or death. Any of these occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product
candidates receives marketing approval, and we or others later identify undesirable side effects caused by any such product, including during any long-term <FONT STYLE="white-space:nowrap">follow-up</FONT> observation period recommended or required
for patients who receive treatment using our products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes
for the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or
contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide
outlining the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product could become less competitive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients;&nbsp;and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Success in preclinical studies or clinical trials may not be indicative
of results in future clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from previous preclinical studies or clinical trials are not necessarily predictive
of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in
preclinical studies or having successfully advanced through initial clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Success in preclinical testing and early clinical
trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Frequently, product candidates that have shown promising results in
early clinical trials have subsequently suffered significant setbacks in later clinical trials. In addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical
trial may not become apparent until the clinical trial is well advanced. We have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for
drugs and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical
testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or
rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and
prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, EMA and other regulatory authorities are lengthy, time
consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA, EMA and other regulatory authorities is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain
approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our product candidates in
clinical programs or any other product candidates we may seek to develop in the future will ever obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States or the
European Union until we receive regulatory approval of a BLA from the FDA or a MAA from the EMA, respectively. It is possible that the FDA may refuse to accept for substantive review any biologic license applications, or BLAs, or the EMA any of our
MAAs, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product candidate in the United States, the European Union or elsewhere, we or our
collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses.
Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA,
EMA or other regulatory authorities. The FDA or EMA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical
development program. Depending on the extent of these or any other FDA or EMA required studies, approval of any regulatory approval applications that we submit may be delayed by several years, or may require us to expend significantly more resources
than we have available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of potential products in development, only a small percentage successfully complete the FDA,
EMA or other foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product
candidates, which would significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA or EMA approval for <FONT
STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> or <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT>
in the United States or European Union, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements
on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy. Approval by the FDA in the United States or the EMA in the European Union does not ensure approval by
regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be
accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review
periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from
country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in
obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our
target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive
regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with
regulatory requirements or experience unanticipated problems with our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate for which we
obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such
product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA, EMA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding
maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and EMA closely regulate the post-approval marketing and promotion of genetic therapy medicines to ensure they are marketed only for
the approved indications and in accordance with the provisions of the approved labeling. The FDA and EMA imposes stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use and if we
market our products for uses beyond their approved indications, we may be subject to enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing. Violations of the U.S. federal Food, Drug, and Cosmetic Act, or FDCA, relating
to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing
processes, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on manufacturing such products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of marketing approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation and
contains provisions applicable to the development of gene therapies, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained which would adversely affect our business, prospects and ability to achieve or sustain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or
executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of
a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of
guidance, and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these
executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our
clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> or preliminary data from our clinical
trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or <FONT
STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications
that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and
managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later
prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights
to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Healthcare Laws and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product
candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the European Union and other jurisdictions, there have
been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a
number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the
pharmaceutical and biotechnology industries include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, <FONT STYLE="white-space:nowrap">non-deductible</FONT> fee payable by any entity that manufactures or
imports certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report certain financial arrangements with physicians and teaching hospitals, including
reporting &#147;transfers of value&#148; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a licensure framework for follow on biologic products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or
CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain
aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Most recently, the Tax Cuts and Jobs Act of 2017 was enacted, which includes a provision repealing, effective January&nbsp;1, 2019, the <FONT
STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual
mandate&#148;. The current Trump administration and Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. It is uncertain the extent to which any such changes may impact our business
or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was
enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments to the statute will remain in effect through 2027 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments
to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws or any
other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop
new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S.
Congressional inquiries and proposed and enacted federal legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and
manufacturer patient programs. The Trump administration&#146;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for
example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for <FONT
STYLE="white-space:nowrap">low-income</FONT> patients. Additionally, on May&nbsp;11, 2018, President Trump laid out his administration&#146;s &#147;Blueprint&#148; to reduce the cost of prescription drugs while preserving innovation and cures. The
Department of Health and Human Services, or HHS, has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others under its existing authority. Although some of these, and
other, proposals will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug
costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in
reduced demand for our product candidates or additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly
passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business,
results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included
in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product
candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our
operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union,
law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary
constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to
develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In markets outside of the United States and the European Union, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States, the European Union or any other jurisdiction. If we or any third parties we may engage are
slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that
may have been obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and current and future relationships with
investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our
operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the
referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and
Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False
Claims Act, which prohibit, among other things, , including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval
that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay
money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the
False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional
federal criminal statutes which prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its
implementing regulations, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization
by covered entities subject to the rule, such as certain health plans, healthcare clearinghouses and healthcare providers as well as their business associates, independent contractors of a covered entity that perform certain services involving the
use or disclosure of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate
commerce of a biological product unless a biologics license is in effect for that product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers
of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments
and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply
to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that
require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to
healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of
value provided to healthcare professionals and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting
requirements detailing interactions with and payments to healthcare providers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations
and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with
current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other
governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and
Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> disgorgement, individual imprisonment, contractual
damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws,
they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions
can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection
with environmental compliance or remediation activities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, including our development, testing and manufacturing
activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous
materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail
to comply with such laws and regulations, we could be subject to fines or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As with other companies engaged in activities
similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and
regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our
development efforts may be interrupted or delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to our international operations, we are subject to anti-corruption laws, as well as export
control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act; the U.S. Foreign Corrupt Practices
Act, or FCPA; and other anti-corruption laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA, and these other laws generally prohibit us, our officers and our employees and intermediaries from
bribing, being bribed by, or providing prohibited payments or anything else of value to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose
a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA, or local anti-corruption
laws. In addition, we cannot predict the nature, scope, or effect of future regulatory requirements to which any of our international operations might be subject or the manner in which existing laws might be administered or interpreted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also are subject to other laws and regulations governing any international operations,
including regulations administered by the governments of the United Kingdom and the United States, and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and
currency exchange regulations, or, collectively, the Trade Control laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that we will be completely effective in
ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA, or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA, and other anti-corruption
laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement, and other sanctions and remedial measures and legal expenses. Any investigation of any potential violations of the Bribery Act, the FCPA, other
anti-corruption laws, or Trade Control laws by U.K., U.S., or other authorities, even if it is ultimately determined that we did not violate such laws, could be costly and time-consuming, require significant personnel resources, and harm our
reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will seek to build and continuously improve our systems of internal controls and to remedy any weaknesses identified.
There can be no assurance, however, that the policies and procedures will be followed at all times or effectively detect and prevent violations of the applicable laws by one or more of our employees, consultants, agents, or collaborators and, as a
result, we could be subject to fines, penalties, or prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory
approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new gene therapy products is highly competitive. Moreover, the gene regulation and manufacturing
fields are characterized by rapidly changing technologies, significant competition, and a strong emphasis on intellectual property. We will face competition with respect to any product candidates that we may seek to develop or commercialize in the
future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations
that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development
of products for the treatment of the disease indications for which we have research programs, including inherited retinal diseases and neurodegenerative diseases. Some of these competitive products and therapies are based on scientific approaches
that are similar to our approach, and others are based on entirely different approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platform and products focus on the
development of gene therapies and gene regulation technology. There are a number of companies developing gene therapy products include Applied Genetic Technologies Corporation, Nightstar Therapeutics plc and Spark Therapeutics, Inc. In addition to
competition from other gene therapies, any products we may develop may also face competition from other types of therapies, such as small molecule, antibody, protein or other therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our current or potential competitors, either alone or with their collaboration partners, have greater financial resources and
expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, and
gene therapy industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in
acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side
effects, are more convenient, or are less expensive than any products that we may develop or that would render any products that we may develop obsolete or <FONT STYLE="white-space:nowrap">non-competitive.</FONT> Our competitors also may obtain FDA,
EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies
developed by our competitors may render our potential product candidates uneconomic or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a result of the expiration or successful challenge of our patent rights, we
could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#146; products. The availability of our competitors&#146; products could limit the demand, and the price we are able to charge, for any
products that we may develop and commercialize. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates will depend in part on the extent to
which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our
ability to market those products and decrease our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability of coverage and adequacy of
reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford medical services and pharmaceutical products such as our
product candidates, assuming FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by governmental authorities, private health insurers and other organizations will
have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered
under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our
products or procedures using our products, could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates or procedures using our product candidates by a third-party payor, the resulting
reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or
elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may
refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as
substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the
amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an
appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates, and may not be able to obtain a
satisfactory financial return on our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and
reimbursement of newly-approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and
biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some
third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time
what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No uniform policy for
coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a
time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently
or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market
regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical
products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or
other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the
United States and may be insufficient to generate commercially-reasonable revenue and profits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party payors in the United States and
abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We
expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward
pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or
others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates receive marketing approval, they may
nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant product revenues or become
profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of treatment in relation to alternative treatments, including any similar generic treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, EMA or other regulatory authorities, including any
limitations or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our product together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenues for a substantial
period, the failure of this product to find market acceptance would harm our business and could require us to seek additional financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are
unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates or realizing the synergies in the target indications of
our programs, even if they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any infrastructure for the sales, marketing or distribution of our
products, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. We expect to build a focused sales, distribution and marketing infrastructure to market our product candidates in the United
States and European Union, if approved. There are significant expenses and risks involved with establishing our own sales, marketing and distribution capabilities, including our ability to hire, retain and appropriately incentivize qualified
individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities could delay any product launch, which would adversely impact the commercialization of our product candidates. Additionally, if the commercial launch of our product candidates for which we recruit a sales force
and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or
reposition our sales and marketing personnel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not have the resources in the foreseeable future to allocate to the sales and
marketing of our product candidates in certain international markets. Therefore, our future sales in these markets will largely depend on our ability to enter into and maintain collaborative relationships for such capabilities, the
collaborator&#146;s strategic interest in the product and such collaborator&#146;s ability to successfully market and sell the product. We may pursue collaborative arrangements regarding the sale and marketing of
<FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and
<FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT> if approved, for certain markets overseas; however, we cannot assure that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective
sales forces. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of <FONT
STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1,</FONT>
we may be forced to delay the potential commercialization of <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT>
<FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> or reduce the scope of our sales or marketing activities for <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT>
<FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1.</FONT> If we elect to increase our expenditures to
fund commercialization activities internationally, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We could enter into arrangements with collaborative partners at an earlier stage than
otherwise would be ideal and we may be required to relinquish rights to <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT
STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some indications targeted by our ophthalmology programs are rare, but we anticipate realizing synergies in commercializing of our IRD product
candidates, should they be approved. Failure to realize synergies in our sales, marketing and distribution efforts may harm our commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, either on our own or in collaboration with third
parties, we will not be successful in commercializing <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT>
<FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> and may not become profitable and may incur significant additional losses. We will be competing with many companies that currently have extensive
and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we obtain approval to commercialize any products outside of the United States or the European Union, a variety of risks associated with international
operations could adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">AAV-CNGB3,</FONT> <FONT
STYLE="white-space:nowrap">AAV-CNGA3,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPGR,</FONT> <FONT STYLE="white-space:nowrap">AAV-RPE65</FONT> and <FONT STYLE="white-space:nowrap">AAV-AQP1</FONT> are approved for commercialization, we intend to
enter into agreements with third parties to market them in certain jurisdictions outside the United States and the European Union. We expect that we will be subject to additional risks related to international pharmaceutical operations, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for drug and biologic approvals and rules governing drug and biologic
commercialization in foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters
including earthquakes, typhoons, floods and fires, or from economic or political instability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">greater difficulty with enforcing our contracts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential noncompliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar
anti-bribery and anticorruption laws in other jurisdictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax,
labor and other legal requirements imposed by individual countries in Europe with which we will need to comply. If we are unable to successfully manage the challenges of international expansion and operations, our business and operating results
could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an
abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may
not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which
the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the
competing product containing the sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is
complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted
by the FDA, any such processes could have an adverse effect on the future commercial prospects for our biological products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a
risk that any of our product candidates approved as a biological product under a BLA would not qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity or that this exclusivity could be shortened due to congressional
action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of
which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to
traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our recently completed cGMP manufacturing facility is unable to supply our product candidates for all of our current preclinical, clinical and
potential commercial needs, we will be forced to seek out third-party manufacturers. We currently contract with third parties for the manufacture of plasmid used in producing our product candidates. Relying on third parties increases the risk that
we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our
development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have begun producing our product candidates in our facility. However, if our facility
is damaged, suffers any form of delay or regulatory challenges, or we are unable to scale our internal manufacturing capabilities to meet demand for our product candidates, we will need to contract with third-party manufacturers to produce our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on third-party manufacturers for the manufacture of plasmid used in the production of our product
candidates. We do not have a long-term supply agreement with any of the third-party manufacturers, and we purchase our required supply on a purchase order basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish
agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and
related reporting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers may not be able to comply with cGMP regulations or similar
regulatory requirements that might be required by the FDA or EMA. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil
penalties, delays, suspension or withdrawal of approvals, license revocations, seizures or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could adversely affect supplies of our candidates
and harm our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any therapies that we may develop may compete with
other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of
our existing or future manufacturers could delay clinical development or marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future
dependence upon others for the manufacture of any product candidates we may develop or any components required for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product
candidates that receive marketing approval on a timely and competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may collaborate with third parties for the development and
commercialization of our product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our product candidates successfully, if at all.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek collaborative relationships for the development and commercialization of our product candidates. Failure to obtain a
collaborative relationship for our product candidates may significantly impair their commercial potential. We also may need to enter into collaborative relationships to provide funding to support our other research and development programs. The
process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may shift its priorities and resources away from our product candidates due to a change
in business strategies, or a merger, acquisition, sale or downsizing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory
clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic
collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may not devote sufficient capital or resources towards our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may change the success criteria for a product candidate thereby delaying or ceasing
development of such candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a significant delay in initiation of certain development activities by a collaboration partner will also delay
payment of milestones tied to such activities, thereby impacting our ability to fund our own activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner could develop a product that competes, either directly or indirectly, with our product
candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources
to the marketing, distribution or sale of a product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality issues
and be unable to meet demand requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaboration partner may terminate a strategic alliance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a dispute may arise between us and a partner concerning the research, development or commercialization of a
product candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation or arbitration which may divert management attention and resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a partner may use our products or technology in such a way as to make us subject to litigation with a third
party. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our research, clinical
development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility
of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition terminated collaborative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense or find
alternative sources of capital. Moreover, any collaborative partners we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate or terminate their relationships with
us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on proprietary technology licensed from others. If we lose our existing licenses or are unable to acquire or license additional proprietary
rights from third parties, we may not be able to continue developing our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently <FONT
STYLE="white-space:nowrap">in-license</FONT> certain intellectual property from UCL Business, Plc, or UCLB, and Brandeis University, or Brandeis. We are a party to agreements with UCL for certain technology and AAV vector-related patents and with
Brandeis for certain preclinical technology for the treatment of ALS, and we may enter into additional agreements, including license agreements, with other parties in the future that impose diligence, development and commercialization timelines,
milestone payments, royalties, insurance and other obligations on us. For example, in exchange for the rights granted to us by UCL, we are obligated to pay an annual management fee, milestone payments for certain commercial sales thresholds, and a
certain percentages of proceeds on sublicensing revenues. If we fail to comply with our obligations to UCL, Brandeis, or any of our other collaborators, our counterparties may have the right to terminate these agreements, in which event we might not
be able to develop, manufacture or market any product candidate that is covered by these agreements, which could adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or
reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important
intellectual property or technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely on other third parties from whom we license proprietary technology to file and prosecute
patent applications and maintain patents and otherwise protect the intellectual property we license from them. We may have limited control over these activities or any other intellectual property that may be related to our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. For example, we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will result in valid and
enforceable patents and other intellectual property rights. We may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain
of the intellectual property that may be licensed to us. It is possible that the licensors&#146; infringement proceeding or defense activities may be less vigorous than if we conduct them ourselves. The licensing and acquisition of third-party
intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may
consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization
capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.
Furthermore, we may be unable to <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes, or other third-party intellectual property rights from third parties, which we identify as necessary for our product
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent protection for our technology and product candidates or if the scope of the patent
protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a
combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our proprietary technologies, product candidate development programs and product candidates. Our success depends in large
part on our ability to secure and maintain patent protection in the United States and other countries with respect to our current product candidates and any future product candidates we may develop. We seek to protect our proprietary position by
filing or collaborating with our licensors to file patent applications in the United States and abroad related to our proprietary technologies, development programs and product candidates. The patent prosecution process is expensive and
time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Moreover, the issuance, scope, validity, enforceability and commercial value of our patent rights
are highly uncertain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that we will fail to identify patentable aspects of our research and development output before
it is too late to obtain patent protection. We may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and patent
applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with
claims that cover our proprietary products and technology, including current product candidates, any future product candidates we may develop, and our gene regulation technology in the United States or in other foreign countries, in whole or in
part. Alternately, our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. There is no assurance that all potentially
relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or later invalidate or narrow the scope of an issued patent. For example, publications of
discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore,
we cannot know with certainty whether we were the first to make the inventions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Even if patents do successfully issue and even if such patents
cover our current product candidates, any future product candidates we may develop and our gene regulation technology, third parties may challenge their validity, enforceability or scope thereof, which may result in such patents being narrowed,
invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any of our product candidates or gene
regulation technology. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Further, if we encounter delays in regulatory
approvals, the period of time during which we could market a product candidate and our gene regulation technology under patent protection could be reduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or have <FONT STYLE="white-space:nowrap">in-licensed</FONT> with respect to our development programs and
product candidates fail to issue, if their validity, breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for any of our current or future product candidates or technology, it could dissuade companies
from collaborating with us to develop product candidates, encourage competitors to develop competing products or technologies and threaten our ability to commercialize future product candidates. Any such outcome could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies is highly uncertain, involves complex legal and factual questions, and is
characterized by the existence of large numbers of patents and frequent litigation based on allegations of patent or other intellectual property infringement or violation. In addition, the laws of jurisdictions outside the United States may not
protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Changes in either the patent laws or
interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Since patent applications in the United States and other jurisdictions are confidential
for a period of time after filing, we cannot be certain that we were the first to file for patents covering our inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain.
Our pending and future patent applications may not result in the issuance of patents, or may result in the issuance of patents which fail to protect our technology or products, in whole or in part, or which fail to effectively prevent others from
commercializing competitive technologies and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity
or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and
products. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage.
Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is
limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third parties may assert claims against us alleging infringement of their patents and
proprietary rights, or we may need to become involved in lawsuits to defend or enforce our patents, either of which could result in substantial costs or loss of productivity, delay or prevent the development and commercialization of our product
candidates, prohibit our use of proprietary technology or sale of products or put our patents and other proprietary rights at risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or
actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate
patents or other intellectual property rights owned or controlled by third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is
common, including patent infringement lawsuits, interferences, oppositions and <I>inter partes </I>reviews, and reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO, and corresponding foreign patent offices. The various
markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and
pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist
in the fields in which we are developing product candidates, and as the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the
intellectual property rights of third parties. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time
than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to third-party claims including infringement, interference or derivation
proceedings, post-grant review and inter partes review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if such claims are without merit, a court of competent jurisdiction could hold that these
third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such
patents expire or are finally determined to be invalid or unenforceable. There may be third-party patents or patent applications with claims to compositions, formulations, or methods of treatment, prevention use, or manufacture of our product
candidates or technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties
may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, or methods of
treatment, prevention or use, the holders of any such patents may be able to prohibit our use of those compositions, formulations, methods of treatment, prevention or use or other technologies, effectively blocking our ability to develop and
commercialize the applicable product candidate until such patent expires or is finally determined to be invalid or unenforceable or unless we obtained a license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages
if we are found to be infringing a third party&#146;s patent rights. These damages potentially include increased damages (possibly treble damages) and attorneys&#146; fees if we are found to have infringed such rights willfully. Further, if a patent
infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. As a result
of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require payment of substantial royalties or fees, or require us to grant a
cross-license under our intellectual property rights. These licenses may not be available on reasonable terms or at all. Even if a license can be obtained on reasonable terms, the rights may be nonexclusive, which would give our competitors access
to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, or forced to modify such product candidates, or to cease some
aspect of our business operations, which could harm our business significantly. We might also be forced to redesign or modify our product candidates so that we no longer infringe the third-party intellectual property rights, which may result in
significant cost or delay to us, or which redesign or modification could be impossible or technically infeasible. Even if we were ultimately to prevail, any of these events could require us to divert substantial financial and management resources
that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> is threatened, it could
dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may
infringe our patents or other intellectual property. If we or one of our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent
is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of
several statutory requirements, for example, lack of novelty, obviousness lack of written description, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Third parties might allege unenforceability of our patents because during prosecution
of the patent an individual connected with such prosecution withheld relevant information, or made a misleading statement. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to
determine the priority of inventions with respect to our patents or patent applications. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of
patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution, but that an adverse third party may identify and submit in support of such assertions of
invalidity. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Our patents and other intellectual property rights
also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a
risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, and if
securities analysts or investors view these announcements in a negative light, the price of our ordinary shares could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources
available for development activities. We may not have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more
effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the
marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party
patent, which might adversely affect our ability to develop, manufacture and market our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee
that any of our or our licensors&#146; patent searches or analyses, including but not limited to the identification of relevant patents, analysis of the scope of relevant patent claims or determination of the expiration of relevant patents, are
complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. For example, in the United States, applications filed before November&nbsp;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents
issue. Patent applications in the United States, the European Union and elsewhere are published approximately 18&nbsp;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the
priority date. Therefore, patent applications covering our product candidates could be filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in
a manner that could cover our product candidates or the use of our product candidates. After issuance, the scope of patent claims remains subject to construction as determined by an interpretation of the law, the written disclosure in a patent and
the patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine
that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the
United States, the European Union or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may
negatively impact our ability to develop and market our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to correctly identify or interpret relevant
patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we
may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates in a manner that no longer infringes third-party intellectual property rights. Any of
these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property,
particularly patents. Obtaining and enforcing patents in the biotechnology and genetic medicine industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biotechnology and genetic medicine patents is
costly, time-consuming and inherently uncertain. In addition, the Leahy-Smith America Invents Act, or the AIA, which was passed in September&nbsp;2011, resulted in significant changes to the U.S. patent system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned from a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party
should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system,
assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party
that files&nbsp;a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be
cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&nbsp;a patent infringement suit and
providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to
the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be
insufficient to invalidate the claim if first presented in a district court action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent
claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its
implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#146; patent applications and the enforcement or defense of our or our licensors&#146; issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, inter partes review or other proceedings challenging our or our
licensors&#146; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection
available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to
our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations
governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively
stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new
patents in the future that may be important for our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various
procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO, European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO, European and other patent agencies over the lifetime of a patent. While an inadvertent
failure to make payment of such fees or to comply with such provisions can in many cases be cured by additional payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with such provisions will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. <FONT
STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits,
<FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product
candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, it can create opportunities for competitors to enter the market, which would hurt our competitive position and could impair our ability
to successfully commercialize our product candidates in any indication for which they are approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enjoy only limited geographical protection
with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing,
prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than
those in the United States. <FONT STYLE="white-space:nowrap">In-licensing</FONT> patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And <FONT
STYLE="white-space:nowrap">in-licensing</FONT> or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may
use our and our licensors&#146; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our
licensors have patent protection, but enforcement is not as strong as that in the United States or the European Union. These products may compete with our product candidates, and our or our licensors&#146; patents or other intellectual property
rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may decide to abandon national and regional
patent applications while they are still pending. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications may be rejected by the relevant patent office, while
substantively similar applications are granted by others. For example, relative to other countries, China has a heightened requirement for patentability and specifically requires a detailed description of medical uses of a claimed drug. Furthermore,
generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#146; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings.
Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions do not protect intellectual property rights to the same
extent as the laws or regulations in the United States and the European Union, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain
countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing
competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from
other aspects of our business, and additionally could put at risk our or our licensors&#146; patents of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#146; patent applications not issuing, or could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other
remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property
that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we
may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates
in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such
jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent
owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented
from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may
be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of any
individual patent depends on applicable law in the country where the patent is granted. In the United States, provided all maintenance fees are timely paid, a patent generally has a term of 20&nbsp;years from its application filing date or earliest
claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Extensions may be available under certain circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors
obtain patents covering our product candidates, when the terms of all patents covering a product expire, our business may become subject to competition from competitive medications, including generic medications. Given the amount of time required
for the development, testing and regulatory review and approval of new product candidates, patents protecting such candidates may expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio
may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent
term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may be eligible for a term
extension designed to restore the period of the patent term that is lost during the premarket regulatory review process conducted by the FDA. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one
or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, which permits a patent term extension of up to five years for a patent
covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. In the European Union, our product candidates may be eligible for term extensions based on similar
legislation. In either jurisdiction, however, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Even if we are
granted such extension, the duration of such extension may be less than our request. If we are unable to obtain a patent term extension, or if the term of any such extension is less than our request, the period during which we can enforce our patent
rights for that product will be in effect shortened and our competitors may obtain approval to market competing products sooner. The resulting reduction of years of revenue from applicable products could be substantial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our proprietary rights may not adequately protect our technologies and product candidates, and do not
necessarily address all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our
intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are the same as or similar to our product candidates but that are not
covered by the claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others, including inventors or developers of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT>
patented technologies who may become involved with competitors, may independently develop similar technologies that function as alternatives or replacements for any of our technologies without infringing our intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or our other collaboration partners might not have been the first to conceive and reduce to
practice the inventions covered by the patents or patent applications that we own, license or will own or license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or our other collaboration partners might not have been the first to file patent applications
covering certain of the patents or patent applications that we or they own or have obtained a license, or will own or will have obtained a license; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors may fail to meet obligations to the U.S. government with respect to <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not result in issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#146; patents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or exclusively license may not provide us with any competitive advantage, or may be
held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent
rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ownership, validity or enforceability of our or our licensors&#146; patents or patent applications may be
challenged by third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse
effect on our business. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties may require us to share our trade secrets, which increases the possibility
that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consider proprietary trade secrets, confidential <FONT STYLE="white-space:nowrap">know-how</FONT> and unpatented <FONT
STYLE="white-space:nowrap">know-how</FONT> to be important to our business. We may rely on trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection is believed by
us to be of limited value. However, trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> are difficult to protect, and we have limited control over the protection of trade secrets and confidential <FONT
STYLE="white-space:nowrap">know-how</FONT> used by our licensors, collaborators and suppliers. Because we have relied in the past on third parties to manufacture our product candidates, because we may continue to do so in the future, and because we
expect to collaborate with third parties on the development of our current product candidates and any future product candidates we develop, we may, at times, share trade secrets with them. We also conduct joint research and development programs that
may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. Under such circumstances, trade secrets and confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to
maintain as confidential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To protect this type of information against disclosure or appropriation by competitors, our policy is to
require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or
disclosing proprietary information. These agreements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and
advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share
trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.
Given that our competitive position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive
position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive,
time consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Courts outside the United States are sometimes less willing to protect proprietary information, technology and <FONT
STYLE="white-space:nowrap">know-how.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees,
third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover
our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our
competitive position and have an adverse impact on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be
able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our trademarks and trade
names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our trademark MeiraGTx has been registered in the EU and a U.S. application is pending. We
may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to
ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks
that incorporate variations of our unregistered trademarks or trade names. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we
may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be
ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to license additional intellectual property from third parties, and such licenses may not be available or may not be available on
commercially reasonable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The growth of our business may depend in part on our ability to acquire or <FONT
STYLE="white-space:nowrap">in-license</FONT> additional proprietary rights. For example, our programs may involve product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also
require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may develop products containing our compositions and
<FONT STYLE="white-space:nowrap">pre-existing</FONT> pharmaceutical compositions. These pharmaceutical products may be covered by intellectual property rights held by others. We may be required by the FDA, EMA or other foreign regulatory authorities
to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by intellectual property rights held by others. We may be unable to acquire or
<FONT STYLE="white-space:nowrap">in-license</FONT> any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on
reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe
on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property
rights, any such license may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which may allow our competitors access to the same technologies licensed to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
their former employers or other third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at other biotechnology or
pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such
parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#146; former
employers or other third parties. We may also be subject to claims that former employers or other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result
in substantial cost and reputational loss and be a distraction to our management and other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, we had 58 full-time employees. We will need to significantly expand our organization, and we may have difficulty
identifying, hiring and integrating new personnel. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and
contractors. Also, our management may need to divert a disproportionate amount of its attention away from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of
time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of
employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management
is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and
our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. Our expected growth could require significant capital expenditures and may divert financial
resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our potential ability to generate revenue
could be reduced and we may not be able to implement our business strategy. Many of the biotechnology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a
longer history in the industry than we do. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and operate our business will be
limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the
development, regulatory, commercialization and business development expertise of Alexandria Forbes, Ph.D., our President and Chief Executive Officer, Rich Giroux, our Chief Operating Officer and Stuart Naylor, Ph.D., our Chief Development Officer,
as well as the other principal members of our management, scientific and clinical teams. Although we have formal employment agreements with our executive officers, these agreements do not prevent them from terminating their employment with us at any
time and, for certain of our executive officers, entitle them to receive severance payments in connection with their voluntary resignation of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be
seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to
develop, gain regulatory approval of and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms
given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we
rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have
commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to develop and commercialize product candidates
will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any
products that we may develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The use of our product candidates in clinical trials and the sale of any products for which we
obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with
our products. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability
and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impairment of our business reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of participants from our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation and related litigation; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distraction of management&#146;s attention from our primary business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates, if approved for commercial sale; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain
include general liability, clinical trial liability, employment practices liability, property, auto, workers&#146; compensation, umbrella, and directors&#146; and officers&#146; insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses
we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we
obtain marketing approval for our product candidates, we intend to acquire insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate
amounts. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including
preventing or limiting the commercialization of any product candidates we develop. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude
coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our
resources, and our clinical trials or regulatory approvals could be suspended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that operating as a public company will
make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a
result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. We do not know, however, if we will be able to maintain existing insurance with
adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our cash position and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees and independent contractors, including consultants, vendors, and any third parties we may engage in connection with development and
commercialization may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Misconduct by our employees and independent contractors, including consultants, vendors, and any third parties we may engage in connection with
development and commercialization, could include intentional, reckless or negligent conduct or unauthorized activities that violate: (i)&nbsp;the laws and regulations of the FDA, EMA and other similar regulatory authorities, including those laws
that require the reporting of true, complete and accurate information to such authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;data privacy, security, fraud and abuse and other healthcare laws and regulations; or (iv)&nbsp;laws that
require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud,
misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal
misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to
detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or
regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or
asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions,
integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings,
and curtailment of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of system failures. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our computer systems, as well as those of our contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access,
natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate
development programs. For example, the loss of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the
further development of our product candidates could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we collect and store sensitive
data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure
processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, or breached due
to employee error, a technical vulnerability, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored
there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant
regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development
of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage in acquisitions that could disrupt our business, cause dilution to our shareholders or reduce our
financial resources. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do
identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or
investors. We may decide to incur debt in connection with an acquisition or issue our ordinary shares or other equity securities to the shareholders of the acquired company, which would reduce the percentage ownership of our existing shareholders.
We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel,
technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future
acquisitions or the effect that any such transactions might have on our operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The United Kingdom&#146;s withdrawal from the European
Union may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the vote of a majority of the eligible members of the electorate in the United Kingdom to withdraw from the European Union in a
national referendum held on June&nbsp;23, 2016, the U.K. government served notice under Article 50 of the Treaty of the European Union on March&nbsp;29, 2017 to formally initiate a withdrawal process. The United Kingdom and the European Union have a
<FONT STYLE="white-space:nowrap">two-year</FONT> period under Article 50 to negotiate the terms for withdrawal. Any extension of the negotiation period for withdrawal will require the consent of all of the remaining 27 member states. The referendum
and withdrawal have created significant uncertainty about the future relationship between the United Kingdom and the European Union. Lack of clarity about future U.K. laws and regulations as the United Kingdom determines which <FONT
STYLE="white-space:nowrap">EU-derived</FONT> laws and regulations to replace or replicate as part of a withdrawal, including healthcare and pharmaceutical regulations; financial laws and regulations; tax and free trade agreements; intellectual
property rights; supply chain logistics; environmental, health, and safety laws and regulations; immigration laws; and employment laws, could decrease foreign direct investment in the United Kingdom, increase costs, depress economic activity, and
restrict our access to capital. If the United Kingdom and the European Union are unable to negotiate acceptable withdrawal terms or if other EU member states pursue withdrawal, barrier-free access between the U.K. and other EU member states or among
the European economic area overall could be diminished or eliminated. These developments, or the perception that any of them could occur, have had and may continue to have a significant adverse effect on global economic conditions and the stability
of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Asset valuations, currency exchange rates, and credit ratings may be
especially subject to increased market volatility. In addition, changes to U.K. border and immigration policy could occur as a result of the United Kingdom&#146;s withdrawal from the European Union, affecting our ability to recruit and retain
employees from outside the United Kingdom. Any of these factors could have an adverse effect on our business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the vote for the United Kingdom&#146;s withdrawal from the European Union has
resulted in a decision to move the EMA from the United Kingdom to the Netherlands, with operations currently scheduled to begin in the Netherlands by end of March 2019. This transition may cause disruption in the administrative and medical
scientific links between the EMA and the UK Medicines and Healthcare products Regulatory Agency, or the MHRA, including delays in granting clinical trial authorization or marketing authorization, disruption of importation and export of active
substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add considerably to
the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange
rate fluctuations may adversely affect our results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Owing to the international scope of our
operations, fluctuations in exchange rates, particularly between the pound sterling and the U.S. dollar, may adversely affect us. Although some of our operations are based in the United Kingdom, we source research and development, manufacturing,
consulting and other services from the United States and the European Union. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and the market price of our securities may be
affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the euro, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do
not have any exchange rate hedging arrangements in place. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our
ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price is likely to be volatile. The stock market in general and the market for smaller
biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your ordinary shares at or
above your purchase price. The market price for our ordinary shares may be influenced by many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials of our product candidates or those of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our existing or any future collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">development of new product candidates that may address our markets and make our product candidates less
attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us, our partners or our competitors of significant acquisitions, strategic partnerships, joint
ventures, collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our product candidates or clinical development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed financial estimates and projections of the investment community or that we provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
additional product candidates or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or expected changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section and elsewhere in this Quarterly Report on
Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and Nasdaq and
biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a security
has been volatile, holders of that security have sometimes instituted securities class action litigation against the issuer. If any of the holders of our ordinary shares were to bring such a lawsuit against us, we could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also
subject us to significant liabilities. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating performance. Further, a decline in the financial markets and related factors
beyond our control may cause the price of our ordinary shares to decline rapidly and unexpectedly. If the market price of our ordinary shares does not exceed your purchase price, you may not realize any return on your investment in us and may lose
some or all of your investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive officers, directors and principal shareholders, if they choose to act together, have the ability to
control or significantly influence all matters submitted to shareholders for approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, our executive
officers, directors and shareholders who owned more than 5% of our outstanding ordinary shares and their respective affiliates, in the aggregate, hold ordinary shares representing approximately 56.0% of our outstanding ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, if these shareholders choose to act together, they would be able to control or significantly influence all matters submitted to
our shareholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors, the composition of our management and approval of
any merger, consolidation, sale of all or substantially all of our assets or other business combination that other shareholders may desire. Any of these actions could adversely affect the market price of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of
our ordinary shares to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of our ordinary
shares in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our ordinary shares. Substantially all of our 27,184,132 Ordinary Shares are or will
become eligible to be sold within 4 months of our IPO. Moreover, holders of an aggregate of 16,059,333 ordinary shares will have rights, subject to specified conditions, to require us to file registration statements covering their shares or to
include their shares in registration statements that we may file for ourselves or other shareholders, until such shares can otherwise be sold without restriction under Rule&nbsp;144 or until the rights terminate pursuant to the terms of the
shareholders agreement between us and such holders. We have also registered 4,669,342 ordinary shares subject to equity awards issued or reserved for future issuance under our equity compensation plans on a registration statement on Form <FONT
STYLE="white-space:nowrap">S-8.</FONT> Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements.
Any sales of securities by these shareholders could have a negative impact on the trading price of our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging
growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain
an emerging growth company until the last day of the fiscal year following the fifth anniversary of our IPO. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148;
our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of
such five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies.
These exemptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in this Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict whether investors will find our
ordinary shares less attractive if we rely on these exemptions. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be reduced or more
volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of
these accounting standards until they would otherwise apply to private companies. We have elected to take advantage of this extended transition period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an
emerging growth company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq listing
requirements and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our
management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more
time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract
and retain qualified members of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are evaluating these rules and regulations, and cannot predict or estimate the
amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve
over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to furnish a report by our management
on our internal control over financial reporting. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard,
we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes
as appropriate, validate through testing whether such controls are functioning as documented, and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we
will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse
reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do
not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our ordinary shares, our share price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our ordinary shares relies in part on the research and reports that industry or securities analysts publish about us or
our business. We do not control these analysts.&nbsp;Furthermore, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our share performance, or if any of our
preclinical studies or clinical trials and operating results fail to meet the expectations of analysts, our share price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we
could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our organizational documents and Cayman Islands law may discourage or
prevent a change of control, even if an acquisition would be beneficial to our shareholders, which could depress the price of our ordinary shares and prevent attempts by our shareholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our memorandum and articles of association contain provisions that may discourage unsolicited takeover proposals that shareholders may consider
to be in their best interests. Our board of directors is divided into three classes with staggered, three year terms. Our board of directors has the ability to designate the terms of and issue preferred shares without shareholder approval. We are
also subject to certain provisions under Cayman Islands law that could delay or prevent a change of control. Together these provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve
payment of a premium over prevailing market prices for our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There may be difficulties in enforcing foreign judgments against our
management or us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our directors and management reside outside the United States. A significant portion of our assets
and such persons&#146; assets are located outside the United States. As a result, it may be difficult or impossible for investors to effect service of process upon us within the United States or other jurisdictions, including judgments predicated
upon the civil liability provisions of the federal securities laws of the United States. In particular, investors should be aware that there is uncertainty as to whether the courts of the Cayman Islands or any other applicable jurisdictions would
recognize and enforce judgments of U.S. courts obtained against us or our directors or management as well as against the selling shareholders predicated upon the civil liability provisions of the securities laws of the United States or any state in
the United States or entertain original actions brought in the Cayman Islands or any other applicable jurisdictions courts against us or our directors or officers as well as against the selling shareholders predicated upon the securities laws of the
United States or any state in the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The rights of our shareholders differ from the rights typically offered to shareholders of a U.S.
corporation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate affairs and the rights of holders of ordinary shares are governed by Cayman Islands law, including the
provisions of the Cayman Islands Companies Law (2018 Revision), or the Companies Law, the common law of the Cayman Islands and by our memorandum and articles of association. We will also be subject to the federal securities laws of the United
States. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the
Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, the decisions of whose courts are of persuasive authority, but are not
binding on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are different from what they would be under statutes or judicial precedent in some jurisdictions in
the United States. In particular, the Cayman Islands has a different body of securities laws as compared to the United States, and certain states, such as Delaware, may have more fully developed and judicially interpreted bodies of corporate law. In
addition, Cayman Islands companies may not have standing to initiate a shareholders derivative action in a Federal court of the United States. As a result of all of the above, public shareholders may have more difficulty in protecting their
interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a United States company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results
or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;404(a) of the Sarbanes-Oxley Act, or Section&nbsp;404(a), requires that beginning with our second annual report following our
initial public offering on June&nbsp;7, 2018, management assess and report annually on the effectiveness of our internal control over financial reporting and identify any material weaknesses in our internal control over financial reporting. Although
Section&nbsp;404(b) of the Sarbanes-Oxley Act, or Section&nbsp;404(b), requires our independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal control over financial reporting, we have
opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply with SEC rules that implement Section&nbsp;404(b) until such time as we are no longer an &#147;emerging growth company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our first Section&nbsp;404(a) assessment will take place for our annual report for the fiscal year ending December&nbsp;31, 2019.
Effective internal controls over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or
improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404, or any subsequent testing by our
independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose
confidence in our reported financial information, which could have a negative effect on the trading price of our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not
anticipate paying any cash dividends on our ordinary shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current Cayman Islands law, the company may only make distributions by way of dividend out of profits, or out of its share premium account (provided that
immediately following the date that the dividend is proposed to be paid the company is able to pay its debts as they fall due in the ordinary course of business). We have never declared or paid any cash dividends on our ordinary shares. We currently
anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. As a result, capital appreciation, if any, of our
ordinary shares would be your sole source of gain on an investment in our ordinary shares for the foreseeable future.<B><I> </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be
subject to securities class action litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a
company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could
result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to be treated as
resident in the United Kingdom for tax purposes, but may be treated as a dual resident company for United Kingdom tax purposes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It
is the intention of our board of directors to conduct our affairs so that the central management and control of the company is exercised in the United Kingdom. As a result, we expect to be treated as resident in the United Kingdom for UK tax
purposes. Accordingly, we expect to be subject to UK taxation on our income and gains, except where an exemption applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, we may
be treated as a dual resident company for UK tax purposes. As a result, our right to claim certain reliefs from UK tax may be restricted, and changes in law or practice in the United Kingdom could result in the imposition of further restrictions on
our right to claim UK tax reliefs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be classified as a passive foreign investment company for U.S. federal income tax purposes, which could
result in adverse U.S. federal income tax consequences to U.S. investors in our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the current and
anticipated value of our assets, including goodwill, and the composition of our income, assets and operations, we do not believe we were a &#147;passive foreign investment company,&#148; or PFIC, for the taxable year ending on December&nbsp;31,
2017, and do not expect to be a PFIC for the current taxable year. However, the application of the PFIC rules is subject to uncertainty in several respects, and we cannot assure you that the U.S. Internal Revenue Service, or the IRS, will not take a
contrary position. Furthermore, a separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. Accordingly, we cannot assure you that we were not a PFIC for our taxable year ending on
December&nbsp;31, 2017 and that we will not be a PFIC for our current taxable year or any future taxable year. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company will be considered a PFIC for any taxable year if (i)&nbsp;at least 75% of its
gross income is passive income (including interest income), or (ii)&nbsp;at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for
the production of passive income. If we were to be classified as a PFIC for any taxable year during which a U.S. Holder (as defined below under &#147;Material U.S. Federal Income Tax Consequences&#148;) holds our ordinary shares, certain adverse
U.S. federal income tax consequences could apply to such U.S. Holder, including (i)&nbsp;the treatment of all or a portion of any gain on disposition of our ordinary shares as ordinary income, (ii)&nbsp;the application of a deferred interest charge
on such gain and the receipt of certain dividends and (iii)&nbsp;the obligation to comply with certain reporting requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a United States
person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the value or voting power of our ordinary
shares, such U.S. Holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group (if any). If our group includes one or more U.S. subsidiaries, certain of our <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> subsidiaries could be treated as controlled foreign corporations (regardless of whether we are treated as a controlled foreign corporation). A United States shareholder of a controlled foreign corporation
may be required to report annually and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible <FONT STYLE="white-space:nowrap">low-taxed</FONT> income&#148; and investments in U.S. property by
controlled foreign corporations, regardless of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or
foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject you to significant monetary penalties and may prevent the statute of limitations from
starting with respect to your U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether any of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
subsidiaries is treated as a controlled foreign corporation or whether such investor is treated as a United States shareholder with respect to any of such controlled foreign corporations. Further, we cannot provide any assurances that we will
furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax payment obligations. U.S. Holders should consult their tax advisors regarding the potential application of these rules to
their investment in our ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. government has recently enacted comprehensive tax legislation that includes significant changes to the taxation of
business entities, referenced herein as the Tax Reform Act. These changes include, among others, a permanent reduction to the corporate income tax rate, limiting interest deductions and the use of net operating losses, adopting elements of a
territorial tax system and introducing certain anti-base erosion provisions. We continue to examine the impact this tax reform legislation may have on our business. The effect of the Tax Reform Act on our business, whether adverse or favorable, is
uncertain, and may not become evident for some period of time. U.S. Holders should consult their legal and tax advisors regarding any such legislation and the potential tax consequences of investing in our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in tax laws or challenges to our tax position could adversely affect our results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to complex tax laws. Changes in tax laws, regulations and treaties, or the interpretation thereof, tax policy initiatives and
reforms under consideration and the practices of tax authorities in jurisdictions in which we operate could adversely affect our tax position, including our effective tax rate or tax payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2015, the Organization for Economic <FONT STYLE="white-space:nowrap">Co-Operation</FONT> and Development released a final package
of measures to be implemented by member nations in response to a 2013 action plan calling for a coordinated multi-jurisdictional approach to &#147;base erosion and profit shifting&#148; by multinational companies. Multiple member jurisdictions,
including the countries in which we operate, have begun implementing recommended changes such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> reporting requirements and changes to double tax
treaties. Additional multilateral changes are anticipated in upcoming years. We often rely on generally available interpretations of applicable tax laws, treaties and regulations. There cannot be certainty that the relevant tax authorities are in
agreement with our interpretation of these laws, regulations or treaties, or with tax positions that we have taken. If our interpretation or tax position is challenged by the relevant tax authorities, we could be required to pay taxes that we
currently do not collect or pay, may be subject to interest and penalties and there could be an increase to the costs of our services to track and collect such taxes, which could increase our costs of operations or our effective tax rate. Similarly,
a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#147;permanent establishment&#148; under international tax treaties, and such an
assertion, if successful, could increase our expected tax liability in one or more jurisdictions. The occurrence of any of the foregoing tax risks could have a material adverse effect on our business, financial condition and results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are unable to predict what national or international tax reform may be proposed or enacted in the future or what effect such changes
would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices, could impact the tax treatment of our earnings, adversely affect our profitability and increase the complexity,
burden and cost of tax compliance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have significant net operating losses, or NOLs, and U.K. carryforward tax losses which we may not be able to
realize or which may be restricted following the Corporate Reorganization or any future change of control. We also benefit from certain tax incentive regimes, such as research and development tax credits, in the jurisdictions in which we operate and
any adverse change to these regimes, the application thereof or challenges to the tax position we have adopted under these regimes could adversely affect our results of operations and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, we had federal and state NOL carryforwards in the United States of $10.9&nbsp;million and $10.9&nbsp;million,
respectively, and cumulative carryforward tax losses in the United Kingdom of $85.4&nbsp;million, which we expect to be available to reduce future taxable income subject to any relevant restrictions (including those in the UK that limit the
percentage of profits that can be reduced by carried forward losses). The U.S. federal and state NOL carry forwards will begin to expire in 2035 and the U.K. carryforward tax losses will continue indefinitely, subject to relevant restrictions, under
current UK legislation. Also, as of June&nbsp;30, 2018, we had research and development credits in the U.S. in the amount of $697,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NOL carry forwards and U.K. carryforward tax losses are subject to review and possible
adjustment by the U.S., U.K. and state tax authorities. NOL carryforwards and U.K. carryforward tax losses may become subject to limitations in the event of certain cumulative changes in the ownership interest of significant shareholders, as defined
under Sections 382 Internal Revenue Code, as well as the Corporation Tax Act 2010 Part 14 under the UK tax rules. This could limit the amount of NOLs or carryforward tax losses that we can utilize annually to offset future taxable income or tax
liabilities. Subsequent ownership changes and changes to the UK (or US) tax rules in respect of the utilization of losses carried forward may further affect the limitation in future years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have not undertaken a study on the completeness of the U.S. research and development credit. As such, the U.S. research and
development credits may change and may be subject to review and adjustment by the tax authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_14"></A>Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;7, 2018, the SEC declared effective our Registration Statement (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-224914).</FONT> Pursuant to the Registration Statement, we registered the offer and sale of 5,000,000 Ordinary Shares with an aggregate offering price of approximately $75.0&nbsp;million. Merrill Lynch,
Pierce, Fenner&nbsp;&amp; Smith Incorporated and Barclays Capital Inc. acted as representatives of the underwriters for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;7, 2018, we issued and sold 5,000,000 Ordinary Shares at a price to the public of $15.00 per share. Upon completion of the IPO on June&nbsp;12, 2018, we received net proceeds of approximately $65.9&nbsp;million, after deducting the
underwriting discount of $5.3&nbsp;million and offering expenses of $3.8&nbsp;million. No payments for such expenses were made directly or indirectly to (i)&nbsp;any of our officers or directors or their associates, (ii)&nbsp;any persons owning 10%
or more of any class of our equity securities or (iii)&nbsp;any of our affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering terminated after the sale of all
securities registered pursuant to the Registration Statement.There has been no material change in the expected use of the net proceeds from our IPO as described in our Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;12, 2018, we issued an aggregate of 1,212,671 Preferred Shares for aggregate consideration of $12,707,536 pursuant to
Section&nbsp;4(a)(2) and Rule 506 of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_15"></A>Item&nbsp;3. Defaults Upon Senior Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_16"></A>Item&nbsp;4.
Mine Safety Disclosures. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_17"></A>Item&nbsp;5. Other Information. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="tx570173_18"></A>Item&nbsp;6. Exhibits. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1735438/000119312518182614/d544323dex33.htm">Memorandum and Articles of Association of the Registrant, dated June&nbsp;
7, 2018 (incorporated by reference to Exhibit 3.3 of the Company&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File No. <FONT STYLE="white-space:nowrap">333-224914)</FONT> filed on June&nbsp;4, 2018).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1735438/000119312518176071/d544323dex1015.htm">MeiraGTx Holdings plc 2018 Employee Share Purchase Plan, dated June&nbsp;
6, 2018 (incorporated by reference to Exhibit 10.15 of the Company&#146;s Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> (File No. <FONT STYLE="white-space:nowrap">333-224914)</FONT> filed on May&nbsp;29, 2018).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1735438/000119312518176071/d544323dex103.htm">MeiraGTx Holdings plc <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Plan, dated June&nbsp;
7, 2018 (incorporated by reference to Exhibit 10.3 of the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File No. <FONT STYLE="white-space:nowrap">333-224914)</FONT> filed on May&nbsp;29, 2018).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1735438/000119312518176071/d544323dex102.htm">MeiraGTx Holdings plc 2018 Incentive Award Plan, dated June&nbsp;
7, 2018 (incorporated by reference to Exhibit 10.2 of the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File No. <FONT STYLE="white-space:nowrap">333-224914)</FONT> filed on May&nbsp;29, 2018.
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570173dex104.htm">Lease agreement by and between Moorfields Eye Hospital NHS Foundation Trust and MeiraGTx UK II Limited, dated July&nbsp;30, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570173dex105.htm">Lease agreement by and between Moorfields Eye Hospital NHS Foundation Trust and MieraGTx UK II Limited, dated July&nbsp;30, 2018 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570173dex311.htm">Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> and <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> Certification of Principal Executive Officer. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570173dex312.htm">Rule <FONT STYLE="white-space:nowrap">13a-14(a)</FONT> and <FONT STYLE="white-space:nowrap">15d-14(a)</FONT> Certification of Principal Financial Officer. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570173dex321.htm">Section&nbsp;1350 Certification of Principal Executive Officer. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d570173dex322.htm">Section&nbsp;1350 Certification of Principal Financial Officer. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Furnished herewith. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx570173_19"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Company Name</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 8, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alexandria Forbes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Alexandria Forbes</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chief Executive Officer</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 8, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard Giroux</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Richard Giroux</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chief Operating Officer (principal financial officer and principal accounting officer)</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>d570173dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July&nbsp;30, 2018 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lease </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>relating to
</B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Premises known as </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Third Floor, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>15 Ebenezer
Street and 25 Provost Street, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N1 7NP </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Moorfields Eye Hospital NHS Foundation Trust </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MeiraGTx UK II
Limited </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR1. Date of lease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR2. Landlord&#146;s title number(s) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR3. Parties to
this lease </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moorfields Eye Hospital NHS
Foundation Trust of Moorfields Eye Hospital, 162 City Road, London EC1V 2PD.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MeiraGTx UK II Limited<B> </B>incorporated and registered in England and Wales with company number 9348737 whose registered office is at 92 Britannia Walk,
London N1 7NQ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR4. Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In the case of a
conflict between this clause and the remainder of this lease then, for the purposes of registration, this clause shall prevail. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the definition of
Premises in clause 1.36 of this lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR5. Prescribed statements etc </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR6. Term for which the Property is leased </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term as specified in this lease at clause 1.7 (&#145;The Contractual Term&#146;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR7. Prohibitions or restrictions on disposing of this lease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This lease contains a provision that prohibits or restricts dispositions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8. Rights of acquisition etc </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8.1 Tenant&#146;s
contractual rights to renew this lease, to acquire the reversion or another lease of the Property, or to acquire an interest in other land </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8.2 Tenant&#146;s covenant to (or offer to) surrender this lease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8.3 Landlord&#146;s contractual rights to acquire
this lease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR9. Restrictive covenants given in
this lease by the Landlord in respect of land other than the Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR10. Easements </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR10.1 Easements granted by this
lease for the benefit of the Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Part 1 Schedule 1 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR10.2 Easements granted or reserved by this lease over the Property for the benefit of other property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Part 2 Schedule 1 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR11. Estate rentcharge burdening the
Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR12. Application for standard form
of restriction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS LEASE is made between the parties referred to in clause LR3 and the provisions that follow have effect
subject to the provisions contained, and terms used, in clauses LR1 to LR12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW THIS DEED WITNESSES as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and interpretation </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">For all purposes of this lease the terms defined in this clause have the meanings specified. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;1954 Act&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;1954 Act&#146; means the Landlord and Tenant Act 1954 and all statutes, regulations and orders included by virtue of clause 1.39 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;1995 Act&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;1995 Act&#146; means the Landlord and Tenant (Covenants) Act 1995 and all statutes, regulations and orders included by virtue of clause
1.39 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Act of Insolvency&#146; </B>means any of the following:<B> </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the taking of any step in connection with any voluntary arrangement or any other compromise or arrangement for
the benefit of any creditors of the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making of an application for an administration order or the making of an administration order in relation
to the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the giving of any notice of intention to appoint an administrator, or the filing at court of the prescribed
documents in connection with the appointment of an administrator, or the appointment of an administrator, in any case in relation to the Tenant or any guarantor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the appointment of a receiver or manager or an administrative receiver in relation to any property or income of
the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the commencement of a voluntary <FONT STYLE="white-space:nowrap">winding-up</FONT> in respect of the Tenant or
any guarantor, except a <FONT STYLE="white-space:nowrap">winding-up</FONT> for the purpose of amalgamation or reconstruction of a solvent company in respect of which a statutory declaration of solvency has been filed with the Registrar of Companies;
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making of a petition for a <FONT STYLE="white-space:nowrap">winding-up</FONT> order or a <FONT
STYLE="white-space:nowrap">winding-up</FONT> order in respect of the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">striking-off</FONT> of the Tenant or any guarantor from the Register of
Companies or the making of an application for the Tenant or any guarantor to be <FONT STYLE="white-space:nowrap">struck-off;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant or any guarantor otherwise ceasing to exist (but excluding where the Tenant or any guarantor dies);
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making of an application for a bankruptcy order, the presentation of a petition for a bankruptcy order or
the making of a bankruptcy order against the Tenant or any guarantor. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The paragraphs above shall apply in relation to a
partnership or limited partnership (as defined in the Partnership Act 1890 and the Limited Partnerships Act 1907 respectively) subject to the modifications referred to in the Insolvent Partnerships Order 1994 (SI 1994/2421) (as amended), and a
limited liability partnership (as defined in the Limited Liability Partnerships Act 2000) subject to the modifications referred to in the Limited Liability Partnerships Regulations 2001 (SI 2001/1090) (as amended). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Act of Insolvency includes any analogous proceedings or events that may be taken pursuant to the legislation of another jurisdiction in
relation to a tenant or guarantor incorporated or domiciled in such relevant jurisdiction. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Building&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means the land and premises known as 15 Ebenezer Street and 25 Provost Street as the same is demised by the Superior Lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Common Parts&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">the Building other than the Premises and the Lettable Units. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Conduits&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Conduits&#146; means the pipes, sewers, drains, mains, ducts, conduits, gutters, watercourses, wires, cables, laser optical fibres, data
or impulse transmission, communication or reception systems, channels, flues and all other conducting media, including any fixings, louvres, cowls, covers and any other ancillary apparatus, in, on, over or under the Premises. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Contractual Term&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Contractual Term&#146; means a term of years commencing on 27&nbsp;July 2018 until 24&nbsp;May 2027. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Development&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;development&#146; are references to development as defined by the Town and Country Planning Act 1990 section 55. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;End Date&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The last day of the Term (howsoever it arises). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Existing Lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Lease of the Premises dated 6&nbsp;July 2017 made between (1)&nbsp;the Landlord and (2)&nbsp;the Tenant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Gender and number </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Words importing one gender include all other genders; words importing the singular include the plural and vice versa. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Group Company&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In relation to any company, any other company within the same group of companies as that company within the meaning of section 42 of the 1954
Act </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The clause, paragraph and schedule headings do not form part of this document and are not to be taken into account in its construction or
interpretation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Head Lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The lease of the Building made the 31st day of May 2002 between (1)&nbsp;J.F. Miller Properties Limited (2)&nbsp;and Islington and Shoreditch
Housing Association Limited </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Initial Rent&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Initial Rent&#146; means the sum of &pound;142,501.20 per year and then as revised pursuant to this lease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Insurance Rent&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Insurance Rent&#146; means the due proportion relating to the Premises of the sum payable by the Landlord to the Superior Landlord
pursuant to clause 2.1.2 of the Superior Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Insured Risks&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Insured Risks&#146; means the risks of loss or damage by fire, storm, tempest, earthquake, lightning, explosion, riot, civil commotion,
malicious damage, terrorism, impact by vehicles and by aircraft and articles dropped from aircraft, other than war risks, flood damage and bursting and overflowing of water pipes and tanks, subsidence, landslip and heave, and such other risks,
whether or not in the nature of the foregoing, as the Landlord or the Superior Landlord (as the case may be) acting reasonably from time to time decides to insure against. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Interest&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;interest&#146; are references to interest payable during the period from the date on which the payment is due to the date
of payment, both before and after any judgment, at the Interest Rate then prevailing or, should the base rate referred to in clause 1.19 cease to exist, at another rate of interest closely comparable with the Interest Rate to be agreed between the
parties or in default of agreement to be determined by a chartered accountant appointed by agreement between the parties or in default of agreement nominated by the President of the Institute of Chartered Accountants in England and Wales, acting as
an expert and not as an arbitrator. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Interest Rate&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Interest Rate&#146; means the rate of 4% a year above the base lending rate of Barclays Bank Plc or such other bank being a member of
the Committee of London and Scottish Bankers as the Landlord from time to time nominate in writing. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Interior Decorating Years&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Interior Decorating Years&#146; means every fifth year of the Term and during the last year thereof. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;consent&#146; and &#145;approved&#146; </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">References to &#145;consent of the Landlord&#146; or words to similar effect are references to a prior written
consent signed by or on behalf of the Landlord and references to the need for anything to be &#145;approved by the Landlord&#146; or words to similar effect are references to the need for a prior written approval by or on behalf of the Landlord.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any provisions in this lease referring to the consent or approval of the Landlord are to be construed as also
requiring the consent or approval of any mortgagee of the Premises and any head landlord, where that consent is required under a mortgage or head lease in existence at the date of this document. Nothing in this lease is to be construed as imposing
any obligation on a mortgagee or head landlord not to refuse any such consent or approval unreasonably. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;the Landlord&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The expression &#145;the Landlord&#146; includes the person or persons from time to time entitled to possession of the Premises when this
lease comes to an end. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;the last year of the Term&#146; and &#145;the end of the Term&#146; </B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;the last year of the Term&#146; are references to the actual last year of the Term howsoever it
determines, and references to the &#145;end of the Term&#146; are references to the end of the Term whensoever and howsoever it determines. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;the Tenant&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;The Tenant&#146; includes any person who is for the time being bound by the tenant covenants of this lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;this lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Unless expressly stated to the contrary, the expression &#145;this lease&#146; includes any document supplemental to or collateral with this
document or entered into in accordance with this document. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint and several liability </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Where any party to this lease for the time being comprises two or more persons, obligations expressed or implied to be made by or with that
party are deemed to be made by or with the persons comprising that party jointly and severally. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Lettable Unit&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">a floor or part of a floor of the Building other than the Premises, that is capable of being let or occupied.<B> </B> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Lifts&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">all lifts and lift machinery and equipment in the Building.<B> </B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Losses&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;losses&#146; are references to liabilities, damages or losses, awards of damages or compensation, penalties, costs,
disbursements and expenses arising from any claim, demand, action or proceedings. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation not to permit or suffer </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any covenant by the Tenant or the Landlord not to do anything includes an obligation to use reasonable endeavours not to permit or suffer that
thing to be done by another person where the Landlord or Tenant (as applicable) is aware that the thing is being done. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Office Covenants&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Office Covenants&#146; mean the covenants set out in Schedule 3. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Permitted Hours&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means 7am to 10pm Mondays to Fridays (inclusive) and 9am to 6pm on Saturdays Sundays and bank holidays. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Permitted Use&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Permitted Use&#146; means Class&nbsp;B1 of the Town and Country Use Classes Order 1987 (to include laboratory and light industrial use).
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Plan 1, Plan 2&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The plans annexed to this lease and so numbered. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Planning Acts&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Planning Acts&#146; means the Town and Country Planning Act 1990, the Planning (Listed Buildings and Conservation Areas) Act 1990, the
Planning (Consequential Provisions) Act 1990, the Planning (Hazardous Substances) Act 1990, the Planning and Compensation Act 1991, the Planning and Compulsory Purchase Act 2004 and all statutes, regulations and orders included by virtue of clause
1.39. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570173page098.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570173page099.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Premises&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The third floor of the Building (the floor plan of which is shown edged red on Plan 1) bounded by and including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the floorboards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the ceiling plaster; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the interior plasterwork and finishes of exterior walls and columns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the plasterwork and finishes of the interior structural walls and columns that adjoin another Lettable Unit or
the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the doors and windows within the interior structural walls and columns that adjoin another Lettable Unit or the
Common Parts and their frames and fittings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one half of the thickness of the interior <FONT STYLE="white-space:nowrap">non-structural</FONT> walls and
columns that adjoin another Lettable Unit or the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the doors and windows within the interior <FONT STYLE="white-space:nowrap">non-structural</FONT> walls and
columns that adjoin the Common Parts and their frames and fittings; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">but excluding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the windows in the exterior walls and their frames and fittings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all conducting media within that part of the Building but which do not exclusively serve that part of the
Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the load-bearing structure of the Building including the load-bearing structure of the roof, foundations,
external and internal walls and columns and the structural slabs of the ceilings and floors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the external surfaces of the Building (except the external surfaces of any finishes referred to in
(c)&nbsp;above) and the whole of the windows and window frames and fittings constructed in the external walls of the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References to clauses and schedules </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any reference in this document to a clause, subclause, paragraph, subparagraph or schedule without further designation is to be construed as a
reference to the clause, subclause, paragraph, subparagraph or schedule of this document so numbered. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References to rights of access </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to any right of the Landlord to have access to the Premises are to be construed as extending to any head landlord and any mortgagee
of the Premises where the head lease or mortgage grants such rights of access to the head landlord or mortgagee, and to all persons authorised in writing by the Landlord and any head landlord or mortgagee, including agents, professional advisers,
contractors, workmen and others, but subject to the provisos to any such access rights contained in this Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References to statutes </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Unless expressly stated to the contrary, any reference to a specific statute includes any statutory extension or modification, amendment or <FONT
STYLE="white-space:nowrap">re-enactment</FONT> of that statute and any regulations or orders made under it, and any general reference to a statute includes any regulations or orders made under that statute. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Ramp Car Park&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Ramp Car Park&#146; means the access ramp leading to the Landlord Parking Bays and the Tenant Parking Bays edged and cross-hatched
orange on Plan 2 excluding the Landlord Parking Bays. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Rent&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Until the Review Date &#145;the Rent&#146; means the Initial Rent. Thereafter &#145;the Rent&#146; means the sum ascertained in accordance
with Schedule 2. &#145;The Rent&#146; does not include the Insurance Rent, but the term &#145;the Lease Rents&#146; means the Rent and the Insurance Rent and the Service Charge. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Rent Commencement Date&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Rent Commencement Date&#146; means
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ]. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Review Date&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Review Date&#146; means 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> May 2022. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.44</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Service Charge&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">a fair and reasonable proportion of the Service Costs. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Service Charge Year&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">is the annual accounting period relating to the Services and the Service Costs beginning on 1&nbsp;April in 2018 and each subsequent year
during the Term. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.46</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Service Costs&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">the costs listed in clause 9.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.47</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Services&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means the services listed in clause 9.1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.48</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Superior Landlord&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means the landlord for the time being of the Superior Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.49</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Superior Lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Superior Lease&#146; means the lease by virtue of which the Landlord holds the Premises, which is dated
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] and made between (1)&nbsp;Islington and Shoreditch Housing Association Limited and (2)&nbsp;the Landlord and any documents
made supplemental to it. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.50</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Surveyor&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Surveyor&#146; means any person or firm appointed by the Landlord in his place. The Surveyor may be an employee of the Landlord or a
Group Company of the Landlord. The expression &#145;the Surveyor&#146; includes the person or firm appointed by the Landlord to collect the Lease Rents. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.51</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Term&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Term&#146; means the Contractual Term. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.52</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms from the 1995 Act </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Where the expressions &#145;landlord covenants&#146;, &#145;tenant covenants&#146;, or &#145;authorised guarantee agreement&#146; are used in
this lease they are to have the same meaning as is given by section 28(1) of the 1995 Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.53</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Uninsured Risk </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Uninsured Risk&#146; means an Insured Risk against which insurance is or ceases to be obtainable on normal commercial terms in the
London insurance market at rates generally available in the London insurance market for a property of this type, size and location. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.54</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;VAT&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;VAT&#146; means value added tax or any other tax of a similar nature and, unless otherwise expressly stated, all references to rents or
other sums payable by the Tenant are exclusive of VAT. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Demise </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord lets the Premises to the Tenant with full title guarantee together with the easements and rights (if any) contained or referred
to in Part 1 of Schedule 1, excepting and reserving to the Landlord the easements and other rights (if any) contained or referred to in Part 2 of Schedule 1 to hold to the Tenant and subject to (a)&nbsp;all rights easements quasi-easements and
privileges to which the Premises are or may be subject and (b)&nbsp;the matters set out in Part 3 of the Schedule 1 from and including the first day of the Contractual Term for the Term yielding and paying to the Landlord: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Firstly throughout the Term (and proportionately for any part of a year) the Rent, without any deduction or set
off, by equal quarterly payments in advance on the usual quarter days in every year and proportionately for any period of less than a year, the first such payment, being a proportionate sum in respect of the period from and including the Rent
Commencement Date to and including the day before the quarter day next after the Rent Commencement Date, to be paid on the date of this lease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Secondly by way of further rent, the Insurance Rent, payable within 28 days of a written demand.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Thirdly by way of further rent, the Service Charge payable at the times and in the manner specified in Clause
9.9. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fourthly by way of further rent, all interest payable at the times and in the manner specified in Clause 4.4.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Tenant&#146;s Covenants </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant covenants with the Landlord to observe and perform the following requirements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rent </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Lease Rents on the days and in the manner set out in this lease, and must not exercise
or seek to exercise any right or claim to withhold rent, or any right or claim to legal or equitable <FONT STYLE="white-space:nowrap">set-off.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Lease Rents by banker&#146;s order or credit transfer to any bank and account in the
United Kingdom that the Landlord nominates from time to time, or by such other method as properly requested by Landlord in writing from time to time (acting reasonably). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Outgoings and VAT </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must pay, and must indemnify the Landlord against: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rates, taxes, assessments, duties, charges, impositions and outgoings that are now or may at any time
during the Term be charged, assessed or imposed on the Premises or on the owner or occupier of them Provided That the foregoing shall not extend to payment of any rates, taxes, assessments, duties, charges, impositions and outgoings payable only as
a direct result of any dealing by the Landlord with its reversionary interest in the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all VAT that may from time to time be charged on the Lease Rents or other sums payable by the Tenant under this
lease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all VAT incurred in relation to any costs the Tenant is obliged to pay or in respect of which he is required to
indemnify the Landlord under the terms of this lease, save where it is recoverable or available for <FONT STYLE="white-space:nowrap">set-off</FONT> by the Landlord as input tax. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To contribute towards Common Structures </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">To pay to the Landlord within 28 days of receipt of written demand a fair and proper proportion of any expense incurred in cleaning lighting
repairing maintaining and (where beyond economic repair) rebuilding or renewing any walls fences sewers gutters drains pipes wires roadways pavements access ways and other similar items which are used or enjoyed or are capable of being used or
enjoyed by an occupier of the Premises in common with any other person </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cost of utilities services consumed </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must pay to the suppliers, and indemnify the Landlord against, all charges for electricity, water, gas, telecommunications and
other services consumed or used at or in relation to the Premises, including meter rents and standing charges, and must comply with the lawful requirements and regulations of their respective suppliers. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Repair, cleaning and decoration </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Repair of the premises </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must repair the Premises and keep them in good condition and repair, except for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">damage caused by one or more of the Insured Risks save to the extent that the insurance money is irrecoverable
due to any act or default of the Tenant or anyone at the Premises expressly or by implication with the Tenant&#146;s authority and under his control; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">damage caused by an Uninsured Risk but only to the extent that the Uninsured Risk has not become an Uninsured
Risk due to any act or omission of the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Replacement of landlord&#146;s fixtures </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must replace any landlord&#146;s fixtures and fittings in the Premises that are beyond repair at any time during or at the end of
the Term. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cleaning and tidying </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must keep the Premises clean and tidy and clear of all rubbish. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Decoration </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must redecorate the inside of the Premises in each of the Interior Decorating Years and the last year of the Term (unless carried
out during the previous 12 months), in all instances in a good and workmanlike manner, with appropriate materials of good quality, to the reasonable satisfaction of the Landlord. Any change in the tints, colours and patterns of the decoration must
be approved by the Landlord, whose approval may not be unreasonably withheld or delayed. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Waste, additions and alterations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not commit any waste, make any addition to the Premises, unite the Premises with any adjoining premises, or make any
alteration to the Premises except as permitted by the provisions of this clause 3.6. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Internal alterations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant may make internal <FONT STYLE="white-space:nowrap">non-structural</FONT> alterations to the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Removal of alterations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">At the end of the Term, if so requested by the Landlord, the Tenant must remove any additional buildings, additions, alterations or
improvements made by it to the Premises (whether pursuant to the terms of this lease or the Existing Lease), and must make good any part of the Premises damaged by their removal. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Structural alterations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to carry out any structural alterations or additions whatsoever in or to the Premises or to the Conduits
exclusively serving the Premises without the previous consent in writing of the Landlord such consent not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When applying for the consent of the Landlord hereunder to supply to the Landlord adequate plans and
specifications showing the nature and extent of the alterations or additions which the Tenant wishes to carry out and to pay all reasonable and proper costs and expenses which the Landlord may incur whether by way of surveyor&#146;s or legal
expenses or otherwise in connection with the consideration approval of the alterations and additions and to carry out the said alterations or additions only in accordance with the plans and specifications approved in writing by the Landlord and in
accordance with all statutory and local authority and insurers requirements and recommendations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the Tenant failing to observe this covenant it shall be lawful for the Landlord and its agents
or surveyors with or without workmen and others and all persons authorised by the Landlord with all necessary materials and appliances to enter upon the Premises and remove any alterations or additions and execute such works as may be necessary to
restore the Premises to their former state and the properly incurred costs and expenses thereof together with all reasonable and proper solicitors&#146; and surveyors&#146; charges and other expenses and losses whether direct or indirect which may
be incurred by the Landlord in connection therewith shall be repaid by the Tenant to the Landlord on demand as a debt. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provisions of this lease the parties hereby agree that all fixtures, fittings, fit
out works and alterations installed by the Tenant pursuant to this Lease or the Existing Lease shall remain the property of the Tenant without claim by the Landlord (the Tenant being free to remove any such items provided that any damage caused to
the Premises and and/or any items within it by such removal shall be promptly made good by the Tenant to the Landlord&#146;s reasonable satisfaction). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to prejudice easements </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not by building or otherwise to stop up or darken any window or light in the Premises not to stop up or
obstruct any access of light enjoyed to any adjoining or neighbouring premises nor permit any new wayleave easement right privilege or encroachment shall be made or attempted to be made to give immediate notice thereof to the Landlord and the
Superior Landlord and to permit the Landlord and/or the Superior Landlord and their respective agents to enter upon the Premises (on giving reasonable, prior written notice and at reasonable times) for the purposes of ascertaining the nature of any
such easement right privilege or encroachment and at the request of the Landlord and/or the Superior Landlord and at the cost of the Landlord to adopt such means as may be reasonably required or deemed proper for preventing any such encroachment or
the acquisition of any such easement right privilege or encroachment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to give any third party any acknowledgement that the Tenant enjoys the access of light to any of the
windows or openings in the Premises by the consent of such third party nor to pay such third party any sum of money nor to enter into any agreement with such third party for the purpose of inducing or binding such third party to abstain from
obstructing the access of light to any windows or openings in the event of any of the owners or occupiers of adjacent land or buildings doing or threatening to do anything which obstructs the access of light to any of the said windows or openings to
notify the same forthwith to the Landlord and the Superior Landlord and to permit the Landlord and/or the Superior Landlord to bring such proceedings as it may think fit in the name of and at the cost of the Landlord against any of the owners and/or
occupiers of the adjacent land in respect of the obstruction of the access of light to any of the windows or openings in the Premises. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to make claims </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Subject to Clause 5.1, not at any time during the Term to bring any action or make any claim or demand on account of any injury to the
Premises in consequence of the erection of any building or the alteration of any building on any land adjacent neighbouring or opposite to the Premises by the Landlord and/or the Superior Landlord or for which the Landlord and/or the Superior
Landlord shall have given its consent or for which the Landlord and/or the Superior Landlord may give its consent pursuant to any power reserved by this Lease or in respect of any easement right or privilege granted or to be granted by the Landlord
and/or the Superior Landlord for the benefit of any land or building erected or to be erected on any land adjacent neighbouring or opposite to the Premises and (if required) to concur with the Landlord and/or the Superior Landlord at the expense of
the Landlord or the Superior Landlord (as the case may be) in any consent which it may give or any grant which it may make as hereinbefore mentioned. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Planning </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In relation to the Planning Acts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At all times during the Term to comply in all respects with the Planning Acts and to keep the Landlord and the
Superior Landlord indemnified in respect thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to apply for nor implement any planning permissions or other planning consent in respect of the Premises
unless the application permission or other consent shall be been approved in writing by the Landlord (such approval not to be unreasonably withheld or delayed). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the Landlord shall otherwise direct to carry out before the expiration or determination of the Term
(howsoever the same may be determined) any works stipulated to be carried out to the Premises by a date subsequent to such expiration or sooner determination as a condition of any planning permission which the Tenant has implemented or partially
implemented. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forthwith after receiving notice of the same to give full particulars to the Landlord and the Superior Landlord
of any order notice certificate designation direction or other such matter or any proposal thereof made given or issued to the Tenant by any competent authority under or by virtue of the Planning Acts affecting or capable of affecting the Premises
and if so required by the Landlord and/or the Superior Landlord to produce such matter or proposal thereof to the Landlord and the Superior Landlord. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the request of the Landlord and/or the Superior Landlord but at the cost of the Landlord to make or join
with the Landlord and/or the Superior Landlord in making such objection or representation against or in respect of any proposal referred to in the previous <FONT STYLE="white-space:nowrap">sub-clause</FONT> as the Landlord and/or the Superior
Landlord shall deem expedient unless the making or joining is contrary to the business interests or statutory obligations of the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If called upon so to do produce to the Landlord and/or the Superior Landlord all plans documents and other
evidence as the Landlord and/or the Superior Landlord may reasonably require in order to satisfy itself that the provisions of this <FONT STYLE="white-space:nowrap">sub-clause</FONT> have been complied with. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not without the consent of the Landlord to enter into any planning obligation under Section&nbsp;106 of the
Town and Country Act 1990. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not without the consent of the Landlord to serve any notice under Part VI of the Town and Country Planning Act
1990. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Connection to the Conduits </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not make any connection with the Conduits except in accordance with plans and specifications approved by the Landlord, whose
approval may not be unreasonably withheld or delayed, and subject to consent to make the connection having previously been obtained from the competent authority, undertaker or supplier. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Aerials, signs and advertisements </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Masts </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not, without the consent of the Landlord, whose consent may not be unreasonably withheld or delayed, erect any mast whether in
connection with telecommunications or otherwise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Advertisements </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Without the consent of the Landlord and other than pursuant to paragraph 8 of Schedule 3, whose consent may not be unreasonably withheld or
delayed, the Tenant must not fix to or exhibit on the outside of the Premises, fix to or exhibit through any window of the Premises, or display anywhere on the Premises, any placard, sign, notice, fascia board or advertisement. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statutory obligations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must comply in all respects with the requirements of any statutes and any other obligations imposed by law or by any byelaws
applicable to the Premises or the trade or business for the time being carried on there. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Particular obligations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Without prejudice to the generality of clause 3.8.1 the following provisions shall apply: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Works required by statute, department or authority </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must execute all works and provide and maintain all arrangements on or in respect of the Premises or the use of them required to
comply with the requirements of any statute already or in the future to be passed, or the requirements of any government department, local authority or other public or competent authority or court of competent jurisdiction, regardless of whether
they are imposed on the owner, the occupier, or any other person. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acts causing losses </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not do in or near the Premises anything by reason of which the Landlord and/or the Superior Landlord may incur any losses
under any statute. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Construction (Design and Management) Regulations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with the provisions of the Construction (Design and Management) Regulations 2015 (&#145;the CDM
Regulations&#146;), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be the only client as defined in the provisions of the CDM Regulations, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fulfil, in relation to all and any works, all the obligations of the client as set out in or reasonably to be
inferred from the CDM Regulations, and make a declaration to that effect to the Health and Safety Executive in accordance with Regulation 6 and Schedule 1 Paragraph 15 of the CDM Regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Delivery of health and safety files </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">At the end of the Term, the Tenant must forthwith deliver to the Landlord any and all health and safety files relating to the Premises
required to be maintained under the CDM Regulations. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entry to inspect and notice to repair </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entry and notice </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must permit the Landlord and/or the Superior Landlord on reasonable, prior written notice during normal business hours except in
emergency: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to enter the Premises to ascertain whether or not the covenants and conditions of this lease have been observed
and performed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to view the state of repair and condition of the Premises; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to give to the Tenant or leave on the Premises, a written notice specifying the works required to remedy any
breach of the Tenant&#146;s obligations in this lease (&#145;a notice to repair&#146;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Provided that the Landlord (and
anyone authorised by it) shall in exercising its rights under this clause take all reasonable steps to minimise disruption and interference to the Tenant and provided further that any damage caused to the Property and/or any items within it shall be
promptly made good by the Landlord to the Tenant&#146;s reasonable satisfaction. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Works to be carried out </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must carry out the works specified in a notice to repair immediately, including making good any opening up that revealed a breach
of the terms of this lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Landlord&#146;s power in default </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If within 1 month of the service of a notice to repair the Tenant has not started to execute the work referred to in that notice or is not
proceeding diligently with it, or if the Tenant fails to finish the work within a reasonable time thereafter, or if in a case of emergency and in the Superior Landlord&#146;s or the Landlord&#146;s or the Surveyor&#146;s reasonable opinion the
Tenant is unlikely to finish the work within that period, the Tenant must permit the Landlord and/or the Superior Landlord to enter the Premises to execute the outstanding work, and must within 14 days of a written demand pay to the Landlord the
reasonable and properly incurred costs of so doing and all reasonable expenses properly incurred by the Landlord and/or the Superior Landlord, including legal costs and surveyor&#146;s fees. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alienation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to underlet the Premises in whole or in part. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not (save as hereinafter permitted) to assign transfer mortgage charge part with or share possession or
occupation of the Premises otherwise than as a whole. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to part with or share possession of the whole of the Premises or permit any company or person to have
occupation or possession of the Premises except by way of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an assignment or transfer of the whole of Premises in accordance with the provisions of Clause 3.11;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sharing of occupation in accordance with Clause 3.10.5. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to permit the Premises or any part of them to be held on trust for or by any person body or corporation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant may share occupation of the Premises with a Group Company of the Tenant on condition that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant notifies the Landlord of the identity of the occupier and the part of the Premises to be occupied;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no relationship of landlord and tenant is created; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sharing of occupation ends if the occupier is no longer a Group Company of the Tenant; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant notifies the Landlord as soon as reasonably practicable after the occupation ends.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assignment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not assign the whole of this Lease without the consent of the Landlord, such consent not to be
unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not assign part only of this Lease. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord and the Tenant agree that for the purposes of section 19(1A) of the Landlord and Tenant Act 1927
the Landlord may give its consent to an assignment subject to all or any of the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a condition that the assignor, where reasonable in the circumstances, enters into an authorised guarantee
agreement which: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in respect of all the tenant covenants of this Lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in respect of the period beginning with the date the assignee becomes bound by those covenants and ending on
the date when the assignee is released from those covenants by virtue of section 5 of the Landlord and Tenant (Covenants) Act 1995; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">imposes principal debtor liability on the assignor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">requires (in the event of a disclaimer of this Lease) the assignor to enter into a new tenancy for a term equal
to the unexpired residue of the Contractual Term; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is otherwise in a form reasonably required by the Landlord; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if required by the Landlord (acting reasonably) a condition that a person of standing acceptable to the
Landlord (acting reasonably) enters into a guarantee and indemnity of the tenant covenants of this Lease in the form set out in the Schedule 1 (but with such amendments and additions as the Landlord may reasonably require). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord and the Tenant agree that for the purposes of section 19(1A) of the Landlord and Tenant Act 1927
the Landlord may refuse its consent to an assignment if any of the following circumstances exist at the date of the Tenant&#146;s application for consent to assign this Lease: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Annual Rent or any other money due under this Lease is outstanding or there is a material breach of
covenant by the Tenant that has not been remedied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this clause shall prevent the Landlord from giving consent subject to any other reasonable
condition, nor from refusing consent to an assignment in any other circumstance where it is reasonable to do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Underletting </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet the whole of the Premises except in accordance with this clause nor without the
consent of the Landlord, such consent not to be unreasonably withheld or delayed. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet or agree to underlet the whole of the Premises without first procuring that any
intended undertenant shall covenant with the Landlord and the Superior Landlord as from the date of the underlease to observe and perform the covenants and conditions herein contained (excluding the covenant to pay the rents hereinbefore reserved)
and not without the prior written consent of the Landlord and the Superior Landlord to assign the Premises and that such covenants are included in the underlease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet part only of the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet the Premises: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">together with any property or any right over property that is not included within this Lease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at a fine or premium or reverse premium; nor </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allowing any rent free period to the undertenant that exceeds the period as is then usual in the open market in
respect of such a letting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet the Premises unless, before the underlease is granted, the Tenant has given the
Landlord: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certified copy of the notice served on the undertenant, as required by section 38A(3)(a) of the LTA 1954,
applying to the tenancy to be created by the underlease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certified copy of the declaration or statutory declaration made by the undertenant in accordance with the
requirements of section 38A(3)(b) of the LTA 1954. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any underletting by the Tenant shall be by deed and shall include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an agreement between the Tenant and the undertenant that the provisions of sections 24 to 28 of the LTA 1954
are excluded from applying to the tenancy created by the underlease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the reservation of a rent which is not less than the full open market rental value of the Premises at the date
the Premises is underlet and which is payable at the same times as the Rent under this Lease (but this shall not prevent an underlease providing for a rent-free period of a length permitted by clause 3.17.4.3); </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provisions for the review of rent at the same dates and on the same basis as the review of rent in this Lease,
unless the term of the underlease does not extend beyond the next Review Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provisions requiring the consent of the Landlord to be obtained in respect of any matter for which the consent
of the Landlord is required under this Lease, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and shall otherwise be consistent with and include tenant covenants no less onerous (other than as to the Rent)
than those in this Lease and in a form approved by the Landlord, such approval not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In relation to any underlease granted by the Tenant, the Tenant shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not vary the terms of the underlease nor accept a surrender of the underlease without the consent of the
Landlord, such consent not to be unreasonably withheld or delayed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforce the tenant covenants in the underlease and not waive any of them nor allow any reduction in the rent
payable under the underlease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensure that in relation to any rent review the revised rent is not agreed without the approval of the Landlord,
such approval not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Charging of the whole </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not charge the whole of the Premises without the consent of the Landlord, whose consent may not be unreasonably withheld or
delayed, provided that the consent of the Landlord is not required for a floating charge over the whole of the undertaking of the Tenant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration of permitted dealings </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Within 28 days of any assignment, charge or any transmission or other devolution relating to the Premises, the Tenant must produce a certified
copy of any relevant document for registration with the Landlord&#146;s solicitor, and must pay the Landlord&#146;s solicitor&#146;s reasonable charges for registration of at least &pound;50 plus VAT. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to introduce dangerous things </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Not to bring into the Premises or to place or store or permit to remain in or about the Premises any article or thing which is or may become
dangerous offensive combustible inflammable radioactive explosive harmful polluting or contaminating. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to overload </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Not to place in the Premises or to place or to carry in the lifts (if any) in the building any articles in such position or in such quantity
or weight to otherwise in such manner howsoever as to overload or cause damage to or to be in the opinion of the Landlord and/or the Superior Landlord likely to overload or exceed any prescribed loading capacity of or cause damage to the Premises or
the lifts and not to overload the electrical wiring or installation or other Conduits in the Premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to harm drains </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Not to allow to pass into the Conduits serving the Premises any noxious or deleterious effluent or other substance which might cause any
obstruction in or harm to the Conduits and in the event of any such obstruction or harm forthwith to make good all such damage to the reasonable satisfaction of the Landlord and/or the Superior Landlord. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nuisance etc </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nuisance </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not do anything on the Premises, or allow anything to remain on them, that may be or become or cause a legal nuisance, injury
or damage to the Landlord and/or the Superior Landlord or its respective tenants or the owners or occupiers of adjacent or neighbouring premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Auctions etc </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not use the Premises for any auction sale, any dangerous, noxious, noisy or offensive trade, business, manufacture or
occupation, or any illegal or immoral act or purpose but use for the Permitted Use is not a breach of this clause. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Animals etc </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not use the Premises as sleeping accommodation or for residential purposes, or keep any animal on them. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of applications, notices and recovery of arrears </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Save in the case of the circumstances set out in 3.24.1 (in which cases such costs shall be reasonable and not payable on an indemnity basis),
the Tenant must pay to the Landlord and/or the Superior Landlord on an indemnity basis all costs, fees, charges, disbursements and expenses, including, without prejudice to the generality of the above, those payable to counsel, solicitors, surveyors
and enforcement agents, properly and reasonably incurred by the Landlord and/or the Superior Landlord in relation to or incidental to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every application made by the Tenant for a consent or licence required by the provisions of this lease, whether
it is granted, refused or offered subject to any lawful<B> </B>qualification or condition, or the application is withdrawn unless the refusal, qualification or condition is unlawful whether because it is unreasonable or otherwise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the contemplation, preparation and service of a notice under the Law of Property Act 1925 section 146, or the
contemplation or taking of proceedings under sections 146 or 147 of that Act, even if forfeiture is avoided otherwise than by relief granted by the court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the recovery or attempted recovery of arrears of rent or other sums due under this lease; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other steps taken in contemplation of or in direct connection with the enforcement of the covenants on the
part of the Tenant contained in this lease whether during or within 6 months after the end of the Term including the preparation, service and negotiation of schedules of dilapidations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-conditions</FONT> for development </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Notwithstanding any consent that may be granted by the Landlord under this lease, the Tenant must not carry out any development on or at the
Premises until: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all necessary notices under the Planning Acts have been served and copies produced to the Landlord and the
Superior Landlord; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all necessary permissions under the Planning Acts have been obtained and produced to the Landlord and/or the
Superior Landlord; and </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord and the Superior Landlord have acknowledged that every necessary planning permission is acceptable
to them, such acknowledgement not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord or the Superior Landlord may
refuse to acknowledge their respective acceptance of a planning permission on the grounds that any condition contained in it or anything omitted from it or the period referred to in it would, in the reasonable opinion of the Superior Landlord and/or
Landlord and/or the Surveyor, be, or be likely to be, prejudicial to the Landlord and/or the Superior Landlord or to their respective reversionary interests in the Premises whether during or following the end of the Term. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Completion of development </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Where a condition of any planning permission granted for development begun before the end of the Term requires works to be carried out to the
Premises by a date after the end of the Term, the Tenant must, unless the Landlord and/or the Superior Landlord directs otherwise, finish those works before the end of the Term. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Security for compliance with conditions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In any case where a planning permission is granted subject to conditions, and if the Landlord and/or the Superior Landlord reasonably so
requires, the Tenant must provide sufficient security for his compliance with the conditions and must not implement the planning permission until the security has been provided. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plans, documents and information </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evidence of compliance with this lease </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If so requested, the Tenant must produce to the Landlord or the Surveyor and the Superior Landlord any plans, documents and other evidence the
Landlord and/or the Superior Landlord reasonably requires to satisfy himself that the provisions of this lease have been complied with. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information for renewal or rent review </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If so requested, the Tenant must produce to the Landlord, the Surveyor, or any person acting as the third party determining the Rent in
default of agreement between the Landlord and the Tenant under the provisions for rent review contained in this lease any information reasonably requested in writing in relation to any pending or intended step under the 1954 Act or the
implementation of any provisions for rent review in any sublease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To inform Landlord and Superior Landlord of notices </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Upon the happening of any occurrence or upon the receipt of any notice order requisition direction or other thing which may be capable of
adversely affecting the Landlord&#146;s interest and/or the Superior Landlord&#146;s interest in the Premises the Tenant shall promptly at its own expense deliver full particulars or a copy thereof to the Landlord and the Superior Landlord. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To inform Landlord and Superior Landlord of contaminants and defects </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">To inform the Landlord and Superior Landlord promptly in writing of the existence of any contaminant or pollutant on or any defect in the
Premises of which the Tenant becomes aware which might give rise to a duty imposed by common law or statute on the Landlord and/or Superior Landlord. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To comply with covenants in the Superior Lease </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant shall observe and perform the tenant covenants in the Superior Lease except the covenants to pay the rents reserved by the Superior
Lease but in the event of any conflict between the covenants by the Tenant in this Lease and the tenant covenants in the Superior Lease then the covenants by the Tenant in this Lease shall prevail. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnities </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must keep the Landlord and the Superior Landlord fully indemnified against all losses arising directly or indirectly out of any
material breach or material <FONT STYLE="white-space:nowrap">non-observance</FONT> by the Tenant of the covenants, conditions or other provisions of this lease or any of the matters to which this demise is subject provided that the Landlord shall
take reasonable steps to mitigate such losses. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reletting boards and viewing </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must permit the Landlord and/or the Superior Landlord to enter the Premises at any time during the last 6 months of the Contractual
Term and at any time thereafter (provided that it does not impede access to the Premises or the use of the Premises for the Permitted Use) to fix and retain anywhere on the exterior of the Premises a board advertising them for reletting. While any
such board is on the Premises the Tenant must permit viewing of them at reasonable times of the day provided that reasonable prior notice shall be given of any prospective viewing. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Obstruction and encroachment </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not stop up, darken or obstruct any window or light belonging to the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yielding up </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">At the end of the Term the Tenant must yield up the Premises with vacant possession, decorated and repaired in accordance with and in the
condition required by the provisions of this lease and to an open plan configuration, give up all keys of the Premises to the Landlord, remove tenant&#146;s fixtures and fittings if requested to do so by the Landlord, and remove any signs erected by
the Tenant in, on or near the Premises, immediately making good any damage caused by their removal. For the avoidance of doubt the air conditioning units and pipes within or attaching to or connecting into the Premises do not form part of the
Premises for the purposes of yielding up. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest on arrears </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must pay interest on any of the Lease Rents or other sums due under this Lease that are not paid within 14 days of the date due,
whether formally demanded or not in respect of the Rent, the interest to be recoverable as rent. Nothing in this clause entitles the Tenant to withhold or delay any payment of the Rent or any other sum due under this Lease or affects the rights of
the Landlord in relation to any <FONT STYLE="white-space:nowrap">non-payment.</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statutory notices </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give to the Landlord and the Superior Landlord full particulars of any notice, direction, order or proposal relating to the
Premises made, given or issued to the Tenant by any government department or local, public, regulatory or other authority or court within 7 days of receipt, and if so requested by the Landlord and/or the Superior Landlord must produce it to the
Landlord and the Superior Landlord. The Tenant must without delay take all necessary steps to comply with the notice, direction or order. At the request of the Landlord and/or the Superior Landlord, and at the Landlord&#146;s cost, the Tenant must
make or join with the Landlord and/or the Superior Landlord in making any objection or representation the Landlord and/or the Superior Landlord reasonably deems expedient against or in respect of any notice, direction, order or proposal unless the
making or joining is contrary to the business interests or statutory obligations of the Tenant or <FONT STYLE="white-space:nowrap">sub-tenants.</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Keyholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must ensure that at all times the Landlord has written notice of the name, home address and home telephone number of at least <I>2
</I>keyholders of the Premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Viewing on sale of reversion </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must, on reasonable prior notice and at reasonable times of the day at any time during the Term, permit prospective purchasers of
the Landlord&#146;s reversion or any other interest superior to the Term, or agents instructed in connection with the sale of the reversion or such an interest, to view the Premises without interruption provided they have the prior written authority
of the Landlord or the Superior Landlord or their respective agents and further provided that it does not impede access to the Premises or the use of the Premises for the Permitted Use and the Landlord shall procure that any damage so caused is
promptly made good. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defective premises </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give notice to the Landlord and the Superior Landlord of any defect in the Premises that might give rise to an obligation on
the Landlord and/or the Superior Landlord to do or refrain from doing anything in order to comply with the provisions of this lease or the duty of care imposed on the Landlord and/or the Superior Landlord, whether pursuant to the Defective Premises
Act 1972 or otherwise, and must at all times display and maintain any notices the Landlord and/or the Superior Landlord from time to time reasonably requires him to display at the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise of the landlord&#146;s rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must permit the Landlord and/or the Superior Landlord to exercise any of the rights granted to him by virtue of the provisions of
this lease at all times during the Term without interruption or interference. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The office covenants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must observe and perform the Office Covenants. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Landlord&#146;s covenants </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord covenants with the Tenant to permit the Tenant peaceably and quietly to hold and enjoy the
Premises without any interruption or disturbance from or by the Landlord or any person claiming under or in trust for him or by title paramount. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall not cause any wilful damage to the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the request and cost of the Tenant, on a full indemnity basis, the Landlord covenants with the Tenant to use
reasonable endeavours to enforce the Landlord&#146;s covenants in the Superior Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall pay the rents reserved by the Superior Lease and perform the covenants on the part of the
tenant contained in the Superior Lease so far as the Tenant is not liable for such performance under the terms of this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall refund all Rent paid in advance by the Tenant in relation to any period falling after the
End Date within 10 working days after the End Date, provided that this clause shall not apply if the Landlord terminates this Lease pursuant to Clause 7 or if this Lease is disclaimed by the Crown or by a liquidator or trustee in bankruptcy of the
Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Warranty as to convictions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant warrants that before the execution of this document he has disclosed to the Landlord in writing any conviction, judgment or finding
of any court or tribunal relating to the Tenant, or any member, director, other officer or major shareholder of the Tenant, or any partner in the partnership, of such a nature as to be likely to affect the decision of any insurer or underwriter to
grant or to continue insurance of any of the Insured Risks. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of the insurance rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant covenants to pay the Insurance Rent for the period commencing on the Rent Commencement Date and ending on the day before the next
policy renewal date on the date of this document, and subsequently to pay the Insurance Rent within 28 days of receipt of written demand and, if so demanded, in advance of the policy renewal date, but not more than 3<I> </I>months in advance. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s further insurance covenants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant covenants with the Landlord to observe and perform the following requirements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Requirements of insurers </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must comply with all the requirements and reasonable recommendations of the insurers. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Policy avoidance and additional premiums </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not do or omit anything that could cause any insurance policy on or in relation to the Premises to become wholly or partly
void or voidable, or do or omit anything by which additional insurance premiums may become payable unless he has previously notified the Landlord and the Superior Landlord and has agreed to pay the increased premium. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire-fighting equipment </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must comply with the requirements of and the duties imposed by the Regulatory Reform (Fire Safety) Order 2005 and the reasonable
requirements of the Landlord and/or the Superior Landlord as to fire safety at the Premises. In particular the Tenant must keep the Premises supplied with such fire-fighting equipment as is necessary to comply with the Regulatory Reform (Fire
Safety) Order 2005 and as the insurers require, and must maintain the equipment to their satisfaction<I> </I>as the Landlord and/or the Superior Landlord reasonably requires, and must maintain the equipment to the reasonable satisfaction of the
insurers and in efficient working order. The Tenant must cause any sprinkler system and other fire-fighting equipment to be inspected by a competent person at least once in every 6 months. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire escapes, equipment and doors </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not obstruct the access to any fire equipment or the means of escape from the Premises, or lock any fire door while the
Premises are occupied. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Combustible materials </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not store on the Premises or bring onto them any dangerous substances as defined by the Regulatory Reform (Fire Safety) Order
2005, and must comply with the requirements and recommendations of the fire authority and the reasonable requirements of the Landlord and/or the Superior Landlord as to fire precautions relating to the Premises. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of events affecting the policy </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give immediate notice to the Landlord and Superior Landlord of any event that might affect any insurance policy on or relating
to the Premises, and any event against which the Superior Landlord may have insured under this lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of convictions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give immediate notice to the Landlord and the Superior Landlord of any conviction, judgment or finding of any court or
tribunal relating to the Tenant, or any member, director, other officer or major shareholder of the Tenant, or any partner in the partnership, of such a nature as to be likely to affect the decision of any insurer or underwriter to grant or to
continue any insurance. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other insurance </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If at any time the Tenant is entitled to the benefit of any insurance of the Premises that is not effected or maintained in pursuance of any
obligation contained in this lease, the Tenant must apply all money received by virtue of that insurance in making good the loss or damage in respect of which the money is received. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s obligations in default </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">To the extent that, at any time during the Contractual Term, the Premises or any part of them are damaged or destroyed by one or more of the
Insured Risks and the insurance money under the policy of insurance effected by the Superior Landlord pursuant to his obligations contained in the Superior Lease is wholly or partially irrecoverable because of any act or default of the Tenant or of
anyone at the Premises expressly or by implication with his authority and under his control, the Tenant must on demand pay to the Landlord the amount of the insurance money so irrecoverable, in which case the provisions of clauses 6.5 and 6.6 shall
apply. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Landlord&#146;s further insurance covenants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord covenants with the Tenant to observe and perform the following requirements in relation to the insurance policy the Superior
Landlord effects pursuant to the Superior Landlord&#146;s obligations contained in the Superior Lease: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Copy policy </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord must produce to the Tenant on receipt from the Superior Landlord a copy of the policy and the last premium renewal receipt
reasonable evidence of the terms of the policy and the fact that the last premium has been paid. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Noting of the Tenant&#146;s interest </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord must use reasonable endeavours to get the Superior Landlord to get the Superior Landlord to ensure that the interest of the
Tenant is noted or endorsed on the policy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Change of risks </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord must notify the Tenant of any material change in the risks covered by the policy from time to time provided the Superior Landlord
makes the Landlord aware of such change. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Damage by Insured Risk </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Premises are damaged or destroyed by an Insured Risk so as to be unfit for occupation and use or
inaccessible or unusable then, (unless the policy of insurance in relation to the Premises has been vitiated in whole or in part in consequences of any act or omission of the Tenant or their respective workers, contractors or agents or any other
person on the Premises with the actual or implied authority of any of them and the Tenant has not paid the irrevocable sum to the Landlord in accordance with Clause 6.3.9) payment of the Rent, or a fair proportion of it according to the nature and
extent of the damage, shall be suspended until the Premises have been reinstated and made fit for occupation and use or accessible or useable (as the case may be), or until the end of three years from the date of damage or destruction, if sooner
(the <B>&#147;Rent Suspension&#148;</B>)<B></B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that any Rent and/or Service Charge have been paid in advance by the Tenant and the Premises are
damaged or destroyed by an Insured Risk so as to be unfit for occupation and use or inaccessible or unusable (and provided that (i)&nbsp;the policy of insurance in relation to the Premises has not been vitiated in whole or in part in consequence of
any act or omission of the Tenant or its respective workers, contractors or agents or any other person on the Premises with the actual or implied authority of any of them or (ii)&nbsp;if the policy of insurance in relation to the Premises has been
vitiated in whole or in part in consequence of any act or omission of the Tenant or its respective workers, contractors or agents or any other person on the Premises with the actual or implied authority of any of them, the Tenant has otherwise paid
the irrecoverable insurance sum to the Landlord in accordance with Clause 6.3.9), the Landlord shall: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as reasonably practicable following the date that the Premises become unfit for occupation and use or
inaccessible or unusable, refund to the Tenant the proportionate amount of Rent and/or Service Charge paid in advance from and including the date of damage or destruction until and excluding the date that the Premises are again made fit for
occupation and use and accessible by the Tenant; or </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following the date that the Premises become fit again for occupation and use and accessible by the Tenant,
credit against future Rent and/or Service Charge payable (as applicable) the equivalent proportionate amount that the Tenant paid in advance from and including the date of damage or destruction until and excluding the date that the Premises are
again made fit for occupation and use and accessible by the Tenant; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that the Lease is terminated following damage or destruction in accordance with Clauses 6.5.3 and
6.5.4, refund to the Tenant as soon as reasonably practicable following termination, the proportionate amount of Rent and/or Service Charge paid in advance from and including the date of damage or destruction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, after 3 years following damage to or destruction of the Premises, the Superior Landlord has, having used
all reasonable endeavours to reinstate the Premises, been unable to complete such reinstatement, the Superior Landlord may terminate this Lease by giving written notice to the Tenant. On giving such written notice this Lease shall determine but this
shall be without prejudice to any right or remedy of the Landlord or the Tenant in respect of any breach of the landlord or tenant covenants of this Lease. Any proceeds of the insurance (other than any insurance for plate glass) shall belong to the
Landlord and/or the Superior Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant may terminate this Lease by giving written notice to the Landlord if, following damage or
destruction of the Premises by an Insured Risk, the Premises has not been reinstated so as to be fit for occupation and use has not been reinstated so as to make the Premises accessible or useable within three years after the date of damage or
destruction. On giving this written notice this Lease shall determine but this shall be without prejudice to any right or remedy of either party in respect of any breach of the obligations and covenants of this Lease. Any proceeds of the insurance
shall belong to the Landlord and/or the Superior Landlord. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Damage by Uninsured Risk </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this clause: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These provisions shall apply from the date on which any Insured Risk becomes an Uninsured Risk but only in
relation to the Uninsured Risk. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall notify the Tenant in writing promptly after the Superior Landlord informs the Landlord that
an Insured Risk becomes an Uninsured Risk. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, during the Contractual Term, the Premises or a substantial part of it shall be damaged or destroyed by an
Uninsured Risk so as to make the Premises or a substantial part of it inaccessible or unfit for occupation and use: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Rent or a fair proportion of it according to the nature and extent of the damage sustained will not be
payable until the earlier of the date on which: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Premises shall again be fit for occupation or use; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Lease shall be terminated in accordance with the provisions of clause 6.6.1.3(b). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Superior Landlord may, within one year of the date of such damage or destruction, serve notice on the
Landlord (the &#147;Reinstatement Notice&#148;) confirming that it will reinstate the Premises so that the Premises shall be fit for occupation and use or made accessible and the Landlord shall deliver a copy of the Reinstatement Notice to the
Tenant immediately upon receipt. If the Superior Landlord fails to serve a Reinstatement Notice the Lease will automatically end on the date one year after the date of such damage or destruction and immediately prior to termination of the Superior
Lease. The termination of this Lease shall be without prejudice to any right of the Landlord or the Tenant in respect of any breach of the covenants of the other party to this Lease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 6.6.1.3(b) shall not apply if an Insured Risk shall have become an Uninsured Risk owing to the act or
default of the Tenant or any person deriving title under the Tenant or their respective agents, employees, licensees or contractors. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Superior Landlord has served a Reinstatement Notice but such reinstatement has not been completed by the
date two years from the date of the Reinstatement Notice, then at any time after that date the Tenant may </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminate this Lease by serving not less than three months&#146; notice on the Landlord stating that it terminates this Lease. The termination of this Lease shall be without prejudice to any right of the Landlord or the
Tenant in respect of any breach of the covenants of the other party to this Lease. If by the end of such notice the Premises, and/or access to the Premises have been reinstated so that the Premises are fit for occupation and use and are accessible,
the notice shall be void and this Lease shall continue in full force and effect. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Forfeiture </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may <FONT STYLE="white-space:nowrap">re-enter</FONT> the Premises (or any part of the Premises in
the name of the whole) at any time after any of the following occurs: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rent is unpaid 21 days after becoming payable whether it has been formally demanded or not;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any breach of any condition of, or tenant covenant in, this Lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Act of Insolvency. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord <FONT STYLE="white-space:nowrap">re-enters</FONT> the Premises (or any part of the Premises in
the name of the whole) pursuant to this clause, this Lease shall immediately end, but without prejudice to any right or remedy of the Landlord in respect of any breach of covenant by the Tenant or any guarantor. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusion of warranty as to use </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Nothing in this lease or in any consent granted by the Landlord under this lease is to imply or warrant that the Premises may lawfully be used
under the Planning Acts for the Permitted Use. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusion of third party rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Nothing in this lease is intended to confer any benefit on any person who is not a party to it. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Representations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant acknowledges that this lease has not been entered into in reliance wholly or partly on any statement or representation made by or
on behalf of the Landlord other than any expressly set out in this lease or made by the Landlord&#146;s solicitors in any written response to enquiries raised by the Tenant&#146;s solicitors in connection with the grant of this lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Documents under hand </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">While the Landlord is a limited liability partnership, a limited company or other corporation, any licence, consent, approval or notice
required to be given by the Landlord shall be sufficiently given if given under the hand of a member, director, the secretary or other duly authorised officer of the Landlord. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s property </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If, after the Tenant has vacated the Premises at the end of the Term, any property of his remains in or on the Premises and he fails to remove
it within 7 days after a written request from the Landlord to do so, or, if the Landlord is unable to make such a request to the Tenant, within 14 days from the first attempt to make it, then the Landlord may, as the agent of the Tenant, sell that
property. The Tenant must indemnify the Landlord against any liability incurred by the Landlord to any third party whose property is sold by him in the mistaken belief held in good faith, which shall be presumed unless the contrary is proved, that
the property belonged to the Tenant. If, having made reasonable efforts to do so, the Landlord is unable to locate the Tenant, then the Landlord may retain the proceeds of sale absolutely unless the Tenant claims them within 6 months of the date on
which he vacated the Premises. The Tenant must indemnify the Landlord against any damage occasioned to the Premises and any losses caused by or related to the presence of the property in or on the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No implied easements </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Neither the granting of this Lease nor anything herein contained shall by implication of law or otherwise operate or to be deemed to confer
upon the Tenant any easement right or privilege whatsoever over or against any adjoining or neighbouring premises or which would or might restrict or prejudicially affect the future rebuilding alteration or development of any adjoining or
neighbouring premises and the Landlord and/or the Superior Landlord shall have the right at any time to make such alterations to or to pull down and rebuild or redevelop any adjoining or neighbouring premises as it may deem fit without obtaining any
consent from or making any compensation to the Tenant. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rights of light and air </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any light or air at any time enjoyed shall be deemed to be enjoyed by consent and not as of right. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No restrictions on adjoining property </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Neither the granting of this Lease nor anything herein contained or implied shall impose or be deemed to impose any restriction on the use of
any land or building not comprised in this Lease or give the Tenant the benefit of or the right to enforce or to have enforced or to prevent the release or modification of any covenant agreement or condition entered into by any purchaser from or by
any lessee or occupier of the Landlord or the Superior Landlord (as the case may be) in respect of the property not comprised in this Lease or prevent or restrict in any way the development of any land not comprised in this Lease Provided always
that the provisions of this <FONT STYLE="white-space:nowrap">sub-clause</FONT> shall not substantially interfere with or affect the quiet enjoyment and use of the Premises by the Tenant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acceptance of rent </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No demand for or acceptance of or receipt of the Rent or the grant of any licence or approval or the
registration of any document by the Landlord after knowledge or notice received by the Landlord or its agents of any breach of any of the Tenant&#146;s covenants hereunder shall be or operate as a waiver wholly or partially to the extent that any
such breach shall be subsisting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord shall properly refrain from demanding or accepting the Rent or any other monies due under this
Lease in circumstances in which the Landlord has reasonable grounds to believe either that the Tenant is in breach of any of the provisions of this Lease or that the Tenant might acquire against the Landlord any rights or entitlement then
notwithstanding such restraint interest at the base rate shall be payable as specified in Clause 3.2 from the due date until the Landlord shall accept the Rent from the Tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Arbitration </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any dispute or difference arising between the Landlord and the Tenant in respect of any decision made by or on
behalf of the Landlord on any matter which is required to be decided under the provisions of this Lease (save in relation to Clause 3.11 (Assignment) or as otherwise provided in this Lease) shall be referred to the decision of a sole arbitrator to
be agreed upon by the Landlord and by the Tenant or </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in default of agreement to an arbitrator to be appointed at the written request of either the Landlord or the Tenant by or on behalf of the then President of the Royal Institution of Chartered
Surveyors (or his nominee) such arbitrator to act in accordance with the Arbitration Acts from time to time in force and his fees shall be within his award. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusion of S.62 LPA </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The operation of Section&nbsp;62 of the Law of Property Act 1925 shall be excluded from this Lease and the only
rights granted to the Tenant are those expressly set out in this Lease and the Tenant shall not by virtue of this Lease be deemed to have acquired or be entitled to and the Tenant shall not during the Term acquire or become entitled by any means
whatsoever to any easement from or over or affecting any other land premises now or at any time hereafter belonging to the Landlord or the Superior Landlord (as the case may be) and not comprised in this Lease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Representation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that this Lease has not been entered into in reliance wholly or partly on any statement
or representation made by or on behalf of the Landlord except any such statement or representation that is expressly set out in this Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notices </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Form and service of notices </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">A notice under this lease must be in writing and, unless the receiving party or his authorised agent acknowledges receipt, is valid if, and
only if it is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">given by hand, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sent by registered post or recorded delivery, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">and is served: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the receiving party is a limited liability partnership or company incorporated within Great Britain, at
the registered office, </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the receiving party is the Tenant and the Tenant is not such a limited liability partnership or company,
at the Tenant&#146;s address shown in this lease or at any address specified in a notice given by the Landlord to the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the receiving party is the Landlord and the Landlord is not such a limited liability partnership or
company, at the Landlord&#146;s address shown in this lease or at any address specified in a notice given by the Landlord to the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deemed delivery </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Special delivery or recorded mail </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Unless it is returned through the Royal Mail undelivered, a notice sent by special delivery or recorded mail shall be treated as served on the
third working day after posting whenever and whether or not it is received. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working day </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;a working day&#146; are references to a day when the United Kingdom clearing banks are open for business in the City of
London. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joint recipients </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If the receiving party consists of more than one person, a notice to one of them is notice to all. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Lease </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">This lease is a new tenancy for the purposes of section 1 of the 1995 Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Exclusion of sections 24&#150;28 of the 1954 Act </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman"><B>The parties confirm that:</B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord served a notice on the Tenant, as required by section 38A(3)(a) of the 1954 Act applying to the
tenancy created by this Lease, before this Lease was entered into; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15.2</TD>
<TD ALIGN="left" VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] who was duly
authorised by the Tenant to do so made a statutory declaration dated [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] in accordance with the requirements of section 38A(3)(b)
of the 1954 Act and </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there is no agreement for lease to which this Lease gives effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree that the provisions of sections 24 to 28 of the 1954 Act are excluded in relation to the
tenancy created by this Lease. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Services and Service Charge </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The &#147;Services&#148; are: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining and repairing the Common Parts including all conducting media forming part of the Common
Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning the outside of the windows of the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">lighting the Common Parts and cleaning, maintaining, repairing and replacing lighting machinery and equipment
on the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing refuse bins on the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing signage for the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing, operating and replacing security machinery and equipment (including closed
circuit television) on the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing, operating and replacing fire prevention, detection and fighting machinery and
equipment and fire alarms on the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing a signboard showing the names and logos of the tenants and other
occupiers in the entrance hall of the Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintaining the landscaped and grassed areas of the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the Lifts in the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">decorating the internal areas of the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the floor coverings on the internal areas of the Common Parts;
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the furniture and fittings on the Common Parts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the furniture, fittings and equipment in the lavatories on the
Common Parts and providing hot and cold water, soap, paper, towels and other supplies for them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">heating the internal areas of the Common Parts and cleaning, maintaining, repairing and replacing heating
machinery and equipment serving the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(if provided as at the date of this lease) providing <FONT STYLE="white-space:nowrap">air-conditioning</FONT>
for the internal areas of the Building and cleaning, maintaining, repairing and replacing any such <FONT STYLE="white-space:nowrap">air-conditioning</FONT> equipment serving the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(if provided as at the date of this lease) providing security reception cleaning and maintenance staff for the
Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other service or amenity that the Landlord may in its reasonable discretion provide for the benefit of the
tenants and occupiers of the Building, provided that the Tenant actually benefits from such service. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any replacement, rebuilding or renewal of items listed in this Clause 9 shall be undertaken by the Landlord
only where such items are beyond economic repair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The &#147;Service Costs&#148; are the total of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The whole of the costs of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing the Services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the supply and removal of electricity, gas, water, sewage and other utilities to and from the Building (where
the Tenant does not otherwise obtain such supplies to the Premises itself); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">complying with the recommendations and requirements of the insurers of the Building (insofar as those
recommendations are reasonable and those recommendations and requirements relate to the Common Parts); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">complying with all laws relating to the Common Parts, their use and any works carried out at them, and relating
to the use of all conducting media, machinery and equipment at or serving the Common Parts and to any materials kept at or disposed of from the Common Parts; </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">complying with the Third Party Rights insofar as they relate to the Common Parts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taking any steps (including proceedings) that the Landlord reasonably considers necessary to prevent or remove
any encroachment over the Common Parts or to prevent the acquisition of any right over the Common Parts (or the Building as a whole) or to remove any obstruction to the flow of light or air to the Common Parts (or the Building as a whole);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the reasonable and proper costs, fees and disbursements of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">managing agents employed by the Landlord for the carrying out and provision of the Services or, where managing
agents are not employed, a management fee for the carrying out and provision of the Services of 10% of the cost of the Services; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">accountants employed by the Landlord to prepare and audit the service charge accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of the salaries and employer costs (including pension, welfare and insurance contributions) and
uniforms of any security reception cleaning and maintenance staff for the Building and of all equipment and supplies needed for the proper performance of their duties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rates, taxes, impositions and outgoings payable in respect of the Common Parts, their use and any works
carried out on them (other than any taxes payable by the Landlord in connection with any dealing with or disposition of its reversionary interest in the Building); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any VAT payable by the Landlord in respect of any of the items mentioned above except to the extent that the
Landlord obtains credit for such VAT under the VATA 1994. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall, acting reasonably and in the interests of good estate management: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">supply the Services in an efficient manner at all appropriate times; </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">repair the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide heating and (if provided as at the date of this lease)
<FONT STYLE="white-space:nowrap">air-conditioning</FONT> to the internal areas of the Common Parts during such periods of the year as the Landlord considers appropriate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide electricity and water to the Premises; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the internal areas of the Common Parts clean, and to clean the outside of the windows of the Building as
often as the Landlord considers appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the internal areas of the Common Parts reasonably well lit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">supply hot and cold water, soap, paper, towels and other supplies for the lavatories on the Common Parts; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the Lifts in reasonable working order. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may, but shall not be obliged to, provide any of the other Services not listed in Clause 9.3,
provided that the Tenant&#146;s use and enjoyment of the Premises is not materially impaired. The Landlord shall not be obliged to carry out any works where the need for those works has arisen by reason of any damage or destruction by a risk against
which the Superior Landlord is not obliged to insure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall not be obliged to provide any of the Services outside the Permitted Hours.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall not be liable for: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any interruption in, or disruption to, the provision of any of the Services for any reason that is outside the
reasonable and foreseeable control of the Landlord; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any absence or insufficiency of any of the Services or where there is any breakdown or defect in any conducting
media, except where due to the negligence of the Landlord and provided that the Landlord seeks to make good the breakdown or defect. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Service charge exclusions </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following costs shall be expressly excluded from the Service Charge: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs arising from any damage or destruction to the Building caused by an Insured Risk or an Uninsured Risk, or
repair costs recovered by the Landlord under third party warranties or guarantees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Capital costs of the construction, alteration or extension of the Building, save for alterations made to the
Common Parts or structure of the Building (other than any such alterations made in the last year of the Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of upgrading, innovation or improvement resulting from any repair, maintenance, reinstatement, rebuilding
or replacement, but this will not prevent the Landlord including costs within the Service Charge where they arise: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where an item is to be replaced by way of repair and the replacement is broadly the modern day or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> equivalent of what was there previously; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Landlord considers replacement to be more economical than repair (and the Landlord is entitled to
take into consideration the medium/long-term benefits of replacement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where an item has to be replaced or installed to comply with any Act or the requirements of the Insurers; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where replacement or renewal is reasonable and cost-effective and will reduce operating costs for the benefit
of the tenants of the Lettable Units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of any unlet Lettable Unit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rent collection costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs incurred in dealing with any lettings or rent reviews at the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unrecovered costs due from another tenant of the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs incurred in respect of any disposal of the Landlord&#146;s interest in the Building, including the costs
of advertising and promotional or publicity activities relating to any proposed dealing with the Landlord&#146;s interest in the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Before or as soon as possible after the start of each Service Charge Year, the Landlord shall prepare and send
the Tenant an estimate of the Service Costs for that Service Charge Year and a statement of the estimated Service Charge for that Service Charge Year. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall pay the estimated Service Charge for each Service Charge Year in four equal instalments on
each of the Rent Payment Dates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In relation to the Service Charge Year current at the date of this Lease, the Tenant&#146;s obligations to pay
the estimated Service Charge and the actual Service Charge shall be limited to an apportioned part of those amounts, such apportioned part to be calculated on a daily basis for the period from and including the date of this Lease to the end of the
Service Charge Year. The estimated Service Charge for which the Tenant is liable shall be paid in equal instalments on the date of this Lease and the remaining Rent Payment Dates during the period from and including the date of this Lease until the
end of the Service Charge Year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as reasonably practicable after the end of each Service Charge Year, the Landlord shall prepare and
send to the Tenant a certificate showing the Service Costs and the Service Charge for that Service Charge Year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any cost relating to any Services actually provided to and benefitting the Tenant is omitted from the
calculation of the Service Charge in any Service Charge Year, the Landlord shall be entitled to include it in the estimate and certificate of the Service Charge in any following Service Charge Year. Otherwise, and except in the case of fraud or
wilful or manifest error, the Service Charge certificate shall be conclusive as to all matters of fact to which it refers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, in respect of any Service Charge Year, the Landlord&#146;s estimate of the Service Charge is less than the
Service Charge, the Tenant shall pay the difference within 14 days of receipt of written demand. If, in respect of any Service Charge Year, the Landlord&#146;s estimate of the Service Charge is more than the Service Charge, the Landlord shall credit
the difference against the Tenant&#146;s next instalment of the estimated Service Charge (and where the difference exceeds the next instalment then the balance of the difference shall be credited against each succeeding instalment until it is fully
credited), and if such reconciliation occurs after the end of the Contractual Term, the Landlord shall, as soon within 14 days of the production of such reconciliation, pay to the Tenant the equivalent amount that the Tenant paid in excess of the
actual Service Costs incurred. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Guarantee and Indemnity </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of the Schedule 4 apply. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Act of Insolvency occurs in relation to a guarantor, or if any guarantor (being an individual) dies or
becomes incapable of managing his affairs the Tenant shall, if the Landlord requests, procure that a person of standing acceptable to the Landlord, within 10 days of that request, enters into a replacement or additional guarantee and indemnity of
the tenant covenants of this Lease in the same form as that entered into by the former guarantor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 10.2 shall not apply in the case of a person who is guarantor by reason of having entered into an
authorised guarantee agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For so long as any guarantor remains liable to the Landlord, the Tenant shall, if the Landlord requests,
procure that that guarantor joins in any consent or approval required under this Lease and consents to any variation of the tenant covenants of this Lease. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Lease has been entered into as a deed on the date stated at the beginning of it. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part 1&#151;Rights Granted </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following rights are granted to
the Tenant in common with the Landlord, the Superior Landlord and all others similarly entitled: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Passage of water soil gas electricity and other services through the Conduits now existing or to be constructed
during the Term passing in through over or under adjoining land and serving the Premises and which do not form part of the Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(In case of emergency only) to pass on foot only across the courtyard shown edged green on plan 2 attached to
the Head Lease (the Courtyard) in order to exit through the gates of the Courtyard and from there to the public highway for the purpose of emergency egress from the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To use the Courtyard for general recreational use in common with the Landlord and the owners and occupiers of
the adjoining land with access onto the Courtyard and those authorised by them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To pass and <FONT STYLE="white-space:nowrap">re-pass</FONT> at all times on foot only across the Courtyard
between the doorways marked &#147;X&#148; and &#147;Y&#148; on plan 1 attached to the Head Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To use the lifts stairs and corridors forming part of the Common Parts for the purposes of access to and egress
from the Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to put refuse in any refuse bins allocated on the Common Parts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to display the name and logo of the Tenant on a sign or noticeboard provided by the Landlord in the
entrance hall of the Building in a form and manner approved by the Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to use the lavatories in the Common Parts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to support and protection from the Common Parts to the extent that the Common Parts provide support and
protection to the Premises at the date of this Lease. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part 2&#151;The Rights Reserved </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following rights are reserved to the Landlord and the Superior Landlord and all other persons authorised by the Landlord or the Superior Landlord or
otherwise entitled to such rights: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights reserved by the Superior Lease insofar as they relate to the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to use and to connect into conducting media at, but not forming part of, the Premises which are in
existence at the date of this Lease or which are installed or constructed during the Contractual Term; the right to install and construct conducting media at the Premises to serve any part of the Building (whether or not such conducting media also
serve the Premises); and the right to <FONT STYLE="white-space:nowrap">re-route</FONT> any conducting media mentioned in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to erect scaffolding at the Premises or the Building and attach it to any part of the Premises or the
Building in connection with any of the rights reserved pursuant to this Part 2 where reasonable prior written notice has been given to the Tenant and provided that the Tenant&#146;s access to and egress from, the Premises is not materially adversely
affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to attach any structure, fixture or fitting to the boundary of the Premises in connection with any of
the rights reserved pursuant to this Part 2; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to <FONT STYLE="white-space:nowrap">re-route</FONT> any means of access to or egress from the
Premises or the Building and to change the areas over which the rights mentioned paragraph 5 of Schedule 1 are exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to <FONT STYLE="white-space:nowrap">re-route</FONT> and replace any conducting media over which the
rights mentioned paragraph 1 of Schedule 1 are exercised. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord reserves the right to enter the Premises: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to repair, maintain, install, construct, <FONT STYLE="white-space:nowrap">re-route</FONT> or replace any
conducting media or structure relating to any of the rights reserved pursuant to this Part 2; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to carry out any works to any other Lettable Unit; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for any other purpose mentioned in or connected with: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Lease; </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights reserved pursuant to this Part 2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord&#146;s interest in the Premises and/or the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall allow all those entitled to exercise any right to enter the Premises, to do so with their
workers, contractors, agents and professional advisors, and to enter the Premises at any reasonable time (where reasonably practicable during usual business hours) and, except in the case of an emergency, after having given reasonable prior written
notice to the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall promptly make good all damage caused to the Premises or its contents by the exercise of such
rights. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part 3 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matters to which this
lease is subject </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The matters mentioned in the Property and Charges Register of Title Number EGL440236 as of 15&nbsp;February
2018 timed at 12:26:09 insofar as they affect or relate to the Premises or the exercise of rights granted by this Lease save for any financial charges. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deed of Covenant dated 31&nbsp;May 2002 and made between (2)&nbsp;National Car Parks Limited and (2)&nbsp;J.F.
Miller Properties Limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agreement dated 4&nbsp;July 2000 and made between (1)&nbsp;London Borough of Hackney and (2)&nbsp;the Tenant
pursuant to s.106 of Town&nbsp;&amp; Country Planning Act 1990. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Superior Lease. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2&#151;The Rent and Rent Review </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all purposes of this schedule the terms defined in this paragraph have the meanings specified </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An arbitrator </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References to an arbitrator are references to a person appointed by agreement between the Landlord and the Tenant or, in the absence of agreement within 14
days of one of them giving notice to the other of his nomination nominated by the President on the application of either made no earlier than 6 months before the review date or at any time thereafter to determine the rent under this schedule. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Assumptions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Assumptions means: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.1 the assumption
that no work has been carried out on the Premises during or prior to the Term by the Tenant that has diminished the rental value of the Premises other than work carried out in compliance with clause 3.8.2.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.2 the assumption that if the Premises have been destroyed or damaged they have been fully rebuilt or reinstated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.3 the assumption that the covenants contained in this Lease on the part of the Tenant have been fully performed and observed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.4 the assumption that the Premises are available to let by a willing landlord to a willing tenant in the open market by one lease
(&#145;the Hypothetical Lease&#146;) without a premium being paid by either party and with vacant possession. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.5 the assumption that
the Premises have already been fitted out and equipped by and at the expense of the incoming tenant so that they are capable of being used by the incoming tenant from the beginning of the Hypothetical Lease for all purposes required by the incoming
tenant that would be permitted under this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.6 the assumption that the Hypothetical Lease contains the same terms as this Lease,
except the amount of the Initial Rent, and except any rent free or concessionary period allowed to the Tenant for fitting out the Premises for its occupation and use at the commencement of the Term and including the provisions for rent review on the
5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> anniversary of the term commencement date of the Hypothetical Lease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.7 the assumption that the term of the Hypothetical Lease is equal in length to the
Contractual Term and that such terms begins on the Review Date, that the rent commences to be payable on that date and that the years during which the tenant covenants to decorate the Premises are at the same intervals after the beginning of the
terms of the Hypothetical Lease as those specified in this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.8 the assumption that every prospective willing landlord and
willing tenant is able to recover VAT in full. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Disregards </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Disregards means: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.1 disregard of any
effect on rent of the fact that the Tenant, his subtenants or their predecessors in title or any lawful occupier have been in occupation of the Premises or any part of them; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.2 disregard of any goodwill attached to the Premises by reason of the carrying on at the Premises of the business of the Tenant, its
undertenants or their respective predecessors in title in their respective business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.3 disregard of any increase in value of the
Premises attributable to the existence at the review date to any alteration or improvement (and for the avoidance of doubt the expressions &#147;alteration&#148; and &#147;improvement&#148; shall include
<FONT STYLE="white-space:nowrap">fitting-out</FONT> works and similar alterations) to the Premises or any part of them carried out otherwise that in pursuance of an obligation to the Landlord or his predecessors in title. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.3 disregard of the taxable status of the Landlord or the Tenant for the purposes of VAT. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The President </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The President means the President for the time being of the Royal Institution of Chartered Surveyors or any person authorised by him to make appointments on
this behalf. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The review period </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References to the review period are references to the period beginning on the Review Date and ending on the expiry of the Lease. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ascertaining the Rent </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until the Review Date the Rent is to be the Initial Rent and thereafter the Rent is to be a sum equal to the greater of the sum of &pound;142,501.20 per annum
or the Open Market Rent to be determined in accordance with clause 1.6.3 of this Schedule. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agreement of the Rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Six months before each review date, time not being of the essence, the Landlord and Tenant must explore the possibility of open negotiations with a view to
reaching a written agreement as to the Rent for the review period and the Rent for that period may be agreed at any time or, in the absence of agreement, is to be determined by an arbitrator not earlier that the review date. The Rent for the review
period may be agreed at any time or, in the absence of agreement, is to be determined by an arbitrator not earlier that the review date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Open market rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sum to be determined by the arbitrator must be the sum at which he decides the Premises might reasonably be expected to be let in the open market at the
Review Date making the Assumptions but disregarding Disregards. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conduct of the arbitration </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The arbitration must be conducted in accordance with the Arbitration Act 1996, except that if an arbitrator dies or declines to act the President may on the
application of either the Landlord or the Tenant appoint another in his place. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Memoranda of agreement </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever the Rent has been ascertained in accordance with this schedule, memoranda to that effect must be signed by or on behalf of the Landlord and the
Tenant, and annexed to this document and its counterpart and the Landlord and the Tenant must bear their own costs in this respect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reimbursement of costs </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on publication of the arbitrator&#146;s award, the Landlord or the Tenant pays all his fees and expenses, the paying party may, in default of payment
within 21 days of a demand to that effect, recover such proportion of them, if any, as the arbitrator awards against the other in the case of the Landlord as rent arrears or in the case of the Tenant by deduction from the Rent. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of the Rent as ascertained </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Rent is not ascertained by a Review Date </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Rent payable during the review period has not be ascertained by the Review Date, then rent is to continue to be payable at the rate previously payable,
such payments being on account of the Rent for that review period. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Review Date is not a quarter day </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Rent for the review period is ascertained by the Review Date but that date is not a quarter day then the Tenant must pay to the Landlord on the Review
Date the difference between the Rent due for that quarter and the Rent already paid for it. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Back-payment where review delayed </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Rent payable during the review period has not been ascertained by the Review Date, then the Tenant must pay to the Landlord, within 7 days of the date
on which the Rent is agreed or the arbitrator&#146;s award is received by him, any shortfall between the Rent that would have been paid for that period had it been ascertained on or before the Review Date and the payments made by the Tenant on
account and any VAT payable thereon, and interest, at 4% a year below the Interest Rate in respect of each instalment of rent due on or after that Review Date on the amount by which the instalment of the Rent that would have been paid had it been
ascertained exceeds the amount paid by the Tenant on account, the interest to be payable for their period from the date on which the instalment was due up to the date of payment of the shortfall. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Effect of counter-inflation provisions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If at any review date a statute prevents restricts or modifies the Landlord&#146;s right either to review the Rent in accordance with this Lease or to recover
any increase in the Rent then the Landlord may, when the restriction or modification is removed, relaxed or varied &#150; without prejudice to his rights, if any, to recover any rent the payment of which has only been deferred by statue on giving
not less than 1 month&#146;s nor more than 3 months&#146; notice to the Tenant at any time within 6 months of the restriction or modification being removed, relaxed or varied time being of the essence, require the Tenant to proceed with the review
of the Rent that has been prevented or to review the Rent further where the Landlord&#146;s right was restricted or modified. The date of expiry of the notice is to be treated as a Review Date provided that nothing in this paragraph is to be
construed as varying the review date. The Landlord may recover any increase in the Rent with effect from the earliest date permitted by law. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3&#151;The Office Covenants </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Use </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must use the Premises for the Permitted Use only. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Security </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not leave the Premises continuously unoccupied for a period of one month or longer. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discharges </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not discharge any oil, grease or other deleterious matter, or any substance that might be or become a source of danger or injury to the
drainage system, into any of the Conduits. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Window cleaning </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must clean the insides of all windows and window frames forming part of the Premises as often as reasonably necessary. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Noise </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not play or use in the Premises any musical instrument, audio or other equipment or apparatus that produces sound that may be heard outside the
Premises if the Landlord and/or the Superior Landlord in their absolute discretions considers such sounds to be undesirable and gives notice to the Tenant to that effect. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ceiling and floor loading </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Heavy items </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not bring onto or permit to remain on the Premises any safes, machinery, goods or other articles that will or may strain or damage the Premises
or any part of them, save for any items approved by the Landlord. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Protection of ceilings </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not suspend anything from any ceiling on the Premises that will or may damage the Premises or any part of them. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Machinery </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Noisy machinery </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not install or use (save where otherwise consented to by the Landlord under this Lease) in or on the Premises any machinery or apparatus that
will cause noise or vibration that can be heard or felt in nearby premises or outside the Premises or that may cause damage. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintenance of machinery </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to avoid damage to the Premises, the Tenant must keep all machinery and equipment on the Premises (&#145;the Machinery&#146;) properly maintained and
in reasonable working order and for that purpose must employ reputable contractors to carry out reasonable, periodic inspection and maintenance of the Machinery. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Renewal of parts </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must renew all working and other parts of the Machinery when beyond economic repair. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operation </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must ensure by directions to his staff and otherwise that the Machinery is properly operated. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Signs</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must at all times display and maintain at a point on the Premises to be specified in writing by the Landlord, a suitable sign, of a size and kind
first approved by the Landlord (acting reasonably), showing the Tenant&#146;s trading name and business. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4&#151;The Authorised Guarantee Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS GUARANTEE is made the ......... day of ................ BETWEEN: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>(name of outgoing tenant)</I> [of <I>(address)</I> <I>(or)</I> the registered office of which is at
<I>(address)</I>] [Company Registration no ...] (&#145;the Guarantor&#146;), and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>(name of landlord)</I> [of <I>(address)</I> <I>(or)</I> the registered office of which is at
<I>(address)</I>] [Company Registration no ...] (&#145;the Landlord&#146;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW THIS DEED WITNESSES as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and interpretation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all purposes of this guarantee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Assignee&#146; means <I>(name of incoming tenant)</I> <B>[</B>Company Registration no ...<B>]</B>,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words importing one gender include all other genders, words importing the singular include the plural and vice
versa, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the clause headings do not form part of this document and are not to be taken into account in its construction
or interpretation, <I>(amend if marginal notes are used instead of headings)</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless expressly stated to the contrary, the expression &#145;this guarantee&#146; includes any document
supplemental to or collateral with this document or entered into in accordance with this document, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if any party to this guarantee at any time comprises two or more persons, obligations expressed or implied to
be made by or with that party are deemed to be made by or with the persons comprising that party jointly and severally, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Lease&#146; means the <B>[</B>lease <I>(or)</I> sublease<B>]</B> of the Premises dated <I>(date)</I>
and made between (1) <B>[</B>the Landlord <I>(or)</I> <I>(name of original landlord)</I><B>]</B> and (2) <B>[</B>the Guarantor <I>(or)</I> <I>(name of original tenant)</I><B>]</B> for the Term, and includes all or any deeds and documents
supplemental to that lease whether or not expressed to be so, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Liability Period&#146; means the period during which the Assignee is bound by the tenant covenants of
the Lease, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the 1995 Act&#146; means the Landlord and Tenant (Covenants) Act 1995 <B>[</B>and all statutes,
regulations and orders included by virtue of clause 1.11<B>]</B>, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Premises&#146; means the property demised by the Lease, </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any reference in this guarantee to a clause without further designation shall be construed as a reference to
the clause of this document so numbered, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless expressly stated to the contrary, any reference to a specific statute includes any statutory extension
or modification, amendment or <FONT STYLE="white-space:nowrap">re-enactment</FONT> of that statute and any regulations or orders made under it, and any general reference to a statute includes any regulations or orders made under that statute,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Term&#146; means the term of years created by the Lease, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;tenant covenants&#146; and &#145;authorised guarantee agreement&#146; have the same meaning as is given
by section 28(1) of the 1995 Act. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recitals</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This guarantee is supplemental to the Lease by which the Premises were let for the Term subject to the payment
of the <B>[</B>rent <I>(or if additional payments are reserved as rent by the lease)</I> rents<B>]</B> reserved by and the performance and observance of the covenants on the tenant&#146;s part and the conditions contained in the Lease.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The immediate reversion to the Lease <B>[</B>remains <I>(or as appropriate)</I> is now<B>]</B> vested in the
Landlord and the unexpired residue of the Term <B>[</B>remains <I>(or as appropriate)</I> is now<B>]</B> vested in the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By clause <I>(number)</I> of the Lease, the Landlord&#146;s consent to an assignment of the Lease is required.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord has agreed to give consent to assignment of the Lease to the Assignee on condition that the
Guarantor enters into this guarantee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This guarantee is intended to take effect only when the Lease is assigned to the Assignee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This guarantee is intended to be an authorised guarantee agreement within the meaning of the 1995 Act.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The COMMON SEAL of <B>MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST</B> was hereunto affixed in the presence of:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">EXECUTED as a DEED by <B>MEIRAGTX UK II LIMITED</B> acting by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Director/Secretary</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>d570173dex105.htm
<DESCRIPTION>EX-10.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.5 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated July&nbsp;30, 2018 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lease </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>relating to
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Premises known as </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fourth Floor, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>15
Ebenezer Street and 25 Provost Street, </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N1 7NP </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>between </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Moorfields Eye Hospital NHS Foundation Trust </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MeiraGTx UK II
Limited </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR1. Date of lease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR2. Landlord&#146;s title number(s) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR3. Parties to
this lease </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Landlord </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moorfields Eye Hospital NHS
Foundation Trust of Moorfields Eye Hospital, 162 City Road, London EC1V 2PD.<B> </B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tenant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MeiraGTx UK II Limited<B> </B>incorporated and registered in England and Wales with company number 9348737 whose registered office is at 92 Britannia Walk,
London N1 7NQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR4. Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In the case of a
conflict between this clause and the remainder of this lease then, for the purposes of registration, this clause shall prevail. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the definition of
Premises in clause 1.36 of this lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR5. Prescribed statements etc </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR6. Term for which the Property is leased </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term as specified in this lease at clause 1.7 (&#145;The Contractual Term&#146;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR7. Prohibitions or restrictions on disposing of this lease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This lease contains a provision that prohibits or restricts dispositions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8. Rights of acquisition etc </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8.1 Tenant&#146;s
contractual rights to renew this lease, to acquire the reversion or another lease of the Property, or to acquire an interest in other land </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8.2 Tenant&#146;s covenant to (or offer to) surrender this lease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR8.3 Landlord&#146;s contractual rights to acquire
this lease </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR9. Restrictive covenants given in
this lease by the Landlord in respect of land other than the Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR10. Easements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR10.1 Easements granted by this
lease for the benefit of the Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Part 1 Schedule 1 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR10.2 Easements granted or reserved by this lease over the Property for the benefit of other property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Part 2 Schedule 1 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR11. Estate rentcharge burdening the
Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LR12. Application for standard form
of restriction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS LEASE is made between the parties referred to in clause LR3 and the provisions that follow have effect
subject to the provisions contained, and terms used, in clauses LR1 to LR12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW THIS DEED WITNESSES as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B>1<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and interpretation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">For all purposes of this lease the terms defined in this clause have the meanings specified. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B>1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;1954 Act&#146; </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;1954 Act&#146; means the Landlord and Tenant Act 1954 and all statutes, regulations and orders included by virtue of clause 1.39 </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B>1.2<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;1995 Act&#146; </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;1995 Act&#146; means the Landlord and Tenant (Covenants) Act 1995 and all statutes, regulations and orders included by virtue of clause
1.39 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B></B>1.3<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Act of Insolvency&#146; </B>means any of the following:<B> </B><B> </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the taking of any step in connection with any voluntary arrangement or any other compromise or arrangement for
the benefit of any creditors of the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making of an application for an administration order or the making of an administration order in relation
to the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the giving of any notice of intention to appoint an administrator, or the filing at court of the prescribed
documents in connection with the appointment of an administrator, or the appointment of an administrator, in any case in relation to the Tenant or any guarantor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the appointment of a receiver or manager or an administrative receiver in relation to any property or income of
the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the commencement of a voluntary <FONT STYLE="white-space:nowrap">winding-up</FONT> in respect of the Tenant or
any guarantor, except a <FONT STYLE="white-space:nowrap">winding-up</FONT> for the purpose of amalgamation or reconstruction of a solvent company in respect of which a statutory declaration of solvency has been filed with the Registrar of Companies;
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making of a petition for a <FONT STYLE="white-space:nowrap">winding-up</FONT> order or a <FONT
STYLE="white-space:nowrap">winding-up</FONT> order in respect of the Tenant or any guarantor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">striking-off</FONT> of the Tenant or any guarantor from the Register of
Companies or the making of an application for the Tenant or any guarantor to be <FONT STYLE="white-space:nowrap">struck-off;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant or any guarantor otherwise ceasing to exist (but excluding where the Tenant or any guarantor dies);
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the making of an application for a bankruptcy order, the presentation of a petition for a bankruptcy order or
the making of a bankruptcy order against the Tenant or any guarantor. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The paragraphs above shall apply in relation to a
partnership or limited partnership (as defined in the Partnership Act 1890 and the Limited Partnerships Act 1907 respectively) subject to the modifications referred to in the Insolvent Partnerships Order 1994 (SI 1994/2421) (as amended), and a
limited liability partnership (as defined in the Limited Liability Partnerships Act 2000) subject to the modifications referred to in the Limited Liability Partnerships Regulations 2001 (SI 2001/1090) (as amended). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Act of Insolvency includes any analogous proceedings or events that may be taken pursuant to the legislation of another jurisdiction in
relation to a tenant or guarantor incorporated or domiciled in such relevant jurisdiction. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Building&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means the land and premises known as 15 Ebenezer Street and 25 Provost Street as the same is demised by the Superior Lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Common Parts&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">the Building other than the Premises and the Lettable Units. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Conduits&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Conduits&#146; means the pipes, sewers, drains, mains, ducts, conduits, gutters, watercourses, wires, cables, laser optical fibres, data
or impulse transmission, communication or reception systems, channels, flues and all other conducting media, including any fixings, louvres, cowls, covers and any other ancillary apparatus, in, on, over or under the Premises. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Contractual Term&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Contractual Term&#146; means a term of years commencing on 27&nbsp;July 2018 until 24&nbsp;May 2027. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Development&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;development&#146; are references to development as defined by the Town and Country Planning Act 1990 section 55. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;End Date&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The last day of the Term (howsoever it arises). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Existing Lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Lease of the Premises dated 6&nbsp;July 2017 made between (1)&nbsp;the Landlord and (2)&nbsp;the Tenant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Gender and number </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Words importing one gender include all other genders; words importing the singular include the plural and vice versa. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Group Company&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In relation to any company, any other company within the same group of companies as that company within the meaning of section 42 of the 1954
Act </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Headings </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The clause, paragraph and schedule headings do not form part of this document and are not to be taken into account in its construction or
interpretation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Head Lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The lease of the Building made the 31st day of May 2002 between (1)&nbsp;J.F. Miller Properties Limited (2)&nbsp;and Islington and Shoreditch
Housing Association Limited </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Initial Rent&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Initial Rent&#146; means the sum of &pound;132,468.80 per year and then as revised pursuant to this lease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Insurance Rent&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Insurance Rent&#146; means the due proportion relating to the Premises of the sum payable by the Landlord to the Superior Landlord
pursuant to clause 2.1.2 of the Superior Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Insured Risks&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Insured Risks&#146; means the risks of loss or damage by fire, storm, tempest, earthquake, lightning, explosion, riot, civil commotion,
malicious damage, terrorism, impact by vehicles and by aircraft and articles dropped from aircraft, other than war risks, flood damage and bursting and overflowing of water pipes and tanks, subsidence, landslip and heave, and such other risks,
whether or not in the nature of the foregoing, as the Landlord or the Superior Landlord (as the case may be) acting reasonably from time to time decides to insure against. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Interest&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;interest&#146; are references to interest payable during the period from the date on which the payment is due to the date
of payment, both before and after any judgment, at the Interest Rate then prevailing or, should the base rate referred to in clause 1.19 cease to exist, at another rate of interest closely comparable with the Interest Rate to be agreed between the
parties or in default of agreement to be determined by a chartered accountant appointed by agreement between the parties or in default of agreement nominated by the President of the Institute of Chartered Accountants in England and Wales, acting as
an expert and not as an arbitrator. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Interest Rate&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Interest Rate&#146; means the rate of 4% a year above the base lending rate of Barclays Bank Plc or such other bank being a member of
the Committee of London and Scottish Bankers as the Landlord from time to time nominate in writing. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Interior Decorating Years&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Interior Decorating Years&#146; means every fifth year of the Term and during the last year thereof. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;consent&#146; and &#145;approved&#146; </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">References to &#145;consent of the Landlord&#146; or words to similar effect are references to a prior written
consent signed by or on behalf of the Landlord and references to the need for anything to be &#145;approved by the Landlord&#146; or words to similar effect are references to the need for a prior written approval by or on behalf of the Landlord.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any provisions in this lease referring to the consent or approval of the Landlord are to be construed as also
requiring the consent or approval of any mortgagee of the Premises and any head landlord, where that consent is required under a mortgage or head lease in existence at the date of this document. Nothing in this lease is to be construed as imposing
any obligation on a mortgagee or head landlord not to refuse any such consent or approval unreasonably. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;the Landlord&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The expression &#145;the Landlord&#146; includes the person or persons from time to time entitled to possession of the Premises when this
lease comes to an end. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;the last year of the Term&#146; and &#145;the end of the Term&#146; </B>
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;the last year of the Term&#146; are references to the actual last year of the Term howsoever it
determines, and references to the &#145;end of the Term&#146; are references to the end of the Term whensoever and howsoever it determines. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;the Tenant&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;The Tenant&#146; includes any person who is for the time being bound by the tenant covenants of this lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation of &#145;this lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Unless expressly stated to the contrary, the expression &#145;this lease&#146; includes any document supplemental to or collateral with this
document or entered into in accordance with this document. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.26</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint and several liability </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Where any party to this lease for the time being comprises two or more persons, obligations expressed or implied to be made by or with that
party are deemed to be made by or with the persons comprising that party jointly and severally. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.27</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Lettable Unit&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">a floor or part of a floor of the Building other than the Premises, that is capable of being let or occupied.<B> </B> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.28</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Lifts&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">all lifts and lift machinery and equipment in the Building.<B> </B> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.29</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Losses&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;losses&#146; are references to liabilities, damages or losses, awards of damages or compensation, penalties, costs,
disbursements and expenses arising from any claim, demand, action or proceedings. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.30</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation not to permit or suffer </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any covenant by the Tenant or the Landlord not to do anything includes an obligation to use reasonable endeavours not to permit or suffer that
thing to be done by another person where the Landlord or Tenant (as applicable) is aware that the thing is being done. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.31</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Office Covenants&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Office Covenants&#146; mean the covenants set out in Schedule 3. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.32</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Permitted Hours&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means 7am to 10pm Mondays to Fridays (inclusive) and 9am to 6pm on Saturdays Sundays and bank holidays. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.33</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Permitted Use&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Permitted Use&#146; means Class&nbsp;B1 of the Town and Country Use Classes Order 1987 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">(to include laboratory and light industrial use). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.34</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Plan 1, Plan 2&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The plans annexed to this lease and so numbered. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.35</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Planning Acts&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Planning Acts&#146; means the Town and Country Planning Act 1990, the Planning (Listed Buildings and Conservation Areas) Act 1990, the
Planning (Consequential Provisions) Act 1990, the Planning (Hazardous Substances) Act 1990, the Planning and Compensation Act 1991, the Planning and Compulsory Purchase Act 2004 and all statutes, regulations and orders included by virtue of clause
1.39. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570173page161.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g570173page162.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.36</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Premises&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The fourth floor of the Building (the floor plan of which is shown edged red on Plan 1) bounded by and including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the floorboards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the ceiling plaster; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the interior plasterwork and finishes of exterior walls and columns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the plasterwork and finishes of the interior structural walls and columns that adjoin another Lettable Unit or
the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the doors and windows within the interior structural walls and columns that adjoin another Lettable Unit or the
Common Parts and their frames and fittings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one half of the thickness of the interior <FONT STYLE="white-space:nowrap">non-structural</FONT> walls and
columns that adjoin another Lettable Unit or the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the doors and windows within the interior <FONT STYLE="white-space:nowrap">non-structural</FONT> walls and
columns that adjoin the Common Parts and their frames and fittings; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">but excluding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the windows in the exterior walls and their frames and fittings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all conducting media within that part of the Building but which do not exclusively serve that part of the
Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the load-bearing structure of the Building including the load-bearing structure of the roof, foundations,
external and internal walls and columns and the structural slabs of the ceilings and floors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the external surfaces of the Building (except the external surfaces of any finishes referred to in
(c)&nbsp;above) and the whole of the windows and window frames and fittings constructed in the external walls of the Building.&nbsp;&nbsp;&nbsp;&nbsp; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.37</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References to clauses and schedules </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any reference in this document to a clause, subclause, paragraph, subparagraph or schedule without further designation is to be construed as a
reference to the clause, subclause, paragraph, subparagraph or schedule of this document so numbered. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.38</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References to rights of access </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to any right of the Landlord to have access to the Premises are to be construed as extending to any head landlord and any mortgagee
of the Premises where the head lease or mortgage grants such rights of access to the head landlord or mortgagee, and to all persons authorised in writing by the Landlord and any head landlord or mortgagee, including agents, professional advisers,
contractors, workmen and others, but subject to the provisos to any such access rights contained in this Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.39</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>References to statutes </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Unless expressly stated to the contrary, any reference to a specific statute includes any statutory extension or modification, amendment or <FONT
STYLE="white-space:nowrap">re-enactment</FONT> of that statute and any regulations or orders made under it, and any general reference to a statute includes any regulations or orders made under that statute. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.40</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Ramp Car Park&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Ramp Car Park&#146; means the access ramp leading to the Landlord Parking Bays and the Tenant Parking Bays edged and cross-hatched
orange on Plan 2 excluding the Landlord Parking Bays. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.41</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Rent&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Until the Review Date &#145;the Rent&#146; means the Initial Rent. Thereafter &#145;the Rent&#146; means the sum ascertained in accordance
with Schedule 2. &#145;The Rent&#146; does not include the Insurance Rent, but the term &#145;the Lease Rents&#146; means the Rent and the Insurance Rent and the Service Charge. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.42</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Rent Commencement Date&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Rent Commencement Date&#146; means [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ].
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.43</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Review Date&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Review Date&#146; means 31st May 2022. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.44</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Service Charge&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">a fair and reasonable proportion of the Service Costs. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.45</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Service Charge Year&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">is the annual accounting period relating to the Services and the Service Costs beginning on 1&nbsp;April in 2018 and each subsequent year
during the Term. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.46</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Service Costs&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">the costs listed in clause 9.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.47</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Services&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means the services listed in clause 9.1. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.48</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Superior Landlord&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">means the landlord for the time being of the Superior Lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.49</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Superior Lease&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Superior Lease&#146; means the lease by virtue of which the Landlord holds the Premises, which is dated
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] and made between (1)&nbsp;Islington and Shoreditch Housing Association Limited and (2)&nbsp;the Landlord and any documents made supplemental to it.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.50</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Surveyor&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Surveyor&#146; means any person or firm appointed by the Landlord in his place. The Surveyor may be an employee of the Landlord or a
Group Company of the Landlord. The expression &#145;the Surveyor&#146; includes the person or firm appointed by the Landlord to collect the Lease Rents. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.51</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;Term&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Term&#146; means the Contractual Term. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.52</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms from the 1995 Act </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Where the expressions &#145;landlord covenants&#146;, &#145;tenant covenants&#146;, or &#145;authorised guarantee agreement&#146; are used in
this lease they are to have the same meaning as is given by section 28(1) of the 1995 Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.53</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Uninsured Risk </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;Uninsured Risk&#146; means an Insured Risk against which insurance is or ceases to be obtainable on normal commercial terms in the
London insurance market at rates generally available in the London insurance market for a property of this type, size and location. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.54</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&#145;VAT&#146; </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">&#145;VAT&#146; means value added tax or any other tax of a similar nature and, unless otherwise expressly stated, all references to rents or
other sums payable by the Tenant are exclusive of VAT. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Demise </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord lets the Premises to the Tenant with full title guarantee together with the easements and rights (if any) contained or referred
to in Part 1 of Schedule 1, excepting and reserving to the Landlord the easements and other rights (if any) contained or referred to in Part 2 of Schedule 1 to hold to the Tenant and subject to (a)&nbsp;all rights easements quasi-easements and
privileges to which the Premises are or may be subject and (b)&nbsp;the matters set out in Part 3 of the Schedule 1 from and including the first day of the Contractual Term for the Term yielding and paying to the Landlord: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Firstly throughout the Term (and proportionately for any part of a year) the Rent, without any deduction or set
off, by equal quarterly payments in advance on the usual quarter days in every year and proportionately for any period of less than a year, the first such payment, being a proportionate sum in respect of the period from and including the Rent
Commencement Date to and including the day before the quarter day next after the Rent Commencement Date, to be paid on the date of this lease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Secondly by way of further rent, the Insurance Rent, payable within 28 days of a written demand.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Thirdly by way of further rent, the Service Charge payable at the times and in the manner specified in Clause
9.9. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fourthly by way of further rent, all interest payable at the times and in the manner specified in Clause 4.4.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Tenant&#146;s Covenants</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant covenants with the Landlord to observe and perform the following requirements:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rent </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Lease Rents on the days and in the manner set out in this lease, and must not exercise
or seek to exercise any right or claim to withhold rent, or any right or claim to legal or equitable <FONT STYLE="white-space:nowrap">set-off.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay the Lease Rents by banker&#146;s order or credit transfer to any bank and account in the
United Kingdom that the Landlord nominates from time to time, or by such other method as properly requested by Landlord in writing from time to time (acting reasonably). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Outgoings and VAT </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay, and must indemnify the Landlord against: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rates, taxes, assessments, duties, charges, impositions and outgoings that are now or may at any time
during the Term be charged, assessed or imposed on the Premises or on the owner or occupier of them Provided That the foregoing shall not extend to payment of any rates, taxes, assessments, duties, charges, impositions and outgoings payable only as
a direct result of any dealing by the Landlord with its reversionary interest in the Premises; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all VAT that may from time to time be charged on the Lease Rents or other sums payable by the Tenant under this
lease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all VAT incurred in relation to any costs the Tenant is obliged to pay or in respect of which he is required to
indemnify the Landlord under the terms of this lease, save where it is recoverable or available for <FONT STYLE="white-space:nowrap">set-off</FONT> by the Landlord as input tax. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To contribute towards Common Structures </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To pay to the Landlord within 28 days of receipt of written demand a fair and proper proportion of any expense
incurred in cleaning lighting repairing maintaining and (where beyond economic repair) rebuilding or renewing any walls fences sewers gutters drains pipes wires roadways pavements access ways and other similar items which are used or enjoyed or are
capable of being used or enjoyed by an occupier of the Premises in common with any other person </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cost of utilities services consumed </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must pay to the suppliers, and indemnify the Landlord against, all charges for electricity, water,
gas, telecommunications and other services consumed or used at or in relation to the Premises, including meter rents and standing charges, and must comply with the lawful requirements and regulations of their respective suppliers.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Repair, cleaning and decoration </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Repair of the premises </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must repair the Premises and keep them in good condition and repair, except for:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">damage caused by one or more of the Insured Risks save to the extent that the insurance money is irrecoverable
due to any act or default of the Tenant or anyone at the Premises expressly or by implication with the Tenant&#146;s authority and under his control; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">damage caused by an Uninsured Risk but only to the extent that the Uninsured Risk has not become an Uninsured
Risk due to any act or omission of the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Replacement of landlord&#146;s fixtures </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must replace any landlord&#146;s fixtures and fittings in the Premises that are beyond repair at any
time during or at the end of the Term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cleaning and tidying </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must keep the Premises clean and tidy and clear of all rubbish. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Decoration </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must redecorate the inside of the Premises in each of the Interior Decorating Years and the last
year of the Term (unless carried out during the previous 12 months), in all instances in a good and workmanlike manner, with appropriate materials of good quality, to the reasonable satisfaction of the Landlord. Any change in the tints, colours and
patterns of the decoration must be approved by the Landlord, whose approval may not be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Waste, additions and alterations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant must not commit any waste, make any addition to the Premises, unite the Premises with any adjoining
premises, or make any alteration to the Premises except as permitted by the provisions of this clause 3.6. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Internal alterations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant may make internal <FONT STYLE="white-space:nowrap">non-structural</FONT> alterations to the
Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Removal of alterations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the end of the Term, if so requested by the Landlord, the Tenant must remove any additional buildings,
additions, alterations or improvements made by it to the Premises (whether pursuant to the terms of this lease or the Existing Lease), and must make good any part of the Premises damaged by their removal. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Structural alterations </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to carry out any structural alterations or additions whatsoever in or to the Premises or to the Conduits
exclusively serving the Premises without the previous consent in writing of the Landlord such consent not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When applying for the consent of the Landlord hereunder to supply to the Landlord adequate plans and
specifications showing the nature and extent of the alterations or additions which the Tenant wishes to carry out and to pay all reasonable and proper costs and expenses which the Landlord may incur whether by way of surveyor&#146;s or legal
expenses or otherwise in connection with the consideration approval of the alterations and additions and to carry out the said alterations or additions only in accordance with the plans and specifications approved in writing by the Landlord and in
accordance with all statutory and local authority and insurers requirements and recommendations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of the Tenant failing to observe this covenant it shall be lawful for the Landlord and its agents
or surveyors with or without workmen and others and all persons authorised by the Landlord with all necessary materials and appliances to enter upon the Premises and remove any alterations or additions and execute such works as may be necessary to
restore the Premises to their former state and the properly incurred costs and expenses thereof together with all reasonable and proper solicitors&#146; and surveyors&#146; charges and other expenses and losses whether direct or indirect which may
be incurred by the Landlord in connection therewith shall be repaid by the Tenant to the Landlord on demand as a debt. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any other provisions of this lease the parties hereby agree that all fixtures, fittings, fit
out works and alterations installed by the Tenant pursuant to this Lease or the Existing Lease shall remain the property of the Tenant without claim by the Landlord (the Tenant being free to remove any such items provided that any damage caused to
the Premises and and/or any items within it by such removal shall be promptly made good by the Tenant to the Landlord&#146;s reasonable satisfaction). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to prejudice easements </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not by building or otherwise to stop up or darken any window or light in the Premises not to stop up or
obstruct any access of light enjoyed to any adjoining or neighbouring premises nor permit any new wayleave easement right privilege or encroachment shall be made or attempted to be made to give immediate notice thereof to the Landlord and the
Superior Landlord and to permit the Landlord and/or the Superior Landlord and their respective agents to enter upon the Premises (on giving reasonable, prior written notice and at reasonable times) for the purposes of ascertaining the nature of any
such easement right privilege or encroachment and at the request of the Landlord and/or the Superior Landlord and at the cost of the Landlord to adopt such means as may be reasonably required or deemed proper for preventing any such encroachment or
the acquisition of any such easement right privilege or encroachment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to give any third party any acknowledgement that the Tenant enjoys the access of light to any of the
windows or openings in the Premises by the consent of such third party nor to pay such third party any sum of money nor to enter into any agreement with such third party for the purpose of inducing or binding such third party to abstain from
obstructing the access of light to any windows or openings in the event of any of the owners or occupiers of adjacent land or buildings doing or threatening to do anything which obstructs the access of light to any of the said windows or openings to
notify the same forthwith to the Landlord and the Superior Landlord and to permit the Landlord and/or the Superior Landlord to bring such proceedings as it may think fit in the name of and at the cost of the Landlord against any of the owners and/or
occupiers of the adjacent land in respect of the obstruction of the access of light to any of the windows or openings in the Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to make claims </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Clause 5.1, not at any time during the Term to bring any action or make any claim or demand on
account of any injury to the Premises in consequence of </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the erection of any building or the alteration of any building on any land adjacent neighbouring or opposite to
the Premises by the Landlord and/or the Superior Landlord or for which the Landlord and/or the Superior Landlord shall have given its consent or for which the Landlord and/or the Superior Landlord may give its consent pursuant to any power reserved
by this Lease or in respect of any easement right or privilege granted or to be granted by the Landlord and/or the Superior Landlord for the benefit of any land or building erected or to be erected on any land adjacent neighbouring or opposite to
the Premises and (if required) to concur with the Landlord and/or the Superior Landlord at the expense of the Landlord or the Superior Landlord (as the case may be) in any consent which it may give or any grant which it may make as hereinbefore
mentioned. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Planning </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In relation to the Planning Acts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At all times during the Term to comply in all respects with the Planning Acts and to keep the Landlord and the
Superior Landlord indemnified in respect thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to apply for nor implement any planning permissions or other planning consent in respect of the Premises
unless the application permission or other consent shall be been approved in writing by the Landlord (such approval not to be unreasonably withheld or delayed). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the Landlord shall otherwise direct to carry out before the expiration or determination of the Term
(howsoever the same may be determined) any works stipulated to be carried out to the Premises by a date subsequent to such expiration or sooner determination as a condition of any planning permission which the Tenant has implemented or partially
implemented. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forthwith after receiving notice of the same to give full particulars to the Landlord and the Superior Landlord
of any order notice certificate designation direction or other such matter or any proposal thereof made given or issued to the Tenant by any competent authority under or by virtue of the Planning Acts affecting or capable of affecting the Premises
and if so required by the Landlord and/or the Superior Landlord to produce such matter or proposal thereof to the Landlord and the Superior Landlord. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the request of the Landlord and/or the Superior Landlord but at the cost of the Landlord to make or join
with the Landlord and/or the Superior Landlord in making such objection or representation against or in respect of any proposal referred to in the previous <FONT STYLE="white-space:nowrap">sub-clause</FONT> as the Landlord and/or the Superior
Landlord shall deem expedient unless the making or joining is contrary to the business interests or statutory obligations of the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If called upon so to do produce to the Landlord and/or the Superior Landlord all plans documents and other
evidence as the Landlord and/or the Superior Landlord may reasonably require in order to satisfy itself that the provisions of this <FONT STYLE="white-space:nowrap">sub-clause</FONT> have been complied with. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not without the consent of the Landlord to enter into any planning obligation under Section&nbsp;106 of the
Town and Country Act 1990. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.6.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not without the consent of the Landlord to serve any notice under Part VI of the Town and Country Planning Act
1990. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.6.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Connection to the Conduits </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not make any connection with the Conduits except in accordance with plans and specifications approved by the Landlord, whose
approval may not be unreasonably withheld or delayed, and subject to consent to make the connection having previously been obtained from the competent authority, undertaker or supplier. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Aerials, signs and advertisements </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Masts </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not, without the consent of the Landlord, whose consent may not be unreasonably withheld or delayed, erect any mast whether in
connection with telecommunications or otherwise. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Advertisements </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Without the consent of the Landlord and other than pursuant to paragraph 8 of Schedule 3, whose consent may not be unreasonably withheld or
delayed, the Tenant must not fix to or exhibit on the outside of the Premises, fix to or exhibit through any window of the Premises, or display anywhere on the Premises, any placard, sign, notice, fascia board or advertisement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statutory obligations </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must comply in all respects with the requirements of any statutes and any other obligations imposed by law or by any byelaws
applicable to the Premises or the trade or business for the time being carried on there. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Particular obligations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Without prejudice to the generality of clause 3.8.1 the following provisions shall apply: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Works required by statute, department or authority </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must execute all works and provide and maintain all arrangements on or in respect of the Premises or the use of them required to
comply with the requirements of any statute already or in the future to be passed, or the requirements of any government department, local authority or other public or competent authority or court of competent jurisdiction, regardless of whether
they are imposed on the owner, the occupier, or any other person. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acts causing losses </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not do in or near the Premises anything by reason of which the Landlord and/or the Superior Landlord may incur any losses
under any statute. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Construction (Design and Management) Regulations </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">comply with the provisions of the Construction (Design and Management) Regulations 2015 (&#145;the CDM
Regulations&#146;), </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be the only client as defined in the provisions of the CDM Regulations, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fulfil, in relation to all and any works, all the obligations of the client as set out in or reasonably to be
inferred from the CDM Regulations, and make a declaration to that effect to the Health and Safety Executive in accordance with Regulation 6 and Schedule 1 Paragraph 15 of the CDM Regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.8.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Delivery of health and safety files </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">At the end of the Term, the Tenant must forthwith deliver to the Landlord any and all health and safety files relating to the Premises
required to be maintained under the CDM Regulations. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entry to inspect and notice to repair </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entry and notice </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must permit the Landlord and/or the Superior Landlord on reasonable, prior written notice during normal business hours except in
emergency: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to enter the Premises to ascertain whether or not the covenants and conditions of this lease have been observed
and performed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to view the state of repair and condition of the Premises; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to give to the Tenant or leave on the Premises, a written notice specifying the works required to remedy any
breach of the Tenant&#146;s obligations in this lease (&#145;a notice to repair&#146;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Provided that the Landlord (and
anyone authorised by it) shall in exercising its rights under this clause take all reasonable steps to minimise disruption and interference to the Tenant and provided further that any damage caused to the Property and/or any items within it shall be
promptly made good by the Landlord to the Tenant&#146;s reasonable satisfaction. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Works to be carried out </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must carry out the works specified in a notice to repair immediately, including making good any opening up that revealed a breach
of the terms of this lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Landlord&#146;s power in default </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If within 1 month of the service of a notice to repair the Tenant has not started to execute the work referred to in that notice or is not
proceeding diligently with it, or if the Tenant fails to finish the work within a reasonable time thereafter, or if in a case of emergency and in the Superior Landlord&#146;s or the Landlord&#146;s or the Surveyor&#146;s reasonable opinion the
Tenant is unlikely to finish the work within that period, the Tenant must permit the Landlord and/or the Superior Landlord to enter the Premises to execute the outstanding work, and must within 14 days of a written demand pay to the Landlord the
reasonable and properly incurred costs of so doing and all reasonable expenses properly incurred by the Landlord and/or the Superior Landlord, including legal costs and surveyor&#146;s fees. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Alienation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to underlet the Premises in whole or in part. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not (save as hereinafter permitted) to assign transfer mortgage charge part with or share possession or
occupation of the Premises otherwise than as a whole. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to part with or share possession of the whole of the Premises or permit any company or person to have
occupation or possession of the Premises except by way of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an assignment or transfer of the whole of Premises in accordance with the provisions of Clause 3.11;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sharing of occupation in accordance with Clause 3.10.5. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to permit the Premises or any part of them to be held on trust for or by any person body or corporation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant may share occupation of the Premises with a Group Company of the Tenant on condition that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant notifies the Landlord of the identity of the occupier and the part of the Premises to be occupied;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no relationship of landlord and tenant is created; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sharing of occupation ends if the occupier is no longer a Group Company of the Tenant; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Tenant notifies the Landlord as soon as reasonably practicable after the occupation ends.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assignment </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not assign the whole of this Lease without the consent of the Landlord, such consent not to be
unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not assign part only of this Lease. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord and the Tenant agree that for the purposes of section 19(1A) of the Landlord and Tenant Act 1927
the Landlord may give its consent to an assignment subject to all or any of the following conditions: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a condition that the assignor, where reasonable in the circumstances, enters into an authorised guarantee
agreement which: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in respect of all the tenant covenants of this Lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is in respect of the period beginning with the date the assignee becomes bound by those covenants and ending on
the date when the assignee is released from those covenants by virtue of section 5 of the Landlord and Tenant (Covenants) Act 1995; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">imposes principal debtor liability on the assignor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">requires (in the event of a disclaimer of this Lease) the assignor to enter into a new tenancy for a term equal
to the unexpired residue of the Contractual Term; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is otherwise in a form reasonably required by the Landlord; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if required by the Landlord (acting reasonably) a condition that a person of standing acceptable to the
Landlord (acting reasonably) enters into a guarantee and indemnity of the tenant covenants of this Lease in the form set out in the Schedule 1 (but with such amendments and additions as the Landlord may reasonably require). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord and the Tenant agree that for the purposes of section 19(1A) of the Landlord and Tenant Act 1927
the Landlord may refuse its consent to an assignment if any of the following circumstances exist at the date of the Tenant&#146;s application for consent to assign this Lease: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Annual Rent or any other money due under this Lease is outstanding or there is a material breach of
covenant by the Tenant that has not been remedied; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this clause shall prevent the Landlord from giving consent subject to any other reasonable
condition, nor from refusing consent to an assignment in any other circumstance where it is reasonable to do so. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Underletting </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet the whole of the Premises except in accordance with this clause nor without the
consent of the Landlord, such consent not to be unreasonably withheld or delayed. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet or agree to underlet the whole of the Premises without first procuring that any
intended undertenant shall covenant with the Landlord and the Superior Landlord as from the date of the underlease to observe and perform the covenants and conditions herein contained (excluding the covenant to pay the rents hereinbefore reserved)
and not without the prior written consent of the Landlord and the Superior Landlord to assign the Premises and that such covenants are included in the underlease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet part only of the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet the Premises: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">together with any property or any right over property that is not included within this Lease;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at a fine or premium or reverse premium; nor </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allowing any rent free period to the undertenant that exceeds the period as is then usual in the open market in
respect of such a letting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall not underlet the Premises unless, before the underlease is granted, the Tenant has given the
Landlord: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certified copy of the notice served on the undertenant, as required by section 38A(3)(a) of the LTA 1954,
applying to the tenancy to be created by the underlease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a certified copy of the declaration or statutory declaration made by the undertenant in accordance with the
requirements of section 38A(3)(b) of the LTA 1954. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any underletting by the Tenant shall be by deed and shall include: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an agreement between the Tenant and the undertenant that the provisions of sections 24 to 28 of the LTA 1954
are excluded from applying to the tenancy created by the underlease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the reservation of a rent which is not less than the full open market rental value of the Premises at the date
the Premises is underlet and which is payable at the same times as the Rent under this Lease (but this shall not prevent an underlease providing for a rent-free period of a length permitted by clause 3.17.4.3); </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provisions for the review of rent at the same dates and on the same basis as the review of rent in this Lease,
unless the term of the underlease does not extend beyond the next Review Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provisions requiring the consent of the Landlord to be obtained in respect of any matter for which the consent
of the Landlord is required under this Lease, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and shall otherwise be consistent with and include tenant covenants no less onerous (other than as to the Rent)
than those in this Lease and in a form approved by the Landlord, such approval not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In relation to any underlease granted by the Tenant, the Tenant shall: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not vary the terms of the underlease nor accept a surrender of the underlease without the consent of the
Landlord, such consent not to be unreasonably withheld or delayed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enforce the tenant covenants in the underlease and not waive any of them nor allow any reduction in the rent
payable under the underlease; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.17.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ensure that in relation to any rent review the revised rent is not agreed without the approval of the Landlord,
such approval not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Charging of the whole </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not charge the whole of the Premises without the consent of the Landlord, whose consent may not be unreasonably withheld or
delayed, provided that the consent of the Landlord is not required for a floating charge over the whole of the undertaking of the Tenant. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration of permitted dealings </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Within 28 days of any assignment, charge or any transmission or other devolution relating to the Premises, the Tenant must produce a certified
copy of any relevant document for registration with the Landlord&#146;s solicitor, and must pay the Landlord&#146;s solicitor&#146;s reasonable charges for registration of at least &pound;50 plus VAT. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to introduce dangerous things </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Not to bring into the Premises or to place or store or permit to remain in or about the Premises any article or thing which is or may become
dangerous offensive combustible inflammable radioactive explosive harmful polluting or contaminating. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to overload </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Not to place in the Premises or to place or to carry in the lifts (if any) in the building any articles in such position or in such quantity
or weight to otherwise in such manner howsoever as to overload or cause damage to or to be in the opinion of the Landlord and/or the Superior Landlord likely to overload or exceed any prescribed loading capacity of or cause damage to the Premises or
the lifts and not to overload the electrical wiring or installation or other Conduits in the Premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Not to harm drains </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Not to allow to pass into the Conduits serving the Premises any noxious or deleterious effluent or other substance which might cause any
obstruction in or harm to the Conduits and in the event of any such obstruction or harm forthwith to make good all such damage to the reasonable satisfaction of the Landlord and/or the Superior Landlord. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nuisance etc </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nuisance </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not do anything on the Premises, or allow anything to remain on them, that may be or become or cause a legal nuisance, injury
or damage to the Landlord and/or the Superior Landlord or its respective tenants or the owners or occupiers of adjacent or neighbouring premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Auctions etc </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not use the Premises for any auction sale, any dangerous, noxious, noisy or offensive trade, business, manufacture or
occupation, or any illegal or immoral act or purpose but use for the Permitted Use is not a breach of this clause. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.23.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Animals etc </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not use the Premises as sleeping accommodation or for residential purposes, or keep any animal on them. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of applications, notices and recovery of arrears </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Save in the case of the circumstances set out in 3.24.1 (in which cases such costs shall be reasonable and not payable on an indemnity basis),
the Tenant must pay to the Landlord and/or the Superior Landlord on an indemnity basis all costs, fees, charges, disbursements and expenses, including, without prejudice to the generality of the above, those payable to counsel, solicitors, surveyors
and enforcement agents, properly and reasonably incurred by the Landlord and/or the Superior Landlord in relation to or incidental to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">every application made by the Tenant for a consent or licence required by the provisions of this lease, whether
it is granted, refused or offered subject to any lawful<B> </B>qualification or condition, or the application is withdrawn unless the refusal, qualification or condition is unlawful whether because it is unreasonable or otherwise;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the contemplation, preparation and service of a notice under the Law of Property Act 1925 section 146, or the
contemplation or taking of proceedings under sections 146 or 147 of that Act, even if forfeiture is avoided otherwise than by relief granted by the court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the recovery or attempted recovery of arrears of rent or other sums due under this lease; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other steps taken in contemplation of or in direct connection with the enforcement of the covenants on the
part of the Tenant contained in this lease whether during or within 6 months after the end of the Term including the preparation, service and negotiation of schedules of dilapidations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-conditions</FONT> for development </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Notwithstanding any consent that may be granted by the Landlord under this lease, the Tenant must not carry out any development on or at the
Premises until: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all necessary notices under the Planning Acts have been served and copies produced to the Landlord and the
Superior Landlord; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all necessary permissions under the Planning Acts have been obtained and produced to the Landlord and/or the
Superior Landlord; and </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord and the Superior Landlord have acknowledged that every necessary planning permission is acceptable
to them, such acknowledgement not to be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord or the Superior Landlord may
refuse to acknowledge their respective acceptance of a planning permission on the grounds that any condition contained in it or anything omitted from it or the period referred to in it would, in the reasonable opinion of the Superior Landlord and/or
Landlord and/or the Surveyor, be, or be likely to be, prejudicial to the Landlord and/or the Superior Landlord or to their respective reversionary interests in the Premises whether during or following the end of the Term. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Completion of development </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Where a condition of any planning permission granted for development begun before the end of the Term requires works to be carried out to the
Premises by a date after the end of the Term, the Tenant must, unless the Landlord and/or the Superior Landlord directs otherwise, finish those works before the end of the Term. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.24.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Security for compliance with conditions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">In any case where a planning permission is granted subject to conditions, and if the Landlord and/or the Superior Landlord reasonably so
requires, the Tenant must provide sufficient security for his compliance with the conditions and must not implement the planning permission until the security has been provided. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plans, documents and information </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evidence of compliance with this lease </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If so requested, the Tenant must produce to the Landlord or the Surveyor and the Superior Landlord any plans, documents and other evidence the
Landlord and/or the Superior Landlord reasonably requires to satisfy himself that the provisions of this lease have been complied with. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Information for renewal or rent review </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If so requested, the Tenant must produce to the Landlord, the Surveyor, or any person acting as the third party determining the Rent in
default of agreement between the Landlord and the Tenant under the provisions for rent review contained in this lease any information reasonably requested in writing in relation to any pending or intended step under the 1954 Act or the
implementation of any provisions for rent review in any sublease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To inform Landlord and Superior Landlord of notices </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Upon the happening of any occurrence or upon the receipt of any notice order requisition direction or other thing which may be capable of
adversely affecting the </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Landlord&#146;s interest and/or the Superior Landlord&#146;s interest in the Premises the </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Tenant shall promptly at its own expense deliver full particulars or a copy thereof to the Landlord and the Superior Landlord. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To inform Landlord and Superior Landlord of contaminants and defects </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">To inform the Landlord and Superior Landlord promptly in writing of the existence of any contaminant or pollutant on or any defect in the
Premises of which the Tenant becomes aware which might give rise to a duty imposed by common law or statute on the Landlord and/or Superior Landlord. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.25.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To comply with covenants in the Superior Lease </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant shall observe and perform the tenant covenants in the Superior Lease except the covenants to pay the rents reserved by the Superior
Lease but in the event of any conflict between the covenants by the Tenant in this Lease and the tenant covenants in the Superior Lease then the covenants by the Tenant in this Lease shall prevail. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnities </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must keep the Landlord and the Superior Landlord fully indemnified against all losses arising directly or indirectly out of any
material breach or material <FONT STYLE="white-space:nowrap">non-observance</FONT> by the Tenant of the covenants, conditions or other provisions of this lease or any of the matters to which this demise is subject provided that the Landlord shall
take reasonable steps to mitigate such losses. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reletting boards and viewing </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must permit the Landlord and/or the Superior Landlord to enter the Premises at any time during the last 6 months of the Contractual
Term and at any time thereafter (provided that it does not impede access to the Premises or the use of the Premises for the Permitted Use) to fix and retain anywhere on the exterior of the Premises a board advertising them for reletting. While any
such board is on the Premises the Tenant must permit viewing of them at reasonable times of the day provided that reasonable prior notice shall be given of any prospective viewing. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Obstruction and encroachment </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not stop up, darken or obstruct any window or light belonging to the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Yielding up </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">At the end of the Term the Tenant must yield up the Premises with vacant possession, decorated and repaired in accordance with and in the
condition required by the provisions of this lease and to an open plan configuration, give up all keys of the Premises to the Landlord, remove tenant&#146;s fixtures and fittings if requested to do so by the Landlord, and remove any signs erected by
the Tenant in, on or near the Premises, immediately making good any damage caused by their removal. For the avoidance of doubt the air conditioning units and pipes within or attaching to or connecting into the Premises do not form part of the
Premises for the purposes of yielding up. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Interest on arrears </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must pay interest on any of the Lease Rents or other sums due under this Lease that are not paid within 14 days of the date due,
whether formally demanded or not in respect of the Rent, the interest to be recoverable as rent. Nothing in this clause entitles the Tenant to withhold or delay any payment of the Rent or any other sum due under this Lease or affects the rights of
the Landlord in relation to any <FONT STYLE="white-space:nowrap">non-payment.</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Statutory notices </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give to the Landlord and the Superior Landlord full particulars of any notice, direction, order or proposal relating to the
Premises made, given or issued to the Tenant by any government department or local, public, regulatory or other authority or court within 7 days of receipt, and if so requested by the Landlord and/or the Superior Landlord must produce it to the
Landlord and the Superior Landlord. The Tenant must without delay take all necessary steps to comply with the notice, direction or order. At the request of the Landlord and/or the Superior Landlord, and at the Landlord&#146;s cost, the Tenant must
make or join with the Landlord and/or the Superior Landlord in making any objection or representation the Landlord and/or the Superior Landlord reasonably deems expedient against or in respect of any notice, direction, order or proposal unless the
making or joining is contrary to the business interests or statutory obligations of the Tenant or <FONT STYLE="white-space:nowrap">sub-tenants.</FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Keyholders </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must ensure that at all times the Landlord has written notice of the name, home address and home telephone number of at least <I>2
</I>keyholders of the Premises. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Viewing on sale of reversion </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must, on reasonable prior notice and at reasonable times of the day at any time during the Term, permit prospective purchasers of
the Landlord&#146;s reversion or any other interest superior to the Term, or agents instructed in connection with the sale of the reversion or such an interest, to view the Premises without interruption provided they have the prior written authority
of the Landlord or the Superior Landlord or their respective agents and further provided that it does not impede access to the Premises or the use of the Premises for the Permitted Use and the Landlord shall procure that any damage so caused is
promptly made good. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defective premises </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give notice to the Landlord and the Superior Landlord of any defect in the Premises that might give rise to an obligation on
the Landlord and/or the Superior Landlord to do or refrain from doing anything in order to comply with the provisions of this lease or the duty of care imposed on the Landlord and/or the Superior Landlord, whether pursuant to the Defective Premises
Act 1972 or otherwise, and must at all times display and maintain any notices the Landlord and/or the Superior Landlord from time to time reasonably requires him to display at the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise of the landlord&#146;s rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must permit the Landlord and/or the Superior Landlord to exercise any of the rights granted to him by virtue of the provisions of
this lease at all times during the Term without interruption or interference. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The office covenants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must observe and perform the Office Covenants. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Landlord&#146;s covenants </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord covenants with the Tenant to permit the Tenant peaceably and quietly to hold and enjoy the
Premises without any interruption or disturbance from or by the Landlord or any person claiming under or in trust for him or by title paramount. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall not cause any wilful damage to the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At the request and cost of the Tenant, on a full indemnity basis, the Landlord covenants with the Tenant to use
reasonable endeavours to enforce the Landlord&#146;s covenants in the Superior Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall pay the rents reserved by the Superior Lease and perform the covenants on the part of the
tenant contained in the Superior Lease so far as the Tenant is not liable for such performance under the terms of this lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall refund all Rent paid in advance by the Tenant in relation to any period falling after the
End Date within 10 working days after the End Date, provided that this clause shall not apply if the Landlord terminates this Lease pursuant to Clause 7 or if this Lease is disclaimed by the Crown or by a liquidator or trustee in bankruptcy of the
Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Warranty as to convictions </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant warrants that before the execution of this document he has disclosed to the Landlord in writing any
conviction, judgment or finding of any court or tribunal relating to the Tenant, or any member, director, other officer or major shareholder of the Tenant, or any partner in the partnership, of such a nature as to be likely to affect the decision of
any insurer or underwriter to grant or to continue insurance of any of the Insured Risks. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of the insurance rent </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant covenants to pay the Insurance Rent for the period commencing on the Rent Commencement Date and
ending on the day before the next policy renewal date on the date of this document, and subsequently to pay the Insurance Rent within 28 days of receipt of written demand and, if so demanded, in advance of the policy renewal date, but not more than
3<I> </I>months in advance. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s further insurance covenants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant covenants with the Landlord to observe and perform the following requirements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Requirements of insurers </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must comply with all the requirements and reasonable recommendations of the insurers. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Policy avoidance and additional premiums </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not do or omit anything that could cause any insurance policy on or in relation to the Premises to become wholly or partly
void or voidable, or do or omit anything by which additional insurance premiums may become payable unless he has previously notified the Landlord and the Superior Landlord and has agreed to pay the increased premium. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire-fighting equipment </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must comply with the requirements of and the duties imposed by the Regulatory Reform (Fire Safety) Order 2005 and the reasonable
requirements of the Landlord and/or the Superior Landlord as to fire safety at the Premises. In particular the Tenant must keep the Premises supplied with such fire-fighting equipment as is necessary to comply with the Regulatory Reform (Fire
Safety) Order 2005 and as the insurers require, and must maintain the equipment to their satisfaction<I> </I>as the Landlord and/or the Superior Landlord reasonably requires, and must maintain the equipment to the reasonable satisfaction of the
insurers and in efficient working order. The Tenant must cause any sprinkler system and other fire-fighting equipment to be inspected by a competent person at least once in every 6 months. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fire escapes, equipment and doors </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not obstruct the access to any fire equipment or the means of escape from the Premises, or lock any fire door while the
Premises are occupied. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Combustible materials </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must not store on the Premises or bring onto them any dangerous substances as defined by the Regulatory Reform (Fire Safety) Order
2005, and must comply with the requirements and recommendations of the fire authority and the reasonable requirements of the Landlord and/or the Superior Landlord as to fire precautions relating to the Premises. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of events affecting the policy </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give immediate notice to the Landlord and Superior Landlord of any event that might affect any insurance policy on or relating
to the Premises, and any event against which the Superior Landlord may have insured under this lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of convictions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant must give immediate notice to the Landlord and the Superior Landlord of any conviction, judgment or finding of any court or
tribunal relating to the Tenant, or any member, director, other officer or major shareholder of the Tenant, or any partner in the partnership, of such a nature as to be likely to affect the decision of any insurer or underwriter to grant or to
continue any insurance. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other insurance </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If at any time the Tenant is entitled to the benefit of any insurance of the Premises that is not effected or maintained in pursuance of any
obligation contained in this lease, the Tenant must apply all money received by virtue of that insurance in making good the loss or damage in respect of which the money is received. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.3.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s obligations in default </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">To the extent that, at any time during the Contractual Term, the Premises or any part of them are damaged or destroyed by one or more of the
Insured Risks and the insurance money under the policy of insurance effected by the Superior Landlord pursuant to his obligations contained in the Superior Lease is wholly or partially irrecoverable because of any act or default of the Tenant or of
anyone at the Premises expressly or by implication with his authority and under his control, the Tenant must on demand pay to the Landlord the amount of the insurance money so irrecoverable, in which case the provisions of clauses 6.5 and 6.6 shall
apply. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Landlord&#146;s further insurance covenants </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord covenants with the Tenant to observe and perform the following requirements in relation to the insurance policy the Superior
Landlord effects pursuant to the Superior Landlord&#146;s obligations contained in the Superior Lease: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Copy policy </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord must produce to the Tenant on receipt from the Superior Landlord a copy of the policy and the last premium renewal receipt
reasonable evidence of the terms of the policy and the fact that the last premium has been paid. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Noting of the Tenant&#146;s interest </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord must use reasonable endeavours to get the Superior Landlord to get the Superior Landlord to ensure that the interest of the
Tenant is noted or endorsed on the policy. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Change of risks </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Landlord must notify the Tenant of any material change in the risks covered by the policy from time to time provided the Superior Landlord
makes the Landlord aware of such change. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Damage by Insured Risk </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Premises are damaged or destroyed by an Insured Risk so as to be unfit for occupation and use or
inaccessible or unusable then, (unless the policy of insurance in relation to the Premises has been vitiated in whole or in part in consequences of any act or omission of the Tenant or their respective workers, contractors or agents or any other
person on the Premises with the actual or implied authority of any of them and the Tenant has not paid the irrevocable sum to the Landlord in accordance with Clause 6.3.9) payment of the Rent, or a fair proportion of it according to the nature and
extent of the damage, shall be suspended until the Premises have been reinstated and made fit for occupation and use or accessible or useable (as the case may be), or until the end of three years from the date of damage or destruction, if sooner
(the &#147;Rent<B> Suspension&#148;)</B>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that any Rent and/or Service Charge have been paid in advance by the Tenant and the Premises are
damaged or destroyed by an Insured Risk so as to be unfit for occupation and use or inaccessible or unusable (and provided that (i)&nbsp;the policy of insurance in relation to the Premises has not been vitiated in whole or in part in consequence of
any act or omission of the Tenant or its respective workers, contractors or agents or any other person on the Premises with the actual or implied authority of any of them or (ii)&nbsp;if the policy of insurance in relation to the Premises has been
vitiated in whole or in part in consequence of any act or omission of the Tenant or its respective workers, contractors or agents or any other person on the Premises with the actual or implied authority of any of them, the Tenant has otherwise paid
the irrecoverable insurance sum to the Landlord in accordance with Clause 6.3.9), the Landlord shall: </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as soon as reasonably practicable following the date that the Premises become unfit for occupation and use or
inaccessible or unusable, refund to the Tenant the proportionate amount of Rent and/or Service Charge paid in advance from and including the date of damage or destruction until and excluding the date that the Premises are again made fit for
occupation and use and accessible by the Tenant; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">following the date that the Premises become fit again for occupation and use and accessible by the Tenant,
credit against future Rent and/or Service Charge payable (as applicable) the equivalent proportionate amount that the Tenant paid in advance from and including the date of damage or destruction until and excluding the date that the Premises are
again made fit for occupation and use and accessible by the Tenant; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event that the Lease is terminated following damage or destruction in accordance with Clauses 6.5.3 and
6.5.4, refund to the Tenant as soon as reasonably practicable following termination, the proportionate amount of Rent and/or Service Charge paid in advance from and including the date of damage or destruction. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, after 3 years following damage to or destruction of the Premises, the Superior Landlord has, having used
all reasonable endeavours to reinstate the Premises, been unable to complete such reinstatement, the Superior Landlord may terminate this Lease by giving written notice to the Tenant. On giving such written notice this Lease shall determine but this
shall be without prejudice to any right or remedy of the Landlord or the Tenant in respect of any breach of the landlord or tenant covenants of this Lease. Any proceeds of the insurance (other than any insurance for plate glass) shall belong to the
Landlord and/or the Superior Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant may terminate this Lease by giving written notice to the Landlord if, following damage or
destruction of the Premises by an Insured Risk, the Premises has not been reinstated so as to be fit for occupation and use has not been reinstated so as to make the Premises accessible or useable within three years after the date of damage or
destruction. On giving this written notice this Lease shall determine but this shall be without prejudice to any right or remedy of either party in respect of any breach of the obligations and covenants of this Lease. Any proceeds of the insurance
shall belong to the Landlord and/or the Superior Landlord. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Damage by Uninsured Risk </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purposes of this clause: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">These provisions shall apply from the date on which any Insured Risk becomes an Uninsured Risk but only in
relation to the Uninsured Risk. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall notify the Tenant in writing promptly after the Superior Landlord informs the Landlord that
an Insured Risk becomes an Uninsured Risk. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6.6.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, during the Contractual Term, the Premises or a substantial part of it shall be damaged or destroyed by an
Uninsured Risk so as to make the Premises or a substantial part of it inaccessible or unfit for occupation and use: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Rent or a fair proportion of it according to the nature and extent of the damage sustained will not be
payable until the earlier of the date on which: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Premises shall again be fit for occupation or use; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Lease shall be terminated in accordance with the provisions of clause 6.6.1.3(b). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Superior Landlord may, within one year of the date of such damage or destruction, serve notice on the
Landlord (the &#147;Reinstatement Notice&#148;) confirming that it will reinstate the Premises so that the Premises shall be fit for occupation and use or made accessible and the Landlord shall deliver a copy of the Reinstatement Notice to the
Tenant immediately upon receipt. If the Superior Landlord fails to serve a Reinstatement Notice the Lease will automatically end on the date one year after the date of such damage or destruction and immediately prior to termination of the Superior
Lease. The termination of this Lease shall be without prejudice to any right of the Landlord or the Tenant in respect of any breach of the covenants of the other party to this Lease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 6.6.1.3(b) shall not apply if an Insured Risk shall have become an Uninsured Risk owing to the act or
default of the Tenant or any person deriving title under the Tenant or their respective agents, employees, licensees or contractors. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Superior Landlord has served a Reinstatement Notice but such reinstatement has not been completed by the
date two years from the date of the Reinstatement Notice, then at any time after that date the Tenant may terminate this Lease by serving not less than three months&#146; notice on the Landlord stating that it terminates this Lease. The termination
of this Lease shall be without prejudice to any right of the Landlord or the Tenant in respect of any breach of the covenants of the other party to this Lease. If by the end of such notice the Premises, and/or access to the Premises have been
reinstated so that the Premises are fit for occupation and use and are accessible, the notice shall be void and this Lease shall continue in full force and effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Forfeiture </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may <FONT STYLE="white-space:nowrap">re-enter</FONT> the Premises (or any part of the Premises in
the name of the whole) at any time after any of the following occurs: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any rent is unpaid 21 days after becoming payable whether it has been formally demanded or not;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any breach of any condition of, or tenant covenant in, this Lease; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Act of Insolvency. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">7.2 If the Landlord <FONT STYLE="white-space:nowrap">re-enters</FONT> the Premises (or any part of the Premises in the name of the whole)
pursuant to this clause, this Lease shall immediately end, but without prejudice to any right or remedy of the Landlord in respect of any breach of covenant by the Tenant or any guarantor. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Miscellaneous </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusion of warranty as to use </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Nothing in this lease or in any consent granted by the Landlord under this lease is to imply or warrant that the Premises may lawfully be used
under the Planning Acts for the Permitted Use. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusion of third party rights </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Nothing in this lease is intended to confer any benefit on any person who is not a party to it. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Representations </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">The Tenant acknowledges that this lease has not been entered into in reliance wholly or
partly on any statement or representation made by or on behalf of the Landlord other than any expressly set out in this lease or made by the Landlord&#146;s solicitors in any written response to enquiries raised by the Tenant&#146;s solicitors in
connection with the grant of this lease. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Documents under hand </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">While the Landlord is a limited liability partnership, a limited company or other corporation, any licence, consent, approval or notice
required to be given by the Landlord shall be sufficiently given if given under the hand of a member, director, the secretary or other duly authorised officer of the Landlord. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Tenant&#146;s property </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If, after the Tenant has vacated the Premises at the end of the Term, any property of his remains in or on the Premises and he fails to remove
it within 7 days after a written request from the Landlord to do so, or, if the Landlord is unable to make such a request to the Tenant, within 14 days from the first attempt to make it, then the Landlord may, as the agent of the Tenant, sell that
property. The Tenant must indemnify the Landlord against any liability incurred by the Landlord to any third party whose property is sold by him in the mistaken belief held in good faith, which shall be presumed unless the contrary is proved, that
the property belonged to the Tenant. If, having made reasonable efforts to do so, the Landlord is unable to locate the Tenant, then the Landlord may retain the proceeds of sale absolutely unless the Tenant claims them within 6 months of the date on
which he vacated the Premises. The Tenant must indemnify the Landlord against any damage occasioned to the Premises and any losses caused by or related to the presence of the property in or on the Premises. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No implied easements </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Neither the granting of this Lease nor anything herein contained shall by implication of law or otherwise operate or to be deemed to confer
upon the Tenant any easement right or privilege whatsoever over or against any adjoining or neighbouring premises or which would or might restrict or prejudicially affect the future rebuilding alteration or development of any adjoining or
neighbouring premises and the Landlord and/or the Superior Landlord shall have the right at any time to make such alterations to or to pull down and rebuild or redevelop any adjoining or neighbouring premises as it may deem fit without obtaining any
consent from or making any compensation to the Tenant. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rights of light and air </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Any light or air at any time enjoyed shall be deemed to be enjoyed by consent and not as of right. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No restrictions on adjoining property </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Neither the granting of this Lease nor anything herein contained or implied shall impose or be deemed to impose any restriction on the use of
any land or building not comprised in this Lease or give the Tenant the benefit of or the right to enforce or to have enforced or to prevent the release or modification of any covenant agreement or condition entered into by any purchaser from or by
any lessee or occupier of the Landlord or the Superior Landlord (as the case may be) in respect of the property not comprised in this Lease or prevent or restrict in any way the development of any land not comprised in this Lease Provided always
that the provisions of this <FONT STYLE="white-space:nowrap">sub-clause</FONT> shall not substantially interfere with or affect the quiet enjoyment and use of the Premises by the Tenant. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Acceptance of rent </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No demand for or acceptance of or receipt of the Rent or the grant of any licence or approval or the
registration of any document by the Landlord after knowledge or notice received by the Landlord or its agents of any breach of any of the Tenant&#146;s covenants hereunder shall be or operate as a waiver wholly or partially to the extent that any
such breach shall be subsisting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Landlord shall properly refrain from demanding or accepting the Rent or any other monies due under this
Lease in circumstances in which the Landlord has reasonable grounds to believe either that the Tenant is in breach of any of the provisions of this Lease or that the Tenant might acquire against the Landlord any rights or entitlement then
notwithstanding such restraint interest at the base rate shall be payable as specified in Clause 3.2 from the due date until the Landlord shall accept the Rent from the Tenant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Arbitration </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any dispute or difference arising between the Landlord and the Tenant in respect of any decision made by or on
behalf of the Landlord on any matter which is required to be decided under the provisions of this Lease (save in relation to Clause 3.11 (Assignment) or as otherwise provided in this Lease) shall be referred to the decision of a sole arbitrator to
be agreed upon by the Landlord and by the Tenant or </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in default of agreement to an arbitrator to be appointed at the written request of either the Landlord or the Tenant by or on behalf of the then President of the Royal Institution of Chartered
Surveyors (or his nominee) such arbitrator to act in accordance with the Arbitration Acts from time to time in force and his fees shall be within his award. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exclusion of S.62 LPA </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The operation of Section&nbsp;62 of the Law of Property Act 1925 shall be excluded from this Lease and the only
rights granted to the Tenant are those expressly set out in this Lease and the Tenant shall not by virtue of this Lease be deemed to have acquired or be entitled to and the Tenant shall not during the Term acquire or become entitled by any means
whatsoever to any easement from or over or affecting any other land premises now or at any time hereafter belonging to the Landlord or the Superior Landlord (as the case may be) and not comprised in this Lease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Representation </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant acknowledges that this Lease has not been entered into in reliance wholly or partly on any statement
or representation made by or on behalf of the Landlord except any such statement or representation that is expressly set out in this Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notices </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Form and service of notices </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">A notice under this lease must be in writing and, unless the receiving party or his authorised agent acknowledges receipt, is valid if, and
only if it is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">given by hand, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sent by registered post or recorded delivery, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">and is served: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the receiving party is a limited liability partnership or company incorporated within Great Britain, at
the registered office, </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the receiving party is the Tenant and the Tenant is not such a limited liability partnership or company,
at the Tenant&#146;s address shown in this lease or at any address specified in a notice given by the Landlord to the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the receiving party is the Landlord and the Landlord is not such a limited liability partnership or
company, at the Landlord&#146;s address shown in this lease or at any address specified in a notice given by the Landlord to the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deemed delivery </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Special delivery or recorded mail </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Unless it is returned through the Royal Mail undelivered, a notice sent by special delivery or recorded mail shall be treated as served on the
third working day after posting whenever and whether or not it is received. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working day </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">References to &#145;a working day&#146; are references to a day when the United Kingdom clearing banks are open for business in the City of
London. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.13.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Joint recipients </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">If the receiving party consists of more than one person, a notice to one of them is notice to all. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New Lease </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">This lease is a new tenancy for the purposes of section 1 of the 1995 Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Exclusion of sections 24&#150;28 of the 1954 Act </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman"><B>The parties confirm that: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord served a notice on the Tenant, as required by section 38A(3)(a) of the 1954 Act applying to the
tenancy created by this Lease, before this Lease was entered into; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] who was
duly authorised by the Tenant to do so made a statutory declaration dated [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] in accordance with the requirements of section 38A(3)(b) of the 1954 Act and
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there is no agreement for lease to which this Lease gives effect. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties agree that the provisions of sections 24 to 28 of the 1954 Act are excluded in relation to the
tenancy created by this Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Services and Service Charge </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The &#147;Services&#148; are: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining and repairing the Common Parts including all conducting media forming part of the Common
Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning the outside of the windows of the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">lighting the Common Parts and cleaning, maintaining, repairing and replacing lighting machinery and equipment
on the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing refuse bins on the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing signage for the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing, operating and replacing security machinery and equipment (including closed
circuit television) on the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing, operating and replacing fire prevention, detection and fighting machinery and
equipment and fire alarms on the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing a signboard showing the names and logos of the tenants and other
occupiers in the entrance hall of the Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintaining the landscaped and grassed areas of the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the Lifts in the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">decorating the internal areas of the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the floor coverings on the internal areas of the Common Parts;
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the furniture and fittings on the Common Parts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">cleaning, maintaining, repairing and replacing the furniture, fittings and equipment in the lavatories on the
Common Parts and providing hot and cold water, soap, paper, towels and other supplies for them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">heating the internal areas of the Common Parts and cleaning, maintaining, repairing and replacing heating
machinery and equipment serving the Common Parts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(if provided as at the date of this lease) providing <FONT STYLE="white-space:nowrap">air-conditioning</FONT>
for the internal areas of the Building and cleaning, maintaining, repairing and replacing any such <FONT STYLE="white-space:nowrap">air-conditioning</FONT> equipment serving the Building; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(if provided as at the date of this lease) providing security reception cleaning and maintenance staff for the
Building; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other service or amenity that the Landlord may in its reasonable discretion provide for the benefit of the
tenants and occupiers of the Building, provided that the Tenant actually benefits from such service. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any replacement, rebuilding or renewal of items listed in this Clause 9 shall be undertaken by the Landlord
only where such items are beyond economic repair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The &#147;Service Costs&#148; are the total of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The whole of the costs of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">providing the Services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the supply and removal of electricity, gas, water, sewage and other utilities to and from the Building (where
the Tenant does not otherwise obtain such supplies to the Premises itself); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">complying with the recommendations and requirements of the insurers of the Building (insofar as those
recommendations are reasonable and those recommendations and requirements relate to the Common Parts); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">complying with all laws relating to the Common Parts, their use and any works carried out at them, and relating
to the use of all conducting media, machinery and equipment at or serving the Common Parts and to any materials kept at or disposed of from the Common Parts; </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">complying with the Third Party Rights insofar as they relate to the Common Parts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taking any steps (including proceedings) that the Landlord reasonably considers necessary to prevent or remove
any encroachment over the Common Parts or to prevent the acquisition of any right over the Common Parts (or the Building as a whole) or to remove any obstruction to the flow of light or air to the Common Parts (or the Building as a whole);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the reasonable and proper costs, fees and disbursements of: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">managing agents employed by the Landlord for the carrying out and provision of the Services or, where managing
agents are not employed, a management fee for the carrying out and provision of the Services of 10% of the cost of the Services; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">accountants employed by the Landlord to prepare and audit the service charge accounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of the salaries and employer costs (including pension, welfare and insurance contributions) and
uniforms of any security reception cleaning and maintenance staff for the Building and of all equipment and supplies needed for the proper performance of their duties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all rates, taxes, impositions and outgoings payable in respect of the Common Parts, their use and any works
carried out on them (other than any taxes payable by the Landlord in connection with any dealing with or disposition of its reversionary interest in the Building); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any VAT payable by the Landlord in respect of any of the items mentioned above except to the extent that the
Landlord obtains credit for such VAT under the VATA 1994. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall, acting reasonably and in the interests of good estate management: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">supply the Services in an efficient manner at all appropriate times; </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">repair the Common Parts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide heating and (if provided as at the date of this lease)
<FONT STYLE="white-space:nowrap">air-conditioning</FONT> to the internal areas of the Common Parts during such periods of the year as the Landlord considers appropriate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide electricity and water to the Premises; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the internal areas of the Common Parts clean, and to clean the outside of the windows of the Building as
often as the Landlord considers appropriate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the internal areas of the Common Parts reasonably well lit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">supply hot and cold water, soap, paper, towels and other supplies for the lavatories on the Common Parts; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">keep the Lifts in reasonable working order. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord may, but shall not be obliged to, provide any of the other Services not listed in Clause 9.3,
provided that the Tenant&#146;s use and enjoyment of the Premises is not materially impaired. The Landlord shall not be obliged to carry out any works where the need for those works has arisen by reason of any damage or destruction by a risk against
which the Superior Landlord is not obliged to insure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall not be obliged to provide any of the Services outside the Permitted Hours.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall not be liable for: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any interruption in, or disruption to, the provision of any of the Services for any reason that is outside the
reasonable and foreseeable control of the Landlord; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any absence or insufficiency of any of the Services or where there is any breakdown or defect in any conducting
media, except where due to the negligence of the Landlord and provided that the Landlord seeks to make good the breakdown or defect. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Service charge exclusions </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following costs shall be expressly excluded from the Service Charge: </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs arising from any damage or destruction to the Building caused by an Insured Risk or an Uninsured Risk, or
repair costs recovered by the Landlord under third party warranties or guarantees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Capital costs of the construction, alteration or extension of the Building, save for alterations made to the
Common Parts or structure of the Building (other than any such alterations made in the last year of the Term). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of upgrading, innovation or improvement resulting from any repair, maintenance, reinstatement, rebuilding
or replacement, but this will not prevent the Landlord including costs within the Service Charge where they arise: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where an item is to be replaced by way of repair and the replacement is broadly the modern day or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> equivalent of what was there previously; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the Landlord considers replacement to be more economical than repair (and the Landlord is entitled to
take into consideration the medium/long-term benefits of replacement); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where an item has to be replaced or installed to comply with any Act or the requirements of the Insurers; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where replacement or renewal is reasonable and cost-effective and will reduce operating costs for the benefit
of the tenants of the Lettable Units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs of any unlet Lettable Unit. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Rent collection costs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs incurred in dealing with any lettings or rent reviews at the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unrecovered costs due from another tenant of the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs incurred in respect of any disposal of the Landlord&#146;s interest in the Building, including the costs
of advertising and promotional or publicity activities relating to any proposed dealing with the Landlord&#146;s interest in the Building. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Before or as soon as possible after the start of each Service Charge Year, the Landlord shall prepare and send
the Tenant an estimate of the Service Costs for that Service Charge Year and a statement of the estimated Service Charge for that Service Charge Year. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall pay the estimated Service Charge for each Service Charge Year in four equal instalments on
each of the Rent Payment Dates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In relation to the Service Charge Year current at the date of this Lease, the Tenant&#146;s obligations to pay
the estimated Service Charge and the actual Service Charge shall be limited to an apportioned part of those amounts, such apportioned part to be calculated on a daily basis for the period from and including the date of this Lease to the end of the
Service Charge Year. The estimated Service Charge for which the Tenant is liable shall be paid in equal instalments on the date of this Lease and the remaining Rent Payment Dates during the period from and including the date of this Lease until the
end of the Service Charge Year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as reasonably practicable after the end of each Service Charge Year, the Landlord shall prepare and
send to the Tenant a certificate showing the Service Costs and the Service Charge for that Service Charge Year. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any cost relating to any Services actually provided to and benefitting the Tenant is omitted from the
calculation of the Service Charge in any Service Charge Year, the Landlord shall be entitled to include it in the estimate and certificate of the Service Charge in any following Service Charge Year. Otherwise, and except in the case of fraud or
wilful or manifest error, the Service Charge certificate shall be conclusive as to all matters of fact to which it refers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If, in respect of any Service Charge Year, the Landlord&#146;s estimate of the Service Charge is less than the
Service Charge, the Tenant shall pay the difference within 14 days of receipt of written demand. If, in respect of any Service Charge Year, the Landlord&#146;s estimate of the Service Charge is more than the Service Charge, the Landlord shall credit
the difference against the Tenant&#146;s next instalment of the estimated Service Charge (and where the difference exceeds the next instalment then the balance of the difference shall be credited against each succeeding instalment until it is fully
credited), and if such reconciliation occurs after the end of the Contractual Term, the Landlord shall, as soon within 14 days of the production of such reconciliation, pay to the Tenant the equivalent amount that the Tenant paid in excess of the
actual Service Costs incurred. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Guarantee and Indemnity </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The provisions of the Schedule 4 apply. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If an Act of Insolvency occurs in relation to a guarantor, or if any guarantor (being an individual) dies or
becomes incapable of managing his affairs the Tenant shall, if the Landlord requests, procure that a person of standing acceptable to the Landlord, within 10 days of that request, enters into a replacement or additional guarantee and indemnity of
the tenant covenants of this Lease in the same form as that entered into by the former guarantor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clause 10.2 shall not apply in the case of a person who is guarantor by reason of having entered into an
authorised guarantee agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For so long as any guarantor remains liable to the Landlord, the Tenant shall, if the Landlord requests,
procure that that guarantor joins in any consent or approval required under this Lease and consents to any variation of the tenant covenants of this Lease. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Lease has been entered into as a deed on the date stated at the beginning of it. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part 1 &#150; Rights Granted </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following rights are granted
to the Tenant in common with the Landlord, the Superior Landlord and all others similarly entitled: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Passage of water soil gas electricity and other services through the Conduits now existing or to be constructed
during the Term passing in through over or under adjoining land and serving the Premises and which do not form part of the Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(In case of emergency only) to pass on foot only across the courtyard shown edged green on plan 2 attached to
the Head Lease (the Courtyard) in order to exit through the gates of the Courtyard and from there to the public highway for the purpose of emergency egress from the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To use the Courtyard for general recreational use in common with the Landlord and the owners and occupiers of
the adjoining land with access onto the Courtyard and those authorised by them. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To pass and <FONT STYLE="white-space:nowrap">re-pass</FONT> at all times on foot only across the Courtyard
between the doorways marked &#147;X&#148; and &#147;Y&#148; on plan 1 attached to the Head Lease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To use the lifts stairs and corridors forming part of the Common Parts for the purposes of access to and egress
from the Premises. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to put refuse in any refuse bins allocated on the Common Parts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to display the name and logo of the Tenant on a sign or noticeboard provided by the Landlord in the
entrance hall of the Building in a form and manner approved by the Landlord. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to use the lavatories in the Common Parts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Right to support and protection from the Common Parts to the extent that the Common Parts provide support and
protection to the Premises at the date of this Lease. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part 2&#151;The Rights Reserved </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following rights are reserved to the Landlord and the Superior Landlord and all other persons authorised by the Landlord or the Superior Landlord or
otherwise entitled to such rights: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights reserved by the Superior Lease insofar as they relate to the Premises. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to use and to connect into conducting media at, but not forming part of, the Premises which are in
existence at the date of this Lease or which are installed or constructed during the Contractual Term; the right to install and construct conducting media at the Premises to serve any part of the Building (whether or not such conducting media also
serve the Premises); and the right to <FONT STYLE="white-space:nowrap">re-route</FONT> any conducting media mentioned in this clause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to erect scaffolding at the Premises or the Building and attach it to any part of the Premises or the
Building in connection with any of the rights reserved pursuant to this Part 2 where reasonable prior written notice has been given to the Tenant and provided that the Tenant&#146;s access to and egress from, the Premises is not materially adversely
affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to attach any structure, fixture or fitting to the boundary of the Premises in connection with any of
the rights reserved pursuant to this Part 2; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to <FONT STYLE="white-space:nowrap">re-route</FONT> any means of access to or egress from the
Premises or the Building and to change the areas over which the rights mentioned paragraph 5 of Schedule 1 are exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the right to <FONT STYLE="white-space:nowrap">re-route</FONT> and replace any conducting media over which the
rights mentioned paragraph 1 of Schedule 1 are exercised. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord reserves the right to enter the Premises: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to repair, maintain, install, construct, <FONT STYLE="white-space:nowrap">re-route</FONT> or replace any
conducting media or structure relating to any of the rights reserved pursuant to this Part 2; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to carry out any works to any other Lettable Unit; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for any other purpose mentioned in or connected with: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this Lease; </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the rights reserved pursuant to this Part 2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Landlord&#146;s interest in the Premises and/or the Building. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tenant shall allow all those entitled to exercise any right to enter the Premises, to do so with their
workers, contractors, agents and professional advisors, and to enter the Premises at any reasonable time (where reasonably practicable during usual business hours) and, except in the case of an emergency, after having given reasonable prior written
notice to the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord shall promptly make good all damage caused to the Premises or its contents by the exercise of such
rights. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Part 3 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matters to which this
lease is subject </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The matters mentioned in the Property and Charges Register of Title Number EGL440236 as of 15&nbsp;February
2018 timed at 12:26:09 insofar as they affect or relate to the Premises or the exercise of rights granted by this Lease save for any financial charges. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Deed of Covenant dated 31&nbsp;May 2002 and made between (2)&nbsp;National Car Parks Limited and (2)&nbsp;J.F.
Miller Properties Limited. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agreement dated 4&nbsp;July 2000 and made between (1)&nbsp;London Borough of Hackney and (2)&nbsp;the Tenant
pursuant to s.106 of Town&nbsp;&amp; Country Planning Act 1990. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Superior Lease. </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2&#151;The Rent and Rent Review </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all purposes of this schedule the terms defined in this paragraph have the meanings specified </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.1&nbsp;&nbsp;&nbsp;&nbsp;An</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">arbitrator </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References to an arbitrator are references to a person appointed by agreement between the Landlord and the Tenant or, in the absence of agreement within 14
days of one of them giving notice to the other of his nomination nominated by the President on the application of either made no earlier than 6 months before the review date or at any time thereafter to determine the rent under this schedule. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Assumptions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Assumptions means: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.1 the assumption
that no work has been carried out on the Premises during or prior to the Term by the Tenant that has diminished the rental value of the Premises other than work carried out in compliance with clause 3.8.2.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.2 the assumption that if the Premises have been destroyed or damaged they have been fully rebuilt or reinstated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.3 the assumption that the covenants contained in this Lease on the part of the Tenant have been fully performed and observed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.4 the assumption that the Premises are available to let by a willing landlord to a willing tenant in the open market by one lease
(&#145;the Hypothetical Lease&#146;) without a premium being paid by either party and with vacant possession. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.5 the assumption that
the Premises have already been fitted out and equipped by and at the expense of the incoming tenant so that they are capable of being used by the incoming tenant from the beginning of the Hypothetical Lease for all purposes required by the incoming
tenant that would be permitted under this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.6 the assumption that the Hypothetical Lease contains the same terms as this Lease,
except the amount of the Initial Rent, and except any rent free or concessionary period allowed to the Tenant for fitting out the Premises for its occupation and use at the commencement of the Term and including the provisions for rent review on the
5th anniversary of the term commencement date of the Hypothetical Lease. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.7 the assumption that the term of the Hypothetical Lease is equal in length to the
Contractual Term and that such terms begins on the Review Date, that the rent commences to be payable on that date and that the years during which the tenant covenants to decorate the Premises are at the same intervals after the beginning of the
terms of the Hypothetical Lease as those specified in this Lease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.2.8 the assumption that every prospective willing landlord and
willing tenant is able to recover VAT in full. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Disregards </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Disregards means: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.1 disregard of any
effect on rent of the fact that the Tenant, his subtenants or their predecessors in title or any lawful occupier have been in occupation of the Premises or any part of them; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.2 disregard of any goodwill attached to the Premises by reason of the carrying on at the Premises of the business of the Tenant, its
undertenants or their respective predecessors in title in their respective business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.3 disregard of any increase in value of the
Premises attributable to the existence at the review date to any alteration or improvement (and for the avoidance of doubt the expressions &#147;alteration&#148; and &#147;improvement&#148; shall include
<FONT STYLE="white-space:nowrap">fitting-out</FONT> works and similar alterations) to the Premises or any part of them carried out otherwise that in pursuance of an obligation to the Landlord or his predecessors in title. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">1.3.3 disregard of the taxable status of the Landlord or the Tenant for the purposes of VAT. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The President </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The President means the President for the time being of the Royal Institution of Chartered Surveyors or any person authorised by him to make appointments on
this behalf. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The review period </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References to the review period are references to the period beginning on the Review Date and ending on the expiry of the Lease. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ascertaining the Rent </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:10%; font-size:10pt; font-family:Times New Roman">Until the Review Date the Rent is to be the Initial Rent and thereafter the Rent is to be a sum equal to the greater of the sum of
&pound;132,468.80 per annum or the Open Market Rent to be determined in accordance with clause 1.6.3 of this Schedule. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Agreement of the Rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Six months before each review date, time not being of the essence, the Landlord and Tenant must explore the possibility of open negotiations with a view to
reaching a written agreement as to the Rent for the review period and the Rent for that period may be agreed at any time or, in the absence of agreement, is to be determined by an arbitrator not earlier that the review date. The Rent for the review
period may be agreed at any time or, in the absence of agreement, is to be determined by an arbitrator not earlier that the review date. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Open market rent </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sum to be determined by the arbitrator must be the sum at which he decides the Premises might reasonably be expected to be let in the open market at the
Review Date making the Assumptions but disregarding Disregards. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Conduct of the arbitration </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The arbitration must be conducted in accordance with the Arbitration Act 1996, except that if an arbitrator dies or declines to act the President may on the
application of either the Landlord or the Tenant appoint another in his place. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Memoranda of agreement </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever the Rent has been ascertained in accordance with this schedule, memoranda to that effect must be signed by or on behalf of the Landlord and the
Tenant, and annexed to this document and its counterpart and the Landlord and the Tenant must bear their own costs in this respect. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.6.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reimbursement of costs </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on publication of the arbitrator&#146;s award, the Landlord or the Tenant pays all his fees and expenses, the paying party may, in default of payment
within 21 days of a demand to that effect, recover such proportion of them, if any, as the arbitrator awards against the other in the case of the Landlord as rent arrears or in the case of the Tenant by deduction from the Rent. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment of the Rent as ascertained </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Rent is not ascertained by a Review Date </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Rent payable during the review period has not be ascertained by the Review Date, then rent is to continue to be payable at the rate previously payable,
such payments being on account of the Rent for that review period. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where the Review Date is not a quarter day </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Rent for the review period is ascertained by the Review Date but that date is not a quarter day then the Tenant must pay to the Landlord on the Review
Date the difference between the Rent due for that quarter and the Rent already paid for it. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Back-payment where review delayed </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Rent payable during the review period has not been ascertained by the Review Date, then the Tenant must pay to the Landlord, within 7 days of the date
on which the Rent is agreed or the arbitrator&#146;s award is received by him, any shortfall between the Rent that would have been paid for that period had it been ascertained on or before the Review Date and the payments made by the Tenant on
account and any VAT payable thereon, and interest, at 4% a year below the Interest Rate in respect of each instalment of rent due on or after that Review Date on the amount by which the instalment of the Rent that would have been paid had it been
ascertained exceeds the amount paid by the Tenant on account, the interest to be payable for their period from the date on which the instalment was due up to the date of payment of the shortfall. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Effect of counter-inflation provisions </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If at any review date a statute prevents restricts or modifies the Landlord&#146;s right either to review the Rent in accordance with this Lease or to recover
any increase in the Rent then the Landlord may, when the restriction or modification is removed, relaxed or varied &#150; without prejudice to his rights, if any, to recover any rent the payment of which has only been deferred by statue on giving
not less than 1 month&#146;s nor more than 3 months&#146; notice to the Tenant at any time within 6 months of the restriction or modification being removed, relaxed or varied time being of the essence, require the Tenant to proceed with the review
of the Rent that has been prevented or to review the Rent further where the Landlord&#146;s right was restricted or modified. The date of expiry of the notice is to be treated as a Review Date provided that nothing in this paragraph is to be
construed as varying the review date. The Landlord may recover any increase in the Rent with effect from the earliest date permitted by law. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3&#151;The Office Covenants </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Use </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must use the Premises for the Permitted Use only. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Security </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not leave the Premises continuously unoccupied for a period of one month or longer. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Discharges </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not discharge any oil, grease or other deleterious matter, or any substance that might be or become a source of danger or injury to the
drainage system, into any of the Conduits. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Window cleaning </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must clean the insides of all windows and window frames forming part of the Premises as often as reasonably necessary. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Noise </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not play or use in the Premises any musical instrument, audio or other equipment or apparatus that produces sound that may be heard outside the
Premises if the Landlord and/or the Superior Landlord in their absolute discretions considers such sounds to be undesirable and gives notice to the Tenant to that effect. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ceiling and floor loading </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Heavy items </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not bring onto or permit to remain on the Premises any safes, machinery, goods or other articles that will or may strain or damage the Premises
or any part of them, save for any items approved by the Landlord. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Protection of ceilings </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not suspend anything from any ceiling on the Premises that will or may damage the Premises or any part of them. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Machinery </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Noisy machinery </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must not install or use (save where otherwise consented to by the Landlord under this Lease) in or on the Premises any machinery or apparatus that
will cause noise or vibration that can be heard or felt in nearby premises or outside the Premises or that may cause damage. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Maintenance of machinery </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to avoid damage to the Premises, the Tenant must keep all machinery and equipment on the Premises (&#145;the Machinery&#146;) properly maintained and
in reasonable working order and for that purpose must employ reputable contractors to carry out reasonable, periodic inspection and maintenance of the Machinery. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Renewal of parts </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must renew all working and other parts of the Machinery when beyond economic repair. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Operation </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must ensure by directions to his staff and otherwise that the Machinery is properly operated. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Signs </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tenant must at all times display and maintain at a point on the Premises to be specified in writing by the Landlord, a suitable sign, of a size and kind
first approved by the Landlord (acting reasonably), showing the Tenant&#146;s trading name and business. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 4&#151;The Authorised Guarantee Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS GUARANTEE is made the <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> BETWEEN: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><I>(1)</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>(name of outgoing tenant)</I> [of <I>(address)</I> <I>(or)</I> the registered office of which is at
<I>(address)</I>] [Company Registration no ...] (&#145;the Guarantor&#146;), and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>(name of landlord)</I> [of <I>(address)</I> <I>(or)</I> the registered office of which is
at&nbsp;&nbsp;&nbsp;&nbsp;<I>(address)</I>] [Company Registration no ...] (&#145;the Landlord&#146;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW THIS DEED WITNESSES as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and interpretation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all purposes of this guarantee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Assignee&#146; means <I>(name of incoming tenant)</I> <B>[Company</B> Registration no ...<B>],</B>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words importing one gender include all other genders, words importing the singular include the plural and vice
versa, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the clause headings do not form part of this document and are not to be taken into account in its construction
or interpretation, <I>(amend if marginal notes are used instead of headings)</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless expressly stated to the contrary, the expression &#145;this guarantee&#146; includes any document
supplemental to or collateral with this document or entered into in accordance with this document, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if any party to this guarantee at any time comprises two or more persons, obligations expressed or implied to
be made by or with that party are deemed to be made by or with the persons comprising that party jointly and severally, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Lease&#146; means the <B>[lease</B> <I>(or)</I> sublease] of the Premises dated <I>(date)</I> and
made between (1) <B>[the</B> Landlord <I>(or)</I> <I>(name of original landlord)</I><B>]</B> and (2) <B>[the</B> Guarantor <I>(or)</I> <I>(name of original tenant)</I><B>]</B> for the Term, and includes all or any deeds and documents supplemental to
that lease whether or not expressed to be so, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Liability Period&#146; means the period during which the Assignee is bound by the tenant covenants of
the Lease, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the 1995 Act&#146; means the Landlord and Tenant (Covenants) Act 1995 <B>[and</B> all statutes,
regulations and orders included by virtue of clause 1.11], </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Premises&#146; means the property demised by the Lease, </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any reference in this guarantee to a clause without further designation shall be construed as a reference to
the clause of this document so numbered, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">unless expressly stated to the contrary, any reference to a specific statute includes any statutory extension
or modification, amendment or <FONT STYLE="white-space:nowrap">re-enactment</FONT> of that statute and any regulations or orders made under it, and any general reference to a statute includes any regulations or orders made under that statute,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;the Term&#146; means the term of years created by the Lease, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;tenant covenants&#146; and &#145;authorised guarantee agreement&#146; have the same meaning as is given
by section 28(1) of the 1995 Act. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recitals </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This guarantee is supplemental to the Lease by which the Premises were let for the Term subject to the payment
of the <B>[rent</B> <I>(or if additional payments are reserved as rent by the lease)</I> rents] reserved by and the performance and observance of the covenants on the tenant&#146;s part and the conditions contained in the Lease.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The immediate reversion to the Lease <B>[remains</B> <I>(or as appropriate)</I> is now] vested in the Landlord
and the unexpired residue of the Term <B>[remains</B> <I>(or as appropriate)</I> is now] vested in the Tenant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By clause <I>(number)</I> of the Lease, the Landlord&#146;s consent to an assignment of the Lease is required.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Landlord has agreed to give consent to assignment of the Lease to the Assignee on condition that the
Guarantor enters into this guarantee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This guarantee is intended to take effect only when the Lease is assigned to the Assignee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This guarantee is intended to be an authorised guarantee agreement within the meaning of the 1995 Act.
</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.50in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The COMMON SEAL of <B>MOORFIELDS EYE HOSPITAL NHS FOUNDATION TRUST</B> was hereunto affixed in the presence of:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">EXECUTED as a DEED by <B>MEIRAGTX UK II LIMITED</B> acting by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Director/Secretary</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d570173dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Alexandria Forbes,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MeiraGTx Holdings
plc; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">[Omitted]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 8, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alexandria Forbes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Alexandria Forbes</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chief Executive Officer</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d570173dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Richard Giroux, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> of MeiraGTx Holdings
plc; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> for the registrant and have: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[Omitted]; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: August 8, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard Giroux</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Richard Giroux</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chief Operating Officer (principal financial officer)</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d570173dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of MeiraGTx Holdings plc (the &#147;Company&#148;) on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ending June&nbsp;30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant
to &#167; 906 of the Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
result of operations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 8, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alexandria Forbes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Alexandria Forbes</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chief Executive Officer</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>d570173dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.50in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report of MeiraGTx Holdings plc (the &#147;Company&#148;) on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ending June&nbsp;30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant
to &#167; 906 of the Sarbanes-Oxley Act of 2002, that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of
1934; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Report fairly presents, in all material respects, the financial condition and
result of operations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August 8, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Richard Giroux</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Richard Giroux</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Chief Operating Officer (principal financial officer)</B></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>mgtx-20180630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS Xcelerate Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2018-08-08T01:33:44Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:mgtx="http://meiragtx.com/20180630" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mgtx-20180630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20180731_0" unitRef="shares" decimals="INF" id="id_10515943_F6700940-0FBA-4E19-A1B2-49167DEFAE93_2_500005">27184132</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20201031_0_3078046x3395641_3080792x3244897_3081295x3078919" unitRef="iso4217_GBP" decimals="0" id="id_10515943_5760E60F-ACA2-4251-9B08-93F2356FB710_1001_0">797343</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20201031_0_3078046x3395641_3080792x3244897_3081295x3078919" unitRef="iso4217_USD" decimals="0" id="id_10515943_5760E60F-ACA2-4251-9B08-93F2356FB710_1002_0">1052791</us-gaap:DueToRelatedPartiesNoncurrent>
  <mgtx:WeightedAverageNumberOfSharesOutstandingDilutedPercent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180301_0_3080924x3065411" unitRef="pure" decimals="2" id="id_10515943_D4B72C00-5786-4CDE-A288-E5A2FB20A591_3001_1">0.03</mgtx:WeightedAverageNumberOfSharesOutstandingDilutedPercent>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE1053578-1810-Q0003_STD_0_20180605_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10515943_C8633B69-F2CA-4280-8B1F-3F03745DB905_1001_1">10.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20180605_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_0EF1D430-85F9-48B6-83CD-014FEA3BE24F_2001_0">4194408</us-gaap:WarrantsAndRightsOutstanding>
  <mgtx:WeightedAverageNumberOfSharesOutstandingDilutedPercent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180607_0" unitRef="pure" decimals="2" id="id_10515943_58CB6A43-BCDA-4E7B-BD73-EF403EBBC810_2001_1">0.05</mgtx:WeightedAverageNumberOfSharesOutstandingDilutedPercent>
  <us-gaap:SharePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180607_0_3064218x3079518" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_4004_6">15.00</us-gaap:SharePrice>
  <mgtx:WeightedAverageNumberOfSharesOutstandingDilutedPercent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180607_0_3064218x3079518" unitRef="pure" decimals="2" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_4004_5">0.05</mgtx:WeightedAverageNumberOfSharesOutstandingDilutedPercent>
  <us-gaap:SharePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180607_0_3080924x3065411" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_C6BB7D84-DDA4-452D-AED9-98A143BFCB0E_2001_1">15.00</us-gaap:SharePrice>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="eol_PE1053578-1810-Q0003_STD_0_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_3002_36">5330794</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <mgtx:PromissoryNoteIssued contextRef="eol_PE1053578-1810-Q0003_STD_0_20171026_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_F6207DEE-FF9A-4C65-AEDD-6786012EC152_2001_1">1442009</mgtx:PromissoryNoteIssued>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_12">5289261</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_5">103985789</us-gaap:AssetsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_4">733409</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_33">221080313</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AssetRetirementObligation contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_1001_4">180350</us-gaap:AssetRetirementObligation>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_11">3461441</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedRentCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_3">128683</us-gaap:AccruedRentCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_34">-801235</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:Assets contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_8">117676971</us-gaap:Assets>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_15">28715</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_18">20732</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_2">102060551</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_3001_36">102183927</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_22" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_32">27184132</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_30">0.00003881</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_31">27184132</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_29">1055</us-gaap:CommonStockValue>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_19">224367</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_91C9C7B8-02E7-4A32-8A55-ABD903297314_1_0">0</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_17">8779417</us-gaap:LiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_21">9204866</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_37">117676971</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_7">180179</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_4">311283</us-gaap:OtherAssetsCurrent>
  <us-gaap:NoncurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="INF" id="id_10515943_7224652D-0643-4ED8-B2D3-6EE5D84B5E26_1001_2">13691182</us-gaap:NoncurrentAssets>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_3">1613955</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_20">180350</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_6">13567806</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCash contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_7">123376</us-gaap:RestrictedCash>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_35">-111808028</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CB32D0B8-7D14-435D-9135-4699E5E63134_4001_4">999410</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_4001_10">265221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_4001_8">7.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_4001_6">1614322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_4001_6">5.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_26">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CB32D0B8-7D14-435D-9135-4699E5E63134_4001_2">9884932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_1_36">108472105</us-gaap:StockholdersEquity>
  <mgtx:AccruedClinicalTrialCosts contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_0">2297893</mgtx:AccruedClinicalTrialCosts>
  <mgtx:AccruedInterest contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_5">30600</mgtx:AccruedInterest>
  <mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_1">645286</mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits>
  <mgtx:AccruedTravelExpense contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_6">135664</mgtx:AccruedTravelExpense>
  <mgtx:AccruedConsultingExpenses contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1001_2">1137547</mgtx:AccruedConsultingExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518" unitRef="shares" decimals="0" id="id_10515943_550D8CCD-0E57-4181-8A86-810A9A7955F0_4001_400004">870898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <mgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518" unitRef="iso4217_USD" decimals="0" id="id_10515943_92D72802-08EC-4186-BEAE-4136B4429372_4001_4">13063470</mgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue>
  <us-gaap:SharePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518_3081731x3265585" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_5002_2">7.72</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518_3081731x3329283" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_6002_3">7.76</us-gaap:SharePrice>
  <mgtx:FairValueNetAssetLiabilityEndingBalance contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3068684x3069375_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_24C26A06-509D-4FD0-8B50-BB91B585F0A7_2001_4">0</mgtx:FairValueNetAssetLiabilityEndingBalance>
  <us-gaap:FairValueNetAssetLiability contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3068684x3069635_3069102x3275696_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_92A65557-455E-4A06-9053-5A74B7577901_2002_1">123376</us-gaap:FairValueNetAssetLiability>
  <us-gaap:FairValueNetAssetLiability contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3069102x3275696_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_92A65557-455E-4A06-9053-5A74B7577901_2001_1">123376</us-gaap:FairValueNetAssetLiability>
  <us-gaap:LettersOfCreditOutstandingAmount contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_C68C93E5-AECF-4AD9-935A-0275AF0BB816_1001_0">122866</us-gaap:LettersOfCreditOutstandingAmount>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_A8E26F5E-3692-47F7-A95E-E3E1E3A637A5_1001_0">1927187</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <mgtx:DeferredRent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_A83E3E68-3659-4B59-8646-160EAB4638EE_2001_2">220722</mgtx:DeferredRent>
  <mgtx:DeferredRent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_627F1488-1186-4455-AAAD-22E71A7053F5_2001_5">0</mgtx:DeferredRent>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_9305BB40-9AF5-4EF2-A7E1-72420D1026CB_1001_0">374873</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3326238" unitRef="iso4217_USD" decimals="0" id="id_10515943_36BC329E-4D66-4174-A78F-DE5F71025E42_1001_0">374983</us-gaap:DueToRelatedPartiesCurrent>
  <mgtx:PotentialMilestonePaymentsUponAchievementOfMilestone contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_GBP" decimals="-5" id="id_10515943_069E1A83-9BFD-4C9F-B36E-9A0CDC8CEB5A_2002_1">39800000</mgtx:PotentialMilestonePaymentsUponAchievementOfMilestone>
  <mgtx:PotentialMilestonePaymentsUponAchievementOfMilestone contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_USD" decimals="-5" id="id_10515943_069E1A83-9BFD-4C9F-B36E-9A0CDC8CEB5A_2001_1">52600000</mgtx:PotentialMilestonePaymentsUponAchievementOfMilestone>
  <mgtx:AnnualMaintenanceFee contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_GBP" decimals="0" id="id_10515943_069E1A83-9BFD-4C9F-B36E-9A0CDC8CEB5A_2002_2">50000</mgtx:AnnualMaintenanceFee>
  <mgtx:AnnualMaintenanceFee contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_USD" decimals="0" id="id_10515943_069E1A83-9BFD-4C9F-B36E-9A0CDC8CEB5A_2001_2">66000</mgtx:AnnualMaintenanceFee>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3063589" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_3005_800022">221080313</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3064029" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_3006_900022">-801235</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_3003_600023">27184132</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_3003_700022">1055</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3078149" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_3007_1000022">-111808028</us-gaap:StockholdersEquity>
  <us-gaap:SharePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3264360" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_76E8944F-46ED-4B0B-94B0-86334BBE7EBA_2001_1">10.48</us-gaap:SharePrice>
  <us-gaap:NoncurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080926x3070630" unitRef="iso4217_USD" decimals="INF" id="id_10515943_7224652D-0643-4ED8-B2D3-6EE5D84B5E26_2001_1">13277701</us-gaap:NoncurrentAssets>
  <us-gaap:NoncurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080926x3082109" unitRef="iso4217_USD" decimals="INF" id="id_10515943_7224652D-0643-4ED8-B2D3-6EE5D84B5E26_3001_0">413481</us-gaap:NoncurrentAssets>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3081731x3324986" unitRef="iso4217_USD" decimals="0" id="id_10515943_757904BB-73D2-4908-AD7D-8FEF73B31C35_2001_0">3823995</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3081731x3395613" unitRef="iso4217_USD" decimals="0" id="id_10515943_3A2D4C4C-503E-4662-A395-C037211E75CE_2001_0">2596655</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:AssetRetirementObligation contextRef="eol_PE1053578-1810-Q0003_STD_0_20161231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_2001_0">221254</us-gaap:AssetRetirementObligation>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="eol_PE1053578-1810-Q0003_STD_0_20161231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_4001_35">17921485</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_12">9332944</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_5">11475114</us-gaap:AssetsCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_4">231923</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_33">20080713</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AssetRetirementObligation contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_1002_0">178419</us-gaap:AssetRetirementObligation>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_11">7055380</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedRentCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_3">387267</us-gaap:AccruedRentCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_34">-2022477</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:Assets contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_8">25854219</us-gaap:Assets>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_15">30850</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_18">34298</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_2">8548638</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_5001_35">8672014</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_22" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_32">8714563</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_30">0.00003881</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_31">8826190</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_29">342</us-gaap:CommonStockValue>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_19">266290</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_16">861030</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_17">21401846</us-gaap:LiabilitiesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_21">21880853</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_37">25854219</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:NotesPayableCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_13">1442009</us-gaap:NotesPayableCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_7">213527</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_4">965233</us-gaap:OtherAssetsCurrent>
  <us-gaap:NoncurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="INF" id="id_10515943_7224652D-0643-4ED8-B2D3-6EE5D84B5E26_1002_2">14379105</us-gaap:NoncurrentAssets>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_3">1961243</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_20">178419</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_6">14255729</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedCash contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_7">123376</us-gaap:RestrictedCash>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_35">-65423843</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_1001_9">186395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_1001_7">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_1001_1">938637</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_1001_1">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_27">52455700</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_26">5005935</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_24">51338631</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CB32D0B8-7D14-435D-9135-4699E5E63134_1001_1">1420650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_36">-47365265</us-gaap:StockholdersEquity>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FCBE2F64-3471-4C10-8A98-47BA85E91A2B_2_14">2679633</us-gaap:WarrantsAndRightsOutstanding>
  <mgtx:AccruedClinicalTrialCosts contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_0">4859410</mgtx:AccruedClinicalTrialCosts>
  <mgtx:AccruedInterest contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_5">33437</mgtx:AccruedInterest>
  <mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_1">2386903</mgtx:AccruedLiabilitiesAccruedCompensationAndBenefits>
  <mgtx:AccruedConsultingExpenses contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_CC3AA753-E62E-49D5-A2F0-49201027788E_1002_2">1220477</mgtx:AccruedConsultingExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3064218x3079518" unitRef="shares" decimals="0" id="id_10515943_550D8CCD-0E57-4181-8A86-810A9A7955F0_1001_400001">105913</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <mgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3064218x3079518" unitRef="iso4217_USD" decimals="0" id="id_10515943_92D72802-08EC-4186-BEAE-4136B4429372_1001_1">865861</mgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue>
  <us-gaap:FairValueNetAssetLiability contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3068684x3069375_3069102x3082828_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_CD0FDE89-A89E-4CBD-AE2F-8FD7D8570642_2004_2">2679633</us-gaap:FairValueNetAssetLiability>
  <us-gaap:FairValueNetAssetLiability contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3068684x3069635_3069102x3275696_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_CD0FDE89-A89E-4CBD-AE2F-8FD7D8570642_3002_1">123376</us-gaap:FairValueNetAssetLiability>
  <us-gaap:FairValueNetAssetLiability contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3069102x3082828_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_CD0FDE89-A89E-4CBD-AE2F-8FD7D8570642_2001_2">2679633</us-gaap:FairValueNetAssetLiability>
  <us-gaap:FairValueNetAssetLiability contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3069102x3275696_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_CD0FDE89-A89E-4CBD-AE2F-8FD7D8570642_3001_1">123376</us-gaap:FairValueNetAssetLiability>
  <mgtx:DeferredRent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_A83E3E68-3659-4B59-8646-160EAB4638EE_1002_2">231276</mgtx:DeferredRent>
  <mgtx:DeferredRent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_627F1488-1186-4455-AAAD-22E71A7053F5_1004_5">0</mgtx:DeferredRent>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_9305BB40-9AF5-4EF2-A7E1-72420D1026CB_1002_0">775315</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3078046x3395641_3080792x3326238" unitRef="iso4217_USD" decimals="0" id="id_10515943_36BC329E-4D66-4174-A78F-DE5F71025E42_1002_0">2466142</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3063589" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_1005_800001">20080713</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3064029" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_1006_900001">-2022477</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_1003_600002">8826190</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_1003_700001">342</us-gaap:StockholdersEquity>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_1001_400002">5005935</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_1001_500001">51338631</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:StockholdersEquity contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3078149" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_1007_1000001">-65423843</us-gaap:StockholdersEquity>
  <us-gaap:NoncurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080926x3070630" unitRef="iso4217_USD" decimals="INF" id="id_10515943_7224652D-0643-4ED8-B2D3-6EE5D84B5E26_2002_1">13942642</us-gaap:NoncurrentAssets>
  <us-gaap:NoncurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080926x3082109" unitRef="iso4217_USD" decimals="INF" id="id_10515943_7224652D-0643-4ED8-B2D3-6EE5D84B5E26_3002_0">436463</us-gaap:NoncurrentAssets>
  <mgtx:PeriodOfAgreement contextRef="eol_PE1053578-1810-Q0003_STD_1_20150424_0_3078046x3395534_3080792x3395636" id="id_10515943_F4A25AF4-AEF7-4082-92C9-0379E0BCC986_1001_1">P3Y</mgtx:PeriodOfAgreement>
  <mgtx:TerminationDate contextRef="eol_PE1053578-1810-Q0003_STD_1_20150424_0_3078046x3395534_3080792x3395636" id="id_10515943_F4A25AF4-AEF7-4082-92C9-0379E0BCC986_1001_2">2018-04-24</mgtx:TerminationDate>
  <mgtx:RelatedPartyAdministrativeExpensePercentage contextRef="eol_PE1053578-1810-Q0003_STD_1_20150424_0_3078046x3395534_3080792x3395636" unitRef="pure" decimals="2" id="id_10515943_F4A25AF4-AEF7-4082-92C9-0379E0BCC986_1001_0">0.07</mgtx:RelatedPartyAdministrativeExpensePercentage>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_1_20180301_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_D4B72C00-5786-4CDE-A288-E5A2FB20A591_2001_2">3096104</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_1_20180301_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_D4B72C00-5786-4CDE-A288-E5A2FB20A591_2001_0">550162</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_1_20180315_0_3080792x3331058_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_B3447CFA-4C7D-4554-BF98-1ACCC405DA24_1001_0">13360</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_1_20180604_0_3069102x3082828" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1003_3">P1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE1053578-1810-Q0003_STD_1_20180604_0_3069102x3082828" unitRef="pure" decimals="2" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1003_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE1053578-1810-Q0003_STD_1_20180604_0_3069102x3082828" unitRef="pure" decimals="4" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1003_0">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE1053578-1810-Q0003_STD_1_20180604_0_3069102x3082828" unitRef="pure" decimals="2" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1003_1">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE1053578-1810-Q0003_STD_1_20180605_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_C8633B69-F2CA-4280-8B1F-3F03745DB905_1_2">9720000</us-gaap:ProceedsFromWarrantExercises>
  <mgtx:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="eol_PE1053578-1810-Q0003_STD_1_20180605_0" unitRef="shares" decimals="0" id="id_10515943_C8633B69-F2CA-4280-8B1F-3F03745DB905_1_0">927594</mgtx:ClassOfWarrantOrRightExercisedDuringPeriod>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0" unitRef="pure" decimals="3" id="id_10515943_F23BDE6E-223E-46C9-8137-C441BC4B427A_1_400000">0.257</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <mgtx:AccretionOfDeferredFinancingCosts contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_0F9372D3-E869-4A8C-BCEE-C08E9DF29CC4_1_1">664718</mgtx:AccretionOfDeferredFinancingCosts>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3064218x3079518" unitRef="shares" decimals="0" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_1004_4">1306348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_F99D3726-AEA8-4B7A-9AAB-05D377AF3612_1001_3">9541530</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_F99D3726-AEA8-4B7A-9AAB-05D377AF3612_1001_2">75000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_0F9372D3-E869-4A8C-BCEE-C08E9DF29CC4_1001_0">11501432</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_C6BB7D84-DDA4-452D-AED9-98A143BFCB0E_1001_0">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <mgtx:ProceedsFromIssuanceInitialPublicOfferingNet contextRef="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3080924x3065411" unitRef="iso4217_USD" decimals="-5" id="id_10515943_C6BB7D84-DDA4-452D-AED9-98A143BFCB0E_1001_2">65900000</mgtx:ProceedsFromIssuanceInitialPublicOfferingNet>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE1053578-1810-Q0003_STD_1_20180727_0_3073336x3396760_3081213x3080964" id="id_10515943_96BE28B1-5A61-4EC7-866E-B85EE2A89FD8_1001_1">2027-05-24</us-gaap:LeaseExpirationDate1>
  <mgtx:NumberOfLeasesTerminated contextRef="eol_PE1053578-1810-Q0003_STD_1_20180727_0_3073336x3396760_3081213x3080964" unitRef="Lease" decimals="INF" id="id_10515943_96BE28B1-5A61-4EC7-866E-B85EE2A89FD8_1001_2">2</mgtx:NumberOfLeasesTerminated>
  <mgtx:NumberOfNewFacilityLeases contextRef="eol_PE1053578-1810-Q0003_STD_1_20180727_0_3073336x3396760_3081213x3080964" unitRef="Lease" decimals="INF" id="id_10515943_96BE28B1-5A61-4EC7-866E-B85EE2A89FD8_1001_3">2</mgtx:NumberOfNewFacilityLeases>
  <mgtx:AnnualBaseRentAndOperatingExpense contextRef="eol_PE1053578-1810-Q0003_STD_1_20180727_0_3073336x3396760_3081213x3080964" unitRef="iso4217_USD" decimals="0" id="id_10515943_96BE28B1-5A61-4EC7-866E-B85EE2A89FD8_1001_0">363000</mgtx:AnnualBaseRentAndOperatingExpense>
  <mgtx:BaseRentAndManagementFees contextRef="eol_PE1053578-1810-Q0003_STD_156_20180331_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_627F1488-1186-4455-AAAD-22E71A7053F5_1002_3">563507</mgtx:BaseRentAndManagementFees>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BB2368F-D672-497E-9616-497FB4A90F2D_2_2">1535090</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_2_3">2274770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CapitalLeaseObligationsIncurred contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_42">78063</us-gaap:CapitalLeaseObligationsIncurred>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_33">-12660382</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_13">-14475018</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:Depreciation contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_7">373276</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_17">-1.64</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_34">69691</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_4_1">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_4_0">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:FairValueOfAssetsAcquired contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_38">1561299</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_7">598874</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_1">4370436</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_26063376-73C3-436C-8D80-8B574B95113D_4_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_16">1646167</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_14">784493</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_12">739977</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_11">-6134</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_17">352544</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_10">59020</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_18">70200</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:InterestPaidNet contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_46">1337</us-gaap:InterestPaidNet>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_9">18380</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_16">-14052266</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_23">-2324514</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_32">194863</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_19">-10530731</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_11">-13999104</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_12">-475914</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OperatingExpenses contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_3">14557338</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_4">-14557338</us-gaap:OperatingIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_22">4824514</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_29">210244</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_21">2500000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_25">9257</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_2_3">306008</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_2">10186902</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_5">1535090</us-gaap:ShareBasedCompensation>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_15">53162</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_8AA31AFC-DA54-4C45-B213-022A62FA73D1_2_0">927915</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="shares" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_4_18">8545437</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_78A8C930-8D68-49C8-A906-7A482D3B6344_2_3">-14052266</mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <mgtx:AmortizationOfInterestOnAssetRetirementObligation contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_8">9255</mgtx:AmortizationOfInterestOnAssetRetirementObligation>
  <mgtx:IncreaseDecreaseInDueToAndFromRelatedParties contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2_15">30065</mgtx:IncreaseDecreaseInDueToAndFromRelatedParties>
  <mgtx:AccretionOfDeferredFinancingCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_78A8C930-8D68-49C8-A906-7A482D3B6344_2_1">53162</mgtx:AccretionOfDeferredFinancingCosts>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3064118x3069261" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_1002_2">444473</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3064118x3076421" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_2002_0">1584469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3064118x3079518" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_3002_1">245828</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3071648x3070631" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BB2368F-D672-497E-9616-497FB4A90F2D_1002_1">295167</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3071648x3078843" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BB2368F-D672-497E-9616-497FB4A90F2D_2002_0">1239923</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_29FA6256-25E9-4638-A118-29EE6159A831_1002_0">243780</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_0279E676-9FE4-4C33-BE9F-5AD05A4FD9BB_1002_0">781806</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078040x3395633" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_1002_0">275524</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078040x3395634" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_2002_1">25278</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078040x3395635" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_3002_2">5206</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <mgtx:PaymentToRelatedParty contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395534_3080792x3395636" unitRef="iso4217_USD" decimals="0" id="id_10515943_2FB37CD1-B326-4E23-AF13-E123AAA6EE8B_1001_0">275941</mgtx:PaymentToRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_CDE0A7CD-972C-43E5-A9F6-57DC9CC10E36_1002_0">222000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395641_3080792x3326238" unitRef="iso4217_USD" decimals="0" id="id_10515943_50C5451E-7C67-48E6-A3D9-255CC472124D_1002_0">1042518</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_USD" decimals="INF" id="id_10515943_EC339817-6004-4981-859C-7693FA646B2E_1004_0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078512x3074821_3081731x3297706" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_1002_5">P9Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078512x3075282_3081731x3297706" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_2002_4">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2002_30">6124</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3297706" unitRef="pure" decimals="2" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3002_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3297706" unitRef="pure" decimals="4" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3002_0">0.0229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3297706" unitRef="pure" decimals="2" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3002_2">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3297706" unitRef="pure" decimals="4" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3002_1">0.0231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3324986" unitRef="shares" decimals="INF" id="id_10515943_2050E10C-2E05-496E-AC36-489F7A419859_1002_0">135271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3395613" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_D02C408A-C546-411E-9A1C-DE3A05380E35_1002_0">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3395613" unitRef="shares" decimals="INF" id="id_10515943_86680BBF-AD30-493F-A2FF-6A3A3653AEE9_1002_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_D7AF77CA-CFE0-4E8F-B8A5-7A4BD5BC7114_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Accrued expenses for the period presented were comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Clinical Trial Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,297,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,859,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Compensation and Benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;645,286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,386,903&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Consulting&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,137,547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,220,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;387,267&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Professional Fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;733,409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;231,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Travel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;135,664&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,179&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;213,527&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,289,261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,332,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BB2368F-D672-497E-9616-497FB4A90F2D_1_2">12633556</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_1_3">2485220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AssetRetirementObligationsPolicy contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_884C8D7A-D0AE-4C4E-B66E-72AFFAEE7E1C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Asset Retirement Obligation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Accounting for Asset Retirement Obligations requires legal
 obligations associated with the retirement of long-lived assets to
 be recognized at fair value when incurred and capitalized as part
 of the related long-lived asset. In the absence of quoted market
 prices, we estimate the fair value of our asset retirement
 obligations using Level&amp;#xA0;3 present value techniques, in which
 estimates of future cash flows associated with retirement
 activities are discounted using a credit-adjusted risk-free rate.
 Asset retirement obligations currently reported as other
 liabilities on our Consolidated Balance Sheet were measured during
 a period of historically low interest rates. The impact on
 measurements of new asset retirement obligations using different
 rates in the future may be significant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company uses estimates to determine the amount of the asset
 retirement obligations at the end of the lease term and discounts
 such asset retirement obligations using an estimated discount rate.
 Interest on the discounted asset retirement obligation is amortized
 over the term of the lease using the effective interest method and
 is recorded as interest expense in the consolidated statements of
 operations and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The change in asset retirement obligations is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 For&amp;#xA0;the&amp;#xA0;six&amp;#xA0;month&amp;#xA0;period&lt;br /&gt;
 ended June&amp;#xA0;30, 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;For&amp;#xA0;the&amp;#xA0;year&amp;#xA0;ended&lt;br /&gt;
 December&amp;#xA0;31,&amp;#xA0;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;221,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amortization of interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in estimate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(75,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effects of exchange rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,350&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AssetRetirementObligationsPolicy>
  <dei:AmendmentFlag contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B0B79FCF-91C3-42A1-89A9-168C11BDA041_1_1">false</dei:AmendmentFlag>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5008_1100011">4194408</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_1_3">-5391</us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_93C29444-1C49-4351-864B-76D9F29DD1FD_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Organization and Basis of Presentation:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;The Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 MeiraGTx Holdings plc, a limited company under the laws of the
 Cayman Islands, is a clinical-stage biotech company developing
 novel gene therapy treatments for a wide range of inherited and
 acquired disorders for which there are no effective treatments
 available. The Company is focused on developing therapies for
 ocular diseases, including rare inherited blindness as well as
 Xerostomia following radiation treatment for head and neck cancers
 and neurodegenerative diseases such as amyothrophic lateral
 sclerosis (&amp;#x201C;ALS&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reorganization and Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 On May&amp;#xA0;28, 2018, the Board of Directors of MeiraGTx Limited
 approved the Reorganization Transactions, effective June&amp;#xA0;7,
 2018, pursuant to which the Board of Directors approved the
 transfer of the shares held by each of the MeiraGTx Limited&amp;#x2019;s
 shareholders for the equivalent class and number of shares issued
 by Meira Holdings. On June&amp;#xA0;7, 2018, the Company completed its
 IPO, selling 5,000,000 Series A ordinary shares (&amp;#x201C;Ordinary
 Shares&amp;#x201D;) at a public offering price of $15.00 per share, and
 receiving $65.9&amp;#xA0;million in net proceeds, after deducting
 underwriting discounts and commissions and offering expenses
 payable by us.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reverse Share Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 On June&amp;#xA0;7, 2018 MeiraGTx Limited&amp;#x2019;s Board of Directors
 and shareholders approved a 1:3.881 reverse share split. All share
 information presented in these financial statements and
 accompanying footnotes have been retroactively adjusted to reflect
 the decreased number of shares resulting from this action.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The accompanying condensed consolidated financial statements have
 been prepared in conformity with accounting principles generally
 accepted in the United States of America (&amp;#x201C;GAAP&amp;#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to the authoritative United States generally accepted accounting
 principles as found in the Accounting Standards Codification
 (&amp;#x201C;ASC&amp;#x201D;) and Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) of the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Interim Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The accompanying condensed consolidated financial statements have
 been prepared in accordance with GAAP for interim financial
 information and with the instructions to&amp;#xA0;Form &lt;font style="WHITE-SPACE: nowrap"&gt;10-Q&lt;/font&gt; and Article 10 of Regulation
 &lt;font style="WHITE-SPACE: nowrap"&gt;S-X.&lt;/font&gt; Accordingly, they do
 not include all the information and footnotes required by generally
 accepted accounting principles for complete consolidated financial
 statements. In the opinion of management, the condensed
 consolidated financial statements include all adjustments
 (consisting of normal recurring accruals) necessary in order to
 make the condensed consolidated financial statements not
 misleading. Operating results for the three-month and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018&amp;#xA0;are not necessarily indicative of the final results that
 may be expected for the year ended December&amp;#xA0;31, 2018. These
 unaudited condensed consolidated financial statements should be
 read in conjunction with the audited consolidated financial
 statements&amp;#xA0;for the year ended December&amp;#xA0;31, 2017 and the
 notes thereto for the year ended December&amp;#xA0;31, 2017 included in
 the Company&amp;#x2019;s final prospectus that forms a part of the
 Company&amp;#x2019;s Registration Statement on Form &lt;font style="WHITE-SPACE: nowrap"&gt;S-1&lt;/font&gt; (Reg. &lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;333-224914),&lt;/font&gt; filed with the
 Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;) pursuant to
 Rule 424(b)(4) on June&amp;#xA0;8, 2018 (the
 &amp;#x201C;Prospectus&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company has not generated any revenues and has not yet achieved
 profitable operations. There is no assurance that profitable
 operations, if ever achieved, could be sustained on a continuing
 basis. In addition, development activities, clinical and
 preclinical testing, and commercialization of the Company&amp;#x2019;s
 product candidates will require significant additional financing.
 Management expects to incur substantial and increasing losses in
 future periods. The success of the Company is subject to certain
 risks and uncertainties, including among others, uncertainty of
 product development; competition in the Company&amp;#x2019;s field of
 use; uncertainty of capital availability; uncertainty in the
 Company&amp;#x2019;s ability to enter into agreements with collaborative
 partners; dependence on third parties; and dependence on key
 personnel. The Company has not generated positive cash flows from
 operations, and there are no assurances that the Company will be
 successful in obtaining an adequate level of financing for the
 development and commercialization of its product candidates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 As of June&amp;#xA0;30, 2018, the Company had cash and cash equivalents
 in the amount of $102,060,551, which consisted of depository
 accounts. The Company estimates that its cash and cash equivalents
 on hand at June&amp;#xA0;30, 2018 will cover its expenses into the
 second quarter of 2020.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company operates in an industry that is subject to intense
 competition, government regulation and rapid technological change.
 The Company&amp;#x2019;s operations are subject to significant risk and
 uncertainties including financial, operational, technological,
 regulatory and other risks, including the potential risk of
 business failure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s limited capital resources and operations to
 date have been funded primarily with the proceeds from private
 equity offerings and the IPO. In the future, the Company may seek
 to raise additional capital through equity offerings, debt
 financings, marketing and distribution arrangements and other
 collaborations, strategic alliances and licensing arrangements or
 other sources to enable it to complete the development and
 potential commercialization of its product candidates.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_1FE02F4E-FC0A-45B6-91BF-139075EDA0F4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The accompanying condensed consolidated financial statements have
 been prepared in conformity with accounting principles generally
 accepted in the United States of America (&amp;#x201C;GAAP&amp;#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to the authoritative United States generally accepted accounting
 principles as found in the Accounting Standards Codification
 (&amp;#x201C;ASC&amp;#x201D;) and Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) of the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;).&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_33">93726489</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_13">-45162943</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ConversionOfStockAmountIssued1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="INF" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_40">120520391</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B8787438-5431-47B1-B820-2E2D0AEB1AE7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The accompanying condensed consolidated financial statements
 include the accounts of Meira Holdings and its wholly owned
 subsidiaries:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx Limited, a limited company under the laws of England and
 Wales (&amp;#x201C;Meira Limited);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx, LLC, a Delaware corporation (&amp;#x201C;Meira
 LLC&amp;#x201D;);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 BRI-Alzan, Inc., a Delaware corporation
 (&amp;#x201C;BRI-Alzan&amp;#x201D;);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx B.V., a Netherlands corporation (&amp;#x201C;Meira
 BV&amp;#x201D;);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx UK II Limited, (&amp;#x201C;Meira UK II&amp;#x201D;), a limited
 company under the laws of England and Wales;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx UK Limited (&amp;#x201C;Meira UK&amp;#x201D;), a limited company
 under the laws of England and Wales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 All intercompany balances and transactions between the consolidated
 companies have been eliminated in consolidation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_F6700940-0FBA-4E19-A1B2-49167DEFAE93_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:Depreciation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_7">1015079</us-gaap:Depreciation>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_6E1CB56F-3B89-4B21-BCCC-68254FA1F865_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;2018 and 2016 Equity Incentive Plans&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company maintains the 2018 Incentive Award Plan and 2016 Equity
 Incentive Plan (together, the &amp;#x201C;Plans&amp;#x201D;), under which,
 the Company has granted share options to selected officers,
 employees and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;consultants. The
 Company&amp;#x2019;s board of directors administer the Plans. Options
 granted under the Plans have a maximum contractual term of ten
 years. Options granted to employees and consultants generally vest
 25% on the first anniversary date of grant and the balance ratably
 over the next 36 months. Options granted to directors generally
 vest on the first anniversary date of grant. Upon the adoption of
 the 2018 Incentive Award Plan, the Company ceased issuing awards
 under the 2016 Equity Incentive Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 A summary of the Company&amp;#x2019;s share option activity related to
 employees,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;members
 of the board of directors and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;consultants
 as of and for the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;period
 ended June&amp;#xA0;30, 2018 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&amp;#xA0;Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;br /&gt;
 Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Instrinsic&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;938,637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,420,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;675,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.63&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,614,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,884,932&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options outstanding
 as of December&amp;#xA0;31, 2017 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options outstanding
 as of June&amp;#xA0;30, 2018 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options exercisable at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;186,395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options exercisable at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;265,221&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;999,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options exercisable
 as of December&amp;#xA0;31, 2017 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options exercisable
 as of June&amp;#xA0;30, 2018 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The total fair value of options vested during the three-month
 periods ended June&amp;#xA0;30, 2018 and 2017 was $247,202 and
 $229,250, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The total fair value of options vested during
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended&amp;#xA0;June 30, 2018 and 2017 was $556,349 and $927,915,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017, the Company granted 533,330 and
 0 share options, respectively, to employees
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;members
 of the board of directors. No options were granted during the
 three-month periods ended June&amp;#xA0;30, 2018 and 2017. The grant
 date fair values of the stock options granted to those groups were
 estimated using the Black-Scholes option valuation model with the
 following ranges of assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.32%&amp;#xA0;-&amp;#xA0;2.40%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;90%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of employee and Board of Directors&amp;#x2019; options (in
 years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.5&amp;#xA0;-&amp;#xA0;6.1&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of June&amp;#xA0;30, 2018, the total compensation expense relating
 to unvested options granted to employees
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;members
 of the board of directors that had not yet been recognized was
 $2,596,655, which is expected to be realized over a period of 3.5
 years. The Company will issue shares upon exercise of options from
 Ordinary Shares reserved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017, the Company granted 142,355 and
 135,271 share options, respectively
 to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;consultants.
 No options were granted during the three-month period ended
 June&amp;#xA0;30, 2018. In accordance with
 ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;505-50,&lt;/font&gt;&amp;#xA0;on
 June&amp;#xA0;30, 2017 and 2018, the Company remeasured the fair value,
 of all unvested outstanding options that had been granted
 to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;consultants
 using the Black-Scholes option valuation model with the following
 ranges of assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.80%&amp;#xA0;-&amp;#xA0;2.84%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.29%&amp;#xA0;-&amp;#xA0;2.31%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;90%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;80%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;options
 (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7.7&amp;#xA0;-&amp;#xA0;9.5&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;8.7&amp;#xA0;-&amp;#xA0;9.7&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of June&amp;#xA0;30, 2018, the total compensation expense relating
 to unvested options granted to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;consultants
 that had not yet been recognized was $3,823,995, which is expected
 to be realized over a period of 3.5 years. The Company will issue
 shares upon exercise of options from Ordinary Shares reserved.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The weighted average grant date fair value of options granted to
 employees,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;members
 of the board of directors and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;consultants
 during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017 was $5.63 and $6.13,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Ordinary Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In 2015, in connection with certain service and consulting
 agreements, certain employees and a consultant were awarded an
 aggregate of 867,935 restricted Ordinary Shares of the Company.
 Such shares were subject to forfeiture over a three-year service
 period. The shares granted to the consultant and employees were
 valued at $7.72 and $7.76 per share, respectively, and were
 included in loss from operations over the requisite service period.
 As of June&amp;#xA0;30, 2018, all such shares are no longer subject to
 forfeiture as the three-year service period has been completed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On June&amp;#xA0;7, 2018, 1,306,348 restricted Ordinary Shares, which
 represented 5% of the fully-diluted outstanding shares of the
 Company as of such date, were issued to certain members of senior
 management in accordance with their employment
 agreements.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;One-third&lt;/font&gt;&amp;#xA0;of such
 shares vested immediately, with the balance vesting quarterly over
 the next eight quarters beginning three months after the
 effectiveness of the Company&amp;#x2019;s registration statement on
 Form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;S-1&lt;/font&gt;&amp;#xA0;filed with the
 SEC on June&amp;#xA0;7, 2018 (the &amp;#x201C;Registration
 Statement&amp;#x201D;). The shares were valued at $15.00 per share and
 are included in loss from operations over the requisite service
 period. Additionally, under the terms of the employment agreements,
 the Company was required to pay the income taxes incurred by the
 grantees in connection with the grant of those restricted shares.
 Total compensation expense in connection with the issuance of those
 restricted Ordinary Shares, in the amount of $13,620,866, of which
 $6,531,750 was share-based, was recorded as general and
 administrative expense during the three-month period ended
 June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 A summary of the restricted Ordinary Shares is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Ordinary&amp;#xA0;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;$ Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-vested&lt;/font&gt;&amp;#xA0;at
 December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,913&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;865,861&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issued during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;period
 ended June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,306,348&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,595,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;period
 ended June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(541,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,397,611&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-vested&lt;/font&gt;&amp;#xA0;at
 June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;870,898&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,063,470&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Ordinary Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On March&amp;#xA0;1, 2018, a funding milestone was met under the
 employment agreements for certain members of senior management.
 Accordingly, the employees were issued an aggregate of 550,162
 fully vested Ordinary Shares, which represented 3% of the
 fully-diluted outstanding shares of the Company as of such date.
 The shares were recorded as share-based compensation in the amount
 of $3,096,104. Additionally, under the terms of the employment
 agreements, the Company was required to pay the income taxes
 incurred by the grantees in connection with the grant of those
 shares. Total compensation expense in connection with the issuance
 of those Ordinary Shares, in the amount of $6,456,215, of which
 $3,096,012 was share-based, was recorded as general and
 administrative expense during the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;period
 ended June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the three-month and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017 the Company recognized total
 share-based compensation expense in the accompanying condensed
 consolidated statements of operations and comprehensive loss as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,045,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;550,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,318,224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total share based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,363,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;682,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="8"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,890,511&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,239,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,743,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;295,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total share based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,633,556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,535,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company does not expect to realize any tax benefits from its
 share option activity or the recognition of share-based
 compensation expense because the Company currently has net
 operating losses and has a full valuation allowance against its
 deferred tax assets. Accordingly, no amounts related to excess tax
 benefits have been reported in cash flows from operations or cash
 flows from financing activities for the three-month
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;periods ended June&amp;#xA0;30,
 2018 and 2017.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B0B79FCF-91C3-42A1-89A9-168C11BDA041_1_4">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B0B79FCF-91C3-42A1-89A9-168C11BDA041_1_3">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B0B79FCF-91C3-42A1-89A9-168C11BDA041_1_0">10-Q</dei:DocumentType>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_17">-4.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_41E4F699-2C50-4DB0-B25A-5C18C28A068D_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Net Loss per Share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company computes net loss per share in accordance with
 ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;260-10,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Earnings
 per Share&lt;/i&gt;&amp;#xA0;(see Note 2).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Basic and diluted net loss per share is computed as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;For&amp;#xA0;the&amp;#xA0;three-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,980,832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,178,719&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of Preferred Shares financing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(666,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,401&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(475,227&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Adjusted net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,122,626&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,209,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average ordinary shares outstanding:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,611,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,505,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="8"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;For&amp;#xA0;the&amp;#xA0;six-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46,384,185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,999,104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of Preferred Shares financing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(761,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(53,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,045,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Adjusted net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(48,190,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,052,266&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average ordinary shares outstanding:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,280,804&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,545,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following securities are considered to be Ordinary Share
 equivalents, but were not included in the computation of diluted
 net loss per Ordinary Share because to do so would have been
 anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Preferred Shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,584,469&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 A restricted ordinary shares subject to forfeiture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;870,898&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;245,828&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,614,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;444,473&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,485,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,274,770&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_911D8BCF-1F7E-42A5-9860-FEF8B199D7E9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The grant date fair values of the stock options granted to those
 groups were estimated using the Black-Scholes option valuation
 model with the following ranges of assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.32%&amp;#xA0;-&amp;#xA0;2.40%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;90%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of employee and Board of Directors&amp;#x2019; options (in
 years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.5&amp;#xA0;-&amp;#xA0;6.1&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.80%&amp;#xA0;-&amp;#xA0;2.84%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.29%&amp;#xA0;-&amp;#xA0;2.31%&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;90%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;80%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;options
 (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7.7&amp;#xA0;-&amp;#xA0;9.5&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;8.7&amp;#xA0;-&amp;#xA0;9.7&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_7859EFE8-69C3-4117-B165-6CB8AE99C608_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss per Ordinary Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Basic net loss per Ordinary Share is computed by dividing net loss
 attributable to the Company&amp;#x2019;s shareholders by the weighted
 average number of shares of the Company&amp;#x2019;s Ordinary Shares
 assumed to be outstanding during the period of computation. Diluted
 net loss per ordinary share is computed similar to basic net loss
 per share except that the denominator is increased to include the
 number of additional Ordinary Shares that would have been
 outstanding if the potential ordinary shares had been issued at the
 beginning of the year and if the additional ordinary shares were
 dilutive (treasury stock method) or the &lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt; method, whichever is more
 dilutive. For all periods presented, basic and diluted net loss per
 Ordinary Share are the same, as any additional Ordinary Share
 equivalents would be anti-dilutive.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_F6700940-0FBA-4E19-A1B2-49167DEFAE93_1_400002">0001735438</dei:EntityCentralIndexKey>
  <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_34">-214576</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_2_1">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <dei:EntityRegistrantName contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_F6700940-0FBA-4E19-A1B2-49167DEFAE93_1_400001">MeiraGTx Holdings plc</dei:EntityRegistrantName>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_2_0">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_BF5DA5F4-99D5-44B0-9334-73404715448A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The table below represents the values of the Compnay&amp;#x2019;s
 financial assets and liabilities that are required to be measured
 at fair value on a recurring basis:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;Fair Value Measurement Using:&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Observable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;Fair Value Measurement Using:&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Observable Inputs&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant Other&lt;br /&gt;
 Observable Inputs&lt;br /&gt;
 (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <dei:DocumentPeriodEndDate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B0B79FCF-91C3-42A1-89A9-168C11BDA041_1_2">2018-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityFilerCategory contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_F6700940-0FBA-4E19-A1B2-49167DEFAE93_1_400004">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_8">1514775</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_0E414732-6AC5-4787-8111-D84E920AD4C5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Fair value is defined as the price that would be received upon sale
 of an asset or paid upon transfer of a liability in an orderly
 transaction between market participants at the measurement date and
 in the principal or most advantageous market for that asset or
 liability. The fair value should be calculated based on assumptions
 that market participants would use in pricing the asset or
 liability, not on assumptions specific to the entity. In addition,
 the fair value of liabilities should include consideration of
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-performance&lt;/font&gt; risk
 including our own credit risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company follows ASC Topic 820, &lt;i&gt;Fair Value Measurements and
 Disclosures&lt;/i&gt;, or ASC 820, for application to financial assets.
 In addition to defining fair value, the standard expands the
 disclosure requirements around fair value and establishes a fair
 value hierarchy for valuation inputs. The hierarchy prioritizes the
 inputs into three levels based on the extent to which inputs used
 in measuring fair value are observable in the market. Each fair
 value measurement is reported in one of the three levels which are
 determined by the lowest level input that is significant to the
 fair value measurement in its entirety. These levels are:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Level&amp;#xA0;1: Observable inputs such as quoted prices
 in active markets for identical assets the reporting entity has the
 ability to access as of the measurement date;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Level&amp;#xA0;2: Inputs, other than the quoted prices in
 active markets, that are observable either directly or indirectly;
 and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;Level&amp;#xA0;3: Unobservable inputs in which there is
 little or no market data, which require the reporting entity to
 develop its own assumptions.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The table below represents the values of the Compnay&amp;#x2019;s
 financial assets and liabilities that are required to be measured
 at fair value on a recurring basis:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;Fair Value Measurement Using:&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Observable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;Fair Value Measurement Using:&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Observable Inputs&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant Other&lt;br /&gt;
 Observable Inputs&lt;br /&gt;
 (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 The table below represents a rollforward of the assets and
 liabilities that are required to be measured at fair value on a
 recurring basis from December&amp;#xA0;31, 2017 to June&amp;#xA0;30,
 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,514,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,194,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The warrants were classified as liabilities because the underlying
 Preferred Shares had a redemption feature in the event of a change
 of control of the Company. On June&amp;#xA0;5, 2018, the warrants were
 exercised at which time the warrant liability was determined to be
 $4,194,408, which represented the difference in the market value of
 the Preferred Shares and the exercise price of the warrants. This
 resulted in an increase of the warrant liability in the amount of
 $2,184,183 and $1,514,775 for the three-month and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, respectively. The related warrant liability of $4,194,408 was
 reclassified as Capital in Excess of Nominal Value at such
 time.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The fair values of the warrants at December&amp;#xA0;31, 2017,
 March&amp;#xA0;31, 2018 and June&amp;#xA0;4, 2018 were estimated using the
 Black-Scholes valuation model with the following assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;March&amp;#xA0;31,&amp;#xA0;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;4,&amp;#xA0;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&amp;#xA0;months&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.5&amp;#xA0;months&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&amp;#xA0;day&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 For the unobservable inputs for the warrants, the expected
 volatility was determined at each measurement date by taking an
 average of the volatility of other publicly-traded peer
 biotechnology companies. The expected life was determined at each
 measurement date based upon the Company&amp;#x2019;s estimate of the
 time until the Company has a conversion event.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The fair value of the Preferred Shares was based upon recent
 issuances of the Company&amp;#x2019;s Preferred Shares on or about
 December&amp;#xA0;31, 2017, March&amp;#xA0;31, 2018 and June&amp;#xA0;5,
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The estimated fair values of the Company&amp;#x2019;s warrants are not
 necessarily indicative of the amounts that would be realized in a
 current market exchange. The determination of the fair value of the
 warrants are sensitive to changes in in the assumptions used and a
 change in those inputs could result in a significantly higher or
 lower fair value measurement. If the volatility were to increase or
 the expected life were to increase, the fair value of the warrant
 would increase. Conversely, if the volatility were to decrease or
 the expected life were to decrease, the fair value of the warrant
 would decrease.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_350A8827-8D5A-4044-8D5B-F1D90543DDEC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The fair values of the warrants at December&amp;#xA0;31, 2017,
 March&amp;#xA0;31, 2018 and June&amp;#xA0;4, 2018 were estimated using the
 Black-Scholes valuation model with the following assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;March&amp;#xA0;31,&amp;#xA0;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;4,&amp;#xA0;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&amp;#xA0;months&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.5&amp;#xA0;months&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&amp;#xA0;day&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueOfAssetsAcquired contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_38">298551</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_7">-1748000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_1">28500068</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_26063376-73C3-436C-8D80-8B574B95113D_2_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_16">-2413642</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_14">-42095</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_12">-650528</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_11">-317130</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_48CA8761-3DE0-4A01-AF03-CAB64122FA64_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company did not record a provision for income taxes for the
 three months and six month ended June&amp;#xA0;30, 2018 and 2017, as
 the Company has generated losses for all periods.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company periodically evaluates the realizability of its net
 deferred tax assets based on all available evidence, both positive
 and negative. The realization of net deferred tax assets is
 dependent on the Company&amp;#x2019;s ability to generate sufficient
 future taxable income during periods prior to the expiration of tax
 attributes to fully utilize these assets. The Company weighed both
 positive and negative evidence and determined that there is a
 continued need for a full valuation allowance on its deferred tax
 assets in the United States and United Kingdom as of June&amp;#xA0;30,
 2018. Should the Company determine that it would be able to realize
 its remaining deferred tax assets in the foreseeable future, an
 adjustment to its remaining deferred tax assets would cause a
 material increase to income in the period such determination is
 made.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_17">-4748762</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_10">37063</us-gaap:InterestExpense>
  <us-gaap:InterestPaidNet contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_46">31531</us-gaap:InterestPaidNet>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_9">50662</us-gaap:InvestmentIncomeInterest>
  <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_C2FBED0D-88E9-436E-B083-A533B389B953_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The following table summarizes &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt; assets by geographical
 area:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;413,481&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;436,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United Kingdom&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,277,701&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,942,642&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,691,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,379,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_16">-48190697</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_406E1ECC-E661-4F9B-827B-5B6E78581911_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In June&amp;#xA0;2018, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2018-07,&lt;/font&gt; Improvements to Nonemployee
 Share-Based Accounting, which simplifies the accounting for
 share-based payments granted to nonemployees for goods and
 services. The ASU supersedes ASC &lt;font style="WHITE-SPACE: nowrap"&gt;505-50&lt;/font&gt; and expands the scope of ASC
 718 to include &lt;i&gt;all&lt;/i&gt; share-based payment arrangements related
 to the acquisition of goods and services from both nonemployees and
 employees. As a result, most of the guidance in ASC 718 associated
 with employee share-based payments, including most of its
 requirements related to classification and measurement, applies to
 nonemployee share-based payment arrangements.&amp;#xA0;ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2018-07&lt;/font&gt; generally requires an entity
 to use a modified retrospective transition approach, with a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the fiscal year, for all (1)&amp;#xA0;liability-classified
 nonemployee awards that have not been settled as of the adoption
 date and (2)&amp;#xA0;equity-classified nonemployee awards for which a
 measurement date has not been established. The guidance is
 applicable to public business entities for fiscal years beginning
 after December&amp;#xA0;15, 2019 and interim periods within those
 years. The Company is currently evaluating the potential impact of
 the adoption of this standard on its consolidated results of
 operations, financial position and cash flows and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In January 2017, the FASB issued &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2017-01,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Business
 Combinations (Topic 805), Clarifying the Definition of a
 Business,&lt;/i&gt;&amp;#xA0;or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&lt;/font&gt;&lt;i&gt;,&lt;/i&gt;&amp;#xA0;that
 clarifies the definition of a business to assist entities with
 evaluating whether transactions should be accounted for as
 acquisitions (or disposals) of assets or businesses. &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&lt;/font&gt; requires an entity to
 evaluate if substantially all of the&amp;#xA0;fair value of the gross
 assets acquired or disposed of is concentrated in a single
 identifiable asset or a group of similar identifiable assets; if
 so, the set of transferred assets and activities is not a business.
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&amp;#xA0;also&lt;/font&gt;
 requires a business to include at least an input and one
 substantive process that together significantly contribute to the
 ability to create output and removes the evaluation of whether a
 market participant could replace missing elements. &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&amp;#xA0;should&lt;/font&gt; be
 applied prospectively and is effective for annual periods beginning
 after December&amp;#xA0;15, 2017 and interim periods within those
 annual periods. The adoption of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2017-01&lt;/font&gt; on January&amp;#xA0;1, 2018 did
 not have a material effect on the Company&amp;#x2019;s financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In December 2016, the FASB &lt;font style="WHITE-SPACE: nowrap"&gt;issued&amp;#xA0;ASU&amp;#xA0;No.&amp;#xA0;2016-20,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Technical
 Corrections and Improvements to Topic 606, Revenue from Contracts
 with Customers,&lt;/i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&amp;#xA0;or&amp;#xA0;ASU&amp;#xA0;2016-20,&amp;#xA0;that&amp;#xA0;allows&lt;/font&gt;
 entities not to disclose variable consideration allocated to
 performance obligations related to either: (1)&amp;#xA0;sales&amp;#x2014;or
 usage -based royalties on licenses of intellectual property or
 (2)&amp;#xA0;variable consideration allocated entirely to a wholly
 unsatisfied performance obligation or to a wholly unsatisfied
 promise to transfer a distinct good or service that forms part of a
 single performance obligation when certain criteria are
 &lt;font style="WHITE-SPACE: nowrap"&gt;met.&amp;#xA0;ASU&amp;#xA0;2016-20&amp;#xA0;also&amp;#xA0;requires&lt;/font&gt;
 entities that use any of the new or previously existing optional
 exemptions to expand their qualitative disclosures. It also makes
 12 additional technical corrections and improvements to the new
 revenue standard, &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09.&lt;/font&gt; The amendments have
 the same effective date and transition requirements as &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09.&lt;/font&gt; The adoption of
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-20&lt;/font&gt; did not
 have a material effect on its financial position, results of
 operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In November 2016, the Financial Accounting Standards Board, or FASB
 issued &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-18,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Statement
 of Cash Flows (Topic 230), Restricted Cash&lt;/i&gt;&amp;#xA0;(a consensus of
 the Emerging Issues Task Force), or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18,&amp;#xA0;which&lt;/font&gt; changes
 the presentation of the cash flow statement to include amounts
 generally described as restricted cash or restricted cash
 equivalents, together with cash and cash equivalents, when
 reconciling &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;the&amp;#xA0;beginning-of-period&amp;#xA0;and&amp;#xA0;end-of-period&amp;#xA0;amounts&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;
 shown on the statement of cash flows. &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18&amp;#xA0;also&lt;/font&gt; requires
 additional disclosures concerning the nature of the restrictions on
 cash and cash equivalents and a reconciliation between amounts of
 cash, cash equivalents and restricted cash on the balance sheet and
 statement of cash flows for each period presented. &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18&amp;#xA0;will&lt;/font&gt; be applied
 retrospectively to all periods presented and is effective for
 public business entities for fiscal years beginning after
 December&amp;#xA0;15, 2017, and interim periods within those fiscal
 years. Early adoption is permitted, including adoption in an
 interim period. Prior to adoption, the Company presented changes in
 restricted cash as an operating activity in the statement of cash
 flows. Upon adoption of &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18&lt;/font&gt; on January&amp;#xA0;1,
 2018,&amp;#xA0;such changes are now reflected in the beginning and
 ending balances of cash, cash equivalents and restricted cash for
 all periods presented.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In October 2016, the FASB issued &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-16,&amp;#xA0;Income&lt;/font&gt; Taxes
 (Topic 740):&lt;i&gt;&amp;#xA0;Intra-Entity Transfers of Assets Other than
 Inventory&lt;/i&gt;, or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-16&amp;#xA0;which&lt;/font&gt; requires
 that an entity recognize the income tax consequences of an
 intra-entity transfer of assets other than inventory when the
 transfer occurs. The guidance must be applied using the modified
 retrospective basis. The Company does not expect the provisions of
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-16&amp;#xA0;to&lt;/font&gt;
 have a material impact on its current financial statements. This
 update will be effective for the Company at the beginning of fiscal
 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In May 2016, the FASB issued &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-12&lt;/font&gt;&lt;i&gt;, Revenue
 from Contracts with Customers (Topic 606), Narrow-Scope
 Improvements and Practical Expedients&lt;/i&gt;, or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-12,&amp;#xA0;which&lt;/font&gt; amends
 guidance in the new revenue standard, &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2014-09&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue
 from Contracts with Customers (Topic 606)&lt;/i&gt;, or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;on&lt;/font&gt;
 collectability, noncash consideration, presentation of sales tax
 and transition. The amendments in &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-12&amp;#xA0;are&lt;/font&gt; effective
 for annual reporting periods beginning after December&amp;#xA0;15, 2017
 (i.e., January&amp;#xA0;1, 2018), including interim periods within
 those reporting periods, which is the same as for &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;as&lt;/font&gt; amended by
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2015-14,&lt;/font&gt;
 &lt;i&gt;Revenue from Contracts with Customers (Topic 606): Deferral of
 the Effective Date&lt;/i&gt;, or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2015-14&lt;/font&gt;&lt;i&gt;.&lt;/i&gt;&amp;#xA0;In April
 2016, the FASB issued &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-10,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue
 from Contracts with Customers (Topic 606), Identifying&lt;/i&gt;
 &lt;i&gt;Performance Obligations and Licensing&lt;/i&gt;, or &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-10&lt;/font&gt;&lt;i&gt;,&lt;/i&gt;&amp;#xA0;which
 clarifies the principle for determining whether a good or service
 is &amp;#x201C;separately identifiable&amp;#x201D; from other promises in the
 contract and, therefore, should be accounted for as a separate
 performance obligation. In that regard, &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-10&amp;#xA0;requires&lt;/font&gt; that an
 entity determine whether its promise is to transfer individual
 goods or services to the customer, or a combined item (or items) to
 which the individual goods and services are inputs. In addition,
 ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2016-10&amp;#xA0;categorizes&lt;/font&gt; intellectual
 property, or IP, into two categories: &amp;#x201C;functional&amp;#x201D; and
 &amp;#x201C;symbolic.&amp;#x201D; Functional IP has significant standalone
 functionality. All other IP is considered symbolic IP. Revenue from
 licenses of functional IP is generally recognized at a point in
 time, while revenue from licenses of symbolic IP is recognized over
 time. &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-10&amp;#xA0;has&lt;/font&gt; the same
 effective date and transition requirements as &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;as&lt;/font&gt; amended by
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2015-14.&amp;#xA0;In&lt;/font&gt;
 March 2016, the FASB issued &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-08,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue
 from Contracts with Customers (Topic 606), Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)&lt;/i&gt;, or
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-08,&amp;#xA0;which&lt;/font&gt; clarifies
 the implementation guidance on principal versus agent
 considerations contained in &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09&lt;/font&gt;&amp;#xA0;by specifying
 that the determination as to whether an entity that is involved in
 providing a good or a service to a customer is a principal or an
 agent is based upon whether the entity controls the good or the
 service before it is transferred to the customer. &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-08&amp;#xA0;has&lt;/font&gt; the same
 effective date and transition requirements as &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;as&lt;/font&gt; amended by
 &lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2015-14.&amp;#xA0;The&lt;/font&gt;
 adoption of these ASU&amp;#x2019;s on January&amp;#xA0;1, 2018 did not have
 a material effect on the Company&amp;#x2019;s financial position,
 results of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In February 2016, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt; &lt;i&gt;Leases (Topic 842)&lt;/i&gt;.
 The FASB issued the update to require the recognition of lease
 assets and liabilities on the balance sheet of lessees. The
 standard will be effective for fiscal years beginning after
 December&amp;#xA0;15, 2018, including interim periods within such
 fiscal years. The ASU requires a modified retrospective transition
 method with the option to elect a package of practical expedients.
 Early adoption is permitted. The Company is currently evaluating
 the potential impact of the adoption of this standard on its
 consolidated results of operations, financial position and cash
 flows and related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In May 2014, the FASB issued ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue from
 Contracts with Customers&lt;/i&gt;, or ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt; which provides a single,
 comprehensive revenue recognition model for all contracts with
 customers. The core principal of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt; is that an entity should
 recognize revenue when it transfers control of promised goods or
 services to customers in an amount that reflects the consideration
 to which the entity expects to be entitled in exchange for those
 goods or services. ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt; also requires additional
 disclosure about the nature, amount, timing and uncertainty of
 revenue and cash flows arising from customer contracts, including
 significant judgments and changes in judgments and assets
 recognized from costs incurred to obtain or fulfill a contract. ASU
 &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt; is effective for
 annual periods, and interim periods within those annual periods,
 beginning after December&amp;#xA0;15, 2017 for public companies and
 December&amp;#xA0;15, 2018 for &lt;font style="WHITE-SPACE: nowrap"&gt;non-public&lt;/font&gt; companies. The Company is
 allowed to adopt ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt; either
 (1)&amp;#xA0;retrospectively to each prior reporting period presented
 using several practical expedients related to completed contracts
 and required disclosures, or (2)&amp;#xA0;using a modified
 retrospective approach, with the cumulative effect of initially
 applying ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;
 recognized as an adjustment to the opening balance of retained
 earnings of the annual reporting period that includes the date of
 initial application, including disclosure of the effect of using
 this method of adoption on the financial statement line items.
 Because the Company has no contracts with customers, the adoption
 of ASU &lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt; on
 January&amp;#xA0;1, 2018 did not have a material effect on the
 Company&amp;#x2019;s financial position, results of operations or cash
 flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_23">-1318016</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_32">131469856</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_19">-36425351</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_11">-46384185</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_12">1221242</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5008_1100020">1221242</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OperatingExpenses contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_3">43218084</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_4">-43218084</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_6">83075</us-gaap:OtherNonoperatingIncome>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_22">1318016</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_27">69750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_29">56849592</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_26">9720000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_7DCB4A94-3ECD-4E67-A6E6-729C7A3F0568_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Related Party Transactions:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Transition Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Effective April&amp;#xA0;24, 2015, the Company entered into a
 three-year transition services agreement (the &amp;#x201C;TSA&amp;#x201D;)
 with Kadmon, whereby Kadmon would provide office and laboratory
 facilities as well as certain other personnel support activities to
 the Company. Under the agreement, the Company was charged for
 (i)&amp;#xA0;rent based upon the square footage of the office and
 laboratory facilities used by the Company (ii)&amp;#xA0;other personnel
 support activities based upon the hours of the personnel providing
 the support activities, and (iii)&amp;#xA0;and other direct costs
 incurred by Kadmon on behalf of the Company, plus a 7%
 administrative fee. The TSA terminated on April&amp;#xA0;24, 2018 and
 the Company is currently leasing office space on a month to month
 basis from Kadmon.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the three-month periods ended June&amp;#xA0;30, 2018 and 2017,
 the Company incurred the following charges from Kadmon, which are
 included in loss from operations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;139,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,746&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;126&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total charges incurred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;139,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,041&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017, the Company incurred the
 following charges from Kadmon, which are included in loss from
 operations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275,674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275,524&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,493&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,278&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total charges incurred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;282,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;306,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the three-month periods ended June&amp;#xA0;30, 2018 and 2017,
 the Company made cash payments totaling $145,887 and $0,
 respectively, to Kadmon.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017, the Company made cash payments
 totaling $1,143,304 and $275,941, respectively, to Kadmon.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The amount due to Kadmon at June&amp;#xA0;30, 2018 and
 December&amp;#xA0;31, 2017 is $0 and $861,030, respectively and is
 disclosed as Due to Kadmon on the Company&amp;#x2019;s condensed
 consolidated balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Research Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Effective October&amp;#xA0;23, 2016, the Company entered into a
 four-year master services agreement with UCL Consultants Limited,
 an entity affiliated with University College of London
 (&amp;#x201C;UCL&amp;#x201D;), which is a shareholder of the Company.
 Pursuant to the agreement, UCL Consultants Limited
 provides&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-clinical&lt;/font&gt;&amp;#xA0;research
 and development under the direction of the Company. In connection
 with the agreement, the Company issued several work orders during
 the years ended December&amp;#xA0;31, 2016 and 2017 in the aggregate
 amounts of &amp;#xA3;1,161,149 and &amp;#xA3;241,053, respectively, or
 approximately $1,574,000 and $311,000, based upon the average
 exchange rates during the years ended December&amp;#xA0;31, 2016 and
 2017, respectively. Either party may terminate the agreement by
 giving 30 days written notice.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total research and development expenses under this agreement for
 the three-month periods ended June&amp;#xA0;30, 2018 and 2017 were
 approximately $183,000 and $114,000, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total research and development expenses under this agreement for
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017 was approximately $372,000 and
 $222,000, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Future obligations, under the agreement equal &amp;#xA3;797,343, or
 approximately $1,052,791 through October 2020.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The amount due to UCL under the master services agreement at
 June&amp;#xA0;30, 2018 and December&amp;#xA0;31, 2017 is $374,873 and
 $775,315, respectively, and is included in accounts payable and
 accrued expenses on the condensed consolidated balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Manufacturing Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Effective September&amp;#xA0;1, 2016, the Company entered into a
 manufacturing and drug supply agreement with UCL. Pursuant to the
 agreement, UCL manufactured materials for the Company&amp;#x2019;s
 clinical trials under the direction of the Company. Either party
 could terminate the agreement by giving 30 days written notice. The
 agreement was terminated in January 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total research and development expenses under this agreement for
 the three-month periods ended June&amp;#xA0;30, 2018 and 2017 was
 approximately $0 and $479,494, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total research and development expenses under this agreement for
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017 was approximately $0 and
 $1,042,518, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The amount due to UCL under the manufacturing and drug supply
 agreement at June&amp;#xA0;30, 2018 and December&amp;#xA0;31, 2017 is
 $374,983 and $2,466,142, respectively, and is included in accrued
 expenses in the condensed consolidated balance sheet.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Effective March&amp;#xA0;15, 2018, the Company entered into an
 exclusive worldwide license agreement with UCL Business, PLC
 (&amp;#x201C;UCL Business&amp;#x201D;), to develop up to eight programs using
 certain ocular gene therapy technology. Under the terms of the
 agreement, the Company has agreed to pay UCL Business certain sales
 milestone payments, if achieved, in the aggregate amount of
 &amp;#xA3;39.8&amp;#xA0;million, or approximately $52.6&amp;#xA0;million using
 the exchange rate at June&amp;#xA0;30, 2018, and royalties on net
 sales, as defined upon commercialization. Additionally, the Company
 is responsible for all patent prosecution and maintenance costs
 incurred and has also agreed to pay UCL Business an annual
 maintenance fee of &amp;#xA3;50,000, or approximately $66,000, until
 the first commercial sale of a product. The agreement will
 terminate upon the later of (i)&amp;#xA0;the last valid claim in a
 relevant product (ii)&amp;#xA0;the expiration of regulatory exclusivity
 to all licensed products, or (iii)&amp;#xA0;the 10&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;th&lt;/sup&gt;&amp;#xA0;anniversary
 of the first commercial sale of a product.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company did not incur any research and development expenses
 under the agreement during the three-month
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;December 2016 Lease&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Effective December&amp;#xA0;15, 2016, the Company entered into
 another&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cancellable&lt;/font&gt;&amp;#xA0;operating
 lease with ARE, expiring on October&amp;#xA0;31, 2032, for laboratory
 and office facilities in New York. The lease provided for monthly
 base rent, including rent escalations, property management fees and
 rent holidays, plus operating expenses during the lease term. The
 Company recorded monthly rent expense on a straight-line basis from
 December&amp;#xA0;15, 2016 through October&amp;#xA0;31, 2032. On
 October&amp;#xA0;26, 2017, the lease was amended, whereby the lease
 would terminate on March&amp;#xA0;31, 2018 and only base rent and
 management fees in the aggregate amount of $563,507 would be due
 from November&amp;#xA0;1, 2017 through March&amp;#xA0;31, 2018. Under the
 amendment, the Company issued a note to ARE in the amount of
 $1,442,009, removed the balance of the deferred rent and accrued
 the future rent payments, all of which were recorded as rent
 expense at the time of the amendment, in accordance with ASC 420,
 Exit and Disposal Activities, as the Company had a cease use date
 as of the date of the amendment. Tthe balance of deferred lease
 obligation, representing the difference between cash rent paid and
 straight-line rent expense, was $0 as of December&amp;#xA0;31, 2017 and
 June&amp;#xA0;30, 2018,.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total rent expense under this operating lease was $0 and $390,903
 for the three-month periods ended June&amp;#xA0;30, 2018 and 2017,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total rent expense under this operating lease was $0 and $781,806
 for the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On October&amp;#xA0;26, 2017, in connection with the amendment to the
 lease, the Company issued a promissory note in the amount of
 $1,442,009 to ARE. The note accrued interest at the rate of 5% per
 annum and was due on December&amp;#xA0;31, 2018. However, if the
 Company had sufficient liquidity, as defined in the note, then the
 note, including accrued interest, would become due and payable at
 that time. In accordance with the sufficient liquidity provision,
 the Company repaid the note, plus accrued interest, in the
 aggregate amount of $1,472,433 during the three-month period ended
 March&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company recorded interest expense of $0 and $30,424 for the
 three-month and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;July 2016 Lease&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Effective July&amp;#xA0;1, 2016, the Company entered into
 a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-cancellable&lt;/font&gt;&amp;#xA0;operating
 lease for laboratory and related office facilities in New York with
 ARE, an entity that is under common control by an entity that is a
 minority shareholder of the Company and whose CEO is a director of
 the Company. The lease provides for monthly base rent and property
 management fees, including rent escalations and rent holidays, plus
 operating expenses during the lease term, which expires on
 December&amp;#xA0;31, 2021. The Company records monthly rent expense on
 a straight-line basis from July&amp;#xA0;1, 2016 through
 December&amp;#xA0;31, 2021. As of June&amp;#xA0;30, 2018 and
 December&amp;#xA0;31, 2017, the balance of deferred rent, representing
 the difference between cash rent paid and straight-line rent
 expense, was $220,722 and $231,276, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total rent expense under this operating lease was $121,890 and
 $121,890 for the three-month periods ended June&amp;#xA0;30, 2018 and
 2017, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Total rent expense under this operating lease was $243,780 and
 $243,780 for the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of June&amp;#xA0;30, 2018, the aggregate future minimum rental
 payments under this lease are $1,927,187.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In connection with the signing of this lease, the Company entered
 into a standby letter of credit agreement for $122,866, which
 serves as a security deposit for the premises. The standby letter
 of credit expires on July&amp;#xA0;7, 2017 and is automatically renewed
 annually through July&amp;#xA0;7, 2021. This standby letter of credit
 is secured with restricted cash in a money market account.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_25">15701</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfNotesPayable contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_31">1442009</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_1_3">282167</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_2">14718016</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_C9E6B23D-7970-49CA-B75A-858E5D0AB153_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to, employee-related
 expenses, including salaries, benefits and travel of the
 Company&amp;#x2019;s research and development personnel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical and preclinical studies
 and manufacture the drug product for the clinical studies and
 preclinical activities; acquisition of &lt;font style="WHITE-SPACE: nowrap"&gt;in-process&lt;/font&gt; research and development;
 facilities; supplies; rent, insurance, certain legal fees,
 stock-based compensation, depreciation and other costs associated
 with clinical and preclinical activities and regulatory operations.
 Refundable research and development tax credits received are
 recorded as an offset to these costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Costs for certain development activities, such as Company funded
 outside research programs, are recognized based on an evaluation of
 the progress to completion of specific tasks with respect to their
 actual costs incurred. Payments for these activities are based on
 the terms of the individual arrangements, which may differ from the
 pattern of costs incurred, and are reflected in the financial
 statements as prepaid or accrued research and development expense,
 as the case may be.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_C68D703C-690B-48F6-9C75-E0C1610F067E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 12pt"&gt;
 The following securities are considered to be Ordinary Share
 equivalents, but were not included in the computation of diluted
 net loss per Ordinary Share because to do so would have been
 anti-dilutive:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Preferred Shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,584,469&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 A restricted ordinary shares subject to forfeiture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;870,898&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;245,828&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Stock options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,614,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;444,473&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,485,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,274,770&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_A8069823-0474-42E3-B815-6D86140A09F1_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 The table below represents a rollforward of the assets and
 liabilities that are required to be measured at fair value on a
 recurring basis from December&amp;#xA0;31, 2017 to June&amp;#xA0;30,
 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,514,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,194,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_E12D69B1-3882-4C59-AA01-5F8A62BB1A79_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 During the three-month periods ended June&amp;#xA0;30, 2018 and 2017,
 the Company incurred the following charges from Kadmon, which are
 included in loss from operations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;139,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;152,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,746&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;126&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total charges incurred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;139,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;159,041&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 During the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;
 periods ended June&amp;#xA0;30, 2018 and 2017, the Company incurred the
 following charges from Kadmon, which are included in loss from
 operations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275,674&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275,524&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,493&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,278&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,206&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total charges incurred&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;282,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;306,008&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_4C29E7C1-E4FA-4A7D-A3FE-C90E5E5FC8F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 A summary of the restricted Ordinary Shares is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Ordinary&amp;#xA0;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;$ Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-vested&lt;/font&gt; at
 December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,913&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;865,861&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issued during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended June&amp;#xA0;30,
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,306,348&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,595,220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended June&amp;#xA0;30,
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(541,363&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,397,611&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-vested&lt;/font&gt; at
 June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;870,898&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,063,470&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_604B67C7-7460-4E01-B613-39EE78C81BDE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Accrued expenses for the period presented were comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Clinical Trial Costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,297,893&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,859,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Compensation and Benefits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;645,286&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,386,903&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Consulting&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,137,547&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,220,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Rent&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;387,267&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Professional Fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;733,409&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;231,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Travel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;135,664&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,179&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;213,527&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,289,261&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,332,944&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_4CFE5C49-B3DA-4D9F-A429-B84381967BA3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The change in asset retirement obligations is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 For&amp;#xA0;the&amp;#xA0;six&amp;#xA0;month&amp;#xA0;period&lt;br /&gt;
 ended June&amp;#xA0;30, 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;For&amp;#xA0;the&amp;#xA0;year&amp;#xA0;ended&lt;br /&gt;
 December&amp;#xA0;31,&amp;#xA0;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;221,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amortization of interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in estimate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(75,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effects of exchange rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,350&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfChangeInAssetRetirementObligationTableTextBlock>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_1FBD0478-6B26-4AB5-B111-CE39F7E8BC73_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During the three-month and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018 and 2017 the Company recognized total
 share-based compensation expense in the accompanying condensed
 consolidated statements of operations and comprehensive loss as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,045,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;550,708&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,318,224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131,427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total share based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,363,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;682,135&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="8"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,890,511&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,239,923&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,743,045&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;295,167&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total share based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,633,556&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,535,090&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_5">12633556</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_6001_4">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_6001_8">P8Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD_per_shares" decimals="0" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_6001_3">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD_per_shares" decimals="0" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_6001_4">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_C2730757-8DCA-4502-8772-2BF70FE4B85E_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Summary of Significant Accounting Policies and
 Recent Accounting Pronouncements:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Certain of the Company&amp;#x2019;s significant accounting policies are
 described below. All of the Company&amp;#x2019;s significant accounting
 policies are disclosed in the notes to the audited consolidated
 financial statements as of and for the year ended December&amp;#xA0;31,
 2017 included in the Company&amp;#x2019;s Prospectus.&amp;#xA0;Since the
 date of such financial statements, there have been no changes to
 the Company&amp;#x2019;s significant accounting policies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The accompanying condensed consolidated financial statements
 include the accounts of Meira Holdings and its wholly owned
 subsidiaries:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx Limited, a limited company under the laws of England and
 Wales (&amp;#x201C;Meira Limited);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx, LLC, a Delaware corporation (&amp;#x201C;Meira
 LLC&amp;#x201D;);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 BRI-Alzan, Inc., a Delaware corporation
 (&amp;#x201C;BRI-Alzan&amp;#x201D;);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx B.V., a Netherlands corporation (&amp;#x201C;Meira
 BV&amp;#x201D;);&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx UK II Limited, (&amp;#x201C;Meira UK II&amp;#x201D;), a limited
 company under the laws of England and Wales;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 MeiraGTx UK Limited (&amp;#x201C;Meira UK&amp;#x201D;), a limited company
 under the laws of England and Wales.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 All intercompany balances and transactions between the consolidated
 companies have been eliminated in consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Management considers many factors in selecting appropriate
 financial accounting policies and controls, and in developing the
 estimates and assumptions that are used in the preparation of these
 consolidated financial statements. Management must apply
 significant judgment in this process. In addition, other factors
 may affect estimates, including expected business and operational
 changes, sensitivity and volatility associated with the assumptions
 used in developing estimates, and whether historical trends are
 expected to be representative of future trends. The estimation
 process often may yield a range of potentially reasonable estimates
 of the ultimate future outcomes and management must select an
 amount that falls within that range of reasonable estimates. This
 process may result in actual results differing materially from
 those estimated amounts used in the preparation of the consolidated
 financial statements if these results differ from historical
 experience, or other assumptions do not turn out to be
 substantially accurate, even if such assumptions are reasonable
 when made. In preparing these consolidated financial statements,
 management used significant estimates in the following areas, among
 others: valuation of A ordinary shares (&amp;#x201C;Ordinary
 Shares&amp;#x201D;) issued prior to the Company&amp;#x2019;s initial public
 offering, for the acquisition of assets, the accounting for
 research and development costs, warrants, share based compensation,
 asset retirement obligations and accrued expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value is defined as the price that would be received upon sale
 of an asset or paid upon transfer of a liability in an orderly
 transaction between market participants at the measurement date and
 in the principal or most advantageous market for that asset or
 liability. The fair value should be calculated based on assumptions
 that market participants would use in pricing the asset or
 liability, not on assumptions specific to the entity. In addition,
 the fair value of liabilities should include consideration
 of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-performance&lt;/font&gt;&amp;#xA0;risk
 including our own credit risk.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company follows ASC Topic 820,&amp;#xA0;&lt;i&gt;Fair Value
 Measurements and Disclosures&lt;/i&gt;, or ASC 820, for application to
 financial assets. In addition to defining fair value, the standard
 expands the disclosure requirements around fair value and
 establishes a fair value hierarchy for valuation inputs. The
 hierarchy prioritizes the inputs into three levels based on the
 extent to which inputs used in measuring fair value are observable
 in the market. Each fair value measurement is reported in one of
 the three levels which are determined by the lowest level input
 that is significant to the fair value measurement in its entirety.
 These levels are:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;Level&amp;#xA0;1: Observable inputs such as quoted prices
 in active markets for identical assets the reporting entity has the
 ability to access as of the measurement date;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;Level&amp;#xA0;2: Inputs, other than the quoted prices in
 active markets, that are observable either directly or indirectly;
 and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;Level&amp;#xA0;3: Unobservable inputs in which there is
 little or no market data, which require the reporting entity to
 develop its own assumptions.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The table below represents the values of the Compnay&amp;#x2019;s
 financial assets and liabilities that are required to be measured
 at fair value on a recurring basis:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;Fair Value Measurement Using:&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Observable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&amp;#xA0;Other&lt;br /&gt;
 Observable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;Fair Value Measurement Using:&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell"&gt;
 Description&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Observable Inputs&lt;br /&gt;
 (Level 1)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant Other&lt;br /&gt;
 Observable Inputs&lt;br /&gt;
 (Level 2)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;123,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The table below represents a rollforward of the assets and
 liabilities that are required to be measured at fair value on a
 recurring basis from December&amp;#xA0;31, 2017 to June&amp;#xA0;30,
 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;Significant&lt;br /&gt;
 Unobservable&amp;#xA0;Inputs&lt;br /&gt;
 (Level 3)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,679,633&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,514,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,194,408&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance as of June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The warrants were classified as liabilities because the underlying
 Preferred Shares had a redemption feature in the event of a change
 of control of the Company. On June&amp;#xA0;5, 2018, the warrants were
 exercised at which time the warrant liability was determined to be
 $4,194,408, which represented the difference in the market value of
 the Preferred Shares and the exercise price of the warrants. This
 resulted in an increase of the warrant liability in the amount of
 $2,184,183 and $1,514,775 for the three-month
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018, respectively. The related warrant
 liability of $4,194,408 was reclassified as Capital in Excess of
 Nominal Value at such time.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair values of the warrants at December&amp;#xA0;31, 2017,
 March&amp;#xA0;31, 2018 and June&amp;#xA0;4, 2018 were estimated using the
 Black-Scholes valuation model with the following assumptions:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;March&amp;#xA0;31,&amp;#xA0;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;4,&amp;#xA0;2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;80&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&amp;#xA0;months&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.5&amp;#xA0;months&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1&amp;#xA0;day&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 For the unobservable inputs for the warrants, the expected
 volatility was determined at each measurement date by taking an
 average of the volatility of other publicly-traded peer
 biotechnology companies. The expected life was determined at each
 measurement date based upon the Company&amp;#x2019;s estimate of the
 time until the Company has a conversion event.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair value of the Preferred Shares was based upon recent
 issuances of the Company&amp;#x2019;s Preferred Shares on or about
 December&amp;#xA0;31, 2017, March&amp;#xA0;31, 2018 and June&amp;#xA0;5,
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The estimated fair values of the Company&amp;#x2019;s warrants are not
 necessarily indicative of the amounts that would be realized in a
 current market exchange. The determination of the fair value of the
 warrants are sensitive to changes in in the assumptions used and a
 change in those inputs could result in a significantly higher or
 lower fair value measurement. If the volatility were to increase or
 the expected life were to increase, the fair value of the warrant
 would increase. Conversely, if the volatility were to decrease or
 the expected life were to decrease, the fair value of the warrant
 would decrease.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Net Loss per Ordinary Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Basic net loss per Ordinary Share is computed by dividing net loss
 attributable to the Company&amp;#x2019;s shareholders by the weighted
 average number of shares of the Company&amp;#x2019;s Ordinary Shares
 assumed to be outstanding during the period of computation. Diluted
 net loss per ordinary share is computed similar to basic net loss
 per share except that the denominator is increased to include the
 number of additional Ordinary Shares that would have been
 outstanding if the potential ordinary shares had been issued at the
 beginning of the year and if the additional ordinary shares were
 dilutive (treasury stock method) or
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;two-class&lt;/font&gt;&amp;#xA0;method,
 whichever is more dilutive. For all periods presented, basic and
 diluted net loss per Ordinary Share are the same, as any additional
 Ordinary Share equivalents would be anti-dilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Asset Retirement Obligation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Accounting for Asset Retirement Obligations requires legal
 obligations associated with the retirement of long-lived assets to
 be recognized at fair value when incurred and capitalized as part
 of the related long-lived asset. In the absence of quoted market
 prices, we estimate the fair value of our asset retirement
 obligations using Level&amp;#xA0;3 present value techniques, in which
 estimates of future cash flows associated with retirement
 activities are discounted using a credit-adjusted risk-free rate.
 Asset retirement obligations currently reported as other
 liabilities on our Consolidated Balance Sheet were measured during
 a period of historically low interest rates. The impact on
 measurements of new asset retirement obligations using different
 rates in the future may be significant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company uses estimates to determine the amount of the asset
 retirement obligations at the end of the lease term and discounts
 such asset retirement obligations using an estimated discount rate.
 Interest on the discounted asset retirement obligation is amortized
 over the term of the lease using the effective interest method and
 is recorded as interest expense in the consolidated statements of
 operations and comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The change in asset retirement obligations is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 For&amp;#xA0;the&amp;#xA0;six&amp;#xA0;month&amp;#xA0;period&lt;br /&gt;
 ended June&amp;#xA0;30, 2018&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;For&amp;#xA0;the&amp;#xA0;year&amp;#xA0;ended&lt;br /&gt;
 December&amp;#xA0;31,&amp;#xA0;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at beginning of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;221,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Amortization of interest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in estimate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(75,011&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effects of exchange rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(5,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance at end of period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,350&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to, employee-related
 expenses, including salaries, benefits and travel of the
 Company&amp;#x2019;s research and development personnel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical and preclinical studies
 and manufacture the drug product for the clinical studies and
 preclinical activities; acquisition
 of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;in-process&lt;/font&gt;&amp;#xA0;research
 and development; facilities; supplies; rent, insurance, certain
 legal fees, stock-based compensation, depreciation and other costs
 associated with clinical and preclinical activities and regulatory
 operations. Refundable research and development tax credits
 received are recorded as an offset to these costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs for certain development activities, such as Company funded
 outside research programs, are recognized based on an evaluation of
 the progress to completion of specific tasks with respect to their
 actual costs incurred. Payments for these activities are based on
 the terms of the individual arrangements, which may differ from the
 pattern of costs incurred, and are reflected in the financial
 statements as prepaid or accrued research and development expense,
 as the case may be.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Management has concluded it has a single reporting segment for
 purposes of reporting financial condition and results of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following table summarizes&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&amp;#xA0;assets
 by geographical area:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;413,481&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;436,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United Kingdom&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,277,701&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,942,642&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,691,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,379,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In June&amp;#xA0;2018, the FASB issued
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2018-07,&lt;/font&gt;&amp;#xA0;Improvements
 to Nonemployee Share-Based Accounting, which simplifies the
 accounting for share-based payments granted to nonemployees for
 goods and services. The ASU supersedes
 ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;505-50&lt;/font&gt;&amp;#xA0;and expands
 the scope of ASC 718 to
 include&amp;#xA0;&lt;i&gt;all&lt;/i&gt;&amp;#xA0;share-based
 payment arrangements related to the acquisition of goods and
 services from both nonemployees and employees. As a result, most of
 the guidance in ASC 718 associated with employee share-based
 payments, including most of its requirements related to
 classification and measurement, applies to nonemployee share-based
 payment arrangements.&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2018-07&lt;/font&gt;generally requires an entity to
 use a modified retrospective transition approach, with a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the fiscal year, for all (1)&amp;#xA0;liability-classified
 nonemployee awards that have not been settled as of the adoption
 date and (2)&amp;#xA0;equity-classified nonemployee awards for which a
 measurement date has not been established. The guidance is
 applicable to public business entities for fiscal years beginning
 after December&amp;#xA0;15, 2019 and interim periods within those
 years. The Company is currently evaluating the potential impact of
 the adoption of this standard on its consolidated results of
 operations, financial position and cash flows and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In January 2017, the FASB issued&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2017-01,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Business
 Combinations (Topic 805), Clarifying the Definition of a
 Business,&lt;/i&gt;&amp;#xA0;or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&lt;/font&gt;&lt;i&gt;,&lt;/i&gt;&amp;#xA0;that
 clarifies the definition of a business to assist entities with
 evaluating whether transactions should be accounted for as
 acquisitions (or disposals) of assets or
 businesses.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&lt;/font&gt;&amp;#xA0;requires
 an entity to evaluate if substantially all of the&amp;#xA0;fair value
 of the gross assets acquired or disposed of is concentrated in a
 single identifiable asset or a group of similar identifiable
 assets; if so, the set of transferred assets and activities is not
 a business.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&amp;#xA0;also&lt;/font&gt;&amp;#xA0;requires
 a business to include at least an input and one substantive process
 that together significantly contribute to the ability to create
 output and removes the evaluation of whether a market participant
 could replace missing elements.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2017-01&amp;#xA0;should&lt;/font&gt;&amp;#xA0;be
 applied prospectively and is effective for annual periods beginning
 after December&amp;#xA0;15, 2017 and interim periods within those
 annual periods. The adoption of ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2017-01&lt;/font&gt;&amp;#xA0;on
 January&amp;#xA0;1, 2018 did not have a material effect on the
 Company&amp;#x2019;s financial position, results of operations or cash
 flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In December 2016, the FASB&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;issued&amp;#xA0;ASU&amp;#xA0;No.&amp;#xA0;2016-20,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Technical
 Corrections and Improvements to Topic 606, Revenue from Contracts
 with Customers,&lt;/i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&amp;#xA0;or&amp;#xA0;ASU&amp;#xA0;2016-20,&amp;#xA0;that&amp;#xA0;allows&lt;/font&gt;&amp;#xA0;entities
 not to disclose variable consideration allocated to performance
 obligations related to either: (1)&amp;#xA0;sales&amp;#x2014;or usage -based
 royalties on licenses of intellectual property or (2)&amp;#xA0;variable
 consideration allocated entirely to a wholly unsatisfied
 performance obligation or to a wholly unsatisfied promise to
 transfer a distinct good or service that forms part of a single
 performance obligation when certain criteria
 are&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;met.&amp;#xA0;ASU&amp;#xA0;2016-20&amp;#xA0;also&amp;#xA0;requires&lt;/font&gt;&amp;#xA0;entities
 that use any of the new or previously existing optional exemptions
 to expand their qualitative disclosures. It also makes 12
 additional technical corrections and improvements to the new
 revenue standard,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09.&lt;/font&gt;&amp;#xA0;The
 amendments have the same effective date and transition requirements
 as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09.&lt;/font&gt;&amp;#xA0;The
 adoption of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-20&lt;/font&gt;&amp;#xA0;did
 not have a material effect on its financial position, results of
 operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2016, the Financial Accounting Standards Board, or FASB
 issued&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-18,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Statement
 of Cash Flows (Topic 230), Restricted Cash&lt;/i&gt;&amp;#xA0;(a consensus of
 the Emerging Issues Task Force), or&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18,&amp;#xA0;which&lt;/font&gt;&amp;#xA0;changes
 the presentation of the cash flow statement to include amounts
 generally described as restricted cash or restricted cash
 equivalents, together with cash and cash equivalents, when
 reconciling&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;the&amp;#xA0;beginning-of-period&amp;#xA0;and&amp;#xA0;end-of-period&amp;#xA0;amounts&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&amp;#xA0;shown
 on the statement of cash flows.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18&amp;#xA0;also&lt;/font&gt;&amp;#xA0;requires
 additional disclosures concerning the nature of the restrictions on
 cash and cash equivalents and a reconciliation between amounts of
 cash, cash equivalents and restricted cash on the balance sheet and
 statement of cash flows for each period
 presented.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18&amp;#xA0;will&lt;/font&gt;&amp;#xA0;be
 applied retrospectively to all periods presented and is effective
 for public business entities for fiscal years beginning after
 December&amp;#xA0;15, 2017, and interim periods within those fiscal
 years. Early adoption is permitted, including adoption in an
 interim period. Prior to adoption, the Company presented changes in
 restricted cash as an operating activity in the statement of cash
 flows. Upon adoption of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-18&lt;/font&gt;&amp;#xA0;on
 January&amp;#xA0;1, 2018,&amp;#xA0;such changes are now reflected in the
 beginning and ending balances of cash, cash equivalents and
 restricted cash for all periods presented.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In October 2016, the FASB issued&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-16,&amp;#xA0;Income&lt;/font&gt;&amp;#xA0;Taxes
 (Topic 740):&lt;i&gt;&amp;#xA0;Intra-Entity Transfers of Assets Other than
 Inventory&lt;/i&gt;, or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-16&amp;#xA0;which&lt;/font&gt;&amp;#xA0;requires
 that an entity recognize the income tax consequences of an
 intra-entity transfer of assets other than inventory when the
 transfer occurs. The guidance must be applied using the modified
 retrospective basis. The Company does not expect the provisions
 of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-16&amp;#xA0;to&lt;/font&gt;&amp;#xA0;have
 a material impact on its current financial statements. This update
 will be effective for the Company at the beginning of fiscal
 2019.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2016, the FASB issued&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-12&lt;/font&gt;&lt;i&gt;, Revenue
 from Contracts with Customers (Topic 606), Narrow-Scope
 Improvements and Practical Expedients&lt;/i&gt;,
 or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-12,&amp;#xA0;which&lt;/font&gt;&amp;#xA0;amends
 guidance in the new revenue
 standard,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2014-09&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue
 from Contracts with Customers (Topic 606)&lt;/i&gt;,
 or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;on&lt;/font&gt;&amp;#xA0;collectability,
 noncash consideration, presentation of sales tax and transition.
 The amendments in&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-12&amp;#xA0;are&lt;/font&gt;effective for
 annual reporting periods beginning after December&amp;#xA0;15, 2017
 (i.e., January&amp;#xA0;1, 2018), including interim periods within
 those reporting periods, which is the same as
 for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;as&lt;/font&gt;&amp;#xA0;amended
 by&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2015-14,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Revenue
 from Contracts with Customers (Topic 606): Deferral of the
 Effective Date&lt;/i&gt;, or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2015-14&lt;/font&gt;&lt;i&gt;.&lt;/i&gt;&amp;#xA0;In April
 2016, the FASB issued&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-10,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue
 from Contracts with Customers (Topic 606),
 Identifying&amp;#xA0;&lt;/i&gt;&lt;i&gt;Performance Obligations and
 Licensing&lt;/i&gt;, or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-10&lt;/font&gt;&lt;i&gt;,&lt;/i&gt;&amp;#xA0;which
 clarifies the principle for determining whether a good or service
 is &amp;#x201C;separately identifiable&amp;#x201D; from other promises in the
 contract and, therefore, should be accounted for as a separate
 performance obligation. In that
 regard,&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-10&amp;#xA0;requires&lt;/font&gt;&amp;#xA0;that
 an entity determine whether its promise is to transfer individual
 goods or services to the customer, or a combined item (or items) to
 which the individual goods and services are inputs. In addition,
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-10&amp;#xA0;categorizes&lt;/font&gt;&amp;#xA0;intellectual
 property, or IP, into two categories: &amp;#x201C;functional&amp;#x201D; and
 &amp;#x201C;symbolic.&amp;#x201D; Functional IP has significant standalone
 functionality. All other IP is considered symbolic IP. Revenue from
 licenses of functional IP is generally recognized at a point in
 time, while revenue from licenses of symbolic IP is recognized over
 time.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-10&amp;#xA0;has&lt;/font&gt;&amp;#xA0;the
 same effective date and transition requirements
 as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;as&lt;/font&gt;&amp;#xA0;amended
 by&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2015-14.&amp;#xA0;In&lt;/font&gt;&amp;#xA0;March
 2016, the FASB issued&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;No.&amp;#xA0;2016-08,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue
 from Contracts with Customers (Topic 606), Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)&lt;/i&gt;,
 or&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-08,&amp;#xA0;which&lt;/font&gt;&amp;#xA0;clarifies
 the implementation guidance on principal versus agent
 considerations contained in&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09&lt;/font&gt;&amp;#xA0;by specifying
 that the determination as to whether an entity that is involved in
 providing a good or a service to a customer is a principal or an
 agent is based upon whether the entity controls the good or the
 service before it is transferred to the
 customer.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2016-08&amp;#xA0;has&lt;/font&gt;&amp;#xA0;the
 same effective date and transition requirements
 as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2014-09,&amp;#xA0;as&lt;/font&gt;&amp;#xA0;amended
 by&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;ASU&amp;#xA0;2015-14.&amp;#xA0;The&lt;/font&gt;&amp;#xA0;adoption
 of these ASU&amp;#x2019;s on January&amp;#xA0;1, 2018 did not have a
 material effect on the Company&amp;#x2019;s financial position, results
 of operations or cash flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In February 2016, the FASB issued
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Leases
 (Topic 842)&lt;/i&gt;. The FASB issued the update to require the
 recognition of lease assets and liabilities on the balance sheet of
 lessees. The standard will be effective for fiscal years beginning
 after December&amp;#xA0;15, 2018, including interim periods within such
 fiscal years. The ASU requires a modified retrospective transition
 method with the option to elect a package of practical expedients.
 Early adoption is permitted. The Company is currently evaluating
 the potential impact of the adoption of this standard on its
 consolidated results of operations, financial position and cash
 flows and related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2014, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&lt;i&gt;&amp;#xA0;Revenue from
 Contracts with Customers&lt;/i&gt;, or ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&amp;#xA0;which
 provides a single, comprehensive revenue recognition model for all
 contracts with customers. The core principal of
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;is that an
 entity should recognize revenue when it transfers control of
 promised goods or services to customers in an amount that reflects
 the consideration to which the entity expects to be entitled in
 exchange for those goods or services.
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;also
 requires additional disclosure about the nature, amount, timing and
 uncertainty of revenue and cash flows arising from customer
 contracts, including significant judgments and changes in judgments
 and assets recognized from costs incurred to obtain or fulfill a
 contract. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;is effective
 for annual periods, and interim periods within those annual
 periods, beginning after December&amp;#xA0;15, 2017 for public
 companies and December&amp;#xA0;15, 2018
 for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-public&lt;/font&gt;&amp;#xA0;companies.
 The Company is allowed to adopt ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;either
 (1)&amp;#xA0;retrospectively to each prior reporting period presented
 using several practical expedients related to completed contracts
 and required disclosures, or (2)&amp;#xA0;using a modified
 retrospective approach, with the cumulative effect of initially
 applying ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;recognized
 as an adjustment to the opening balance of retained earnings of the
 annual reporting period that includes the date of initial
 application, including disclosure of the effect of using this
 method of adoption on the financial statement line items. Because
 the Company has no contracts with customers, the adoption of
 ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;on
 January&amp;#xA0;1, 2018 did not have a material effect on the
 Company&amp;#x2019;s financial position, results of operations or cash
 flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssued1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_39">1356129</us-gaap:StockIssued1>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_09799424-8669-44E5-B688-48734E50CE25_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 49px; MARGIN-TOP: 6pt"&gt;
 Basic and diluted net loss per share is computed as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;br class="Apple-interchange-newline" /&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;For&amp;#xA0;the&amp;#xA0;three-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(29,980,832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,178,719&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of Preferred Shares financing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(666,567&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(30,401&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(475,227&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Adjusted net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,122,626&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,209,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average ordinary shares outstanding:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,611,452&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,505,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="8"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;For&amp;#xA0;the&amp;#xA0;six-month&amp;#xA0;periods&amp;#xA0;ended&amp;#xA0;June&amp;#xA0;30,&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(46,384,185&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,999,104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of Preferred Shares financing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(761,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(53,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,045,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Adjusted net loss&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(48,190,697&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,052,266&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average ordinary shares outstanding:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,280,804&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,545,437&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic and Diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td style="FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_6001_12">P7Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_6001_5">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_3C20714A-6C7C-4401-A338-7CA6A13F3E74_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 A summary of the Company&amp;#x2019;s share option activity related to
 employees, &lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;
 members of the board of directors and &lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt; consultants as of and for
 the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended
 June&amp;#xA0;30, 2018 is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="57%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Number&amp;#xA0;of&amp;#xA0;Options&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted-&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;br /&gt;
 Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Aggregate&lt;br /&gt;
 Instrinsic&amp;#xA0;Value&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;938,637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,420,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;675,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.63&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,614,322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.34&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,884,932&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options outstanding
 as of December&amp;#xA0;31, 2017 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options outstanding
 as of June&amp;#xA0;30, 2018 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options exercisable at December&amp;#xA0;31, 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;186,395&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options exercisable at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;265,221&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;999,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options exercisable
 as of December&amp;#xA0;31, 2017 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted average remaining contractual life of options exercisable
 as of June&amp;#xA0;30, 2018 (yrs)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.86&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_4191E641-B495-4CAB-8534-A94964AA993F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Management has concluded it has a single reporting segment for
 purposes of reporting financial condition and results of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following table summarizes&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&amp;#xA0;assets
 by geographical area:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;413,481&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;436,463&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United Kingdom&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,277,701&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,942,642&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,691,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,379,105&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_6001_2">675685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_15">1806512</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <dei:TradingSymbol contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_F6700940-0FBA-4E19-A1B2-49167DEFAE93_1_400000">MGTX</dei:TradingSymbol>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD_per_shares" decimals="0" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_6001_5">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_6DDF9577-97B1-4AD3-AB0B-E4BE567F80DF_6001_2">5.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_8AA31AFC-DA54-4C45-B213-022A62FA73D1_1_0">556349</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_8DD566CC-4F38-4843-8F65-C7E0D59356FF_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Subsequent Events:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Management has evaluated subsequent events through the date of this
 filing. Based on our evaluation, the following disclosures have
 been made:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 On July&amp;#xA0;27, 2018 two leases for office and laboratory
 facilities in London, UK expired. Effective July&amp;#xA0;27, 2018, the
 Company entered into two new &lt;font style="WHITE-SPACE: nowrap"&gt;non-cancellable&lt;/font&gt; operating leases for
 the same office and laboratory facilities in London. The leases
 provide for annual base rent in the aggregate amount of
 approximately $363,000, plus operating expenses, through
 May&amp;#xA0;31, 2022, at which time the annual base rent will be
 revalued based on market rates at that time. The leases expire on
 May&amp;#xA0;24, 2027.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_BFB59EE7-1F1D-4167-B55C-85F5F7C51506_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Ordinary Shares and Convertible Preferred C
 Shares:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Ordinary Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 As discussed in Note 3, on March&amp;#xA0;1, 2018, a funding milestone
 was met under the employment agreements for certain members of
 senior management. Accordingly, the employees were issued an
 aggregate of 550,162 fully vested Ordinary Shares.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 In connection with the Company&amp;#x2019;s initial public offering, on
 June&amp;#xA0;7, 2018, the Company issued 5,000,000 Ordinary Shares at
 an offering price of $15.00 per share for gross proceeds of
 $75,000,000, excluding offering costs of $9,541,530.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Also as discussed in Note 3, on June&amp;#xA0;7, 2018, upon the
 effectiveness of the Company&amp;#x2019;s Registration Statement,
 1,306,348 restricted Ordinary Shares, which represented 5% of the
 fully-diluted outstanding shares of the Company as of such date,
 were issued to certain members of senior management in accordance
 with their employment agreements. &lt;font style="WHITE-SPACE: nowrap"&gt;One-third&lt;/font&gt; of such shares vested
 immediately, with the balance vesting quarterly over the next eight
 quarters.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 On June&amp;#xA0;5, 2018, all of the outstanding warrants to purchase
 927,594 Preferred Shares at an exercise price of approximately
 $10.48 per share were exercised for aggregate cash proceeds of
 $9,720,000.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Preferred C Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 During the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;
 period ended June&amp;#xA0;30, 2018, the Company issued 5,425,124
 Preferred Shares at an offering price of approximately $10.48 per
 share for gross proceeds of $56,849,592, excluding offering costs
 of $690,473.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Also, during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;
 period ended June&amp;#xA0;30, 2018, the Company issued 129,419
 Preferred Shares in lieu of payment of accounts payable in the
 aggregate amount $1,356,129 to certain vendors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 On March&amp;#xA0;15, 2018, the Company issued 13,360 Preferred Shares
 in connection with a license agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 On June&amp;#xA0;7, 2018, upon effectiveness of the Company&amp;#x2019;s
 Registration Statement on Form &lt;font style="WHITE-SPACE: nowrap"&gt;S-1,&lt;/font&gt; all of the 11,501,432 outstanding
 Preferred Shares were automatically converted into 11,501,432
 Ordinary Shares. In connection with the conversion of the Preferred
 Shares, $664,718 of unaccredited financing costs were fully
 accreted.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_6001_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5008_1100013">120520391</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5008_1100018">12633556</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:UseOfEstimates contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_CE048389-2BCC-40E8-B28C-D97AF0F510F2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 Management considers many factors in selecting appropriate
 financial accounting policies and controls, and in developing the
 estimates and assumptions that are used in the preparation of these
 consolidated financial statements. Management must apply
 significant judgment in this process. In addition, other factors
 may affect estimates, including expected business and operational
 changes, sensitivity and volatility associated with the assumptions
 used in developing estimates, and whether historical trends are
 expected to be representative of future trends. The estimation
 process often may yield a range of potentially reasonable estimates
 of the ultimate future outcomes and management must select an
 amount that falls within that range of reasonable estimates. This
 process may result in actual results differing materially from
 those estimated amounts used in the preparation of the consolidated
 financial statements if these results differ from historical
 experience, or other assumptions do not turn out to be
 substantially accurate, even if such assumptions are reasonable
 when made. In preparing these consolidated financial statements,
 management used significant estimates in the following areas, among
 others: valuation of A ordinary shares (&amp;#x201C;Ordinary
 Shares&amp;#x201D;) issued prior to the Company&amp;#x2019;s initial public
 offering, for the acquisition of assets, the accounting for
 research and development costs, warrants, share based compensation,
 asset retirement obligations and accrued expenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="shares" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_3_18">11280804</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <mgtx:ReclassificationOfWarrantLiabilityUponExercise contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_41">4194408</mgtx:ReclassificationOfWarrantLiabilityUponExercise>
  <mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_78A8C930-8D68-49C8-A906-7A482D3B6344_1_3">-48190697</mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <mgtx:LiquidityPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_AD1DD411-5A40-46A7-A4D3-961A8BD570E0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company has not generated any revenues and has not yet achieved
 profitable operations. There is no assurance that profitable
 operations, if ever achieved, could be sustained on a continuing
 basis. In addition, development activities, clinical and
 preclinical testing, and commercialization of the Company&amp;#x2019;s
 product candidates will require significant additional financing.
 Management expects to incur substantial and increasing losses in
 future periods. The success of the Company is subject to certain
 risks and uncertainties, including among others, uncertainty of
 product development; competition in the Company&amp;#x2019;s field of
 use; uncertainty of capital availability; uncertainty in the
 Company&amp;#x2019;s ability to enter into agreements with collaborative
 partners; dependence on third parties; and dependence on key
 personnel. The Company has not generated positive cash flows from
 operations, and there are no assurances that the Company will be
 successful in obtaining an adequate level of financing for the
 development and commercialization of its product candidates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 As of June&amp;#xA0;30, 2018, the Company had cash and cash equivalents
 in the amount of $102,060,551, which consisted of depository
 accounts. The Company estimates that its cash and cash equivalents
 on hand at June&amp;#xA0;30, 2018 will cover its expenses into the
 second quarter of 2020.&lt;/p&gt;
 &lt;/div&gt;</mgtx:LiquidityPolicyTextBlock>
  <mgtx:InterimFinancialStatementsPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_8B1FF836-8564-4A9A-92C3-7B22A288C9F0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;&lt;i&gt;Interim Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 The accompanying condensed consolidated financial statements have
 been prepared in accordance with GAAP for interim financial
 information and with the instructions
 to&amp;#xA0;Form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;10-Q&lt;/font&gt;&amp;#xA0;and Article 10
 of Regulation&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;S-X.&lt;/font&gt;Accordingly, they do not include
 all the information and footnotes required by generally accepted
 accounting principles for complete consolidated financial
 statements. In the opinion of management, the condensed
 consolidated financial statements include all adjustments
 (consisting of normal recurring accruals) necessary in order to
 make the condensed consolidated financial statements not
 misleading. Operating results for the three-month
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018&amp;#xA0;are not necessarily indicative of the
 final results that may be expected for the year ended
 December&amp;#xA0;31, 2018. These unaudited condensed consolidated
 financial statements should be read in conjunction with the audited
 consolidated financial statements&amp;#xA0;for the year ended
 December&amp;#xA0;31, 2017 and the notes thereto for the year ended
 December&amp;#xA0;31, 2017 included in the Company&amp;#x2019;s final
 prospectus that forms a part of the Company&amp;#x2019;s Registration
 Statement on Form&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;S-1&lt;/font&gt;&amp;#xA0;(Reg.&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;No.&amp;#xA0;333-224914),&lt;/font&gt;&amp;#xA0;filed
 with the Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;)
 pursuant to Rule 424(b)(4) on June&amp;#xA0;8, 2018 (the
 &amp;#x201C;Prospectus&amp;#x201D;).&lt;/p&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;
 &lt;/div&gt;</mgtx:InterimFinancialStatementsPolicyTextBlock>
  <mgtx:DescriptionOfBusinessPolicyPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_B746AE2D-11AA-429E-AA8E-B2785076BA07_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;&lt;i&gt;The Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 MeiraGTx Holdings plc, a limited company under the laws of the
 Cayman Islands, is a clinical-stage biotech company developing
 novel gene therapy treatments for a wide range of inherited and
 acquired disorders for which there are no effective treatments
 available. The Company is focused on developing therapies for
 ocular diseases, including rare inherited blindness as well as
 Xerostomia following radiation treatment for head and neck cancers
 and neurodegenerative diseases such as amyothrophic lateral
 sclerosis (&amp;#x201C;ALS&amp;#x201D;).&lt;/p&gt;
 &lt;/div&gt;</mgtx:DescriptionOfBusinessPolicyPolicyTextBlock>
  <mgtx:ReorganizationAndInitialPublicOfferingPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_042867A0-A021-4C0E-B59C-C51187DC6109_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;&lt;i&gt;Reorganization and Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On May&amp;#xA0;28, 2018, the Board of Directors of MeiraGTx Limited
 approved the Reorganization Transactions, effective June&amp;#xA0;7,
 2018, pursuant to which the Board of Directors approved the
 transfer of the shares held by each of the MeiraGTx Limited&amp;#x2019;s
 shareholders for the equivalent class and number of shares issued
 by Meira Holdings. On June&amp;#xA0;7, 2018, the Company completed its
 IPO, selling 5,000,000 Series A ordinary shares (&amp;#x201C;Ordinary
 Shares&amp;#x201D;) at a public offering price of $15.00 per share, and
 receiving $65.9&amp;#xA0;million in net proceeds, after deducting
 underwriting discounts and commissions and offering expenses
 payable by us.&lt;/p&gt;
 &lt;/div&gt;</mgtx:ReorganizationAndInitialPublicOfferingPolicyTextBlock>
  <mgtx:RiskAndUncertaintiesPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_8143CA8C-2F5E-4215-8322-55453C5885DB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company operates in an industry that is subject to intense
 competition, government regulation and rapid technological change.
 The Company&amp;#x2019;s operations are subject to significant risk and
 uncertainties including financial, operational, technological,
 regulatory and other risks, including the potential risk of
 business failure.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s limited capital resources and operations to
 date have been funded primarily with the proceeds from private
 equity offerings and the IPO. In the future, the Company may seek
 to raise additional capital through equity offerings, debt
 financings, marketing and distribution arrangements and other
 collaborations, strategic alliances and licensing arrangements or
 other sources to enable it to complete the development and
 potential commercialization of its product candidates.&lt;/p&gt;
 &lt;/div&gt;</mgtx:RiskAndUncertaintiesPolicyTextBlock>
  <mgtx:ReverseStockSplitPolicyTextBlock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" id="id_10515943_E8F7037F-D82B-48DA-A00B-676D0377B520_1_0">&lt;div&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 &lt;b&gt;&lt;i&gt;Reverse Share Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"&gt;
 On June&amp;#xA0;7, 2018 MeiraGTx Limited&amp;#x2019;s Board of Directors
 and shareholders approved a 1:3.881 reverse share split. All share
 information presented in these financial statements and
 accompanying footnotes have been retroactively adjusted to reflect
 the decreased number of shares resulting from this action.&lt;/p&gt;
 &lt;/div&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;
 &lt;/div&gt;</mgtx:ReverseStockSplitPolicyTextBlock>
  <mgtx:AmortizationOfInterestOnAssetRetirementObligation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_8">7322</mgtx:AmortizationOfInterestOnAssetRetirementObligation>
  <mgtx:AccretionOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5008_1100009">-761012</mgtx:AccretionOfStockIssuanceCosts>
  <mgtx:PreferredSharesIssuedInConnectionWithLicenseAgreement contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_4">137973</mgtx:PreferredSharesIssuedInConnectionWithLicenseAgreement>
  <mgtx:IncreaseDecreaseInDueToAndFromRelatedParties contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1_15">-861030</mgtx:IncreaseDecreaseInDueToAndFromRelatedParties>
  <mgtx:AccretionOfDeferredFinancingCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_78A8C930-8D68-49C8-A906-7A482D3B6344_1_1">761012</mgtx:AccretionOfDeferredFinancingCosts>
  <mgtx:AccretionOfWarrant contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_78A8C930-8D68-49C8-A906-7A482D3B6344_1_2">1045500</mgtx:AccretionOfWarrant>
  <mgtx:AccretionOfPreferredStockAndWarrants contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5008_1100010">-1045500</mgtx:AccretionOfPreferredStockAndWarrants>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064118x3069261" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_1001_2">1614322</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064118x3079518" unitRef="shares" decimals="0" id="id_10515943_3AA6CFD0-C804-4993-8A50-BF9D3FAFED73_3001_1">870898</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064218x3079518" unitRef="shares" decimals="0" id="id_10515943_550D8CCD-0E57-4181-8A86-810A9A7955F0_5001_400002">1306348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064218x3079518" unitRef="shares" decimals="0" id="id_10515943_550D8CCD-0E57-4181-8A86-810A9A7955F0_5001_400003">541363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064218x3079518" unitRef="iso4217_USD" decimals="0" id="id_10515943_92D72802-08EC-4186-BEAE-4136B4429372_5001_3">7397611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <mgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064218x3079518" unitRef="iso4217_USD" decimals="0" id="id_10515943_92D72802-08EC-4186-BEAE-4136B4429372_5001_2">19595220</mgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3068684x3069375_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_24C26A06-509D-4FD0-8B50-BB91B585F0A7_3001_2">1514775</us-gaap:FairValueAdjustmentOfWarrants>
  <mgtx:ClassOfWarrantOrRightExercisedDuringPeriodValue contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3068684x3069375_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_24C26A06-509D-4FD0-8B50-BB91B585F0A7_3001_3">-4194408</mgtx:ClassOfWarrantOrRightExercisedDuringPeriodValue>
  <mgtx:FairValueNetAssetLiabilityBeginningBalance contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3068684x3069375_3070059x3069669" unitRef="iso4217_USD" decimals="0" id="id_10515943_24C26A06-509D-4FD0-8B50-BB91B585F0A7_3001_1">2679633</mgtx:FairValueNetAssetLiabilityBeginningBalance>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3069085x3063336_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_6001_500003">1356129</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3069085x3063336_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_6001_400004">129419</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3071648x3070631" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BB2368F-D672-497E-9616-497FB4A90F2D_1001_1">10743045</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3071648x3070631_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_D4B72C00-5786-4CDE-A288-E5A2FB20A591_1002_3">3096012</us-gaap:ShareBasedCompensation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3071648x3078843" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BB2368F-D672-497E-9616-497FB4A90F2D_2001_0">1890511</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:LesseeOperatingLeaseDescription contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395655" id="id_10515943_A83E3E68-3659-4B59-8646-160EAB4638EE_1001_1">The Company records monthly rent expense on a  straight-line basis from July 1, 2016 through December 31, 2021.</us-gaap:LesseeOperatingLeaseDescription>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395655" id="id_10515943_A83E3E68-3659-4B59-8646-160EAB4638EE_1001_0">2021-12-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_29FA6256-25E9-4638-A118-29EE6159A831_1001_0">243780</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:InterestExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_C0794E5A-4B87-44F9-9B8B-2756E13D1794_1002_0">30424</us-gaap:InterestExpense>
  <us-gaap:LesseeOperatingLeaseDescription contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" id="id_10515943_627F1488-1186-4455-AAAD-22E71A7053F5_1001_1">The Company recorded monthly rent  expense on a straight-line basis from December 15, 2016 through October 31,  2032.</us-gaap:LesseeOperatingLeaseDescription>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" id="id_10515943_627F1488-1186-4455-AAAD-22E71A7053F5_1001_0">2032-10-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_0279E676-9FE4-4C33-BE9F-5AD05A4FD9BB_1001_0">0</us-gaap:OperatingLeasesRentExpenseNet>
  <mgtx:PromissoryNotesRepaymentDueDate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" id="id_10515943_F6207DEE-FF9A-4C65-AEDD-6786012EC152_1002_2">2018-12-31</mgtx:PromissoryNotesRepaymentDueDate>
  <mgtx:LeaseTerminationDate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" id="id_10515943_627F1488-1186-4455-AAAD-22E71A7053F5_1001_2">2018-03-31</mgtx:LeaseTerminationDate>
  <mgtx:PromissoryNotesInterestRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664" unitRef="pure" decimals="2" id="id_10515943_F6207DEE-FF9A-4C65-AEDD-6786012EC152_1002_0">0.05</mgtx:PromissoryNotesInterestRate>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078040x3395633" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_1001_0">275674</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078040x3395634" unitRef="iso4217_USD" decimals="0" id="id_10515943_1988757E-9206-494E-B41F-A2A8C48C3E77_2001_1">6493</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <mgtx:PaymentToRelatedParty contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395534_3080792x3395636" unitRef="iso4217_USD" decimals="0" id="id_10515943_2FB37CD1-B326-4E23-AF13-E123AAA6EE8B_1002_0">1143304</mgtx:PaymentToRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_CDE0A7CD-972C-43E5-A9F6-57DC9CC10E36_1001_0">372000</us-gaap:ResearchAndDevelopmentExpense>
  <mgtx:RelatedPartyTransactionAgreementNoticePeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3244897" id="id_10515943_DC82D00A-7DB3-490F-8C60-CA4C4C2BDA32_1005_1">P30D</mgtx:RelatedPartyTransactionAgreementNoticePeriod>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3326238" unitRef="iso4217_USD" decimals="0" id="id_10515943_50C5451E-7C67-48E6-A3D9-255CC472124D_1001_0">0</us-gaap:ResearchAndDevelopmentExpense>
  <mgtx:RelatedPartyTransactionAgreementNoticePeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3326238" id="id_10515943_E0994EAB-726F-4BD1-B0BF-4156E1CD6BB4_1001_0">P30D</mgtx:RelatedPartyTransactionAgreementNoticePeriod>
  <mgtx:RelatedPartyTransactionAgreementTerminationDate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3326238" id="id_10515943_E0994EAB-726F-4BD1-B0BF-4156E1CD6BB4_1001_1">2018-01</mgtx:RelatedPartyTransactionAgreementTerminationDate>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_USD" decimals="INF" id="id_10515943_EC339817-6004-4981-859C-7693FA646B2E_1002_0">0</us-gaap:ResearchAndDevelopmentExpense>
  <mgtx:NumberOfPrograms contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3331058" unitRef="Program" decimals="INF" id="id_10515943_069E1A83-9BFD-4C9F-B36E-9A0CDC8CEB5A_1001_0">8</mgtx:NumberOfPrograms>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3074821" id="id_10515943_49FBC453-5B4B-4577-9827-81278479FEA6_1001_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3074821_3081731x3297706" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_1001_5">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3074821_3081731x3395600" id="id_10515943_EF76E166-A803-42B5-92C2-465238FA1B1A_1001_5">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3075282_3081731x3297706" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_2001_4">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3075282_3081731x3395600" id="id_10515943_EF76E166-A803-42B5-92C2-465238FA1B1A_2001_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080792x3279407_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_7001_500007">56159119</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080792x3279407_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_7001_400008">5425124</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080792x3331058_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_8001_500005">140000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080792x3331058_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_8001_400006">13360</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589" unitRef="iso4217_USD" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5005_800011">4194408</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5005_800013">120519945</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5005_800018">12633483</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <mgtx:AccretionOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5005_800009">-761012</mgtx:AccretionOfStockIssuanceCosts>
  <mgtx:AccretionOfPreferredStockAndWarrants contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5005_800010">-1045500</mgtx:AccretionOfPreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589_3080974x3073300" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_6005_800015">65458276</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3064029" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5006_900020">1221242</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1001_28">2781553</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_D4B72C00-5786-4CDE-A288-E5A2FB20A591_2002_2">6456215</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5003_600014">11501432</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="shares" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5003_600019">1856510</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5003_700013">446</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5003_700018">73</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <mgtx:NoncashOrPartNoncashStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_1001_43">1509977</mgtx:NoncashOrPartNoncashStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411_3080974x3073300" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_6003_700015">194</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411_3080974x3073300" unitRef="shares" decimals="INF" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_6003_600016">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="iso4217_USD" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_5001_500011">9720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2001_30">610473</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_5001_400014">-11501432</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_5001_500013">-120520391</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <mgtx:NoncashOrPartNoncashStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="iso4217_USD" decimals="0" id="id_10515943_720E2F35-729A-4E53-866C-621F8B6F7DDE_2001_44">80000</mgtx:NoncashOrPartNoncashStockIssuanceCosts>
  <mgtx:ClassOfWarrantOrRightExercisedDuringPeriod contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="shares" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_5001_400012">927594</mgtx:ClassOfWarrantOrRightExercisedDuringPeriod>
  <mgtx:TemporaryEquityAccretionOfIssuanceCost contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="iso4217_USD" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_5001_500009">761012</mgtx:TemporaryEquityAccretionOfIssuanceCost>
  <mgtx:TemporaryEquityAccretionOfWarrants contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342" unitRef="iso4217_USD" decimals="INF" id="id_10515943_41F4F41D-5E9C-48BF-95D4-0C9345D8CB56_5001_500010">1045500</mgtx:TemporaryEquityAccretionOfWarrants>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342_3081998x3274559" unitRef="iso4217_USD" decimals="0" id="id_10515943_309354B8-8F8E-4FBC-847B-AAB9C853D5EB_1001_1">1356129</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342_3081998x3274559" unitRef="shares" decimals="INF" id="id_10515943_309354B8-8F8E-4FBC-847B-AAB9C853D5EB_1001_0">129419</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:NetIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3078149" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_5007_1000021">-46384185</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3264360" unitRef="iso4217_USD" decimals="0" id="id_10515943_76E8944F-46ED-4B0B-94B0-86334BBE7EBA_1001_3">690473</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3264360" unitRef="iso4217_USD" decimals="0" id="id_10515943_76E8944F-46ED-4B0B-94B0-86334BBE7EBA_1001_2">56849592</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3264360" unitRef="shares" decimals="INF" id="id_10515943_76E8944F-46ED-4B0B-94B0-86334BBE7EBA_1001_0">5425124</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080925x3063589" unitRef="iso4217_USD" decimals="INF" id="id_10515943_0EF1D430-85F9-48B6-83CD-014FEA3BE24F_1003_2">4194408</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080974x3073300" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_6008_1100017">9541530</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080974x3073300" unitRef="iso4217_USD" decimals="0" id="id_10515943_B6213991-5702-4AB2-BF1E-6A5B80544951_6008_1100015">65458470</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3297706" unitRef="pure" decimals="2" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3001_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3297706" unitRef="pure" decimals="4" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3001_0">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3297706" unitRef="pure" decimals="2" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3001_2">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3297706" unitRef="pure" decimals="4" id="id_10515943_AB05193C-206A-4601-9F50-371CB262F7A9_3001_1">0.0284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3324986" id="id_10515943_757904BB-73D2-4908-AD7D-8FEF73B31C35_1001_1">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3324986" unitRef="shares" decimals="INF" id="id_10515943_2050E10C-2E05-496E-AC36-489F7A419859_1001_0">142355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395600" unitRef="pure" decimals="2" id="id_10515943_EF76E166-A803-42B5-92C2-465238FA1B1A_3001_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395600" unitRef="pure" decimals="4" id="id_10515943_EF76E166-A803-42B5-92C2-465238FA1B1A_3001_0">0.0232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395600" unitRef="pure" decimals="2" id="id_10515943_EF76E166-A803-42B5-92C2-465238FA1B1A_3001_2">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395600" unitRef="pure" decimals="4" id="id_10515943_EF76E166-A803-42B5-92C2-465238FA1B1A_3001_1">0.0240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395613" id="id_10515943_3A2D4C4C-503E-4662-A395-C037211E75CE_1001_1">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395613" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_D02C408A-C546-411E-9A1C-DE3A05380E35_1001_0">5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395613" unitRef="shares" decimals="INF" id="id_10515943_86680BBF-AD30-493F-A2FF-6A3A3653AEE9_1001_0">533330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3082820x3299846" unitRef="pure" decimals="2" id="id_10515943_49FBC453-5B4B-4577-9827-81278479FEA6_2001_1">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3082820x3395607" id="id_10515943_49FBC453-5B4B-4577-9827-81278479FEA6_3001_2">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE1053578-1810-Q0003_STD_365_20151231_0_3064218x3079518" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_1001_1">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE1053578-1810-Q0003_STD_365_20151231_0_3064218x3079518_3080924x3065411" unitRef="shares" decimals="0" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_3001_0">867935</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:AssetRetirementObligationRevisionOfEstimate contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_2_2">-75011</us-gaap:AssetRetirementObligationRevisionOfEstimate>
  <us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_2_3">12863</us-gaap:AssetRetirementObligationForeignCurrencyTranslationGainLoss>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_2001_7">P9Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0" id="id_10515943_16331F30-AE44-4D78-B1F6-7DA4CA6C42F3_2001_11">P8Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <mgtx:AmortizationOfInterestOnAssetRetirementObligation contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_248BFC88-CBCB-487A-B861-1D343156289B_2_1">19313</mgtx:AmortizationOfInterestOnAssetRetirementObligation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3069102x3082828" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1001_3">P9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3069102x3082828" unitRef="pure" decimals="2" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1001_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3069102x3082828" unitRef="pure" decimals="4" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1001_0">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3069102x3082828" unitRef="pure" decimals="2" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1001_1">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3078046x3395641_3080792x3244897" unitRef="iso4217_GBP" decimals="0" id="id_10515943_DC82D00A-7DB3-490F-8C60-CA4C4C2BDA32_1002_0">241053</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_DC82D00A-7DB3-490F-8C60-CA4C4C2BDA32_1004_0">311000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_366_20161231_0_3078046x3395641_3080792x3244897" unitRef="iso4217_GBP" decimals="0" id="id_10515943_DC82D00A-7DB3-490F-8C60-CA4C4C2BDA32_1001_0">1161149</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_366_20161231_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_DC82D00A-7DB3-490F-8C60-CA4C4C2BDA32_1003_0">1574000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3069102x3082828" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1002_3">P5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3069102x3082828" unitRef="pure" decimals="2" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1002_2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3069102x3082828" unitRef="pure" decimals="4" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1002_0">0.0186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3069102x3082828" unitRef="pure" decimals="2" id="id_10515943_DC560B89-8C8A-4922-A2BD-0AAD3D7D75CA_1002_1">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <mgtx:RepaymentOfPromissoryNotes contextRef="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_F6207DEE-FF9A-4C65-AEDD-6786012EC152_1003_3">1472433</mgtx:RepaymentOfPromissoryNotes>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BF9B518-C5AB-469E-A793-0BDAB34436BC_2_2">682135</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_13">-7523738</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_17">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_3_1">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_3_0">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_7">449625</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_1">2221896</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_26063376-73C3-436C-8D80-8B574B95113D_3_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_10">50894</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_9">7991</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_16">-7209120</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_11">-7178719</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_12">-345019</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OperatingExpenses contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_3">7585441</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_4">-7585441</us-gaap:OperatingIncomeLoss>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_A42112D8-D8B9-4D09-8A91-6929550BCBF8_2_3">159041</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_2">5363545</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_15">30401</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_91B0166B-B6A8-40B0-A5AF-103F3BC7AF06_2_0">229250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="shares" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_2_18">8505149</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FE7374B3-C82A-411F-A08F-0CE28DA1DEEB_2_3">-7209120</mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <mgtx:AccretionOfDeferredFinancingCosts contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FE7374B3-C82A-411F-A08F-0CE28DA1DEEB_2_1">30401</mgtx:AccretionOfDeferredFinancingCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3071648x3070631" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BF9B518-C5AB-469E-A793-0BDAB34436BC_1002_1">131427</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3071648x3078843" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BF9B518-C5AB-469E-A793-0BDAB34436BC_2002_0">550708</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_725D271D-EAFC-4BE2-8519-26D190AA552F_1002_0">121890</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_0AB410A5-2547-4035-B2FC-9E6B68113501_1002_0">390903</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078040x3395633" unitRef="iso4217_USD" decimals="0" id="id_10515943_A42112D8-D8B9-4D09-8A91-6929550BCBF8_1002_0">152169</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078040x3395634" unitRef="iso4217_USD" decimals="0" id="id_10515943_A42112D8-D8B9-4D09-8A91-6929550BCBF8_2002_1">6746</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078040x3395635" unitRef="iso4217_USD" decimals="0" id="id_10515943_A42112D8-D8B9-4D09-8A91-6929550BCBF8_3002_2">126</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <mgtx:PaymentToRelatedParty contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395534_3080792x3395636" unitRef="iso4217_USD" decimals="0" id="id_10515943_F328F9D9-2A17-4A2D-8DFC-27F19F690782_1001_0">0</mgtx:PaymentToRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_997D6592-BE2B-4870-A21B-F9E0DF98F9A0_1002_0">114000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395641_3080792x3326238" unitRef="iso4217_USD" decimals="0" id="id_10515943_9D6981AC-09C4-4968-AECF-7BBCF72F7B1D_1002_0">479494</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_USD" decimals="INF" id="id_10515943_EC339817-6004-4981-859C-7693FA646B2E_1003_0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3081731x3395613" unitRef="shares" decimals="INF" id="id_10515943_86680BBF-AD30-493F-A2FF-6A3A3653AEE9_1004_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BF9B518-C5AB-469E-A793-0BDAB34436BC_1_2">8363785</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_13">-28001825</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_17">-2.29</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_1_1">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities>
  <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_061BD34A-8C6C-495D-BF29-7EB553945051_1_0">0</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_8">2184183</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_7">-2726624</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_1">17378052</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_26063376-73C3-436C-8D80-8B574B95113D_1_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_10">9708</us-gaap:InterestExpense>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_9">25354</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_16">-31122626</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_11">-29980832</us-gaap:NetIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_12">1979007</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OperatingExpenses contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_3">25168746</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_4">-25168746</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_6">83075</us-gaap:OtherNonoperatingIncome>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_A42112D8-D8B9-4D09-8A91-6929550BCBF8_1_3">139321</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_2">7790694</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_15">1141794</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_91B0166B-B6A8-40B0-A5AF-103F3BC7AF06_1_0">247202</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="shares" decimals="0" id="id_10515943_4EE8CA9F-ACA5-45B5-828C-5D0F5A45B4E9_1_18">13611452</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FE7374B3-C82A-411F-A08F-0CE28DA1DEEB_1_3">-31122626</mgtx:AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted>
  <mgtx:AccretionOfDeferredFinancingCosts contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FE7374B3-C82A-411F-A08F-0CE28DA1DEEB_1_1">666567</mgtx:AccretionOfDeferredFinancingCosts>
  <mgtx:AccretionOfWarrant contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0" unitRef="iso4217_USD" decimals="0" id="id_10515943_FE7374B3-C82A-411F-A08F-0CE28DA1DEEB_1_2">475227</mgtx:AccretionOfWarrant>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3064218x3079518" unitRef="iso4217_USD" decimals="0" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_1002_8">13620866</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3064218x3079518_3071648x3070631" unitRef="iso4217_USD" decimals="0" id="id_10515943_C48768F7-FF09-465C-BBC5-B1AC515D83AC_2002_7">6531750</us-gaap:ShareBasedCompensation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3071648x3070631" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BF9B518-C5AB-469E-A793-0BDAB34436BC_1001_1">7318224</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3071648x3078843" unitRef="iso4217_USD" decimals="0" id="id_10515943_6BF9B518-C5AB-469E-A793-0BDAB34436BC_2001_0">1045561</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3073336x3395655" unitRef="iso4217_USD" decimals="0" id="id_10515943_725D271D-EAFC-4BE2-8519-26D190AA552F_1001_0">121890</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:InterestExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_C0794E5A-4B87-44F9-9B8B-2756E13D1794_1001_0">0</us-gaap:InterestExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3073336x3395664" unitRef="iso4217_USD" decimals="0" id="id_10515943_0AB410A5-2547-4035-B2FC-9E6B68113501_1001_0">0</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078040x3395633" unitRef="iso4217_USD" decimals="0" id="id_10515943_A42112D8-D8B9-4D09-8A91-6929550BCBF8_1001_0">139321</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <mgtx:PaymentToRelatedParty contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395534_3080792x3395636" unitRef="iso4217_USD" decimals="0" id="id_10515943_F328F9D9-2A17-4A2D-8DFC-27F19F690782_1002_0">145887</mgtx:PaymentToRelatedParty>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395641_3080792x3244897" unitRef="iso4217_USD" decimals="0" id="id_10515943_997D6592-BE2B-4870-A21B-F9E0DF98F9A0_1001_0">183000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395641_3080792x3326238" unitRef="iso4217_USD" decimals="0" id="id_10515943_9D6981AC-09C4-4968-AECF-7BBCF72F7B1D_1001_0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395641_3080792x3331058" unitRef="iso4217_USD" decimals="INF" id="id_10515943_EC339817-6004-4981-859C-7693FA646B2E_1001_0">0</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3081731x3324986" unitRef="shares" decimals="INF" id="id_10515943_2050E10C-2E05-496E-AC36-489F7A419859_1003_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3081731x3395613" unitRef="shares" decimals="INF" id="id_10515943_86680BBF-AD30-493F-A2FF-6A3A3653AEE9_1003_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3081731x3395613">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndNonEmployeeBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3081731x3324986">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeConsultantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395641_3080792x3331058">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395641_3080792x3326238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078046x3395534_3080792x3395636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:KadmonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:TransitionServicesAgreementWithRelatedPartyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3078040x3395633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyRentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3073336x3395655">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwoThousandsSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3071648x3078843">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3071648x3070631">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3064218x3079518_3071648x3070631">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20180630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3081731x3395613">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndNonEmployeeBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395641_3080792x3331058">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395641_3080792x3326238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078046x3395534_3080792x3395636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:KadmonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:TransitionServicesAgreementWithRelatedPartyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078040x3395635">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyOtherExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078040x3395634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyPersonnelExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3078040x3395633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyRentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3073336x3395655">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwoThousandsSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3071648x3078843">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0_3071648x3070631">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_91_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_90_20180331_0_3069102x3082828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_366_20161231_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_365_20171231_0_3069102x3082828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_365_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_365_20151231_0_3064218x3079518_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_365_20151231_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3082820x3395607">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:OverThreeYearsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3082820x3299846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">mgtx:FirstAnniversaryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395613">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndNonEmployeeBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3395600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3324986">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeConsultantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3081731x3297706">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080974x3073300">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080925x3063589">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3264360">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgtx:ClasscPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3078149">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342_3081998x3274559">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">mgtx:PaymentsInLieuMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411_3080974x3073300">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3064029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589_3080974x3073300">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080924x3063589">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080792x3331058_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3080792x3279407_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:SalesAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3075282_3081731x3395600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3075282_3081731x3297706">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3074821_3081731x3395600">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3074821_3081731x3297706">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078512x3074821">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3331058">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3326238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078046x3395534_3080792x3395636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:KadmonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:TransitionServicesAgreementWithRelatedPartyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078040x3395634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyPersonnelExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3078040x3395633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyRentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3073336x3395655">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwoThousandsSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3071648x3078843">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3071648x3070631_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3071648x3070631">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3069085x3063336_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3068684x3069375_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064118x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0_3064118x3069261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20180630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3395613">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndNonEmployeeBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3324986">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeConsultantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3081731x3297706">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078512x3075282_3081731x3297706">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078512x3074821_3081731x3297706">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395641_3080792x3331058">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395641_3080792x3326238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078046x3395534_3080792x3395636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:KadmonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:TransitionServicesAgreementWithRelatedPartyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078040x3395635">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyOtherExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078040x3395634">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyPersonnelExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3078040x3395633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mgtx:RelatedPartyRentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3073336x3395655">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwoThousandsSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3071648x3078843">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3071648x3070631">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3064118x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3064118x3076421">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0_3064118x3069261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_181_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_156_20180331_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-10-27</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180727_0_3073336x3396760_3081213x3080964">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwentySevenTwoThousandEighteenLeaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-07-27</startDate>
      <endDate>2018-07-27</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-06-07</startDate>
      <endDate>2018-06-07</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180607_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-06-07</startDate>
      <endDate>2018-06-07</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180607_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2018-06-07</startDate>
      <endDate>2018-06-07</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180605_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <startDate>2018-06-05</startDate>
      <endDate>2018-06-05</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180604_0_3069102x3082828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-06-04</startDate>
      <endDate>2018-06-04</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180315_0_3080792x3331058_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-03-15</startDate>
      <endDate>2018-03-15</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20180301_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-03-01</startDate>
      <endDate>2018-03-01</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_1_20150424_0_3078046x3395534_3080792x3395636">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:KadmonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:TransitionServicesAgreementWithRelatedPartyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-04-24</startDate>
      <endDate>2015-04-24</endDate>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080926x3082109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080926x3070630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3078149">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3066342">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3064029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3080924x3063589">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3078046x3395641_3080792x3326238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3073336x3395655">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwoThousandsSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3069102x3275696_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3069102x3082828_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3068684x3069635_3069102x3275696_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3068684x3069375_3069102x3082828_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3081731x3395613">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeAndNonEmployeeBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3081731x3324986">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:NonemployeeConsultantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080926x3082109">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080926x3070630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3264360">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgtx:ClasscPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3078149">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3064029">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3080924x3063589">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3331058">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3326238">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ManufacturingAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3078046x3395641_3080792x3244897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3073336x3395655">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:JulyTwoThousandsSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3069102x3275696_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3068684x3069635_3069102x3275696_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">mgtx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3068684x3069375_3070059x3069669">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518_3081731x3329283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:EmployeeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518_3081731x3265585">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">mgtx:ConsultantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20171026_0_3073336x3395664">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">mgtx:DecemberTwoThousandSixteenLeaseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-10-26</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180607_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-07</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180607_0_3064218x3079518">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-07</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180607_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2018-06-07</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180605_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2018-06-05</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180301_0_3080924x3065411">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-03-01</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20201031_0_3078046x3395641_3080792x3244897_3081295x3078919">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mgtx:UclConsultantsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgtx:ResearchAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2020-10-31</instant>
    </period>
  </context>
  <context id="eol_PE1053578-1810-Q0003_STD_0_20180731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001735438</identifier>
    </entity>
    <period>
      <instant>2018-07-31</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_GBP">
    <measure>iso4217:GBP</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Lease">
    <measure>mgtx:Lease</measure>
  </unit>
  <unit id="Program">
    <measure>mgtx:Program</measure>
  </unit>
</xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mgtx-20180630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Schema - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2018-08-08T01:33:44Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:srt-types="http://fasb.org/srt-types/2018-01-31"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:us-types="http://fasb.org/us-types/2018-01-31"
  xmlns:mgtx="http://meiragtx.com/20180630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  targetNamespace="http://meiragtx.com/20180630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
        <link:definition>105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" id="Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
        <link:definition>109 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>111 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>112 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>113 - Disclosure - Ordinary Shares and Convertible Preferred C Shares</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>114 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>116 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>118 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>119 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
        <link:definition>120 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>121 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables">
        <link:definition>122 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
        <link:definition>123 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation" id="DisclosureOrganizationAndBasisOfPresentationAdditionalInformation">
        <link:definition>124 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements">
        <link:definition>125 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Company's Financial Instruments Carried at Fair Value Measurements (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
        <link:definition>126 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation">
        <link:definition>127 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel">
        <link:definition>128 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations">
        <link:definition>129 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Change in Asset Retirement Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea" id="DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea">
        <link:definition>130 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Non-Current Assets by Geographical Area (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses" id="DisclosureAccruedExpensesScheduleOfAccruedExpenses">
        <link:definition>131 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation" id="DisclosureShareBasedCompensationAdditionalInformation">
        <link:definition>132 - Disclosure - Share based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants" id="DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants">
        <link:definition>133 - Disclosure - Share Based Compensation - Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel" id="DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel">
        <link:definition>134 - Disclosure - Share Based Compensation - Schedule of Grant Date Fair Values of the Stock Option Granted Black Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares" id="DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares">
        <link:definition>135 - Disclosure - Share Based Compensation - Summary of Restricted Ordinary Shares (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense" id="DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense">
        <link:definition>136 - Disclosure - Share Based Compensation - Schedule of Share Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation" id="DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation">
        <link:definition>137 - Disclosure - Ordinary Shares and Convertible Preferred C Shares - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" id="DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
        <link:definition>138 - Disclosure - Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" id="DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
        <link:definition>139 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>140 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation" id="DisclosureRelatedPartyTransactionsAdditionalInformation">
        <link:definition>141 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations" id="DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations">
        <link:definition>142 - Disclosure - Related Party Transactions - Incurred Charges included in Loss from Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>143 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mgtx-20180630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mgtx-20180630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mgtx-20180630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mgtx-20180630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <element name="AccretionOfDeferredFinancingCosts" id="mgtx_AccretionOfDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccretionOfPreferredStockAndWarrants" id="mgtx_AccretionOfPreferredStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccretionOfStockIssuanceCosts" id="mgtx_AccretionOfStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccretionOfWarrant" id="mgtx_AccretionOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedClinicalTrialCosts" id="mgtx_AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedConsultingExpenses" id="mgtx_AccruedConsultingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedInterest" id="mgtx_AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedLiabilitiesAccruedCompensationAndBenefits" id="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedTravelExpense" id="mgtx_AccruedTravelExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" id="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmortizationOfInterestOnAssetRetirementObligation" id="mgtx_AmortizationOfInterestOnAssetRetirementObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnnualBaseRentAndOperatingExpense" id="mgtx_AnnualBaseRentAndOperatingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnnualMaintenanceFee" id="mgtx_AnnualMaintenanceFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BaseRentAndManagementFees" id="mgtx_BaseRentAndManagementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClasscPreferredStockMember" id="mgtx_ClasscPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisedDuringPeriod" id="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisedDuringPeriodValue" id="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsultantMember" id="mgtx_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DecemberTwoThousandSixteenLeaseMember" id="mgtx_DecemberTwoThousandSixteenLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRent" id="mgtx_DeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfBusinessPolicyPolicyTextBlock" id="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="mgtx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeAndBoardOfDirectorsMember" id="mgtx_EmployeeAndBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeAndNonEmployeeBoardOfDirectorsMember" id="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeMember" id="mgtx_EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueNetAssetLiabilityBeginningBalance" id="mgtx_FairValueNetAssetLiabilityBeginningBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueNetAssetLiabilityEndingBalance" id="mgtx_FairValueNetAssetLiabilityEndingBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstAnniversaryMember" id="mgtx_FirstAnniversaryMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDueToAndFromRelatedParties" id="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterimFinancialStatementsPolicyTextBlock" id="mgtx_InterimFinancialStatementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JulyTwentySevenTwoThousandEighteenLeaseMember" id="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="JulyTwoThousandsSixteenLeaseMember" id="mgtx_JulyTwoThousandsSixteenLeaseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="KadmonMember" id="mgtx_KadmonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseTerminationDate" id="mgtx_LeaseTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementMember" id="mgtx_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LiquidityPolicyTextBlock" id="mgtx_LiquidityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManufacturingAgreementMember" id="mgtx_ManufacturingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NoncashOrPartNoncashStockIssuanceCosts" id="mgtx_NoncashOrPartNoncashStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonemployeeConsultantsMember" id="mgtx_NonemployeeConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonemployeeMember" id="mgtx_NonemployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfLeasesTerminated" id="mgtx_NumberOfLeasesTerminated" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfNewFacilityLeases" id="mgtx_NumberOfNewFacilityLeases" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPrograms" id="mgtx_NumberOfPrograms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperationByGeographicalLineItems" id="mgtx_OperationByGeographicalLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperationByGeographicalTable" id="mgtx_OperationByGeographicalTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="OrganizationAndNatureOfBusinessTextualAbstract" id="mgtx_OrganizationAndNatureOfBusinessTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OverThreeYearsMember" id="mgtx_OverThreeYearsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentsInLieuMember" id="mgtx_PaymentsInLieuMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentToRelatedParty" id="mgtx_PaymentToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfAgreement" id="mgtx_PeriodOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialMilestonePaymentsUponAchievementOfMilestone" id="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredSharesIssuedInConnectionWithLicenseAgreement" id="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceInitialPublicOfferingNet" id="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PromissoryNoteIssued" id="mgtx_PromissoryNoteIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PromissoryNotesInterestRate" id="mgtx_PromissoryNotesInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PromissoryNotesRepaymentDueDate" id="mgtx_PromissoryNotesRepaymentDueDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReclassificationOfWarrantLiabilityUponExercise" id="mgtx_ReclassificationOfWarrantLiabilityUponExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyAdministrativeExpensePercentage" id="mgtx_RelatedPartyAdministrativeExpensePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyOtherExpenseMember" id="mgtx_RelatedPartyOtherExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyPersonnelExpenseMember" id="mgtx_RelatedPartyPersonnelExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyRentExpenseMember" id="mgtx_RelatedPartyRentExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyTransactionAgreementNoticePeriod" id="mgtx_RelatedPartyTransactionAgreementNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RelatedPartyTransactionAgreementTerminationDate" id="mgtx_RelatedPartyTransactionAgreementTerminationDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReorganizationAndInitialPublicOfferingPolicyTextBlock" id="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RepaymentOfPromissoryNotes" id="mgtx_RepaymentOfPromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAgreementMember" id="mgtx_ResearchAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedCashMember" id="mgtx_RestrictedCashMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReverseStockSplitPolicyTextBlock" id="mgtx_ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RiskAndUncertaintiesPolicyTextBlock" id="mgtx_RiskAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesAgreementMember" id="mgtx_SalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfDescriptionOfBusinessLineItems" id="mgtx_ScheduleOfDescriptionOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfDescriptionOfBusinessTable" id="mgtx_ScheduleOfDescriptionOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" id="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" id="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationExpenseLineItems" id="mgtx_ShareBasedCompensationExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationExpenseTable" id="mgtx_ShareBasedCompensationExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="TemporaryEquityAccretionOfIssuanceCost" id="mgtx_TemporaryEquityAccretionOfIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TemporaryEquityAccretionOfWarrants" id="mgtx_TemporaryEquityAccretionOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TerminationDate" id="mgtx_TerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TransitionServicesAgreementWithRelatedPartyMember" id="mgtx_TransitionServicesAgreementWithRelatedPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UclConsultantsLimitedMember" id="mgtx_UclConsultantsLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" id="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageNumberOfSharesOutstandingDilutedPercent" id="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mgtx-20180630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Calculation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2018-08-08T01:33:44Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DocumentandEntityInformation" roleURI="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfFinancialPositionClassified" roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfFinancialPositionClassifiedParen" roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfIncomeAlternative" roleURI="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfCashFlowsIndirect" roleURI="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureOrganizationAndBasisOfPresentationAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations" roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCash" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AmortizationOfInterestOnAssetRetirementObligation" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.2300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.2800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mgtx_AmortizationOfInterestOnAssetRetirementObligation" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.1400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedClinicalTrialCosts" xlink:label="mgtx_AccruedClinicalTrialCosts"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedConsultingExpenses" xlink:label="mgtx_AccruedConsultingExpenses"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedInterest" xlink:label="mgtx_AccruedInterest"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedTravelExpense" xlink:label="mgtx_AccruedTravelExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedClinicalTrialCosts" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedConsultingExpenses" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedRentCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedInterest" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="mgtx_AccruedTravelExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfDeferredFinancingCosts" xlink:label="mgtx_AccretionOfDeferredFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfWarrant" xlink:label="mgtx_AccretionOfWarrant"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="mgtx_AccretionOfDeferredFinancingCosts" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="mgtx_AccretionOfWarrant" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mgtx-20180630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Definition Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2018-08-08T01:33:44Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DocumentandEntityInformation" roleURI="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfFinancialPositionClassified" roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfFinancialPositionClassifiedParen" roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfIncomeAlternative" roleURI="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfCashFlowsIndirect" roleURI="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureOrganizationAndBasisOfPresentationAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations" roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfPreferredStockAndWarrants" xlink:label="mgtx_AccretionOfPreferredStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfStockIssuanceCosts" xlink:label="mgtx_AccretionOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_SalesAgreementMember" xlink:label="mgtx_SalesAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TemporaryEquityAccretionOfIssuanceCost" xlink:label="mgtx_TemporaryEquityAccretionOfIssuanceCost"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TemporaryEquityAccretionOfWarrants" xlink:label="mgtx_TemporaryEquityAccretionOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_LicenseAgreementMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_SalesAgreementMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_AccountsPayableMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_AccretionOfStockIssuanceCosts" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_AccretionOfPreferredStockAndWarrants" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_TemporaryEquityAccretionOfIssuanceCost" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_TemporaryEquityAccretionOfWarrants" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AmortizationOfInterestOnAssetRetirementObligation" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NoncashOrPartNoncashStockIssuanceCosts" xlink:label="mgtx_NoncashOrPartNoncashStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="mgtx_ReclassificationOfWarrantLiabilityUponExercise"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mgtx_AmortizationOfInterestOnAssetRetirementObligation" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mgtx_ReclassificationOfWarrantLiabilityUponExercise" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mgtx_NoncashOrPartNoncashStockIssuanceCosts" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.4400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="mgtx_ScheduleOfDescriptionOfBusinessTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharePrice" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RestrictedCashMember" xlink:label="mgtx_RestrictedCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="mgtx_RestrictedCashMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_WarrantMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FairValueNetAssetLiabilityBeginningBalance" xlink:label="mgtx_FairValueNetAssetLiabilityBeginningBalance"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FairValueNetAssetLiabilityEndingBalance" xlink:label="mgtx_FairValueNetAssetLiabilityEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mgtx_FairValueNetAssetLiabilityBeginningBalance" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mgtx_FairValueNetAssetLiabilityEndingBalance" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_WarrantMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="country_GB"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OperationByGeographicalLineItems" xlink:label="mgtx_OperationByGeographicalLineItems"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OperationByGeographicalTable" xlink:label="mgtx_OperationByGeographicalTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgtx_OperationByGeographicalLineItems" xlink:to="mgtx_OperationByGeographicalTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_OperationByGeographicalLineItems" xlink:to="us-gaap_NoncurrentAssets" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgtx_OperationByGeographicalTable" xlink:to="srt_StatementGeographicalAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ConsultantMember" xlink:label="mgtx_ConsultantMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" xlink:label="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeMember" xlink:label="mgtx_EmployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FirstAnniversaryMember" xlink:label="mgtx_FirstAnniversaryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NonemployeeConsultantsMember" xlink:label="mgtx_NonemployeeConsultantsMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OverThreeYearsMember" xlink:label="mgtx_OverThreeYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_NonemployeeConsultantsMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_ConsultantMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_EmployeeMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_FirstAnniversaryMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_OverThreeYearsMember" order="1.2300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeAndBoardOfDirectorsMember" xlink:label="mgtx_EmployeeAndBoardOfDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NonemployeeMember" xlink:label="mgtx_NonemployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_EmployeeAndBoardOfDirectorsMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_NonemployeeMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationExpenseLineItems" xlink:label="mgtx_ShareBasedCompensationExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationExpenseTable" xlink:label="mgtx_ShareBasedCompensationExpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgtx_ShareBasedCompensationExpenseLineItems" xlink:to="mgtx_ShareBasedCompensationExpenseTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgtx_ShareBasedCompensationExpenseLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgtx_ShareBasedCompensationExpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfDeferredFinancingCosts" xlink:label="mgtx_AccretionOfDeferredFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClasscPreferredStockMember" xlink:label="mgtx_ClasscPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PaymentsInLieuMember" xlink:label="mgtx_PaymentsInLieuMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_LicenseAgreementMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgtx_ClasscPreferredStockMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_AccretionOfDeferredFinancingCosts" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="mgtx_PaymentsInLieuMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AnnualMaintenanceFee" xlink:label="mgtx_AnnualMaintenanceFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_BaseRentAndManagementFees" xlink:label="mgtx_BaseRentAndManagementFees"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DecemberTwoThousandSixteenLeaseMember" xlink:label="mgtx_DecemberTwoThousandSixteenLeaseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DeferredRent" xlink:label="mgtx_DeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_JulyTwoThousandsSixteenLeaseMember" xlink:label="mgtx_JulyTwoThousandsSixteenLeaseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_KadmonMember" xlink:label="mgtx_KadmonMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LeaseTerminationDate" xlink:label="mgtx_LeaseTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ManufacturingAgreementMember" xlink:label="mgtx_ManufacturingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfPrograms" xlink:label="mgtx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PaymentToRelatedParty" xlink:label="mgtx_PaymentToRelatedParty"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PeriodOfAgreement" xlink:label="mgtx_PeriodOfAgreement"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNoteIssued" xlink:label="mgtx_PromissoryNoteIssued"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNotesInterestRate" xlink:label="mgtx_PromissoryNotesInterestRate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNotesRepaymentDueDate" xlink:label="mgtx_PromissoryNotesRepaymentDueDate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyAdministrativeExpensePercentage" xlink:label="mgtx_RelatedPartyAdministrativeExpensePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyTransactionAgreementNoticePeriod" xlink:label="mgtx_RelatedPartyTransactionAgreementNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyTransactionAgreementTerminationDate" xlink:label="mgtx_RelatedPartyTransactionAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RepaymentOfPromissoryNotes" xlink:label="mgtx_RepaymentOfPromissoryNotes"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ResearchAgreementMember" xlink:label="mgtx_ResearchAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TerminationDate" xlink:label="mgtx_TerminationDate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TransitionServicesAgreementWithRelatedPartyMember" xlink:label="mgtx_TransitionServicesAgreementWithRelatedPartyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_UclConsultantsLimitedMember" xlink:label="mgtx_UclConsultantsLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_ResearchAgreementMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_ManufacturingAgreementMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_LicenseAgreementMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_TransitionServicesAgreementWithRelatedPartyMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="mgtx_JulyTwoThousandsSixteenLeaseMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="mgtx_DecemberTwoThousandSixteenLeaseMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_UclConsultantsLimitedMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_KadmonMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyAdministrativeExpensePercentage" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PeriodOfAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_TerminationDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PaymentToRelatedParty" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyTransactionAgreementNoticePeriod" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyTransactionAgreementTerminationDate" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_NumberOfPrograms" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_AnnualMaintenanceFee" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_LeaseTerminationDate" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_BaseRentAndManagementFees" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PromissoryNoteIssued" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_DeferredRent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PromissoryNotesInterestRate" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PromissoryNotesRepaymentDueDate" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RepaymentOfPromissoryNotes" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpense" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyOtherExpenseMember" xlink:label="mgtx_RelatedPartyOtherExpenseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyPersonnelExpenseMember" xlink:label="mgtx_RelatedPartyPersonnelExpenseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyRentExpenseMember" xlink:label="mgtx_RelatedPartyRentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mgtx_RelatedPartyRentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mgtx_RelatedPartyPersonnelExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mgtx_RelatedPartyOtherExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AnnualBaseRentAndOperatingExpense" xlink:label="mgtx_AnnualBaseRentAndOperatingExpense"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" xlink:label="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfLeasesTerminated" xlink:label="mgtx_NumberOfLeasesTerminated"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfNewFacilityLeases" xlink:label="mgtx_NumberOfNewFacilityLeases"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgtx_AnnualBaseRentAndOperatingExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgtx_NumberOfLeasesTerminated" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgtx_NumberOfNewFacilityLeases" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mgtx-20180630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Labels Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2018-08-08T01:33:44Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_10515943_3063306_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_10515943_3063306_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3063328_1_1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3063328_2_1">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_10515943_3063969_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_10515943_3063969_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" id="id_10515943_3063336_1_1">Accounts Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US" id="id_10515943_3063336_2_1">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfDeferredFinancingCosts" xlink:label="mgtx_AccretionOfDeferredFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccretionOfDeferredFinancingCosts_lbl" xml:lang="en-US" id="id_10515943_3395556_3_1">Accretion of deferred financing costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccretionOfDeferredFinancingCosts_lbl" xml:lang="en-US" id="id_10515943_3395556_1_1">Accretion of Deferred Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccretionOfDeferredFinancingCosts_lbl" xml:lang="en-US" id="id_10515943_3395556_2_1">Preferred share conversion value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgtx_AccretionOfDeferredFinancingCosts_lbl" xml:lang="en-US" id="id_10515943_3395556_14_1">Accretion of Preferred Shares financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccretionOfDeferredFinancingCosts" xlink:to="mgtx_AccretionOfDeferredFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfPreferredStockAndWarrants" xlink:label="mgtx_AccretionOfPreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccretionOfPreferredStockAndWarrants_lbl" xml:lang="en-US" id="id_10515943_3396756_3_1">Accretion of preferred stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccretionOfPreferredStockAndWarrants_lbl" xml:lang="en-US" id="id_10515943_3396756_1_1">Accretion of Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccretionOfPreferredStockAndWarrants_lbl" xml:lang="en-US" id="id_10515943_3396756_2_1">Accretion of warrants issued in connection with convertible preferred C shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccretionOfPreferredStockAndWarrants" xlink:to="mgtx_AccretionOfPreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfStockIssuanceCosts" xlink:label="mgtx_AccretionOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccretionOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3395551_3_1">Accretion of stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccretionOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3395551_1_1">Accretion of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccretionOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3395551_2_1">Accretion of issuance costs on convertible preferred C shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccretionOfStockIssuanceCosts" xlink:to="mgtx_AccretionOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfWarrant" xlink:label="mgtx_AccretionOfWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccretionOfWarrant_lbl" xml:lang="en-US" id="id_10515943_3395632_3_1">Accretion of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccretionOfWarrant_lbl" xml:lang="en-US" id="id_10515943_3395632_1_1">Accretion of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mgtx_AccretionOfWarrant_lbl" xml:lang="en-US" id="id_10515943_3395632_14_1">Accretion of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccretionOfWarrant" xlink:to="mgtx_AccretionOfWarrant_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedClinicalTrialCosts" xlink:label="mgtx_AccruedClinicalTrialCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedClinicalTrialCosts_lbl" xml:lang="en-US" id="id_10515943_3102149_3_1">Accrued Clinical Trial Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedClinicalTrialCosts_lbl" xml:lang="en-US" id="id_10515943_3102149_1_1">Accrued Clinical Trial Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedClinicalTrialCosts_lbl" xml:lang="en-US" id="id_10515943_3102149_2_1">Clinical Trial Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedClinicalTrialCosts" xlink:to="mgtx_AccruedClinicalTrialCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedConsultingExpenses" xlink:label="mgtx_AccruedConsultingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedConsultingExpenses_lbl" xml:lang="en-US" id="id_10515943_3187121_3_1">Accrued Consulting Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedConsultingExpenses_lbl" xml:lang="en-US" id="id_10515943_3187121_1_1">Accrued Consulting Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedConsultingExpenses_lbl" xml:lang="en-US" id="id_10515943_3187121_2_1">Consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedConsultingExpenses" xlink:to="mgtx_AccruedConsultingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedInterest" xlink:label="mgtx_AccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedInterest_lbl" xml:lang="en-US" id="id_10515943_3114712_3_1">Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedInterest_lbl" xml:lang="en-US" id="id_10515943_3114712_1_1">Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedInterest_lbl" xml:lang="en-US" id="id_10515943_3114712_2_1">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedInterest" xlink:to="mgtx_AccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" xml:lang="en-US" id="id_10515943_3123754_3_1">Accrued Liabilities Accrued Compensation And Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" xml:lang="en-US" id="id_10515943_3123754_1_1">Accrued Liabilities Accrued Compensation And Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl" xml:lang="en-US" id="id_10515943_3123754_2_1">Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:to="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3063365_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3063365_2_1">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3063365_6_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_10515943_3063780_1_1">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="id_10515943_3063780_2_1">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US" id="id_10515943_3064002_1_1">Accrued Rent, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US" id="id_10515943_3064002_2_1">Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedTravelExpense" xlink:label="mgtx_AccruedTravelExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AccruedTravelExpense_lbl" xml:lang="en-US" id="id_10515943_3145341_3_1">Accrued travel expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AccruedTravelExpense_lbl" xml:lang="en-US" id="id_10515943_3145341_1_1">Accrued Travel Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AccruedTravelExpense_lbl" xml:lang="en-US" id="id_10515943_3145341_2_1">Travel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AccruedTravelExpense" xlink:to="mgtx_AccruedTravelExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3064026_1_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3064026_2_1">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_10515943_3064029_1_1">AOCI Attributable to Parent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="id_10515943_3064029_2_1">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_10515943_3063807_1_1">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_10515943_3063807_2_1">Capital in excess of nominal value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_10515943_3063589_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_10515943_3063589_2_1">Capital in Excess of Nominal Value [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3146164_3_1">Adjusted Net Income Loss Available To Common Stockholders Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3146164_1_1">Adjusted Net Income Loss Available To Common Stockholders Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3146164_6_1">Adjusted net loss-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:to="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_10515943_3063818_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation and Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_10515943_3063818_2_1">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US" id="id_10515943_3063818_12_1">Exercise of warrants liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3064049_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3064049_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_10515943_3063435_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_10515943_3063435_2_1">Total share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_10515943_3063668_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_10515943_3063668_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AmortizationOfInterestOnAssetRetirementObligation" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3395537_3_1">Amortization of interest on asset retirement obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3395537_1_1">Amortization of Interest on Asset Retirement Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3395537_2_1">Amortization of interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3395537_12_1">Amortization of interest on asset retirement obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AmortizationOfInterestOnAssetRetirementObligation" xlink:to="mgtx_AmortizationOfInterestOnAssetRetirementObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AnnualBaseRentAndOperatingExpense" xlink:label="mgtx_AnnualBaseRentAndOperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AnnualBaseRentAndOperatingExpense_lbl" xml:lang="en-US" id="id_10515943_3396761_3_1">Annual base rent and operating expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AnnualBaseRentAndOperatingExpense_lbl" xml:lang="en-US" id="id_10515943_3396761_1_1">Annual Base Rent and Operating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AnnualBaseRentAndOperatingExpense_lbl" xml:lang="en-US" id="id_10515943_3396761_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AnnualBaseRentAndOperatingExpense" xlink:to="mgtx_AnnualBaseRentAndOperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AnnualMaintenanceFee" xlink:label="mgtx_AnnualMaintenanceFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_AnnualMaintenanceFee_lbl" xml:lang="en-US" id="id_10515943_3164895_3_1">Annual maintenance fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_AnnualMaintenanceFee_lbl" xml:lang="en-US" id="id_10515943_3164895_1_1">Annual Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_AnnualMaintenanceFee_lbl" xml:lang="en-US" id="id_10515943_3164895_2_1">Annual maintenance fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_AnnualMaintenanceFee" xlink:to="mgtx_AnnualMaintenanceFee_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_10515943_3063481_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_10515943_3063481_2_1">Antidilutive securities excluded from computation of earning per share, amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_10515943_3064118_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_10515943_3064118_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_10515943_3063684_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_10515943_3063684_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_10515943_3064119_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_10515943_3064119_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_10515943_3063890_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_10515943_3063890_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3063898_1_1">Asset Retirement Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3063898_4_1">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AssetRetirementObligation_lbl" xml:lang="en-US" id="id_10515943_3063898_5_1">Balance at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligation" xlink:to="us-gaap_AssetRetirementObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationAbstract" xlink:label="us-gaap_AssetRetirementObligationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationAbstract_lbl" xml:lang="en-US" id="id_10515943_3063899_1_1">Asset Retirement Obligation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationAbstract_lbl" xml:lang="en-US" id="id_10515943_3063899_2_1">Asset Retirement Obligation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US" id="id_10515943_3063902_1_1">Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_lbl" xml:lang="en-US" id="id_10515943_3063902_2_1">Effects of exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl" xml:lang="en-US" id="id_10515943_3063497_1_1">Asset Retirement Obligation, Revision of Estimate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl" xml:lang="en-US" id="id_10515943_3063497_2_1">Change in estimate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:to="us-gaap_AssetRetirementObligationRevisionOfEstimate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:label="us-gaap_AssetRetirementObligationsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xml:lang="en-US" id="id_10515943_3063500_1_1">Asset Retirement Obligation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetRetirementObligationsPolicy_lbl" xml:lang="en-US" id="id_10515943_3063500_2_1">Asset Retirement Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetRetirementObligationsPolicy" xlink:to="us-gaap_AssetRetirementObligationsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_10515943_3064141_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_10515943_3064141_6_1">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_10515943_3063501_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_10515943_3063501_2_1">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_10515943_3063503_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_10515943_3063503_6_1">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_10515943_3064144_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_10515943_3064144_2_1">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3064218_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3064218_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_BaseRentAndManagementFees" xlink:label="mgtx_BaseRentAndManagementFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_BaseRentAndManagementFees_lbl" xml:lang="en-US" id="id_10515943_3395662_3_1">Base rent and management fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_BaseRentAndManagementFees_lbl" xml:lang="en-US" id="id_10515943_3395662_1_1">Base Rent and Management Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_BaseRentAndManagementFees_lbl" xml:lang="en-US" id="id_10515943_3395662_2_1">Base rent and management fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_BaseRentAndManagementFees" xlink:to="mgtx_BaseRentAndManagementFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3064678_1_1">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3064678_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_10515943_3064343_1_1">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_10515943_3064343_2_1">Organization and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="id_10515943_3064590_1_1">Capital Lease Obligations, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="id_10515943_3064590_2_1">Capitalized lease obligation-current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" id="id_10515943_3064795_1_1">Capital Lease Obligations Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US" id="id_10515943_3064795_2_1">Capitalized lease obligation for equipment purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3064591_1_1">Capital Lease Obligations, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3064591_2_1">Capitalized lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10515943_3065278_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_10515943_3065278_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="id_10515943_3065291_1_1">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="id_10515943_3065291_4_1">Cash, cash equivalents and restricted cash at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="id_10515943_3065291_5_1">Cash, cash equivalents and restricted cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="id_10515943_3065292_1_1">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="id_10515943_3065292_6_1">Net increase (decrease) in cash, cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClasscPreferredStockMember" xlink:label="mgtx_ClasscPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClasscPreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3264360_3_1">Classc Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClasscPreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3264360_1_1">Classc Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClasscPreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3264360_2_1">Preferred C Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClasscPreferredStockMember" xlink:to="mgtx_ClasscPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_10515943_3065156_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_10515943_3065156_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" id="id_10515943_3206606_3_1">Class of warrant or right exercised during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" id="id_10515943_3206606_1_1">Class Of Warrant Or Right Exercised During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" id="id_10515943_3206606_2_1">Exercise of warrants, Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" id="id_10515943_3206606_12_1">Preferred shares, purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue_lbl" xml:lang="en-US" id="id_10515943_3145192_3_1">Class of warrant or right exercised during period value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue_lbl" xml:lang="en-US" id="id_10515943_3145192_1_1">Class of Warrant or Right Exercised During Period Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue_lbl" xml:lang="en-US" id="id_10515943_3145192_2_1">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_10515943_3065157_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_10515943_3065157_2_1">Preferred shares, exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_10515943_3065406_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_10515943_3065406_2_1">COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" id="id_10515943_3065411_1_1">Common Class A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" id="id_10515943_3065411_2_1">A Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10515943_3065857_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_10515943_3065857_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_10515943_3065859_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_10515943_3065859_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3065417_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3065417_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_10515943_3065862_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_10515943_3065862_2_1">A Ordinary Shares, $0.00003881 nominal value 27,184,132 issued and outstanding at June 30, 2018 8,826,190 issued and 8,714,563 issued and outstanding at December 31, 2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3065872_1_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3065872_6_1">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3066117_1_1">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3066117_2_1">Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ConsultantMember" xlink:label="mgtx_ConsultantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ConsultantMember_lbl" xml:lang="en-US" id="id_10515943_3265585_3_1">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ConsultantMember_lbl" xml:lang="en-US" id="id_10515943_3265585_1_1">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ConsultantMember_lbl" xml:lang="en-US" id="id_10515943_3265585_2_1">Consultant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ConsultantMember" xlink:to="mgtx_ConsultantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" id="id_10515943_3065952_1_1">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" id="id_10515943_3065952_2_1">Conversion of convertible preferred C shares into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3066342_1_1">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3066342_2_1">Convertible Preferred C Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_10515943_3066670_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_10515943_3066670_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DecemberTwoThousandSixteenLeaseMember" xlink:label="mgtx_DecemberTwoThousandSixteenLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_DecemberTwoThousandSixteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3395664_3_1">December two thousand sixteen lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_DecemberTwoThousandSixteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3395664_1_1">December Two Thousand Sixteen Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_DecemberTwoThousandSixteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3395664_2_1">December 2016 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_DecemberTwoThousandSixteenLeaseMember" xlink:to="mgtx_DecemberTwoThousandSixteenLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DeferredRent" xlink:label="mgtx_DeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_DeferredRent_lbl" xml:lang="en-US" id="id_10515943_3184119_3_1">Deferred rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_DeferredRent_lbl" xml:lang="en-US" id="id_10515943_3184119_1_1">Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_DeferredRent_lbl" xml:lang="en-US" id="id_10515943_3184119_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_DeferredRent" xlink:to="mgtx_DeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3067063_1_1">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3067063_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_10515943_3067617_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_10515943_3067617_2_1">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DescriptionOfBusinessPolicyPolicyTextBlock" xlink:label="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3345095_3_1">Description Of Business Policy Policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3345095_1_1">Description Of Business Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3345095_2_1">The Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock" xlink:to="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_10515943_3068434_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_10515943_3068434_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_10515943_3067742_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_10515943_3067742_2_1">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" id="id_10515943_3068437_1_1">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" id="id_10515943_3068437_2_1">Schedule of Grant Date Fair Values of the Stock Option Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DocumentAndEntityInformationAbstract" xlink:label="mgtx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_10515943_3085999_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_10515943_3085999_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_10515943_3085999_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="mgtx_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_10515943_3067826_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_10515943_3067826_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_10515943_3067827_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_10515943_3067827_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_10515943_3069166_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_10515943_3069166_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_10515943_3067831_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_10515943_3067831_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3068231_1_1">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3068231_2_1">Amount due under services agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3068231_12_1">Due to Kadmon</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3068499_1_1">Due to Related Parties, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3068499_2_1">Future obligations under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_10515943_3069192_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_10515943_3069192_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3068242_1_1">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3068242_2_1">Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3068242_12_1">Basic and diluted net loss per ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" id="id_10515943_3068503_1_1">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" id="id_10515943_3068503_2_1">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3068509_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3068509_2_1">Net Loss per Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_10515943_3068250_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_10515943_3068250_2_1">Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="id_10515943_3068791_1_1">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="id_10515943_3068791_2_1">Effect of exchange rate changes on cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeAndBoardOfDirectorsMember" xlink:label="mgtx_EmployeeAndBoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_EmployeeAndBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_10515943_3395600_3_1">Employee and Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_EmployeeAndBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_10515943_3395600_1_1">Employee and Board of Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_EmployeeAndBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_10515943_3395600_2_1">Employee and Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_EmployeeAndBoardOfDirectorsMember" xlink:to="mgtx_EmployeeAndBoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" xlink:label="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_10515943_3395613_3_1">Employee and non employee board of directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_10515943_3395613_1_1">Employee And Non Employee Board Of Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_10515943_3395613_2_1">Employee and Non Employee Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" xlink:to="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeMember" xlink:label="mgtx_EmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_EmployeeMember_lbl" xml:lang="en-US" id="id_10515943_3329283_3_1">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_EmployeeMember_lbl" xml:lang="en-US" id="id_10515943_3329283_1_1">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_EmployeeMember_lbl" xml:lang="en-US" id="id_10515943_3329283_2_1">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_EmployeeMember" xlink:to="mgtx_EmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_10515943_3068967_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_10515943_3068967_2_1">Unvested options expected to be realized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_10515943_3069258_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_10515943_3069258_2_1">Total unvested options compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_10515943_3069261_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_10515943_3069261_2_1">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_10515943_3068584_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_10515943_3068584_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3069289_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3069289_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_10515943_3069296_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_10515943_3069296_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_10515943_3069005_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_10515943_3069005_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_10515943_3069019_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_10515943_3069019_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_lbl" xml:lang="en-US" id="id_10515943_3068914_1_1">Excess Tax Benefit from Share-based Compensation, Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_lbl" xml:lang="en-US" id="id_10515943_3068914_2_1">Excess Tax Benefit from Share-based Compensation, Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_lbl" xml:lang="en-US" id="id_10515943_3069065_1_1">Excess Tax Benefit from Share-based Compensation, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_lbl" xml:lang="en-US" id="id_10515943_3069065_2_1">Excess Tax Benefit from Share-based Compensation, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US" id="id_10515943_3069085_1_1">Extinguishment of Debt [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US" id="id_10515943_3069085_2_1">Extinguishment of Debt [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xml:lang="en-US" id="id_10515943_3068671_1_1">Extinguishment of Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xml:lang="en-US" id="id_10515943_3068671_2_1">Extinguishment of Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3069602_1_1">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3069602_2_1">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3069602_12_1">Change in fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3069602_14_1">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_10515943_3068681_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_10515943_3068681_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_10515943_3068682_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_10515943_3068682_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" id="id_10515943_3068683_1_1">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" id="id_10515943_3068683_2_1">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" id="id_10515943_3069604_1_1">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" id="id_10515943_3069604_2_1">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3070044_1_1">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3070044_2_1">Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_10515943_3069095_1_1">Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_10515943_3069095_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_10515943_3069097_1_1">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_10515943_3069097_2_1">Compnay's Financial Assets and Liabilities Measured at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_10515943_3069102_1_1">Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_10515943_3069102_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_10515943_3068684_1_1">Fair Value Hierarchy and NAV [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_10515943_3068684_2_1">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_10515943_3070059_1_1">Measurement Frequency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="id_10515943_3070059_2_1">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_10515943_3069635_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_10515943_3069635_2_1">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_10515943_3069375_1_1">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_10515943_3069375_2_1">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_10515943_3070122_1_1">Fair Value, Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="id_10515943_3070122_2_1">Fair Value, Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3069668_1_1">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3069668_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_10515943_3069403_1_1">Fair Value Hierarchy and NAV [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_10515943_3069403_2_1">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_10515943_3069669_1_1">Fair Value, Measurements, Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="id_10515943_3069669_2_1">Fair Value, Measurements, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US" id="id_10515943_3070141_1_1">Fair Value, Net Asset (Liability)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US" id="id_10515943_3070141_2_1">Fair value, net asset (liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FairValueNetAssetLiabilityBeginningBalance" xlink:label="mgtx_FairValueNetAssetLiabilityBeginningBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FairValueNetAssetLiabilityBeginningBalance_lbl" xml:lang="en-US" id="id_10515943_3395585_3_1">Fair value net asset liability beginning balance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FairValueNetAssetLiabilityBeginningBalance_lbl" xml:lang="en-US" id="id_10515943_3395585_1_1">Fair Value Net Asset Liability Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FairValueNetAssetLiabilityBeginningBalance_lbl" xml:lang="en-US" id="id_10515943_3395585_2_1">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FairValueNetAssetLiabilityBeginningBalance" xlink:to="mgtx_FairValueNetAssetLiabilityBeginningBalance_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FairValueNetAssetLiabilityEndingBalance" xlink:label="mgtx_FairValueNetAssetLiabilityEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FairValueNetAssetLiabilityEndingBalance_lbl" xml:lang="en-US" id="id_10515943_3395586_3_1">Fair value net asset liability ending balance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FairValueNetAssetLiabilityEndingBalance_lbl" xml:lang="en-US" id="id_10515943_3395586_1_1">Fair Value Net Asset Liability Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FairValueNetAssetLiabilityEndingBalance_lbl" xml:lang="en-US" id="id_10515943_3395586_2_1">Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FairValueNetAssetLiabilityEndingBalance" xlink:to="mgtx_FairValueNetAssetLiabilityEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US" id="id_10515943_3070146_1_1">Fair Value of Assets Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US" id="id_10515943_3070146_2_1">Fixed asset acquisition included in accounts payable and accrued expenses at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="us-gaap_FederalHomeLoanBanksAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalHomeLoanBanksAbstract_lbl" xml:lang="en-US" id="id_10515943_3069758_1_1">Federal Home Loan Banks [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalHomeLoanBanksAbstract_lbl" xml:lang="en-US" id="id_10515943_3069758_2_1">Federal Home Loan Banks [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalHomeLoanBanksAbstract" xlink:to="us-gaap_FederalHomeLoanBanksAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FirstAnniversaryMember" xlink:label="mgtx_FirstAnniversaryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_FirstAnniversaryMember_lbl" xml:lang="en-US" id="id_10515943_3299846_3_1">First Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_FirstAnniversaryMember_lbl" xml:lang="en-US" id="id_10515943_3299846_1_1">First Anniversary [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_FirstAnniversaryMember_lbl" xml:lang="en-US" id="id_10515943_3299846_2_1">First Anniversary [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_FirstAnniversaryMember" xlink:to="mgtx_FirstAnniversaryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="id_10515943_3070707_1_1">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="id_10515943_3070707_2_1">Foreign currency (loss) gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" id="id_10515943_3070707_14_1">Foreign currency loss (gain)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="country_GB"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl" xml:lang="en-US" id="id_10515943_3070630_1_1">UNITED KINGDOM</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_GB_lbl" xml:lang="en-US" id="id_10515943_3070630_2_1">United Kingdom</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_10515943_3071073_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_10515943_3071073_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3070631_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3070631_2_1">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_10515943_3071185_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_10515943_3071185_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_10515943_3071648_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_10515943_3071648_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_10515943_3071649_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_10515943_3071649_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_10515943_3071190_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_10515943_3071190_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3071466_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3071466_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10515943_3071193_1_1">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_10515943_3071193_2_1">Provision for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_10515943_3071214_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_10515943_3071214_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_10515943_3071935_1_1">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_10515943_3071935_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" id="id_10515943_3071227_1_1">Increase (Decrease) in Deferred Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" id="id_10515943_3071227_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties_lbl" xml:lang="en-US" id="id_10515943_3395553_3_1">Increase (decrease) in due to and from related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties_lbl" xml:lang="en-US" id="id_10515943_3395553_1_1">Increase (Decrease) in Due to and from Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties_lbl" xml:lang="en-US" id="id_10515943_3395553_2_1">Due to Kadmon</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" xlink:to="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" id="id_10515943_3071254_1_1">Increase (Decrease) in Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US" id="id_10515943_3071254_2_1">Decrease (increase) in operating assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3071255_1_1">Increase (Decrease) in Operating Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3071255_2_1">Increase (decrease) in operating liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" id="id_10515943_3071257_1_1">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US" id="id_10515943_3071257_14_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" id="id_10515943_3072199_1_1">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" id="id_10515943_3072199_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_10515943_3071267_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_10515943_3071267_14_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_10515943_3071986_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_10515943_3071986_2_1">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_10515943_3071986_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="id_10515943_3072747_1_1">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="id_10515943_3072747_2_1">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_InterimFinancialStatementsPolicyTextBlock" xlink:label="mgtx_InterimFinancialStatementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_InterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3343555_3_1">Interim Financial Statements Policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_InterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3343555_1_1">Interim Financial Statements Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_InterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3343555_2_1">Interim Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_InterimFinancialStatementsPolicyTextBlock" xlink:to="mgtx_InterimFinancialStatementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_10515943_3073036_1_1">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_10515943_3073036_2_1">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_10515943_3073300_1_1">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_10515943_3073300_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" xlink:label="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3396760_3_1">July twenty seven two thousand eighteen lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3396760_1_1">July Twenty Seven Two Thousand Eighteen Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3396760_2_1">July 27, 2018 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" xlink:to="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_JulyTwoThousandsSixteenLeaseMember" xlink:label="mgtx_JulyTwoThousandsSixteenLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_JulyTwoThousandsSixteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3395655_3_1">July two thousands sixteen lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_JulyTwoThousandsSixteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3395655_1_1">July Two Thousands Sixteen Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_JulyTwoThousandsSixteenLeaseMember_lbl" xml:lang="en-US" id="id_10515943_3395655_2_1">July 2016 Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_JulyTwoThousandsSixteenLeaseMember" xlink:to="mgtx_JulyTwoThousandsSixteenLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_KadmonMember" xlink:label="mgtx_KadmonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_KadmonMember_lbl" xml:lang="en-US" id="id_10515943_3395534_3_1">Kadmon [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_KadmonMember_lbl" xml:lang="en-US" id="id_10515943_3395534_1_1">Kadmon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_KadmonMember_lbl" xml:lang="en-US" id="id_10515943_3395534_2_1">Kadmon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_KadmonMember" xlink:to="mgtx_KadmonMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3073336_1_1">Lease Arrangement, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3073336_2_1">Lease Arrangement, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" id="id_10515943_3073565_1_1">Lease Arrangement, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" id="id_10515943_3073565_2_1">Lease Arrangement, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_10515943_3073339_1_1">Lease Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_10515943_3073339_2_1">Operating lease expiration date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_10515943_3073339_12_1">Operating lease termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LeaseTerminationDate" xlink:label="mgtx_LeaseTerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_LeaseTerminationDate_lbl" xml:lang="en-US" id="id_10515943_3234567_3_1">Lease termination date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_LeaseTerminationDate_lbl" xml:lang="en-US" id="id_10515943_3234567_1_1">Lease Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_LeaseTerminationDate_lbl" xml:lang="en-US" id="id_10515943_3234567_2_1">Operating lease termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_LeaseTerminationDate" xlink:to="mgtx_LeaseTerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US" id="id_10515943_3073151_1_1">Lessee, Operating Lease, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US" id="id_10515943_3073151_2_1">Operating leases rent expense payment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" id="id_10515943_3073194_1_1">Letters of Credit Outstanding, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" id="id_10515943_3073194_2_1">Letter of credit outstanding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_10515943_3073419_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_10515943_3073419_6_1">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_10515943_3073420_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_10515943_3073420_6_1">TOTAL LIABILITIES, CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10515943_3073204_1_1">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10515943_3073204_2_1">LIABILITIES, CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3072894_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3072894_6_1">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_10515943_3073422_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_10515943_3073422_2_1">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3331058_3_1">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3331058_1_1">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_LicenseAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3331058_2_1">License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_LicenseAgreementMember" xlink:to="mgtx_LicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LiquidityPolicyTextBlock" xlink:label="mgtx_LiquidityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_LiquidityPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3343053_3_1">Liquidity [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_LiquidityPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3343053_1_1">Liquidity [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_LiquidityPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3343053_2_1">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_LiquidityPolicyTextBlock" xlink:to="mgtx_LiquidityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3074051_1_1">Long-lived Assets by Geographic Areas [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3074051_2_1">Summary of Non-Current Assets by Geographical Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ManufacturingAgreementMember" xlink:label="mgtx_ManufacturingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ManufacturingAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3326238_3_1">Manufacturing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ManufacturingAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3326238_1_1">Manufacturing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ManufacturingAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3326238_2_1">Manufacturing Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ManufacturingAgreementMember" xlink:to="mgtx_ManufacturingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" id="id_10515943_3074821_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" id="id_10515943_3074821_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" id="id_10515943_3075282_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" id="id_10515943_3075282_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_10515943_3075138_1_1">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_10515943_3075138_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3075384_1_1">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3075384_2_1">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_10515943_3074968_1_1">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_10515943_3074968_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3075386_1_1">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3075386_2_1">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_10515943_3075387_1_1">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_10515943_3075387_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3074970_1_1">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_10515943_3074970_2_1">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10515943_3075391_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10515943_3075391_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10515943_3075391_6_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_10515943_3075391_12_1">Net loss-basic and diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_10515943_3074619_1_1">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_10515943_3074619_6_1">Adjusted net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3074638_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3074638_2_1">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_10515943_3075423_1_1">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_10515943_3075423_2_1">Supplemental disclosure of non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NoncashOrPartNoncashStockIssuanceCosts" xlink:label="mgtx_NoncashOrPartNoncashStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NoncashOrPartNoncashStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3100491_3_1">Non-cash or part non-cash stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NoncashOrPartNoncashStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3100491_1_1">Noncash or Part Noncash Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NoncashOrPartNoncashStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3100491_2_1">Issuance costs in connection with sale of convertible preferred C shares included in accrued expenses at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NoncashOrPartNoncashStockIssuanceCosts" xlink:to="mgtx_NoncashOrPartNoncashStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US" id="id_10515943_3076083_1_1">Long-Lived Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US" id="id_10515943_3076083_2_1">Non current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NonemployeeConsultantsMember" xlink:label="mgtx_NonemployeeConsultantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NonemployeeConsultantsMember_lbl" xml:lang="en-US" id="id_10515943_3324986_3_1">Nonemployee Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NonemployeeConsultantsMember_lbl" xml:lang="en-US" id="id_10515943_3324986_1_1">Nonemployee Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NonemployeeConsultantsMember_lbl" xml:lang="en-US" id="id_10515943_3324986_2_1">Non-employee consultants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NonemployeeConsultantsMember" xlink:to="mgtx_NonemployeeConsultantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NonemployeeMember" xlink:label="mgtx_NonemployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NonemployeeMember_lbl" xml:lang="en-US" id="id_10515943_3297706_3_1">Non Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NonemployeeMember_lbl" xml:lang="en-US" id="id_10515943_3297706_1_1">Nonemployee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NonemployeeMember_lbl" xml:lang="en-US" id="id_10515943_3297706_2_1">Non Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NonemployeeMember" xlink:to="mgtx_NonemployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" id="id_10515943_3074687_1_1">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US" id="id_10515943_3074687_2_1">Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfLeasesTerminated" xlink:label="mgtx_NumberOfLeasesTerminated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NumberOfLeasesTerminated_lbl" xml:lang="en-US" id="id_10515943_3218592_3_1">Number Of Leases Terminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NumberOfLeasesTerminated_lbl" xml:lang="en-US" id="id_10515943_3218592_1_1">Number Of Leases Terminated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NumberOfLeasesTerminated_lbl" xml:lang="en-US" id="id_10515943_3218592_2_1">Number of leases expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NumberOfLeasesTerminated" xlink:to="mgtx_NumberOfLeasesTerminated_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfNewFacilityLeases" xlink:label="mgtx_NumberOfNewFacilityLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NumberOfNewFacilityLeases_lbl" xml:lang="en-US" id="id_10515943_3219478_3_1">Number Of New Facility Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NumberOfNewFacilityLeases_lbl" xml:lang="en-US" id="id_10515943_3219478_1_1">Number Of New Facility Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NumberOfNewFacilityLeases_lbl" xml:lang="en-US" id="id_10515943_3219478_2_1">Number of new leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NumberOfNewFacilityLeases" xlink:to="mgtx_NumberOfNewFacilityLeases_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfPrograms" xlink:label="mgtx_NumberOfPrograms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_10515943_3219725_3_1">Number of programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_10515943_3219725_1_1">Number Of Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_10515943_3219725_2_1">Number of programs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_NumberOfPrograms" xlink:to="mgtx_NumberOfPrograms_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_10515943_3075924_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_10515943_3075924_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_10515943_3075761_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_10515943_3075761_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_10515943_3076165_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_10515943_3076165_2_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_10515943_3075932_1_1">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_10515943_3075932_2_1">Aggregate future minimum rental payments under operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_10515943_3076187_1_1">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_10515943_3076187_2_1">Operating lease rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OperationByGeographicalLineItems" xlink:label="mgtx_OperationByGeographicalLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OperationByGeographicalLineItems_lbl" xml:lang="en-US" id="id_10515943_3092425_3_1">Operation By Geographical [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OperationByGeographicalLineItems_lbl" xml:lang="en-US" id="id_10515943_3092425_1_1">Operation By Geographical [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OperationByGeographicalLineItems_lbl" xml:lang="en-US" id="id_10515943_3092425_2_1">Operation By Geographical [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OperationByGeographicalLineItems" xlink:to="mgtx_OperationByGeographicalLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OperationByGeographicalTable" xlink:label="mgtx_OperationByGeographicalTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OperationByGeographicalTable_lbl" xml:lang="en-US" id="id_10515943_3238995_3_1">Operation By Geographical [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OperationByGeographicalTable_lbl" xml:lang="en-US" id="id_10515943_3238995_1_1">Operation By Geographical [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OperationByGeographicalTable_lbl" xml:lang="en-US" id="id_10515943_3238995_2_1">Operation By Geographical [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OperationByGeographicalTable" xlink:to="mgtx_OperationByGeographicalTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OrganizationAndNatureOfBusinessTextualAbstract" xlink:label="mgtx_OrganizationAndNatureOfBusinessTextualAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OrganizationAndNatureOfBusinessTextualAbstract_lbl" xml:lang="en-US" id="id_10515943_3085951_3_1">Organization And Nature Of Business Textual [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OrganizationAndNatureOfBusinessTextualAbstract_lbl" xml:lang="en-US" id="id_10515943_3085951_1_1">Organization And Nature Of Business Textual [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OrganizationAndNatureOfBusinessTextualAbstract_lbl" xml:lang="en-US" id="id_10515943_3085951_2_1">Organization And Nature Of Business Textual [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OrganizationAndNatureOfBusinessTextualAbstract" xlink:to="mgtx_OrganizationAndNatureOfBusinessTextualAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3075431_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_10515943_3075431_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_10515943_3075435_1_1">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_10515943_3075435_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3075849_1_1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3075849_2_1">Foreign currency translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3075476_1_1">Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="id_10515943_3075476_2_1">Other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3076709_1_1">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="id_10515943_3076709_2_1">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="id_10515943_3076547_1_1">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="id_10515943_3076547_2_1">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_10515943_3075550_1_1">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_10515943_3075550_2_1">Other non-operating income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OverThreeYearsMember" xlink:label="mgtx_OverThreeYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_OverThreeYearsMember_lbl" xml:lang="en-US" id="id_10515943_3395607_3_1">Over Three Years Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_OverThreeYearsMember_lbl" xml:lang="en-US" id="id_10515943_3395607_1_1">Over Three Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_OverThreeYearsMember_lbl" xml:lang="en-US" id="id_10515943_3395607_2_1">Over Three Years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_OverThreeYearsMember" xlink:to="mgtx_OverThreeYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_10515943_3076645_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_10515943_3076645_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PaymentsInLieuMember" xlink:label="mgtx_PaymentsInLieuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PaymentsInLieuMember_lbl" xml:lang="en-US" id="id_10515943_3274559_3_1">Payments In Lieu [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PaymentsInLieuMember_lbl" xml:lang="en-US" id="id_10515943_3274559_1_1">Payments In Lieu [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PaymentsInLieuMember_lbl" xml:lang="en-US" id="id_10515943_3274559_2_1">Payments In Lieu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PaymentsInLieuMember" xlink:to="mgtx_PaymentsInLieuMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3077083_1_1">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3077083_2_1">Offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3077083_12_1">Sale of A ordinary shares in initial public offering, issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_10515943_3077083_14_1">Issuance costs in connection with shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_10515943_3076865_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_10515943_3076865_14_1">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PaymentToRelatedParty" xlink:label="mgtx_PaymentToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PaymentToRelatedParty_lbl" xml:lang="en-US" id="id_10515943_3167954_3_1">Payment To Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PaymentToRelatedParty_lbl" xml:lang="en-US" id="id_10515943_3167954_1_1">Payment To Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PaymentToRelatedParty_lbl" xml:lang="en-US" id="id_10515943_3167954_2_1">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PaymentToRelatedParty" xlink:to="mgtx_PaymentToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PeriodOfAgreement" xlink:label="mgtx_PeriodOfAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PeriodOfAgreement_lbl" xml:lang="en-US" id="id_10515943_3231401_3_1">Period Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PeriodOfAgreement_lbl" xml:lang="en-US" id="id_10515943_3231401_1_1">Period Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PeriodOfAgreement_lbl" xml:lang="en-US" id="id_10515943_3231401_2_1">Services agreement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PeriodOfAgreement" xlink:to="mgtx_PeriodOfAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_10515943_3138618_3_1">Potential milestone payments upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_10515943_3138618_1_1">Potential Milestone Payments Upon Achievement Of Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_10515943_3138618_2_1">Potential milestone payment upon achievement of milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:to="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement_lbl" xml:lang="en-US" id="id_10515943_3395552_3_1">Preferred C shares issued in connection with license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement_lbl" xml:lang="en-US" id="id_10515943_3395552_1_1">Preferred C Shares Issued in Connection with License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement_lbl" xml:lang="en-US" id="id_10515943_3395552_2_1">Preferred C shares issued in connection with a license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" xlink:to="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3076421_1_1">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="id_10515943_3076421_2_1">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_10515943_3076444_1_1">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_10515943_3076444_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_10515943_3077690_1_1">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_10515943_3077690_2_1">Proceeds from issuance initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" id="id_10515943_3105535_3_1">Proceeds From Issuance Initial Public Offering Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" id="id_10515943_3105535_1_1">Proceeds From Issuance Initial Public Offering Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" id="id_10515943_3105535_2_1">Proceeds from issuance initial public offering net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:to="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_10515943_3077144_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_10515943_3077144_2_1">Proceeds from the sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_10515943_3077897_1_1">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_10515943_3077897_2_1">Gross proceeds from preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_10515943_3077897_12_1">Proceeds from the sale of convertible preferred C shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_10515943_3077922_1_1">Proceeds from (Repayments of) Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_10515943_3077922_2_1">Issuance of long-term note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="id_10515943_3077956_1_1">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="id_10515943_3077956_2_1">Exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" id="id_10515943_3077956_12_1">Preferred shares, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNoteIssued" xlink:label="mgtx_PromissoryNoteIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PromissoryNoteIssued_lbl" xml:lang="en-US" id="id_10515943_3153799_3_1">Promissory note issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PromissoryNoteIssued_lbl" xml:lang="en-US" id="id_10515943_3153799_1_1">Promissory Note Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PromissoryNoteIssued_lbl" xml:lang="en-US" id="id_10515943_3153799_2_1">Promissory note issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PromissoryNoteIssued" xlink:to="mgtx_PromissoryNoteIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNotesInterestRate" xlink:label="mgtx_PromissoryNotesInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PromissoryNotesInterestRate_lbl" xml:lang="en-US" id="id_10515943_3369060_3_1">Promissory notes interest rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PromissoryNotesInterestRate_lbl" xml:lang="en-US" id="id_10515943_3369060_1_1">Promissory Notes Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PromissoryNotesInterestRate_lbl" xml:lang="en-US" id="id_10515943_3369060_2_1">Promissory note rate of interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PromissoryNotesInterestRate" xlink:to="mgtx_PromissoryNotesInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNotesRepaymentDueDate" xlink:label="mgtx_PromissoryNotesRepaymentDueDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_PromissoryNotesRepaymentDueDate_lbl" xml:lang="en-US" id="id_10515943_3213248_3_1">Promissory notes repayment due date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_PromissoryNotesRepaymentDueDate_lbl" xml:lang="en-US" id="id_10515943_3213248_1_1">Promissory Notes Repayment Due Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_PromissoryNotesRepaymentDueDate_lbl" xml:lang="en-US" id="id_10515943_3213248_2_1">Promissory note expiration due date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_PromissoryNotesRepaymentDueDate" xlink:to="mgtx_PromissoryNotesRepaymentDueDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_10515943_3077229_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_10515943_3077229_2_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" id="id_10515943_3078512_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" id="id_10515943_3078512_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" id="id_10515943_3077288_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" id="id_10515943_3077288_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="mgtx_ReclassificationOfWarrantLiabilityUponExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ReclassificationOfWarrantLiabilityUponExercise_lbl" xml:lang="en-US" id="id_10515943_3125431_3_1">Reclassification of warrant liability upon exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ReclassificationOfWarrantLiabilityUponExercise_lbl" xml:lang="en-US" id="id_10515943_3125431_1_1">Reclassification Of Warrant Liability Upon Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ReclassificationOfWarrantLiabilityUponExercise_lbl" xml:lang="en-US" id="id_10515943_3125431_2_1">Reclassification of warrant liability upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ReclassificationOfWarrantLiabilityUponExercise" xlink:to="mgtx_ReclassificationOfWarrantLiabilityUponExercise_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyAdministrativeExpensePercentage" xlink:label="mgtx_RelatedPartyAdministrativeExpensePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyAdministrativeExpensePercentage_lbl" xml:lang="en-US" id="id_10515943_3395637_3_1">Related party administrative expense percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyAdministrativeExpensePercentage_lbl" xml:lang="en-US" id="id_10515943_3395637_1_1">Related Party Administrative Expense Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyAdministrativeExpensePercentage_lbl" xml:lang="en-US" id="id_10515943_3395637_2_1">Percentage of administrative fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyAdministrativeExpensePercentage" xlink:to="mgtx_RelatedPartyAdministrativeExpensePercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_10515943_3078036_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_10515943_3078036_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyOtherExpenseMember" xlink:label="mgtx_RelatedPartyOtherExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyOtherExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395635_3_1">Related party other expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyOtherExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395635_1_1">Related Party Other Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyOtherExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395635_2_1">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyOtherExpenseMember" xlink:to="mgtx_RelatedPartyOtherExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyPersonnelExpenseMember" xlink:label="mgtx_RelatedPartyPersonnelExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyPersonnelExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395634_3_1">Related party personnel expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyPersonnelExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395634_1_1">Related Party Personnel Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyPersonnelExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395634_2_1">Personnel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyPersonnelExpenseMember" xlink:to="mgtx_RelatedPartyPersonnelExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyRentExpenseMember" xlink:label="mgtx_RelatedPartyRentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyRentExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395633_3_1">Related party rent expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyRentExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395633_1_1">Related Party Rent Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyRentExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3395633_2_1">Rent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyRentExpenseMember" xlink:to="mgtx_RelatedPartyRentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyTransactionAgreementNoticePeriod" xlink:label="mgtx_RelatedPartyTransactionAgreementNoticePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyTransactionAgreementNoticePeriod_lbl" xml:lang="en-US" id="id_10515943_3395648_3_1">Related party transaction agreement notice period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyTransactionAgreementNoticePeriod_lbl" xml:lang="en-US" id="id_10515943_3395648_1_1">Related Party Transaction Agreement Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyTransactionAgreementNoticePeriod_lbl" xml:lang="en-US" id="id_10515943_3395648_2_1">Agreement termination notice period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyTransactionAgreementNoticePeriod" xlink:to="mgtx_RelatedPartyTransactionAgreementNoticePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyTransactionAgreementTerminationDate" xlink:label="mgtx_RelatedPartyTransactionAgreementTerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RelatedPartyTransactionAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10515943_3395649_3_1">Related party transaction agreement termination date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RelatedPartyTransactionAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10515943_3395649_1_1">Related Party Transaction Agreement Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RelatedPartyTransactionAgreementTerminationDate_lbl" xml:lang="en-US" id="id_10515943_3395649_2_1">Agreement termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RelatedPartyTransactionAgreementTerminationDate" xlink:to="mgtx_RelatedPartyTransactionAgreementTerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_10515943_3078813_1_1">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_10515943_3078813_2_1">Related party transaction amounts of work orders issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_10515943_3078813_12_1">Total charges incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_10515943_3078040_1_1">Related Party Transaction [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="id_10515943_3078040_2_1">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_10515943_3078043_1_1">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="id_10515943_3078043_2_1">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_10515943_3079109_1_1">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="id_10515943_3079109_2_1">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_10515943_3078816_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_10515943_3078816_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_10515943_3078046_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_10515943_3078046_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078623_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078623_2_1">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock" xlink:label="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3347150_3_1">Reorganization And Initial Public Offering Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3347150_1_1">Reorganization And Initial Public Offering Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3347150_2_1">Reorganization and Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock" xlink:to="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RepaymentOfPromissoryNotes" xlink:label="mgtx_RepaymentOfPromissoryNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RepaymentOfPromissoryNotes_lbl" xml:lang="en-US" id="id_10515943_3128588_3_1">Repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RepaymentOfPromissoryNotes_lbl" xml:lang="en-US" id="id_10515943_3128588_1_1">Repayment Of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RepaymentOfPromissoryNotes_lbl" xml:lang="en-US" id="id_10515943_3128588_2_1">Repayment of promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RepaymentOfPromissoryNotes" xlink:to="mgtx_RepaymentOfPromissoryNotes_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" id="id_10515943_3078633_1_1">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" id="id_10515943_3078633_14_1">Payments on capitalized lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_10515943_3078634_1_1">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_10515943_3078634_14_1">Payment of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ResearchAgreementMember" xlink:label="mgtx_ResearchAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ResearchAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3244897_3_1">Research Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ResearchAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3244897_1_1">Research Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ResearchAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3244897_2_1">Research Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ResearchAgreementMember" xlink:to="mgtx_ResearchAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10515943_3078842_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10515943_3078842_2_1">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_10515943_3078842_12_1">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3078843_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_10515943_3078843_2_1">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_10515943_3078844_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_10515943_3078844_2_1">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" id="id_10515943_3078085_1_1">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" id="id_10515943_3078085_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RestrictedCashMember" xlink:label="mgtx_RestrictedCashMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RestrictedCashMember_lbl" xml:lang="en-US" id="id_10515943_3275696_3_1">Restricted Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RestrictedCashMember_lbl" xml:lang="en-US" id="id_10515943_3275696_1_1">Restricted Cash [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RestrictedCashMember_lbl" xml:lang="en-US" id="id_10515943_3275696_2_1">Restricted Cash [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RestrictedCashMember" xlink:to="mgtx_RestrictedCashMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_10515943_3079518_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_10515943_3079518_2_1">Restricted Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_10515943_3079374_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_10515943_3079374_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_10515943_3078149_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_10515943_3078149_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReverseStockSplitPolicyTextBlock" xlink:label="mgtx_ReverseStockSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3352747_3_1">Reverse Stock Split [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3352747_1_1">Reverse Stock Split [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ReverseStockSplitPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3352747_2_1">Reverse Share Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ReverseStockSplitPolicyTextBlock" xlink:to="mgtx_ReverseStockSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RiskAndUncertaintiesPolicyTextBlock" xlink:label="mgtx_RiskAndUncertaintiesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_RiskAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3347858_3_1">Risk and Uncertainties, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_RiskAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3347858_1_1">Risk And Uncertainties, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_RiskAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3347858_2_1">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_RiskAndUncertaintiesPolicyTextBlock" xlink:to="mgtx_RiskAndUncertaintiesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_10515943_3078893_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_10515943_3078893_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_SalesAgreementMember" xlink:label="mgtx_SalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_SalesAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3279407_3_1">Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_SalesAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3279407_1_1">Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_SalesAgreementMember_lbl" xml:lang="en-US" id="id_10515943_3279407_2_1">Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_SalesAgreementMember" xlink:to="mgtx_SalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_10515943_3078919_1_1">Scenario, Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_10515943_3078919_2_1">Scenario, Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_10515943_3079283_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_10515943_3079283_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079494_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079494_2_1">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_10515943_3079666_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_10515943_3079666_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078926_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078926_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079679_1_1">Schedule of Change in Asset Retirement Obligation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079679_2_1">Schedule of change in asset retirement obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:to="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079682_1_1">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079682_2_1">Schedule of Share Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_10515943_3091539_3_1">Schedule Of Description Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_10515943_3091539_1_1">Schedule Of Description Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessLineItems_lbl" xml:lang="en-US" id="id_10515943_3091539_2_1">Schedule Of Description Of Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="mgtx_ScheduleOfDescriptionOfBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_10515943_3239545_3_1">Schedule Of Description Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_10515943_3239545_1_1">Schedule Of Description Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessTable_lbl" xml:lang="en-US" id="id_10515943_3239545_2_1">Schedule Of Description Of Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:to="mgtx_ScheduleOfDescriptionOfBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079975_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079975_2_1">Schedule of Basic and Diluted Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078953_1_1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078953_2_1">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_10515943_3080415_1_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="id_10515943_3080415_2_1">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078989_1_1">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3078989_2_1">Incurred Charges Included in Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_10515943_3079002_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_10515943_3079002_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079003_1_1">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079003_2_1">Summary of Restricted Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3080430_1_1">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_10515943_3080430_2_1">Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_10515943_3080316_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_10515943_3080316_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3080485_1_1">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_10515943_3080485_2_1">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3079780_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3079780_2_1">Share based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3079780_12_1">Share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_10515943_3080374_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_10515943_3080374_2_1">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_10515943_3080527_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_10515943_3080527_2_1">Vesting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080378_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080378_2_1">Issued, Ordinary Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080378_12_1">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" id="id_10515943_3103166_3_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" id="id_10515943_3103166_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" id="id_10515943_3103166_2_1">Issued, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_lbl" xml:lang="en-US" id="id_10515943_3153816_3_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_lbl" xml:lang="en-US" id="id_10515943_3153816_1_1">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_lbl" xml:lang="en-US" id="id_10515943_3153816_4_1">Non-vested Value, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_lbl" xml:lang="en-US" id="id_10515943_3153816_5_1">Non-vested Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_10515943_3080379_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_10515943_3080379_4_1">Non-vested Ordinary Shares, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_10515943_3080379_5_1">Non-vested Ordinary Shares, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080381_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080381_14_1">Vesting, Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" id="id_10515943_3080383_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" id="id_10515943_3080383_14_1">Vesting, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_10515943_3079788_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_10515943_3079788_2_1">Ordinary shares forfeiture period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_10515943_3080149_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_10515943_3080149_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_10515943_3079790_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_10515943_3079790_2_1">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_10515943_3079790_12_1">Expected life of employee and Board of Directors' options (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_10515943_3080387_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_10515943_3080387_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10515943_3080152_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_10515943_3080152_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" id="id_10515943_3080535_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" id="id_10515943_3080535_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" id="id_10515943_3080153_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" id="id_10515943_3080153_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_10515943_3080537_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_10515943_3080537_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_10515943_3079795_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_10515943_3079795_2_1">Aggregate Intrinsic Value, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_10515943_3080542_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_10515943_3080542_2_1">Number of options, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080543_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080543_2_1">Weighted- average exercise price, option exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_10515943_3080158_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_10515943_3080158_2_1">Weighted average remaining contractual life of options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" id="id_10515943_3079796_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" id="id_10515943_3079796_2_1">Number of options, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080159_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_10515943_3080159_2_1">Number of options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_10515943_3080547_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_10515943_3080547_2_1">Number of options, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_10515943_3080547_12_1">Share options granted during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10515943_3080160_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_10515943_3080160_2_1">Weighted average grant date fair value of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_10515943_3081064_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_10515943_3081064_4_1">Aggregate Intrinsic Value, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_10515943_3081064_5_1">Aggregate Intrinsic Value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_10515943_3080549_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_10515943_3080549_4_1">Number of options, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_10515943_3080549_5_1">Number of options, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080551_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080551_5_1">Weighted- average exercise price, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080551_2_1">Weighted- average exercise price, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_10515943_3079805_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_10515943_3079805_2_1">Weighted average remaining contractual life of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_10515943_3081067_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_10515943_3081067_2_1">Fair value of options Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_10515943_3079817_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_10515943_3079817_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3079818_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3079818_2_1">Weighted- average exercise price, exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3079819_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3079819_2_1">Weighted- average exercise price, expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080828_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080828_2_1">Weighted- average exercise price, forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080829_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_10515943_3080829_2_1">Weighted- average exercise price, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationExpenseLineItems" xlink:label="mgtx_ShareBasedCompensationExpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ShareBasedCompensationExpenseLineItems_lbl" xml:lang="en-US" id="id_10515943_3093542_3_1">Share Based Compensation Expense [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ShareBasedCompensationExpenseLineItems_lbl" xml:lang="en-US" id="id_10515943_3093542_1_1">Share Based Compensation Expense [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ShareBasedCompensationExpenseLineItems_lbl" xml:lang="en-US" id="id_10515943_3093542_2_1">Share Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ShareBasedCompensationExpenseLineItems" xlink:to="mgtx_ShareBasedCompensationExpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationExpenseTable" xlink:label="mgtx_ShareBasedCompensationExpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_ShareBasedCompensationExpenseTable_lbl" xml:lang="en-US" id="id_10515943_3238162_3_1">Share Based Compensation Expense [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_ShareBasedCompensationExpenseTable_lbl" xml:lang="en-US" id="id_10515943_3238162_1_1">Share Based Compensation Expense [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_ShareBasedCompensationExpenseTable_lbl" xml:lang="en-US" id="id_10515943_3238162_2_1">Share Based Compensation Expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_ShareBasedCompensationExpenseTable" xlink:to="mgtx_ShareBasedCompensationExpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_10515943_3081081_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_10515943_3081081_2_1">Ordinary shares awarded, per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_10515943_3081081_12_1">Ordinary shares, offering price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3081084_1_1">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3081084_4_1">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3081084_5_1">Beginning Balance, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079878_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_10515943_3079878_2_1">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_10515943_3080924_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_10515943_3080924_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_10515943_3080925_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_10515943_3080925_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_10515943_3080926_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_10515943_3080926_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_10515943_3080927_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_10515943_3080927_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_10515943_3079913_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_10515943_3079913_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_10515943_3081293_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_10515943_3081293_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10515943_3080929_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10515943_3080929_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_10515943_3081295_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_10515943_3081295_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_10515943_3081160_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_10515943_3081160_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10515943_3081310_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10515943_3081310_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10515943_3081310_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_10515943_3081310_6_1">Total Shareholders' Equity (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10515943_3081311_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_10515943_3081311_2_1">SHAREHOLDERS' EQUITY (DEFICIT):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3081316_1_1">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_10515943_3081316_2_1">Ordinary Shares and Convertible Preferred C Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_10515943_3081319_1_1">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="id_10515943_3081319_2_1">Reverse share split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_10515943_3079932_1_1">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="id_10515943_3079932_2_1">Issuance of convertible preferred C shares in connection with payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10515943_3080940_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10515943_3080940_2_1">Conversion of convertible preferred C shares into A ordinary shares, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10515943_3080940_12_1">Preferred shares conversion into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_10515943_3081183_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_10515943_3081183_2_1">Issuance of shares, net of issuance costs, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_10515943_3081183_12_1">Ordinary shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3081326_1_1">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3081326_2_1">Share-based compensation, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_10515943_3081328_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_10515943_3081328_2_1">Number of options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10515943_3081330_1_1">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_10515943_3081330_2_1">Conversion convertible preferred C shares into A ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10515943_3079941_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10515943_3079941_2_1">Sale of A ordinary shares in initial public offering, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10515943_3079941_12_1">Shares issued, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3081335_1_1">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" id="id_10515943_3081335_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_10515943_3080631_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_10515943_3080631_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_10515943_3080964_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_10515943_3080964_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_10515943_3080965_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_10515943_3080965_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_10515943_3081212_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_10515943_3081212_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_10515943_3080632_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_10515943_3080632_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3081213_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3081213_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_10515943_3080966_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_10515943_3080966_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_10515943_3080974_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_10515943_3080974_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_10515943_3081372_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_10515943_3081372_2_1">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TemporaryEquityAccretionOfIssuanceCost" xlink:label="mgtx_TemporaryEquityAccretionOfIssuanceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_TemporaryEquityAccretionOfIssuanceCost_lbl" xml:lang="en-US" id="id_10515943_3397079_3_1">Temporary Equity, Accretion of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_TemporaryEquityAccretionOfIssuanceCost_lbl" xml:lang="en-US" id="id_10515943_3397079_1_1">Temporary Equity, Accretion of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_TemporaryEquityAccretionOfIssuanceCost_lbl" xml:lang="en-US" id="id_10515943_3397079_2_1">Accretion of issuance costs on convertible preferred C shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_TemporaryEquityAccretionOfIssuanceCost" xlink:to="mgtx_TemporaryEquityAccretionOfIssuanceCost_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TemporaryEquityAccretionOfWarrants" xlink:label="mgtx_TemporaryEquityAccretionOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_TemporaryEquityAccretionOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3397080_3_1">Temporary Equity, Accretion of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_TemporaryEquityAccretionOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3397080_1_1">Temporary Equity, Accretion of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_TemporaryEquityAccretionOfWarrants_lbl" xml:lang="en-US" id="id_10515943_3397080_2_1">Accretion of warrants issued in connection with convertible preferred C shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_TemporaryEquityAccretionOfWarrants" xlink:to="mgtx_TemporaryEquityAccretionOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_10515943_3080695_1_1">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" id="id_10515943_3080695_14_1">Accretion on convertible preferred C shares and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_10515943_3081033_1_1">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_10515943_3081033_4_1">Temporary equity, ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_10515943_3081033_5_1">Temporary equity, beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" id="id_10515943_3080699_1_1">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" id="id_10515943_3080699_2_1">Preferred Stock, Liquidation Preference, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3080701_1_1">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3080701_4_1">Temporary equity, ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3080701_5_1">Temporary equity, beginning Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_10515943_3080701_2_1">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10515943_3080702_1_1">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_10515943_3080702_2_1">Issuance of convertible preferred C shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_10515943_3081041_1_1">Temporary Equity, Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_10515943_3081041_2_1">Convertible Preferred C Shares 0 and 5,005,935 outstanding at June 30, 2018 December 31, 2017, respectively (liquidation preference of $52,455,700 at December 31, 2017)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TerminationDate" xlink:label="mgtx_TerminationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_TerminationDate_lbl" xml:lang="en-US" id="id_10515943_3386650_3_1">Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_TerminationDate_lbl" xml:lang="en-US" id="id_10515943_3386650_1_1">Termination Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_TerminationDate_lbl" xml:lang="en-US" id="id_10515943_3386650_2_1">Services termination date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_TerminationDate" xlink:to="mgtx_TerminationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_10515943_3081731_1_1">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_10515943_3081731_2_1">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_10515943_3081732_1_1">Relationship to Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_10515943_3081732_2_1">Relationship to Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_10515943_3080759_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_10515943_3080759_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US" id="id_10515943_3081749_1_1">Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransactionDomain_lbl" xml:lang="en-US" id="id_10515943_3081749_2_1">Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3081998_1_1">Transaction Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US" id="id_10515943_3081998_2_1">Transaction Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TransitionServicesAgreementWithRelatedPartyMember" xlink:label="mgtx_TransitionServicesAgreementWithRelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_TransitionServicesAgreementWithRelatedPartyMember_lbl" xml:lang="en-US" id="id_10515943_3395636_3_1">Transition services agreements with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_TransitionServicesAgreementWithRelatedPartyMember_lbl" xml:lang="en-US" id="id_10515943_3395636_1_1">Transition Services Agreement with Related Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_TransitionServicesAgreementWithRelatedPartyMember_lbl" xml:lang="en-US" id="id_10515943_3395636_2_1">Transition Services Agreement with Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_TransitionServicesAgreementWithRelatedPartyMember" xlink:to="mgtx_TransitionServicesAgreementWithRelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_10515943_3080792_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_10515943_3080792_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_UclConsultantsLimitedMember" xlink:label="mgtx_UclConsultantsLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_UclConsultantsLimitedMember_lbl" xml:lang="en-US" id="id_10515943_3395641_3_1">UCL consultants limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_UclConsultantsLimitedMember_lbl" xml:lang="en-US" id="id_10515943_3395641_1_1">UCL Consultants Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_UclConsultantsLimitedMember_lbl" xml:lang="en-US" id="id_10515943_3395641_2_1">UCL Consultants Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_UclConsultantsLimitedMember" xlink:to="mgtx_UclConsultantsLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_10515943_3082109_1_1">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_10515943_3082109_2_1">United States</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_10515943_3082249_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_10515943_3082249_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_10515943_3082820_1_1">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_10515943_3082820_2_1">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_10515943_3082821_1_1">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_10515943_3082821_2_1">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_10515943_3082828_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_10515943_3082828_2_1">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_10515943_3081912_1_1">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_10515943_3081912_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3082590_1_1">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3082590_2_1">Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_10515943_3082590_12_1">Weighted-average number of ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" id="id_10515943_3087684_3_1">Weighted Average Number Of Shares Outstanding Basic And Diluted Disclosure Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" id="id_10515943_3087684_1_1">Weighted Average Number Of Shares Outstanding Basic And Diluted Disclosure Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" id="id_10515943_3087684_2_1">Weighted-average ordinary shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent_lbl" xml:lang="en-US" id="id_10515943_3395610_3_1">Weighted average number of shares outstanding diluted percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent_lbl" xml:lang="en-US" id="id_10515943_3395610_1_1">Weighted Average Number Of Shares Outstanding Diluted Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent_lbl" xml:lang="en-US" id="id_10515943_3395610_2_1">Fully-diluted outstanding shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent_lbl" xml:lang="en-US" id="id_10515943_3395610_12_1">Percentage of fully diluted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mgtx-20180630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Presentation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2018-08-08T01:33:44Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DocumentandEntityInformation" roleURI="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfFinancialPositionClassified" roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfFinancialPositionClassifiedParen" roleURI="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfIncomeAlternative" roleURI="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#StatementOfCashFlowsIndirect" roleURI="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureOrganizationAndBasisOfPresentationAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense" roleURI="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare" roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations" roleURI="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgtx-20180630.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DocumentAndEntityInformationAbstract" xlink:label="mgtx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCash" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CapitalLeaseObligationsCurrent" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1.1600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfPreferredStockAndWarrants" xlink:label="mgtx_AccretionOfPreferredStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfStockIssuanceCosts" xlink:label="mgtx_AccretionOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="us-gaap_ExtinguishmentOfDebtAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_SalesAgreementMember" xlink:label="mgtx_SalesAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TemporaryEquityAccretionOfIssuanceCost" xlink:label="mgtx_TemporaryEquityAccretionOfIssuanceCost"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TemporaryEquityAccretionOfWarrants" xlink:label="mgtx_TemporaryEquityAccretionOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_LicenseAgreementMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_SalesAgreementMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_AccountsPayableMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_AccretionOfStockIssuanceCosts" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_AccretionOfPreferredStockAndWarrants" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_TemporaryEquityAccretionOfIssuanceCost" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_TemporaryEquityAccretionOfWarrants" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AmortizationOfInterestOnAssetRetirementObligation" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" xlink:label="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NoncashOrPartNoncashStockIssuanceCosts" xlink:label="mgtx_NoncashOrPartNoncashStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" xlink:label="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReclassificationOfWarrantLiabilityUponExercise" xlink:label="mgtx_ReclassificationOfWarrantLiabilityUponExercise"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="mgtx_AmortizationOfInterestOnAssetRetirementObligation" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.2200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1.2300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="mgtx_IncreaseDecreaseInDueToAndFromRelatedParties" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="1.2000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mgtx_ReclassificationOfWarrantLiabilityUponExercise" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalLeaseObligationsIncurred" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="mgtx_NoncashOrPartNoncashStockIssuanceCosts" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OrganizationAndNatureOfBusinessTextualAbstract" xlink:label="mgtx_OrganizationAndNatureOfBusinessTextualAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:label="mgtx_ScheduleOfDescriptionOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_OrganizationAndNatureOfBusinessTextualAbstract" xlink:to="mgtx_ScheduleOfDescriptionOfBusinessTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharePrice" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="mgtx_ProceedsFromIssuanceInitialPublicOfferingNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ScheduleOfDescriptionOfBusinessTable" xlink:to="mgtx_ScheduleOfDescriptionOfBusinessLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RestrictedCashMember" xlink:label="mgtx_RestrictedCashMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="mgtx_RestrictedCashMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_WarrantMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FairValueNetAssetLiabilityBeginningBalance" xlink:label="mgtx_FairValueNetAssetLiabilityBeginningBalance"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FairValueNetAssetLiabilityEndingBalance" xlink:label="mgtx_FairValueNetAssetLiabilityEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mgtx_FairValueNetAssetLiabilityBeginningBalance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="mgtx_FairValueNetAssetLiabilityEndingBalance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_WarrantMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AmortizationOfInterestOnAssetRetirementObligation" xlink:label="mgtx_AmortizationOfInterestOnAssetRetirementObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligation" xlink:label="us-gaap_AssetRetirementObligation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationAbstract" xlink:label="us-gaap_AssetRetirementObligationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationRevisionOfEstimate" xlink:label="us-gaap_AssetRetirementObligationRevisionOfEstimate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="mgtx_AmortizationOfInterestOnAssetRetirementObligation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationRevisionOfEstimate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetRetirementObligationAbstract" xlink:to="us-gaap_AssetRetirementObligation_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="country_GB"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OperationByGeographicalLineItems" xlink:label="mgtx_OperationByGeographicalLineItems"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OperationByGeographicalTable" xlink:label="mgtx_OperationByGeographicalTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_OperationByGeographicalTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_OperationByGeographicalLineItems" xlink:to="us-gaap_NoncurrentAssets" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_OperationByGeographicalTable" xlink:to="srt_StatementGeographicalAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_OperationByGeographicalTable" xlink:to="mgtx_OperationByGeographicalLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedClinicalTrialCosts" xlink:label="mgtx_AccruedClinicalTrialCosts"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedConsultingExpenses" xlink:label="mgtx_AccruedConsultingExpenses"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedInterest" xlink:label="mgtx_AccruedInterest"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" xlink:label="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccruedTravelExpense" xlink:label="mgtx_AccruedTravelExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedClinicalTrialCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedConsultingExpenses" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedRentCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedInterest" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="mgtx_AccruedTravelExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ConsultantMember" xlink:label="mgtx_ConsultantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" xlink:label="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeMember" xlink:label="mgtx_EmployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:label="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_FirstAnniversaryMember" xlink:label="mgtx_FirstAnniversaryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NonemployeeConsultantsMember" xlink:label="mgtx_NonemployeeConsultantsMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_OverThreeYearsMember" xlink:label="mgtx_OverThreeYearsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_NonemployeeConsultantsMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_ConsultantMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_EmployeeMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_FirstAnniversaryMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="mgtx_OverThreeYearsMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_EmployeeAndBoardOfDirectorsMember" xlink:label="mgtx_EmployeeAndBoardOfDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NonemployeeMember" xlink:label="mgtx_NonemployeeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_EmployeeAndBoardOfDirectorsMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="mgtx_NonemployeeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" xlink:label="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue_2" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationExpenseLineItems" xlink:label="mgtx_ShareBasedCompensationExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ShareBasedCompensationExpenseTable" xlink:label="mgtx_ShareBasedCompensationExpenseTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mgtx_ShareBasedCompensationExpenseTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ShareBasedCompensationExpenseLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ShareBasedCompensationExpenseTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_ShareBasedCompensationExpenseTable" xlink:to="mgtx_ShareBasedCompensationExpenseLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfDeferredFinancingCosts" xlink:label="mgtx_AccretionOfDeferredFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClasscPreferredStockMember" xlink:label="mgtx_ClasscPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PaymentsInLieuMember" xlink:label="mgtx_PaymentsInLieuMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionDomain" xlink:label="us-gaap_TransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_LicenseAgreementMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgtx_ClasscPreferredStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_ClassOfWarrantOrRightExercisedDuringPeriod" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgtx_AccretionOfDeferredFinancingCosts" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TransactionTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="mgtx_PaymentsInLieuMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfDeferredFinancingCosts" xlink:label="mgtx_AccretionOfDeferredFinancingCosts"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AccretionOfWarrant" xlink:label="mgtx_AccretionOfWarrant"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" xlink:label="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="mgtx_AccretionOfDeferredFinancingCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="mgtx_AccretionOfWarrant" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AnnualMaintenanceFee" xlink:label="mgtx_AnnualMaintenanceFee"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_BaseRentAndManagementFees" xlink:label="mgtx_BaseRentAndManagementFees"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DecemberTwoThousandSixteenLeaseMember" xlink:label="mgtx_DecemberTwoThousandSixteenLeaseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DeferredRent" xlink:label="mgtx_DeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_JulyTwoThousandsSixteenLeaseMember" xlink:label="mgtx_JulyTwoThousandsSixteenLeaseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_KadmonMember" xlink:label="mgtx_KadmonMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LeaseTerminationDate" xlink:label="mgtx_LeaseTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LicenseAgreementMember" xlink:label="mgtx_LicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ManufacturingAgreementMember" xlink:label="mgtx_ManufacturingAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfPrograms" xlink:label="mgtx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PaymentToRelatedParty" xlink:label="mgtx_PaymentToRelatedParty"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PeriodOfAgreement" xlink:label="mgtx_PeriodOfAgreement"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" xlink:label="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNoteIssued" xlink:label="mgtx_PromissoryNoteIssued"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNotesInterestRate" xlink:label="mgtx_PromissoryNotesInterestRate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_PromissoryNotesRepaymentDueDate" xlink:label="mgtx_PromissoryNotesRepaymentDueDate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyAdministrativeExpensePercentage" xlink:label="mgtx_RelatedPartyAdministrativeExpensePercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyTransactionAgreementNoticePeriod" xlink:label="mgtx_RelatedPartyTransactionAgreementNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyTransactionAgreementTerminationDate" xlink:label="mgtx_RelatedPartyTransactionAgreementTerminationDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RepaymentOfPromissoryNotes" xlink:label="mgtx_RepaymentOfPromissoryNotes"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ResearchAgreementMember" xlink:label="mgtx_ResearchAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TerminationDate" xlink:label="mgtx_TerminationDate"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_TransitionServicesAgreementWithRelatedPartyMember" xlink:label="mgtx_TransitionServicesAgreementWithRelatedPartyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_UclConsultantsLimitedMember" xlink:label="mgtx_UclConsultantsLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_ResearchAgreementMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_ManufacturingAgreementMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_LicenseAgreementMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgtx_TransitionServicesAgreementWithRelatedPartyMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="mgtx_JulyTwoThousandsSixteenLeaseMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="mgtx_DecemberTwoThousandSixteenLeaseMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_UclConsultantsLimitedMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="mgtx_KadmonMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyAdministrativeExpensePercentage" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PeriodOfAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_TerminationDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PaymentToRelatedParty" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyTransactionAgreementNoticePeriod" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RelatedPartyTransactionAgreementTerminationDate" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_NumberOfPrograms" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_AnnualMaintenanceFee" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_LeaseTerminationDate" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_BaseRentAndManagementFees" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PromissoryNoteIssued" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_DeferredRent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PromissoryNotesInterestRate" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_PromissoryNotesRepaymentDueDate" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="mgtx_RepaymentOfPromissoryNotes" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestExpense" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyOtherExpenseMember" xlink:label="mgtx_RelatedPartyOtherExpenseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyPersonnelExpenseMember" xlink:label="mgtx_RelatedPartyPersonnelExpenseMember"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RelatedPartyRentExpenseMember" xlink:label="mgtx_RelatedPartyRentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mgtx_RelatedPartyRentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mgtx_RelatedPartyPersonnelExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="mgtx_RelatedPartyOtherExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_AnnualBaseRentAndOperatingExpense" xlink:label="mgtx_AnnualBaseRentAndOperatingExpense"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" xlink:label="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfLeasesTerminated" xlink:label="mgtx_NumberOfLeasesTerminated"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_NumberOfNewFacilityLeases" xlink:label="mgtx_NumberOfNewFacilityLeases"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgtx_AnnualBaseRentAndOperatingExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgtx_NumberOfLeasesTerminated" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgtx_NumberOfNewFacilityLeases" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetRetirementObligationsPolicy" xlink:label="us-gaap_AssetRetirementObligationsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_DescriptionOfBusinessPolicyPolicyTextBlock" xlink:label="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_InterimFinancialStatementsPolicyTextBlock" xlink:label="mgtx_InterimFinancialStatementsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_LiquidityPolicyTextBlock" xlink:label="mgtx_LiquidityPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock" xlink:label="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_ReverseStockSplitPolicyTextBlock" xlink:label="mgtx_ReverseStockSplitPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgtx-20180630.xsd#mgtx_RiskAndUncertaintiesPolicyTextBlock" xlink:label="mgtx_RiskAndUncertaintiesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_DescriptionOfBusinessPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_RiskAndUncertaintiesPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_ReverseStockSplitPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_LiquidityPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="mgtx_InterimFinancialStatementsPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetRetirementObligationsPolicy" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" xlink:label="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FederalHomeLoanBanksAbstract" xlink:label="us-gaap_FederalHomeLoanBanksAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalHomeLoanBanksAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g570173page098.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570173page098.jpg
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M  (" P$! 0$           @)!@<$!0H" P$+ 0$  04! 0$!
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M?X ^=I2OP6\I/S4N0'Y/\ ?.TI7X+>4GYJ7(#\G^ /G:4K\%O*3\U+D!^3_
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M 83M><R5;F9I]'.Y%5Q6(5"KHQ:+(57#Q"9<MUW9%/7?,%% 3.C)%ZIIFZ"
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MUEV^]Z3JY2[;8D9N<BZKKIZ2.K2;@;-.R*S"'C8\%'CB/8(&E)%TZC4TG[U
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MERMIR]P_UQL@$D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"KSDC),8;N1\%)>
M3<ILXV*UIRDDI!VL/A2:L6.NG3IVY5-_V4T$$C&,/\ !@&X7:S"Q,*OLS=,-
M8MA3>S9)$^E./$0BDM%0D(LP&4C2S$"ZE&5:GK.2#3&2GYN>6"/B15]4; D!
M"B[ C;9^'W'6>LD_-SG9,XKV^9EIJ3D92UR>O^%4C)65\\>K.',](/YN(+,.
MWTLJH*ZJCK_.#**"*@B;J. ='\RCC!_<5<2?BRX+?6K 'S*.,']Q5Q)^++@M
M]:L ?,HXP?W%7$GXLN"WUJP!\RCC!_<5<2?BRX+?6K 'S*.,']Q5Q)^++@M]
M:L ?,HXP?W%7$GXLN"WUJP!\RCC!_<5<2?BRX+?6K 'S*.,']Q5Q)^++@M]:
ML ?,HXP?W%7$GXLN"WUJP!\RCC!_<5<2?BRX+?6K 'S*.,']Q5Q)^++@M]:L
M V#K/C%HO75E-9Z=V>./FI)=M%2:!K90*/P]A[49BX0\+R'C'-3;QDFJ>53
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MQK9(R#(QC$1<K>%50"D+X1$2[QK2E\$I:<="$JYNSGCQCKVG^HIFO)HP!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@'G9[Y-PM6O7!+W1I^2JESJ'!#N!S]6LT,N
M#:7@)MAI&5492L8X$IP0>-3CU(?H/0< L1OMIL<7W0N'NOHZ9?,J/,<&^<5A
ME*JW4*2&?3M3W!P/BJU*KMO /^>0<99Y%!N8!#P)/%0Z#XO0!-#;FR(_3VL;
MUM27@+)9H;7U:D[;-PU00B'5C7A(1 SZ9<QC6=F:_&.5(R,25='3.[2.=)$P
M)@=42)G B;QN[CW';E1=9>B:Q)?T)B#@-<S<FI;JPUKB+=QLVMJV>$@3,UII
MQ.>Z3-DV73<.?4PB5ED1]3>.TSHJ* ; D.</&^"5NZ=LO(4Q/7MUE:#9'EI8
M.(R/1L$59B5+P-GP NU<MI"9,)&Y@,!C)D,<Y2%# - \A=Y<?.1;YSQO3NK9
MA(5>=T)NM6TNJ6PV%4YA*M[Q$[2CPZ$;<8F8C[5+6G6<A!/%G"*"3$172 55
M@,D4#&=_<<]&VZ)J^O%]EF:6:5=,=CUYWM6D6'=M/GJXRK5[*ZBK7%#9:U!6
M1<Z)G3YJ"\FDZ1?L6JB*:@)E((&"TW2&@;F,;41EMMDD.(4369H^^I>F4YQ9
M#J;$T4ZU\T^#R4?N[99(&>AG9DY\2K01O4Y=@D!O6%$$E2 8'IVP\7>8]Z^;
M/7%-S;1::GL%-V2]N6V:KIZVTEXGHS;56A&C\SF/M 2,=)W*"UT>J*I$@F#E
M:#?@L[9D!0QEP,_F]K\?>Y7';/9:KN=K@$](DT#;]@%V!K6.MNM;/&Q3Z&W_
M  -/M.K5[O!V"ZQC^/?HH2()&8(D RJ!72Q3BF8#2K+6W#?B]8..M?L/(76\
M=>W-GFK2T5M.L:VPL=_:UKAXXT<L\0?.[Y&#6JBB76LS-)^>K(G=OG2S-'T
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MQQ3^I[A_LZ9IB4, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M6YK1LQALW6E;O]@UJ[K$@UA;.[ES1ON),$EX^0(>"3?I0CEVVEHOQ)K/&KH
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M\)4R",:_3E:3;CZR*M'=JNS4_P!5S-63Q@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8!_.H"(@ @(ATZAU](=?8ZA_!UP#^X P!@#
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M/P5A;G=P$U$SC5-045',/(LY-NFL =12.LR673*H >R41ZX!VV , 8 P!@#
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ML4MJ7DW5X*K0.MHN+F(67LKW7]S2MM(3MLFC7(Y_6J<PJTE'.6QH]](Q$I,
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MD8>182T>OXO(?1KQN^9K> PD/Y3IJHJ@IX#@(#T,/00Z8!S\ 8 P!@# & ,
M\VO?Z^QN?_=\]P[Y#I3 +$]H$\WNV\,$O%X?-[?W<%3\7A(?IX]W=O,.HD4*
M9,_3KUZ& 0'^$, Z&T=N;6U5TWJW7C2Z[LGXO6,>]JT0W@$Z*BN["P6ZJ6]6
M7-"Q^O5X*MOC2=)9-_6HMDR(V474>^$KH1<8!$_F'7ZK*HN&>X-3<HB5RQUM
M\$+9B6K7#>E4R6^"=YK*P--.5P^OY:TI6F2A]GOGKUFK%LW=DE84RC!N^124
M H$QM-OJK%\;KNYGZE;JS5*ERHVZS1;7FQO]<R,I$M=QV%"&V(8?@UU^P@*E
M;/=E"6A(UH@Y9(0KE@V-(J*)JII@1CY1:K>S%:M.Z9'7/)T+=IG7$U>H!U!W
M'7%L@KZ\ME!JR;L] %E0MEA!6"CIPC)51\M!QJ*IDI K<7J*JQ5 )H;QN)ZQ
M#5N@IPNXG#NXMHO=7OOH.QZ)7):WW:'DV,JMJ^MPMS(%YGEYI:/377C8RL(M
MR,CD2 4'*J;4X&*O-GIH:IXN;9K,1L2>]ZY; ]4UY2]SZHK3=>]SU0(C#ZBV
M$G<6U/8VNP">?49LXY,8M\R=I"NY2$"G.4#3?,6#87/4 =*QN._SBW(NGP\[
MJ#6EKI5BN%(#8#6]5<]NL\=#:RV4:!"$B[S(*)%>M4Q;/VC)X:2;%; [(!U,
M=Q;UY'\.=D:8@M;;+Y&4W?&Q-H[,O41!6W1<[LG6%[D)]K8B5>/M3F)C:Q(R
MR$TJ+)BL[.=>':CY9E01)YA0.VV#P5KQN$<-I16%W\[B:-<MB6)A$4)SJZN[
M$D6MPC[2NNNE7*SK]O1V+%)U,F0+%QK%,RO4R@JN3JG*L!$[BEQ:X_VC75[:
M;++=N&"FR^.MMU^\+9=DTJE;0N*'(R6F;/L*V'4LFD-2V6L#1'Y?<6'B$"'K
MC9B) ]S&KE,>H$E&TW6V6LJENZ3H-[BZMQ>U/R0JE-E*O+U*B4O9M>JVRR-D
M&RC^GZDB8P9[82^DV9(^$;HDJ\@UL)A;K2RJB"QP-(-(O5O'L\&TXYZOWKO[
M5&V)O4S$=A4RS/H*J:W1A-<UC2R$S-3&J])V*S(1[.N4F-GWC!VF=W%S$TY5
M;-D3O'11 N.U#QN#3^QKI?V>X]NWM&]5R.@Y:L[(DZM8(YDXA;;;[5"R<'(L
M*I"3<8$:%YD616H.#M5&QTQ4(99(JF 5==P_]GSWB_QI)?)!Q1P"5'&_[YO'
M#[0^Y3^E_I/ *)O\5VU(K-=N&3,H"9JM+\MK<41\7U1*OT_3KN2;>U >OKD,
M+E'T^CZIZ<PWR:K?+VO@71Y=?:UTT/&@R%I5W#IO&*+D+J3:Q") <JQ3*P\[
MX% \A(H>$6RCJ#,8I3#Y8"N'3J'3K-E-68\)1[/TN'UA&;BFEWK0M0U?337.
M]1OO5AVTG<+4BTAXE5$Y?794ITSN&$:W6-YB?G.$R^!("E 51,!?%T'J%FM2
MK;TESI%DNSV?C'W:>0\%K&7DZB\;V-EL.O2?N1+05BJ(0\5"S[%\JVL$-8YR
M0LT:6&6A4B$ZND$I%-18_E B/H,,*5]<DXO4NKC*;4'\;1OU<#E<3NXCMO97
M+FJZ2L[VHQ&G[HK=*NQJ%?<M)[QSKN"=+T.2D+@>*BG4VZ8SL85NB!6T>5,C
M]0JB:HD*?*2Q:IT/(BO:CQ3?H[]/62*[)JQ5-K1/0EWR]@GJVM9AXS21,XA7
M+24$%':K,2-45DSN#MEFS9THDY1*!!)XB@0Q?$03% WB"-"2C)2?89(IUV-R
M^R? IUW[%/55;A8TDUSLK35:9L*.!9V,RQBI)$A=:71)N7ZH@FT.9XQ64%(
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ME]F,IQX4OB*<6%#@IRY(G(KT$A!"QQ,:4Y1]*B1SE#^, -PX P!@# & , 8
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M^2; 'P([[^F=M/XJ^.7Y)L ? COOZ9VT_BKXY?DFP!\".^_IG;3^*OCE^2;
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M#CJ73LE-ZRT_0/\ 6'R86# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8!J!T)I;>\0@*15&U(U=,OSG]JH5.3V#9HEC'JG*/I:N4(Z@O
MB)&#TJ).5B^@ 'J!M_ & , 8 P!@# & , 8 P!@# & , 8 P!@&HMZ JZUI,
M0*"QD'%RDJM0DCD$?&4EYM4+57JOED^J+(-(Z5677(7TBW24]@ $0 VV4I2%
M*0A2D(0H%(4H 4I2E#H4I0#T 4 #H 8!]8!YM>_U]C<_^[Y[AWR'2F 6+[+_
M &N7"O\ J!=P+Y<.WE@%F> , 8 P!@# & , 8 P!@# & 41]P_\ 9\]XO\:2
M7R0<4< E1QO^^;QP^T/N4_I?Z3P"A?\ Q9<8SEYCML,W[B400-9.5YP+#,FK
MU^Z6]YFHDTFJ?K[QA',TU#*>([APJ5%(I/3U$2AELN,6EVZ%&TN+[#QS[V>U
M^3D*^WA))LNVBVCN!)$M'C!XC%H-4VRX$]9AW4E$BY<.ESBJ!'*HB<AA'^ <
MS[<IPJDI)I-ZI_4(]LYP>J:Y6=WJFQ(5#>\LPEGH(1U@KD55CKF.;RB3\-!1
M*[<[DX&ZE\PL>Z("@@(>(W\'\.S<)**EVZF"V[F@F^U=OZA)?D)5_=U'6%N3
MFK+%.:C+R!(XM7G202"[YT$3/P[Q63]1DE$7+1S7U!2,BF!A P]3EZER#?%5
MS4X_&U*XUD?ZK0TC4="56I6!K=*\]F)^=,I%V]1U/OH\M09QTR5A/$\0-(UB
MV&9@@D"K^(5%14.U5(4$C&'PXI7V27+)KB;&4Y223[$N!/?A3O.#T;';;KUR
M"4F&%H4KLE&1]9/!R;AK9(%Q-M7B\FLG(-8:+9#$S!$%#F<*/#.4"F,F8IQ.
M779$E/1)/5,I%<S4?2;#LUX@]YRUI>0$(]AU4X%-@S.H_B79W<Y579K_ %%=
M4T>H1)K(NV+2=2.AU7\2"!^BY@$2%UV;2HT5Y4VE&%O;QX=SU]3)F([/%GBP
MTYIQ[>[6+U7$BKM2RZ_<:PUO5:Y9;/2KGKZ#GF2*TQ<[.M+5VW5VJR<G97$+
M.KK,Y,7=X2F4_5 ;+)IHK."MTA4*@CX]BUD9%TK*4ODCBM6EH]5V-^HI;/EJ
M4)?MCU]SMX%EE<Y8:LKFO-:R6T-CT"L/F=)KWNJP2M$1*S1YA>%3]W/&QK+B
M9G729I@[@?+3;JF367,HH %,!QQ*JR<^2$6Y$,K?W3S*96^=FF\'-RU^K)Y,
MCZ$!K3E*K'QB":BZ+%JU>6224<,GY(YSX7@M8DC9=8"B05R=<UN^]'XW5&WQ
MP-TYX4PN4URM*3T36FO'1/7BUQX:)\3[7Y$>?76WT=^K<KK7H.&'/><G;;<)
MK*KE;4H6SJL5GAQG#GE"52Y8R?+[3>A&A_NFYRLE+%KU:C&SB7CE8@[69([N
M[ABBNF9,7T)%JH1-9BI;RB^(%D8LQB' 3>+)&S]$=.;&E\AHJ4U]DXQ<W[L]
M-6EZ&7^8_P!([SM\V,F5_7746XY6-+73'C=;5BPU;;Y,>%BKBN.B3U2BDNXQ
M"3I&R 2!GL&4GB%:^0*1-@V461FAW@$43=-89TJU1*HLT4*)3LV8>),0'VV=
M7"N,(\L."]WZB?H]1\,5-<==-4W+5O7BWZWVLEIJ_;M3:1T;6).50LEAA3L3
MK1T/%J.'-V@(M9NX?-'SZ=70.\\,<V.#U'U0X+IE\TA3]1Z:+(Q51=XGN+M)
MU5C\/DCPEQ?'LT,/YS<AN/.[:I1:?IKB^QT$^BI?WTN95A+0+HDA6)B&=)MJ
M\5"*A(M;Q,GBY'!U3"=,@@)2%#QB(;G!H3L>6FM8N4>+[-.#]XB2GRZ:I\60
M^BJ78->T!_?))FWK<W;ZZHTK@/EW;">A(,BB,@G,UQR4K06%GG2L0\HQS>(K
M<P#[43F <N3?'(MC7!IP4EQ[N)=WFT88(=315!>LK3:K'?K3.V!E=&$Y+2#I
M&/<P4DX:5MO#,GZ"9BHR4<9J[54*98BIUDA X'3,7(,J&\VQ<%RI+U:=H)QT
M"RI:EVKQ;AHAFBS>2_)#B]2VLFV*LR.TF9O>.O%Y*7]<:'1,,N]AJU*(IG,<
M3BFNK[)0$,BUOQ[=&GRIOX-&G]73WAV'^I'F<# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8!I[7P^ZFP-TV(QA4!*RUNBLSG 2G)'5*
MIQTN=N7H4$SH)V"YR)RF 3&\:AP-T\(% #<. , 8 P!@# & , 8 P!@# & ,
M 8 P!@# -/;'!.4NVEJR8!/X[G+W-X3J9/I'4NHS0(JD6 HE%1*TST5U3] J
M)"<>O0I@$#<. , \VO?Z^QN?_=\]P[Y#I3 +%]E_M<N%?]0+N!?+AV\L LSP
M!@# & , 8 P!@# & , 8 P"B/N'_ +/GO%_C22^2#BC@$J.-_P!\WCA]H?<I
M_2_TG@'G=_QB#&6DVO;5C(-D_D95_=N4R#1G&><+U42435[I44BH')XRIH-C
M&4 _5/RP,)O8#,V.D[4_1Q,&2N:II]FJ/$]"-3O91DCX>GNF_:IF3.8XB59^
MZ;IG6Z@8")F4!3IU H"/3^$1$<V'ND-N/(DD^?O-C/[$4EPL[IF_;-EALZ[Q
MEZVY,G$J*1,P\!$CQ,B8@JIZFN/@'S$SE(!@ >IPZ2\>/*FVUJ_A,-D9R6D6
MO6;>K&[IA1-S6[]9C2]0.=-TW2IU4;RBS)Q'J&,5!%PV8S*ZK5<HG\15C%,
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MS!Z=!()CY,)Q6-*,T^?AI[FOH,.0^>V,DN&K_0/];7,)D& , 8 P!@# & ,
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M_K[&Y_\ =\]P[Y#I3 +%]E_M<N%?]0+N!?+AV\L LSP!@# & , 8 P!@# &
M, 8 P"B/N'_L^>\7^-)+Y(.*. 2HXW_?-XX?:'W*?TO])X!YYO\ &#RJT2R[
M<2K001?O[1RKAX]^*I6XQ3J5I&J&II(K@QB@V.BS,J0%>H"F*GB#H(=<SXW&
MW3U%LOBOW'^@>+>F5F6L3Q"!@6J[MU'MGLRY.JU<JLV</#)=)!Q("T,X]7:/
MW;I-%852*%$BX 80 1'-S4VI.KF79P]U_HFK;2CKZ$9LU@7];<)^Z$(BR]8.
MJ=)Y',#G07\!Q3=F;"T:G<'19IJD\P% +X/&7J!0]C#;"<)M3UYM?08Z[8V:
MI+30[M2$LCMT!&-:LJA2-SNW""K08@ CDR$55=",FJU2,U! X*BJFF?RTS>,
M?:AE55;;#1/1)<.!11Y'*?;KW&6H.)Q@<S1B^@_+B5F[M69D+6!'(.'**;\K
MQ).+:R#ITV,N85$GB:I/,*4#$$! >DS6N*Y'IHNX*M.2L7!]K)@Z[Y.6>V6"
MN:_?VJE%M<PHC"L'T915K(#P@1KUV24>N[7;#LC. ,Q3;E;A$/DE%%"+&3(7
MS.NBR:FK'-<4V^Q=AL*8U6+3EXI$@9V.M=?8*6^1D1MTY&R4&Y!G8(V.:,E'
M"42O K^N.(IM'I#%OV;E1(0421]32*02F$2^(NIR:X2FI-N+G[+DNW37L7K9
M+BE%:+L15;N*=G7DY,1]E4_^/U1V->E&S9;S/<)V512-59$E$E"+2""3^+3%
M!<!$PI*E'J !US?40A\F^X+V7V2[O7_R=QK[)2G;K+B]=/>7=\!^FT+,^3/H
M?>D40[9QZK$,WQ_6E57#VSZ_D2S#A[U1C6R;(CT7XMU"^>Y6,HD<ZAB H! M
MKKY8RC+CKVDN;Y(J4.%2^Q]WUEJZW)6!OC.LO'- B L39,RE5<6EI7+G5I)S
M,1RC1@QD8ZS0:L4IZZ]<M#I"\079 NB!E"^+PAFER]OMIA*ZJS[G'BTUV+])
M+TBO)K<])+V?=-<7U+7<Y$KVC9DE7F<O+D?@U9R":[.NHR:*13%6K6IC%:5Z
M+9/C1R)Q9LH8B:P%(0I>ABAFMC";?-*3<=.[5?H$W6AQYN7CKV:_5(Q5$HLN
M2M83,5^J"M7L"L!&@@K%IC%N8V(DXU9E700C5&*)F1')?7"M (<I 2\PPE A
M=C!RACN?'1R6GU_A,$U6Y\\5H]"5&QRN55$32->EB>75[2HW34$/'ZTN: /Z
MN B143QP)HJ>:Y*/E)'\L>H"(9CMR%)12BV^9&2F*G)I]FA3':V;=1_)NG+T
MD8]:56HNHQLHY:(J2"IHF(8JLDBN%R*OC-TE5#@BB!U3%**H%\!!$-Q@2E\E
MY>V*LF]/^<RR45%Z)IHFS4*[4U:.TFGM2K[QU&4EG* 'N09!=1R2*,]&3,HH
M1)-1=1R4JI2F\!S*CZ2AT\00)Y=O/X?-PYN/9V>CWNPD1C7X/-+MXF<6+2'-
MNRSZNRZ]JVPP=;W?%Q6[*=&NKAKQ)*7H=Z,JO7I]2"1M:K5N653CU1^JID<B
ML03& !Z9(=V)!.%FJM6J?!\&1C[UK"[@U=R:XGQF\-%,ZX:[\GN.<?5[,^CZ
M\"Q'L1OC73Z27BI*LR2C=*1!N8B9_/0$#HK&#T]1S)"==E;\"7%?&X=OH*'^
MLAF$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , TWL@ON
MW=M/4WPG416M,GL&62+U\)XC747YK-18 \(@DVO-B@U $#?^U(0!*8HFZ ;D
MP!@# & , 8 P!@# & , 8 P!@# & , 8!\**$13455.5--(AE%#F'H4A"%$Q
MSF$?0!2E#J. :FT61535U<F'"8INK<K/7UR40_DJW^QRUR!,AN@'.@@G.%31
M$WM_)(0!](8!MS & >;7O]?8W/\ [OGN'?(=*8!8OLO]KEPK_J!=P+Y<.WE@
M%F> , 8 P!@# & , 8 P!@# & 41]P_]GSWB_P :27R0<4< E1QO^^;QP^T/
MN4_I?Z3P#1_<*X^:/Y.]PGMAZHY#:JI&Y=;.J#SZL*])V#!-+'7%)Z!JO'<T
M-,&C'Q#MS2$9ZVL"*@@(D!4W3V<)M/5=H-]Q79S[6<"JNM!<#>-,(LZ;&9.E
MH?6T-%JN61SE4.S<*L$VYUVAU" 84C")!, "(=0#+N>?I?PEO)#T+X#^I]G3
MM:(KMW2/ [C4BZ:=0:N4M;PZ;AJ!C <P-ER$!5 #' !'P"'40ZX<YO@Y2T]U
ME%76NR,?@1^*G9L[5JQ!36X$<952&,H<Q%=90BA3&6'JL82G2, F5$?;#_VO
MX>N5\6U=DI?"RO+'T+X#A?V+/::\ )_V>O%3RRE\!2?!)6O 4@"(@4I?5?"!
M0$PCT]CTCE'.;XMO7W1R1]"^ ^FO9<[3S%V@_8]OGBPR?M%"+-7S/4]<:O6J
MR9@.FJV=H-DW""J9P\13$, @/I >N.:3[6RJ278D9*KVD.V@N50J_"C0:Q5B
MB18JU+;*E6((& 2*E44,"A1 X@(&Z@/4?X\L:3[4GQ*G0NNS-VIWR[ET^X \
M7WKIZ83O73S5T Z<O#B<%!.[77045<G%0/%U.)A\7I]G+U.45RQ;4?0GP^ I
MRQUUT6I]F[-/:K/'%AS\!.,1X=-V9^G$GUA!&BTWQBF*9ZG'&1%F1X8IS *H
M$!00$0$?3CGEZ7\)5K7@S]@[.?:T!N1H' [C4#5,A$TVH:WAP;)D3\/ED(@!
M/*(1/PAX0   O0.GL8YY^E_"6\L?0O@/M/L[]KA$B*:7!'C<DFW.95N1/7,2
M0K=4YRJ'50 I0\E0RA"F$Q>@B( /LAF/ECZ%\!<?@AV;>U<VD?=AMP(XRMY?
MPG)[K-]90B,IX%0,"A/=%-(KSP* <0,'CZ& 1Z^SE=%IR_8^@';+]HSMF.NG
MK7"7C^YZ)+(!ZS2&B_1!R!"N4 \TY^B+@J904)_).!0Z@/0,IRQ]"^ KJUQ1
MC*W97[3#DP'<=O/BDX.4$RE,OJ.LK&*5%,$D2E,HT,)2HI% I #^24.@= R]
M-Q6D>"]7 H=X3L_=K]-'U=/@QQS3;@F"0-T]?1A$/*#IT2\DO1/R@Z?R>GA_
MZ,MY8]NBU*ZO33N,D2[6';P019-T.(VG46\;%L8.-;HP*Z2$="18*EBX6/1(
M]*FRAXPJYP;M4@(@@!S> I?$/4XQ?%I:E#\4.U-VX4+'5K?\S+0KFSTB=CK1
M3YV1I#&4DJS8HA^UE8R:@W,D+L\;),I)BBNFJEX3 HD4W7J4,JO9^+P!8'@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , TK!.VT]OG8"
MOK!3*T"B4JKH,S*>%PW<W%]-VF:>@U/U,$?(LXR)32<$Z)K+LUTA\1F_M -U
M8 P!@# & , 8 P!@# & , 8 P!@# & , UAN>4>Q.K;JK%F5),2,,>MP)FYO
M"Y]\-M70JU?!MZ#>)T,U,( F7_M'Z!U#KUP#.X.'8UZ%AX"+02:QL'%Q\/'-
MD2>6BW8QC1%DT023ZF\"2+= I2AU'H =, [3 & >;7O]?8W/_N^>X=\ATI@%
MB^R_VN7"O^H%W OEP[>6 69X P!@# & , 8 P!@# & , 8!1'W#_ -GSWB_Q
MI)?)!Q1P"5'&_P"^;QP^T/N4_I?Z3P#@\E?VI7:[_%3W$/N3XWX!:%@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# -,:B.:==[)V IXC$MM]EHN%,8PF$M7UZ/O&C@2$3&*5I(3
M,/)2*(%$"B1_XA #F/U W/@# & , 8 P!@# & , 8 P!@# & , 8 P#3VSQ"
M5L6HZ>58Q1EM@)6>10('B \+KR)D+05=4ANB:B"=N0ADN@CXBJ+D.4!\'H W
M#@# & >;7O\ 7V-S_P"[Y[AWR'2F 6+[+_:Y<*_Z@7<"^7#MY8!9G@# & ,
M8 P!@# & , 8 P!@%$?</_9\]XO\:27R0<4< E1QO^^;QP^T/N4_I?Z3P#@\
ME?VI7:[_ !4]Q#[D^-^ 6A8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!@VS+2K2Z!;;.U("LE%P
MCP\*U\)#F?V%R3U*NQJ::AB)J+2<XY;MR%,8I3'5 !$ ]. <^BUA&E4NJ5%
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MW^*GN(?<GQOP"T+ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@'XN$T%4%DW1$56QTSE73<%(= Z0E'
MS"K$4 4S)B7V0'T=/9P#4^HJK7H9C8++6X*.K<;>9@)F.B(9H2-BTH-HV3CH
M1\A%M@28-'$ZU1&16%)),QSO.BGB,43"!M[ & , 8 P!@# & , 8 P!@# &
M, 8 P#"=D6OWC4&WVXJ95W$# 23]@U,8Q0?2I&YR1$>!BIJF \C)G10+T*;V
MR@>@< _37=4)1J)4:@0Y53UZOQ<8Z<$(! >/V[1,))^) ,<"G?OQ46, "(>)
M0>F 9E@# & , \VO?Z^QN?\ W?/<.^0Z4P"Q?9?[7+A7_4"[@7RX=O+ +,\
M8 P!@# & 4!]K#8I%^8_,JF^NJ&]^S^V[%*BIY?B>N(+;UC9K/UA YC"Y%M>
M4NOH#^6(#U$.H@7^8 P!@# & , HC[A_[/GO%_C22^2#BC@$J.-_WS>.'VA]
MRG]+_2> <'DK^U*[7?XJ>XA]R?&_ +0L 8 P!@# & , 8 P!@# & , 8 P!@
M# & , QVW6ZKT&KS]VNU@B*I4:M%/9RR62>?-XR&A(>.1,X?24D_='3;M&C5
M @F.<Y@  # (\?/@XD_A]UY_K8_\WP#L6O,WB<[2%4G(K4#< .)/!)7J!B7
MB  /B!K*/&;DR0^+T' G@$0$ 'J ] *(N9E!G]_<V&&\:9S3H,1J&-U?"U*$
M@M;]RB\\87$3;F]Y>2LC,3%?UPJ^+-1;BK1\8BNY;F;RBIUGZ "JEZF* $M]
M$;0L%9N-9GMK\N>,"Q*R9A[IM8CE<6X4*SMYII3&LNTJE3F:9!VRG-M<1L3,
M-(A-]*NS2[F2!Z_45,H=%L!90YYE\3FJ)EC\B].KE*)2^6POU>E'(^(>@"1G
M&OG;LY0_[0@00*'I'H& =9\^#B3^'W7G^MC_ ,WP#GH<S>*+MN=5#D5IUN</
M&0B<K>X*)5\P"@)3&:R3QF[% 3"'MP)X1Z" "(@/0#SQVS5>T)'E_OKD%"\U
M=0N(NZVB,F-4Q;SN;[7H&G(N*CH6G/EJ_LW0>NS+I3U:>7!Q;$%(QFX!F_CE
M(,SI,BJ,D=<"S[C;NF IL['R^X>3W'B0.V&S14V_?<I(_94W/)BNY4AK?%K@
MPIL)%A9#K$.M$*1R8021 :MU7! !7 )ON^9W$YFF50_(G4#@#' @$C;S!2ZX
M"(&-XC-HIV\<$2#P]!.)0( B "/40 0.O^?!Q)_#[KS_ %L?^;X!S/GE\5W3
M%99CR,TJ@Z,BN#1*8O\  1ABN2E.5'UMF\?-I!) 50 1'RP$Q/27J @. ><R
MB:;V]6.0>[]P+<YM3N7=]W/LNUTI6=[FNT/@>C-<7.0I;.&CI_CC7"OJ\[LE
M8KK*<6C&!EEH)C*.&2I2)D0%,@%L?&;=%:HTX2Q[:Y9:*=-I.N(P\E5Y7DU6
M-KRT'(,3*D=2;"Y(5K7;>9-;)!JG*+"Y9*&:F>K-FY6:"*3; )J.^9W$YFF5
M0_(G4+D#' G@C;Q!RZP"(";Q';Q3MZNFE[7H)S% @"(!UZB "!U_SX.)/X?=
M>?ZV/_-\ D96+/7;K6X"XU";B[+5+5#1EBK5BA'J$C#SL#-,T9&)EXJ0:G4;
M/8^18N$UD54S&(HF<# /0< [W (-ZJ[E_ 7=^PEM3:KY9:7N.T$GKR/+KUC;
M6S2Y/'<>!S2*497)0C&5EPC@)_G!FJ2Q$!$H'$HF+U EA4=BT6^GE$Z9:H6R
M*PAV24RC%/4G2\4K(M0>L49%$H^:S6=,S J0B@%,*9@-TZ"'4#-, 8!@5^.N
M_9,*>Q.HF[N3LT6Z61\0'95I%/UBTO\ S"AU0$8OJT14#H)';Q'IT]D ,Y22
M2022003(BBBF1)%)(A2)I))E B::9"@!2$(0    .@ & ?I@# & , 8 P!@#
M & , 8 P!@# & , 8!IO:)AFK#JFAI']$Y=F]OF2"3Q@%=UBF6V%5]@ $37=
M."0Z>(H^%<QO; 02& W)@# & , 8!YM>_P!?8W/_ +OGN'?(=*8!8OLO]KEP
MK_J!=P+Y<.WE@%F> , 8 P!@# /)1VYKW[@]P6NR$H<C9*\6_<]&05\SU8CL
M)@+%*1R:P )2F,,A HI$1, ^)7PB4I>A>H'K7P!@# & , 8!1'W#_P!GSWB_
MQI)?)!Q1P"5'&_[YO'#[0^Y3^E_I/ .#R5_:E=KO\5/<0^Y/C?@%H6 , 8 P
M!@# & , 8 P!@# & , 8 P!@# & 16YO")>)V]#%$2F+2')BF 1 2F!\Q$!
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M# & , \VO?Z^QN?_ '?/<.^0Z4P"Q?9?[7+A7_4"[@7RX=O+ +,\ 8 P!@#
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M[0^Y3^E_I/ .#R5_:E=KO\5/<0^Y/C?@%H6 , 8 P!@# & , 8 P!@# & ,
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MVHFE'-D46I(QR6L-&Z0=#F/T8P"1SG,/4ZISCT* @4'A5_K8_ A\MS?OUO\
M5R_3,8NF\...MI\M5V)M_25"M!F:$B6MW38%$JT^:/=&4(U?%AYR68R(LW)T
M3@FKY?@.)1 !'H./"K_6Q^!#Y=F_?K?ZN7Z9!*6XX]HC8C%_&0FI>#.VY:,9
MSMC3IT<^U18';A!['1,787Q8U@O,+"#J$BF;10_JYBG;MT&XB"8$*#PZ_P!;
M'X%^D4^6YOW^_P#=)_;&YM407%YB[UO1M1:)U_#FK;*ZTR 3J\!#2%<U(@A
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M^"9^!G;7FV[=N=-N-N%$W"RJV$J[*YQ>DH3A-*4))\'&233[4=AF0B# & ,
M8 P!@'&>/6<>W4=OW;9BT2$@*NGBZ39NF*JA$4P466.1,@J*J%*7J(=3&  ]
M(X!^Y3%.4IR&*<AR@8ARB!BF*8.I3%,'4#%, ]0$/9P#ZP!@# .,]>-HYF[D
M'JR;=FQ;+O';A4Q2)(-FR1UEUE#F$"D322()A$1   , U7HUHN&N8FPOFIFD
MM?WDOLF6153,FX0<7N3<V-FP<D.4BA%86&?-6 %, '*FU*4WM@$< V[@&.6Y
MW.,JS-+UAH1]8Q8JMX%NJ!O5AF'G1I&JOC%35%..;/%R*N3^$P$0(<PAT# .
MKAK-(@X90MBK-@BI)0@(DD2()SL$^523$3*A,PA#D8^<5,QA%\W8!XP$H%]L
MGXP,WP!@'FU[_7V-S_[OGN'?(=*8!8OLO]KEPK_J!=P+Y<.WE@%F> , 8 P#
M"KVZ?EB6D-%+KM).U2K.N-GS8>B\:V=@LYF9- X=3)NF$"S=*-S=! '()^+H
M7J( <]\P8050?QT8U291T77WK=FU2*/E(-VS!4$R !C>(_0I?2)C>(P]1$>H
MB. >.UGPTV#(3O'&A/[%#QJ_*K2#_<&L[>WBI1]&MGK#6DOL,U&EB.%84J<]
M&&:,FZZR"ZA2)OB."D4*4Q0 ]<6B;L39>DM0["(<ZH7C65&M2AEE 66\Z>K,
M9)N".% _EN$UW)BJ=>@^,!Z@ ]0P#MZ@W& E;#34P,$5&A'SE:*8PF*TA)X[
M]-2&1$0#ZA#S$8Y!$@")4&:R"0="E+@&?X P!@# *(^X?^SY[Q?XTDOD@XHX
M!*CC?]\WCA]H?<I_2_TG@'!Y*_M2NUW^*GN(?<GQOP"T+ & , 8 P!@# & ,
M 8 P!@# & 1\Y'[%O>NJI3!ULG40MU[VUKG6<<_O$=,S%;ATKG.%8OI=[$0$
MS7I2449LDS^2B1\V 53%$Q_" E$"/-LW?MBA3SRK7CEWV_Z=9HXK8\A7K14K
M7 S;$KQNF[:&>1<IR=:OFP.6BQ%4_&0OC3.4P=0$!S3Y?4.P8%[Q<[-Q*<F.
MFL)W5QDM5JM8RDFM5Q7#L/H_3_D[YM]5[57OO2_2_4.X[)<Y*O(QMOR[Z9N$
MG"?);55*$N6:<9:2>DDT^*:*HNX-RS/O36FSN(]PO=0N$)9(^"1?[>XU,0=4
MZ0:N'5=MB4=[DR>^TU7,G%.XL&SE,9,Z8%4$Y13./A)@75?2[[-RP?W>O[8V
ML_(#SWK>D^B^JDWZ=JS5^C3J06U=L2*U&M'R5.EGL!*Q4A(+,8RJ<:^.E2UN
MG&SE\6NUA!>DL=@.[+(6R08K$K[:7<V99*+@8^.1:,4U6BBSJOYU=,?C'!_=
MZ_MBS^03SS_S,ZI_)>;^!+4>/?<<?+N*[IF EJ-JIF^=3;U'9W(L4'M3AD6T
M<\F%(MV>(W%"+N9"6<-O+;%!PU2\Y90_3T%1-1]5]+Q[=RP5_7Z_MB^'T?\
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MWRRC>+!D=C&0+%Q8!3565<1UEDUC"E ]5$VQR*QK5FL9R55%-3ZL@(  "8,
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M0Y/-ZBN(D:IG$)IS1(W3.N":LH497'#E)_8';A[8KE+I+OUT)>Y6%P:1GW+
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M.1'7V+HOB:Q%ES(TF FC9"N\P*"V#H2.GC0.HN0L>T*82D*WGF+1KI[93I!
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M[U K9U%1KMXL>'BW*())J)NV<4")5RJ>(Y5_&'7H   &58 P#S:]_K[&Y_\
M=\]P[Y#I3 +%]E_M<N%?]0+N!?+AV\L LSP!@# & =//PK:PP[^&=G612>I
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MG%Z2C.$DI1E%\'&233X-&S"E*4H%* %*4 *4I0 "E* =   #T  !EY&/[@#
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M\F)LE0H%=L"VTN1NW;3N6S3*\*C T@S*<L%GH=$-'6:>!'W27(V0\E\Y!VY
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M%>5")CF3YA$S:;1P[8(MTP<I*BB1-!),Y$2D*(&[< 8 P!@# & , 8 P!@#
M& , @MP\^^IW!?ZYJGZ,_'#.0Z9_QIO?\*+]YXIZ+\\/\A?*[_02?^T>_DZ<
MZ\\Z# & , 8 P#56R;;;ZPO!IU6&0G!D32"3YL>&G7RC)%)FLJG,^MQAR-?5
M8UP0GFLQZNGA5.B(D$IC8!Q*!;M@3L\\C[36FD?%$KD3,M9=DQEV")7D@5$
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M_BP!ZUVI?]([>W^5XX?^+ (\<F'7;$]Y-&][KG@/ZU\X?C#Z_P"Y:W'7UGW
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M@&7<N$TB=3G* @3*8LTV+8B!!$Q@ZG66-Z5'#@_MEG"IO9,JLH(B(_\ J#T
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MCJ& 8-$*V<C9=F[:-R2"+A4)1Y'>K+^M.EBE6];9%?R#;R4ETCE\H%2'!(H
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MKN_8VRXGV[P/)+SHXXLL3R]\S+/^CLE;/IG.L?WNV7BY6Q6SD_BW2R]M7W[
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MAXW4DI!T91VZ766744,!.GX<]Q_0NWY_Y[XH?K'8 ^'/<?T+M^?^>^*'ZQV
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M0.(&O]'Z\Y?,-7Z[1VI?P/<&["G.;<SD9="6LH-VL<9*Q1$I-0IQK,C=?-,
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MV3Y%'S%6H)J&*0%/*.8"'(80, &I%M5R5/6%Y0+5)TA450.=H[7<V*E2:IO
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M*J ;6I<$I6:I 0*R@*N(V-;H.CE.8Z0O!+YKP&XF HE:%<J'!$O0 (D!2@
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MO7TRR5GH'5VB(&RS=F?V.N+)0[EWK6^WU]*P,G$$?K2*,B4B(N46PD44'Q
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MST8 P!@# .&_CV,JS7CY-FVD&#HGEN6;Q!-RV7(!@.!5452G3.!3E 0ZAZ!
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MP$@HX[Q2/8J2 -ROSLVIWP-2.$VH/#($,Y!L1V4CLC<%A-X 5 % +T\0 /7
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MKF]<P%X82%TI4"3(L&3!VX4DXU8SIT\1D_,DF:1K,HS2:QB9DBJ-UQ4ZK+'
MOB3ZAE]?37D?'/YI[[F2PG.4DO#FM(1<-*YOP%)N>L^6<=/92UTDR/E^=O\
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M4R"):$+:DW%*4;1HQB)$P0!DFB8RPG72;B@/J[U4BWEJ*I&(=5(A"'\14R
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M]N1?YOOGW_F1U?\ D;<?\&.63E9Q=4*4Z?)+09R'#J4Y-Q:\,4P#[ E,6Q"
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M'3:+Z/JVO"PA'M48&,JE"2#APJ3S 6,3'YV=+?C/;_[XI^W'\WWSZ_S(ZO\
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M'M]F_9D*.3XGR>BZ5&/R>B"HJK45V*.B7!$Q,Z$^.# & , 8 P!@# & , 8
MP!@# /-KW^OL;G_W?/<.^0Z4P"T._P!VL##N<\3=<M5(TM4M?"SFA=9QN>%B
ME9-U8]?[:X6052=I3RC0TRT0B8O9<XF#=)8J"GKYQ,41Z#@%@^ , 8!!CDIW
M,N W$--T7D+RNTWK^8:%.96GC:VMFV 82%;'\"6O:>6?NJAC%=IF 08>'PF\
M77P@80B9&=AXO[?9"+]&O'X%Q^H=!M/2O4>^M?-6%?=!O3F46H?NDM(+WY'G
MBY-_XP3B=2"OXGBOQ_VGOF832,1G:+^\8:<H9G BEX'"#=1O;+Q(MDR&/XDU
MHV-.8Q0 # 4WC#19/5.'7JL>,K)>OV5]=_41]7V7R$ZCS>6S>+Z<2I]J6MLU
M[J]F*U[FI2//'R8_Q/O=2W_Z_&4S8=*XRU5V8Y"1.C*@W:V &YB"0"+WV[+V
M^U).2@<?JL>K&^GH(% 2@(:')ZEW&[A6XUQ]2X_"]7\&A]:V;R0Z-VU*>;&W
M,O7?9+V=?5&'+%KU24BJ2G]PWG?0MC.MN53F)R3C-CR#D'4K:U=QWJ4?S2GG
M$<"E/H3$U(,)YD=5(OB;O$5VYP#PF()?1FKAN>?"SQ8W6<_NOC[OI.YR>B.D
MLK$^0W;?B?)DM$E7%<OKCHEROUK1LO-XQ?XL[N)Z@"-B-\UG4O*>M,TVS=P\
MGX7X+=C+MT"MD1\%MH;8E84<G10,(K.:\Z5.JJ8YS'] !NL;JG-KX9$8V1^!
M_"N'U#YGO7D+TUFMV;1==AVM\%KXE:[?L9OG_P#F):'HIXQ?XL7MQ;C!A%;S
MB-K<5[,Y.FDX<6VO'V+KU-0Y!$3(6_7J,C.%1*<O03O(-D0.I1Z^SX=_C=2[
M==PLYJY>M:KX5^DCY'O7DCUCMFMF$JLVA?K)<L]/7&>B]Y3D_?/01HOE5QIY
M.0A;#QYWSJ;<\4*955E==7NN6ARQ*<RQ"EE(V+?KR<0L)FR@>6Z114]H/H]
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MR9I\U"V.5W[SCW)!1DB12?UL'(,->.K-%+MW#51&/MK+DAYT8]8.5TG90%1
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MJDI/UBQS#&O)ZLU31T%I9]3I:=KZ3MY*TIXH1%%VN)&YDQ.(',)"]>>=23>
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MQ#%.8"3'&_[YO'#[0^Y3^E_I/ .#R5_:E=KO\5/<0^Y/C?@%H6 , 8 P!@#
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MSVST8A:,C'\U))2?,;6C!2/AXJ.)+R<L^(ZY6I&:1D=$J%=+KJ 5)%N8%#F
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MCA]H?<I_2_TG@'!Y*_M2NUW^*GN(?<GQOP"T+ & , 8 P!@# & , 8 P!@#
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M[B;-RCVZ^[I)*)E!E.[(=O(IP19!8CMM%T'C95)!0OD*JBD9K8:X]:G(IX%
M4;FZEZ" B!)[C?\ ?-XX?:'W*?TO])X!P>2O[4KM=_BI[B'W)\;\ M"P!@#
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M6'DG3!TV83*3#4<&Q>JQ;U9$C:239/$S(JF1,<$E2B0W0P"& 2<P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M:%@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MT,:/:5)ZR[$@TX*"=H5LP+3+./I#:172,<!1;RJ15?+."7K $@?F4</?HN:
M^*2C?63 'S*.'OT7- ?%)1OK)@#YE'#WZ+F@/BDHWUDP"";'@UIRT\E-[,->
MZPX]T*.J=ST[(V1K+<>]>7=G.U:2T7:F85R-CY)BR2@E1N<A'2RCE!1-13U
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M2*V7VIHPIDF"!BQ_#SDNS*9"*9LHZ+1$&W+],!2C8^-;(-R^PBBW3(3H4A0
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1CBBS8)$.I( "94$D0(<#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g570173page099.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570173page099.jpg
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M96(1CT5!*BHYKD7KF/V5M58U3C#J2"/@(Z$2L#D9'9/U2EIT5%2IK$5/:BI
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M<RI,XQV6BK;(K5[G,BZM>R^,]CE']J*G=J\N5)=U^%J]?@7,J\HCVC?;CB<
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MY^K86'%6^2S:GX,[FMJ4)^PECH_V"H,H;CYHL.U<-]XY_.Z2CO4K 8.ZXFW
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M%%C1IVU;I9!#& -H@ 8.QV.4SPA#8C6ITZ(B8B>AG%7&3%Z_N?Z@9?A[IE#
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M8>++ :-)"1.K#1SC<(PGI]%A!O5%_$7+&FVRBU;Z25N1@RD=H(.01]H]9]$
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M+/F#R]RP\M<7L=E1QM&VN4U-;9?XBW"G<*UM]CO;6PN+CPR4"T!RJ$X.[>=
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M'FQ6=55C&/Z/1$Y6;]JW)/I Y)@I!Y#@4=CLM/=;)7;MK9&5=-M%/JQZR+9
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MM=XX!I*JAH]3V&_B7]+M=#6;Q=;)0:PZYU?D06SU\NSLM4B3[IGN^17H<(V
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MB:R\<%N"^C;@-=AGP[2_'K>M1KRPKA315\NWB5UA%LC0//B&<\)\P+_".U2
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ML3]DMJ;1]3 ZM6Z2%7092CD[C/V,0E=,JTD$8R"%JR7+W,Z,:ULAL_(WG"Q
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M*J["$0]PV.%K-AT!B5LT46MP^A5+$=N,=/@SDCK]CMQU^#-?=$_NF_\ C?\
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M7<@BI\*(5JK\.93YC)NV?$[QQBZWC &^$^#N-QMT;[7AU(H^RI^"4*>C6+Z
M_P"> ?SS+)S%I7E8;&4>O<BZ9L)504#985CQ]9'<1K!,M#D%?Z>\_=T1&//!
ML88NJ_&DV F)\9Z(N6\6C<EY8WW&)UW.TL3>(,9)K -.YQ]D!Z;6^!*78]%.
M*#]RY7]# J?M]H_FC[9E&5OI<MX1IL1_*#ZG4Q6]Y*IJW7-/J@7D"CL+F?:5
M]5+O]FF[16&=419C8K2!JXZ*(+5Z(O7,3 ).!VRO/U#QKZ;:V0V'<65ERG<@
M([Q:VQOMEY*D>(WX6R='UA9E!&1%3X%JQ,3\;,BH\I>8KJAN'VKT;4C(LW!7
M;UD?8LO:M#]PF43?4#@-EO@'4_>&9;5#+EU<-E=QOPR+6ZMRJK'VZZ_QY2]&
M^QI&U5)'O-@&[HOL::L"OXV5CPG"[3/TGRE)<?$VM;[A_M:F\"@_;6]IYXEC
M>HA^VQ _1/YDS:4O)5KV+;;K4ZV%557P]+UT,B<Q%^ :W^VEN8DA$_NFU,=?
MQL'?^5=GD;+87;JST-NKBJ'[/@[85,OVCN'$:;V]9@H_G1_-.?SI_6\5ZE(5
MC]A9;;H9CE>J[G=6.P07O7VJ]M!*.FLQW=?^9A"1/I9X?.',U97C#3L$/]ZU
M)2^/@\91X[?T5K1[/6?7RQ_GB3^9V?F2=P:^!5Q10JR##KH04[0Q(,8,2*)/
MI"CQV#$-/QD3,>W&YW&[M.XW=CVWMVL[%F/VR2296 "C"@ 3V90GL8B,1&(D
M=O=OU76$8NQ;'24CBHK@BL[.'#/(Z?VL:.<S#R7JOL1HVN<J^Q$R3X_A.8Y8
MGZ,VNXW '::ZV8+^F8 A1]DD"?#V5U^NP'VS(S^Z,R?T35]/W;9^YBO9)'1K
MK56J? UZ6>['UD$H+OA[XJ2>J>U$7X,EOR7;;=>7WVPVF#@J;?'L^UX>U%Y4
M_8LT?9(E/QL_-J[?<P/OMC\S,=W*]MT[1:1I4=S%^,5]OO5I[>O1'!$FF5L(
M[4^D6:-%_NDQCR=L^T[_ ']@/H%>TK^^?:G8?T-1^U'[8;\!1]UC_P#DC\^?
MQ= MY/0UCR;OQYR(BM- /KM-# _X5\O60-=;%*/K\"2_-NZ?"Y<?E'LJOD]K
MQ/&KM_@<76L1]FQ[M0/V:_#'P 1X+'JUCY^X/S,?GYGWK%I?U^S6FC[-8BO"
M1Z>)L6N[#Y(-=/LZDTV576$*ZB0T'6OMJ66,"OD111@'%,'T -S'*_SEMIQN
MYXFGG^*J;;JU[4W4ZBZ5V!5=&J9LN*[5+X2QG=&K;Y1@PT^ULXL-3G/3(/9D
M=G7T9'V,=O9+&S%Y6E<<H*PM%2U;D[ENM[X_K^Q%Z=X0[A3VL]GXJ+65A^OX
MG7,H\I!DY"_=CIX'';Q\_ 3MK*T_YRQ?NRA?Z@7X77\\'\X2@O4E>S[G8J'B
MU[T!JIZ!^Z;9'8JN)M#07(JVCUF;\#1ZZDL)9<\7QEGJ(,=_2.L@9L7E>4^R
M2"0XGA20'>QY6E01Q&>P@C. =I$8]SFO#(8YCT7HK2(K5Z.14Q$_3$2(1/C<
MS:LG_,:+<O\ QO.;UHS/ZG7R/];$3=_$2\,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2GMFZ[;R=J.H,ZOJ=*CLY)V=$ZJ)
M]F\LNHX_K#.:[IU=8"GV?:OY4E8%WP*F(EPXB,1&(FHOK'Y@MN.>.H>GZ/YF
M3ROS!8MT308%<3PK0)+(D6#;7D,G3I&/ 99 BQCK\4%C.BO>GA-(J(GHXLXL
MJ_3=QC0:N>6.D'2Q6R+SD*C>ONRSO[#L?8GV?7YW>\D!)3FQ(1.DAX((0B:6
M*C41*E5-M]@JH5GL/8%!)^\/@]/P"?+.J+J<@+\)F9TQ#@';<H6SQZI*W1H;
M2)?0A)+TJ/IL!#DH(FSUA)'?KQY$>0:SL#*0/@RII!/G/036)*<M973X?%;<
MAJ=MD,RGNV7-CQ7'P@$"M#Z4K##UC+;:J6U;IP0]F, ]JH,Z1]W)8_98CT3F
MW-DWWK+]0<4 B2(VO[((E?#+#?(&FK<#ZO+82[OHY7@$>';\D3YK?+/>QIAD
MM837=4KW*D/+N=L*VM@4U=7U%5#CUU750HM;6U\03 1(,"" <6'#B@&B,#'C
M1Q-8QK41&M:B)B)[<1&(C$1B(Q$8B43ZA)\6MTJ%)F/,P2[#! U(\.=8'(8T
M6>@QBAUL:7,,]ZHO1&#<N(FI<5=@L58E/Q[R?;H3HHR"T#8*6.1%^!S)FWQM
M9@JQ?I^+T_%Q$^K7BW<K6377&P<,:U&/5#F#J;WDW8^-H1:<-D,8[%M?.A%W
MFQJQSPB:V0P31^,UB(]%1$3*^WVNYW;^'M:[+;/@12Q^\ 3/"RJ,L0!/V%KU
MLQ& -R)P32A")K$B:]9[+R7*B "Q&M&RLHHFG*)D<;>B-1$:UJ=$]F3U?D[S
M38-;;#<UU_A6H:5_IK="_FRD=Q0/C G['7\Z8"TM>-J'N=L7J$L3=IJN.^!I
MO'=%K$UQ[Q"K2QP!Y$D['+*6X:!ZQ$8CUD-8YS.Y$5<^1Y;N0E=YN^-H(]#;
MJIS_ $M#6MG[&,_8CQA\57/]"1^?B8GY>>G=E_K&M1]BY,Y%V'<YEG UJDC<
MM5"+:3*78K'4+F,5O"LU8%:6JVVHE5<D<IP'AGQR1WM0K',3T<3P59QN>6H)
M_J5&ZL_->FD?FX^S'B6GLK/W2H_.)F"JO7=3ZAK=QJ_$WI^VG7X>O%UV8=]P
MS8;V=*E\D<M3N,(-P"FKZRRVW<26NXQ)I?."),).%'5T9);G,&OBU>4MO\I9
M?O\ =,.Q%IKH5OL&YKK64?#BAC&;ST 5?LY)_,P/SYT0]/UY0[=PYQ_O6O@L
MP1>0M<K=\FK>GK9.QDN=KBBM[=-E/4JM?[^B3I#X\D0D8.(\/EV#$P31,L.7
MY;<<SO/:[U2M BI76F?#JJ0:4KK#$G2H':269BSN6=F8_==8K72.OI)]))[2
M9<F1<^YC+FFJ]AK)E-=08]E5SQ(*5#DM[AD:U[2C>U45KQ' 8;2"(Q6D$5C7
ML<US45+O8[[><9NTWVPL:K=UG*LO:.F"/@(()5E.59258$$B?+*KJ5894RJ]
MEUCAK4HH;;D6UJQ5WC)'CS.5M[L+:I\?HY[ !3?;^96>,C4541K>_P!G7VK[
M<G/RQ\P(I79VU[3/:=M31M6/VVV]=;?FX]'9*?L]1]8%OTQ+?GDREMC]<GI6
MT"GM_<VY0=B!K&IS-RFTW'U4DL4/78;B=9*2R)4ZS#61'$LH3"S!*ZO[9OLA
MN:=<>OW&XW5IOW3O9>W:S,68_;)))E4 *,*,"6EQ/SH7E/<=OU?]S[8],C:Q
MJ/'FY0;+9[/7"RMEJ.1DV9E9+KJG7[.[=#AP)NHSXAWRCA*LJ.]&"</M*ZC/
M9?V(C$1B)&[W<=3UCL38MDI*5Y$ZA!96<.))D?2;%BE*V3*>Y?@:-CG*OP)D
MIQ_!\SRV?HS:[B]1VE*V95_3,!I4?98@"?#V5U^NP'VS(W^Z,D_XNKZ;N^S=
MS.YDIM)\EZM>OY5WO#=Y&M,D@=\/?%9)ZI[41<E?R8.VZ\OOMAM,'JOB^/9_
M2;47Z3]BPI]DB4_&S\VKM]S ^^V/S,QUY7MNG1ND:5'<SX7.M]ZM/C?38WY&
M5L([4_OIHT7^Z3&/)VS]._W]@/\ 4]I7]_\ ;3L/N5'[4?MAOP%'W6/_ .2/
MSY^9= 9($^1N&];G>A&%SI GWK-/IA,1%<57QM+!K;BQD;UZMEFDIV_EE7'Y
M3C;=.(V&PVO7HQJ]HL_IMT;PI^S6M?V (\'/SC.WW<#_ .7'YN97H^4_3AQ_
M(-%UJPU:5;HU[),3CFC-N5Z4C>J.'9ETZON)C#O<G173",]OM<Y$]N1?(\[S
M7+ #D]UN+T!Z*[LRK^E0G2H^PH $J)577ZB@'[4C5IZF+>5U9J/%UGVJCD2P
MW[8:K5HR+\#2#K*!FZ7A&I\*L."&[Z"JU<BI]RM[3D[F:^ZI+WFLU6.Y'-=#
MT'5H09/8[KU:^]W0NVD*Y$7IX@84-WT41JXB?CQO;;/2\K<?#C[EN5L';KJU
MU[98.S[/;[-!M*Z/I>W;-'DBA6\F1$I+*NLJ(2A+7,B-41"B(PC'-\-$VZDN
M\7ERG8B(B0N.-E<Y?HN]Z;-JB,1?Q&>Z'=/_ )2YE%0T>2[V_7.4H_YNC<9^
M_P"(/O2B?[8'V$/YI'Z$L?,7E:5UNBC/L_%4!R*Y7;G9V;F_0\*KT/<$:YR=
M/@'.F 7\?IF3\%JKXGF-R.F-C77]VS=[;\]%?[DHV];*Q_/$_>4S63FYW_OP
M1R]52-Q7JZ]$7HO27N.Z.=T545$5?=Z?D9C$K3GCZ?/3ER%Q3S%RYR'N&XT.
MQ:]N:["/2J.OG;/+DZG&V3>7[C:1(,"RB5U%KE/82>ABQ(Z3SNDJU7RR>&XA
MT3<[$2(5GQN:('_U#C^J3\99V_/7_P 9*W^MB)N_B)>&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3S3)D6NAR["<<46%!C'F3
M)1G(P,:+&$X\@Y7K[&"")BN<OT$3$2F^"*.QC:I.W*^GV5IL/)EU-W61*N60
MV64+7[!ZLTC7BLA1XH0CH=19$$X:,16R'&5>KG.542[<1&(GX2I4:%&D3)D@
M$2'$ 65+ERBC!&BQ@#<4\B0<KF"" (F*Y[W*C6M155>F(G.[T\1)'J2YWW#U
M57L<RZ/J!97'_ ]?,$YC%BQ&R8]IMC0$[%9))&L#?&5JJV39R(Q/CUPE1$Z!
M7E#2;-5RJ38JFONZB<UK)=;:1 S84AK'M(Q"QY#'C?V$:CD54ZHJ(J>W+C:;
MO=;#<+NME8]6Y3L9"58?:(ZRG;57<AKN4-6>T$9$Y\^M_>J/1]:@\3ZI(37)
MN]5$J;O[:L_N^KK>)*IBQ;-DZ(+I&B2-MD1TK!G&P9W5PIZH3H'M6B[O8YLL
M)-C$DD]I).23]DGJ9]@!0%7HH&!]J6AZ+>(#:)Q\;?MB@/A;KRH.NN3PY(4%
M+US2HHS/TK5R"ZKY62R%.+8SA=&N'86!@NZM"/I\SV;F8B,1&(C$1B(Q$8B1
M;9ZPUNE5!!<6U$]\XKUGTKX YZ#' EJ\#"6,"R ,1T7HY6C0B=/BN:N7FPW:
M;+<C<644[A0"-%H<ID]A(1T)(] )T_"#/EE+# )'VO\ \<S!?N7:Z9G9:66Z
MWG5>KTM=]W%\<B_1\2MB74.I5J_2\!$_$Z9.?E;R=;:MG5L-O\'A[/;!A]IV
MJ:S_ .?,I^ A]8L?ML?SLXD5E1^ ]4LR5I*725V"&X:2($#7(^R;/'>40I O
M-1:VNM;T9"@*PC?$;U<UR.3JBHN2]-OO&YC:#=+?O_HUP<.]YHH8 D'2SO74
M0""#@]""/1*9&TK;3A-8^QD_F F1GF.)5\R\1\D</UNK<C A<A:/LFFMN(&E
M/I&TC[^IE5T:WCQ=UL-(#*6KD'8=!>*)I?#[>]J+W)$OY;LZV\ER'&U,>W5N
M!>WW?91N#/L7#L1'/W,?JL32,7S<\/8-H%N6P"V0=\,6ME;X>R:OJ%%'M-8B
M:A619\?79E3Z@QR02ZG1*T)XLV7+&1["D<Y>X+8]'Z,\NT#]L\HUAQV;?:NX
M^_N+-K^IGNNX^JF/ML!^<&EHQ?0[P]0[4'?)?R(TS<8YY4LFP0]LY&':29DZ
MYVR\L)LPU)R!QK1OG6$O=)@Y!FUC'2(HXH"H\4.,T?UXGD^C 6GDMR?A:ZG;
M@_T"TWG[GB?=C&X/I1?N$_S1^=)[IW!?IEX]2F=1[?H5/,URLB4M')H0\:"M
MZ>FKT)[OIZJ_M*O8]YAU==XK_+1V6GA@[W=B)W+U\7FN*V_39\5M.GQKGW%S
M?>-R5?\ -1X;GUG;[@ _F9_-ET0K"96P)^P<<;I/Y(KJ W79-,LGUEA-D12#
M'.DNUNPA5M=91-C\H1QXPI+I,2P=]1^HN)YD=]L]YP?.VCCN2VVVV%]AQ7N:
M=:(CGU?:*V=T-+' =T"65 ^)FP*:F^66VH:T)8#M!](^P>W/V\@]G3MEVU=G
M NJRON*J4*=66L*+8UTP*JHI4*:%DB+('W(UW88)&N3JB+T7VIF*[O:;G8;J
MW8[Q#7NZ;&1U/:K*2K*?L@@B5U8,H9>JD9$]^6\]FCAO1?66W-^^<I[#L\6Q
MHMDV_0.0*'73:^*VN:7;](N]?M4G+M&S3+N;%KYU5765(2#!2+#=3W9A-$)P
M0NQ$SNF^@CTN:.. *HX]D&%#U;Y'28D[:=I=3WM&>IJ*:WC;/K,.WA:ML3-C
MC4<8MB.7"*"7*:^0\?C%*]Z)?X"<4\3U\*GBKI&A0HT)L*NJ8B4]&]T)DN9/
M;$@UX$!)E-=86,@_8-CW//((_HKR/597CN#YGELGC-KN+T':R5LRK^F8#2H^
MRQ $^'MKK]=@/MF?S]T59_Q=7TO=]E[F=[)2TOR5J_;T[7>>W<^N.DA7KU[X
MHI/5/:B+DI^3 VW7E]_Q^UZ]5\7VBS^DVHOTG[%C5_9(E/QL_-J[?<P/_FQ^
M9F/_ 'L6WT=(TH#F?0][[U:?&_%7Y&5L([4_$FC1?[I,?_9VS_O_ ']@/]3V
ME?\ _=.P_8C]J/VPWX"C[K'_ /)'Y\_,V@!.(DG<-YW*^ ,+G2!FOF:C3"&B
M=2J2)I@=98:+TZ]6RRR4[?RRKC\I_9NG$;'8;7KT;PO:+/Z?=&_2?LUBO[ $
M>#GYQG;[N!_\N/S<RO1\K^G'03GB:S8:O+MNUS),/C:A-N-R4C5Z*.S-IM=;
MG&=SD]KII6>WVN<GPY%<ASG,\M@<GNMQ>H[ ]C,J_I5)TJ/L* !*B55U^HH'
MVA(U9^I:ZEH]-0XML6B1CU6SW_8JO6(HD3KT.E;KS-TN7#3X59(%"=]!5:N1
M<^Y3UWS=R/:V$:HM.5-:U"9/LVT(*'0Z*JC6I;>123ME#4/L]QD;C+6R-KE=
M(G#0<."5\4+BL1$3KB)$YVM5ET4<C:"6VZR1KW,/O-Y;[>P;NJKW1ZZ]F3::
M"O5>O2-&"U/H(F(F=",<< XT<8X\82=!1@#8&.)J? T0!(T0VI])J(F(GWB(
MQ$S.B?&YCX@'TZ]E]MLI?Q$#QMN,95_J+.1/ZN(FX &^)R[:N_S/CB@:B_2]
MY;-LJK^3[J3\C,HL.GR72/P^4N_^2BC^R2@/[9/V$'YI/Z$L?,7E>5U<,;)Y
M1T4*N14@:GR!;*WV^POGM'J0._'<*S.B?B(N9/L2:O*/(6?KF\V=?W-&[L/Y
MM:?F2BW6]!\"L?U(_FS5SF=Z%YNO%_S;C/CJ/^,I-EY3DKU_'1Z?D9C$K2#X
MB,1(A1_'YEF._P"8TGCX7XRRMVWDO3\=4B)B)N_B)>&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$2C>7K5+NQU/AB-&LG2N32S
M)%W-#$DI6PN/M8/72MV'(LVM\N&7<QI@*L0O:]?>/?T1&]<1+Q:UK&M8QK6L
M:U&M:U$:UK6IT:UK4Z(C41/8F(G]Q$8B:5>MNRY#L]*T[A_CVENRFYMVL.E;
M%ME?5SK&KUC6U\N:TC6[X#7NC,O8Q'(1"]@3UD:<+Q&%<'N1-IM!TBAXVTS6
M]$UB.Z-1ZO51JJ"TBM=(.@6JZ1/G%8QB2+*SEO)(DEZ(II!7O7VN7$3W[7M%
M'I.LW^X;-.'6:_K-187ES/+U5L6NK(Q)<HB,;U>4GA"5&,:BO(]4:U%<J)B)
MQWXFU>\]5_J%L]EW6 1M&Z=7<@\B5Q^TL>JU>ND$B<5\1/>T:@<LMU<I+$:(
M@Y+(=FYW3SS55$[48B,1&(C$1B(Q$8B,1(QLDFTB+4FIJL5Q/\\5@X1[%E6'
ML? E^(8LQ\>6HV"1$ZHT3W+U]B8B8A7<H3'IT'H>O"7IU5Q=@V\J)]'XC1:2
M-%_^<J?BKB)@J'CK9:EMJTG)-L+WS>W&P3$H==UBM1TRYENDE&TES7[/*\O%
M8K0A[BN(T(VM5Z].N2'(<E?R34M?@"G;UTJ!G&FI=(/4GJQRS8P"S$@#,^$0
M)G'I)/WYG&\=UI4=[TV#>;E7IT?YK=-@@!?]/NAZ_-I8#D7Z2B[?Q,CY]PSB
MSCU%[C:I5V#OHNN&&NW+]'XRVYIJNZK]/X<1,K%T72(+D?"T[58;D7JCHNO5
M$=R+]-%##8O7$22!C@CM[(X @9_<!&P3?_!8UJ8B0$O2JY2B$1S6 W'39,0K
M>WIW66EV@I4%$<B>TTFNVR6J^WJK(J?0:F(GGXU[:T>X:CVC&NJ;K=CB"9[&
MI3[.\6ZU'ALZ_%C1 ;&Z&SI[$6(YJ?E<ROS5G=-L>:R3[9L*BQ/Z[0#M;,G\
M)C0+3Z?E ?3*%'=U5_@L?O'O#\_'W)9F8I*\KN^N=FL-G33M1+65A8=)'OMC
MV.V@&MAUL:TES8%%6U=2"PK$EV=D6JFE>4ID%$%';W",IVHS)^.V/$[;B?IS
MFA;:C[@TT45N*R[5JCVO984LTUH+*E"JNJQG.'05G51=K#9X5>!@9)/7&>P
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MIT5\DEEN6]ZGDVO<+M7\F>46720]J[?=% Y["J^UZFK7L8YU/U9, !6R5?\
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M!_V=RG_>\S']#Y2_[\GK@_9QQ7^"),?D'RO\9?,'[-1^]X_WLO(/_@E[H/\
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M-H#KU=]2JAR93B6IHVS6<P&;A';U 0+'L'II)SI91\X^-.GN,"Q03+:>^O;
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MJ[V>A!'0  =  ,!0O="X"]W$I+FC?"\:LKM@UBIFV]Y;;7Q_INP@A&J05=?
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MQRFUPEB@8UGU-E(P+E6!X7U%P5[T52.*Y;GA? /C,VH\KKQ?KQK##.D#'05
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M+<TT4]DMO)>V9I\%&NFW$Y1N(2TH1.<P8;((V*28CE:$P6J1RM*U%)#\I:W
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MCOLTEVONEM7V]/?B ]V]JV#G?%2K\3Q4?]45WENA%Z5^E]P=W^3V1]-Z,FS
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MU/40Z\M7>V;'\GR+=^JOR#*&I3UDTD96]O0RL.]4GQO6<:,+9R5^?<IZR)Z
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M[1_N#;5'-LU.A2RK0;WN592N0Y.]4(YZ=J-YG^M3P^SV/D;B+=F&K/Y2[$,
M<BPZ=QA[,Y+6 Y^4SK;)#%AC'>'_ *;'*;O>_6U\OU;LA_E 5)&#7^V-OE4Q
M@*A '<QI7 *A3G/6?A+_ &,\1_O8Z#^U6ISJ;A?X'VG^#5?J%G%?O._VD^8?
M\^;_ /=5LL[)*8/&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(G*;YXW^:7J__$]Z9?XV*+-<^\[^!-G_ )YX_P#=-<[1^HQ_M/\
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M:@>O@HIQJI.!X@.#:0')5EK\.O\ 3*5#V"BLGA#ZU;'#6']=8C.+1D^&1D5
ME &5K/$]H=LC1XDSWX-:VVJ_ '.K!^)*))+*>H8!:1&L0UK%MCM[(RL9XCB=
M1/:TK7L;<5\W3738.1'A;ZG >L98L6.$-6!FQ;#TKP,ELHP#AE%!^'MLN3V
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MO8QMFP;'$6OLE:U@8]['"Q7+T1HY8VJ0:(Y"#'7VV[NV%R\=R;:E;I3<< 6
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MB1$U%$]BR:\ T^UOZ)0-3K"]KV)X'<T5%:5\MJ/94 \O#M11_:W\\@'XC\)
M/DO67Y/(2JUK>8&/M#9YT]CL?[8_G7)_'?@L?G?5;OX+^Z?:RK>2^DUR0UCF
MM$ZXOQ(,X*>.<;##!"5R/!+O9<<C7B8J.''&Y#%1440C7.YWEV]N/'\4V" /
M%N&"*E(! 3M#7,I!4=512+'!!1++?;[2K9U#?<DN02?#J.0;"#@ENPK4I!#'
MHSD%$QAV3PMHETY%FZO#*6L>YQKV@$KS2)A2.4DF_KG$<XA]@*]RDEM<Y76*
MJKU7S'M);#CCP7[8X>LMLR<W4CJS$]6N3/4W$Y:P$YOZDGQ>K5SO_IKY#E7
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M=[F2F[A^*FN>)\;QT=X?O+N^K^/V_P#XMY?(SA_:?;3]/Z?I[0=&GYKPNF?
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M/NFKX5?$-H+VU %A0"3G<@#J<G):A<->P+5X86EM?;"FCEML'Y=O#%6$KM)
M-Q &-N2>G08Q<<K2I"V94UA9KKT*OB5PSU\OWFEEVV$BY>49SW!SC9^?RG$B
M">CQHUHVL1HA":T8VM8UK4G^+V^UHVHLVK^-XW?:TD$VD@=\D=#D8"@855 5
M0%  @^2OW-VY->Y3PO"[BUX(%8!/< /7H<DDY9F)9B6),C.T&D:Y-9:ZW&6S
MO;97--J0BM W8VQF#82Q:9_4%5,JPJSOF$1!%%VQR=Q'1E9$<O9;Q6X&\XE/
M%Y&_MVP('CZ0 ;,GI6U8QFT]UEQ6V6-6F5XI*^3H.TY-_"V%/9N",^#J)(3
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M)//3[QW=\4\0:AH6R2ZJ;>4;+Q]C(I"RSU3CW&RW-Z@X1Y\.OF&$ =FT?>0
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MC$=*;,0CQ#D5,@8D22%[FM>UJ.1S",&1DGRFTJNJ]J\04;F@%DNZ=SIEM62
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MXP,#L1!UTUKDZ5R<Y+,6=F8Z1WN^\?31MU-6QJ/<3/7)[7<]-5C8&IL#L"J
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M\ZM[8DM[D85C520]I&>*;;-O(GR[IV_(%[=G8P3;OZUC.WJ;=\GJY[*["0&
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MVZR0F'R([SH>I\DZW*U'=Z<=]KDV55S9=6:3.BA/*I;.)<U97DKY,20JPK6
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M:3@BL$8UOC(:Y@<>D5J2BDDN[4-QN:=E2VPX]M1;I;:.ALP<Z$](J!&?0;"
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MFX_CF*;=#BZY?1\-51_7#\=QTJ'0?*>I3HHIX^I=[OU#7L,U5'T_!9:/UO\
M!3ML/;\GZWD2K^12)(U^$YVM>UUGKT,;B/KW.57FNJ,#.YY"$>JDFQ6]727*
MXX^LA7MD41L_R?'B\96?HG\90HR4])MI ZDD]ZVL=;#FQ?E2PMK>U_3GR?(N
M!R?Q+F. _P %=I[ !V5N>B#"-\GI-?LEWQ+5XJO59$>3)DQP2Y5TSLE5]+72
MV(0$KJG4,RSF!7NBQ^JIT^JEZ#1K25[^2;>LNSX9E>UT#-:,,E2,,AO@:QAU
MK3L^._<P'HT\>NT4[KEE9:E8JM1[KVNIP5^%44]+'_H$[V2O'?Y\7585)Z!=
MS)3K)$L[;J7WI'[O,K>61*':6LMYKGM<8MX14[2':J..SM81'(,7A\Q?6EX7
M;\?Y'XI]B74V>9MCX@];Q7*7_*N3U-Q[&<=7&%;(5-/>7_IO<Q;N_K9>7O;]
M&BIAH8]T5(-QM\UKZ!4.T*>B'++@L^KR\ _.J_-_ZAZ9^!-&V3U'Z]5;7J.D
M<2U>QTQM2Y((>KL-=;K_ +YC&+'TPT8CX/DR]RC>]J]GQ57V9N7CO>O[OJ..
MVU%O)(MJ;>I6'AW]&5%!'S7H((D;YU_]/SZX/*>=>:Y38>2MU;L-US.^NJ<;
MWBP'JMW5ME;C.^!PR,K $ X/49Z38_\ IC/FUO\ >FUC]AW*/W#9>_RN>[K_
M *SK_8K_ .Q3&O\ V[OKF?Q(W?\ CO%_OZ?7],3\VROM3U1ZVJ?332^4U3\E
M-%Z8_E;]W?\ UDG[%?\ V*?!_P#3Q^N0#@^2=R#_ (=Q7[_G]_IB/FV?]Z+6
M_P!A7*?W"9[_ "M^[S_K)/V*_P#L4?\ MY?7'_B5N?\ '^*_?\?TQ'S;/^]%
MK?["N4_N$Q_*W[O/^LD_8K_[%'_MY?7'_B5N?\?XK]_S U?SOOS<,>TV4YO4
M]KK SK*$>(]=+Y15#"%1U41[VHFC*J(V1'>WV]%ZM^EC^5OW>?\ 62?L5_\
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MWR5=K#:UPF6K+-@U1QXY"M>$4$(7KYQQD6/Y=RM(CD<C'1'.F@TUIASR9?\
M:^C L\0#M4GH$ /RI;*:"0X.0IN>%\<6N_=''A?E]>37H)["!U+$CY,+A]8!
M4C!(\&HI)'-FLVA0NWEX&NG&"U[*V15L(G@KJK3.>45"$KT0@G.60R0O4ZN5
MPGOMN#\5=Q8O,:3YB*]\C(K:O/3V?.2*0?64DN'.;"249KCF/":A&XK4.!#=
MT'&L6$=?'Q@&T@=& "%.E8&&49W:74Z4YFW32D 0H&1!1/$]YELU(CJ]E/X+
MFR$MDD-1P'#5KF.;W=6M:JI)<R=B-BPWX)K) 4+GQ#9GN"K'>\35U0K@@C.0
M 2+#BAO#O =D0+ "6+8T!,=_Q,]/#QT8'((.,$D"1/6FV8;D'RZ<U^PD 5FL
MF3PEK6UWAJZ1% HD;&3;O+MZV+FHUIVHKHJ)':08X3B1NZ]^OY1X/*%2-N>F
MC1CO*,=WVG3UO(P' )I J#*LOR9VK[)OH$$<<&!O'77KST8Y[WL^?F0<E20+
M<V%6;3+YSC_8GQE_Q'<3_P#E7^:S]_?]K^4?]?.&_KELV'[D_G_-/^I?+?UN
MN1'T$_[3>6/H?]P= ^'X?;LN^K_7ZYOP]IFDAV3J3GD]C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(G-#YR2SH:*@X7NK4L)+0&[;'6:M%>TQ9
M\S9+S3["MHP. 41:IVL2+PL0%RYW98MB'1*\C)+DZHFX_F-Y_N-%_P# VS_[
M)Q$U6XF+J4_YP#U!R]3M)\NVK=&JZGD6HMJ_C:@BU=P4&C'I+73_ )*R*[>-
MYBVL&(2+9V&Q5\P]?(@"C L&1W!BJB=$<1&(C$1B(Q$YA^OQ$=OO"35]J.U7
ME1%^A[%N^*D7V_C8B3CT=^GJNJZCC'U R]TV6WV'9>,O'?KTB%K$/7:XF\1Z
M&TG^46NHXMP5L+W6P0$-*)\1SE?WNZ*B)T$Q$8B,1.;W$G\[CB/_ ('MD_CK
MUO-![C_B@VO^HFX_TIMYNW;_ /#GNO\ 7/;_ .C;YN?L);2NN);=&&I[&2-L
MK;(3!L+$A1R,:T=S$$16QW[@\#/SO$<YK)S&HIU:U@WYLOE'WFUWSCRZ-6Z<
M:MR@ *HI'2U0>GM1 [E9(%P -F %::]XU=IN=DAYXZ=LIT[=B2&8CMK8CK[.
M">_8 343\GDEEDTUH-0.HC/I#+*AR5))?-*]Y)DZ61ZI,DV)"M8=UDZ0QS3H
M1&O&]JL5K>WM2?XE-BNQ1N/;70^6+DDL[$]YG)P=>K(<, 5(TD#&!"<F^\;>
M,N^&FY<+I  55 [JH!TT8P5QD$'4"<Y,:VM\R'91CZB,$C=9,?HM8<CQ55C4
MA<]JGV0HFO?#C0R.=Y20U%/XZJ)B.&\J)$\TU]&[2S@PK>8'7YLDBMZQZ;R,
ME54_-N!KU]Q05+@2G$"F[:M7S!9>#5O7 S8EA]%(. S,,>(A.G3WV(8(9E]0
M97N@'EQRR9-I*DJFP2;(3 6_O8+6M+$L([%<R$D)CD:  U4# *U1*]CD(^^X
M-=L=LU];.^\=_EF< 6>(!@JZCHF@=$1>X$P4)4AFLN9;<#<+38%7:(OR*H2:
M_#/8R$]6U'JS'O%LAP&!45URAT!NW%<RN1?E2V3N(* 86HY\\CM<>0U=8)TZ
M+0E[&NE/<K6@[6D:YI4'UE-^/"X;=[C9Y^FL4K3I&2_RH)1_Z@>VUB0$&'4A
MPN;?C?E-Y71NL?1/>:W)P$[I =/ZL.RL#.LDHP*%L3G4%\R2?,N.GRR;X<:^
MCO55;5B<KB18--W-:K]<(K7/CG1$=+5'/*C3->,<'P?RK6W[[^'AA;E/96.I
M5*OAH/4HX -ARSXL#(E]S/R:UT[/^!3EJB/CGL9K/ZL.@=3TKZ*F4*LWOVYM
M:VL;*FGDQ)D60QU)+KV-+;CMRHX<4%6!47SDB7U4;@.11&$KFD3P^Y4N>;7:
M#:"[<,Z7HP\)D&;1:>BBL?&9O5*'*LN0_=R10X<[D[HU4*KTNI\57.*S6.K&
MP_%"]H<=Y6P5[V)@M6=.G6I#[D($;<8D9SH=6!ZEJ8-2;M$^=0E?_E9Y:N:R
M<5>I8Y50'^!\,AX[ACN=QO#9SRJG/(G=K!S6E9P"])/K%N@N;UD;Y/YO2UE_
MRPV]&T%?"EFX9V[SD8L:P=0MH'JA>IJ7U77Y3U]2URS80U!:B8MX1@*X#&R2
MRE*\!(9 /:2/+BR!*AP38YT:X+QKXB$Z=OMZ)DURB;%]C9](D+M5&HMD@J0<
MJRL.H<'!4KWM6,=9$<<^\3>)[ "VY8X"XR&!Z%6!Z%2,A@>[ISGI.7/SALS8
MY/$?&3=H\W&[?4'Q4NNC4/EV6M>KK[Q+&_&%B!B;.T:-\2%\40AN\0:*]Q1Q
MN:_?#?RMK>45YC6F//'#^ ,:18GBV9>X 87<8QJJZ*H.I,L76KH+W54\96OF
MD\5H;/D[E?&.<FM_#KPE1/5J,YQ;U9B-+84*UN7]!/\ M-Y7_6!Q]^3\I-\S
MJ4]LYN'9.I.>3V,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B:.
M>M(NF#?P@7=K3D37XE=R'*OJ/8=&V_B+5(5;L])3%DU0-D9S5(B:=>Q[@3S1
M PT>Z2?QBC:(@R%1$3;3SL;_ #J3_P"%JW_G8B:VZ3#YNC^L?E<^QFW!>#IG
M&E(718]K=:#9ZS\J?/TX;>115FM4-=M^OA6/'(QK+^3+*<S9+XY5!V!CHFX.
M(C$1B(Q$8B<Q/7U]OW"/ZUN4_LWQ5B)M]Z5OYMG!?[UFE?8*'B)?N(C$1B)R
MVU"RM:SU2\0&JXW<TGHGV,-G9]$D.UZL=S+0O/=CJT8XMP^*]C6^ SVIW^(Y
M',&YCN:_,>[WNS^LKL[-FF5/D?<"RSUO K^DZ";17VVE2 - [,ZSE5*GH'@-
MMM-U]7W=)NFP1YQH*)V>,_T==BHOV5ANIU'MQI&"P(Z:4L"NKZX ZQZ2(TA/
M.+.4Z2BV992(4EE(F(J^<-,ZH]2=>BIT1O1J(B=#\?MMKM=JJ[0ZJF[^O.HV
M%NIL9OC%NW5Z>F.F!-$[[<;G<;EFW0TV+W=.-(0+T"!?BA>S'V\]<F0G99$[
M7;-3ZA%2SNK9CI-IK"=R131V= OV=[FN:V#,AHU&]O5JVG8@$Z$1I18_RUNX
MXO=^)P:>-R%XU6;?XI4=#N#CU&7LQT]HP*QWP'2=XRNCDMKX?,OX6QI.E+_C
M GJ*!^$K=N<'P,^)ZI*/)M6BUS*Y+&%-=;GMU27871F]DJPE,ZA<TPE:UT)D
M)S5"R)VM2*C5'VHY'=9?AJ=J-K[5M[/'LO[SVD89V'3J/B!.JBO \/&G (,B
M^5MW+;GV:]/!KI[J5CU44]>A^,6]8V9/B9U9((F(VQSZB1&N:)B'VF7TAQJ-
MKT$/;1 :XGD)K^U[8383'J]EBYJI!15[D>-[A/L>:+;&U-_QPU<P_=6G.!N0
M.NASUT:,Y%Y!%6>NI6*-=\0%WE;;+?G3Q2=YK<9.W)Z:U'QM78:0?E?1A@'6
M$1VBF[GQY=R3NEWTF9MT2U\8*@)2E#KSGOUT$1ZO?!C0G*URIU592JAU<]'L
M=D]Y56N_A^1Y*UM?)N*DMR,&HK:#X 4]45"<_#9D6$L&4RPYYK*=WM]A6H3C
MTU-7@Y%@9<>,6'KLV,?SF#6 I#"6'MPXL6.&[9*=7W<%R1ZF0$#I1[ TI[>V
MA) $YA;2+9D8B*!%1S7(A6.&X:/;$<VE--2\@K^%R%9TU,!J+EOQ)0$&Q;".
MJ9!!&M2I74+GAVMML;8LGB;&P9L4G2$"_C0QR*V0'HW81W"&#:3C]4>:ZF'M
M]C D/:8">6?KCC)(#J8)3%5K81T8,=FZS&Q5=8L:C3M11,0:#(/+;A6LY"]M
M]RJ^'S-7=-&=0VRM^ >@L\0#)O  < HH4*RRYY=4V-*[/C6U\39WO&Q@[@K^
M$.I30>RDG*DAVU%E:9_98M:2M?.L)BU3JKK.B70U:V152&M5B'"KFO0R&1_A
MO K7,D,<HW-<CNF27+4[1]J=QNK/!-/?6T>M6W9D?#GU2A!#@Z"#G$CN+MW*
M[D4;=/&%O=:L]E@[<'X,=H8$%"-0(QF1/79,[9+(;]OB^[;*J:R;3ZX]CQQY
M(&N08MN<,KG.-**YZ=L5RO?4/<C"=QG,*L+Q=VXY7=@\XG@[ND:ZJ""%8=@W
M.#VL?16<G;$Z7RY5Y+\E51QFU(X=_%VUQTV7#!*GM.WR.Q1Z;!@;@#*X0,DT
MQ^<X_P!B?&7_ !'<3_\ E7^:S]_?]K^4?]?.&_KELV)[D_G_ #3_ *E\M_6Z
MY$/03_M-Y7_>^X^_K;+OR=/ZG3-]GMFDAV3J5GD]C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(G.'YRK9[+6>+="?76EG7GLN0HD6K=1;).UB\
M@[;7P).PZ=L\&1&D>6N!:M=4K3EK2QI)97>UT5OFQ :]$VT[MS_575_L-W+[
MJ,1*=XMY5V_;/5+S-H-K/T\5/HL,L6%7AUZGA[U+K&+KDVE)8W(=VL+:70PB
M[)+<%'T\5G?(1SGHI&*5$W,Q$8B,1&(C$3F)Z^OM^X1_6MRG]F^*L1-OO2M_
M-LX+_>LTK[!0\1+]Q$8B,1.;W$G\[CB/_@>V3^.O6\T'N/\ B@VO^HFX_P!*
M;>;MV_\ PY[K_7/;_P"C;YN=>6,G2):QM>CI91;-AYIZ-$(\>JL<14D[1V Z
MF9K33.5TB(-/%>7JL5JJI4397(;JWR]=X7%KXM-P+FGJ1MAGO;C ZBC.2]2]
MXMDTC.L#7VPVU7.U>+R+>%;40HMZ WG'=HZ]#=CHEA[H7 M/J$S:@JXD"(LD
M,OWK+M?"G3KMSAO);$>-%"=CPJH606!<C8PAKX0A=$;]%5R#C=G3MJ?&1_&O
MNP[V]";"1T((Z! .B*O=5>@]),%R&ZNW%WA.GA4U95*NH%8!ZCKU+$]78]YF
MR3Z (SLAS:I*2XH8I+.=;F<V5I\5XV&V&0,2*^RK%*YH(-G""Q%D&>K0& U&
MD7Q$"Y(GE;'X6[V_C4-VXO;#;92 ;F ^<KST2Q ,NQPCH,.=6@B4XQ$Y>GV+
MD'%5%*]W<-DBD$]$?'5D8]$4996.5&G6)E]6B@D ^499P;>TMPHAK +"#CQ(
MPR.Z4U;'.C3P8<$[5:09$:=YVN<9$(G:R]X>FJVOZ5>Q;]Y>O5P"%50?FJU/
M5%0Y#!@'+@FSO=%L^5MLJL^C$K:G:TMT0X)8D?..1T9F'4$$J%("=WJ:ZY*[
M:;=^.-C@=K;5LC9XJU[>O_>?_NZ=8U+X3%17V;W(OE#HCG 7N[D4*D3)3=XX
M[B-_S&UP-]C;H4Z_M@>-W:<#ML.3X3X)0YU?)ZY0V&=_NZ.+W.3L\V-JZ?(=
MSO6Y/XL8'B)D!QC'?TF3?5D]_/\ E/:^RW$\\$5*3HOR/7HU)540:*YKKM[%
M;YJ2G5I6*U .6.K7$A.&_P I-]+[S^W@2@J/]R_A5D=GBD8\2SJ&&/#)J(+7
MW+?Y/7Z*VG]ID!C:/[H_!L!_6AUT)VJ<^(/$!"Y'9XD8<9;]L\--94P2$CVQ
M6N<#P'*U2UMD%BM?.K9SVM:X*?5/$[7B5I6L7+GF**EJ^DQ:NWW6W4E;#U&/
M2C@=7K<X!4=[5@IAPIEOQ5UK6_1YK-^VO8 UCMSZ'0GU'49(;LQD/E"1,%KD
MD^WRO>6P0B5,JE,%\73I;FO/5G>QSHU[9=$0<T\QJ.="<U/#CL145$E-*T,=
MQ5UG.7>U\G6:+MNP*[5NIK8CNW6>ARPR:B.Z@SG%P<5W_)55\/3[-QSBZJ]3
MJW"]C@>M4GI4+T%H]9SC&:BI>5WM7$L8B%/)6ND5SGSH-P-PQGJ3C&[NE-(7
MZDH%%W-.,G410JYCT5JKDUR.SHW5.NQ_"MJ)=+00#60/6!/3&,AU;NLN0P(,
MB-ANKMM;HK7Q*[>ZU9R18"?5P.N<X*D=Y6P5((G+[YPS9;38.(>-F6 QU8XG
MJ#XG?$CH)S%VD!"WS&[17>8[C1Z%W1$$!5\RQ[^IN@U"XW-OO@Y;><H?*2[D
M"E*_/'#%5QCVA3;8/:$U=5I_!3YP$Y?NFLV= >ZKC-IQWY3MMR;6?R=RP8Y^
M8(KK/@/CH;?PF]0@83O!PF2]!/\ M-Y6^#_9]Q^GL_$V?D#V+^+G49[9S@.R
M=2L\GL8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$YP_.*V.N5%
M3Z>K/;*T1->B\WU?OJ]91Z1LUG15CZ:R\<U71[Y6WE/*>PS!39!?)^+$BUY#
M"E19# /<B;W=L'_.2?\ 5:W_ ,S$32SBFKB+ZYN<+O\ =-T"TA)K)*[7^(J/
M9[*SVO4;@PM")NVX[!JDS4ZVNU&?LAZ^,(I8,TJ6 1@+())(]J1$3H'B(Q$8
MB,1&(G,3U]?;]PC^M;E/[-\58B;?>E;^;9P7^]9I7V"AXB7[B(Q$8B<N=,O3
M4/JJX<,"(XY9OHJV"O9,,BMJ*=QN9Z!S;38)#7M)$J N&C'/:BJXKV,ZL1RD
M9S;YAY&SC?K+[*RI-3V>2-P@8_-59Y.@^)<W:M0Q@D9RQ5>Z"67H#@M@G(?5
M[W==CZ43SA0Y4?.68XZ[Y.D=C6'.0#V*&;J0%/2VFIA5 C.<8DZRG$;(M;60
MUJ2;"4C>Q'.:WX@(P&?$ !G081HC6I\*KT'L-@FQ1B6-F[L.JRQO6=OS@H'1
M$'=1>@]).C-[O7WCJ HKVU8Q76/51?YK'M9CU8]3Z (;=V"\>N\S C%LJBT,
M;LUJ)[9E?.=U-(LJD:-?X=$SN4M@SIV1&=QQHJJX3X'D-R?+!\7;(;=C<QQ0
MOK(_:UE8ZXI'K7C&*QFQ>THTUL=O^40\+<,*MY4HS<WJNG8$L/IM^+2>VPXK
M;T.LFH*SL1UY-EQ[6XM8XG$L8SN^"&"_H:/74OM=X=2/N1R.Z]\EZ^*15541
MLOQFSTCZ1W#K=OKE!+KU0(>JI5\%8[0>USWVZD 1?(;K5^T:$:K9U,<(WKEN
MPO;\-A[,=B#NJ,9)P^Q$^2+S[/7,(<4LPV6VMQD1\F_ED;X8#4$=7-:[:'-8
MC4'U:R8QO:56JUA1V'*-]!LW+[4%D=@+*%ZM<QZ TK_?'3 '06@8<@A76]XU
M?IA5XO<D*Z*37<W94HZD6G]8ZYSU-9.5!!*-"E8ZYW?B_:9YP29,LNXI61(Y
M'$AT4-U 09H3.Y&*6W5XE9,,]K2-(UP6HQC51V0>6T.^XG>\UN7#VV)4*U4Y
M2E?%P5'9FW/2UR 00:P%4$&.YIALMU5Q%"E*T9B[$8:UM.0Q[<5XZU*"00=9
M)8@BP]BC)5>/M<"1&@S8<=B63)9%!7W< *KX<*>]K".'+&XBI$D-:\@B/[.U
MXWN&Z(Y2H;/5S6V9*]Q6O?#'"6H.Q'/7##/R;@%E8Z<,K%3=<;:=WIXC<*UE
M#MW-(R]3GM9.S*G'RB$A6 SE64,,?KQ_EFX.Q6(31(T&2YM9J\UB"G4T\*(K
MY6RQ4<]K-@&CT40>KAQ1N:]CGO>A$M>+L^GF7E=TK)56_P GMW&'J<=K7KUQ
M<,Y5.JUJ0REF8,+CD:_H0'C=LP>VQ>_>IRMB'XM+=,TG'>;H;""I"@:3G;ZJ
M;(:.VBRQ55Q5",2+:%1/+)&Z(63!M6=XTDT\A!HI6*YJC5$(QS",:Y)+DMF+
M0-[2ZT[ZE25L/JZ>UDLZC54V.\,C& ZE64$6''[LUD[.U#=L[B U8];5V*U?
M;BP9[IP<Y*L"I(D3I;%>0WO=81W5U15O X^O'<JGNI*]21K25W,&LC4CJ-20
M/BM2>C>\K6(Q0Y";#=GS0Q.Z4U;*DC-![;6[5L;H-6V.-5/0>-C4X72:Y+[[
M;#RXH&V86[RT'%P[*E[&K7J<;@9Q;U/A9TH3G7-+?G/!C=PIQ>5PV.*'U'<4
M^$16-4@O$=>L)X;U3N9XC/8[I\*?#FK_ '_JIV_E!R!K7SYPV#Z1FVP'!]&1
MVS8WN09A?YI0$Z&\E\MD>@XKK(S]KT2+>@G_ &E\K>S_ -@-!_J_]Y]^^'.@
M#VG[<T>.R=2<\GL8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$T
M<];-&/9:/3ZF(2MD7+8W(4GW7)O-RU*6FNR-+FU5_L#MFT:5%MY-'K;)X9-C
MKA56-M$9KHC^G8CVHG]^6_!WWS>)?X'P?FN(D0XR@QF>OWF.S6+ 12\?R8%?
M('4<G1ME X<K1I%S"NKC;&%TF9JTF6YDNL!KQV@:<Q22 ^(HW-1.B.(C$1B(
MQ$8B<Q/7U]OW"/ZUN4_LWQ5B)M]Z5OYMG!?[UFE?8*'B)?N(C$1B)S;XH&,W
MJTXG$4;"B+Z&]G&41&M>,@W\U:XUXR,<BM>Q[55%14Z*F:!W:J_UG=LC@%#Y
M$W((/4$'E-OD$>D&;OVK,GU==RZ$AQYTVY!'0@CCK\$'X9NO97*\=("&5I;.
MDL'K&UZ.TO6;42_B]M=,.7N0>KB1R*DXJ]E:SXA54:C5NT-UO_R6TT.&NX^T
MZ:5SWZF_ 8GLVX_76Z4#NN=&G&N-MLAYDU7*15OJQFXX[MB_AJ!VWG]:7K<>
MJ#5JS+::G+$(:TM3#G7\X;62Y0VN;&AQT=WCJJH9/C@K8[_;U7ZH<GU0GQE1
M&S>PV#TNV\WC"SDK!AF'JJO:*ZP>H1?Z9SWFZX B-[O4N5=KM%-?'UG*J?68
M]ALL([7/WD'=7IDF-V\P7'C"VK&&/JTJ0OF::&)\F?6V,ISGH?7H0D<67%F%
MZND0QIU$JN./HU"M6)WUZ>5U.\4,W#NW>J4%GK=LG-"#JRL<EZAZO6Q< .))
M[.EO,;#:,0O+*O=L8A4=%Z8N8]%91ZEA];I6V3H,S%)7FGF#L]P^/(G2 =U1
M%C&9*KJ.NE,:Y&0CC513)\P*HLB6WV$3X@^@D^/?\?M;-S8O+[XJVY9?DU4A
MDI1AV(1T9V&-=H];U4P@ZV6^W";=&XO9!EVZM\HS#2]KKZ6!ZJBGU*SV>LV7
M[*>Y/X>UNPY+XDYX,XS++A"TWJ\!4 (@H]H7D#3#:'<3PMZHCKL-3)Z"$B=L
MUZ-8[ZKX3VSE7F+>>4>#YFGCP#QW+5[<;NLD#4-O>MRV5#'S^0%P"/&&$/>T
M$6E6PJY_>[*C=D^U;4V>SOC.DV(5*.?UGJ3DY\(Y8=W6#:E)UVY8>T3O95L>
MI]=IGHK717C<\2VEV%Z(YM\Q[7-;&>B+7*BM<GF.Y68WQ^>;*<QN/[3!S14?
MBD9'B6CT7 Y K/S'4$>+G3);[_(X?BJ/[:(Q=8/C ]?#J/ZUV$N/GNA!\/&K
M(75:6*<FR5#P1K.-'Z6 9)DC5]W71D>3RMD945D8\9JN6-+5%6.JJCNX3GL6
MZW^U>FP\KL2J;M%[X8Z4M1<G2Y[%*]2EG:AR#E"RFWV.Y2VL<9O S;5F[A4:
MGJ=NFI!\8-T#U_'Z$8<*1@:F<+D8;+%S#1]5BG1C::8)8]A;6(.PBNOH;_CQ
MJR*YS7@C.ZI,16G=W <)"1NRW">:E&Z(9>&1L>$PTO8XP?EE/5:UZ%$/SO2P
MYK*:[_=T/Y;8[<%6Y9USXBG*5H<CY)OC.W4,X^;ZUC%@;3*+JE?/<"PKSMK[
MVO:]($]6*03Q$5KC5UD%KF+,JI;F)X@^J.8Y$(-6D:UR3&_V#;DKNMJPJY&H
M'0^,@@]J6#IJK;'>7.0<,I#@$16RWHVX;;;E39L+"-:9P01V.AZZ;%ST.,$9
M5@5)$YE_.);:_:N'>/@1X;(8J?U'<3Q;A3%4KR6BEV%C64SVM&RPI6N 14GH
MGA&<U1,3Q!G:+G3WR\TW-+Y4JJK%:4>?.&6W)R39XMN!41@/5T.+O58@HHU+
M8$WU[IN(7B6\RV6.7:[R7RS5X&,5^'7UL'4I9U&:O64=YCI9"_I]!'^TOE=>
MG_L#H/M__J7??9_4ZYT\>TSG0=DZE9Y/8Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B)S^]>-GY.OXLKH$34W7]Y;[@"ME[0=@D..IU<MZFN@25
MN.BUX(>P6T"&R9-6<2;71QJ>%&+(1KA(EL_N5:I]XKC/]DB_<_B)G]-X7V37
MN>>2>7K[=*[:J?;H$2%I^NRJ&UC6W'04BT<6W@4]N_:YE*6JV%:(!I;&54>0
M20%C_&[>\;D38G$1B(Q$8B,1.8GKZ^W[A']:W*?V;XJQ$VD]+>R:Z#TX<'!/
M?TH3"XOTT9!%M((R#(RDB,>Q['G1S'L>U45%3JBITQ$OGY5:Q^J.A^O%?_\
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MF[23I8CO:/BAS\9AV%^FH $C5DF/WEU.XN\:FL5:@-2@]W5Z2@^*I[0O73U
M.,8^Y>E^]RPC7^PWEFD%YBBA )#J:Q3''X*E?'KH@9)WB$KFC4IR*/O<K>CE
MZY[N-GMMU8C[A0_ADE0>JY(QDKZK$#(4L#IR2,'K/FG=;C;(Z4,4\0 $CHV
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MILDZ=L,Z:3D^%G386+>(9C?;D>8E!VJBK=5 D4CLM':UB]!JW!QFX8'B8U(
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MBVSP+: 72[IFH@=2<]"A'1T/=<=#U"D1O&[BZK<>!6GC5W81JNN+ 3T QU#
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MZ1YYG(P3$[93VJUI2[2OY ^6=.WW1>W86L$VYSFP6'U:')/53\2YB H&+F&
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MS=[[?C:P[5UFQRSI6E: A2]EEC)6BZF50790695&68 V^ZW>WV:"S<-@,VD
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M_-^IR!]?'(W(')?+HN"Z>]U.#QGK6N<<<OQI1==FV5Y/NK,^Z4O8.P#>0 )
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M:EV?&Z;-_:NH>E$0_C;"#ZOX"@AK6&E2 '=+':;!=+;KD-5>RK;2?0[N/Q:
M_&_"8C%8ZMDE5;D3ROP1N?(/K5Y5JN.@Z[+GU_"G$UULLO:M@GT*V,^WV#>
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MZHG1\4;4'6L1% U(Z.8*(VNQ'E56LIU6<78=5Q/5ZW]-@Q^)^&M0!0 /#45
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M(93D$$@@@S 4V]^M&%)6QN?2=JU]:"61#KYI?4AK$5(%,XJ>7CCC-T8HEM)
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MX/\ $1\B=O\ OP[Q]8N+_P '^(CY$[?]^'>/K%Q?^#_$1\B=O^_#O'UBXO\
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M6'KYQI&>UL] !VGH.LRB_P D^<-L0+N,WP)V7MG2ESC:Z#8;VT@Z:A6-;,V
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M'<;CPAX-;EM-U]Z"[6&%JI;N+72MP:T8ZU0/ECC>$?2KZ8=/LZ;E#AD<:T-
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M !)^  D]('QEIQ5*T4_<RN 7P3M'RKR8]0F[&%\(J-W%5&7PRM=VKT7M<B_
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M<>* SG^(-H6L02XK5[KU4;H/NP[[K8>RLRU@,%UJ^MF9V+MW< $@#)F]=_\
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MI8]59Q:UC+"&!PX]@Y@2':0L8#V41Y'X_NBS<;MT554@NN"% &#A!A6 [ZC
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M"^Q$Q$U<]5_H]TOU3;E4;=?;[653]3X6Y8T#4ZY/)$'$WS?)6L3=;W2QGAD
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)7"/_ &<1/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g570173page161.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570173page161.jpg
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M  $% 0$! 0$           @%!@<)"@0# @$+ 0$  04! 0$!
M! (#!08(!P$)"A    8" 0(" P@," D%"P8/ 0(#! 4&  <($1(3"2$4&"(5
MU1976)BX,94V=A>7USAXV%D*03(CU#66UK=1)%6U=QDY>;EA,Y16V7&!0E)T
M)74FMB<WD:&QD]-49F)RDM)#4V.#-$0HJ"D:$0 " @$" P0#!PH/"P@* P
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MS1H^0?L"\0MG216+UTS+(QG!!-:-?E;+G1!['K./-&:.%6+H"=Z1E$DCF3,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P#4CSJV/':>Y>\2-M2[B*:Q>L]*\VKT^7G))
M&'AR(UC3'OL!).5<"",<S75;%3.L8>A /UP#+=>AK7J^0UAQSUU::S"<A]X5
MNX<@.0VW[*T:6>W.F-8<4R"OEIK]>=K-T;!+J778$/!0*+L5(6MPB9$_5U4T
M&S58"E2O$7G,[E))U%^;'O&'C'4@]<1T0'%SA/(!%,5W*BK2-!^[T?ZV^*P;
MG*D"RO554"=QQ$PC@'@]CWGI^UTWC]%#A!^0_ 'L>\]/VNF\?HH<(/R'X!BW
M<&F.:>E*BWNMH\U_DU+1"]JIU1,C4>&O"*P2B$A>;+&U.%=*QJ6ED7*D>29E
MVY%SI HHF4_<!#=!P"-$WM#=$=5)2YP?F^<K;W"1JK=!,:9P:X8O9&3677(0
MWO?$R^DX61!FDS$[H';A-NR<(HJ%;K++%\(0+B<V/D4@YKADO-LY2/:[/6FS
M51]>VO#C@:6C4YW4:;*;!G7]VL+O5C5" CV%,@)%^N E4<M2,5$W"**QT$E@
M/0]L&^_B^QL58\X7DKL!N]EJ3%F84KACPD?RK%._2U%KT'+O6<GIB( D.C8M
MC1<<\53.H=F_,X05(51F[*B!>6Z(+E%HN2:5ZV^;KR8D[?+FH2-8IU7X7<*9
M2=MSW9%^0UK68VMJNM)QT$]D#6ERD1VFH]2%BV4*X7$B(]^ 8KIMWY-W:4B(
MR-\SSFTQ"P-:PZ@)"7X)\&6L?,?'#6!-LU]NT.AJUTZ(Z>UMTS0[%4DNR0?H
M(&$!%0R8&9]5T/F/N"[;.H]6\U3E*U>:BF6E9N<M/</.!<;$LK6YA8.P*5A-
M(NJW,\66:15@;JF%=B@V5((F055)T,8#/7L>\]/VNF\?HH<(/R'X ]CWGI^U
MTWC]%#A!^0_ +CJ7%/FQ!S[*4L7FD[DNT2U(\%>LR7&3AS#1\DLJQ<H,O77]
M=TY&39&S-\HFN<C9RW46!+P_$(!A' +2N>PO6J7;>0]J=42N;^X'[.<T/=%M
MKDFTAZO-ZL(TI-VV)"SSF3?OEX&FVW2=ZCK8E&2CA<T#.(ME2JJ>!XZP&7.,
MO9VTSPS@JG^$#G\*:I?XJB8\NY@2*%](AVG)T$/^0< X-/W@>%=O/-KY7R*+
M559$&_'N-%=L?QCHKGX^T)ST=-D %R@V*@43 H8!2,("'4#!T&91*,:W*7!:
MEIQ?C*7W/*::6CU6-%PF'KR0E])@];70,)^T Z*)J>&<_4/^0>O7[.7/%3]6
MOUI%QQBWJTFRBA:(IHHY*B(LUN@"Y\1H1(X'4,<1$!% H@(B3TF$2@8.G4?X
M,3IA+L6G'T%?,]$ON4^P]\->GL1(-Y*/D7S9(QNCHD3*2D"H]9^(4RC%23B7
MS-PF5PF)NAN\W8I[L"F$! ;=^-"Z'+HD^[@GQ+D;5&;E&*Y7VKL)UP4$RV+3
MW+V"VCMEW7+*W<$?0,G<8^PMS2J1B"=I+I6J G%ROF+](AU52* JH)$U$Q+[
MDPX*V#HL5-JKE./'A'3]#3[.OO$F$ZY5-0C+Q'Q[==.&FG'N]XB&[G%&L6DP
M=?&=J^CR*,57JE@.^<&%NN9/L1!V*C9%ND0@$!(&XD3 .TOH#T9R.)6FI/1]
MC[$8>^]RTY9/5-G]/M>8DF2<1+6FXR:;%159!_(3;Q>6C3J*MU4P@Y)-=):+
M(0[8/<IE*!?2!>T!, _?DS'\1Y+KCH].Y:>_[NI0\NQPY-7[^K+BK.W)[7I7
MCVFOE%5I1LLTD$+$Y<2\4X3<N&3M55>.62\!5WZRQ36*LH?N!8@&$!ZG*>WD
M8&/D5JII1@I)\%IV=Q\HR9TY*R6^::KE#B^Z2TTU]S3L,?%O8IO%6;2+(S1?
M%34,LS00C$42B=5$R3%>+$ZZ:!NP/$2-[GN]( )A'K]C@8\+8VP333[-=4_?
M*>64*VN5*,GKJ4V7NLN[2.2-!L5XF7U5!M)HK"FW1\'O>-V8G?NW3EPT%N()
MJ&#O4('<!$P]R7(+'PXZ^'I%/MX:E$O$BTY-IZ%BMI>;<NUC2-J1]43 3';I
MJ-F#),3EZ>(!EE4$NX5#@'_.B<Q^@>@!Z#75.%->D$N;7L]PDSC*RO5QTGK]
M@FIQSW2V3,UA)J^6%Y'PQ#%KE>"DMG$/"K.'BQ72TW<C2<0M66J+)TJLV0:-
MY!L!0%,X(]>X,-N6/7+]\5P2M?;IW\"["4E+P&VXI$L.1#*N6#3*4H[=N;),
MT.7++LV];,T:,#PLN0'2I59E9%TH*9/$=J&]734[@ IBB(]!S&X%R]H5<O5G
M+N^S]DOW8JLK4HR;6OH('4[3>Q-P,EI6M6BJZXI*KE]&+A$MI*3L[CU82@LV
M=F*9J[<F55( #ZQ)II"3W7A=![!SLKIJ4H5P;G%>YH_>(BKKI>LGK]0FW3E"
M:BUS4H(E)G+I:8&+:P@/HY*&B4#M6"$BNB]L;J7E86J13AVW<&3=K"X="=5(
MA^AE%#%+KUM<U9*S)7+'FTU?%ZDJJ,KN%?'AKZ/T3$^U>5-3H[,\1=4)B5M#
M>3AK.-0AI%E)(P4JT42EHED6UMRPS-$C=VV2,9)NT>G,F<_B%5*?Q#9/;Z%9
M+QJG)Q[GI]<M7J<9.K36&G%^C_T&]3]UFY$V#?W-SEDM*PT9 QE9XQTXL*P8
M@Y6<]DOM41=+/I!R*8NSF][DP*!44BI]!#W0B)AEY::DD^U:E%-<81UB]4SN
MBR(7A@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .<?S_0 U(=%, & >"OF- ("
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M<QK>D=F;[:+SD%LV$;(1G);:5?LE.HQ:W#E/861(&4?I";UE '!A2(!G)IS
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M2+Y<;"V:ZAMGP]4U+'R%+J;" 1O5PN0T2P5A^MVQ<S!L8?7DR\7FY4Z+^8:
MJ].WZ)GZ&33_ ),5 @NFM0^-F^*UT2[O?*HR<9<R[40*MG,6US%"UW$FH6IX
MYS4HEO'JV-A53*2<^YCG[QA(H2#%E*-()NS=OV .56J/4$W)0.FH4!,4<!=?
M/%MGCT:\C>O-KQ]X@;EN<\&^$95QGK#7W.UKT_;,!W7>EWO4*\8WF<:*U>.8
MR$FWBPK<(WAR+1D-+DADVL7"Q*9E'"3EUVMSJJ"1L905/0'<(Q<=)WQ[-922
M^NUK]C4IHW?+NO3NEK7R]G'3W/K&L,EH(_[6IVKA!9%$IRE,=-1-0J': =3D
M]!3%]'\ AZ?0.>A45MRYE\'L)<;8V2T6NIO7\GB0EX*H[:D7:\.>!O5[BOB]
M$L7:LA9865KU=,E/3-BC2H-D:Y5I:/D6*+1\JN=)R[2%$0*IX93XO-BHVJ+_
M &R.J?H[2X7+S-H"X[4GK$SEE7)'(A:9%A&L2@Y;-;;1FM.104DU)%%LV=NY
MZ@NGJ:R/>4>OA#X:ONS8JSPEDQ5G8XZOZ_Z1,IE-4.4--8R^QIJ:KMY463LN
MNM8V*$JL]-VA77S!C,NWC=^M-IQ<'%-7;&9D"@Y*LI*%C(],[=TY,J"J3D2B
M"@G2,79MONKQ;;*&M(.+:2XKBN/V.PCW51FHW/X;>ON$\8L[5>A1$ZHB9:9E
M*95T5G;HHK.5E@;)JH$4*<R904,]DEA5,7M,(G'J(]  )%$&\=0EWK[;,7-N
M-SDNYEDOG00#1TK[XPQ)IPRD9=U.65RY95^'B8I%-24L5C=-TWKR&I59;G3%
M8$BJ*K*'2;(%5>NDB*6KY58E3EJ^:7!+OE+N2]W[2;[A",KK-/??UNTW0_NM
M>QU]@<T>5X18J#0XCCO$EJLD_B$H*QW9\[V^4MAV%;8_UZ0<I34\=FV;(-_%
M,VBHQBUCD>@M5>L3U5-J3?M.B<UKKR\/5CKV)Z<=.WCJ^U&0C7R5IKA#5KZJ
M[6_?U1W*Y4!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M\M@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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ME=5N>,FNJCOO6VKJ#L/3(PU1KJM!@]S4OXPU*P:PUW*W2?WK9;A5575:9O\
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MWN'9^7'S"E&D5<JW#6B-:R2?);@VT3D&S&;9/FJ#XC5TJF"I2@H":AB]>AA
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M51$I2@F0@BA3.JB'.GK+5^CAZ/J?;+49J4G%=J9W%8*Q@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & 6I>K)\3Z9:;0"95U(& E)-LV,)P!V\:LU5&3/J
MFFJ<#/'8$2#H0P]3^@!^Q@'SU_6?B;2*K5S&*JO"04<R?."%*0'DF1L0TJ_,
M0@B0JC^2,JL8 ]'<H/3T8!=^ , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M;,>''.'R-_,T_>;O](6X/^%QPZP#:7Q4_HS77WW\\/K826 ?Y^W[QBUBG/G
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M_:*C7CNB?EH"*0=0CMS%RDA=+>W>2S=BR<I.X4C"5*>-.[525\,6ZJ8E,F8
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M*WAT8P"40%)>8A(]H8 ,4W1WU]( 8! RU@# & , 8 P!@# & , 8 P!@# &
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MC*R<%*-U:E*)-SXQ:?\ FRW?Z.Y_@G-U]HVC_1M_X)__ !.8OD?S$_'?:_\
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M:H_R1 ](CT$TES<X1<_VW3UO?!V$Y0!@# & , 8 P!@# & , 8 P!@# & ,
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M !?L9',X>-CXB/2!NPBV+2.8H )C BS8H)MFR0&,(F,":*10ZB(B/3 /=@#
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M'9MQZ9ZNQM_S8[?MGR7A2E=*JVU:K=L'2"C3"<TYK5*?*XQ[^U&L;BOI#?\
MQVD>6MH<WC8&_P!MMJR2=@V+7+'+ZMKZ=:VT9=!5]8XA^WO<L9NW<PR@1BS-
M%#U=1-F@B0Y19^&'FG2^R;_T]9NV5*_(SXY=DIW0G*B')?JM9Q:MEHG'U'%+
M1J,4GZFAV_Y\>9_E)YQ8?E_L=.U[1TE=T_A5X^WY&/5NF0\G:N62ACVURP:N
M:4;D\F%LY^)&5UMDHM9/.Y%3E3DIN"V"=S/<E6$;/[ /=Y"=A^;]+ACT&79-
MRUYS6:M*L+,@E5Z@DO)IE6A5!.S*]42.*8*B4<V&_%LOHR'*S<HUV9'B.4=R
MKCX4DN1PA)37)7K):UO6/,T]-=#QS:]_PMKW7:(TXG15N;B;0L*NB[HK,N6?
M3.7M$<G*JLQI/)RW&J3AF14;G3&<5-U\Q1Y&JK/K'!3P7;DK%O6'O V91<9S
MGUZUA9/WNK,53D$7D&>?48RBDY\5S/'0F()W4JHZ7 0.<X!9LQ93R(7^-N49
MQY4HQW.I1EI"-:UCSZ2YN3FEPUE-REVMF1P]^JQ=FRMI>V=%7XUOCRG;;T1N
M$KJ_$R;<R3A>J%.I4>TJFK22C5BQHJT<8Q;KVJJK,Z\V8WMT;.<E=@SIPGHX
ME'V'S8H]YJ#IQ;3IRX$+0W=A".*]CT2]\9X*1#MFX]" *?3I(VO%NV_<EEUS
MW+(O]9>%;N-=M;=GK?M3GIJNV&B6B[.!BNO-^VWK#HF?3V;B]%;1M2\"QYNW
M]&9N#EQCB)TZ^W1Q_$Y+&^7)YY25EBUDU/76[-[;PVK0[.PNKG0]Y8G@-#;V
M.52M3]'N<Y'H.[=H)NM9F=<CY8RTNC5E12<N$"]RAD.XQ2G A@R5ON][K@Y,
M<V6#?%UX&3\"5=DDG9BKG4%+UN3@VNW35Z/1F \J_*_H+JK8[>FJ>J]KMCE]
M5[&M,FC-PZ+)0Q-^DL:>194E4\I<U=<WI%3Y4Y1<HLAGQGV7LI33%KJ39ULS
M=C8N_=*6AG9+:[KM.E*R6:Y UJ(2@(9>QSLBK.-F<W5E&AE#F5.WDTU5G?I7
M,&:=TUN6Y/9K<2+R<V/M^--3L<*Y0YLJ$>2+G)\R4H..O%J:;G\(Z1\[>B>B
MH>9.!U!?7LG3%SZ2WG&GCXD,C,JR?!V#)M=]T<>BM42G3E1M44H1LQI5UX_"
MI,S35*!N)DN1K#\D>6=E<EG&+A%.3Y \0;(]Z5]G/,)6OF2&FF;N$'Q+4V6>
M@=N9=-VP9*%$A/$15S6+@;Q"7+3N.[62YT_6RL";]124H?M>C3YTY<-5*,'P
M6J?FF_\ 5OESDU._<>B_+_"I>+.+=6P=6XT/WQ.BRK(3]L4HR@\6R%.EBA*J
M_)@U*7)97EW3,ALG6$I;).5M6XMX"N$= K,MI;[XY.V5/?(O)1T<B#2F(59F
MVFY0# B?UA+O!)D )E*(JB;+;-9N6V6VV6VYF=KI%J_*Q&JVG)\%6H)2EV/5
M=D>"[=?/?,G$Z+ZXP=OPL# Z<Z7Y/$OC/:]BZAA/+@X513E/,EE3E35\./AR
MTYKFYR:5:6?7F_K9'-!?R&IV;!B5PLT,\>;HU$U:%=MBHF<-A<+V0B(.$"N$
MQ.3KW%!0O4 [@ZYZ>_9=</$LQ%&&K6KR*$M5VK5S[5JM5[IY-C>4NP9F0L7#
MW^RW*<%/DALV[2GR2U49<L<=OEDXRTEIH^5Z/@S^\=;2YNE@W[9'42C#"_V=
M7 09MK%!6IL=LWTQJY!-TA-UMV^B'*:YR&]RFJ8Q#%$#=!]&.GLJ69D9^3*"
MAS9,-$IQFM%CT+52@W%Z^X^!\\XMBHZ:VCI+9J,B62J=CR.:<L>_%DI2WC<Y
M.,J<F$+HN*:XRBE)--:HD[FS'AYSA\C?S-/WF[_2%N#_ (7'#K -I?%3^C-=
M???SP^MA)8!5N,/YQ/F+?I-ZP^I9Q;P";> , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 8FH #-V[9UU,)S(.9UI
M084QB)=HP^O".VL@9-0A>\?_ %ZF)I,P"8P ")?L&[B@!EG & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#G(\_S[B7/Z"WF-?W"X!L
M-M7^U]X[_P"[5YB?6>X*8!LJP#$FT]<SUZ5ILI5;J%%L5*F9>5CI52N-[.W5
M3FZI.U1XW4CEY*)$BR3>;%=%8JWN%40 Q#E$0S$[IMU^<Z;<6[P,BF<I*7(I
MKUH2@UHW'NEJGKP:[&CT'H3K+:>EJ]RP=^VSY5V;<\:JJRI9$L:2=.51E0DK
M(UVZIRIY)P</6C-Z2C))D1]3\%)_2?X1OP>;HCX?\*\U+6:]>)JWUWWZM$R:
M+,[L*@N]@*BC()C%@*)$Q*V1,X<&*D!EC#FI[5T-D;+[1\GYL8>U3E.WXC7F
MG+EUGQMX/U>&G!:RT6K9T'U_]*C:?,WY&^>'35V3\@8U6-@Z;GR>#C4^+R8Z
MY,!<U;\7UW+6R:KI4K.6N**@RX$4>.=7)ZPJ_&)FYV&V=-+V9OQ6A$D[<W?2
M<;-/TYUL788-7HR,S"LW;DPD [ARU254$QTRF"Y#H3"KG=.NK;%+(35NF#'X
MQ.2D^9>+H]91C)\.+BF]6D1,GZ6'5&91MN-EYW7%E.SSC/!4NJ+F\24*K*:W
M1+Y/YH>'3==56E+2NNVR$%&,Y)T]3R\];*I)(*TWB^J@@2'3124XM19TTTZ\
M[DG\"D4AMD"7PH=[,.E&Y.G:F+@X ':/3+;\O]M:473MCBN7_P""C]PVX_X[
M[ERDUZ-62X?2_P"M*[)6U[EUS&V;N;:ZGM3;R(5UWO5;=KK="FJ-C[9*N+;U
M6I4H7@93:[<X_8\' \;HS841)LIJ*O#?C%'#;(V6C6'O5'R#&=6V2K(-7#.,
M &Z?8<"D1*4H!T*7I<IZ$P\?,CN-%>W1W"$E*-JPESJ27*FI>-JFH\%Q[.!"
MW+Z5W4F\=-W=&[IE]:7](9%$Z;<*74MGLME5EGBV5SH6W*N49V_&2UBVYMR;
MU;URI:M%[;N<@#^<W;75 -1+YKI=HUU!ZJ@XKNQ5ZHM8>Y0FQA=I/R_$]L5N
MJFH0$@.H(E,(D$F4RMCW;,L\2_-K?Q%M32Q]$X7.#G_CM=?BUHT^&K[>&FB;
M#YI^7W3>'[)M?3&9%K=<'<(SEN_-*.1MT<I8^B>W<CK_ 'W8[(RB^9QAHXI2
M4L6U;A;=*<U>M8K?RKT'[G5RRJD]K*/D3(MM17%.\5>/:(M[9'-$FSR; XR2
MADCNGY53"=8%1\3,9B]&9F'&4:L]RYG1\*E/A19XL$M+$M'+X;T<I:O5Z\3>
MM^^DMTUU'?5?G])1J=4-S25&Y65IRW;#>%E63<L2R;E"G18T5*-5#C%1K</4
M/Y5N!E,H]G&ZTZO\;*S;QE'LY\98?C%'M)@LU)+HN9*7([#9(F3DI%=LF9PL
M7HHMX90.)B@ 9\Q>A</!R?;<.O;:LOF<N>.$E+F;U<M?&[6TM7VO3B?=]^E;
MU)U1L?S9ZCS.M,[I[P(4>S7=2V3I\&N+C74X?)VCKKC*2K@]8PYFXI-MGZ0X
M'4MLVM+)&L<7RLKQ/,;5<F9^*->6:6BS1B<JE'6";:KW]5!]+LDYUZ"2YB^(
M7UM;H/4YNOV/0N%&-L(U;9R7V*=B]A@U.<>;2<D[=')<TM'V^L_24V_2LZEN
MNP,FW.ZY>3M>)/%PYKJG(4\;&M=3LQZ91P%*%,W12Y03Y7X5?#U4?B6X%TJ?
MK#BDSE:XS2].=V1Y<G-6D.+40Z@5[=(LF$=(6@\8IL46OO\ OF,6W36=@4%U
M 1*)C";J(_+>A,*_&>%?7ML\-V.QP>%%Q=C23GR^-ISM12<NUZ(JV_Z5W4VT
M[Y#J;:\WK?'ZCKPH8<<JOJ>Z-\<2N<[*\96+;^;P(3MLE"K7DCSM))<"0W'W
M1$/H"M3M8@E*ZC$RTZUE8Z"I]/;42HU=@QK,!6VL)7JVVE9H&;,"P0N3B+@W
M<NX/VE(4"ES8-@V*G8<:>-1X:JG-24:ZU57!*$(*,(*4M%ZNO;VM]B/(/-WS
M5W'S:WK%WS=5F2S\?%E59?F9<L[+R;)Y-^3*[(R954\\];_#25:TA7'5RDVS
M/>9X\G.<7D>4Q>&O[S:!BF*([!V\8 , @/:?RMN')R&Z#_X)B& 0'^$!ZX!M
M)XJ?T9KK[[^>'UL)+ *MQA_.)\Q;])O6'U+.+> 3;P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"/-<9W#6=KH^
MM(V>BKE6)LUNEW9)B(5C;C6Z^P*N_=S;F?BW9X>R'<VJ<CV8D7CF;E8[Q5P9
MPJ8AB !(; & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#4/6H6+K\07XX21(J&9(Q\:B^GO*9X5SLRX09-BD00-(S,DX<J 0H%%54P@
M=>F ;F^*G]&:Z^^_GA];"2P"K<8?SB?,6_2;UA]2SBW@$V\ 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , P]K, L
M\S<=I*@)T+*^3K-.,80,4E#ISA\S9O6XB0H@G:+&YD9(BA?0LR7:=>OA@. 9
MAP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , YR//\
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M*M:HB"9/-PVMNKZ_5YEXD[ZL''1B=<0[!_E"@;;  "@!2@       =   ]
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M#J/_ ,N:9T[_ /<N_?\ 2<;_ -@=+><B7]B7E,^_Y$WK^MF;O\W,YI& , 8
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MC!R8G'<\L;GK?T3LYUS'J&#CUQJ5.X.W:,1%RNLYH+A==8Y5 *)S&Z]I #H
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MG]&:Z^^_GA];"2P"K<8?SB?,6_2;UA]2SBW@$V\ 8 P!@# & , 8 P!@# &
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MS^I.5HM8$.\H$->/G&"S\]=P:'J\9Q_T'Q+D>).B-=U2_P"[]2U/8;?<&O\
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MXJZ?_P T6FL;!CBG,)8^[QZM4L )>[ B?QNJ+)]#J]H"7IW5X#CV#W''O[B
M6U,3%LN\S1*A+ZXMM533M\=:[-(N3P,S5/>FED6L461O8(>3>%.Z=7)K$E2;
MN$&;HP%55*F9-$PF D#@# & , 8 P##5J>;9;[":/ZK76$Y1X*HKDD8IU8OB
M](V*R3\JD9)6&.HQD(UV>JQ<$(&2>F8IJ&ENI''5$Y# 9#K-@5L3%9TXKUBK
M#EL[49.8JRM&C9ZFLFDBL91!>-?RD3(LS%7 "N&KE= QBF*!^I3  %Q8 P!@
M# .<CS_/N)<_H+>8U_<+@&PVU?[7[CO_ +M7F)]9[@I@&RK & , 8 P!@'(#
MY)=^:Q7FH<U8A-\Y<-]Y.-_32A%.O>M8*3OUW/-G+L##U(8(RV20@ ]QN]4P
M]>W[ '7]@# & , 8 P#G#Y&_F:?O-W^D+<'_  N.'6 ;2^*G]&:Z^^_GA];"
M2P"K<8?SB?,6_2;UA]2SBW@$V\ 8 P!@# & , 8!%GFS^:KNO[TR_P"=XS (
MM<41#V]N>I?==0M%>$?_ !>AJ1K("]>AC=#>Y'IW 3^'M$_NO#T?I3^?-_\
MZ1K_ (M6=2^?_P#PL\H_]C<S^NLTVEYO!RT, 8!;AEW\NZ<-V*YXZ,9+*-7,
M@1-,[Q\[3]RNWC_'(H@@W:'ZD46,0YC*@8A +V"<0*#3JM$5R9MIHX'QCN7S
M4ZAW\F_DA3]:0&4<ILRO7"R<>W7D9!98R2 )I=Y_04    #(. <5O,#:%SY1
M;NY0RW+S==QX=6WC)PIV*^U_0#\,I&:B:5/2NU[?-6!S2MA;/AMDP.QIRNCI
M*@2L=M*FKPG\N],1AZ@!5DC =*OEX;AY+;EU+9ISD=#L'81UP(UU/MEIJF\:
M!<[JUK(UN#G6%MEM&;(>/KG0I2(DY1Q$K+KBV9S:C(7[%HW:+)%,!/W & ,
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M(KI:*(50ZBAO>L5O5Q.8>JADA.(%[N@ 7-@# & , YR//\^XES^@MYC7]PN
M;#;5_M?N._\ NU>8GUGN"F ;*L 8 P!@# & ?Y_GEC7Y'7GF@::N R95QNN_
M]G4>64<N!0(8VUE;U6 *J1(!15*YL<NV%(HB/^- G_%_@ _T \ 8 P!@# &
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M.RV&2MMC3J\!$P!)^US(I#,6>;)$M&A96PRPH$%R]7\1ROV%[SFZ!@%SB &
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MUIBIL9-T$LT7<P=A32!)*>B3)HO#ID]*;:114(HSF6!3!_S#I-4A?LD[#=#
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M>?W_  M\I/\ 8W,_KK--KV;N<MC & , Q31OZ23_ /0\U_[;S> 96P!@# &
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M&_F:?O-W^D+<'_"XX=8!M+XJ?T9KK[[^>'UL)+ *MQA_.)\Q;])O6'U+.+>
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M079K_P!KZ$H/(K8M>YI\()C9]GY!:QOCEUO74=-WG9N+FY96&L>N9O65M9;
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MN"'*H4IR&*<AR@<AR"!BG*8 $IBF 1 Q3 /4!#T"&>AG')^L 8 P!@# & ,
M8 P!@'\,4IRF*8H&*8!*8I@ 2F*(=!*8!Z@(" ^D, M20I%:DFT P6CP0B:S
M*,IB+A(Y=>*A ?Q:Q7<4=Y%1RC5E(-XM^F1TW07(=!-TDFL!/$33,4"[, 8
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MPI-H)-7#*^URA1).XLD_F89M(/%C*&*1(L<^DYV.B8Y0O=Z!6;/ ,80]ST]
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MW77%2O[9-&PQI5'38Q%(^79G%G,QJR9_$2692"0 LF9)3W12F[B ;T]O7H.
M8ED*KNU! ] 3L+:P5"Q'3C5;TLH#.X56",(GETE@%7K*O7D<F=LU<!WK)+K
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M>),\O;+E8W$;'PT&C(R[PQ>C:-81\<U1331;-D4B%( &;< 8 P!@# & , 8
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M;45@Y>C&NWK-%G[UPZS@ZD97&1"*NG2L77VIBMFIW;AT\%!,H*K*F#N$"_,
M8 P!@# & , YR//\^XES^@MYC7]PN 3-WC8KW6O-CXUOM>ZZ#9LPMY=/,!H[
M@QM\/2_4HPW)/@\LI*^^<TW<MG/AND4D? * *#XW?UZ%' +LY*;/Y'.4]#^O
M<5RL?5^2VIG+/_W[T)3UM\BYEA;,?1%^X]8$1#N^P'3 )+?A9Y.?-)+^/N@_
M!> /PL\G/FDE_'W0?@O 'X6>3GS22_C[H/P7@#\+/)SYI)?Q]T'X+P!^%GDY
M\TDOX^Z#\%X _"SR<^:27\?=!^"\ ?A9Y.?-)+^/N@_!> /PL\G/FDE_'W0?
M@O 'X6>3GS22_C[H/P7@#\+/)SYI)?Q]T'X+P"/?)S:/)!SK6 2?\52L&X;\
MXHK%7_#M0EN]TVY2Z<<,&?:6+#P_?%\DFW\0?<I>+WFZ@4< D)^%GDY\TDOX
M^Z#\%X!I'V])V.9X(_O+,G;:H%(L3N^;D/)U8+!'6D(I0GE@<04D2>_L4B@P
M>^M-2$7Z$( H^+X9NIR&$0-M_%3^C-=???SP^MA)8!5N,/YQ/F+?I-ZP^I9Q
M;P":RZ"+E%9LY12<-W"2B"Z"Z9%45T52"FJBLDH!B*)*$,)3%, @(#T' (4N
M+WM>*V5;-<Z\O$%LBP1K6J+Q=5<TN+;TNG-)()=E)M;;9ZF]CG=+:P18,JH(
MN324FX]=1*V9K% P$ FPGW]A/% @*=A?$!,1,0#] [P(8Q2F,0#?8$0 1#^#
M /W@# & , 8!%GFS^:KNO[TR_P"=XS (GZ9J%EO7(?GDPBT*E[UPO(BK*F<3
MCZ[,I7WT>:,UL*J;52G3D 8(T67A=Q555.]4.O8'84V:+TG+7?>H(^C<:_XM
M2=5_2!J<?*CRBM>GK=&9?U$M\W%?9:>OU/=)0?@'M_\ ^ ?]8MX_E(S>CE0?
M@'M__P" ?]8MX_E(P#^#HFXE$!!*@JAZ>I1M.\FXAZ/0('"_N>OI_@[0_P"[
M@'\_ 9<?_N5!_KKO+^V. 794J=L*%F8EE&P58I,;"P<K%OYAE(/[)$6+UN6]
M^67J=??2+:::N4I!^\66=.W9EE%%CB;O[@[0,L>]M^_ZV5O^I;W^V. />V_?
M];*W_4M[_;' 'O;?O^ME;_J6]_MC@#WMOW_6RM_U+>_VQP![VW[_ *V5O^I;
MW^V. 4"!VK4#1I"6>ZTJ+GVKN382;%>P1,6LDO'2;Q@"AXY[)'=,Q<I-BJ@F
M<QA*!^G40](@5C\*6LOE%HG];J_\(8 _"EK+Y1J)_6ZO_"& 5A&XU%PDFNWM
M-<706(51)9&<C%4E4S!U*=-0CHQ#D,'V! 1 < #<*D50B1K37 54Z>&F,W&
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M$2-T$Q,!GZJUBE0U?=I%KE7BXF*F;.W023AHIFQ8,6UADR(H(I)MDT6[= @
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MR:=%W%GN?34 C)K2S<8>;XMVLTHQ7AIF0A'23H\=RV>,%!,YCCF*9%55(Q!
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M3US>SE$8 P!@'F5>-$'#5HLZ;(NGHK R;*KI)N'8MT_%< U1.8%' H)>Z/V
M/:7TCT# /3@# & , 8!@_C[]PLU_I8W?_>_=L JF]]SUCCSJ:Y;DN<+?K%6:
M.S8/92%U=0;3M&^OTY&8CH-NE7:'2HV7L]A<D>2B9U2-6Z@HMRJ+'[4TSF "
M/VCN>>LM\7NLZYA-4<IZ!9+77+!:H[\-/&K:FI8EK$UUC5Y%8)B9N4%'1L/*
M2;.W-#L6*ZA'KKPW(%2ZM'() 3"2KL.BX%R#05%/7'#\A7#EVZ;HO7:YW+AR
MV:.5U6K591PH8_<F0H@(^C ,0WMFWD-W:=9.TQ5;.:;N,BQ"J*HF,4%-<*%[
M543IK)F*<@"!BF P"'H' ,U,XM@P,HHU;%(LM_SSDYE%W:P!Z0!9VX.JY5*
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M977JVSG<AI3CSLC;5:AZJA.N*ZJ:8LE3B7<0RFPDD [8P532!TE4U2(F3-W
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MOBN"6XYL'NFXRT_7>/F^%+7BG4HMM11M@S?SD48 P!@# & , 8 P!@# & ,
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M%[^XC\J-YUV#@&'+C7FFE(:=]^CSFH..NQ*Q-2R?O<^C_>B5=J<MG@.8GN>
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MK(]3XM<9*BV=3DXO9)M2ERJ6BX)-K5\#-AM(>88;IUY0<5"=/_V/#Z?+U_\
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M +M_., >RG$_+IRG_'_=OYQ@%VZYX\5+7%S=[ 1M>U+K;'-86IR$ILO9-FO
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MMP:G_:E4OZ/$/\'8 ]N#4_[4JE_1XA_@[ 'MP:G_ &I5+^CQ#_!V /;@U/\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M_&[D?9MT<5[51)Y"Q5F1XS\@I-:V-*W!2C5=9JY3UC<WBS)\!.GA/9$2#U]
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M0FU8Q[))!HT;I@/N2)D*4/X P"IX P!@# & , 8 P!@# & , 8 P!@# & ,
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MG:%GUU99RH76!J=)DI"4@+'6DXM2>C733XK)JJFBRS37Q5$@41 RH%[Q$#
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MYZ\1C;QN!C&HNW;ARE',1\L'B&\%DP264.1DS%X\66\)("D\54Y^G<<PB!M
MXJ?T9KK[[^>'UL)+ *MQA_.)\Q;])O6'U+.+> 3;P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#G(\_S[B7/Z"WF-?W"
MX!LYN50>,_,UXY[2?R$5'UUWPHY3Z;B$7C@Z,A.WN?W'Q3V2WBHE,R7J[E9M
M3]:2KQ1+Q 6%%N=0A#$26,F!/[ & , UL[UXH;TNMFW%>JEL>5F'=VV14']+
MH2^_]Y:9KM=U?#:+BZ5,5XLYKGWY+#2;S<;0+1V,XDQ5B-A(=R!GKE,H%\5O
M2O*-=;4;>Z[;;'A:-7(:J;%:1EIM*\EM!1J_15E[:C,)1\*K"2,I'*G;*$<I
MO5SH)G!-9JX63>-P+8T;Q:Y(:JO&KI"4Y"2LYK*J(PQ[IKJ5N&P;ZYM4XGK[
M<D'/6(UTV YE;2X3=VVYP+E.*6<!'&+%^L]J;ALV3,!4(WC]R.H.PUMFUN^)
M;%DK+N_<-BM-6M^Y-HUJLQFGKBG+M=8UN!BE8+8-8<2NN"N4G/JJ41%I'4.*
M)79DVR)S@1"I'"#GG!RL2NZW&TB3MU-5D:SZG+CD]L0*HI4=>2%9VU+&I-DK
M$)$;"#>MM<HRJK!^]9$@O!_Q5?Q1 Y0-H3_6VRI37FN*D.RI*'L,%,MW=WMC
M!Z^7D9F.;PEE;F;1JP^J.%R^_CY@N@1Z97M2:E]9,[,4_C 1P8:DYS+4J@U0
M=MT&I/-=/+NVG+&>>NVRK)N^,L N(>OR<M..X?7P:UE:[ 3;YZFB=I:VY9EN
MP,7^2;#W@3$U1";#K]6<1FS;$PM=C2LMI.UGH_QB$D*PI./1J:SUJJS9)Q\R
M:O>KB^;H =JB\%4J!S(]@X!DO & <^'*>GNX?@)^\.7LDC%RU:V]-<A[749"
M*577149TS@AH#2=G:+JJH(HG>P^P]5S+%;P#*I%4;&)W]Y3E*!L>XJ?T9KK[
M[^>'UL)+ *MQA_.)\Q;])O6'U+.+> 3;P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P#G(\_S[B7/Z"WF-?W"X!NNY(O=
M$H4&)9;Y8!,Q4I9HAO1H**CK)+; E=AHMWCJ"3U6RHY#WXM];M47*B#F$%)Z
MT;%75,JDW*L< -6DMQTITO,34DAL_P \R+*\EI%T:(@=_;G;P\0+IR=V6,BV
M9K&Z691K5%P4K5$YS'*V[/2/V1 I_LQU3Y7//D^D#NGX:P![,=4^5SSY/I [
MI^&L >S'5/E<\^3Z0.Z?AK 'LQU3Y7//D^D#NGX:P![,=4^5SSY/I [I^&L
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M-5-P0JY5"@!G3BI_1FNOOOYX?6PDL JW&'\XGS%OTF]8?4LXMX!-O & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M</'>[TV#USQ2N-7+(;MK48P;W:KV;EO'@_9R,)<8I1T[C(FWG27;F542%!^
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MV\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & <]WGD4VS;$;0U%ID4K.VRV<*O,2A:]#(+-6ZTG*.="'%!HFN]7;
M-$C* 0?=**$('3TC@$JN1^B)C=/F'Z9>LIFVU",2\N?F'7:SL:G7JZ4Q2 V/
M8MW\/G-2<. U_=*7-VQBR9Q[J0/&K.%(Y;U4@K 4_@FP#+NO>$]OBK2=]LS>
M]\N=/&#.T+6ZUM?EU3)<L\5.#!M,A9EN5UB*5H"J$D*S061O$*Z;@54@MCF<
M@9HD>+&HXZ/?2!Y;D$H1BS=/#)DY;\LA.H5L@=<Q"@GN=503& G0 *4P]?L
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M#X ]C_9/SUN37V[K_P #X ]C_9/SUN37V[K_ ,#X ]C_ &3\];DU]NZ_\#X
M]C_9/SUN37V[K_P/@#V/]D_/6Y-?;NO_  /@#V/]D_/6Y-?;NO\ P/@#V/\
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?*6B<N%SL]FGH[8#)RE*F<.U%FTFY63<&!0 (4#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g570173page162.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g570173page162.jpg
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M96(1CT5!*BHYKD7KF/V5M58U3C#J2"/@(Z$2L#D9'9/U2EIT5%2IK$5/:BI
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M<RI,XQV6BK;(K5[G,BZM>R^,]CE']J*G=J\N5)=U^%J]?@7,J\HCVC?;CB<
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MY^K86'%6^2S:GX,[FMJ4)^PECH_V"H,H;CYHL.U<-]XY_.Z2CO4K 8.ZXFW
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M%%C1IVU;I9!#& -H@ 8.QV.4SPA#8C6ITZ(B8B>AG%7&3%Z_N?Z@9?A[IE#
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M8>++ :-)"1.K#1SC<(PGI]%A!O5%_$7+&FVRBU;Z25N1@RD=H(.01]H]9]$
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M+/F#R]RP\M<7L=E1QM&VN4U-;9?XBW"G<*UM]CO;6PN+CPR4"T!RJ$X.[>=
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M'FQ6=55C&/Z/1$Y6;]JW)/I Y)@I!Y#@4=CLM/=;)7;MK9&5=-M%/JQZR+9
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MM=XX!I*JAH]3V&_B7]+M=#6;Q=;)0:PZYU?D06SU\NSLM4B3[IGN^17H<(V
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MB:R\<%N"^C;@-=AGP[2_'K>M1KRPKA315\NWB5UA%LC0//B&<\)\P+_".U2
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ML3]DMJ;1]3 ZM6Z2%7092CD[C/V,0E=,JTD$8R"%JR7+W,Z,:ULAL_(WG"Q
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M*J["$0]PV.%K-AT!B5LT46MP^A5+$=N,=/@SDCK]CMQU^#-?=$_NF_\ C?\
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M7<@BI\*(5JK\.93YC)NV?$[QQBZWC &^$^#N-QMT;[7AU(H^RI^"4*>C6+Z
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MFA;:C[@TT45N*R[5JCVO984LTUH+*E"JNJQG.'05G51=K#9X5>!@9)/7&>P
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MIT5\DEEN6]ZGDVO<+M7\F>46720]J[?=% Y["J^UZFK7L8YU/U9, !6R5?\
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M!_V=RG_>\S']#Y2_[\GK@_9QQ7^"),?D'RO\9?,'[-1^]X_WLO(/_@E[H/\
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M-H#KU=]2JAR93B6IHVS6<P&;A';U 0+'L'II)SI91\X^-.GN,"Q03+:>^O;
M/# &3%M8LE5V&-8D8:V6V.QKBS)\EC6,G-FL8C@'&B >!&M$C&,0;+W@VVPV
MS45JZ;Q'^75R#9XA'5G88#ZQU1U&@I@(%5=*VG,KN#N%NL97VC+\BR BOPQV
M*BGU=/8R'O!LEB2=1B*=DC4M(A5J.=MZT57)UTH%1I*U6U\0<JQLG]%1FO-:
MK62QOZI)16B8BF4?2CSNFSPMOM,GG,EJ".VOL#/8?UGL%BGYSHB@N5Q5X757
MXE^Y_@; %P/8_I5$'Z]VFLCU.K,0@;,BT_I')80K?[<U\.3?R"=>VT&BO'%G
MTRN5RMUQBN<R,!JJL15<PO4RO(3S@L5/;M]]_#W1KF/XP=0KU?U =0B#K6<J
M^;"S-[S/RBUW[/\ @3J*@/B'M9+/ZMV%V/SG1DP@55]^W/K75K(<P$B9-F2&
M-HX=>1 VQ+8*.+&D5DA53R1H712/D.5! $CG$7L[D6YYQMH=H*+U9]Q8P\%4
M.+#8.JM6WQ"GK%SW47);NY!M^'7<C<FZEE2A%/BLXS6*ST8./C!NP(.\S8"]
M[!&#U5LZ!:EC[D4$G<9D=S8EL!CA55A4A[2N@T(G_P"1&AJB/FA7H601/'_P
M78,$=PR[C;;TU\\ROSMB=VP#%;UCJ4I!]0KVVKZSM\IZFE:[_EC1N-H+.%#+
MPJ-WJR<V)8>FNTCU@W94WJH/D_7U-9Q9^= _^Z _-3?\0FH_MLBYSQ[T_P#B
M+\F?X%;^[=M/T3^I%_P[^_+_ %!Y'^LI.]F=8S\QXQ$8B?A*_P FD?X@O_JW
M8B8;4_M5UG];]-]CHV(D@Q$C-+^C6X?Z8KOVM4F(DFQ$8B,1(MNGVMS_ /&U
MOV4A8B2G$1B(Q$8B1>N^VS9O]&ZU_P MWB)*,1&(C$2-[E]J.S_K?N/L?(Q$
MDF(C$1B(Q$BU1]LFW?XVC^Q;<1)3B(Q$8B<IOGC?YI>K_P#$]Z9?XV*+-<^\
M[^!-G_GGC_W37.T?J,?[3_,O_EIYO_T'NI:/H _0KF[]\:D_B^U;-D/ZQ^W.
M*-O\PGZ0?G"=",^96C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B<OOG _MUX:_6;RW]E>+<IW?,O^D;]29]U_.I^G7]4)
M*?04M@_TG>G\.T(C='=KI6UBH@T;(MUV>Y\"/L_A.<-M&LA6^0Z]&G/\64C7
M>"A>7_JXG<M[FO+:<QT\O';MX?9AK?:;L+N,=!3JQX/H=^EV#X8?HSW^>SK[
MV.??BNO.B]=?;TK]GJR:,]?%QGQ?2J]:B1K*=&,ZDG.$T2V#U$5-#OS]#!J>
MYBXL;R[7\1[5M</W<6CUS8=@U?3=GU\\>94S;";6<=;?*W>/6M<5L8S+%A1"
M0<=R*E*OR/N-QP]G+;'?4?D=]'6;QJD\3QF%6YOHW%6WRJ?M>@;>R[=O66%=
M1^0+5^+X4W]-(N[3:[O;O^5?CK4C/I\/#5)959=U.=P^M4H5@"[=;0'T>)O/
M&;'9'CLAM"V(T(FQ6QD8V.V.UC4 V.T702!02)V(WXO;TZ>S/:14M2K0%% 4
M:=.-.G'33CIC'9CICLD/:;&L8W:C<6.K5G.<]<YZYSVYZYE%[,Z<+>X;=,22
ML5:_97;JD!K'OC$>77'RC:LQ[7!)N3PJQQQ)U$HE\1S5E*)I<0WYW*;J\<!K
M\'4/:]&#I)]8[<$8.Z(P77U=/>(-V@/E6R&W;;TGF]'BZ3[-KSW@.BB\CJ-L
M#D(WK:AI!%6HI<E$E0VH@>X5 M2H$="='<Y['L>YSWD>\BN,200SG.,XBJ5Q
M5<KU5ZNS)N.&Q&QK^C=/L6GNZ>H(/4DD]2Q.2Q;O%LEN]F8]OSO#O+/I#5[9
MJ[V>A!'0  =  ,!0O="X"]W$I+FC?"\:LKM@UBIFV]Y;;7Q_INP@A&J05=?
MW[;JC2*C8]B?;6%='2356%R)8S0N),.Q%8X;HS7D!:KQ/(<OS%NU\KO4G/+L
MK[[0X8U/5MZ7NTMI5L;EDK9=KJTJ[#3:ZT@NDCMMUM-MQZ/Y@#GAS>B5%<>(
MMECJIT9(/@ L#N,9T@ZJP;2%?X],_-G'//6@6^Z<8DFR:*NWW<=.FV-G)JY5
MG<W6KV20)=Y-?5SIR"]]1U#* (_@20Q2B8\ .U!-RSEO)N[\D64\9O@PWE^U
MJW+ZPXLUW+EUNUJA-M;!JW*@UZDQ4QK"&0 YGZ;=]RNGPJ[&K0*0:PB'N^'I
M) K92&7/>(;+C66ED[?XC)< FO>&N\N$5E0-RN;#D5[7M64S9E&U[V:R,KD5
MY$13#,K?+HXSNQ^"\YK6ZI^+Q^46DBH?%*9[PW&.HVX)!+8+*Q'A N=+9%PV
MDTV+R6?H'(-A^,'QW31GH;R.P>JRY\3"#4N*XB\F[4:LCU.[8UJ:5FR^>1B3
MQRFUPEB@8UGU-E(P+E6!X7U%P5[T52.*Y;GA? /C,VH\KKQ?KQK##.D#'05
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M+<TT4]DMO)>V9I\%&NFW$Y1N(2TH1.<P8;((V*28CE:$P6J1RM*U%)#\I:W
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MCOLTEVONEM7V]/?B ]V]JV#G?%2K\3Q4?]45WENA%Z5^E]P=W^3V1]-Z,FS
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MU/40Z\M7>V;'\GR+=^JOR#*&I3UDTD96]O0RL.]4GQO6<:,+9R5^?<IZR)Z
M-C/$A B$A;-15D;RK?+L97I0;8YD)PA*P98P7L1PVN14&[JK>BJO7G;ZV&PV
M=/D7A;**U1J_,>QK73W<)X>YPF!@%01D YTG)&,G/<O_ *:&]W5WUM^"KN=G
M6RS6VKKE_:-OELGJ&/82.T=#G QU>X2_V,\1_O8Z#^U6ISI[A?X'VG^#5?J%
MG&'O._VD^8?\^;_]U6RSLDI@\8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B<IOGC?YI>K_\ $]Z9?XV*+-<^\[^!-G_GGC_W37.T
M?J,?[3_,O_EIYO\ ]![J6CZ /T*YN_?&I/XOM6S9#^L?MSBC;_,)^D'YPG0C
M/F5HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(G+[YP/[=>&OUF\M_97BW*=WS+_I&_4F?=?SJ?IU_5"6GZ!]>C3/1=Z?Y
M,!S*JYCZQ9385K'"U2,F2-BN$DI-&BC]X0I[0L9("]R>(QC5:YCQB>SGCZN'
M%U7^X?RW;MB*=^NVM=+% R&;<6ZM8Z:T< !U)Z@#!5E1EWO[_>1LH]]//U;C
M-VR;<5JU9/0J**M.D]=#)DE& Z$G(9696VS^6!U=[C;7-^6_;T6B4SO*L!W>
M'\HG3$&CEU7N3V2.SO<3\[]GF>HDW1].VD_1PJ'Y0X^9SW0.SQ]>,^S_  /C
M)/R6GQ<H-2?0U8'MYL_R%^NX[Q/;X.G/S_\ .9P!\IGPL,?:S4(1()V3Y!Y=
MQ+.&?)V%G;'LA649KVQ)-:Y/%;71ZYI7,CQT[Q-$Y[2(7Q3*2NO![=MNR[EF
M??NP=KQW;!8N=+5]NA4R0B#*A2P;7K<O0;F;UO5MNJILD4H*3U0H<:@_9K+X
M!=^C:@"NG2@7QNVLU.YE-=QUD[*7N'21H+6C;MR,1%635L*]61G1FJCIXR.[
M8+?JCG*%6$=0/-6;$C8<BNOEVZ5*G3VG'QJ\GNZ1UN!.*1WB3658UAQ*;T'>
M[%M/&#K:S=?9\_%? [VKLJ(&;3W0 X91[(VKAF!FR-F0-I:6H6@EN8I6Q:V*
MTK) *VD=U'(B AR!M)YAO9(-(8TSE:K1,%<5<.EZ66\MINWERX;&=*+D,*ZN
MQE"L VL8=G L)!"*E&WE7I=*^+U5;2ILKG!9VQ@O;VABP)&@Y14)0 @L6\:[
M [4^VOVB24X7N0-!=(+Q#WI7=4CTA@ 8G?M3NG:,0VHD]$[Q-1R$&.W/)MPO
M[5YARU9.*;<9-Q/JU%1_='H55'RWK( 0Z+7''#E_VQQ2A7 S;5G J'IM!)^8
M])8GY+U7."K-ZX5*:V*ZWVF,$AB@/'@4)?"E0:6#+$X,@9T^/'FV\V.]623?
M&8QCE")>Q2/-7V_'OO7.]YA%-C*52DX9*D888'M5[74XL;J ":T[NIK*-^^K
MV:#9\4S! P+VC*M:ZG((["M:D91>A) =^]I5/(L_Y$(H;J6JZFGL@7LTRN=1
MJJHT=5>2BN5SHCG*C(DMZJKE5H3*I%&\U#VG\GOD]^_^1/B7.?F?@KM8]JGL
MJM)R3BMSKTM95]G^G._LD_RO\>I1\[\-E2CXWILK'8,N@TZE3TQ(<O898+>X
M 6)61#-/144ABC*XHUZAN[L+NBI-14[HL5R?G1.A")YCHT%:FB[E+EWV^4IL
MT;--+#!R.RVT?A>FNL_-^LWRN!72NNJXVEMGLF#[IQBVT=1@]M51_!]#N/G/
M57Y/)L_$C'Z8\DD+7/T\CGEF1FHKG:J]RJ\LZ(U.JKKCE57'"G^0^TC/J'<T
M5)E;@&-M8)X(DEE';MSVEU'ZQZ77\5U9?D\A*BE>;45.<<R!A6_7QZ%;^K>A
M6_&^JWRF"_\ &]=V5A.O33$[2"1J_;=\#QF54_\ 9?X',1/T1]BK^=NB2/1G
MS 0__P"8>T?])^ _X/Z1^O\ ;\S\Z..#!7_\]]A_Z/\ "/\ E_0?UGL^=^;]
M$V#+H)9[NCCDDPI+U-?:_';U=(=T1"7%*+V-9;,:G4P$Z-FM3JG0Z(I*FXVU
M_&W-R''*7V[G-U*_&^&VH>BP?&3LM']4 +4Z+Z>0J78[Y@MZC%5Q]'P5V'];
M_!;MK/\ .>KY$M/ELB1]?FN;K/M;9[!#(X;[%S55AJ6D.Q6D$\;VJ.;*;T=&
M<C@#Z2$(Z/1&\_* >'QEA^B/QERG!?T&JH]H(.5ML'5#FM?E0QJK':?09\3D
M4'TI\2EAD)\%MH["".M2'HXQ8WR>D6>R90DJB"M-5C@CR8T8$652C5D6ONZZ
M(Q!QXO1$:&'9PPM[8LCHB(B>$7J)44=>_C7V;#><,BK<B!6J&%2U%& OP+8H
MZ5OV8[C]S!2C3R"[M3M.69FJ9BRVG+/4[');X61CUL3^C3O9#<<?GR=IK]@]
M FX@JAR)#8FX5#;<I&(!*6P9KFV]*6P&14*R[9U[B1T17 'VO(K4(+Q.7_K3
M\SMN2\C\37L@S!/,^Q%I(QX3^'N/DG!ZBWKED'55PS8#IJ[W_P#3:XK<\=];
M3R]9NRJEV'A@'/BI[3MOE4(Z&H]BOV,<A<E7T];^$O\ 8SQ'^]CH/[5:G.JN
M%_@?:?X-5^H6<3^\[_:3YA_SYO\ ]U6RSLDI@\8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B<IOGC?YI>K_\3WIE_C8HLUS[SOX$
MV?\ GGC_ -TUSM'ZC'^T_P R_P#EIYO_ -![J6CZ /T*YN_?&I/XOM6S9#^L
M?MSBC;_,)^D'YPG0C/F5HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(G+[YP/[=>&OUF\M_97BW*=WS+_I&_4F?=?SJ?IU
M_5"6;Z!MC$+T:<!5=0T5GL)-5GQQ5O>X;8CA;%<J:=;O1KGP:N,TK7*16JIN
MYK1(][VHO.OU;^51/<7Y<V>Q NY0[6Q17G&G&XMR]I[4K7().,MD! S, =]>
M_P"XUW]\W/[K>$U<<-S62^,ZLT586L=C.V" ,X7!+Z0I,W ^1S$#YQM@7Y6(
M3S7RG4+5.Z3V]JPWQ$(C%UU6?4_(=_AH/XR.\Q]7S=WT"HK]H%I^F\ZO:,=2
MWX)7./ QW?!SC'7/B_*33WTTVOP#6/HC&GP,]-/X6K'SWI\7&<],>'\G";@P
M 7PI\$K-I&1D5NNQGH0UC((UR@E51R()AZ4[1N>LIZ,9'8UZ'\-XWL0.=6NL
MT;FLCF00O@*<EV.<-63@&IL$^(<! &%FEE90/#&QQ?M[ >)(+>,PP$ [5L S
MBT9 \,9+DC1J5@29J39XC3+\ZGV&3X9!V4%[A+KSA.4D:-K9"L5T8,5Z_'(]
MO=-=U\=JC5 L]7A%W*-N.3;5RCX(L0D>!CJJT$^J%/:2,VG/B J16OC<P=NX
MHX]=/'+D%&Z^-GHS7 'O%AV 'Y(8\,A@7(>T>YVF@;2YH;2,-'1310$<'9@J
M]H0EI8K/$*2R(5[6%@M5Y1%>G;WB<PCO%YCV -MN9[N\0=TJ#C<#( -2C)-A
M) :H996(QJ0JQ];BO;2NXXGO;5SW@Q&:#C)%C= $ !*VG"LH.<,&4?P6NNV#
MOL=MC,(0PW,K:3Q>X.OQR=%0S) 'IW[&_HBOF"<BQU3PX[D1'D-ZG%GD\[KF
MT!=@0E6>E*GTA@>MY[3:I[GJU$ ,[GY(<=C;<.Q"J<O;CK<1Z,$=*1Z*V'?]
M:P$X5/Z&Y)K3UK=IFM\HUA'U6R258(4\ 6.(Z%:/:U@H]Y&"Q5]B-9,8U2#1
M'(00U>_;B6]DYBSY  FN]L . ,Z+#T"W*!]@6@:D (9%\?9+R8]IXI/EB0+*
M5R2A)QJK'::B?MFLG2Q(TLW\#7EVLB3[^&K*-$5:G7)P47S+7(J-MM@B%16N
MD/:O6/#(BI&:O>1/'5&@\KVK\RWM/)5XX[\70X];^J7*?C'XE1&*QWG'B8%?
MK[E.)7V?CWSO_P 9<I]7^IU,/0/CV#USW5/AY-G]!(-J9A0+(Y#ZV<C0U5O)
M(XA:<KU1H:BZD$57/BO<J-B3'KU5>@3+XG80RNVSA;!MMVQ;B6.*[6.343V5
M6L>I4]E=I^PEAU:6?QZTY=#N-LH7DU&;*U&!8!VV5@=C>FRL?9=!IU*GPGB;
MD5'.1XM0"_JQBHYA-K(-WL>]%Z.9K+')[&_#8+[5_.WLD>=_GGR<KP:GIZ#N
M"/2?@H'H'X[T_)?.^G3PJX&#S)'VQ0#\'PW'TG\3_P K\V>,FFD<>.QY=1*]
M7RH@FN>35GO7J^7"$Q%<_7G.7J8+4ZPO:\:>!W-$97X%S94"W!L<LHZG;D]K
M(/UCTL@^:]91X>0GJLO-**["!S &%8]!>/P6/Z]^"Q^=]5N_@O\ 9YA]J,2N
MJ)) 4 7J*WO8A582P>GL)3T,D:HJ)_:RIHU^H^T05\;O?'^K+[.9L.UV+E>,
M4XLN4X+_  U4L/O66CU?40^)J:ORNE.(0;G>*&Y!AFNIAD)\%EJG[]=9];UW
M&C"V?PU435B+8ZW"[JI4;[WUF$-&M<P;49[THH[>C!68AM3QH[>C9C4ZIT.B
M*3Q]D_#M[5Q->=G^-VZCT#IXE*]@L ]9!@6CLQ9@L3=KRJ^S<F^-W^+O8^D]
M=%I[2A/JN>M9[>YZHU\_8W-KM3F-<(@QDM-B"UI 5$<S4>D:(TK%&?83C7XH
MGM5L1J^(=O7PQ&/R3<J1M>%<%" ;+QU%2GKI7(P;B.Q2,5CO6#U4<G'CC0=S
MRZ$."0E)Z&PCXS8ZBD'M8'-A[M9]9TX__/FZQ5T_H#VZ35L-#7Y3TP)@F%4@
M[1_N#;5'-LU.A2RK0;WN592N0Y.]4(YZ=J-YG^M3P^SV/D;B+=F&K/Y2[$,
M<BPZ=QA[,Y+6 Y^4SK;)#%AC'>'_ *;'*;O>_6U\OU;LA_E 5)&#7^V-OE4Q
M@*A '<QI7 *A3G/6?A+_ &,\1_O8Z#^U6ISJ;A?X'VG^#5?J%G%?O._VD^8?
M\^;_ /=5LL[)*8/&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(G*;YXW^:7J__$]Z9?XV*+-<^\[^!-G_ )YX_P#=-<[1^HQ_M/\
M,O\ Y:>;_P#0>ZEH^@#]"N;OWQJ3^+[5LV0_K'[<XHV_S"?I!^<)T(SYE:,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)R
M_P#G FJ[=>&^GZC>6_HHG_VVXM^GE.[YE_TC?J3/NKYU/TZ_GB0OYOOG'ATO
M%G"G"VO[-*A^H:)J=X&SURTUC<8<6XB4-A>7<FAL+Z;2,I"0:ZK/XL5\>0_R
M92N<-KE(<1>,?JX>=_*%'E+@?(.UNW&W]YR[2\/3=M=W6ERTV77-2U]E(I9*
MZVU5FMV\)F)4'78C];>_[R=YJM\S\WYUW-5%_NZ.YI*W4[G:V-4UU=52VK57
M:;0[V+I<.@\0* Q&A'3J,NX0E@-,.-*?</E.K&:VJ#;;I<M$AGUY&*]0B8(*
MH9TE7+&2,J'1ZB5'+UN>=V_LP=4<[XOX8HZ>+XN,E",X  [QLSX?A_*!BA!/
M+PX:_P!HT,R#9!-?C=?#\/. X/:23W0F->ON:0P('B^1YI3DO)TYH]T:URP[
MF,-Q(U,%ZM>ZB@QBJ-TB@,HVI+&]6/FO:A7*,C >!;?05EQ^D=Q8!SX]2U1E
M:@>O@HIQJI.!X@.#:0')5EK\.O\ 3*5#V"BLGA#ZU;'#6']=8C.+1D^&1D5
ME &5K/$]H=LC1XDSWX-:VVJ_ '.K!^)*))+*>H8!:1&L0UK%MCM[(RL9XCB=
M1/:TK7L;<5\W3738.1'A;ZG >L98L6.$-6!FQ;#TKP,ELHP#AE%!^'MLN3V
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MO8QMFP;'$6OLE:U@8]['"Q7+T1HY8VJ0:(Y"#'7VV[NV%R\=R;:E;I3<< 6
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MB1$U%$]BR:\ T^UOZ)0-3K"]KV)X'<T5%:5\MJ/94 \O#M11_:W\\@'XC\)
M/DO67Y/(2JUK>8&/M#9YT]CL?[8_G7)_'?@L?G?5;OX+^Z?:RK>2^DUR0UCF
MM$ZXOQ(,X*>.<;##!"5R/!+O9<<C7B8J.''&Y#%1440C7.YWEV]N/'\4V" /
M%N&"*E(! 3M#7,I!4=512+'!!1++?;[2K9U#?<DN02?#J.0;"#@ENPK4I!#'
MHSD%$QAV3PMHETY%FZO#*6L>YQKV@$KS2)A2.4DF_KG$<XA]@*]RDEM<Y76*
MJKU7S'M);#CCP7[8X>LMLR<W4CJS$]6N3/4W$Y:P$YOZDGQ>K5SO_IKY#E7
MW0&*K3@!0.BU/CH*@.E9 Q3T 'A]%Y'_ #Z5]567H VD-?+;-=*V&CL6.C->
M48H3J/;A"-*(C>V)XYAO&-A.U[WC>B-7PR=O./UK>3V6Z\B<-7M7\0OYCV+C
M2"0$*[@ L?BY(( ;!)5@!W6QW1_Z:O'[O;?6WX!]PA0)<$[V 2WC[8D*/C8!
M!)&0 5)/>7/5[A+_ &,\1_O8Z#^U6ISJ#A?X'VG^#5?J%G&'O._VD^8?\^;_
M /=5LL[)*8/&(C$1B)42<_<).K3V[>5=$=6 @[5:/FMV6L4!*S1Y%-%VZQC.
M20OG(&O2-CKV23![QC=- G7ZJSNR,^4/-(O&V/'[OQR]2Z?";.J\.:5/3NM8
M*["JG!.A^G=.+#Z5XTH;/'JT ,<ZAV)@.1\(4LN2/A'PB?O,YTX:KG0VS^4=
M%A>\-%E\FPGRMFJ@"E<>P(4^SF[D$Y9+0OUZ-6U4N0^2CO#0$4Y.O8$BM^*O
M*GF:X,:=ANVT;L;5L5.2-PS*JTD 9\0LZ*%[=3J.UE!];D^.3&N^H9J-@RPZ
MU@$E^WU0 3GLP"?09_5YSX;;;65$[E#16W5185-38U;MEJFSHUG>P5LZ: L9
MTE"DE6D%JD QB.<1$5&]5]F/R4\S';INQL-W[+8CNK>$^DK6VEVSC "-T8G&
M/3'TGQWB-5X]7B*0"-0SEAD#'PD=GPRU<Q^7T8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$Y3?/&_S2]7_XGO3+_&Q19KGWG?P)L_\ //'_ +IKG:/U
M&/\ :?YE_P#+3S?_ *#W4M'T ?H5S=^^-2?Q?:MFR']8_;G%&W^83](/SA.A
M&?,K1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q
M$8B,1.7_ ,X$J-W;AER_VFG\LOZ?3[;?BQW3\3KTSY=M",_;I4G[PS/I%UNJ
M=FI@/OG$UD]'NF\P[=RKP'ZDY6@5M=Q@E#R:.@D1MZJ+C8+Z7L=)*UZ'&9K[
M(\297^7L:YRR2%^IQ@]2$5K6KUY"\M>;O.OO=\W^4/>E;P2[#RGLJ>4%##?U
M;F[<MNZ1MU44BNIZM#TY=F#*J$LY4+UZG\P>5O)_NM\J^:O=NG--O?-&[MXW
MQ5]ALV]5"[:TWLQN-EBV:DM&@+@LP"J"6Z=F?DG8CE+MC)49^\NCI',5?$;3
MFJ6D4[=4:WPU,.K$5RO9*[%DI)53.16*L?.F/H7=+=]-!T/F(KI)Z^$:\Y]F
M[,BL'J+,>)XG?(*DU3GCZ7VS5?1!1AP.K('3Q!9C'C]N"Y'0UYT:.X"& LF<
M'M=7[K/92O'AEAG;!G591]]K&M7]B#JDB 4CY4V2\C?+H+O;):]KQJYCFN60
M3FMF=FV[MU5O6VAZR,V+8<8KTC)9V)&C3D."&0E2#+%N(W7M:[:K2ZNNI; <
M5M6,YLU'&E5P=>K!0@JP# B80FKSKX\?9+8ONO9*_P 9^K,%X<H6KBDL0<@,
MEK'H&UDVP40<_P"-X?A_4P.:K/'?'OP^XY*Q.6WK>#RU63MP,,-N&&"&ZXL:
MP8%W7&GN5D$>(U^O*T<?6W&;,>+QEF!>3E3>0<@KD9K6L]:NF<]ZP$'PUS4'
M98_EY[;SP:6RI0^/<QS&3RXHW1_9:0I+VC\W42O#<HB]$<CD4;VL*US$D-MR
MU7A6#D=.WW>W7-JD]T+Z+$8XU5-@Z6P#G*L X*BPOXRSQ*SL=5^VO;%9 ZD^
ME&49TV+D:E[,8924(8X211/WCP)]Z*575L*0*PU>O3\[V<.QC]RPMHG(]CE!
M9A[E6+%>US ,<JG8\CU&&/MXUO,6G<\B'JVE;!]NGJV*Z^IN'R.E@[:ZR"$!
M/B!F;37?U[]>!U;?8%+-RZE+W[49#ZU"X/5#\>P$%B/DR%&I\W57$D<A])L"
MA!;QPO.&6-O@P+R 'HC[*"CW.\$H4<GFHRN5\9ZHJ*X3AD=(;+?6K:>/Y/2N
M^520PZ)<@[73/81T\2O)*$]I0JQL-WLJFK&^X[4VS8@%3U>ISV(_P@_$? #@
M=@8,HPTR%'Y$CEB31>)HY.B.$Y7B?M3QO:01F$8K#1Z&.9C2">Q6DF$:U[50
M"(I["_;U^::VHW"Y\NGT=0=P0<@@C!6E2 5((:U@&!%8'B7M-]GERP74''.C
MT]"* 1@C'4&T@D,""*P2"#83X>3KY\RGF H;TRG;(<HZ&]>U@VVC6-<]*VP0
M;6!CWH!,5?8C1RQM4@T1R$&.[VNZOV-Z\;R3:@QQ3<< 68_%OC 6X >C"V@:
MD (9%MMQMZ=Y2W(;!=)7K;4,GP_Y],Y)J)^')K)TL2"K-Y9Y'[>^920G=NN,
M4\'8;-O1?>?Y8$S7ZEZ]45BIW#FRF^P2=P1+XW>^/1W+-SC/Q]'3BAE+K/US
MT-36?OK;8/5ZHGRFIJJNW5>&5-]?UY,X:E/P/2MU@^\:D/K='?N:19\P/^Y2
MQ*8_VJ*H(-%/7_[1*O:&)16CU^&$J]HX<IR]5]@3+XGAD-YMO_M_1L+/X%Z)
M2_ZSZ%IL/X'8M5A^Q78=6EG]W'^7->]K_A?JUJ?KOI:VL?A=ILK'V70:=2I[
M;*RF6<PM!0&\$P>UMW=M8P@Z09&-(D6(TC7ADW\D+D<,;D<.,QR&,BHHA&N-
MUN[]W>W&\8VFQ?G;>A%0(SI7.0US Y"G(K!#N#E$LH;;;4[6D<AR U(WS578
M;2.FIL=5J!Z$C!<@HA&&=,3$K@\=@8*L _Y$M4A)41GB'D:V<Q'&E6@G.4DB
M73RSD<66URN)&(YQ4ZB5Z"L:=K7Y6K";13^3XR649+4$G+6#M+5,26L!RU;$
MN,H6"7EVY?S)86W3#Z<Z!6Z 7 #"H>P+8H 6LC < (>^ 7SEI=E4H:F@\O-N
M9L=DEA'*I:^JKRJK67%D\+VJZ.]6JD<+7-)+(U6M5K&E*.1WG(N779<9ILW]
MBA@>U*T/9;80>JGKH4$-:PP"%#NEAM=BH5MWR&JO9(Q4CL>QQ^+3/I_#8@BL
M')!8JC<8_GP-2CZWZ!=\DUTLSDMMRJ9NPME,81]M=DU_:&K>]X_"9#FF8-!E
M8QO@.&UB-8Q6=5Y7^M%PE?%>1^,MVKL?'\T;)[M0!\2TI?F[(QI<@:6 &@J%
M 5=/7O[_ --_E[.3^MIY;JW**#256G3D"NH;C;_)8.2RC.5).H,6)9M6!UTX
M2_V,\1_O8Z#^U6ISJWA?X'VG^#5?J%G$OO._VD^8?\^;_P#=5LL[)*8/&(C$
M3\C@%) :,=B$#($0!AJJHCQ%8HR,56JCD1S'*GL5%SZ1F1@Z'# Y'VQ/" 1@
M]AFF-MZ$^)-D@T$':=HY7V,6J:I X]U=9>Y1JL='QS AVU;\AQP=:I**JM:R
M;66O@'FV,>9=/;& ])S2C\1=F[?WL>8ME;=;L*./H;<;AMQ;BDMKW+%&\?5:
M]CHRLFI4K9*!J<>$5;$QVSRQL+E5;WO?PT%:Y<#%8!&C"A000<%F!?H#JR,R
M567HWX3NJ^NKKBNOK =3QQI?$M=+=>%A6D'0=)V"SO8U-!MJH,"QKCWP+<U;
M:38Q0SIE6YP?&8I#/)'T>\KS1M;GNVSU(;-[=NV&@,C;B^M:R[(Y96%906U(
MP-:6@-I.E0M=_+W&V($L#,%I2H'."$1BP (P1JR58@ABO3(R28;2>@3@S7[F
MAV*MG<AI?ZULVJ[C47$W:QV=A'V/1J.TUC3[)Y[&JE*9]%K=S)A=C^HYH2*L
MQ))/CY)[KWN^:MYMK=E>FS]COHMI=%J*J:[W6VY<*XQXEB*^1U1A\D4'26]?
ME;C*K%N0V^*CJX);)#("J')!]521_/#UM1F[>:MF21B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$3E-\\;_-+U?_ (GO3+_&Q19KGWG?P)L_\\\?^Z:Y
MVC]1C_:?YE_\M/-_^@]U+1] 'Z%<W?OC4G\7VK9LA_6/VYQ1M_F$_2#\X3H1
MGS*T8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$3E]\X']NO#7ZS>6_LKQ;E.[YE_TC?J3/NOYU/TZ_JA)SZ -=/5>DG@W<
M:9A+"TEZ;*#:U97B8R=5CV2Y5@*A%\*/7VL?PT=XBJGGU:@Y+U1H"1^:?JU\
M79LO<QY?YW8 V[Q]DXLK) #UC<78%78J6+C.H_/8"VMTK:KH3ZP/)5[OWM<Y
MPN](KVJ;M#6XSE;#15UL[2]9SC3^*R6J'6Q;-ZG;-3I3MO$E*^"]4$-K E6:
M6:I5C)6,@=B2UM5EIX/EE8AD,BL5J.14SH@\ML1L1R(?.W/08!U%LZ?#"8U>
M)J[OAXU!NZ1F:('%[T[WV IB\=3DC2%QG67]7P]/>UYTZ>H.)$WZO;6%@'=B
M^!#VJ*-1U504G?5QZQ4)W5=L\"$9)M93"NZSF(]T%[U''[@J=)4*W#[W=;I?
M,#Z:^908KK)S6M?7Y.PC.JQ@3\L 3225JU(;!=+KRNSV^W/!IJ?B7.;+ ,.S
M]/E*P<::U('R1P+0 UF'%?A2N%L=;)K9=C))[L2L\1ES&L'#">G.$:$,&;T<
MX:(@W(]A&JX9AN:\;G,<U5FMORNTNVC[JT^#X.1:KX!J8#)#^CLZ@@E64AE)
M4@F(OXW<U;E-M4/%\7!K9,D6 G *^GMZ$$!E8%6 ((D6EZ_)W0T2^F^-2NJB
M>:U$!0+YD1^YCVV>PPWN'YD$OPF]M<140+4:5_9+:)T6&OXR[GW3DK]6W-)U
M;8$=X'H?$N4XU*V!BAL:1ASIO"&F6IY&KA$?CZ--XN&G<$'ND=FBENNDKDYN
M'K'*#-)<6RFGN_.^9A6(6UMU6M:ZR@.)WB03^Y!64 [VC\W4R_#<HR]$5JHX
M9$81CV),;'D/:->WW2BKD*@/$3.1@]CH>FJML'2V!C!5@KJRB)WFQ\#3?MF-
MNQM/<?'7/I1QUTV+D:EZYR&4E2"8O95@N1QH*0IH^IQBH>#* [P9]Y/$CFAG
M1"JU5!0@5RHB*BMLVJK7M=#<YLF(W>T3S4NBS4O"H<HPZ/:X['4^BD?>O&0P
M-!(NE=MNF\M-KKPW+L,,IZI4A[48>FT_?H."I%P!JD-/:R&2?<%VT(+@ 7$B
MG"SPH-[ "K6+/KF*KO"*'N:DF+U5\9[DZ*X3AD?)['>VK=]&<@%7?JN5(&$N
M0?'K'H(Z>)7DE"1VH59H[>;2MJOI#8DMLF.&!.6J<_$<^D'KH?L<#T.&48BV
M&W>4EZ^#N36AE6/>VP2$":;(CE17U-!+"X9H\B,<:>8GA<TD4C?# Y)".)'L
MM\H\Q!^,KS]$@Z;K 2"S*>M=+#!5E([]RD&LC361:"U5YLV/ Z.1LQ])D9JK
M(!"@CYRU3D,&![E3 AP=5@-9"V>JG.37"PM7L^Q(G:V+K5LT8P G "-5'4S6
M":P$:[B@&O1&HT<L;5(-$<A!CJ["UN*>OA]YCP<::+   X Z5L!@+:H'HPMJ
MC4H!#HM+>UKR2ORNUSXN=5U>22A)ZV*3U:IB?LFLG2V059OJYEFO#2]7J?#<
MU1K'V*T($4F+519(D5]>(1F$CS+N9')\43VN''&Y"F1440C?6_N?D;'XC98(
MQIOL(#+6K#J@!!5K64]%(*HIUV Y1+/G94IL$3E=WD'.:4!(:QE/1R1@K4I'
M5A@NPT(1AG3PU(!Z$V+1D\1VJE*@:FU.4LB362Y)>J5U_-.\DB6DR03ZA/,]
MQ"D=X<ARE5A#6VRK7RT$X]LGABV*["2S5LQ]2YB2S:F/<N8EF8Z+27*M9<;N
MQO,!;?+CZ6 S96  KJH]>I1@+I4=ZI0 H&JL: RIF[BXD#D,I:5@I-[)$A5\
M9'/A4\)[G#]ZVOAN8[PNYCD !'-)+(U6M5K&E*.0WV^M6T<?QX5^2=<]>J5(
M>GB68QTZ$(@(:Q@0"%#NEAL]G6U9WV])78*<=/6L;M\.O/I["S8*UJ<G+%5:
M,UU.SC@9215/.UJ8595V8K4+85,]Z(AK=J":G?0/1J(2,-J,K6(G@,;&:K Q
M.UV*^5%+4ZK.)L;5:3U>MSVV].VD^FM0!0 /# I&FN5W.\/F5@MNE.40::@.
MB6(.ROKV6CT.23<<ZR;3J?E7\^]-AN^;^VD+94=Q9NTU$B(-I6.?)CBU[:'$
MD :URJ0#&E9U>G5J=[?;\9.N@?K:;BC\@^'K#J7L\R[$J,C+ )?DCX0,CKV=
M1UZB=L_^F?1</K;\ Y1@B6*&.#W2=Q1@'X"<'IV]#\!G5#A+_8SQ'^]CH/[5
M:G.F.%_@?:?X-5^H6<;^\[_:3YA_SYO_ -U6RSLDI@\8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B<IOGC?YI>K_ /$]Z9?XV*+-
M<^\[^!-G_GGC_P!TUSM'ZC'^T_S+_P"6GF__ $'NI:/H _0KF[]\:D_B^U;-
MD/ZQ^W.*-O\ ,)^D'YPG0C/F5HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(G+[YP/[=>&OUF\M_97BW*=WS+_ *1OU)GW
M7\ZGZ=?U0EQ^@>TAT_HCX$G3B.8)FI'&Q@V.-(DR#;-=#CQ(D<:.+)ERBN1@
MQL17/<J(B9H+ZM^\HV/N \N[C<'"#:.  ,LS'<7!551U9F/15'4GI-W>_P!V
MMV]]]_/44#+G=(22<!0-O42S$]%51U8GH!-C4UZY%9KO2PQOM7*KR:@P@5BC
MA."@%E1S*](J[UY1.Q\SN0)0IY/N0:)(S:(XO?IO/RC\,'>'J=L"-(7&-2G.
MGVO3T-N=++\AG3BV:Y/([)]K] :R-H.@W!!U%LYTD>M[+JZBOUE;Y;&K-<G8
M+VID53KMDT3*P8BE/)/UCI%2.KF212QF1A8LB*5CF%$1&D&1JM<B.3IF1U\C
MLK=E]("Q1M I)8]W3IZ,&!P592"&4@%2"",]) 6;#=U[OV$H3NB0 HZZL^J5
M(R&# @JP)!!!!Q(++H++99X-M8%E:>N\)]'2SQO$&[ !ZF ;;PHUQ&D:1RDK
M6*UQ*HKO'<UQ7/"S'+^,W?+;E>;51595@TU."!<H.0=R,9SGO4#!;;L?$(+E
MJUGJ>0VO%[=N'8FVNS(MM0@FHD8(VY[,8Z7'(%ZCPP0H#M.:FZBVT4IFM)$D
M1".CV<"7V#EU<L;&O)'EM:YS$Z,<CV$:YPBB<TC'.8YKER+9;^G>TFP I:AT
MV(V U; 9*MZ.SJ&!*LI#*2I!D#O-E;M+0A(>MQE'7JKJ>@*^GMZ$$!E8%6 8
M$2#VM4[D-P948JUU-6N(^JLT%WFV(S^U"AD!5P_-:/*4;6GCN5J6B-1R*P3!
MD+CV\V1\T%;JCX6PJSX=F,F\^D$=-6T; #H2/:, @JBJSSNTW8\N!JK!XN]M
MQXB9Z4CT$'KIW2Y)5QGP,D$,[,J3"DN%G*:NFQVUUW7-&D^M1_>/PW]S03ZX
MJM'YNIE]B^$1&HK511D:PC'L2<X_?^T:MKN%%7(5 :Z\Y&#T#H>FJML'2V!C
MJK!75E$-OMEX&G<T,;=C83H?&#D=J..NFQ<C4N3GHRDJ03&[R,F^*6EA&D0J
M>OE+YW9H!5CV0[.,KQK"U>:U%6/*CN5PYDMO5C&*^,U'/<50Q7(TCS(3Q]#-
M7L:G[^X0Z;!8N1HV[_%9>JVV#( +5#+%_#D]C;^3X&^O57WMB=VAQE"C8.J]
M?2IZ&NLX)(6TX 37F*":Z"HM8L8\2!808W2O2$%(M7;5D;M$V75 15;'<!JM
M;(B]5=&>J=%<-PR/ON,W!VY7B-VJ5[JM.YH&FNRM<#56/BXZ!Z\DUDCM0JS6
M7(4B\'E-LSV;>QN_J.IZW;KIL/ISU*6= X^!@RCQWY%V5\O4ZYK'C^ILO[96
MH\=(Q>R0$,%WP.V9R=A8_1?SE\60_P!O@C+1Y-OI8OPNU *]!=9VBH=" G_2
M.QDQ\UTM;KH5ZW'K]&!.7W.0W7PJ^PV]H)?^H=JO^N]:UZ:V3YH%^2CHFJS_
M /)B/(VANW^UUP]RO.:-<&7VKM#E[RE*Y?\ M#XQF_'\4;/GC3]#,G#;KYHD
M^#:?QIZDK:?[X[69C\]UL'>UJOUR'^5@_+;?YT >+4/Q8Z -6/UCL55'S/1#
MW=#-D+^Q4SG:Y718ME:V,9R2 31>8K*ZL/W@)/NQ=40D4B(Y@HW5'S'HK&JU
MC2E'<\GNC83Q6U1+=[:G>#C5776<@O:/2IZA:^AM(*C"AW2VX_;A .2W+/5M
M*WZ%3AW<8(2H^AAT+/V5C!.6**V"I(2: K*R8>1/IK&2-1;-/)X]D*S-V '!
MV.6J(I $5&A@2%Z,$-&17(U6B<6.X_;_ ),D;2]FMV%KC&X<YL%AP E[>D'H
MM+]B@+2<80O(;Z_\H<[JE5KWM:G-"#"%!DEJ5]!'5K4[6.JT9RX2575TVL;'
MC1P+87%@I!U=6-Z#?)>-&^-(D%[7I#K(:/:Z1(<U48BHUJ/(\8WS6_WXV@6J
MI?%WUN176#@L1VLQZZ:UR"[D$ $ !G95:)V.Q.Z+6VMX>RKP;+",Z0>P*.FI
MVP0B C)R20H9AQ+^>UU.5K'H&WPR2@3A6VU4A9R*QX/=$D='MQ15NO!^K-C:
MLUQ7J*$KD\L57$1SU*]&\D?6;X2[A_(_&.'6Q+_,VQ+]-/A,%W!"4#KIVXR=
M-6>XV6!;6V/T+_\ 3EY>KE?K9^6T*M6]+@+USXBF_;@O<>FJ_H-5F.^H"D+H
M!/8+A+_8SQ'^]CH/[5:G.M>%_@?:?X-5^H6<.^\[_:3YA_SYO_W5;+.R2F#Q
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)RF^>-_
MFEZO_P 3WIE_C8HLUS[SOX$V?^>>/_=-<[1^HQ_M/\R_^6GF_P#T'NI:/H _
M0KF[]\:D_B^U;-D/ZQ^W.*-O\PGZ0?G"=",^96C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B4=KGJ#T'9^8]GX)KQ;.#D#4:F5?6\:QUR?
M J'4<>560F6];>'1*^V@RY=J,0W1WD5"L(PB,>Q4Q$O'$1B(Q$8B,1.7WS@?
MVZ\-?K-Y;^RO%N4[OF7_ $C?J3/NOYU/TZ_JA)?Z ZB=4>D_@7;GN/=5S-3L
M.ZB$,I5H!%V&\9(OZ..KBDE6L@:JDT:=%>%5\JQA/&9+YC^K;L=QL?<WY=YQ
MBVXVHVEOR(!/@@[BX-=2O4M8PSXJCM7YE5;6+^B??_O*-Y[V.>X==-&Y.YK^
M5) \4BBHK5:>@6M3CPCZ&^=)70:>@:VM:VM]\+.B^ZO*^>]X>,Q8GE%9XJ2$
M.B]BB5GM1>OMSI<[S:#:>W&Q/8]&O7D:=.,ZL]F,3GL;3='=>Q"M_:]>G1@Z
MM6<8QVYS*T+2VMA9?+.- (."TX)C=,.C8[]@2,U&@V*P$;L'$V>.-C5@A(K6
M(QC4E=#>"Z%B3[#>;K=_3U51&V#!O93W3=I[+W!P%W"@#P4; P +L6:#1DZ;
MW:;;;?0EM@-Y4K[2.O@ZNVE",EJ"<BUADY)-64UB^RZ^S@VD$=C".A(I$>JO
M<CA/"\3G#D DB*C"Q9,4K',*,B->-[5:Y$5%3,MVN[V^\VXW6W;-)SU/0@CH
MP8'!5E((92 5(((!$QC<[6_:7G;7KBT8^R"#U!4CHRL,%2,A@002#*WM:J3N
MTGWU3*.+6Q1)':IU>.+R!&$52K6VG8QY$U1'J[P#HU2F*Y7M1T-Q!S,4WFRM
M\P7>W[#";1%P,Y"[U0<^'9@9]GSG0^"S,2P!H++?DNTW=7!U>Q;W+[ISGIU;
M:,1C6F>GCXQK7.E5 !(N"M38%-;QK:,YP1$B2(A/*6%9(:P<NLEL8USHDD;'
M.8G1CD<-[%<(PG->-SF.:Y<FV&]IWM)* I:ATO6V U; >JP'3LP5(RK*0RDJ
M09CV]V=NSM <AZW&I''574_&!/7MR"#AE8%6 8$2%W\(N\2/*4DPM2*F+)";
M;8G7S#Y2_4IFO5CFN&LFO.X:#LB(YJ,[?# YLIGC18#D]N_F&WP>/<T)MRP.
MY7UBW8U-?9J0XQ><C&--9%P\2F;X^]."J\7?(+GO"D;=O5"]JW/VX<9S2,'.
M=3@U'1;)M<L .![D)!!365,  )%,#HD849$4<695.1@DDT\E!KX)$:U6JU1D
M:PC'L27XK=5FOZ/:M=ON]NH#5#U0O8K5]!JJ;'=; Q@JP5U91%\EMW#^W+8U
M^VO8D6'UBW:RV=3IL7/>&3G(925()P^R-=M!7ZU4E)'DPC"D3]EC>'X^K2$'
MW@6I(090DV4H"_$&]KPA 17R6/&]@#V/+*>8<\3LB4MK8,]ZXSMVQD>&2"#>
M0>BD%50YM5E9:[+WC".*0<GNP&J=2$I;.+QG!\0 @BD$=2"&9ABLJREZ_5JY
MFU*,U2< ,.RB#*>,82/2-L4;Q.^1<1B&>0Q)Y#%[IPB/>81W]SG/8]A7UN'<
M;$#A=PJU[I 2I&=-ZYRUJDDDN2<W*265SDEE97:ERJ'>$\MMV9]LY 8'&JEL
M=*V   0 8J8 *RC "LK*OWL\@=@Q^K1(H+&SL0-(4<CQ%ATT/Q?J=U8$"\9@
MN <7=$8-XY!I _J;F(PAA>\Q:NZ4\-0BV[NU02#G34N>EKD$$$$9J"D.[KW2
MH5G3YXJMMLPY6YVKVM;8!&-5C8ZUH""#D'%A(**A[P8LJ/C];"_4CIK]Q(-.
M/9R'&A;9,\/S6RR_"3OCW1!#" -^  NC&,:..:.-/ 8Q&/".UXE&X2P<9OF:
MRRYLIN6QJO;'5;2  +@!@  (R*/#"Z61+GDW'+I]([-1774N&VZYTTKGMJ!)
M)J).222ZN3XA;4';/[#91XT=*U80[BPN!GBPJ-_8K)[%8C)3YJD84<>HCC*B
MR3/:YK6N1J->1XQOD^4W=557LGAB_<W@JE73#C&&+Y!"U*#\HQ! !  9F56C
M^-VMMMAW6LT[>DAFMZY0Y[H7!!-A([B@@DC)*JK,L1H:\^C2NE]+=:@MUC11
M;,?O5]21'*R'K4EQ7D)'H@D*K*\SW.<Y[NR2]\AZ&/"<;MK/+MV.2<W5WZ5&
MX.<UGL6ALY*T@G%+$DDG3:S6L'LE^0W-?/5?M!!2].IC0,8L':UZXP&M(&;5
M   &:@*U*5\N?GX'(GS?>XHJHBNV^E1J*J(KE37]L<J-3X55&HJ_C)FBOK:D
M#R#Q(/:?,^Q_4;B=I?\ IG _[W/EX^@,/W1MYU'X2_V,\1_O8Z#^U6ISI+A?
MX'VG^#5?J%G'GO._VD^8?\^;_P#=5LL[)*8/&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(G*;YXW^:7J_P#Q/>F7^-BBS7/O._@3
M9_YYX_\ =-<[1^HQ_M/\R_\ EIYO_P!![J6CZ /T*YN_?&I/XOM6S9#^L?MS
MBC;_ #"?I!^<)T(SYE:,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B)SZXEJ#2/7CZ@KA6DB4]-I%3 IZF7J&ZZV)UQ?NU>;LNRTMC<SMAU#
M:DLWU@@S)M82@*Q[&(2NE^,ZQ(B=!<1&(C$1B(Q$Y??.!_;KPU^LWEO[*\6Y
M3N^9?](WZDS[K^=3].OZH2Z_F_9<6#Z)N")LR0*-$BZ7.-(D&>T80B%L5XXC
MR/<J-:UJ)[<T/]6J^G;^X+R]N+V5*$V5A9B<  ;B[))FZOK!4VW^^WG:*5+7
M/NZP !DDFBK  E[^[)S)J;0M;*^2*3%LOD;X1%EAE*_Q?EHE>B=RS.]?%6I[
M?BK^>D;Y[J+-A^R;A=Q],&I_H/Q/$]EP=0;.?:M';JSWO9L=/G@/:.Y,$]JH
M:CZ*%J?3&C1[3D:2N,>S:_P<=WVC/7YHGP.]+7CRXLN*&=%D!D0Y 62 2A$8
M\!0/8CV&85JJQPW,7KUZ].F9I5?3?2NXI96H90P8$$$$9!![,8],Q&RFVFTT
M6JRW*V"I&"".F"/AE4V-=+V"7(O:*,XFL$>QUS3-(D=O(K0(UB2HW>K!1011
ML1!D<K67+&H$RI%01'89NMK?R=[<EQRD\02/%JSCV['34N<!0H&%8X&Z ".1
M2$<Y=M]S3QU*[#?N!R@!\.S&?8\]=+8R6+$Y(&3MB2Z VEE%GUEA!M(()M<1
M"12(YC4['!>%X7*(T8\<C6%BR8I6*,@GM:\;VJUR(J*F9?M-UM]YMUW&U.:3
M]C!!'0J0<%64@AE(!4@@@$3%=UMK]I>U&Y&+1]G((/4,",AE8$$,"0P(()!E
M>7T.;M5B8VJ'\@M:U\"XNF&+&#L8@$>I]0#(CHI6C857H6R&CBUQ5<R/W$=(
M:S%^2HW',[IK.%;PC4"EMN2HO )SM@5ZX!R&O7+4,2M66-H7(^/NHXG;!.77
MQ/%P]=6 322!C<$'IG&--)PMR@-9A166FNNSJZ77,!7Q?=GNSMKI-,\8P'IC
M@&SI * 2J)C6"5KAO8KA%$YKQN<QS7+/\7N=K?M17MD\'P<(U1 !J( [A Z#
M P5(RK*0RDJ09!\E1N:=R;-P_B^+WULR2+ 3ZX)Z]N0P.&5@58!@1(QLX9&R
M3656MREK;RH<YTC;@B8=-;22-CR5K DZ M9MH#L\2(15$(2M.3M(V,CXGEZ[
M>5W V?$OX7(T=NY SX&H FL ]+'L&-51[JKBQL,*M4KQ3U\90=WR:>+L+NS;
MDX\;23A\CK6M9SBP=YFS6N5-NG,:K(B!BNHO(MJ+.J1%GUJF))4OF"$?[WCS
M3=#VL2T,CR>:?U*\O>TW:9KVI?<-;372>-\,4;RCUZ\ELZB3XJN>MBV')\0]
MXMJ#XL# 67+5W/:-_P"(;MK=ZCX QI 'ALHZ5M6,#0.Z%P4RA4GR[:YEIX.O
M5X_&V!ZCGPYC'*SY+]JD$'8I!V?&$X:][ 1_AG+WA<G@>.YE#FRN\T\7M1JY
M,X=6']S]H%[$=F.H1.V[O(1X?B%:O$ [75R.Y...&493^/[":0#VYZ%G_%##
M@Z_##?.J)[H(:@M?;L)5)/DVQ$1/E;VH,1;H+ORHS#3L8:&WV04[!C3R_@N<
MX8>PLW&;S^%#EVM/]T]@-H^ CH&J'2D:54>%H)]Y;]N*O(;3^#AA!6/[G[2*
MC\(/4K8>MO5F/B:P,AM,J"L)*@\!+F;<=P8%,TK@$D$"X9%FDE#ZDK(E816%
M?,3HZ.Y&>'W&43'7/,W;<[?V&ROQ]Q?T2K."Q&#J+#K6M9PQM'5#ITYL**;?
MBJK_ !_;:[/!HIZO9C( .1I"GH[.,J*^QQG5A ["/ZU'E:U8>1VF7[TNKA!B
MA[:1B"':L UY Z^HD^IUDFM&KE$)J]LUJ/D=5.X[6QG$UW<3NO9^9?QM_?@+
MN2,"P#)%..RMJQG2HZ6C-O6PV 2'*64\GM_'XI/"V-.2VW!R:\X!NSVNKG&I
MCUK.*^E8K)EU]/KX->1MB#SS)_6O!5-".2>X/)&]J5H(I509W'&CN_O5!,$C
MGD<T;7.2<Y+<[7;;4C=+XBV=P5@!C:6!^3"GH<C.<]T*"S$*"1#\?M]S?N0=
MLWAM7WS9DJ*PI'?+#J,'&,=XMA5!8@'B%\]I17-1Z"MU+=K[R0^R4[*B1YE9
M7R5A>X]J>NL(22K9$X?1&JECVJ>4K$&=&M$'NY"^LWQN_P!CY*XI^0^6#>9-
MB*FU:O9TT[@^SY;!<=A\?&NS&FS 2O/Z(_\ IR\ALMY];'RZFQ^2*V@V#3I\
M=O'VX\? Z*>WY'.BO.JO)9\=B>$O]C/$?[V.@_M5J<ZZX7^!]I_@U7ZA9PS[
MSO\ :3YA_P ^;_\ =5LL[)*8/&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(G*;YXW^:7J_\ Q/>F7^-BBS7/O._@39_YYX_]TUSM
M'ZC'^T_S+_Y:>;_]![J6CZ /T*YN_?&I/XOM6S9#^L?MSBC;_,)^D'YPG0C/
MF5HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FEG$)[Z-ZJ
MN?J.PO;PU8&+#OZ[7I_(=%LD&&V^90=LJ'IT'ERWN-/BJ* A )*TZJ0BRR]L
MLGL=)1-T\1&(C$1B(Q$Y@?. ]%W?AEJIU[M/Y9:B]>G3NM^+&]?Q>G7/EUUH
MR=FI2/OC$^D.EU;X&!^\<S4[TQIZK'GX^].^A<ZZ'1ZMK%'M5UKJ['PY&V1L
M(5)/KIH02VMV:M/9F'.V)Q(Y"DZ1W-[NU[FC4?+GE/W)^]OR?Y?V?E;C/.FR
M^@>/+>!6W"I85U.UBZV?=@OH9F*%LX)![54KTGYC][_NI\U<YN_,G+>4=]],
M[X+XSIR[5@X14.E1M"$#JH#@=HR.PMGH)^Y7\X!_O:<._P#^MW_^0\S7\C/?
ME_'?9?\ 85/[]F+?E;[COXG\C_VT_P"\Y@JCAGUFVT.[@R?5;QS%$E_*#;5$
M7TXP5JY!PJ.0]W@OY"80<2[%('(D@1485SU[NJ$+XD';[M_?FPLHK\Z\:-E;
M8':OZ#KTL>U@0-YC38>MBCNN<Y'>?5(+[P/<PKI=^2'(^TUII5_IERX'8I!]
MC]9!TK8]4&,>JNGYY)UCUM\=<=[MO7\JKCJS;IFJ7FR-JV>G&MA).2DKCSTA
M-E?+^4D1#M!V(_PB=G7KVK\&2"^2OK ]%'G;BPOV."K_ 'Y_,EF/-ON,=P#Y
M/Y(DL/\ \]/Z3_@?\V23TP;WR'S=Z?N+>5K![77FYZLVTY,)4Q6T$?:I8K2P
M@.A:M'8\0*N\! A,&:<QR"(-$C(]"]#PJ/NJ\P>9O/GN\XOS;<<[[>;=FWQK
M J&Y9+K*].W TK7<$0!KEPI&*LZ\6;>K[SN#\N>2O/W)^5]N"-AM-P%V0L;Q
MCMU:M'U7M@FRHNY*U$:@<VZ=&:[]TJ.152:J&^E00ZT8DCQ@!"L9(B1E4#X1
M(CF#?#/#>-1D"]K7B>U6N1%14S>O'V[.[9UMQ^D;0+I4 :=.GH4*]"I4C25(
M!4@@@$32N^KW=6[==]D[HG+$G5JU==0;J&# Y# D,"""09"-F%8VUL\6E''!
MV*O"D>[NG)UKQP'-4XZ"6B-(R3<2$+XD5_81:SO\=[7L?Y:5C_+INM[O2GE]
MA7RE2Z;;?B!.T4MVAK3G-9P?9\^(P96\*Z<XM]ML]H'YM39QUC9JJ^.7[#:O
M85K&,.,CQ\>&I#+XM4HU4U6ZK;$K(Q:]U>1\:PK):JZQ@V+E\>4VR>XA7R9<
MEY?&60KR)*0B&:][7HY9?AK-F=F*=HAJ-1*O6WKH_:WB')+,Q.K7EO$SK#,&
M!,7RR;L;LW;IA8+ &1U]1D[%T# "JH&G1@:,:"JE<##;<A)\F%74#V"W(#5E
M5UGX:FCZ_$,[PS3+L;"!674S5#V>15['SGL3L<-1+(!8\WJW-U>TXT@<\HU)
M9C*TJ>A>T C56^,>#D&XCNE"AMKO>'*[>I]SR )X5CI=,X-S#J%J)!TV+G/B
MX(J![P8.*[/5I[@1Q3*R4(@-E"5LK8/,D0TFSD'3PV709/8))E9,:'MCJQK&
M 8SP.P2B4;:O!&NI+-G<"O+*=5VHY:QCT%H; U5MC"$ ! /#TH4*"ES(LL=-
MU40W&,--.D85 .IJ*Y.EUSEP22Q/B:F#AC][@^(6)&KD":5>2S*77@0C)'L(
M]A&;T]ZCEJPJ5\.O:;\\'>QXE$]1.852M"3ZYUJ'H3:Z6?D7;- 0Z75U_&!L
M'0J9[[D%=)T%7UBMOGAEN2YMSJ5-@BXN+#*%&_%E<C6SX[B@AM0UADT%UQVI
M-D5\^7"V<HI&Z2Q(8]L,3@0+RNC+T$NO@(0RP*^N<;H6#WO( KU(]Q?%0Q+7
MA1;MMR^WY@AN?<9-@&$NK7L\$$G0B9PU.2R,=3%]8L:YY<U[C;I?Q0*\(AP*
MR<O4Y[?%( UN^,K;@*RC2H70460[,:J95%CVT=\X4Y[(D:M BNG6$YR^+%CU
MR-((C)K""\5A6O'Y?PU,KQM&KVRG+OLEV35;U38EA"K6/7=^U0G4$."-08$:
M,:RRA2PCN+3=MNQ9LV%;U@LSGU43L8OT(*D'25(.O.@*Q8*8AK@;*IMP)NQV
MS;F<%8FNV_<CH((BM\4FO([L&,>P(P2.D2>P?O1!^(-K&C\N&#XI-WLMZH\P
ML+-_8NFBWX@7M-'H NZ9=\#VC&I0H7PJYCDGVV\V;'@UT;*LZKJ_C%NP7>DF
MGKA$R? SI8L6\1^77S[_ /\ <^MS_7?2?8#:\T7];3_]0>)_UGV/ZC<3M+_T
MS_\ BZ\N_IA^Z-O.HW"7^QGB/]['0?VJU.=(\+_ ^T_P:K]0LX\]YW^TGS#_
M )\W_P"ZK99V24P>,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1.4WSQO\TO5_P#B>],O\;%%FN?>=_ FS_SSQ_[IKG:/U&/]I_F7
M_P M/-_^@]U+1] 'Z%<W?OC4G\7VK9LA_6/VYQ1M_F$_2#\X3H1GS*T8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$31_BB!HP?5OS3'9R+K
M^P<A5\.SNC<:UE'O,.?QW1;8'CY'W=E+L=NE:1YW=/<L52'ATL4\_P M\4[U
MC2_$1-X,1&(C$1B(Q$Y@?. ?;SPM^M+E?[,\5XB55Z._YQVL?K!Y(_\ KC2<
M1.RF(D-L'&URWD7S1%/1VHP-OV@80QJN9#$@(U\@!][S0R0VL!,[&JX3 A)T
M[&E<B)7OJ.D1Y?IRYIDQ3ADQC\4;P4$B.5A@&&_6[!6D$4;G#(QR>U%151<]
M7MGW5\ZGZ=?SQ*@^;K_F3>G;]8O_ /.[?-%_5I_V&^7O\%L_=-TW)]8?_;1S
M_P#A:?UBJ; 7_O-;B=\AO$\[T'\L_ \#RR@\(?8E9YC\Y_+[R?;Y?O\ J'@=
MOF_9Y7-@\G[9[=9^3F?:.GM6,:<8&/#U=WVS3C1GN:,>/T\&8)QWLOL5?T]C
MP.OLV<ZLY/KX[WLFK.O'>U9\'KXLF^M^YO<T3W#T]W="]O=XWF?,^,_SOO#S
M/Y[]Z>;[_,^/]7\?N\3X_7,AXKV'V!/H[^U>OPZM63KUZN]XFK/B:^_KSJ[V
M9!<G[;[:_M_]L]/@TZ<#3HT]W1IQHT]W3C3TQ(QM?G/><?Y(>7^7'E4ZK)\3
MW/[F\0G3Y5>!]5\HI>_R/9^>?,]WA_4?,Y$<UX_M:_0>G\H='QL^%X63_;&.
MNG.?!Q\IXF='R?C24XCP?96^F=7T%K]&/$\3 ^8STU8QXN>YHQJ[_A3+ZA[N
M\A(\KYOWEYM_RA]Z>%[Z]\^&/QO>OA?4N_PNSP?"_.WEO#\#ZCV9?<'[+[,W
M@Z_:]9\?Q,>+XN!GQ,=,XQHT_)Z-/A_)Z99\Q[3[0OBZ/9='R.C/A>'DX\//
M7&<ZM7?UZO$[^J>;<$$K:_R"$^5J$-\F5B]OCH94'YM;!5^)\F^WL\_XGQ%9
MV^'^>?+Y1Y[1BH;;/TYD^SZ?6STU:_ZAV>-GIC3I^5\*5>%UYL]HQ]#X'CZN
MS'73H_JW;X6.N<ZODO$GY:?U\:Q2ZZ?+;H!;_NZ^$H.I/)K0=_QODKW=_E>G
MQ^_O\?\ //C9\<%\Y;](?_K!@>-GLT]=/@_]'[?#].=7B_+:Y]<SZE?L/\!]
M?"^'/35XO]7[-?HQI\/Y+1,GMGNOW8SW@DI9*2A>Y$K.SWU[Z[2>4]R]_P 7
MSO;W]W?]0\#Q/'^H>+EYS7LGL@]IU^+K'A>'CQ?%ZZ?"S\?MSGN:-7B?)ZY:
M\1[5[4?9]'A:#XNO/A>'TU>)CXO9C'>U:?#^4TS :MY_WL_Y:*#Y9K$?Y'R_
M=[F2F[A^*FN>)\;QT=X?O+N^K^/V_P#XMY?(SA_:?;3]/Z?I[0=&GYKPNF?
MSZ<X\?/?UX_%>%)'E?9_9!]":OH76-6?G/$ZX\;'H[?!QW=.?QOB26[![G]S
MS??WA^Z_#;YCO\7O5_B,\MY7P/SUY_S79Y?P?J_C]GA_'[<F^3]A]AL^DL>Q
MX&K.<YR-.G3WM>K&C1W]>G1WL2'X[VSVVOZ/S[7GIV8[#JU9[NC3G7J[NG.K
MNYG#_P">T^4G\@K<_E1Y_L^4M1\F>[\JE=[AVOO3:/*?G7Y8>%T\3_\ %?"_
MR?ZIYC.0?K-_2WY%<5],>+I_*38^!\&C3N/[8T]WVK&-7XO3\WWO%GZ(_P#I
MR_1G^]CY>^BO#SXJ^/\ I_:-OCP-7>]GSV?'U?.=WPYUTXMLBU7!7$4J/%9-
MD$X^XN@ CDD+$&\UI3Z]6C<62@)+A"$Z5WN5!O54;T1.JYUWPO\  ^T_P:K]
M0LX9]YW^TGS#_GS?_NJV6!YW;?U/TG[)Y?W,9)3!X\[MOZGZ3]D\O[F,1'G=
MM_4_2?LGE_<QB(\[MOZGZ3]D\O[F,1/!%O=HER[2(S7*=KZJ5'BF>[9Y/:5\
MBOB6".%TUE5[6#F(U>O1>Y%Z>SHN(GO\[MOZGZ3]D\O[F,1'G=M_4_2?LGE_
M<QB(\[MOZGZ3]D\O[F,1,?:WVSU, ]@;7*<@P.CM48]GD][ED20QF]O=K2-^
M*XR*O5?@3$3(K,VSJO2@I%]OP_*>7[?Q?;K'7$3^>=VW]3])^R>7]S&(CSNV
M_J?I/V3R_N8Q$>=VW]3])^R>7]S&(G@!>[.>QL*UNNTZ&K@5\@CUV:5X9&V/
MG.Q!]-95W42PU[NJ)^63IU]N(GO\[MOZGZ3]D\O[F,1'G=M_4_2?LGE_<QB(
M\[MOZGZ3]D\O[F,1/!:7FT559869M<IR"KH4J<48]GD^(0<4#SO8SNUIK>]S
M6=$ZJB=<1/?YW;?U/TG[)Y?W,8B/.[;^I^D_9/+^YC$1YW;?U/TG[)Y?W,8B
M/.[;^I^D_9/+^YC$3'QK[9Y4ZS@,URG:2K=":5[MGE=A/.QDDM4?36>OU-J]
MKNO3V_!U3$3(>=VW]3])^R>7]S&(CSNV_J?I/V3R_N8Q$>=VW]3])^R>7]S&
M(G++YX"1?%]*.K-L*JMA@_E/>F7J6+=2)Q>O[JU(J= DI8+53N1$_+_ O7Z'
M3-<^\[^!-G\/TUQ_[I2=G_48)_E0\R#'=_DS\W]?_P!";K'3[_WOLRZO0!^A
M7-W[XU)_%]JV;(?UC]N<5;?YA/T@_.$Z$9\RM&(C$1B(Q$8B,1&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$YS<2QZ)?G"_4185FQ/V>Z)H%5 OJY)%7&C<
M=1P1N/7U]6&!6E5U@7:SH6027+"R8TD1X5,40F!CHG1G$1B(Q$8B,1.8'S@'
MV\\+?K2Y7^S/%>(E5>CO^<=K'ZP>2/\ ZXTG$3LIB(Q$K/?-!U*\U+<H-A5*
MD&ZUR]BW,2!86=/%LX\NNDLE-G@J)L$4I3L<J/<]%<J+[5ST DX';*E6/%7/
M9J'Y\YF^@;G[3V<#<,\-:O>7J[I2\8'O=^HG:?N#Y&O4PMF)'/LVG2)5 ^KV
M"5*6[ CA0R2(:M59#.XXWQY7&GU>//&Q'E#C/=MQ-FZ3S5L]A=;O]O9M]Q6^
MVK7=LKW;<W5+7;83:@:NMG0=; #8C57=9>_SR7OE\W\IY^Y6O;MY<W7(5U;*
M]+Z'2^QML&6F\4V,]2 5.0]@5\XK)",ME74*EV?38E7#%3&F/K7B21&."FV"
M4R6V2JG?-=,]W%=--+(]2$,Y[WE>Y7.5555SK[84[.C9UIL-)VA74I!U:M74
MOJR=18DL6))8DDDDSE/>V[J[=.V]U#<@X8$:=.GIITX&D*!@*  H   $ANQ[
M?%K;0A])27+V"<%I[NF+1WS:\D%&/$&]EHE<SRUR)H%'#;W#6T5GEWN:QB2(
ML!RWMFSWAL\OJ+.3L7-M1(T%,$"YNHTVC&FL9'M&/"8A5\6F;XSV3=;05\XQ
M3CJVQ58 =8;()J7H=59SFPX/@9\102WAVR76=GT\%:DBOFVT]TXQ#V-E)H+]
M;"=9,7P);K%$J1NCS(Q!>"Z.K1I%0:!:QC6(U)?B*=I7M/$VK&QK&)=V]=[!
MT;Q.S#*1I*8'AX"!5"@"+Y2W<ON?#W"BL5@!$7U%0]5T=N58'4'R?$SK+,6)
M.(VK;*B+)AV.O/FOW$K%C5U<^FV"/&OH02-<>)>/;4&?%IH3I'>L[PWN@/?U
M8TBD6.>QYI+*;4W?%@'G2-*)G2MR ]5N/734FK/C8)I)[H8N:K+SB&KNK?;<
MB2.%!U.^,FIB.C5#IJL;&!5D"T#O%=(LKUJVS0=<Y'W:ML-BY-Y&KEV&PA'O
M-7H:+8:>9#NM2A0+"72+<1S-DTVKFJX3'Q8\>,\ZR3/G#EN<5'IL7R+YG^BN
M"OW V>VN\PU UW6W*"U8M9BE0JTL *V<E-5A2RO#$/J+MC_F3CC?ODVZ6.G#
MMAJE0G2^D &TN2,LX7#X4,C#0- 4*NT6V;5K'E8T]DNWBWD4SAZ\>'KEZ:PD
M6!V*]:H,1]>)+*+8,!^>([G-'X3%*KA*)IAX%S==7@+N5+)R*-B@H 79R,^&
M%)&M7 [Z$A=(UDH4#K-<199XS;=@K;!P#<&)"! <>(6 .AD)[C@$ZCH 8.4;
MP:MMM;+FRIVTK*#N487A&JP4^P2H%)6G?T&NOF?3A).K; @>I)ZC8^05BC>@
M_":$=KPRWWWON>855YU!@UAM255D]/!/0O6Y'>NP"[#2P30*UN.6---*;?BB
MS<*QR+"-+6N!U\4=0CH#TJR0BG4I;67;.;'L^G2:LA+2;:01PR"DQ+(-%?CF
MU]AW>##/7/\ =)'.GD*;PAB1K_,>(H581I%8Z2Y6G9V[,OO&-:UD,M@Z.C]B
ME#@]\DZ0N#KU:"K!BIL.,MW5>Z"[50[."K(>JNG:P<=.X -1;(T8UAE*AA%=
M>V^/9V@";NDV+<01.DZ]4LH+YL(T1K$&6_02UST)L/AF1LJ/W$]U=_AL<]KU
MD&A>*]NWF\5O,*BO?5C517TT%<8-V,G-^#BQ,M[/G0I8-XEDOR1V>TVK+P3%
M]G8=-UG74&[13G Q3D9K? \?&I@"OAIS!^?0V"LLO0!N@(CYCB)MM(Y?'JK6
M&SI[BVIO^%FPHXE7J[X.[JOT$S1/ULP3Y XHCL_*?8_J-Q^A.T__ $SR/][K
MRZ/3J'[HV\WF]-',&L\N<!:$77(-_7/TQG#6J7$?8($:"=U@.IT*V9(A>4GV
M 9, \.S&K'][7]W<CFM5/;TAPXQP^T!_O6K^MK..O>4XL]Y'F%AV?3O(#[V[
MN!_-$W(R2F%1B(Q$8B:I<)>IC0N7.1-RU+6JK<(4YXK+8X<V^J8$*LL:O5S:
MYI]H2&:+<3Y+2^])8W#88(5>!W=[%16HB;6XB,1&(D6W3[6Y_P#C:W[*0L1)
M3B(Q$8B,1-4= ]2^A;ISCM/&E75[?'N/&O:.-:6-3 CT$Z?QE:6]5LS(LH-Q
M)G(/S3U6.XL82&8Q5]GL143:[$1B(Q$H_P!0G*NO<2<=3+G8H5Y8CV*7\C:N
M%K\*-.G&N;NMLRQ>]DR=710Q!A@E>0CRM1J-Z(BJJ(J)-.,N0Z/E?1J'?];!
M:1:;8!SGQ(UU%%#M([ZZSFU$P$V,"3, ,HIU>1OQ"D:J(BHJHN(D\Q$8B,1(
MM4?;)MW^-H_L6W$24XB,1&(G*;YXW^:7J_\ Q/>F7^-BBS7/O._@39_YYX_]
MTUSM'ZC'^T_S+_Y:>;_]![J6CZ /T*YN_?&I/XOM6S9#^L?MSBC;_,)^D'YP
MG0C/F5HQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FAO&&L
MW]=ZXN=-I-3Z1$H-BTJJJV/A[95R-Y99T::Q)]Z2=6A;E:R1T-]6VH$,:95U
MLF/+CB:,2@-YJ:B;Y8B,1&(C$1B)S!]?S7.WKA5&M5RKJ7*R=&HJK[;GBOI[
M$^GB)3?HMM*RT]1^OI66$*Q6+H'([I/D90): :LW2@HXRQWD0;5,U6HJ]$5R
M=/AQ$[18B,1/XJ(Y%:Y$<UR*CFJB*BHJ=%147V*BIGH)!R.V)S:X= &-ZL>'
M8T8(H\:/Z&=@!'C@&P(  #S1K(Q!"$:-&(0AM1K6M1$:U$1$Z9H7>V67?6CV
MUMS,]K>1MR2S$DDGE=N223U))ZDGJ9NS; +]7+<A1@#SGM_]&WS=2^F3M7L3
M"U0/O!UBU\^YIFA+)#K@3$>A]N#' J%>UY4>I*P:M+9%:YX.TC9#G[(Y*_<<
M/NFKX5?$-H+VU %A0"3G<@#J<G):A<->P+5X86EM?;"FCEML'Y=O#%6$KM)
M-Q &-N2>G08Q<<K2I"V94UA9KKT*OB5PSU\OWFEEVV$BY>49SW!SC9^?RG$B
M">CQHUHVL1HA":T8VM8UK4G^+V^UHVHLVK^-XW?:TD$VD@=\D=#D8"@855 5
M0%  @^2OW-VY->Y3PO"[BUX(%8!/< /7H<DDY9F)9B6),C.T&D:Y-9:ZW&6S
MO;97--J0BM W8VQF#82Q:9_4%5,JPJSOF$1!%%VQR=Q'1E9$<O9;Q6X&\XE/
M%Y&_MVP('CZ0 ;,GI6U8QFT]UEQ6V6-6F5XI*^3H.TY-_"V%/9N",^#J)(3
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M)//3[QW=\4\0:AH6R2ZJ;>4;+Q]C(I"RSU3CW&RW-Z@X1Y\.OF&$ =FT?>0
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MC$=*;,0CQ#D5,@8D22%[FM>UJ.1S",&1DGRFTJNJ]J\04;F@%DNZ=SIEM62
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MXP,#L1!UTUKDZ5R<Y+,6=F8Z1WN^\?31MU-6QJ/<3/7)[7<]-5C8&IL#L"J
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M\ZM[8DM[D85C520]I&>*;;-O(GR[IV_(%[=G8P3;OZUC.WJ;=\GJY[*["0&
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MVZR0F'R([SH>I\DZW*U'=Z<=]KDV55S9=6:3.BA/*I;.)<U97DKY,20JPK6
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M:3@BL$8UOC(:Y@<>D5J2BDDN[4-QN:=E2VPX]M1;I;:.ALP<Z$](J!&?0;"
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MFX_CF*;=#BZY?1\-51_7#\=QTJ'0?*>I3HHIX^I=[OU#7L,U5'T_!9:/UO\
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M]KK SK*$>(]=+Y15#"%1U41[VHFC*J(V1'>WV]%ZM^EC^5OW>?\ 62?L5_\
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MWR5=K#:UPF6K+-@U1QXY"M>$4$(7KYQQD6/Y=RM(CD<C'1'.F@TUIASR9?\
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M?TH3"XOTT9!%M((R#(RDB,>Q['G1S'L>U45%3JBITQ$OGY5:Q^J.A^O%?_\
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MF[23I8CO:/BAS\9AV%^FH $C5DF/WEU.XN\:FL5:@-2@]W5Z2@^*I[0O73U
M.,8^Y>E^]RPC7^PWEFD%YBBA )#J:Q3''X*E?'KH@9)WB$KFC4IR*/O<K>CE
MZY[N-GMMU8C[A0_ADE0>JY(QDKZK$#(4L#IR2,'K/FG=;C;(Z4,4\0 $CHV
M<X#>L 3C.",X .1TGZLH-.U" ^X+%C0XFO5YI3K6UE2; M57P(A%,5EA;2)<
MB,&/#:Y%5'IT'U3X,J(M.UH"+IKVU:>DX554?">@50.TG  GPS7;FXN=3[BQ
MO0,EF8_ .I))]'4D_#*NAW'R@8*WVWSC:N+NWON/$FM;%!'U^5Q_.F0H3HX4
M&:96BE!5[FR$_/,A'.[5$X:99*=KS6U#.CG9&P%=65%H4Y5M/::V/4!P X 8
MJ5(S>-[3Q&Y*HRC=A"&Q@FLL,%=78+ .A*DE22 P8'%L:;4>ZJ;Q"1&09UU-
MF;!9Q1HK6QIML7S"Q.U55K5@1_#C_%Z(OA=>GM7+ZFBG;IX5"A*\DX'098EB
M<>C)))^R996W6WOXES%K, 9/4X4  9^P  /L"2O*LIS!2]GUV$10R;JM9(1>
MWRK9833%=_<MAA<24]WXB,5<1,'7;_4WJR/DW O=A;%+Y>0>'5E@0PR415)%
M=-OW4\1\D'3H4;'O>%51'HU51%M=KOMIO=9VEBV"MM+%>H#>E2>S4OQESE3T
M8 ])<[G9[K9Z?:JVK+KJ4-T)7T,!VZ3\5L88=5)$HGU,>HS8O3UH-5NK^/H-
MRMWN-7ID*#,VM81HTNVK;JQ%83&P:.S 2,!M,YKAC/WN5Z=')TS#O/?GBKR/
M7Q+V[9MS]*\[L^-&'">&=V7 N.5;4*]/5.Z6SZZXF5^2_)UGG%^42O<+M_HS
MAMUR!RA?Q!M0I-0PRZ2^KHYR%QZID;],/J-W7FW<-UJ-EJM;JZVBU/4;ZL%2
M1[)LELJ]M=GA3!2Y<ZQE-E":&H"K.T051RNZ]45$3.YA<W3Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(
MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$T0]>_#Q^7>/M0#&U8NYS=3V*ZOZ
M:BCZ?/V66+8BZ?>U5)?U\^GF5]A365')G*X CF;3VCB>4LD\J1SFHEO>5Y&_
M2W9_V-<5_P#V7B)LCB(Q$8B,1&(C$1B(Q$8B,1/S*$1QN$<0S"?T1XBL:0;T
M145$<QZ*UW14Z^U/AQ$_1$Z>Q/8B>Q$3Z&(C$3^.<UC5<]S6M:BJYSE1K6HG
MPJJKT1$3$2+3]XU"M_RO8JIKE(T/A ECF'\5_7L&L>&IS(]_1>B=O5>GLRG;
M=30NN]U1,XRQ"C)[!DX'6?==5MS:*59WQG"@DX':<#)F%D$B\ALKH:5DLVFF
M0=K:$NJHT&-?B&HRU56VMM1 F2()Y"I).I0-&\86#7N:5R)2_:O(;7J%MV=R
M=C#*LK#TAAU!'H(P1]B5/VQL=ST+5[JI^T'#*P/H(/0@^D'(/V9B&Z=6.N+^
MJLYTHE'"^1>TP(Y#-8L 55,NW)6GE$0A)=.U];T5A/C)'>H5<HT1$I['9^PU
MG;H[-M@WR:GJ47\ -VE0<Z,]5!TY( Q4WN[]LL%[HJ[@KWR.@=OPR.P,1ZV.
MC$:L DY4DK9MX(&SCWMA3:VXQI#DKHE6)T\+W$2#50Y4R#-F+Y<"L=.F#(-O
MF$4 /RI'LM:=Y?O]WC98''5,0]F,^*PR#75Z-"GU[.N6&A.H=EN;=I3LMKG=
MY._M4%:^SPU/4/9Z=3#U*^F =;_%4^NTUF%33%MYX)^ST)&C]YQ;F=97TBE<
M-C6+:P(<V1)">N5K>LJ.P?>/VE$B_'&[S>7;KCKSO26MXML>(H&6IP,>(F!E
MDQ\XG4CUT^,I]VE.VW](V8TU\BN=#9PMN3GPWST5_P!;?H#ZC_%8953"G/=0
MZ:V'7PVM$ZWOJL$5D6N <3#"B52B&L65=RXQ&N:O1PHHGH4B*KA#)2OWEO)6
M'8\4^*P!XMZX(0, 0M9ZAK64@CM6M2';)**U6G:5\?6-[R:9?)\.EL@N0<%K
M!T*U*00>QK&!1< ,R_;J)VJKY_58;GP_RUUKPGJYUI]$MQ!(=_5=E7VN*\CO
M^T?:AG>+V%;2/''A?VSPU9-'XV@'YSX;4)/S_I8L?E^QSKTN*@WXY;]K\LX%
M_P"*N/Q/@K8 ?,>A0!\CVH-&I#S\^<OV*IM>$./8];(=-<7F33IY'@$3PX0'
M:YO0A,L'/:Q84HQAO8T!$0W<(B*Q.Q_32GOTY39;U/)U6T;Q"WGGAG) .%'B
M7 !\XTL2" A[^5;(&EL;>]S7&[O9MYKLW2^&!Y-Y9 "1ECHJ)T8SJ4 @EAW<
M,N"=0SB/F_/]H/)G[V_''V?WK.CCVS00[)U2SR>QB(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$3F3\Z?Q[)Y!X+U43(>NSZ_5^0(NV7L39=IXOU
M^M)24]#=$L"R*GDS4+MF]QH8G>.:BK+?6IE@P78^:4'BPI*)MG\O]"_55"_8
M"?\ ^P,1-@\1&(C$1B(Q$8B,1&(C$1B)7W*G(E9Q/Q_LO(5Q!GV==K42/)D0
M*ORWGI2RI\2N ("RSQHS561,9W*YZ(UG5?:J=%1-/N*?6Q-Y=YKO^)8VD0M"
MKM?XPE\DR=MO+@NQOD1P;1!UL5>"F@1:4+''\\TJ%289R/3PO"<Y>N:TN]XM
M>U]Y?\GV[VK4UC@K>2;<L_3%>[KVRHB!2'5PX?4'#*P-1KU8,V%3Y"?<^[W\
MN=KN1;8>9JV"[=4ZY?:ON&=F+ J4*%=)32RGQ ^.DV\K*79[N/+E7^S7M?%G
M,1E;55P:REF0HZC(U9DR1'B'G@L)+B(]H$D.2,UK6O5S^_IG.S?>[NNR_<@T
M56#%:8^41<'ON3D!VSD)C"  -J;5,-W2;3:NE.W(NM0YL?\ %L<CNH.A*+C!
M;.7))&%TSS5E/20I2U6VPHTZT"$IX5U=FD6<6[@Q6*\TP+KB1,' LH@D[I4=
MJM1B?5!_4EZ,H;7?V[>SV#EF4;E5)6SHJ7(O4L/0KJ.MB>CUU[A[M;<[*N^O
MVWC QVY8!J_6>IVZ!3Z61CTK?T^JW?\ 6]?NF)NT98\RO$'1.GYUJ' 2.W9E
M:J.%/F :T;@4@2-0D47Q7R'M:9W0:,:^SLVR>9D(WB9\OGU:V&/:/2'<=HJ!
MP:UZ%R YPH4-=IN'\NN#M'QS@[74_,?"BGL-I'1VZA 2@RQ8C*09TRBF1Z.\
MD$E191$!07YU172W*BJ.GN"(B-9<L:G0)EZ-FM3Z!D<UUSM]S?QUZ\=R+%Z7
M.*;C\;X*K3Z+1\5NRT?!9D&WW&WIW]+;_8*$M09NI'Q?ALK'IK/QE[:C_.8(
M@5Y/B;9MA]4C +)JMIU]U783NO2#8TU#;&^5@(RL7Q3Q4%;#KGF3H-33NUCG
M*-_;=T;JCE%NJ12^R&4+GU+#U#JGI95]5F]4ME5)*MBUNVU_'&JUV"[LX<)\
M9!T*%O0"W:%[0,$@!AF9QE^1"QZXO3Y&KX,2JE=$:FK?E0QJB:J=$2A_*CB'
M7_)O8(B]G8](VG_[>T;5_P" >BUM_>_H6M_ZCV"MS\WT1^[I87]O^7=6Y3^&
MNK6+^O\ I:Q?ZKZ;$'K]77KJ6>VPL)EO,/0T)W1_+N0=[>C1KVU+7M:_W?7]
M[7B/?G$]%1%1PX@W(0B*Y1C)<;K=7[Z]N-XUBNDXNN'7P\]="9R#<0?LBH$.
MX)*(U';;:G9TKR'(*&U=:JC^,]&M\=14#]HV$%5P S+C(]8/CX2>YHK_ )'(
MYY9U5'80YZ$QB.-*N8#4[Y$N%*.]Q9P?CE0CG2!]7*1C[2O:+Y93]H(?H'J7
MK7)-))RUJ=I9&)+6KU;438N274W-FZ;S$W[=<?370+8< 6@#"UOV!64 +4W1
M< 5M@!2,M8WA990U.M$C2[*7&#+?8>R564U9)15!:2G">C)))3$58D=KD=)<
MG=U:)KR-O-UR+W.NQXDH^[= Q?UJZJV[+&P<,6'S2 YL/7(0,PM-ML$J0[SE
M R;5&*A/5>QU[:UR.Z%/SCD80=,%RJGG'\Y!J<+7>$=/D59Y#&V7-VHR+T9^
MPSKNW?K>XM]_2B(T?AVY&#1A7L1&$"U@^Q&B%V:%]]?"[?BE\IV[-F M\^<.
MUP.#XMOB6?+,>F+2!AB,!E"KI 1-.[/=#R]W)-YGKW2J35Y+Y45$=/"KT)\D
MHZYK&<J#U#%FR2[ZO'\WY_M!Y,_>WXX^S^]9TJ>V<^#LG5+/)[&(C$1B(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1*&YTX!IN=QZ MGO'(.BSN-MUA;
M[KMEH,W5PE)>P(YHT9MO7[AJ>Y4=K 0,@C'")$^,,I!JY1D(QR)=/DC_ *:3
MO^BJ_P#5N(F0Q$8B,1&(C$1B(Q$8B,1&(FL/K,_FS<J?Z-H_VV4&(G+WT=T$
M:^];UXA"$C3JKTUGM:6</J]:^U%R76 #+?%<]L><-HI#VN$5',5KE5.UZ->W
MG7GN-JY+ZS/'AB4W%/D?<65..NBP<I4 Q7U7&"05;((.1A@&&^>%Y"WC_J\[
M[2 U%OG&BNQ3TUUGC;25#=JG(!#+@Y'7*DJ>WM3>J994"Y8&LNJP/CV %)TA
MFAIU1MQ6G+V^-4F[5ZJ[XX']1EZ.3J[>NRY(V%]MOPM/(4KEQGNE?UVLGMK/
MPGJARKX(ZZ9W>PT!-QLBUNQM;"''>#?K;@=E@^ =''>7(/2/3JH7(H4;9#,#
M41%%*JQL5T>?=38[D)$NU>K?$B5<0J(^*/IUEJG>5% J,+%[C9IYIKQNPR\(
M&#5CU7M=3E;<]JUJ>M:]MGK./#PKR-&[?RV^=L5;F""KGM2M3T:K'8SL.CG\
M7ZJGQ,LF<J;28"6E!?N'[T1CWU]B-B!B;#$"G5\@ T^)&LX[/;*C)^5_P@^H
ME^)([+>7UW_1G)D>V8)1P,+>H[6 [%L4?.5^CUERA[MAN]I393](<?GV3(#H
M3EJ6/H)]*$^H_I]5L,.N*L1CWQDNF:G73^I8ES-:YS'WY!N5AJFI.Q6D#! 5
MO23-$YK^]OA@<CT>0=ENT7S(K[ ?P%U6U^PW$'!KK(ZA >CVJ0<C160P9TN]
MLS>7RF^/\,]&K7T5 ]EE@/0L1U2MLC!U6 J0K?O6&?K<J%06W8^$YK8&L7BC
M&-"!1&H'7[)PV,''LA,"U O1&CF,8G1$,U6NK;.VSB;*^*WASM3A:+<  @>K
M39C %@'1&Z"T#T."#2W52<G6_);08W(RU]?:1GMM3/4UD]7'4UD^E""/VM)D
MB\DRM<IGM8)B+'V*Y48SAKA&&BOJX;#,)'EW<H!/:US7BBC<A"HY7#$3ZWE]
MO(VOQ6P("#NWVX!" CK6H(*M:P/805K4ZG!)5&^=I17L*DY/>@ESUIKR07(/
M2QB,%:E([00UC#2A #,N.K8XN/11JA&JW2^Y 5LPA"&-KACD]D*VE&<0\FLE
M'(JBFE<X@R.[#N5%:3+7:U)Y85-B!_D#.*V))-!)]2UB26K8GNVL2RL=-A((
M:7.YL?S&S;PG_+>,NH  N 'K5J,!74#O5* I49K P5F;MK>4^7[AH4$6Y()A
M94HK%+"H(15<UL^>UKF^-(+VN2+%1S7R'M555HFO(V0WV^N-WT;QN#OR 68C
M*4H?COV98]?#KR"Y&3A S"QV>SJ%/TAR&1L@<*HZ-:P^(GP =-;X(0''5BJF
M/PJ=O'C"FK&29FM2CEG7PG(LFR@64A4=-V('A,1TF'*>G=*BC:C8Z(CHS&C:
MH5C-OL1Y74OM ]G$NQ>X>M8CMZUXP.\K'K96!A!UJ4*"DD;]X?,;!-T53DT4
M+4?51T'JTG)[K*.E;DY?LM8L0\T6^= MX+>">/1QR^?DV/-.CFKH=>HY4FP%
M)I=JB@+$:TC1/"4\T36D5[1JKT^-[4S4WOYW>V>KR=6CJSV>>>'=0#G4@LL[
MPQGN]1WNPY !ZS9WN4VVX2SS78Z,J5^3>55B1C#:$[IS\;H>G:,'/9(]Z &.
M'R)R@-WL</CKCH;D1>J(YFP[VUR(J>Q>BIG0A[9HL=DZH9Y/8Q$8B,1&(C$1
MB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1
M&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)K
M#ZS/YLW*G^C:/]ME!B)S8]#Y&"]<.UE*]@QC]+DPA"$<C&#8SE"G<][WN5&M
M8UJ=55?8B9H7>LJ?6<V;N0$'D+<DD]  .5HR2?@FZ]FK/]7?=H@)8^==N !U
M))XR[H)UYLJ;]T1 2WO)74E>]9&ORFBZR[B4O;^?I@"=J&U0R,1%A%^)9,Z/
M(B"07?LS=[#\J=-[$U<?4=5+8[UK?AL#V[8XQX3=+QWFP@35KS;;W\F]5*@6
M[ZP8M7/=K7\%2.S<#]=7K2>BY8MIEE-<DF%/5V@&0+^ QKY<1CG.CRH[G=@K
M6J(_HZ3627)T]OU0!.HR(CD1736PW[WNVSWBBODZQEE'JLO8+*R?6K;[Z'N/
M@CK$;W9+2J[O:L;./L.%8]JGM-=@'JNOWF'>7(/2.6\0?(3#5(R'CZQ%D+YN
M[A&?%L)]C%<YB1M<G!5IH881D5LB:->KU1P!=>I7,B]]0OF<-LD++Q"-WK5)
M5W=>FFAQU4*>CVKVG-:9[Y62V=S>72-XP5N4=>[4P#(B-\:Y#T8L/4J/9TL;
MX@.7HYYJ\H=8MQQX\V-'[*B5% .)77==%8UJ/A1QH@H4^&%$21$;[&)\<742
M_$O>.W-FV=>(WP5=PBXJ90%2U%':BCHKJ,:ZAV>LF4/=L]_MTW"-RNS+-0S?
M**Q+/4['XQ/5D8^I8>WU6[XZ^2\(NSOF:I7HUT3XH-DME:CQ5K'(PJ5]>J]6
MDV$C5:]CDZI!16F?\?PADH\BQY@V<+ML&CLOL[16.AT)\-Y&"#^)&';O:%:M
ML%'%!.6W.1=VTU]A?M&M_@I'4$?C>J#NZV7XH_\ N@Z'J\[JM81Z@UV[(JN?
M,*5SBK67LAZJY^P$>YSVR2*JV*JKG+YCN1_SQ_\ D,U\/N/[4)Q1:>UB<GP[
MF/4W$Y(L)^7.23XF=7UO_P#+(?E:/[: S=4/B@=-=0]%(& 4'S/0 >'C3D+N
MQ-*,36Z@4>79RH_Y_)*"DFMI:V2CQK+M JJ-DEDL1S8\3JCI+D7N[1-(]MUR
M.[>YSQ.Q"/O'7OEAJKJK;(U6#XQ;J$K[;#G.$#,+;8[9*D')[PLFU1NX%.E[
M77KI0^@+T+V=B#&,N54X*HA#XZ8RN(0\G5Y<A'LO)I5D6-98G[!>'L$Q_1TF
MNDN:UD>2[HD1$9'<C0M$K8W8[=/*JC:L6?A[&Z7.=3UV-@8N;M9&Z!+#TK&F
MHXK"8O\ >7MYD)W*A4Y5%^:481T&3FI?BNO4N@ZV'-@RY?,INKEU>X$" !+"
M\L$?[NKO$4;.P:M::PL#-:]8=5#5[5*56JJJK1C:\KV,=,[_ 'YVQ7;;9?%Y
M&W.A,X&!VNYZZ:UR-38)R0JAG95,5LMD-P&W&X;P]A7C6^,GKV(@Z:K&QW5S
M\+,0H)',3YQK5)FI<):7-KSQK19O/G'-Q91YCR5[&V=7$VNS2/3D$&>E50F:
MTK60D80<8CU*WN>0ZDYU]\?"/PX\J65V"RN_SWPS69&--@MM(\(=0E/5L4YT
MH274EGL+;Y]U'+IRI\S(Z%'I\E\L*\'.4\.H'Q3T+6]!FWM8 (0%5 OL] ;T
M+R/RF5$5$+Q[QZ1$7X40FQ[X]$7I[.J(N=.GMG.H[)U-SR>QB(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$36'
MUF?S9N5/]&T?[;*#$3EMZ1*(U_ZUMA "8^.2'Z:33FQ"_&J;A0\FU3&U6P1F
MM4DNG.XB.>QJM5",8[XR-5CN</,?'/R7UE=A7785=/(VX?2?F[<<K3\G<O:U
M1SD@8[P4]0"IW[P&_3C_ *ON]LL0,K^<:%U#YRO/&V_*4GL6P8P"<]"1T)##
MN?3W K41F."^#8P7MCVE6=S5D0)"M[FHKF_$/%.SXX#L^IF'[4]O<U.@-AOD
MWJ,I4U[JLXLK/K(WYQ4CJCCNL.H](&C][LGVC*P86;:P9KL'8X_F,#T93U4]
M#Z"89>5Z\@/2-722UE75&.UNSQ/9-FSF]0R:NH>CF>+2/5GA61.[LDM10"5'
MHXH8'D-M^4[>%M7-6SI8_MA?6=^QJZSTS4<:;SG#C-:$,"Z36QW \O#Q-RHM
MW5JCY!O55>U7L'HM'K4C&4.+&Z$(\FU^S1[5HYD./4V]3'"PE;&3L@D@LZ C
M6%+\5B%J"HQ&M1$1T=R>$1$<B=TOQF\##Z.OK6C?4* :UZ(4'17J^&HXP!VH
M>XP!'6+Y':D'V^EVNV=S$AV]8,>I2WX+!VGT..\I(/3$;$WY6//K%:\@6Q3"
M?;;'&5&R-=DL:A0#HI"M>U-I1CT<QW1PX;'=Y6N[F!+8\H/IIFXC:$J$8&R]
M?6H8=0*6Z_MCKD'J*@=3@Y5'O>-/T0J\KN@&+J172W9<.PFT?K'3!'0V$:4(
MPSIZ-;-[E4&I6 0Q9<<17U<P+%'$V**URED31JYSW-NFO>KYP7N<1Q'*9JN8
M]5;5XFSZ/T\)NE5+U!-; 86]>UG&<_*]<VJ22238"5)(I<FGMVKF-NS/2Q =
M2<M2W8%/9\GTQ4P   "$!AU_38Y*6GC:I C1I\Z;'8ZQ=+&IJZD@%<O9/L&L
M>-SY3W#58<=KV%*5G=W,&QY&_7*W#>:N%VR);N;%&O4,I4A['?&,L<?)("&9
MAG*JK,/GC*CM=/+[AFKH1NYI.'M<=J)G.%Z_*.0553C#,P4X[7@KIA!:Y9&/
M+CSY+GUFTS7H6;=3S-:CXFRRD:QKMA<T:((W1@I0F-8QK'L0:VW%U_0++Q>[
M9GJM?Y/<.<O:Y^+>V!\MTPK=%L4!5"LNDW/(O]-J>2VJJEE:]^A>BU(/C4KU
M^1ZY9>K5L2S%@VH9^^M&1F,JH\,5M;6PC"B5)53RY8_1!RI=HY6%;&IHS2(A
MB.:[N[D&QKR/8QTER6\6I1LJD%^]O!"UGU2O8S6=#IJ7/?)!SD(H9V53'<?M
M&L8[NQS3M*2"U@[0>U53LS8<=T C&"S%54L(E25SN/B.2SD.LJNU?'&78CM5
M#TLA%4<6FE=SRNC:H!Q5'7JKW>3[NP[GJ]3NA./VI\L.?;'\79W$ WGMJ;L6
MILDZ=L,Z:3D^%G386+>(9C?;D>8E!VJBK=5 D4CLM':UB]!JW!QFX8'B8U(
M!H&E_P Y\0;>"M%&Y[&D+S;J'AL5S4>3LUS='/[&JO<_L;[5Z? F:Q]_C**/
M*"D@,?/?#X'I.++<X^'$V)[DE8W>:6 .D>2^5R?@RE>,R&?-^?[0>3/WM^./
ML_O6;^/;-(CLG5+/)[&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1-8?69_-FY4_T;1_MLH,1.;?H<_GR[1_P
MO2OXT:;-#;O_ (GME_J'N?\ 2U$W5M?^'7=_ZZ;?_1ETZX7E?)W:6X^O2$K8
M]8P\*1?-<1C-F:TGYZU9KP*TQ-><9JMDS!KXHB]6Q7(]"N39'([6[S!?XG%O
MX55(*-=U W'7O;?(ZFC/2RU>\K9%)U:R, V&YJX.GP^17Q;+2&%70FCIW;^O
M078ZI6>ZR];1IT S6@LHLV)Y4,-*F55(*#-HU:)CZEXQH@0#:%&A)!>%J.C%
M&GA%%T5O3HK6S_&;NG<4>"E?@W4X1ZN@-9 Z 8Z%".J,O=9>H]($'R&VMHN\
M5W\:JW++;U(L!/4G/4,#T=3WE;M]!,9V4!MJEI34$HE98TY7/D[A%8,A=<.4
M2=U= :5' L+*>!S4/'(C@" Y'E3O\%KHGEJWYF[V#C7-.ZH;+;I0":"1ZB9Z
M/8XP'0Y14(9^]X8,KQ=B<33[;R""W;7+A=NQ(%P!]=\=41#G2XPS,"J=W61E
MM6DQXP/DX6"*HM*D7<>O$0A02P%(Y??5?).KI%A$GG<YQ"D5QVG<YIE\3XSK
MWAKJJJ_HIZUHWE"]4!)# GYU&;O.KG)9F)<.2+.]U-ERU5EMGTDMANVEQZ.0
M 5('S;J.B,@P HPI4 IW>@\VTO2Y<FL5K&EN'>!-?8)U1FJ,1SEBW;RL5'-L
MD<UWDXZ*CI#D7NZ 0KDH\RPWY^A]J-6^.'+_ -[#XMI(_&=OA(.KG.<5AR*O
M%*=D/I7<G&S&5T?K_P"%4 ?B=GB/V(,8RY0'\]67W"1=8M?;;E>><*Z)T3Y8
M+T:LJU(1$:UET-B-25%3HT+$:H&I'1C1_/#?Y-;Z(WO]O,2XM/\ =7X5A/HM
M QXE?8H \,"H*%^N6_R@OTIM/[3 "FH?W/\ @U@?K9ZZ'[6.?$/B$ELCM$N,
M^+[A\@*ZL;H1!1:@CE8%XF*Q"V$\[$<^!6P'N:YYT3O1_:T2.,YC5N^8OI:G
MZ-\-=QNMP"%J)P,#M=R.J5H<$OV@X"9L*@VW%4VK;[?XAHVU!!:P=3DYPB ]
M'=QD!>S&2^$#$8#7(TC49ON[8IA+:;=$".)N,EJ-)9F&UR1J"P1%5D \)CG-
MA-1?#E,5SE5TIQ7%C.*JMX2_V7E'-U^X("[INVPCU:7]"%!D5 =VP9))N+EY
M'DK*^8I]IXU!310"6VR]B ^M:GI<,<&P]J'  %00)+KVSAU\/PY,=; UBKH$
M*G&P9CVYS#?W0QA+]242B1SC/)T"(*.>148BKDWR.[HVM&BU?%LM[B5  FTD
M'N@'IC&2Q;NJN68A03(?8;6[<W:JF\-*^^UA) K /K$CKG. H'>9L*H)(G+O
MYQ#6[6@X5TQ]D\=H.7S%IS(,E#.(NJQAT&YD35H2R>T\FF;U11R>GF2O8C3)
MX; (+FWWP\5O>,_))MV1<K^>.&"-G/LZBVP^SIJZM5Z5L^<8C%G=6L)T![JN
M3VG(?E0-L#4R>3N6+#&/'8UUCQVT]%L]!3U%!RG>-A?V?-^?[0>3/WM^./L_
MO6=1GMG. [)U2SR>QB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$
M1B(Q$8B,1&(C$1B(Q$8B,1&(C$36'UF?S9N5/]&T?[;*#$3EGZ2*^WLO6EL@
M:F0C6C],\@UI6H[RYK^K;R95MD4L>T0C'TYI+W,<AV]>J,4:JQI%(SF_S-M=
M[N_K)[&O9-@#R+N#97ZINK^E:<U+9D&HL<'6.W&@E0Q==_>7MQL]M]7_ 'C[
MM>I\Y4!'[14_T;;BTUXQ8%&1I/9G4 Q4*>T^M<BZ?>45?;4+;;W&6.-D0@]5
MV$$6,(*('RKV#JO#A>5[>Q6.[6M1$5.K515Z#X_<;7<;56V8"TJ-.C&DUE>A
MK9/B,F,%<#'HZ8,T9OJ-S1N67=$M:QU:LZ@X;J'5OC!NT-GKZ>N1,5;S6;G.
M</C^XA"NJAGE[?98IQG!7QS)XSM8F &KWGL)R+W(U[>ZL[DD=%)V!- \O5N>
M2W9IX1_!Y&@:;-Q\50>IVY'QW?.?3[/D6^MI2R;XNS;\?M?%YA?%V%QU)1\9
MB.@O'X*+V>CQ\&OU=3I,M6DUSJ[W="A.J9%2[RUC3&?XDN!+)W&>\YG.>^<V
M<YSC,E]SO-]RD5RN5W24X:W:G:^R;>LT6T'2]1.61CU))^/KZL+,GQ,ELY)Q
M&\M5N1N?:;[!=7<-26#HKJ.@ 'Q-'137@>'C3C&)B-L:^WDQJ6A(@-JB=)L:
M\8SQ1ZD$Z.'Y^>Q',;-9.:Q6,KG.1)R-7N5C&*8=CS8;?6IL.-.GF4[ZW 9&
MV!Z:W'36'Q@4$CQL==*J76\X@KLZFWN_&KB7[K59P=P1UT(>NDKG)N ^2STU
M,P1O5J#P0A2**4!8>P1G+,M_&*Z02Z(=R#=L4>81K'SXLYS$;UZ(L56H!6L1
MC&Y6X-J]NC\=<NCE$.NW)U&TGIXZL<%U?&/1X>!60H51*7,K9>Z[^IM?',--
M>!@5 =?!*CHC+V^G7DV L6)GZ;<:(:,"G;&=/NIK_,5$8,A8AX)HKD7WZ^>Q
MI"542L<]%?([7*JN036D<1!N^^;>FVI=@J&WD+#FI0=+(5_'%P":UK)&7P<Y
M" ,S!#\\.EM=C;TN*]C6,6,1J#!OQ6@X%C/CHF1V:R5"EA#=6V>HIITJGO+5
MM]MTM?$/?4U?,M![(&(U_:R'&IPV3:=]4Q7(^L[E\NCE,BO0KR+:\*ENPO?9
M\LP?F;>\;\:5W"K^ ,D5^&#UH!.C)L!8.SRXY9Z][2NZXQ2G$UG'@YR:&;\,
MX&OQ,=+B!JP$.DJJR0V.W:Q9MLM=D1)\ZR=$@N^3<RIL*Z?8CM2V JYT-MC'
MAM<QQZD[G':]$B(!2D<-$1V2?+V[1-F:-W7XWC=Q:AZUC=H5>S&,:B^0*P-9
M*@9D?Q=>Y;="[;/X7A=]K#ZM:]F6[<YSI"X)<G0 2<3PZ['GZ[:#9N$GWC96
MC&PJ387/>2-&CN5"CU)Q"-8HIXU8B^;<UCK=S$>]&D8P+8/BJMSQ>\ YU_%W
M=PT57Y)55[1MLG&'&/G" =R1J;#!4$QR5FWY+:%N&7P]M4=5M.,,Q[#N,#.4
M.?FP2-N#I&5)<Z8_.>?[!](_?MT[]KNZ9K/W]_VOY1_U[X;^N6S8?N3^?\T_
MZE\M_6ZY"?F_/]H/)G[V_''V?WK-^'MFDAV3JEGD]C$1B(Q$8B,1&(C$1B(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(FL/K,_FS<
MJ?Z-H_VV4&(G-OT.?SY=H_X7I7\:--FAMW_Q/;+_ %#W/^EJ)NK:_P##KN_]
M=-O_ *,NG2K0A6LS1M,72'J&S!J--'VR4P@QQ)<5D,:BJHI"HZ,S=!@=^=I#
MT<.&-R))1S'"9FR>53>;C?O^3QT[Q0%W+9 5EP,5J3W?:@OS;D%:E(%H*E%F
M <8VTHV2?3HU;1B3MUP2RL3UL8#O>S%O70$&PY\+!#M+BKJ;4[NJADKX3HRP
M4+%#)$Z17[#4S&$<LV-)G,(RT!8))>YTEI2.\8CE<3Q$=U=/<2^Q;8HO'C3M
MTRNDY#*P/?6P'O>)J)+ZLL6)8DYR83E$WB[UVWQU7M@ZA@JRD=TH1TT:<!-.
M   H Q@0?9)MY76\.LA38IMC:@H\#<S@1M?609I'-!5<A0H: "1+21\6O<#P
MT-*]J-C]JJ:*YD7W[I:N$*KY@1?78$UUU'T7@8U*YSX=8.O6"ZZ55R9+B331
MMFLY@,W!NWJ @6/8/323G25'SCD:=/<.6* 6#I[Z]L \2.&3%M(LE5V&-8D8
M:W6V,QKBS+"0Q&LFI-8U' .-$ \"-02-8U!LO.#;;#;-14KIO$?Y97(-GB$=
M6=AT?4,%'7N%,! J@*MKS(W!W"W6%6VC+\BR BOPQV*@/5=)Z,I[P;)<EB6.
M#Y&M8=?&K 0Q29>[2Y)&:5"K/#6S?8]GU<Q5(J"%KX@IUL7'5(_@)T7ZIX>4
MN="V^%1M<_3>2U!7H4(P&=SZ* ,"T'HX(10;"DJ<-JK\2[<X^A\ 7 ]CCJ51
M!Z;CU-9'5#EB0@>874* U@>>+D$PIVX.44JXIPJ5NNR8[7*V'*K1%1AKRB"Y
MSF!9)[AQ2=R."P[GE+\\&?#>W;[[^'^AN;T6#J%>G/9MQU")VUDD69L+._O,
M#Q%KOV?\"=14OIK/0LMN.V\]"[]CC!3%855F^T-J U 8)XI2%(80J&#5>''L
M_>H6N?#=3.3L9#D1$:KU*O:$(D<XJ^%W];KFVVGL@JW"N]S./"5#BTVCJIK/
MQ67J2YPJJ&+G1JEOPXW7M1LH95I53XK/UK%9Z,+!\96[ H[S-@)WL2J-)2RB
M<Q[0'<SQ)&VR>/--2#,CM:ROE50[_=R&BT;'-:6.X#FL=-&_ZH8S?&:B!\,8
MH[AUW-&[*<^5;GG4Z''2IJA@E* ?59>AN4]YVQ9\WH6N_P"5-%VU#\(&7A48
M:D/SBV'(#78]8-U%+#NJN4^<UL]T["6G'3S$O6,+6E8T!H[AO,240SVLCQHH
M HL@\XTA6M T2*52]O9\;IDURC[%=C9](@-M&&"N"2Q)PJJ!WBY; 0+WM6-/
M7$B>.7>MO$]@)&Z!R#D * ,EF)Z!0,EBW=TYU=,SDS\XK?'A\7ZI1;5-GRK>
M!R=I-S4Q0Q;.P2DUR72;W'"':9==%/5FV^8Z*1$*I'+)"%[0,ZL.4_.WO@XG
MS$NW\G;[ET=MI9Y\XBO;.73"A7<M7<-7>W 5EU78\(C"(P?6;>@/=5N>*<^:
M:^*T*X\F\J;AC&MO#KP].1D49SBOHZL=3Y4HM<N^;]3IR#R:GTN-^.$^G_[0
M;W]+V9TR>V<X#LG5+/)[&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$
M8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1-8?69_-FY4_P!&T?[;*#$3EIZ1B7H_
M6IL:TC.YB^FB0ER6/U?<1J;]TVK65(UZ,HB1YEPPB,[!EZ)X:O<QI"-8)_-_
MF9N13ZR6Q/'CI^0NX\4KUM6KZ4IU-0N"&M!QA6]&2H9PJ-O[R\NP;ZO^\&^/
M7\LJ/##=*VL^C;=(N;(*UD9R5]. 2JEG7LIP:R /B#CIM8@O)+JM60+@JJH1
M2A0A2D<[ZH^08SW.*Y_U1Q%<K_C*N="<>NQ395CC=)V17*E3D$'J22>I8DDL
M6[Q8DMWLS1F^;>-N[#R&H;S5A@1@@CH!@=  ,!0.Z% "],3U;0MD&X<[1FB)
MM9(PG7<<JM2I?4HCF DVRN<T;+UC&.;6>UKCN;V&5(S7$#CW+G=)OB?+H!YH
MH#:I^;-?8K6>@78!%'87(TN12"Z3O%#;/L@.>)'$!CX1'SGB=I6OTFK.#?VA
M0=2 VD*^>UZ)03: T:*,DV+/=+%>-M6=UG*L2M\"T'?#>UKVV75.PC%1K1M1
MK!HT36(DOPHV7L6K9%CECXA?YTV]C^+V$6 C!& %  4! HD7RYWGMFG=A1A1
MH"?-BOM3PO04(Z@Y)))+$L6,@\X\RNEK303+(WVE&U-<E2RJ@KK5)"O> NW2
M&->_W)7E$\$N2K7'9($TH4<8[1$L><U)=59QF#YB((J'Q60'O"_&2-N"02V"
MRL1X0-AT-=\/I:JROD,_00(-A^,K'U33G -Y ("Y"LH/B$(-2^GC$4>W=9[A
M8N,;:+'PXDD<YK63*NI3H> $ $5S(]?;-_/8%&JC>!PD57$81[J_!^$4L:S4
M>7U ;C7@.' Z* "0*0"?!TDJ5.K)=G)H\QXH>M:P!Q>":-.=)4]K$G!-I('B
MZ@&##3@($ EFX)";$AF5\D=Z.2K=9?6L&2U?:$&JK&C"*Y@CPSA8OFV&<V/Y
M=KGE<Q&(]KG1MQ0EA+CD@_[7->#8;"/54' *D#Y4,0F@%G*A0P<-XYN=,*=@
M5^7UY%80'M8C)# GY,J"^L@*"3I./U%TDTZ83:6@9O(X[6S(P7/?61:HA&J+
MY+/,P93TAS,12F<UL@DAO:=&]@ALMN#-S[BQN9"CS$%[RC)K6LGI[.3@FHD=
MYB Y<8L THJW/,"I*$7BM1X$MW6. [6 =?' R!: >ZH)0(<UDY=C&KAE2[D'
M<'W+RAC!T/CXL:1%\3WB"R39>065Y*GP6OD+:ND/1@&#:YQ'.[.UR.5JR7,+
ML3L6;?DK4K J5SK%F<(:L9/B:CA H)8G3@@D&.XH[P;Q5V0#6,"&#8T%.UQ9
MG \/ RQ)  &K((!&7UMUG)N0?+EC17X0%+K$;H-*YU?X:L/.$@G/CNVWP']L
M]C7.;%:Y6QE<!SREA.);=V[]?RB&GDU4G;KTT:,8+C&5]IP<7 $BL'%1-99W
MF.3&UJV3?0)SQY8"]NNO7GHISU]GR,U$@%R,V@6!57G]\YSK-C&XVH]G@748
M +WD_C2JD5LBH=*(&;14O)A85@"<RTB)X#Q7+VECN"Y7.8US2M3N:N$>_P W
M]%G!^2^/NJ8V4^\+B7#A\ K8[!E*Z#UR@(8,, D%3T(S_P!R:-[7YI<'H?)7
M*C&/3HKP<_=GQ\W[_M!Y-Z>Q/W-^..GT?_:#>_H^SKFYSVS2P[)U2SR>QB(Q
M$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$36'UF?S9N5/]&T?[;*#$3FWZ'/Y\NT?\+TK^-&FS0V[_XGME_J'N?]
M+43=6U_X==W_ *Z;?_1ETZ5:!)LZ30M*'IH73)4W4ZF=LM6P+I$:FCR )UVF
M)':YGBW1NURI6M<UUHK5>G8]A'DV1R=N[X[>NO KXEU@U[BL#4M0;^Z%7IFT
M]3X (.X(+#2RLS8!QU6VWVT1N;;136=%#DX:PC\0Q]%0Z?+$'P,A3J!55OO7
M(M5'J@%J)'GHT[K/+:/*AY-K).C?&GS)"-9XLDO8C53HUHFM0;6L8QK&S_%4
M[.K9*^Q?Q*K.^;"=36,W:[-Z6/9V * % 55"B#Y.W=V;MDWB^'97W!6!A:U'
M8BCT*.WTEB2Q))),8VLDJHL 6&JQV3MML!JQ^O*9(T+88,5J,=*M9/:]E4M4
MU[4%.<U555;'5']XVLB>9:[8[I=SPRBSF[1@T9TI<B]-5C=17X>1IN(](J(;
M4H64XE:MYMFV_+,:^'K.1=C4U+-UTUCH;/$ZZJ@?AL!72Q,)N!PVPZ:VCS3S
M;;<+-^@;%/D1W19XUOW,:>"6$KB/J!T+X#F B]5\#Q7N[GO(\I+[A$V[[=MX
MCFW>6GY5V&EPZ]/#*=36*\D+7DZ>I)9F9VL^8:]+UVC(*]I6/DE4ZE*MU\0-
MT%ALP"UF.]V *JA%L+;1AKF0;2K7R^RA5M=118XT5;Q%ZE^3TN.Q6H6L(UBO
M<5>B0$:IT<UK7HZASH7;Z-]M3IY@'14 ,F[/7P7'I0]6+'YG!MR &S6X8M?K
MV6X&>*(U6D]!5CIXJGT..@"CYWI7@DKAJ7_:!9=M;IV[8/\ .5I7/7N;K8W]
MIVU%;U:WQ:\O:TGG$1/>*HA%[6M&$+A/VR[[W??PT.Y8A_$ X/A5_"AZ-XH'
MR_1^@"HCE_VNJ;/9_P $'O(X_''L\1_@<=1X?XGJO4EG?W[8"N2N;8RY9*R9
M6$0E3:11*>='GG5H!18L5J*^R2R>K0OAHCDE(Y&(G=VN;<<W7M1M1NKW--])
MS78HRZN>@55'6SQ#A35U\3(&,X(M^(?<G<^S4H+:;1BQ&.%*CJ69NQ- RPLZ
M:,$]F0:ETHEA<\P[/-V^"&NV2NT#2G0:1I%-$KXAKS?!+:03*]16,B:URH0[
M4[H:D=%15Z/(>.X=]QR&Z\;G%%7,4C*49RE:,,>*A[+&LZAG&?"ZTCXSVR'*
MK1L=MX/#,;.+M.&NQA[&'7PG':BIT*IT\7I:?BI7=.P1*N75R%MS)$B1$\\E
MBADBGJSQ45XK&++^&-)C+U5KO:BHJM<CFN<U9KDZ-G=LV.^;10G?UYTFLKU#
MJWQ67T'[8(()!B..NW=.[7V-==S]W1C4+ W0HR_&5O2/N@@@$<NOG$K6^G\,
M:2/8_&@.%S%J+J('E_*,V*!\G]S:2^GB>WOA6B,5J.K>J+$:[Q'=_B-:#FOW
MQ;SDMRWE%.5U5$>>.'-*Z=(O3Q;,W..U+,8S1D&L'6VK4!7T#[J=IQ^W7S0W
M&Z; ?)W*^*<ZC2_AUXJ0]C5]N+NHL(TC&DFSV_-^?[0>3/WM^./L_O6=2GMG
M-X[)U2SR>QB(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C
M$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$36'UF?S9N5/\ 1M'^VR@Q$Y,^F0FQ"]9ET_7IYZER
M>G*1[VN1Q1SH]-4NY#B,-:3X"28LR9$AR'B?V1W=R/:UQ>D="N;SAYDWVZV'
MUD]C;MJ]0;R+N5>P]5H0\I3FYD]:Q5P!I7TD,V*U=AOWR_L]MO?J_;RK</IQ
MYRH*H.C7-]&VXI5_50MU.IO0"JY<J#W2X_U&LT;3Z'6:N66S!6UL,);F2H7S
M;R2V.)A;>:4"((AYO8CD[/J;&=K&(@VM1.@MAM=OM-N%VY+ASK9R0S6,W:[,
M/6+=.HP ,*H"A0-&[W<W[J_5> F@:50#"UJ.Q%7XH'7IVDY+$L23AMCERM2G
M+*UF&^VF73CR9NI1^[ZHYG;YO:(O8CEA)$5Z+-8C5\ZJH@FNEN:T^/\ *77<
M)N?&XBLWW[@EGVR^G'K;A<>II[;1CY7H$!O(6R<XVFKF*/"Y1Q331A5W!]'X
M-#9];5^+.?DNI<BD$I)M8A0V0_>X9[+J;=,#*FWC41$G(B.\$,4:.?Y*MA][
MF@C(J^%U<KU<5Q'OE^(HH%'MJ6#<7[@!FN_#^ *.NFM,D(F>[USER[-%\I?<
M;O8WK-%%!*K5^#\)8_&=NA9_C=,80*HJ'GK?^+N%J2KY-Y&W#4M(ADV[4]=@
M?+#8:W6*C<=QO+!M+IVNQ["TEPH0MIF3Y:"A&>]&-8CDD+Y9CGAN!P7.<CR.
MKRAL]SO_ #"U;L=I0C6/N:Z4-C]U0=+55J6\<X1$!%I\/JOWM=[LCM_9.;NK
MHXI3D7N<#;EB!JS\9'8@-4,LS$&L>)T:T-5&*R:_9)AVR[J2A81QJQXVZZP1
M&J?7HT8R--%?',Q/,O>C2RBM1[N@T"P<=PJINU/+7MKW[Y0C!'@ 'K0JGJI4
M@>(2 UC ,<*$5:O+L^U(XNE=&Q3# Y!\;(Z7%AT8,/4 )5%)4=XNS?>U@!#"
MW8P3&5EO6L:&+)413CM!G*B,H)D..CI%@&PD.1H6#:XXCN1X45RN8_[YJNNB
ML<K78*=]4,*V"18">E+*O><.QPH4%U<ADZY#?/$/9<YXVQ#;L[3EAD H0.MJ
ML>B%!U8DA60$/TP5Q^KD-LDE]Y?QWP;JL(L<6JR'C*[4WF#T<\[Q.?'L+2PC
MO54FC5P/ =X<=>U2O+:<.S\K<>1Y)37OZ3I&W8@^S$CM)&5>QU/SJY30=-1Q
MK9[GE53C*AL./86;*T9-X!'M ![!GJE:$?-MAM0U6#.A4CFZ:TR+NE3O:["6
ME&>L'K,LKP15CUI:]FPW-1;)*(C"M$:5,)$DQWN4$IA1MZ->B.R4Y7;46[8[
MBVSP+: 72[IFH@=2<]"A'1T/=<=#U"D1O&[BZK<>!6GC5W81JNN+ 3T QU#
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MZ1YYG(P3$[93VJUI2[2OY ^6=.WW1>W86L$VYSFP6'U:')/53\2YB H&+F&
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MS=[[?C:P[5UFQRSI6E: A2]EEC)6BZF50790695&68 V^ZW>WV:"S<-@,VD
M L6."<*J@LQP"< 'H">P&5N?U1<%1[+8*4F](MYK,VHK+"B%K6WGO9EK>&KX
MT"HUNE!KY+3<;=)-I'%(B5 ITB&4B,D,$]%1)M?(?FMZ*=RNT_:MZ.RV&VD5
MA$#%GL<V::4PK%7N**X&4+#K+0\SQJLR&SOH0"-+Y);& HTY<]1D)J(]($_D
M_P!4_I\K-+L.19W*FM1])JA&-8[$YTYT&$R/QI-YBDM.@X3SL-%XUK9%J4?9
MX@@A>QS4,U1XJ\@^<;^33AJN/O/*6$!:^[J;.Y79C&6Q@[EEJ!S@E@02IU0W
M-<6NV.[:Y?9@.K=<?-FWX/16"Q^#&.WI/0OJ;X(^4E7J@^1JB1<7,Z%6P5B1
M+B94)-M)5- I@SMDB5IM<JO?]CL4&-7.E2PLL94L08RE*Y&9\?D-YL]BLY [
M*P;:I69LE ^%#LY6LL+'\-:[&L"(QK5&9]*C,]/,\8+5I\4:V( Z$C)( RP&
MD:BP"Y(U$@+DR]\Q.2<8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B
M,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B
M(Q$8B,1&(C$1B(Q$8B,1.:'KJY4W,%I^X95MUF-J&WZ'4[%?V,ZHM+#9/&%N
MIVI%J)0-AK:R -P=?:WN-$EKW%5>GQ41435WT<:Y777K0M#S&KYEGIKMI57,
M&T:3:2QA\E4  V=9(>QZAF>!8D&[JU6/$YPWHX;WL7GCFN.VW(_69V"7CY2O
MR+N7K<8UU6?2E*BRLD'2P!([,,I96!5F!WMQ&_W&Q^KSO6I/R;^<J%L0YTV)
M]&VDHX!&5R ?A# ,I#*".TL+8%A+)KMH+&@6-?%--=/5?+UEM5QNGC6\)Y7J
M@/ 1R>:CN<KXKW)[7#<,C]V[?DSMR^UY@I5NJD+Z_5KLK7ML3/9CIXB$DUDC
MJ4*,VH+^.%X7<\4&LVUCA=':];MV5MCMS\1P ''P,&5<>2H;O#/'V&&1FN(Y
MA:FBE-("1*,)[2Q;ZU9\0\67'*QI8 .K21'M:=_20C&Q[5MB/,*^)RE9'%9!
MKI8$%B#E;K!T*LIPU*=&K(%C8M"BJX7>'@CX?'.#R7466K@A0>C55GJ&4C*V
MMU%@)K7-98V>^!8RJ>6&COI"G0_<RDOBHUC;1@V.(L"Q<UK @O8X6*Y>B-9+
M&U2#1'(08[G;;J[8W+QW)-J#=*KCT\0 9T/V 7*!GT"Q074 AU6WW&VJWM+;
M_CUTE>MM0ZZ,G&M/2:B3CTFLD*V059O"43=\:0)Q-?I#D>(H##1S=Q:J*U["
MC(BHNJJG5%:J?]H_1_.O^46SH/,@-=B@^7CT((_MKX00?[G^P?G_ /D?G;A7
M/ $/62.=&""#_:WP$$?C_L_B?^5^;_:,8VI&!73BD/K1R#C5%H9SGEIBE<@X
MU+;&<JN?#>]R#ARWKUZ]H3+W^&\M2JQ^$L7:[DEN)8A:K#U-1/1:K3Z4)P*K
M#]BMSJTL_P 6HG,(VYVX"\HH+6(.@M ZFRL?A =;*Q]ET&G4J?<N5*V63(J*
MDY8M1%*2->7<=[AF.83E9(HZ0[51S9#7(K)<MJ_G;VB&OC]SH_U?==RUS;'9
M,R;%&*W6KT)(Z-34?PO198/F^J(?$R:OFFJKC*EWF[4/O' :JH]0 >HMM'P>
MFNL^OT9AX>!9Y1PQZ$-J5L9K-)8U$+6Q1=$U)$_+2ZX V^W75_+& U.L->I&
M)X/<T5%*%\M*!M$ \O#MK4?VM_/(!^(]+H/FNK+\GD)5:YO,#$[EL\X>QV/]
ML?SKD_CO0K'YSHK=_!;WV%M*LY*TFN'8AE&(EI>C0<B+2Q9 VE$V-W(\$R[F
M1WH\ E[AB&Y#&16J,9KG<[V[>6_1_%,/$P#9<,%:E89&GM#6LI!1>JJI%CY&
MA;*&WVE6UJ]NY-3HR174<AK6!P=785J4C#MT+$%$ZZF3'LHUTQ'3-:B&/5$>
M\]]1B5YY<J05RDE[%7.>KBR;TY%4DP;E5U@JJ]%\Q_AK9>./ #VCB49MD23=
M2,EF)ZM>F>K7$]ZU3UNZM\[Z]PV_'-GP.3=5W8 %5IZ*H'1:7] J Z5D=*NB
M_-^IR!]?'(W(')?+HN"Z>]U.#QGK6N<<<OQI1==FV5Y/NK,^Z4O8.P#>0 )
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M:EV?&Z;-_:NH>E$0_C;"#ZOX"@AK6&E2 '=+':;!=+;KD-5>RK;2?0[N/Q:
M_&_"8C%8ZMDE5;D3ROP1N?(/K5Y5JN.@Z[+GU_"G$UULLO:M@GT*V,^WV#>
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MZHG1\4;4'6L1% U(Z.8*(VNQ'E56LIU6<78=5Q/5ZW]-@Q^)^&M0!0 /#45
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M(93D$$@@@S 4V]^M&%)6QN?2=JU]:"61#KYI?4AK$5(%,XJ>7CCC-T8HEM)
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MX/\ $1\B=O\ OP[Q]8N+_P '^(CY$[?]^'>/K%Q?^#_$1\B=O^_#O'UBXO\
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M6'KYQI&>UL] !VGH.LRB_P D^<-L0+N,WP)V7MG2ESC:Z#8;VT@Z:A6-;,V
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M'<;CPAX-;EM-U]Z"[6&%JI;N+72MP:T8ZU0/ECC>$?2KZ8=/LZ;E#AD<:T-
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M !)^  D]('QEIQ5*T4_<RN 7P3M'RKR8]0F[&%\(J-W%5&7PRM=VKT7M<B_
MJ8# YP0<'!AZK*PIL5E#KJ7((R,D9&>T9!&1TR"/1(-R9H%)3:FZ=66>^PI?
MRET2'XX>4^34(D:RWO6ZV>%%7;EZ-E099!.^FQZIGL^)-)G'6C5XF'L+7;H(
M"RH4(9IG+7),41)ME+!7UT-A#;DQCI4^?)& (T7O*8C6-17.1%^7=*QJL(52
M0.IQU)  Z^DD@ >DD 2OMMKNMY8:MI79;:M;N0BEB$K1K+'(4$A:ZU9W;L5%
M9F( )GS/X;T:TB$@V*;C.AE)%*2-)Y.Y,,%Y84L$^(1PW[>K5?&FQ1E8O]J]
MB*GM3/J4)[5XLU1555E;PJJO557E+D_VJOPK]N&(E>LT&E7E:31K:[ZM0SCR
M%:-@?NI<F> VQ)LMA%?,1/E=W>.Z,)K%7K^53IB).1<;:4<LH ++<#'A%8":
M$7+')1"Q#% *4,,H;-R5\<I(IQD:UZ(JC>UR>Q47/D.K$JI!93@_8.,]?@Z$
M'[1E6S;WU5I;:CK5:I9"00' 8J2I/1@&5E)&0&4CM!@7&^DG/*C L]P-)@O$
M.;'%RQR40\1YPMD!9*$S<E)'>8#VO:CT17,5%3V+UP'1F*J067M&>HSU&?@Z
M=9[9M]Q54E]J.M-H)1BI"N%)4E21A@&!4XS@@@]9 ][T?48M+4V538[+,D5?
M*?$0'(;DC>[R&&:#ES2!2(LZNL-IGUQB@[^CPG$[M=T56HJ)A71\Z"#@X.#G
M!':#]D?!%VWW&WTC<(]9= ZZE*ZD;U6&0,JWH8=#Z#.)GSM7 5HWU-^FKG>N
MA&/75W)_'T*[,,;GLC5]CMVKB'+(]$5$!7WM>UIE]B,2R$J^SKFK/>;PV]W&
M[X3G-D,U;;D*Z[OAT6VK@]/@QV]GPSM;ZH_O"XWC?*WGOW9\DXJWG+<'NK]F
M6("VV5;.U-Q6/Y\4MK0=KN-(&)'?G..;=+H]$XHT'ECCIO*'$O(NQ;7\JJ^J
MMUUK?]9M]9B4A]:W3CO9U%+AUVP4Z6LL9(TR.:%/CG<$J-1>Y+OWP<KLMC7M
M]ERM/M'#[O<;@VKK*N/"8LCTL/592<G'2SH#TEO]2#R+YB\T<GS/F3R=RJ<1
MYWXO:T-MGNK:_;75;A[&W&UW%"D,];/H8%?E%*C3UFGOHOY^] OHDWG:.9M'
MWSU*[U=[)H%AIC.-MEXMU&LD0AV%Q372E=ME;LHZ:1("6F8'Q.C&*QZN[>J(
MBZN\L>:_('E?>7<KQUW*76OM7J%1VX8*6*M@6@XSE0,M\.3.K/?7[IOK.^^_
MA=EY!YSB?*7&[78[Y=Q[=MM]8:W;0R=[;.#8I(;64!U]0H[9JUZF.>.3_G)/
M4GJ4>LUGW*VUE1>/^*- BG=8MUJILISI5E;7EFP0&S+$W1\^UF(,801HR-:B
M#"CEQ/S-YCY+WE>9:-IL:_#2UO#HJ)SX9QWV)_"*G)]$W7[I/=AY&^J5[J]Y
MN=YO!<-JR[W?[RRHU'<75HVFG;ZB6"%NY6,]6[>I,_U/;MZ#M;YH]'/'?IDM
M=C+K>MT.V<6;=/,E*VW]]T_'UW5V'R<EPBV-6^-'VJDJV1C%0OB1T,YR,<J=
M,ZBY?RMM^:X';>7]V[+MZ!MB6 !+&C22I&0 &(TD@Y ZCK/Q\]W'OSYCR'[T
M.1][&TV?C\KR%7)JE;N4:GZ16RM+<A6!?;AE=5(TL5PPQ)7M/S?O%@#^G6)P
MJL+@75O3UMW*FYU.MZ#KT(7O6XY2XSV3CJ;;#L33!E@7]038&V(II63"%-%&
M-R(Q$5MM9Y*X=?8UXY5V6VV5]MJ)4@"L]M;5L6).<][5J'7H!+OC??[YO>SS
M)NO.YL\Q\GYDX_9[6^W>6DD5;+?[7?)4%4!36YVPI9 %4([,.]B:5ZQ\S0*C
MUKEJDL_4&6UM>6O34STZ7.S1^,G1+>4X?(5#OCN4=GE7'(^Q3MMW>S]P,CSU
M<>* SG^(-H6L02XK5[KU4;H/NP[[K8>RLRU@,%UJ^MF9V+MW< $@#)F]=_\
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MI8]59Q:UC+"&!PX]@Y@2':0L8#V41Y'X_NBS<;MT554@NN"% &#A!A6 [ZC
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M"^Q$Q$U<]5_H]TOU3;E4;=?;[653]3X6Y8T#4ZY/)$'$WS?)6L3=;W2QGAD
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)7"/_ &<1/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772912288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MeiraGTx Holdings plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001735438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,184,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773389760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 102,060,551<span></span>
</td>
<td class="nump">$ 8,548,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,613,955<span></span>
</td>
<td class="nump">1,961,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">311,283<span></span>
</td>
<td class="nump">965,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">103,985,789<span></span>
</td>
<td class="nump">11,475,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">13,567,806<span></span>
</td>
<td class="nump">14,255,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">123,376<span></span>
</td>
<td class="nump">123,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">117,676,971<span></span>
</td>
<td class="nump">25,854,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,461,441<span></span>
</td>
<td class="nump">7,055,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,289,261<span></span>
</td>
<td class="nump">9,332,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,679,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Capitalized lease obligation-current portion</a></td>
<td class="nump">28,715<span></span>
</td>
<td class="nump">30,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to Kadmon</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">861,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">8,779,417<span></span>
</td>
<td class="nump">21,401,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capitalized lease obligation</a></td>
<td class="nump">20,732<span></span>
</td>
<td class="nump">34,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">224,367<span></span>
</td>
<td class="nump">266,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">180,350<span></span>
</td>
<td class="nump">178,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">9,204,866<span></span>
</td>
<td class="nump">21,880,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Convertible Preferred C Shares 0 and 5,005,935 outstanding at June 30, 2018 December 31, 2017, respectively (liquidation preference of $52,455,700 at December 31, 2017)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,338,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">A Ordinary Shares, $0.00003881 nominal value 27,184,132 issued and outstanding at June 30, 2018 8,826,190 issued and 8,714,563 issued and outstanding at December 31, 2017</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital in excess of nominal value</a></td>
<td class="nump">221,080,313<span></span>
</td>
<td class="nump">20,080,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(801,235)<span></span>
</td>
<td class="num">(2,022,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(111,808,028)<span></span>
</td>
<td class="num">(65,423,843)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="nump">108,472,105<span></span>
</td>
<td class="num">(47,365,265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="nump">$ 117,676,971<span></span>
</td>
<td class="nump">$ 25,854,219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772904000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,005,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,455,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00003881<span></span>
</td>
<td class="nump">$ 0.00003881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,184,132<span></span>
</td>
<td class="nump">8,826,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,184,132<span></span>
</td>
<td class="nump">8,714,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773353088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 17,378,052<span></span>
</td>
<td class="nump">$ 2,221,896<span></span>
</td>
<td class="nump">$ 28,500,068<span></span>
</td>
<td class="nump">$ 4,370,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,790,694<span></span>
</td>
<td class="nump">5,363,545<span></span>
</td>
<td class="nump">14,718,016<span></span>
</td>
<td class="nump">10,186,902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,168,746<span></span>
</td>
<td class="nump">7,585,441<span></span>
</td>
<td class="nump">43,218,084<span></span>
</td>
<td class="nump">14,557,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,168,746)<span></span>
</td>
<td class="num">(7,585,441)<span></span>
</td>
<td class="num">(43,218,084)<span></span>
</td>
<td class="num">(14,557,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other non-operating income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">83,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency (loss) gain</a></td>
<td class="num">(2,726,624)<span></span>
</td>
<td class="nump">449,625<span></span>
</td>
<td class="num">(1,748,000)<span></span>
</td>
<td class="nump">598,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(2,184,183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,514,775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">25,354<span></span>
</td>
<td class="nump">7,991<span></span>
</td>
<td class="nump">50,662<span></span>
</td>
<td class="nump">18,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9,708)<span></span>
</td>
<td class="num">(50,894)<span></span>
</td>
<td class="num">(37,063)<span></span>
</td>
<td class="num">(59,020)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,980,832)<span></span>
</td>
<td class="num">(7,178,719)<span></span>
</td>
<td class="num">(46,384,185)<span></span>
</td>
<td class="num">(13,999,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,979,007<span></span>
</td>
<td class="num">(345,019)<span></span>
</td>
<td class="nump">1,221,242<span></span>
</td>
<td class="num">(475,914)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(28,001,825)<span></span>
</td>
<td class="num">(7,523,738)<span></span>
</td>
<td class="num">(45,162,943)<span></span>
</td>
<td class="num">(14,475,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,980,832)<span></span>
</td>
<td class="num">(7,178,719)<span></span>
</td>
<td class="num">(46,384,185)<span></span>
</td>
<td class="num">(13,999,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion on convertible preferred C shares and warrants</a></td>
<td class="num">(1,141,794)<span></span>
</td>
<td class="num">(30,401)<span></span>
</td>
<td class="num">(1,806,512)<span></span>
</td>
<td class="num">(53,162)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Adjusted net loss</a></td>
<td class="num">$ (31,122,626)<span></span>
</td>
<td class="num">$ (7,209,120)<span></span>
</td>
<td class="num">$ (48,190,697)<span></span>
</td>
<td class="num">$ (14,052,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per ordinary share</a></td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (4.27)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of ordinary shares outstanding</a></td>
<td class="nump">13,611,452<span></span>
</td>
<td class="nump">8,505,149<span></span>
</td>
<td class="nump">11,280,804<span></span>
</td>
<td class="nump">8,545,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774484320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2018 - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO [Member]</div></th>
<th class="th"><div>Convertible Preferred C Shares [Member]</div></th>
<th class="th">
<div>Convertible Preferred C Shares [Member] </div>
<div>Accounts Payable [Member]</div>
</th>
<th class="th">
<div>Convertible Preferred C Shares [Member] </div>
<div>License Agreement [Member]</div>
</th>
<th class="th">
<div>Convertible Preferred C Shares [Member] </div>
<div>Sales Agreement [Member]</div>
</th>
<th class="th"><div>A Ordinary Shares [Member]</div></th>
<th class="th">
<div>A Ordinary Shares [Member] </div>
<div>IPO [Member]</div>
</th>
<th class="th"><div>Capital in Excess of Nominal Value [Member]</div></th>
<th class="th">
<div>Capital in Excess of Nominal Value [Member] </div>
<div>IPO [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2017</a></td>
<td class="num">$ (47,365,265)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,080,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,022,477)<span></span>
</td>
<td class="num">$ (65,423,843)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, beginning Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,338,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of A ordinary shares in initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,458,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,458,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,826,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, beginning Balance, Shares at Dec. 31, 2017</a></td>
<td class="nump">5,005,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,005,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccretionOfStockIssuanceCosts', window );">Accretion of issuance costs on convertible preferred C shares</a></td>
<td class="num">$ (761,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(761,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred C shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,356,129<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="nump">$ 56,159,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccretionOfPreferredStockAndWarrants', window );">Accretion of warrants issued in connection with convertible preferred C shares</a></td>
<td class="num">(1,045,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,045,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net of issuance costs, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,419<span></span>
</td>
<td class="nump">13,360<span></span>
</td>
<td class="nump">5,425,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_TemporaryEquityAccretionOfIssuanceCost', window );">Accretion of issuance costs on convertible preferred C shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 761,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_TemporaryEquityAccretionOfWarrants', window );">Accretion of warrants issued in connection with convertible preferred C shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,045,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Exercise of warrants</a></td>
<td class="nump">4,194,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,194,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Exercise of warrants, Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion convertible preferred C shares into A ordinary shares</a></td>
<td class="nump">120,520,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (120,520,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,519,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred C shares into A ordinary shares, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,501,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,501,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 12,633,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,633,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, ending Balance, Shares at Jun. 30, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">$ 1,221,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,384,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,384,185)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2018</a></td>
<td class="nump">$ 108,472,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,080,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (801,235)<span></span>
</td>
<td class="num">$ (111,808,028)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,184,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccretionOfPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccretionOfPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccretionOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccretionOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_TemporaryEquityAccretionOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Accretion of Issuance Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_TemporaryEquityAccretionOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_TemporaryEquityAccretionOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Accretion of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_TemporaryEquityAccretionOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in additional paid in capital related to exercise of share-based payments awards (such as stock options) and the amount of recognized equity-based compensation during the period (such as nonvested shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764212928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Sale of A ordinary shares in initial public offering, issuance costs</a></td>
<td class="nump">$ 9,541,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774098976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,980,832)<span></span>
</td>
<td class="num">$ (7,178,719)<span></span>
</td>
<td class="num">$ (46,384,185)<span></span>
</td>
<td class="num">$ (13,999,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement', window );">Preferred C shares issued in connection with a license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,633,556<span></span>
</td>
<td class="nump">1,535,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency loss (gain)</a></td>
<td class="nump">2,726,624<span></span>
</td>
<td class="num">(449,625)<span></span>
</td>
<td class="nump">1,748,000<span></span>
</td>
<td class="num">(598,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015,079<span></span>
</td>
<td class="nump">373,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AmortizationOfInterestOnAssetRetirementObligation', window );">Amortization of interest on asset retirement obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,322<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
<td class="nump">$ 19,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">2,184,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Decrease (increase) in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,130<span></span>
</td>
<td class="nump">6,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,528<span></span>
</td>
<td class="num">(739,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in operating liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,095)<span></span>
</td>
<td class="nump">784,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_IncreaseDecreaseInDueToAndFromRelatedParties', window );">Due to Kadmon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(861,030)<span></span>
</td>
<td class="nump">30,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,413,642)<span></span>
</td>
<td class="nump">1,646,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,748,762)<span></span>
</td>
<td class="nump">352,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,425,351)<span></span>
</td>
<td class="num">(10,530,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Issuance of long-term note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,318,016)<span></span>
</td>
<td class="num">(4,824,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,318,016)<span></span>
</td>
<td class="num">(2,324,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Payments on capitalized lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,701)<span></span>
</td>
<td class="num">(9,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the sale of convertible preferred C shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,849,592<span></span>
</td>
<td class="nump">210,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,469,856<span></span>
</td>
<td class="nump">194,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,726,489<span></span>
</td>
<td class="num">(12,660,382)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214,576)<span></span>
</td>
<td class="nump">69,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,672,014<span></span>
</td>
<td class="nump">17,921,485<span></span>
</td>
<td class="nump">17,921,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">$ 102,183,927<span></span>
</td>
<td class="nump">$ 5,330,794<span></span>
</td>
<td class="nump">102,183,927<span></span>
</td>
<td class="nump">5,330,794<span></span>
</td>
<td class="nump">$ 8,672,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fixed asset acquisition included in accounts payable and accrued expenses at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,551<span></span>
</td>
<td class="nump">1,561,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of convertible preferred C shares in connection with payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible preferred C shares into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,520,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ReclassificationOfWarrantLiabilityUponExercise', window );">Reclassification of warrant liability upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,194,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Capitalized lease obligation for equipment purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,531<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,456,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs in connection with shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,781,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_NoncashOrPartNoncashStockIssuanceCosts', window );">Issuance costs in connection with sale of convertible preferred C shares included in accrued expenses at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,509,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred C Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs in connection with shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(610,473)<span></span>
</td>
<td class="num">$ (6,124)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_NoncashOrPartNoncashStockIssuanceCosts', window );">Issuance costs in connection with sale of convertible preferred C shares included in accrued expenses at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AmortizationOfInterestOnAssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of interest on asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AmortizationOfInterestOnAssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_IncreaseDecreaseInDueToAndFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in due to and from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_IncreaseDecreaseInDueToAndFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NoncashOrPartNoncashStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash or part non-cash stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NoncashOrPartNoncashStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred C shares issued in connection with license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PreferredSharesIssuedInConnectionWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ReclassificationOfWarrantLiabilityUponExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability upon exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ReclassificationOfWarrantLiabilityUponExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929532976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>1.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Organization and Basis of Presentation:</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <b><i>The Company</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 MeiraGTx Holdings plc, a limited company under the laws of the
 Cayman Islands, is a clinical-stage biotech company developing
 novel gene therapy treatments for a wide range of inherited and
 acquired disorders for which there are no effective treatments
 available. The Company is focused on developing therapies for
 ocular diseases, including rare inherited blindness as well as
 Xerostomia following radiation treatment for head and neck cancers
 and neurodegenerative diseases such as amyothrophic lateral
 sclerosis (&#x201C;ALS&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Reorganization and Initial Public Offering</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 On May&#xA0;28, 2018, the Board of Directors of MeiraGTx Limited
 approved the Reorganization Transactions, effective June&#xA0;7,
 2018, pursuant to which the Board of Directors approved the
 transfer of the shares held by each of the MeiraGTx Limited&#x2019;s
 shareholders for the equivalent class and number of shares issued
 by Meira Holdings. On June&#xA0;7, 2018, the Company completed its
 IPO, selling 5,000,000 Series A ordinary shares (&#x201C;Ordinary
 Shares&#x201D;) at a public offering price of $15.00 per share, and
 receiving $65.9&#xA0;million in net proceeds, after deducting
 underwriting discounts and commissions and offering expenses
 payable by us.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Reverse Share Split</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 On June&#xA0;7, 2018 MeiraGTx Limited&#x2019;s Board of Directors
 and shareholders approved a 1:3.881 reverse share split. All share
 information presented in these financial statements and
 accompanying footnotes have been retroactively adjusted to reflect
 the decreased number of shares resulting from this action.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The accompanying condensed consolidated financial statements have
 been prepared in conformity with accounting principles generally
 accepted in the United States of America (&#x201C;GAAP&#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to the authoritative United States generally accepted accounting
 principles as found in the Accounting Standards Codification
 (&#x201C;ASC&#x201D;) and Accounting Standards Update
 (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board
 (&#x201C;FASB&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Interim Financial Statements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The accompanying condensed consolidated financial statements have
 been prepared in accordance with GAAP for interim financial
 information and with the instructions to&#xA0;Form <font style="WHITE-SPACE: nowrap">10-Q</font> and Article 10 of Regulation
 <font style="WHITE-SPACE: nowrap">S-X.</font> Accordingly, they do
 not include all the information and footnotes required by generally
 accepted accounting principles for complete consolidated financial
 statements. In the opinion of management, the condensed
 consolidated financial statements include all adjustments
 (consisting of normal recurring accruals) necessary in order to
 make the condensed consolidated financial statements not
 misleading. Operating results for the three-month and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018&#xA0;are not necessarily indicative of the final results that
 may be expected for the year ended December&#xA0;31, 2018. These
 unaudited condensed consolidated financial statements should be
 read in conjunction with the audited consolidated financial
 statements&#xA0;for the year ended December&#xA0;31, 2017 and the
 notes thereto for the year ended December&#xA0;31, 2017 included in
 the Company&#x2019;s final prospectus that forms a part of the
 Company&#x2019;s Registration Statement on Form <font style="WHITE-SPACE: nowrap">S-1</font> (Reg. <font style="WHITE-SPACE: nowrap">No.&#xA0;333-224914),</font> filed with the
 Securities and Exchange Commission (&#x201C;SEC&#x201D;) pursuant to
 Rule 424(b)(4) on June&#xA0;8, 2018 (the
 &#x201C;Prospectus&#x201D;).</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i>Liquidity</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company has not generated any revenues and has not yet achieved
 profitable operations. There is no assurance that profitable
 operations, if ever achieved, could be sustained on a continuing
 basis. In addition, development activities, clinical and
 preclinical testing, and commercialization of the Company&#x2019;s
 product candidates will require significant additional financing.
 Management expects to incur substantial and increasing losses in
 future periods. The success of the Company is subject to certain
 risks and uncertainties, including among others, uncertainty of
 product development; competition in the Company&#x2019;s field of
 use; uncertainty of capital availability; uncertainty in the
 Company&#x2019;s ability to enter into agreements with collaborative
 partners; dependence on third parties; and dependence on key
 personnel. The Company has not generated positive cash flows from
 operations, and there are no assurances that the Company will be
 successful in obtaining an adequate level of financing for the
 development and commercialization of its product candidates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 As of June&#xA0;30, 2018, the Company had cash and cash equivalents
 in the amount of $102,060,551, which consisted of depository
 accounts. The Company estimates that its cash and cash equivalents
 on hand at June&#xA0;30, 2018 will cover its expenses into the
 second quarter of 2020.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Risks and Uncertainties</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company operates in an industry that is subject to intense
 competition, government regulation and rapid technological change.
 The Company&#x2019;s operations are subject to significant risk and
 uncertainties including financial, operational, technological,
 regulatory and other risks, including the potential risk of
 business failure.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company&#x2019;s limited capital resources and operations to
 date have been funded primarily with the proceeds from private
 equity offerings and the IPO. In the future, the Company may seek
 to raise additional capital through equity offerings, debt
 financings, marketing and distribution arrangements and other
 collaborations, strategic alliances and licensing arrangements or
 other sources to enable it to complete the development and
 potential commercialization of its product candidates.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609920864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies and Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Summary of Significant Accounting Policies and
 Recent Accounting Pronouncements:</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Certain of the Company&#x2019;s significant accounting policies are
 described below. All of the Company&#x2019;s significant accounting
 policies are disclosed in the notes to the audited consolidated
 financial statements as of and for the year ended December&#xA0;31,
 2017 included in the Company&#x2019;s Prospectus.&#xA0;Since the
 date of such financial statements, there have been no changes to
 the Company&#x2019;s significant accounting policies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The accompanying condensed consolidated financial statements
 include the accounts of Meira Holdings and its wholly owned
 subsidiaries:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx Limited, a limited company under the laws of England and
 Wales (&#x201C;Meira Limited);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx, LLC, a Delaware corporation (&#x201C;Meira
 LLC&#x201D;);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 BRI-Alzan, Inc., a Delaware corporation
 (&#x201C;BRI-Alzan&#x201D;);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx B.V., a Netherlands corporation (&#x201C;Meira
 BV&#x201D;);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx UK II Limited, (&#x201C;Meira UK II&#x201D;), a limited
 company under the laws of England and Wales;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx UK Limited (&#x201C;Meira UK&#x201D;), a limited company
 under the laws of England and Wales.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 All intercompany balances and transactions between the consolidated
 companies have been eliminated in consolidation.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Management considers many factors in selecting appropriate
 financial accounting policies and controls, and in developing the
 estimates and assumptions that are used in the preparation of these
 consolidated financial statements. Management must apply
 significant judgment in this process. In addition, other factors
 may affect estimates, including expected business and operational
 changes, sensitivity and volatility associated with the assumptions
 used in developing estimates, and whether historical trends are
 expected to be representative of future trends. The estimation
 process often may yield a range of potentially reasonable estimates
 of the ultimate future outcomes and management must select an
 amount that falls within that range of reasonable estimates. This
 process may result in actual results differing materially from
 those estimated amounts used in the preparation of the consolidated
 financial statements if these results differ from historical
 experience, or other assumptions do not turn out to be
 substantially accurate, even if such assumptions are reasonable
 when made. In preparing these consolidated financial statements,
 management used significant estimates in the following areas, among
 others: valuation of A ordinary shares (&#x201C;Ordinary
 Shares&#x201D;) issued prior to the Company&#x2019;s initial public
 offering, for the acquisition of assets, the accounting for
 research and development costs, warrants, share based compensation,
 asset retirement obligations and accrued expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value is defined as the price that would be received upon sale
 of an asset or paid upon transfer of a liability in an orderly
 transaction between market participants at the measurement date and
 in the principal or most advantageous market for that asset or
 liability. The fair value should be calculated based on assumptions
 that market participants would use in pricing the asset or
 liability, not on assumptions specific to the entity. In addition,
 the fair value of liabilities should include consideration
 of&#xA0;<font style="WHITE-SPACE: nowrap">non-performance</font>&#xA0;risk
 including our own credit risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company follows ASC Topic 820,&#xA0;<i>Fair Value
 Measurements and Disclosures</i>, or ASC 820, for application to
 financial assets. In addition to defining fair value, the standard
 expands the disclosure requirements around fair value and
 establishes a fair value hierarchy for valuation inputs. The
 hierarchy prioritizes the inputs into three levels based on the
 extent to which inputs used in measuring fair value are observable
 in the market. Each fair value measurement is reported in one of
 the three levels which are determined by the lowest level input
 that is significant to the fair value measurement in its entirety.
 These levels are:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Level&#xA0;1: Observable inputs such as quoted prices
 in active markets for identical assets the reporting entity has the
 ability to access as of the measurement date;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Level&#xA0;2: Inputs, other than the quoted prices in
 active markets, that are observable either directly or indirectly;
 and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left">Level&#xA0;3: Unobservable inputs in which there is
 little or no market data, which require the reporting entity to
 develop its own assumptions.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The table below represents the values of the Compnay&#x2019;s
 financial assets and liabilities that are required to be measured
 at fair value on a recurring basis:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">Fair Value Measurement Using:</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Observable&#xA0;Inputs<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant&#xA0;Other<br />
 Observable&#xA0;Inputs<br />
 (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">Fair Value Measurement Using:</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,<br />
 2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Observable Inputs<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant Other<br />
 Observable Inputs<br />
 (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The table below represents a rollforward of the assets and
 liabilities that are required to be measured at fair value on a
 recurring basis from December&#xA0;31, 2017 to June&#xA0;30,
 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable&#xA0;Inputs<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in fair value of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,514,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,194,408</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The warrants were classified as liabilities because the underlying
 Preferred Shares had a redemption feature in the event of a change
 of control of the Company. On June&#xA0;5, 2018, the warrants were
 exercised at which time the warrant liability was determined to be
 $4,194,408, which represented the difference in the market value of
 the Preferred Shares and the exercise price of the warrants. This
 resulted in an increase of the warrant liability in the amount of
 $2,184,183 and $1,514,775 for the three-month
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018, respectively. The related warrant
 liability of $4,194,408 was reclassified as Capital in Excess of
 Nominal Value at such time.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair values of the warrants at December&#xA0;31, 2017,
 March&#xA0;31, 2018 and June&#xA0;4, 2018 were estimated using the
 Black-Scholes valuation model with the following assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,&#xA0;2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">March&#xA0;31,&#xA0;2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;4,&#xA0;2018</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.72</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.86</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.77</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9&#xA0;months</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.5&#xA0;months</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1&#xA0;day</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 For the unobservable inputs for the warrants, the expected
 volatility was determined at each measurement date by taking an
 average of the volatility of other publicly-traded peer
 biotechnology companies. The expected life was determined at each
 measurement date based upon the Company&#x2019;s estimate of the
 time until the Company has a conversion event.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair value of the Preferred Shares was based upon recent
 issuances of the Company&#x2019;s Preferred Shares on or about
 December&#xA0;31, 2017, March&#xA0;31, 2018 and June&#xA0;5,
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The estimated fair values of the Company&#x2019;s warrants are not
 necessarily indicative of the amounts that would be realized in a
 current market exchange. The determination of the fair value of the
 warrants are sensitive to changes in in the assumptions used and a
 change in those inputs could result in a significantly higher or
 lower fair value measurement. If the volatility were to increase or
 the expected life were to increase, the fair value of the warrant
 would increase. Conversely, if the volatility were to decrease or
 the expected life were to decrease, the fair value of the warrant
 would decrease.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Net Loss per Ordinary Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Basic net loss per Ordinary Share is computed by dividing net loss
 attributable to the Company&#x2019;s shareholders by the weighted
 average number of shares of the Company&#x2019;s Ordinary Shares
 assumed to be outstanding during the period of computation. Diluted
 net loss per ordinary share is computed similar to basic net loss
 per share except that the denominator is increased to include the
 number of additional Ordinary Shares that would have been
 outstanding if the potential ordinary shares had been issued at the
 beginning of the year and if the additional ordinary shares were
 dilutive (treasury stock method) or
 the&#xA0;<font style="WHITE-SPACE: nowrap">two-class</font>&#xA0;method,
 whichever is more dilutive. For all periods presented, basic and
 diluted net loss per Ordinary Share are the same, as any additional
 Ordinary Share equivalents would be anti-dilutive.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Asset Retirement Obligation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Accounting for Asset Retirement Obligations requires legal
 obligations associated with the retirement of long-lived assets to
 be recognized at fair value when incurred and capitalized as part
 of the related long-lived asset. In the absence of quoted market
 prices, we estimate the fair value of our asset retirement
 obligations using Level&#xA0;3 present value techniques, in which
 estimates of future cash flows associated with retirement
 activities are discounted using a credit-adjusted risk-free rate.
 Asset retirement obligations currently reported as other
 liabilities on our Consolidated Balance Sheet were measured during
 a period of historically low interest rates. The impact on
 measurements of new asset retirement obligations using different
 rates in the future may be significant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company uses estimates to determine the amount of the asset
 retirement obligations at the end of the lease term and discounts
 such asset retirement obligations using an estimated discount rate.
 Interest on the discounted asset retirement obligation is amortized
 over the term of the lease using the effective interest method and
 is recorded as interest expense in the consolidated statements of
 operations and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The change in asset retirement obligations is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 For&#xA0;the&#xA0;six&#xA0;month&#xA0;period<br />
 ended June&#xA0;30, 2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">For&#xA0;the&#xA0;year&#xA0;ended<br />
 December&#xA0;31,&#xA0;2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at beginning of period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">221,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Amortization of interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,313</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in estimate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(75,011</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effects of exchange rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,391</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,863</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at end of period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">180,350</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to, employee-related
 expenses, including salaries, benefits and travel of the
 Company&#x2019;s research and development personnel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical and preclinical studies
 and manufacture the drug product for the clinical studies and
 preclinical activities; acquisition
 of&#xA0;<font style="WHITE-SPACE: nowrap">in-process</font>&#xA0;research
 and development; facilities; supplies; rent, insurance, certain
 legal fees, stock-based compensation, depreciation and other costs
 associated with clinical and preclinical activities and regulatory
 operations. Refundable research and development tax credits
 received are recorded as an offset to these costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs for certain development activities, such as Company funded
 outside research programs, are recognized based on an evaluation of
 the progress to completion of specific tasks with respect to their
 actual costs incurred. Payments for these activities are based on
 the terms of the individual arrangements, which may differ from the
 pattern of costs incurred, and are reflected in the financial
 statements as prepaid or accrued research and development expense,
 as the case may be.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Segment Information</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Management has concluded it has a single reporting segment for
 purposes of reporting financial condition and results of
 operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The following table summarizes&#xA0;<font style="WHITE-SPACE: nowrap">non-current</font>&#xA0;assets
 by geographical area:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">413,481</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">436,463</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United Kingdom</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,277,701</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,942,642</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,691,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,379,105</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In June&#xA0;2018, the FASB issued
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2018-07,</font>&#xA0;Improvements
 to Nonemployee Share-Based Accounting, which simplifies the
 accounting for share-based payments granted to nonemployees for
 goods and services. The ASU supersedes
 ASC&#xA0;<font style="WHITE-SPACE: nowrap">505-50</font>&#xA0;and expands
 the scope of ASC 718 to
 include&#xA0;<i>all</i>&#xA0;share-based
 payment arrangements related to the acquisition of goods and
 services from both nonemployees and employees. As a result, most of
 the guidance in ASC 718 associated with employee share-based
 payments, including most of its requirements related to
 classification and measurement, applies to nonemployee share-based
 payment arrangements.&#xA0;ASU&#xA0;<font style="WHITE-SPACE: nowrap">2018-07</font>generally requires an entity to
 use a modified retrospective transition approach, with a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the fiscal year, for all (1)&#xA0;liability-classified
 nonemployee awards that have not been settled as of the adoption
 date and (2)&#xA0;equity-classified nonemployee awards for which a
 measurement date has not been established. The guidance is
 applicable to public business entities for fiscal years beginning
 after December&#xA0;15, 2019 and interim periods within those
 years. The Company is currently evaluating the potential impact of
 the adoption of this standard on its consolidated results of
 operations, financial position and cash flows and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In January 2017, the FASB issued&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2017-01,</font><i>&#xA0;Business
 Combinations (Topic 805), Clarifying the Definition of a
 Business,</i>&#xA0;or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01</font><i>,</i>&#xA0;that
 clarifies the definition of a business to assist entities with
 evaluating whether transactions should be accounted for as
 acquisitions (or disposals) of assets or
 businesses.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01</font>&#xA0;requires
 an entity to evaluate if substantially all of the&#xA0;fair value
 of the gross assets acquired or disposed of is concentrated in a
 single identifiable asset or a group of similar identifiable
 assets; if so, the set of transferred assets and activities is not
 a business.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01&#xA0;also</font>&#xA0;requires
 a business to include at least an input and one substantive process
 that together significantly contribute to the ability to create
 output and removes the evaluation of whether a market participant
 could replace missing elements.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01&#xA0;should</font>&#xA0;be
 applied prospectively and is effective for annual periods beginning
 after December&#xA0;15, 2017 and interim periods within those
 annual periods. The adoption of ASU&#xA0;<font style="WHITE-SPACE: nowrap">2017-01</font>&#xA0;on
 January&#xA0;1, 2018 did not have a material effect on the
 Company&#x2019;s financial position, results of operations or cash
 flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In December 2016, the FASB&#xA0;<font style="WHITE-SPACE: nowrap">issued&#xA0;ASU&#xA0;No.&#xA0;2016-20,</font><i>&#xA0;Technical
 Corrections and Improvements to Topic 606, Revenue from Contracts
 with Customers,</i><font style="WHITE-SPACE: nowrap">&#xA0;or&#xA0;ASU&#xA0;2016-20,&#xA0;that&#xA0;allows</font>&#xA0;entities
 not to disclose variable consideration allocated to performance
 obligations related to either: (1)&#xA0;sales&#x2014;or usage -based
 royalties on licenses of intellectual property or (2)&#xA0;variable
 consideration allocated entirely to a wholly unsatisfied
 performance obligation or to a wholly unsatisfied promise to
 transfer a distinct good or service that forms part of a single
 performance obligation when certain criteria
 are&#xA0;<font style="WHITE-SPACE: nowrap">met.&#xA0;ASU&#xA0;2016-20&#xA0;also&#xA0;requires</font>&#xA0;entities
 that use any of the new or previously existing optional exemptions
 to expand their qualitative disclosures. It also makes 12
 additional technical corrections and improvements to the new
 revenue standard,&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09.</font>&#xA0;The
 amendments have the same effective date and transition requirements
 as&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09.</font>&#xA0;The
 adoption of&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-20</font>&#xA0;did
 not have a material effect on its financial position, results of
 operations or cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2016, the Financial Accounting Standards Board, or FASB
 issued&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-18,</font><i>&#xA0;Statement
 of Cash Flows (Topic 230), Restricted Cash</i>&#xA0;(a consensus of
 the Emerging Issues Task Force), or<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18,&#xA0;which</font>&#xA0;changes
 the presentation of the cash flow statement to include amounts
 generally described as restricted cash or restricted cash
 equivalents, together with cash and cash equivalents, when
 reconciling<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">the&#xA0;beginning-of-period&#xA0;and&#xA0;end-of-period&#xA0;amounts</font></font></font></font>&#xA0;shown
 on the statement of cash flows.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18&#xA0;also</font>&#xA0;requires
 additional disclosures concerning the nature of the restrictions on
 cash and cash equivalents and a reconciliation between amounts of
 cash, cash equivalents and restricted cash on the balance sheet and
 statement of cash flows for each period
 presented.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18&#xA0;will</font>&#xA0;be
 applied retrospectively to all periods presented and is effective
 for public business entities for fiscal years beginning after
 December&#xA0;15, 2017, and interim periods within those fiscal
 years. Early adoption is permitted, including adoption in an
 interim period. Prior to adoption, the Company presented changes in
 restricted cash as an operating activity in the statement of cash
 flows. Upon adoption of&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18</font>&#xA0;on
 January&#xA0;1, 2018,&#xA0;such changes are now reflected in the
 beginning and ending balances of cash, cash equivalents and
 restricted cash for all periods presented.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In October 2016, the FASB issued&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-16,&#xA0;Income</font>&#xA0;Taxes
 (Topic 740):<i>&#xA0;Intra-Entity Transfers of Assets Other than
 Inventory</i>, or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-16&#xA0;which</font>&#xA0;requires
 that an entity recognize the income tax consequences of an
 intra-entity transfer of assets other than inventory when the
 transfer occurs. The guidance must be applied using the modified
 retrospective basis. The Company does not expect the provisions
 of&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-16&#xA0;to</font>&#xA0;have
 a material impact on its current financial statements. This update
 will be effective for the Company at the beginning of fiscal
 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2016, the FASB issued&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-12</font><i>, Revenue
 from Contracts with Customers (Topic 606), Narrow-Scope
 Improvements and Practical Expedients</i>,
 or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-12,&#xA0;which</font>&#xA0;amends
 guidance in the new revenue
 standard,&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2014-09</font><i>&#xA0;Revenue
 from Contracts with Customers (Topic 606)</i>,
 or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;on</font>&#xA0;collectability,
 noncash consideration, presentation of sales tax and transition.
 The amendments in&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-12&#xA0;are</font>effective for
 annual reporting periods beginning after December&#xA0;15, 2017
 (i.e., January&#xA0;1, 2018), including interim periods within
 those reporting periods, which is the same as
 for&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;as</font>&#xA0;amended
 by&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2015-14,</font>&#xA0;<i>Revenue
 from Contracts with Customers (Topic 606): Deferral of the
 Effective Date</i>, or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2015-14</font><i>.</i>&#xA0;In April
 2016, the FASB issued&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-10,</font><i>&#xA0;Revenue
 from Contracts with Customers (Topic 606),
 Identifying&#xA0;</i><i>Performance Obligations and
 Licensing</i>, or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-10</font><i>,</i>&#xA0;which
 clarifies the principle for determining whether a good or service
 is &#x201C;separately identifiable&#x201D; from other promises in the
 contract and, therefore, should be accounted for as a separate
 performance obligation. In that
 regard,&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-10&#xA0;requires</font>&#xA0;that
 an entity determine whether its promise is to transfer individual
 goods or services to the customer, or a combined item (or items) to
 which the individual goods and services are inputs. In addition,
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-10&#xA0;categorizes</font>&#xA0;intellectual
 property, or IP, into two categories: &#x201C;functional&#x201D; and
 &#x201C;symbolic.&#x201D; Functional IP has significant standalone
 functionality. All other IP is considered symbolic IP. Revenue from
 licenses of functional IP is generally recognized at a point in
 time, while revenue from licenses of symbolic IP is recognized over
 time.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-10&#xA0;has</font>&#xA0;the
 same effective date and transition requirements
 as&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;as</font>&#xA0;amended
 by&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2015-14.&#xA0;In</font>&#xA0;March
 2016, the FASB issued&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-08,</font><i>&#xA0;Revenue
 from Contracts with Customers (Topic 606), Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)</i>,
 or&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-08,&#xA0;which</font>&#xA0;clarifies
 the implementation guidance on principal versus agent
 considerations contained in&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09</font>&#xA0;by specifying
 that the determination as to whether an entity that is involved in
 providing a good or a service to a customer is a principal or an
 agent is based upon whether the entity controls the good or the
 service before it is transferred to the
 customer.&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-08&#xA0;has</font>&#xA0;the
 same effective date and transition requirements
 as&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;as</font>&#xA0;amended
 by&#xA0;<font style="WHITE-SPACE: nowrap">ASU&#xA0;2015-14.&#xA0;The</font>&#xA0;adoption
 of these ASU&#x2019;s on January&#xA0;1, 2018 did not have a
 material effect on the Company&#x2019;s financial position, results
 of operations or cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In February 2016, the FASB issued
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2016-02,</font>&#xA0;<i>Leases
 (Topic 842)</i>. The FASB issued the update to require the
 recognition of lease assets and liabilities on the balance sheet of
 lessees. The standard will be effective for fiscal years beginning
 after December&#xA0;15, 2018, including interim periods within such
 fiscal years. The ASU requires a modified retrospective transition
 method with the option to elect a package of practical expedients.
 Early adoption is permitted. The Company is currently evaluating
 the potential impact of the adoption of this standard on its
 consolidated results of operations, financial position and cash
 flows and related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2014, the FASB issued ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font><i>&#xA0;Revenue from
 Contracts with Customers</i>, or ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09,</font>&#xA0;which
 provides a single, comprehensive revenue recognition model for all
 contracts with customers. The core principal of
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;is that an
 entity should recognize revenue when it transfers control of
 promised goods or services to customers in an amount that reflects
 the consideration to which the entity expects to be entitled in
 exchange for those goods or services.
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;also
 requires additional disclosure about the nature, amount, timing and
 uncertainty of revenue and cash flows arising from customer
 contracts, including significant judgments and changes in judgments
 and assets recognized from costs incurred to obtain or fulfill a
 contract. ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;is effective
 for annual periods, and interim periods within those annual
 periods, beginning after December&#xA0;15, 2017 for public
 companies and December&#xA0;15, 2018
 for&#xA0;<font style="WHITE-SPACE: nowrap">non-public</font>&#xA0;companies.
 The Company is allowed to adopt ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;either
 (1)&#xA0;retrospectively to each prior reporting period presented
 using several practical expedients related to completed contracts
 and required disclosures, or (2)&#xA0;using a modified
 retrospective approach, with the cumulative effect of initially
 applying ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;recognized
 as an adjustment to the opening balance of retained earnings of the
 annual reporting period that includes the date of initial
 application, including disclosure of the effect of using this
 method of adoption on the financial statement line items. Because
 the Company has no contracts with customers, the adoption of
 ASU&#xA0;<font style="WHITE-SPACE: nowrap">2014-09</font>&#xA0;on
 January&#xA0;1, 2018 did not have a material effect on the
 Company&#x2019;s financial position, results of operations or cash
 flows.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929746976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Accrued Expenses</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Accrued expenses for the period presented were comprised of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Clinical Trial Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,297,893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,859,410</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Compensation and Benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">645,286</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,386,903</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Consulting</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,137,547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,220,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">387,267</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Professional Fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">733,409</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">231,923</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,437</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Travel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">135,664</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,179</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">213,527</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,289,261</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,332,944</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929663808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>4.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Share-Based Compensation</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>2018 and 2016 Equity Incentive Plans</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company maintains the 2018 Incentive Award Plan and 2016 Equity
 Incentive Plan (together, the &#x201C;Plans&#x201D;), under which,
 the Company has granted share options to selected officers,
 employees and&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>consultants. The
 Company&#x2019;s board of directors administer the Plans. Options
 granted under the Plans have a maximum contractual term of ten
 years. Options granted to employees and consultants generally vest
 25% on the first anniversary date of grant and the balance ratably
 over the next 36 months. Options granted to directors generally
 vest on the first anniversary date of grant. Upon the adoption of
 the 2018 Incentive Award Plan, the Company ceased issuing awards
 under the 2016 Equity Incentive Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 A summary of the Company&#x2019;s share option activity related to
 employees,&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;members
 of the board of directors and&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;consultants
 as of and for the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;period
 ended June&#xA0;30, 2018 is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of&#xA0;Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Weighted-<br />
 Average&#xA0;Exercise<br />
 Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Instrinsic&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">938,637</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,420,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">675,685</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.63</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,614,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,884,932</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options outstanding
 as of December&#xA0;31, 2017 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.09</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options outstanding
 as of June&#xA0;30, 2018 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options exercisable at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">186,395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.72</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options exercisable at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">265,221</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">999,410</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options exercisable
 as of December&#xA0;31, 2017 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options exercisable
 as of June&#xA0;30, 2018 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.86</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The total fair value of options vested during the three-month
 periods ended June&#xA0;30, 2018 and 2017 was $247,202 and
 $229,250, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The total fair value of options vested during
 the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended&#xA0;June 30, 2018 and 2017 was $556,349 and $927,915,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017, the Company granted 533,330 and
 0 share options, respectively, to employees
 and&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;members
 of the board of directors. No options were granted during the
 three-month periods ended June&#xA0;30, 2018 and 2017. The grant
 date fair values of the stock options granted to those groups were
 estimated using the Black-Scholes option valuation model with the
 following ranges of assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="81%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2018</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.32%&#xA0;-&#xA0;2.40%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">90%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life of employee and Board of Directors&#x2019; options (in
 years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.5&#xA0;-&#xA0;6.1</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As of June&#xA0;30, 2018, the total compensation expense relating
 to unvested options granted to employees
 and&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;members
 of the board of directors that had not yet been recognized was
 $2,596,655, which is expected to be realized over a period of 3.5
 years. The Company will issue shares upon exercise of options from
 Ordinary Shares reserved.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017, the Company granted 142,355 and
 135,271 share options, respectively
 to&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;consultants.
 No options were granted during the three-month period ended
 June&#xA0;30, 2018. In accordance with
 ASC&#xA0;<font style="WHITE-SPACE: nowrap">505-50,</font>&#xA0;on
 June&#xA0;30, 2017 and 2018, the Company remeasured the fair value,
 of all unvested outstanding options that had been granted
 to&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;consultants
 using the Black-Scholes option valuation model with the following
 ranges of assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2017</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.80%&#xA0;-&#xA0;2.84%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.29%&#xA0;-&#xA0;2.31%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">90%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">80%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life of&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;options
 (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7.7&#xA0;-&#xA0;9.5</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">8.7&#xA0;-&#xA0;9.7</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As of June&#xA0;30, 2018, the total compensation expense relating
 to unvested options granted to&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;consultants
 that had not yet been recognized was $3,823,995, which is expected
 to be realized over a period of 3.5 years. The Company will issue
 shares upon exercise of options from Ordinary Shares reserved.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The weighted average grant date fair value of options granted to
 employees,&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;members
 of the board of directors and&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;consultants
 during the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017 was $5.63 and $6.13,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Restricted Ordinary Shares</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In 2015, in connection with certain service and consulting
 agreements, certain employees and a consultant were awarded an
 aggregate of 867,935 restricted Ordinary Shares of the Company.
 Such shares were subject to forfeiture over a three-year service
 period. The shares granted to the consultant and employees were
 valued at $7.72 and $7.76 per share, respectively, and were
 included in loss from operations over the requisite service period.
 As of June&#xA0;30, 2018, all such shares are no longer subject to
 forfeiture as the three-year service period has been completed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On June&#xA0;7, 2018, 1,306,348 restricted Ordinary Shares, which
 represented 5% of the fully-diluted outstanding shares of the
 Company as of such date, were issued to certain members of senior
 management in accordance with their employment
 agreements.&#xA0;<font style="WHITE-SPACE: nowrap">One-third</font>&#xA0;of such
 shares vested immediately, with the balance vesting quarterly over
 the next eight quarters beginning three months after the
 effectiveness of the Company&#x2019;s registration statement on
 Form&#xA0;<font style="WHITE-SPACE: nowrap">S-1</font>&#xA0;filed with the
 SEC on June&#xA0;7, 2018 (the &#x201C;Registration
 Statement&#x201D;). The shares were valued at $15.00 per share and
 are included in loss from operations over the requisite service
 period. Additionally, under the terms of the employment agreements,
 the Company was required to pay the income taxes incurred by the
 grantees in connection with the grant of those restricted shares.
 Total compensation expense in connection with the issuance of those
 restricted Ordinary Shares, in the amount of $13,620,866, of which
 $6,531,750 was share-based, was recorded as general and
 administrative expense during the three-month period ended
 June&#xA0;30, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 A summary of the restricted Ordinary Shares is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Ordinary&#xA0;Shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">$ Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-vested</font>&#xA0;at
 December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">105,913</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">865,861</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issued during the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;period
 ended June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,306,348</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,595,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting during the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;period
 ended June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(541,363</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,397,611</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-vested</font>&#xA0;at
 June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">870,898</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,063,470</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Ordinary Shares</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On March&#xA0;1, 2018, a funding milestone was met under the
 employment agreements for certain members of senior management.
 Accordingly, the employees were issued an aggregate of 550,162
 fully vested Ordinary Shares, which represented 3% of the
 fully-diluted outstanding shares of the Company as of such date.
 The shares were recorded as share-based compensation in the amount
 of $3,096,104. Additionally, under the terms of the employment
 agreements, the Company was required to pay the income taxes
 incurred by the grantees in connection with the grant of those
 shares. Total compensation expense in connection with the issuance
 of those Ordinary Shares, in the amount of $6,456,215, of which
 $3,096,012 was share-based, was recorded as general and
 administrative expense during the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;period
 ended June&#xA0;30, 2018.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the three-month and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017 the Company recognized total
 share-based compensation expense in the accompanying condensed
 consolidated statements of operations and comprehensive loss as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,045,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">550,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,318,224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">131,427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total share based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,363,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">682,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="8"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,890,511</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,239,923</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,743,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">295,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total share based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,633,556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,535,090</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company does not expect to realize any tax benefits from its
 share option activity or the recognition of share-based
 compensation expense because the Company currently has net
 operating losses and has a full valuation allowance against its
 deferred tax assets. Accordingly, no amounts related to excess tax
 benefits have been reported in cash flows from operations or cash
 flows from financing activities for the three-month
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>periods ended June&#xA0;30,
 2018 and 2017.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633725776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares and Convertible Preferred C Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalHomeLoanBanksAbstract', window );"><strong>Federal Home Loan Banks [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares and Convertible Preferred C Shares</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>5.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Ordinary Shares and Convertible Preferred C
 Shares:</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 <b><i>Ordinary Shares</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 As discussed in Note 3, on March&#xA0;1, 2018, a funding milestone
 was met under the employment agreements for certain members of
 senior management. Accordingly, the employees were issued an
 aggregate of 550,162 fully vested Ordinary Shares.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In connection with the Company&#x2019;s initial public offering, on
 June&#xA0;7, 2018, the Company issued 5,000,000 Ordinary Shares at
 an offering price of $15.00 per share for gross proceeds of
 $75,000,000, excluding offering costs of $9,541,530.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Also as discussed in Note 3, on June&#xA0;7, 2018, upon the
 effectiveness of the Company&#x2019;s Registration Statement,
 1,306,348 restricted Ordinary Shares, which represented 5% of the
 fully-diluted outstanding shares of the Company as of such date,
 were issued to certain members of senior management in accordance
 with their employment agreements. <font style="WHITE-SPACE: nowrap">One-third</font> of such shares vested
 immediately, with the balance vesting quarterly over the next eight
 quarters.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Warrants</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 On June&#xA0;5, 2018, all of the outstanding warrants to purchase
 927,594 Preferred Shares at an exercise price of approximately
 $10.48 per share were exercised for aggregate cash proceeds of
 $9,720,000.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Preferred C Shares</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 During the <font style="WHITE-SPACE: nowrap">six-month</font>
 period ended June&#xA0;30, 2018, the Company issued 5,425,124
 Preferred Shares at an offering price of approximately $10.48 per
 share for gross proceeds of $56,849,592, excluding offering costs
 of $690,473.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Also, during the <font style="WHITE-SPACE: nowrap">six-month</font>
 period ended June&#xA0;30, 2018, the Company issued 129,419
 Preferred Shares in lieu of payment of accounts payable in the
 aggregate amount $1,356,129 to certain vendors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 On March&#xA0;15, 2018, the Company issued 13,360 Preferred Shares
 in connection with a license agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 On June&#xA0;7, 2018, upon effectiveness of the Company&#x2019;s
 Registration Statement on Form <font style="WHITE-SPACE: nowrap">S-1,</font> all of the 11,501,432 outstanding
 Preferred Shares were automatically converted into 11,501,432
 Ordinary Shares. In connection with the conversion of the Preferred
 Shares, $664,718 of unaccredited financing costs were fully
 accreted.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalHomeLoanBanksAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalHomeLoanBanksAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632049312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>6.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Net Loss per Share</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company computes net loss per share in accordance with
 ASC&#xA0;<font style="WHITE-SPACE: nowrap">260-10,</font>&#xA0;<i>Earnings
 per Share</i>&#xA0;(see Note 2).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Basic and diluted net loss per share is computed as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">For&#xA0;the&#xA0;three-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(29,980,832</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,178,719</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of Preferred Shares financing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(666,567</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(30,401</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(475,227</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Adjusted net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,122,626</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,209,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average ordinary shares outstanding:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,611,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,505,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.29</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.85</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="8"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">For&#xA0;the&#xA0;six-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(46,384,185</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,999,104</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of Preferred Shares financing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(761,012</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(53,162</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,045,500</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Adjusted net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(48,190,697</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(14,052,266</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average ordinary shares outstanding:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,280,804</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,545,437</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.27</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.64</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The following securities are considered to be Ordinary Share
 equivalents, but were not included in the computation of diluted
 net loss per Ordinary Share because to do so would have been
 anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Preferred Shares</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,584,469</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 A restricted ordinary shares subject to forfeiture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">870,898</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">245,828</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,614,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">444,473</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,485,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,274,770</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" /></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764206656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Income Taxes</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company did not record a provision for income taxes for the
 three months and six month ended June&#xA0;30, 2018 and 2017, as
 the Company has generated losses for all periods.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company periodically evaluates the realizability of its net
 deferred tax assets based on all available evidence, both positive
 and negative. The realization of net deferred tax assets is
 dependent on the Company&#x2019;s ability to generate sufficient
 future taxable income during periods prior to the expiration of tax
 attributes to fully utilize these assets. The Company weighed both
 positive and negative evidence and determined that there is a
 continued need for a full valuation allowance on its deferred tax
 assets in the United States and United Kingdom as of June&#xA0;30,
 2018. Should the Company determine that it would be able to realize
 its remaining deferred tax assets in the foreseeable future, an
 adjustment to its remaining deferred tax assets would cause a
 material increase to income in the period such determination is
 made.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635383200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>8.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Related Party Transactions:</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Transition Services Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Effective April&#xA0;24, 2015, the Company entered into a
 three-year transition services agreement (the &#x201C;TSA&#x201D;)
 with Kadmon, whereby Kadmon would provide office and laboratory
 facilities as well as certain other personnel support activities to
 the Company. Under the agreement, the Company was charged for
 (i)&#xA0;rent based upon the square footage of the office and
 laboratory facilities used by the Company (ii)&#xA0;other personnel
 support activities based upon the hours of the personnel providing
 the support activities, and (iii)&#xA0;and other direct costs
 incurred by Kadmon on behalf of the Company, plus a 7%
 administrative fee. The TSA terminated on April&#xA0;24, 2018 and
 the Company is currently leasing office space on a month to month
 basis from Kadmon.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the three-month periods ended June&#xA0;30, 2018 and 2017,
 the Company incurred the following charges from Kadmon, which are
 included in loss from operations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">139,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">152,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,746</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">126</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total charges incurred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">139,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">159,041</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017, the Company incurred the
 following charges from Kadmon, which are included in loss from
 operations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">275,674</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">275,524</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,493</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,278</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total charges incurred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">282,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">306,008</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the three-month periods ended June&#xA0;30, 2018 and 2017,
 the Company made cash payments totaling $145,887 and $0,
 respectively, to Kadmon.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017, the Company made cash payments
 totaling $1,143,304 and $275,941, respectively, to Kadmon.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The amount due to Kadmon at June&#xA0;30, 2018 and
 December&#xA0;31, 2017 is $0 and $861,030, respectively and is
 disclosed as Due to Kadmon on the Company&#x2019;s condensed
 consolidated balance sheets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Research Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Effective October&#xA0;23, 2016, the Company entered into a
 four-year master services agreement with UCL Consultants Limited,
 an entity affiliated with University College of London
 (&#x201C;UCL&#x201D;), which is a shareholder of the Company.
 Pursuant to the agreement, UCL Consultants Limited
 provides&#xA0;<font style="WHITE-SPACE: nowrap">pre-clinical</font>&#xA0;research
 and development under the direction of the Company. In connection
 with the agreement, the Company issued several work orders during
 the years ended December&#xA0;31, 2016 and 2017 in the aggregate
 amounts of &#xA3;1,161,149 and &#xA3;241,053, respectively, or
 approximately $1,574,000 and $311,000, based upon the average
 exchange rates during the years ended December&#xA0;31, 2016 and
 2017, respectively. Either party may terminate the agreement by
 giving 30 days written notice.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total research and development expenses under this agreement for
 the three-month periods ended June&#xA0;30, 2018 and 2017 were
 approximately $183,000 and $114,000, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total research and development expenses under this agreement for
 the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017 was approximately $372,000 and
 $222,000, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Future obligations, under the agreement equal &#xA3;797,343, or
 approximately $1,052,791 through October 2020.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The amount due to UCL under the master services agreement at
 June&#xA0;30, 2018 and December&#xA0;31, 2017 is $374,873 and
 $775,315, respectively, and is included in accounts payable and
 accrued expenses on the condensed consolidated balance sheets.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Manufacturing Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Effective September&#xA0;1, 2016, the Company entered into a
 manufacturing and drug supply agreement with UCL. Pursuant to the
 agreement, UCL manufactured materials for the Company&#x2019;s
 clinical trials under the direction of the Company. Either party
 could terminate the agreement by giving 30 days written notice. The
 agreement was terminated in January 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total research and development expenses under this agreement for
 the three-month periods ended June&#xA0;30, 2018 and 2017 was
 approximately $0 and $479,494, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total research and development expenses under this agreement for
 the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017 was approximately $0 and
 $1,042,518, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The amount due to UCL under the manufacturing and drug supply
 agreement at June&#xA0;30, 2018 and December&#xA0;31, 2017 is
 $374,983 and $2,466,142, respectively, and is included in accrued
 expenses in the condensed consolidated balance sheet.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>License Agreement</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Effective March&#xA0;15, 2018, the Company entered into an
 exclusive worldwide license agreement with UCL Business, PLC
 (&#x201C;UCL Business&#x201D;), to develop up to eight programs using
 certain ocular gene therapy technology. Under the terms of the
 agreement, the Company has agreed to pay UCL Business certain sales
 milestone payments, if achieved, in the aggregate amount of
 &#xA3;39.8&#xA0;million, or approximately $52.6&#xA0;million using
 the exchange rate at June&#xA0;30, 2018, and royalties on net
 sales, as defined upon commercialization. Additionally, the Company
 is responsible for all patent prosecution and maintenance costs
 incurred and has also agreed to pay UCL Business an annual
 maintenance fee of &#xA3;50,000, or approximately $66,000, until
 the first commercial sale of a product. The agreement will
 terminate upon the later of (i)&#xA0;the last valid claim in a
 relevant product (ii)&#xA0;the expiration of regulatory exclusivity
 to all licensed products, or (iii)&#xA0;the 10<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">th</sup>&#xA0;anniversary
 of the first commercial sale of a product.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company did not incur any research and development expenses
 under the agreement during the three-month
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Leases</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>December 2016 Lease</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Effective December&#xA0;15, 2016, the Company entered into
 another&#xA0;<font style="WHITE-SPACE: nowrap">non-cancellable</font>&#xA0;operating
 lease with ARE, expiring on October&#xA0;31, 2032, for laboratory
 and office facilities in New York. The lease provided for monthly
 base rent, including rent escalations, property management fees and
 rent holidays, plus operating expenses during the lease term. The
 Company recorded monthly rent expense on a straight-line basis from
 December&#xA0;15, 2016 through October&#xA0;31, 2032. On
 October&#xA0;26, 2017, the lease was amended, whereby the lease
 would terminate on March&#xA0;31, 2018 and only base rent and
 management fees in the aggregate amount of $563,507 would be due
 from November&#xA0;1, 2017 through March&#xA0;31, 2018. Under the
 amendment, the Company issued a note to ARE in the amount of
 $1,442,009, removed the balance of the deferred rent and accrued
 the future rent payments, all of which were recorded as rent
 expense at the time of the amendment, in accordance with ASC 420,
 Exit and Disposal Activities, as the Company had a cease use date
 as of the date of the amendment. Tthe balance of deferred lease
 obligation, representing the difference between cash rent paid and
 straight-line rent expense, was $0 as of December&#xA0;31, 2017 and
 June&#xA0;30, 2018,.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total rent expense under this operating lease was $0 and $390,903
 for the three-month periods ended June&#xA0;30, 2018 and 2017,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total rent expense under this operating lease was $0 and $781,806
 for the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On October&#xA0;26, 2017, in connection with the amendment to the
 lease, the Company issued a promissory note in the amount of
 $1,442,009 to ARE. The note accrued interest at the rate of 5% per
 annum and was due on December&#xA0;31, 2018. However, if the
 Company had sufficient liquidity, as defined in the note, then the
 note, including accrued interest, would become due and payable at
 that time. In accordance with the sufficient liquidity provision,
 the Company repaid the note, plus accrued interest, in the
 aggregate amount of $1,472,433 during the three-month period ended
 March&#xA0;31, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company recorded interest expense of $0 and $30,424 for the
 three-month and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>July 2016 Lease</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Effective July&#xA0;1, 2016, the Company entered into
 a&#xA0;<font style="WHITE-SPACE: nowrap">non-cancellable</font>&#xA0;operating
 lease for laboratory and related office facilities in New York with
 ARE, an entity that is under common control by an entity that is a
 minority shareholder of the Company and whose CEO is a director of
 the Company. The lease provides for monthly base rent and property
 management fees, including rent escalations and rent holidays, plus
 operating expenses during the lease term, which expires on
 December&#xA0;31, 2021. The Company records monthly rent expense on
 a straight-line basis from July&#xA0;1, 2016 through
 December&#xA0;31, 2021. As of June&#xA0;30, 2018 and
 December&#xA0;31, 2017, the balance of deferred rent, representing
 the difference between cash rent paid and straight-line rent
 expense, was $220,722 and $231,276, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total rent expense under this operating lease was $121,890 and
 $121,890 for the three-month periods ended June&#xA0;30, 2018 and
 2017, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Total rent expense under this operating lease was $243,780 and
 $243,780 for the&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As of June&#xA0;30, 2018, the aggregate future minimum rental
 payments under this lease are $1,927,187.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 In connection with the signing of this lease, the Company entered
 into a standby letter of credit agreement for $122,866, which
 serves as a security deposit for the premises. The standby letter
 of credit expires on July&#xA0;7, 2017 and is automatically renewed
 annually through July&#xA0;7, 2021. This standby letter of credit
 is secured with restricted cash in a money market account.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6639463440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>9.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Subsequent Events:</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Management has evaluated subsequent events through the date of this
 filing. Based on our evaluation, the following disclosures have
 been made:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 On July&#xA0;27, 2018 two leases for office and laboratory
 facilities in London, UK expired. Effective July&#xA0;27, 2018, the
 Company entered into two new <font style="WHITE-SPACE: nowrap">non-cancellable</font> operating leases for
 the same office and laboratory facilities in London. The leases
 provide for annual base rent in the aggregate amount of
 approximately $363,000, plus operating expenses, through
 May&#xA0;31, 2022, at which time the annual base rent will be
 revalued based on market rates at that time. The leases expire on
 May&#xA0;24, 2027.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773011360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_DescriptionOfBusinessPolicyPolicyTextBlock', window );">The Company</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b><i>The Company</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 MeiraGTx Holdings plc, a limited company under the laws of the
 Cayman Islands, is a clinical-stage biotech company developing
 novel gene therapy treatments for a wide range of inherited and
 acquired disorders for which there are no effective treatments
 available. The Company is focused on developing therapies for
 ocular diseases, including rare inherited blindness as well as
 Xerostomia following radiation treatment for head and neck cancers
 and neurodegenerative diseases such as amyothrophic lateral
 sclerosis (&#x201C;ALS&#x201D;).</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_RiskAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Risks and Uncertainties</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company operates in an industry that is subject to intense
 competition, government regulation and rapid technological change.
 The Company&#x2019;s operations are subject to significant risk and
 uncertainties including financial, operational, technological,
 regulatory and other risks, including the potential risk of
 business failure.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company&#x2019;s limited capital resources and operations to
 date have been funded primarily with the proceeds from private
 equity offerings and the IPO. In the future, the Company may seek
 to raise additional capital through equity offerings, debt
 financings, marketing and distribution arrangements and other
 collaborations, strategic alliances and licensing arrangements or
 other sources to enable it to complete the development and
 potential commercialization of its product candidates.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b><i>Basis of Presentation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The accompanying condensed consolidated financial statements have
 been prepared in conformity with accounting principles generally
 accepted in the United States of America (&#x201C;GAAP&#x201D;). Any
 reference in these notes to applicable guidance is meant to refer
 to the authoritative United States generally accepted accounting
 principles as found in the Accounting Standards Codification
 (&#x201C;ASC&#x201D;) and Accounting Standards Update
 (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board
 (&#x201C;FASB&#x201D;).</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ReverseStockSplitPolicyTextBlock', window );">Reverse Share Split</a></td>
<td class="text"><div>
 <div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b><i>Reverse Share Split</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On June&#xA0;7, 2018 MeiraGTx Limited&#x2019;s Board of Directors
 and shareholders approved a 1:3.881 reverse share split. All share
 information presented in these financial statements and
 accompanying footnotes have been retroactively adjusted to reflect
 the decreased number of shares resulting from this action.</p>
 </div>
 <div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 &#xA0;</p>
 </div>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i>Liquidity</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company has not generated any revenues and has not yet achieved
 profitable operations. There is no assurance that profitable
 operations, if ever achieved, could be sustained on a continuing
 basis. In addition, development activities, clinical and
 preclinical testing, and commercialization of the Company&#x2019;s
 product candidates will require significant additional financing.
 Management expects to incur substantial and increasing losses in
 future periods. The success of the Company is subject to certain
 risks and uncertainties, including among others, uncertainty of
 product development; competition in the Company&#x2019;s field of
 use; uncertainty of capital availability; uncertainty in the
 Company&#x2019;s ability to enter into agreements with collaborative
 partners; dependence on third parties; and dependence on key
 personnel. The Company has not generated positive cash flows from
 operations, and there are no assurances that the Company will be
 successful in obtaining an adequate level of financing for the
 development and commercialization of its product candidates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 As of June&#xA0;30, 2018, the Company had cash and cash equivalents
 in the amount of $102,060,551, which consisted of depository
 accounts. The Company estimates that its cash and cash equivalents
 on hand at June&#xA0;30, 2018 will cover its expenses into the
 second quarter of 2020.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock', window );">Reorganization and Initial Public Offering</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b><i>Reorganization and Initial Public Offering</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 On May&#xA0;28, 2018, the Board of Directors of MeiraGTx Limited
 approved the Reorganization Transactions, effective June&#xA0;7,
 2018, pursuant to which the Board of Directors approved the
 transfer of the shares held by each of the MeiraGTx Limited&#x2019;s
 shareholders for the equivalent class and number of shares issued
 by Meira Holdings. On June&#xA0;7, 2018, the Company completed its
 IPO, selling 5,000,000 Series A ordinary shares (&#x201C;Ordinary
 Shares&#x201D;) at a public offering price of $15.00 per share, and
 receiving $65.9&#xA0;million in net proceeds, after deducting
 underwriting discounts and commissions and offering expenses
 payable by us.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_InterimFinancialStatementsPolicyTextBlock', window );">Interim Financial Statements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 <b><i>Interim Financial Statements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">
 The accompanying condensed consolidated financial statements have
 been prepared in accordance with GAAP for interim financial
 information and with the instructions
 to&#xA0;Form&#xA0;<font style="WHITE-SPACE: nowrap">10-Q</font>&#xA0;and Article 10
 of Regulation&#xA0;<font style="WHITE-SPACE: nowrap">S-X.</font>Accordingly, they do not include
 all the information and footnotes required by generally accepted
 accounting principles for complete consolidated financial
 statements. In the opinion of management, the condensed
 consolidated financial statements include all adjustments
 (consisting of normal recurring accruals) necessary in order to
 make the condensed consolidated financial statements not
 misleading. Operating results for the three-month
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018&#xA0;are not necessarily indicative of the
 final results that may be expected for the year ended
 December&#xA0;31, 2018. These unaudited condensed consolidated
 financial statements should be read in conjunction with the audited
 consolidated financial statements&#xA0;for the year ended
 December&#xA0;31, 2017 and the notes thereto for the year ended
 December&#xA0;31, 2017 included in the Company&#x2019;s final
 prospectus that forms a part of the Company&#x2019;s Registration
 Statement on Form&#xA0;<font style="WHITE-SPACE: nowrap">S-1</font>&#xA0;(Reg.&#xA0;<font style="WHITE-SPACE: nowrap">No.&#xA0;333-224914),</font>&#xA0;filed
 with the Securities and Exchange Commission (&#x201C;SEC&#x201D;)
 pursuant to Rule 424(b)(4) on June&#xA0;8, 2018 (the
 &#x201C;Prospectus&#x201D;).</p>
 <div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 &#xA0;</p>
 </div>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Consolidation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The accompanying condensed consolidated financial statements
 include the accounts of Meira Holdings and its wholly owned
 subsidiaries:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx Limited, a limited company under the laws of England and
 Wales (&#x201C;Meira Limited);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx, LLC, a Delaware corporation (&#x201C;Meira
 LLC&#x201D;);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 BRI-Alzan, Inc., a Delaware corporation
 (&#x201C;BRI-Alzan&#x201D;);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx B.V., a Netherlands corporation (&#x201C;Meira
 BV&#x201D;);</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx UK II Limited, (&#x201C;Meira UK II&#x201D;), a limited
 company under the laws of England and Wales;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 MeiraGTx UK Limited (&#x201C;Meira UK&#x201D;), a limited company
 under the laws of England and Wales.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 All intercompany balances and transactions between the consolidated
 companies have been eliminated in consolidation.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Management considers many factors in selecting appropriate
 financial accounting policies and controls, and in developing the
 estimates and assumptions that are used in the preparation of these
 consolidated financial statements. Management must apply
 significant judgment in this process. In addition, other factors
 may affect estimates, including expected business and operational
 changes, sensitivity and volatility associated with the assumptions
 used in developing estimates, and whether historical trends are
 expected to be representative of future trends. The estimation
 process often may yield a range of potentially reasonable estimates
 of the ultimate future outcomes and management must select an
 amount that falls within that range of reasonable estimates. This
 process may result in actual results differing materially from
 those estimated amounts used in the preparation of the consolidated
 financial statements if these results differ from historical
 experience, or other assumptions do not turn out to be
 substantially accurate, even if such assumptions are reasonable
 when made. In preparing these consolidated financial statements,
 management used significant estimates in the following areas, among
 others: valuation of A ordinary shares (&#x201C;Ordinary
 Shares&#x201D;) issued prior to the Company&#x2019;s initial public
 offering, for the acquisition of assets, the accounting for
 research and development costs, warrants, share based compensation,
 asset retirement obligations and accrued expenses.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Fair Value Measurements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Fair value is defined as the price that would be received upon sale
 of an asset or paid upon transfer of a liability in an orderly
 transaction between market participants at the measurement date and
 in the principal or most advantageous market for that asset or
 liability. The fair value should be calculated based on assumptions
 that market participants would use in pricing the asset or
 liability, not on assumptions specific to the entity. In addition,
 the fair value of liabilities should include consideration of
 <font style="WHITE-SPACE: nowrap">non-performance</font> risk
 including our own credit risk.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The Company follows ASC Topic 820, <i>Fair Value Measurements and
 Disclosures</i>, or ASC 820, for application to financial assets.
 In addition to defining fair value, the standard expands the
 disclosure requirements around fair value and establishes a fair
 value hierarchy for valuation inputs. The hierarchy prioritizes the
 inputs into three levels based on the extent to which inputs used
 in measuring fair value are observable in the market. Each fair
 value measurement is reported in one of the three levels which are
 determined by the lowest level input that is significant to the
 fair value measurement in its entirety. These levels are:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Level&#xA0;1: Observable inputs such as quoted prices
 in active markets for identical assets the reporting entity has the
 ability to access as of the measurement date;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Level&#xA0;2: Inputs, other than the quoted prices in
 active markets, that are observable either directly or indirectly;
 and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">Level&#xA0;3: Unobservable inputs in which there is
 little or no market data, which require the reporting entity to
 develop its own assumptions.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The table below represents the values of the Compnay&#x2019;s
 financial assets and liabilities that are required to be measured
 at fair value on a recurring basis:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair Value Measurement Using:</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Observable&#xA0;Inputs<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant&#xA0;Other<br />
 Observable&#xA0;Inputs<br />
 (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair Value Measurement Using:</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,<br />
 2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Observable Inputs<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other<br />
 Observable Inputs<br />
 (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 6px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 The table below represents a rollforward of the assets and
 liabilities that are required to be measured at fair value on a
 recurring basis from December&#xA0;31, 2017 to June&#xA0;30,
 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable&#xA0;Inputs<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in fair value of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,514,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,194,408</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The warrants were classified as liabilities because the underlying
 Preferred Shares had a redemption feature in the event of a change
 of control of the Company. On June&#xA0;5, 2018, the warrants were
 exercised at which time the warrant liability was determined to be
 $4,194,408, which represented the difference in the market value of
 the Preferred Shares and the exercise price of the warrants. This
 resulted in an increase of the warrant liability in the amount of
 $2,184,183 and $1,514,775 for the three-month and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018, respectively. The related warrant liability of $4,194,408 was
 reclassified as Capital in Excess of Nominal Value at such
 time.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The fair values of the warrants at December&#xA0;31, 2017,
 March&#xA0;31, 2018 and June&#xA0;4, 2018 were estimated using the
 Black-Scholes valuation model with the following assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,&#xA0;2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March&#xA0;31,&#xA0;2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;4,&#xA0;2018</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.72</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.86</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.77</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9&#xA0;months</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.5&#xA0;months</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1&#xA0;day</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 For the unobservable inputs for the warrants, the expected
 volatility was determined at each measurement date by taking an
 average of the volatility of other publicly-traded peer
 biotechnology companies. The expected life was determined at each
 measurement date based upon the Company&#x2019;s estimate of the
 time until the Company has a conversion event.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The fair value of the Preferred Shares was based upon recent
 issuances of the Company&#x2019;s Preferred Shares on or about
 December&#xA0;31, 2017, March&#xA0;31, 2018 and June&#xA0;5,
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The estimated fair values of the Company&#x2019;s warrants are not
 necessarily indicative of the amounts that would be realized in a
 current market exchange. The determination of the fair value of the
 warrants are sensitive to changes in in the assumptions used and a
 change in those inputs could result in a significantly higher or
 lower fair value measurement. If the volatility were to increase or
 the expected life were to increase, the fair value of the warrant
 would increase. Conversely, if the volatility were to decrease or
 the expected life were to decrease, the fair value of the warrant
 would decrease.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Ordinary Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Net Loss per Ordinary Share</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Basic net loss per Ordinary Share is computed by dividing net loss
 attributable to the Company&#x2019;s shareholders by the weighted
 average number of shares of the Company&#x2019;s Ordinary Shares
 assumed to be outstanding during the period of computation. Diluted
 net loss per ordinary share is computed similar to basic net loss
 per share except that the denominator is increased to include the
 number of additional Ordinary Shares that would have been
 outstanding if the potential ordinary shares had been issued at the
 beginning of the year and if the additional ordinary shares were
 dilutive (treasury stock method) or the <font style="WHITE-SPACE: nowrap">two-class</font> method, whichever is more
 dilutive. For all periods presented, basic and diluted net loss per
 Ordinary Share are the same, as any additional Ordinary Share
 equivalents would be anti-dilutive.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsPolicy', window );">Asset Retirement Obligation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i>Asset Retirement Obligation</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 Accounting for Asset Retirement Obligations requires legal
 obligations associated with the retirement of long-lived assets to
 be recognized at fair value when incurred and capitalized as part
 of the related long-lived asset. In the absence of quoted market
 prices, we estimate the fair value of our asset retirement
 obligations using Level&#xA0;3 present value techniques, in which
 estimates of future cash flows associated with retirement
 activities are discounted using a credit-adjusted risk-free rate.
 Asset retirement obligations currently reported as other
 liabilities on our Consolidated Balance Sheet were measured during
 a period of historically low interest rates. The impact on
 measurements of new asset retirement obligations using different
 rates in the future may be significant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The Company uses estimates to determine the amount of the asset
 retirement obligations at the end of the lease term and discounts
 such asset retirement obligations using an estimated discount rate.
 Interest on the discounted asset retirement obligation is amortized
 over the term of the lease using the effective interest method and
 is recorded as interest expense in the consolidated statements of
 operations and comprehensive loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The change in asset retirement obligations is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 For&#xA0;the&#xA0;six&#xA0;month&#xA0;period<br />
 ended June&#xA0;30, 2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">For&#xA0;the&#xA0;year&#xA0;ended<br />
 December&#xA0;31,&#xA0;2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at beginning of period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">221,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Amortization of interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,313</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in estimate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(75,011</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effects of exchange rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,391</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,863</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at end of period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">180,350</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt">
 <b><i>Research and Development</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to, employee-related
 expenses, including salaries, benefits and travel of the
 Company&#x2019;s research and development personnel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical and preclinical studies
 and manufacture the drug product for the clinical studies and
 preclinical activities; acquisition of <font style="WHITE-SPACE: nowrap">in-process</font> research and development;
 facilities; supplies; rent, insurance, certain legal fees,
 stock-based compensation, depreciation and other costs associated
 with clinical and preclinical activities and regulatory operations.
 Refundable research and development tax credits received are
 recorded as an offset to these costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Costs for certain development activities, such as Company funded
 outside research programs, are recognized based on an evaluation of
 the progress to completion of specific tasks with respect to their
 actual costs incurred. Payments for these activities are based on
 the terms of the individual arrangements, which may differ from the
 pattern of costs incurred, and are reflected in the financial
 statements as prepaid or accrued research and development expense,
 as the case may be.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Segment Information</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Management has concluded it has a single reporting segment for
 purposes of reporting financial condition and results of
 operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The following table summarizes&#xA0;<font style="WHITE-SPACE: nowrap">non-current</font>&#xA0;assets
 by geographical area:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">413,481</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">436,463</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United Kingdom</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,277,701</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,942,642</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,691,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">14,379,105</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 <b><i>Recent Accounting Pronouncements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In June&#xA0;2018, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2018-07,</font> Improvements to Nonemployee
 Share-Based Accounting, which simplifies the accounting for
 share-based payments granted to nonemployees for goods and
 services. The ASU supersedes ASC <font style="WHITE-SPACE: nowrap">505-50</font> and expands the scope of ASC
 718 to include <i>all</i> share-based payment arrangements related
 to the acquisition of goods and services from both nonemployees and
 employees. As a result, most of the guidance in ASC 718 associated
 with employee share-based payments, including most of its
 requirements related to classification and measurement, applies to
 nonemployee share-based payment arrangements.&#xA0;ASU <font style="WHITE-SPACE: nowrap">2018-07</font> generally requires an entity
 to use a modified retrospective transition approach, with a
 cumulative-effect adjustment to retained earnings as of the
 beginning of the fiscal year, for all (1)&#xA0;liability-classified
 nonemployee awards that have not been settled as of the adoption
 date and (2)&#xA0;equity-classified nonemployee awards for which a
 measurement date has not been established. The guidance is
 applicable to public business entities for fiscal years beginning
 after December&#xA0;15, 2019 and interim periods within those
 years. The Company is currently evaluating the potential impact of
 the adoption of this standard on its consolidated results of
 operations, financial position and cash flows and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In January 2017, the FASB issued <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2017-01,</font><i>&#xA0;Business
 Combinations (Topic 805), Clarifying the Definition of a
 Business,</i>&#xA0;or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01</font><i>,</i>&#xA0;that
 clarifies the definition of a business to assist entities with
 evaluating whether transactions should be accounted for as
 acquisitions (or disposals) of assets or businesses. <font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01</font> requires an entity to
 evaluate if substantially all of the&#xA0;fair value of the gross
 assets acquired or disposed of is concentrated in a single
 identifiable asset or a group of similar identifiable assets; if
 so, the set of transferred assets and activities is not a business.
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01&#xA0;also</font>
 requires a business to include at least an input and one
 substantive process that together significantly contribute to the
 ability to create output and removes the evaluation of whether a
 market participant could replace missing elements. <font style="WHITE-SPACE: nowrap">ASU&#xA0;2017-01&#xA0;should</font> be
 applied prospectively and is effective for annual periods beginning
 after December&#xA0;15, 2017 and interim periods within those
 annual periods. The adoption of ASU <font style="WHITE-SPACE: nowrap">2017-01</font> on January&#xA0;1, 2018 did
 not have a material effect on the Company&#x2019;s financial
 position, results of operations or cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In December 2016, the FASB <font style="WHITE-SPACE: nowrap">issued&#xA0;ASU&#xA0;No.&#xA0;2016-20,</font><i>&#xA0;Technical
 Corrections and Improvements to Topic 606, Revenue from Contracts
 with Customers,</i><font style="WHITE-SPACE: nowrap">&#xA0;or&#xA0;ASU&#xA0;2016-20,&#xA0;that&#xA0;allows</font>
 entities not to disclose variable consideration allocated to
 performance obligations related to either: (1)&#xA0;sales&#x2014;or
 usage -based royalties on licenses of intellectual property or
 (2)&#xA0;variable consideration allocated entirely to a wholly
 unsatisfied performance obligation or to a wholly unsatisfied
 promise to transfer a distinct good or service that forms part of a
 single performance obligation when certain criteria are
 <font style="WHITE-SPACE: nowrap">met.&#xA0;ASU&#xA0;2016-20&#xA0;also&#xA0;requires</font>
 entities that use any of the new or previously existing optional
 exemptions to expand their qualitative disclosures. It also makes
 12 additional technical corrections and improvements to the new
 revenue standard, <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09.</font> The amendments have
 the same effective date and transition requirements as <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09.</font> The adoption of
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-20</font> did not
 have a material effect on its financial position, results of
 operations or cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In November 2016, the Financial Accounting Standards Board, or FASB
 issued <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-18,</font><i>&#xA0;Statement
 of Cash Flows (Topic 230), Restricted Cash</i>&#xA0;(a consensus of
 the Emerging Issues Task Force), or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18,&#xA0;which</font> changes
 the presentation of the cash flow statement to include amounts
 generally described as restricted cash or restricted cash
 equivalents, together with cash and cash equivalents, when
 reconciling <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">the&#xA0;beginning-of-period&#xA0;and&#xA0;end-of-period&#xA0;amounts</font></font></font></font>
 shown on the statement of cash flows. <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18&#xA0;also</font> requires
 additional disclosures concerning the nature of the restrictions on
 cash and cash equivalents and a reconciliation between amounts of
 cash, cash equivalents and restricted cash on the balance sheet and
 statement of cash flows for each period presented. <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18&#xA0;will</font> be applied
 retrospectively to all periods presented and is effective for
 public business entities for fiscal years beginning after
 December&#xA0;15, 2017, and interim periods within those fiscal
 years. Early adoption is permitted, including adoption in an
 interim period. Prior to adoption, the Company presented changes in
 restricted cash as an operating activity in the statement of cash
 flows. Upon adoption of <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-18</font> on January&#xA0;1,
 2018,&#xA0;such changes are now reflected in the beginning and
 ending balances of cash, cash equivalents and restricted cash for
 all periods presented.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In October 2016, the FASB issued <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-16,&#xA0;Income</font> Taxes
 (Topic 740):<i>&#xA0;Intra-Entity Transfers of Assets Other than
 Inventory</i>, or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-16&#xA0;which</font> requires
 that an entity recognize the income tax consequences of an
 intra-entity transfer of assets other than inventory when the
 transfer occurs. The guidance must be applied using the modified
 retrospective basis. The Company does not expect the provisions of
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-16&#xA0;to</font>
 have a material impact on its current financial statements. This
 update will be effective for the Company at the beginning of fiscal
 2019.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In May 2016, the FASB issued <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-12</font><i>, Revenue
 from Contracts with Customers (Topic 606), Narrow-Scope
 Improvements and Practical Expedients</i>, or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-12,&#xA0;which</font> amends
 guidance in the new revenue standard, <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2014-09</font><i>&#xA0;Revenue
 from Contracts with Customers (Topic 606)</i>, or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;on</font>
 collectability, noncash consideration, presentation of sales tax
 and transition. The amendments in <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-12&#xA0;are</font> effective
 for annual reporting periods beginning after December&#xA0;15, 2017
 (i.e., January&#xA0;1, 2018), including interim periods within
 those reporting periods, which is the same as for <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;as</font> amended by
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2015-14,</font>
 <i>Revenue from Contracts with Customers (Topic 606): Deferral of
 the Effective Date</i>, or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2015-14</font><i>.</i>&#xA0;In April
 2016, the FASB issued <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-10,</font><i>&#xA0;Revenue
 from Contracts with Customers (Topic 606), Identifying</i>
 <i>Performance Obligations and Licensing</i>, or <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-10</font><i>,</i>&#xA0;which
 clarifies the principle for determining whether a good or service
 is &#x201C;separately identifiable&#x201D; from other promises in the
 contract and, therefore, should be accounted for as a separate
 performance obligation. In that regard, <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-10&#xA0;requires</font> that an
 entity determine whether its promise is to transfer individual
 goods or services to the customer, or a combined item (or items) to
 which the individual goods and services are inputs. In addition,
 ASU <font style="WHITE-SPACE: nowrap">2016-10&#xA0;categorizes</font> intellectual
 property, or IP, into two categories: &#x201C;functional&#x201D; and
 &#x201C;symbolic.&#x201D; Functional IP has significant standalone
 functionality. All other IP is considered symbolic IP. Revenue from
 licenses of functional IP is generally recognized at a point in
 time, while revenue from licenses of symbolic IP is recognized over
 time. <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-10&#xA0;has</font> the same
 effective date and transition requirements as <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;as</font> amended by
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;2015-14.&#xA0;In</font>
 March 2016, the FASB issued <font style="WHITE-SPACE: nowrap">ASU&#xA0;No.&#xA0;2016-08,</font><i>&#xA0;Revenue
 from Contracts with Customers (Topic 606), Principal versus Agent
 Considerations (Reporting Revenue Gross versus Net)</i>, or
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-08,&#xA0;which</font> clarifies
 the implementation guidance on principal versus agent
 considerations contained in <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09</font>&#xA0;by specifying
 that the determination as to whether an entity that is involved in
 providing a good or a service to a customer is a principal or an
 agent is based upon whether the entity controls the good or the
 service before it is transferred to the customer. <font style="WHITE-SPACE: nowrap">ASU&#xA0;2016-08&#xA0;has</font> the same
 effective date and transition requirements as <font style="WHITE-SPACE: nowrap">ASU&#xA0;2014-09,&#xA0;as</font> amended by
 <font style="WHITE-SPACE: nowrap">ASU&#xA0;2015-14.&#xA0;The</font>
 adoption of these ASU&#x2019;s on January&#xA0;1, 2018 did not have
 a material effect on the Company&#x2019;s financial position,
 results of operations or cash flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In February 2016, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2016-02,</font> <i>Leases (Topic 842)</i>.
 The FASB issued the update to require the recognition of lease
 assets and liabilities on the balance sheet of lessees. The
 standard will be effective for fiscal years beginning after
 December&#xA0;15, 2018, including interim periods within such
 fiscal years. The ASU requires a modified retrospective transition
 method with the option to elect a package of practical expedients.
 Early adoption is permitted. The Company is currently evaluating
 the potential impact of the adoption of this standard on its
 consolidated results of operations, financial position and cash
 flows and related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 In May 2014, the FASB issued ASU <font style="WHITE-SPACE: nowrap">2014-09,</font><i>&#xA0;Revenue from
 Contracts with Customers</i>, or ASU <font style="WHITE-SPACE: nowrap">2014-09,</font> which provides a single,
 comprehensive revenue recognition model for all contracts with
 customers. The core principal of ASU <font style="WHITE-SPACE: nowrap">2014-09</font> is that an entity should
 recognize revenue when it transfers control of promised goods or
 services to customers in an amount that reflects the consideration
 to which the entity expects to be entitled in exchange for those
 goods or services. ASU <font style="WHITE-SPACE: nowrap">2014-09</font> also requires additional
 disclosure about the nature, amount, timing and uncertainty of
 revenue and cash flows arising from customer contracts, including
 significant judgments and changes in judgments and assets
 recognized from costs incurred to obtain or fulfill a contract. ASU
 <font style="WHITE-SPACE: nowrap">2014-09</font> is effective for
 annual periods, and interim periods within those annual periods,
 beginning after December&#xA0;15, 2017 for public companies and
 December&#xA0;15, 2018 for <font style="WHITE-SPACE: nowrap">non-public</font> companies. The Company is
 allowed to adopt ASU <font style="WHITE-SPACE: nowrap">2014-09</font> either
 (1)&#xA0;retrospectively to each prior reporting period presented
 using several practical expedients related to completed contracts
 and required disclosures, or (2)&#xA0;using a modified
 retrospective approach, with the cumulative effect of initially
 applying ASU <font style="WHITE-SPACE: nowrap">2014-09</font>
 recognized as an adjustment to the opening balance of retained
 earnings of the annual reporting period that includes the date of
 initial application, including disclosure of the effect of using
 this method of adoption on the financial statement line items.
 Because the Company has no contracts with customers, the adoption
 of ASU <font style="WHITE-SPACE: nowrap">2014-09</font> on
 January&#xA0;1, 2018 did not have a material effect on the
 Company&#x2019;s financial position, results of operations or cash
 flows.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_DescriptionOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description Of Business Policy Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_DescriptionOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_InterimFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interim Financial Statements Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_InterimFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reorganization And Initial Public Offering Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ReorganizationAndInitialPublicOfferingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse Stock Split [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RiskAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk and Uncertainties, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RiskAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal obligation associated with retirement of long-lived asset that results from acquisition, construction, or development or from normal operation of long-lived asset. Excludes environmental remediation liability from improper or other-than-normal operation of long-lived asset, obligation arising in connection with leased property that meets definition of lease payments or variable lease payments and from plan to sell or otherwise dispose of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929566848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Compnay's Financial Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The table below represents the values of the Compnay&#x2019;s
 financial assets and liabilities that are required to be measured
 at fair value on a recurring basis:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair Value Measurement Using:</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Observable&#xA0;Inputs<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant&#xA0;Other<br />
 Observable&#xA0;Inputs<br />
 (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">Fair Value Measurement Using:</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; DISPLAY: table-cell">
 Description</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,<br />
 2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Observable Inputs<br />
 (Level 1)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant Other<br />
 Observable Inputs<br />
 (Level 2)</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">123,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt">
 The table below represents a rollforward of the assets and
 liabilities that are required to be measured at fair value on a
 recurring basis from December&#xA0;31, 2017 to June&#xA0;30,
 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Significant<br />
 Unobservable&#xA0;Inputs<br />
 (Level 3)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,679,633</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in fair value of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,514,775</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(4,194,408</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance as of June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The fair values of the warrants at December&#xA0;31, 2017,
 March&#xA0;31, 2018 and June&#xA0;4, 2018 were estimated using the
 Black-Scholes valuation model with the following assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December&#xA0;31,&#xA0;2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March&#xA0;31,&#xA0;2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;4,&#xA0;2018</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.72</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.86</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.77</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">80</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9&#xA0;months</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.5&#xA0;months</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1&#xA0;day</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock', window );">Schedule of change in asset retirement obligations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt; TEXT-INDENT: 4%">
 The change in asset retirement obligations is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 For&#xA0;the&#xA0;six&#xA0;month&#xA0;period<br />
 ended June&#xA0;30, 2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">For&#xA0;the&#xA0;year&#xA0;ended<br />
 December&#xA0;31,&#xA0;2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at beginning of period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">221,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Amortization of interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,313</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in estimate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(75,011</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effects of exchange rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(5,391</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,863</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Balance at end of period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">180,350</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178,419</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Summary of Non-Current Assets by Geographical Area</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 The following table summarizes <font style="WHITE-SPACE: nowrap">non-current</font> assets by geographical
 area:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">413,481</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">436,463</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United Kingdom</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,277,701</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,942,642</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,691,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,379,105</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in carrying amount of a liability for asset retirement obligations, for changes such as new obligations, changes in estimates of existing obligations, spending on existing obligations, property dispositions, and foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6393242&amp;loc=d3e13201-110859<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangeInAssetRetirementObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764163392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 Accrued expenses for the period presented were comprised of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Clinical Trial Costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,297,893</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,859,410</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Compensation and Benefits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">645,286</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,386,903</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Consulting</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,137,547</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,220,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,683</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">387,267</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Professional Fees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">733,409</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">231,923</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">33,437</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Travel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">135,664</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,179</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">213,527</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,289,261</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,332,944</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6639806080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 A summary of the Company&#x2019;s share option activity related to
 employees, <font style="WHITE-SPACE: nowrap">non-employee</font>
 members of the board of directors and <font style="WHITE-SPACE: nowrap">non-employee</font> consultants as of and for
 the <font style="WHITE-SPACE: nowrap">six-month</font> period ended
 June&#xA0;30, 2018 is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="57%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number&#xA0;of&#xA0;Options</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted-<br />
 Average&#xA0;Exercise<br />
 Price</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Aggregate<br />
 Instrinsic&#xA0;Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">938,637</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.12</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,420,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">675,685</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5.63</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,614,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.34</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,884,932</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options outstanding
 as of December&#xA0;31, 2017 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.09</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options outstanding
 as of June&#xA0;30, 2018 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options exercisable at December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">186,395</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.72</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options exercisable at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">265,221</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">999,410</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options exercisable
 as of December&#xA0;31, 2017 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.21</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted average remaining contractual life of options exercisable
 as of June&#xA0;30, 2018 (yrs)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.86</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Grant Date Fair Values of the Stock Option Granted</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The grant date fair values of the stock options granted to those
 groups were estimated using the Black-Scholes option valuation
 model with the following ranges of assumptions:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="81%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2018</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.32%&#xA0;-&#xA0;2.40%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">90%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life of employee and Board of Directors&#x2019; options (in
 years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.5&#xA0;-&#xA0;6.1</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" align="center"><b>2017</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.80%&#xA0;-&#xA0;2.84%</font></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">2.29%&#xA0;-&#xA0;2.31%</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">90%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">80%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected life of&#xA0;<font style="WHITE-SPACE: nowrap">non-employee</font>&#xA0;options
 (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7.7&#xA0;-&#xA0;9.5</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">8.7&#xA0;-&#xA0;9.7</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Ordinary Shares</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 A summary of the restricted Ordinary Shares is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Ordinary&#xA0;Shares</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">$ Value</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-vested</font> at
 December&#xA0;31, 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">105,913</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">865,861</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issued during the <font style="WHITE-SPACE: nowrap">six-month</font> period ended June&#xA0;30,
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,306,348</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,595,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting during the <font style="WHITE-SPACE: nowrap">six-month</font> period ended June&#xA0;30,
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(541,363</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,397,611</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-vested</font> at
 June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">870,898</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,063,470</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Share Based Compensation Expense</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 49px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 During the three-month and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018 and 2017 the Company recognized total
 share-based compensation expense in the accompanying condensed
 consolidated statements of operations and comprehensive loss as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="73%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,045,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">550,708</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,318,224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">131,427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total share based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">8,363,785</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">682,135</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="8"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,890,511</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,239,923</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,743,045</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">295,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total share based compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">12,633,556</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,535,090</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6614249568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 49px; MARGIN-TOP: 6pt">
 Basic and diluted net loss per share is computed as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <br class="Apple-interchange-newline" />
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">For&#xA0;the&#xA0;three-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(29,980,832</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,178,719</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of Preferred Shares financing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(666,567</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(30,401</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(475,227</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Adjusted net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,122,626</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(7,209,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average ordinary shares outstanding:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,611,452</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,505,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.29</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.85</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1pt">
 <td height="16"></td>
 <td height="16" colspan="8"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">For&#xA0;the&#xA0;six-month&#xA0;periods&#xA0;ended&#xA0;June&#xA0;30,</font></b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(46,384,185</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(13,999,104</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of Preferred Shares financing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(761,012</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(53,162</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accretion of warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,045,500</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Adjusted net loss&#x2014;basic and diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(48,190,697</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(14,052,266</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average ordinary shares outstanding:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11,280,804</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,545,437</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss per share:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic and Diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4.27</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(1.64</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom"></td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom">&#xA0;&#xA0;</td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom">&#xA0;&#xA0;</td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td style="FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal" valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 12pt">
 The following securities are considered to be Ordinary Share
 equivalents, but were not included in the computation of diluted
 net loss per Ordinary Share because to do so would have been
 anti-dilutive:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="72%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Preferred Shares</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,584,469</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 A restricted ordinary shares subject to forfeiture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">870,898</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">245,828</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Stock options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,614,322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">444,473</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,485,220</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,274,770</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764126064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Incurred Charges Included in Loss from Operations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 During the three-month periods ended June&#xA0;30, 2018 and 2017,
 the Company incurred the following charges from Kadmon, which are
 included in loss from operations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">139,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">152,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,746</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">126</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total charges incurred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">139,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">159,041</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt">
 During the <font style="WHITE-SPACE: nowrap">six-month</font>
 periods ended June&#xA0;30, 2018 and 2017, the Company incurred the
 following charges from Kadmon, which are included in loss from
 operations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="78%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2018</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Rent</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">275,674</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">275,524</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,493</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,278</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,206</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total charges incurred</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">282,167</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">306,008</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760280496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 07, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 01, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ScheduleOfDescriptionOfBusinessLineItems', window );"><strong>Schedule Of Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse share split ratio</a></td>
<td class="nump">0.257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,060,551<span></span>
</td>
<td class="nump">$ 8,548,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ScheduleOfDescriptionOfBusinessLineItems', window );"><strong>Schedule Of Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">550,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares, offering price | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ProceedsFromIssuanceInitialPublicOfferingNet', window );">Proceeds from issuance initial public offering net</a></td>
<td class="nump">$ 65,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ProceedsFromIssuanceInitialPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Initial Public Offering Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ProceedsFromIssuanceInitialPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ScheduleOfDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Description Of Business [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ScheduleOfDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774802976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Company's Financial Instruments Carried at Fair Value Measurements (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">$ 123,376<span></span>
</td>
<td class="nump">$ 123,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,679,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">$ 123,376<span></span>
</td>
<td class="nump">123,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,679,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=mgtx_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=mgtx_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773967632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">$ 2,184,183<span></span>
</td>
<td class="nump">$ 1,514,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_FairValueNetAssetLiabilityBeginningBalance', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,679,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,194,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_FairValueNetAssetLiabilityEndingBalance', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised during period value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClassOfWarrantOrRightExercisedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_FairValueNetAssetLiabilityBeginningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value net asset liability beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_FairValueNetAssetLiabilityBeginningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_FairValueNetAssetLiabilityEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value net asset liability ending balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_FairValueNetAssetLiabilityEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772914832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 05, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,194,408<span></span>
</td>
<td class="nump">$ 2,679,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="nump">$ 2,184,183<span></span>
</td>
<td class="nump">$ 1,514,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Exercise of warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,194,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Capital in Excess of Nominal Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Exercise of warrants liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,194,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in additional paid in capital related to exercise of share-based payments awards (such as stock options) and the amount of recognized equity-based compensation during the period (such as nonvested shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6614496192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model (Detail) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 04, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.77%<span></span>
</td>
<td class="nump">1.86%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">1 day<span></span>
</td>
<td class="text">5 months 15 days<span></span>
</td>
<td class="text">9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762563056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Change in Asset Retirement Obligations (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationAbstract', window );"><strong>Asset Retirement Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Balance at beginning of period</a></td>
<td class="nump">$ 178,419<span></span>
</td>
<td class="nump">$ 221,254<span></span>
</td>
<td class="nump">$ 221,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AmortizationOfInterestOnAssetRetirementObligation', window );">Amortization of interest</a></td>
<td class="nump">7,322<span></span>
</td>
<td class="nump">$ 9,255<span></span>
</td>
<td class="nump">19,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationRevisionOfEstimate', window );">Change in estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss', window );">Effects of exchange rate</a></td>
<td class="num">(5,391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetRetirementObligation', window );">Balance at end of period</a></td>
<td class="nump">$ 180,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AmortizationOfInterestOnAssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of interest on asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AmortizationOfInterestOnAssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationRevisionOfEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the asset retirement obligation from changes in the amount or timing of the estimated cash flows associated with the settlement of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 35<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6392603&amp;loc=d3e7123-110846<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationRevisionOfEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762149408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Non-Current Assets by Geographical Area (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_OperationByGeographicalLineItems', window );"><strong>Operation By Geographical [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non current assets</a></td>
<td class="nump">$ 13,691,182<span></span>
</td>
<td class="nump">$ 14,379,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_OperationByGeographicalLineItems', window );"><strong>Operation By Geographical [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non current assets</a></td>
<td class="nump">413,481<span></span>
</td>
<td class="nump">436,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_OperationByGeographicalLineItems', window );"><strong>Operation By Geographical [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Non current assets</a></td>
<td class="nump">$ 13,277,701<span></span>
</td>
<td class="nump">$ 13,942,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_OperationByGeographicalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operation By Geographical [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_OperationByGeographicalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762605024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccruedClinicalTrialCosts', window );">Clinical Trial Costs</a></td>
<td class="nump">$ 2,297,893<span></span>
</td>
<td class="nump">$ 4,859,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits', window );">Compensation and Benefits</a></td>
<td class="nump">645,286<span></span>
</td>
<td class="nump">2,386,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccruedConsultingExpenses', window );">Consulting</a></td>
<td class="nump">1,137,547<span></span>
</td>
<td class="nump">1,220,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Rent</a></td>
<td class="nump">128,683<span></span>
</td>
<td class="nump">387,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional Fees</a></td>
<td class="nump">733,409<span></span>
</td>
<td class="nump">231,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccruedInterest', window );">Interest</a></td>
<td class="nump">30,600<span></span>
</td>
<td class="nump">33,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccruedTravelExpense', window );">Travel</a></td>
<td class="nump">135,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">180,179<span></span>
</td>
<td class="nump">213,527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 5,289,261<span></span>
</td>
<td class="nump">$ 9,332,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedConsultingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Consulting Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedConsultingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities Accrued Compensation And Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedLiabilitiesAccruedCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccruedTravelExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued travel expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccruedTravelExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776590256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2018</div></th>
<th class="th"><div>Mar. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 247,202<span></span>
</td>
<td class="nump">$ 229,250<span></span>
</td>
<td class="nump">$ 556,349<span></span>
</td>
<td class="nump">$ 927,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent', window );">Fully-diluted outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,633,556<span></span>
</td>
<td class="nump">1,535,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Excess Tax Benefit from Share-based Compensation, Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities', window );">Excess Tax Benefit from Share-based Compensation, Financing Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares awarded, per share</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent', window );">Fully-diluted outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,096,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,456,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">550,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">A Ordinary Shares [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,096,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Ordinary shares</a></td>
<td class="nump">1,306,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Ordinary shares forfeiture period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares awarded, per share</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent', window );">Fully-diluted outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,620,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,531,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member] | A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember', window );">Employee and Non Employee Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">533,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unvested options compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,596,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,596,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested options expected to be realized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mgtx_NonemployeeConsultantsMember', window );">Non-employee consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,355<span></span>
</td>
<td class="nump">135,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unvested options compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,823,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,823,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unvested options expected to be realized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mgtx_ConsultantMember', window );">Consultant [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares awarded, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mgtx_EmployeeMember', window );">Employee [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares awarded, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_FirstAnniversaryMember', window );">First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=mgtx_OverThreeYearsMember', window );">Over Three Years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares outstanding diluted percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mgtx_EmployeeAndNonEmployeeBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mgtx_NonemployeeConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mgtx_NonemployeeConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mgtx_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mgtx_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mgtx_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mgtx_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mgtx_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mgtx_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=mgtx_OverThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=mgtx_OverThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762683520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Ending balance</a></td>
<td class="nump">1,614,322<span></span>
</td>
<td class="nump">1,614,322<span></span>
</td>
<td class="nump">938,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
<td class="text">9 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable</a></td>
<td class="nump">265,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 10 months 9 days<span></span>
</td>
<td class="text">8 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- average exercise price, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- average exercise price, forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- average exercise price, ending balance</a></td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 5.12<span></span>
</td>
<td class="nump">$ 5.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- average exercise price, option exercisable</a></td>
<td class="nump">$ 7.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,420,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 9,884,932<span></span>
</td>
<td class="nump">$ 9,884,932<span></span>
</td>
<td class="nump">$ 1,420,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">$ 999,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776716048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Schedule of Grant Date Fair Values of the Stock Option Granted Black Scholes Valuation Model (Detail)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mgtx_EmployeeAndBoardOfDirectorsMember', window );">Employee and Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">2.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=mgtx_NonemployeeMember', window );">Non Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">2.84%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Employee and Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of employee and Board of Directors' options (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Non Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of employee and Board of Directors' options (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employee and Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of employee and Board of Directors' options (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Non Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of employee and Board of Directors' options (in years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mgtx_EmployeeAndBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mgtx_EmployeeAndBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=mgtx_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=mgtx_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920542896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Restricted Ordinary Shares (Detail) - Restricted Shares [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Ordinary Shares, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued, Ordinary Shares</a></td>
<td class="nump">1,306,348<span></span>
</td>
<td class="nump">1,306,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting, Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(541,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested Ordinary Shares, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue', window );">Non-vested Value, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 865,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue', window );">Issued, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,595,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Vesting, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,397,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue', window );">Non-vested Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,063,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920457520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Schedule of Share Based Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ShareBasedCompensationExpenseLineItems', window );"><strong>Share Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 8,363,785<span></span>
</td>
<td class="nump">$ 682,135<span></span>
</td>
<td class="nump">$ 12,633,556<span></span>
</td>
<td class="nump">$ 1,535,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ShareBasedCompensationExpenseLineItems', window );"><strong>Share Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">1,045,561<span></span>
</td>
<td class="nump">550,708<span></span>
</td>
<td class="nump">1,890,511<span></span>
</td>
<td class="nump">1,239,923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ShareBasedCompensationExpenseLineItems', window );"><strong>Share Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 7,318,224<span></span>
</td>
<td class="nump">$ 131,427<span></span>
</td>
<td class="nump">$ 10,743,045<span></span>
</td>
<td class="nump">$ 295,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ShareBasedCompensationExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Expense [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ShareBasedCompensationExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773245152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares and Convertible Preferred C Shares - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2018</div></th>
<th class="th"><div>Jun. 05, 2018</div></th>
<th class="th"><div>Mar. 15, 2018</div></th>
<th class="th"><div>Mar. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent', window );">Percentage of fully diluted shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Preferred shares, purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Preferred shares, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Preferred shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,849,592<span></span>
</td>
<td class="nump">$ 210,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccretionOfDeferredFinancingCosts', window );">Preferred share conversion value</a></td>
<td class="nump">$ 664,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 666,567<span></span>
</td>
<td class="nump">$ 30,401<span></span>
</td>
<td class="nump">$ 761,012<span></span>
</td>
<td class="nump">53,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares, offering price</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Ordinary shares</a></td>
<td class="nump">1,306,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent', window );">Percentage of fully diluted shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">A Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares, offering price</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance initial public offering</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 9,541,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,781,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent', window );">Percentage of fully diluted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred shares conversion into ordinary shares</a></td>
<td class="nump">11,501,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,501,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">A Ordinary Shares [Member] | Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgtx_ClasscPreferredStockMember', window );">Preferred C Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,425,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Ordinary shares, offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,849,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred C Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610,473<span></span>
</td>
<td class="nump">$ 6,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Preferred shares, purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred shares conversion into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,501,432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred C Shares [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred C Shares [Member] | Payments In Lieu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,356,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccretionOfDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccretionOfDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of shares outstanding diluted percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_WeightedAverageNumberOfSharesOutstandingDilutedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgtx_ClasscPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgtx_ClasscPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=mgtx_PaymentsInLieuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=mgtx_PaymentsInLieuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763100832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss-basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,980,832)<span></span>
</td>
<td class="num">$ (7,178,719)<span></span>
</td>
<td class="num">$ (46,384,185)<span></span>
</td>
<td class="num">$ (13,999,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccretionOfDeferredFinancingCosts', window );">Accretion of Preferred Shares financing costs</a></td>
<td class="num">$ (664,718)<span></span>
</td>
<td class="num">(666,567)<span></span>
</td>
<td class="num">(30,401)<span></span>
</td>
<td class="num">(761,012)<span></span>
</td>
<td class="num">(53,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AccretionOfWarrant', window );">Accretion of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(475,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,045,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Adjusted net loss-basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,122,626)<span></span>
</td>
<td class="num">$ (7,209,120)<span></span>
</td>
<td class="num">$ (48,190,697)<span></span>
</td>
<td class="num">$ (14,052,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average ordinary shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,611,452<span></span>
</td>
<td class="nump">8,505,149<span></span>
</td>
<td class="nump">11,280,804<span></span>
</td>
<td class="nump">8,545,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (4.27)<span></span>
</td>
<td class="num">$ (1.64)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccretionOfDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccretionOfDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AccretionOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AccretionOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Net Income Loss Available To Common Stockholders Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AdjustedNetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of Shares Outstanding Basic And Diluted Disclosure Items [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_WeightedAverageNumberOfSharesOutstandingBasicAndDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763239344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earning per share, amount</a></td>
<td class="nump">2,485,220<span></span>
</td>
<td class="nump">2,274,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earning per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earning per share, amount</a></td>
<td class="nump">870,898<span></span>
</td>
<td class="nump">245,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earning per share, amount</a></td>
<td class="nump">1,614,322<span></span>
</td>
<td class="nump">444,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6644209520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for Income Taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778357456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2015</div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 26, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due under services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amounts of work orders issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 282,167<span></span>
</td>
<td class="nump">$ 306,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,790,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,363,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,718,016<span></span>
</td>
<td class="nump">10,186,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,063<span></span>
</td>
<td class="nump">59,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mgtx_JulyTwoThousandsSixteenLeaseMember', window );">July 2016 Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating leases rent expense payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company records monthly rent expense on a  straight-line basis from July 1, 2016 through December 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_DeferredRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243,780<span></span>
</td>
<td class="nump">243,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Aggregate future minimum rental payments under operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,927,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=mgtx_DecemberTwoThousandSixteenLeaseMember', window );">December 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating leases rent expense payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company recorded monthly rent  expense on a straight-line basis from December 15, 2016 through October 31,  2032.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_LeaseTerminationDate', window );">Operating lease termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_BaseRentAndManagementFees', window );">Base rent and management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PromissoryNoteIssued', window );">Promissory note issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,442,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_DeferredRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">781,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PromissoryNotesInterestRate', window );">Promissory note rate of interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PromissoryNotesRepaymentDueDate', window );">Promissory note expiration due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_RepaymentOfPromissoryNotes', window );">Repayment of promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_UclConsultantsLimitedMember', window );">UCL Consultants Limited [Member] | Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due under services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amounts of work orders issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 241,053<span></span>
</td>
<td class="nump">311,000<span></span>
</td>
<td class="nump">&#163; 1,161,149<span></span>
</td>
<td class="nump">$ 1,574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_RelatedPartyTransactionAgreementNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_UclConsultantsLimitedMember', window );">UCL Consultants Limited [Member] | Manufacturing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amount due under services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,466,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_RelatedPartyTransactionAgreementNoticePeriod', window );">Agreement termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,042,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_RelatedPartyTransactionAgreementTerminationDate', window );">Agreement termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_UclConsultantsLimitedMember', window );">UCL Consultants Limited [Member] | License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_NumberOfPrograms', window );">Number of programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone', window );">Potential milestone payment upon achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 39,800,000<span></span>
</td>
<td class="nump">52,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 50,000<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_UclConsultantsLimitedMember', window );">UCL Consultants Limited [Member] | Scenario, Forecast [Member] | Research Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Future obligations under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 797,343<span></span>
</td>
<td class="nump">$ 1,052,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_KadmonMember', window );">Kadmon [Member] | Transition Services Agreement with Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_RelatedPartyAdministrativeExpensePercentage', window );">Percentage of administrative fees</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PeriodOfAgreement', window );">Services agreement period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_TerminationDate', window );">Services termination date</a></td>
<td class="text">Apr. 24,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_PaymentToRelatedParty', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,143,304<span></span>
</td>
<td class="nump">$ 275,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_BaseRentAndManagementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base rent and management fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_BaseRentAndManagementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_DeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_DeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_LeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_LeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment To Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PotentialMilestonePaymentsUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PromissoryNoteIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Promissory note issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PromissoryNoteIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PromissoryNotesInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Promissory notes interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PromissoryNotesInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_PromissoryNotesRepaymentDueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Promissory notes repayment due date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_PromissoryNotesRepaymentDueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RelatedPartyAdministrativeExpensePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party administrative expense percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RelatedPartyAdministrativeExpensePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RelatedPartyTransactionAgreementNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction agreement notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RelatedPartyTransactionAgreementNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RelatedPartyTransactionAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction agreement termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RelatedPartyTransactionAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_RepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_RepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_TerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_TerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mgtx_JulyTwoThousandsSixteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mgtx_JulyTwoThousandsSixteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mgtx_DecemberTwoThousandSixteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mgtx_DecemberTwoThousandSixteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_UclConsultantsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_UclConsultantsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_ResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_ResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_ManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_ManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_KadmonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_KadmonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgtx_TransitionServicesAgreementWithRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgtx_TransitionServicesAgreementWithRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763371440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Incurred Charges included in Loss from Operations (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Total charges incurred</a></td>
<td class="nump">$ 139,321<span></span>
</td>
<td class="nump">$ 159,041<span></span>
</td>
<td class="nump">$ 282,167<span></span>
</td>
<td class="nump">$ 306,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyRentExpenseMember', window );">Rent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Total charges incurred</a></td>
<td class="nump">$ 139,321<span></span>
</td>
<td class="nump">152,169<span></span>
</td>
<td class="nump">275,674<span></span>
</td>
<td class="nump">275,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyPersonnelExpenseMember', window );">Personnel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Total charges incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">$ 6,493<span></span>
</td>
<td class="nump">25,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyOtherExpenseMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Total charges incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyRentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyRentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyPersonnelExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyPersonnelExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyOtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mgtx_RelatedPartyOtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762077680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Subsequent Event [Member] - July 27, 2018 Lease [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 27, 2018 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_AnnualBaseRentAndOperatingExpense', window );">Deferred rent | $</a></td>
<td class="nump">$ 363,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease termination date</a></td>
<td class="text">May 24,  2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_NumberOfLeasesTerminated', window );">Number of leases expired</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgtx_NumberOfNewFacilityLeases', window );">Number of new leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_AnnualBaseRentAndOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual base rent and operating expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_AnnualBaseRentAndOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NumberOfLeasesTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Leases Terminated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NumberOfLeasesTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgtx_NumberOfNewFacilityLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of New Facility Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgtx_NumberOfNewFacilityLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=mgtx_JulyTwentySevenTwoThousandEighteenLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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ME3%)E4/!DW*E5#UZ6M3T*O4T47,^-*IA(5DW-F$P_1/(_P)02P,$%     @
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MGYVS_SV^QSK)1R>IC^>V[J??V?-;/[3-N95DI:E^G(Z[_70\GMO_"),#\!R
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MCB_#>.K3>7?ZAG&Z&-K#^?M,<?E(M/P/4$L#!!0    (  N#"$U'ZP#@%0(
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MC&4T:FL\C+'D>S30)FUQDP;:*^]D+%S@<)5;<U!KI++*8:(,4L>^*+TFR<M
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M#R]-^VCC<]7?$_4O37D:[L"2RT7<\C]02P,$%     @ "X,(36/Y&2Z'!
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M @C%<R5490-T Y3$,48R@KOI8#<=&">+#7AHP*MQ(LM9K_8:=Q0K<8B!L9\
M_03@)\^0H/U8S^R<SP8/"!T[$PO)4L&(*A!1-DM7E7)D@_4^C_Q:ZV8BT>?V
M%EI'02IC3-9!8,_%J@J%M1%A!R/H8#:2BZ@#,N1,R!;VC=9Q8!L\CH<,!JD!
M$84<DT:Y2IYR! %5M"ZGT*@ZSC**3(6%2P7\DT9)-O]7H^9DH5"?]GDJ 2$Y
MDA *="0(^H]D0=Y7!1.8L,1@,G*>C:*3>:= G*]7H//$A=5*F-BDD:WC$>W'
M&7?4]3$>K9N%A->C/> T)$Q7 GCE F0(\Y4T8$4M"@W8F5@3\ST#Z$*5.%-:
MSYC$I%$L)H]($W96>3)ZXK604\E>6LV8Q*11S#DY"2#1"K$7A08 62^>?&GN
M,3U)XY-S>I+&XDP2T(-700& .NNDD"(6 ]1J@$J&HAL+^&FL*=61F'E6,X\X
M*U<75K-LUL]'VHHI#PI(R3@V@0M5G<7@LP!\7"AX+ :?!>!CS@/60+/.&%,<
M1\PTJYEVC,5Q' &LTFA7AO*Z!RFELI)VD$)8F&O6@;#4.<"].RR@M/Q66)B5
MUH/)+908%L/-@CJ3\Q+# KJ1"T:M6J!+54:!(Q;#S8(ZT^0@L9I9,=@WEAMF
ME@4E'U>Y+XTB'X,K.V,,(P;5'.<;-FL:.5])=#$G)%!:,K9$2,;@8@ NM;LQ
MHI&D'=?$@C,,([; 64[)471Z>B+QL5+'&B2-4OG"_LZ%HS/@6[Y)+ECS+7(Z
MVDB55_Y .4OG"&^X*G"7,0L9L%"50@P(9TE<4&,%*L'H8V$W8<Q!!AS,-]0%
M:[I5/B4GY3LO$%*(*?K\\'_['N5I_!B8#$[ODI]A1]')(<BDTPG'_.QU#:2.
MTR8=U9B *P%L\P9(H<U;X#P?Y],QP3L ![V)2&$388QL!LB6?!-A<#>0<EJ5
M/D!'SJ>C5HDU&.T,T"XYVAD<YWEP5K@ZPV070'915UV:UV334<QP*0D%(UL
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MR>&X#_$QX+N$T:W.)%1R-N8E&(]53G=!$"@H?6 0N%W@#I0*1"CC=>:D2\H
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M-AY?-O:_-L8#2ME=X0BU^,$60T+MP_$6SW8:L\GPII]_$%N^<?$.4$L#!!0
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MZG^-Z"%(V=R%$6K#!YL-!;6/QT,XVW',1L-C-_T@-G_CXA=02P,$%     @
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M*&@F_11MUSUE"(5?  C(G 0S.GA?TP5"X=< "IHI HJW/YWV-HO\,D!!<W6
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M:&5E=#(P+GAM;'54;6_;(!#^*X@?4!R<Q%UD6VI:59NT25&G=9^)?7Y1P7A
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M!\%?UTI* S:5Z,YVM;'OT6QPJ(S;)G:OQJD<#2/[Z<$A\ZN7_P%02P,$%
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M971S+W-H965T,C4N>&ULC55=CYLP$/PKB/>>,=^)"-(E5=5*K11=U?;9(9N
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MRO7<J^.Y..52.U":U.0$/T'^JG=<6:B/<BA*J$3!*H?#<>4^>LMMK/$&\+N
M1@SVCJYDS]B+-KX=5NY,"P(*F=01B%HNL %*=2 EXV\7T^U3:N)P?XW^Q=2N
M:MD3 1M&_Q0'F:_<N>L<X$C.5#ZSYBMT]82NTQ7_'2Y %5PK43DR1H5Y.ME9
M2%9V4924DKRV:U&9M>GB7VEV@M\1_)Z@<M\C!!TA^"P!=P3\1L!W"6%'"$<$
MU-9NFOE$)$D3SAJ'MY]#3?17YRU#=5R9=IK3,>]4/X7R7E(_"A-TT8$ZS+K%
M^ -,A&\AFRG$ZQ%(">A5^#85:W]"]T<)/D0\61!1=(O96C"A76=@[59@^'C
M#^8C&2TD-I#*0+"WP'@VPFVG.#^*%U$0V/5@JQX\T>-'WNCT\#21-\?>/!AU
M>(KS0@_'\3L-"JV"0HN@>)2HQ81W.G23*+(FBB:)%N]T+K;RXT\(C3\\RC81
M&ERV$OC)3#[A9.Q<F:D[\/;#]=$WE_4-WD[F'X2?BDHX>R;5E3<7\\B8!"5G
M]J!:EJN?06]0.$J]C=6>MR.Q-22KNVF/^E].^A]02P,$%     @ "X,(313)
MHBS_ 0  4@8  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULC97OKIL@
M&,9OQ7 !!__5=HV:K#7+EFQ)<Y:=?:;UM9J#XH#6L[L?H'65L>9\J8"_Y^%Y
M*6 Z,/XJ:@#IO;6T$QFJI>RW&(M3#2T13ZR'3KVI&&^)5%U^QJ+G0$HC:BD.
M?3_!+6DZE*=F[,#SE%TD;3HX<$]<VI;PWSN@;,A0@&X#S\VYEGH YVE/SO =
MY(_^P%4/SRYETT(G&M9Y'*H,?0RV1:)Y [PT,(B[MJ<K.3+VJCM?R@SY.A!0
M.$GM0-3C"GN@5!NI&+\F3S1/J87W[9O[)U.[JN5(!.P9_=F4LL[0!GDE5.1"
MY3,;/L-4SPIY4_%?X0I4X3J)FN/$J#"_WNDB)&LG%Q6E)6_CL^G,<YC\;S*W
M()P$X2P(XH>":!)$?P7KAX)X$L36#'@LQ:Q-023)4\X&CX__;D_T)@JVL5K]
MDQXTBVW>J>41:O2:A\DFQ5=M-#&[D0D7S(<ELW<P:W_)% YF-2-8Q9RSALZL
MH=%'BSD"MT'D-(B,0;PP"*UB74QD%>MB8JM8%_.?:F-GV-AAD%AA7<S:"OL.
MIGC,+,*NG&%7#@-[&[D8>QN]@RD>,XNPB3-L\J_!QMJK.Q<36&%=C+6="A<3
M66'QW6'5M^TWPL]-)[PCD^K<F]-9,29!^?E/JOI:7?!SAT(E=7.MVGR\YL:.
M9/UT@^/Y,Y+_ 5!+ P04    "  +@PA-.5.4-V "   \!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R."YX;6R%5=&.FS 0_!7$>P\P&$A$D"Z)JE9JI>BJ
MML\.<0(Z@ZGMA.O?US:$@/%=7\ V,[.S:[/..LI>>8FQ<-YJTO"-6PK1KCV/
M%R6N$7^B+6[DES-E-1)RRBX>;QE&)TVJB0=\/_9J5#5NGNFU \LS>A6D:O"!
M.?Q:UXC]W6)"NXT;N/>%E^I2"K7@Y5F++O@'%C_; Y,S;U0Y535N>$4;A^'S
MQGT.UOM4X37@5X4[/AD[*I,CI:]J\O6T<7UE"!-<"*6 Y.N&=Y@0)21M_!DT
MW3&D(D['=_7/.G>9RQ%QO*/D=W42Y<9-7>>$S^A*Q OMON A'^@Z0_+?\ T3
M"5=.9(R"$JZ?3G'E@M:#BK12H[?^737ZW0WZ=YJ=  8"& DR]D>$<""$#T+T
M(2$:"-&#$.MJ]:GHVNR10'G&:.>P?G=;I Y1L(YD]0NUJ(NMO\GR<+EZRT$:
M9=Y-"0V8;8\!$TPP1^PM"."/&$\Z&&T FXTM6 B >8C=$A%#PX5%!-I-A-9:
MA)H?SFKQCD!D%8BT0#03B(UB]IA$8YJ^5$D:!2LCW24,@ ! 8VOV_X7-7$.K
M:VAQG1BN>PR<Q$E"8&X17)A9 6ANTE(I6(5!:#<<6PW'%L.I$29>A/F40#\(
M['$2:YS$$L?8IVVRC /#E?E_+%&!/!GO))U:S:1+,RO?,),NSU;JA]" [2VP
M^1'L[7B3'E)C=M']F3L%O39"_6:3U?$*> :J!QGKVV"]ZSOY0Z:_5[XC=JD:
M[ARID!U.]Z$SI0)+E_Z3+%<IK[)Q0O!9J&$BQZQOZ/U$T':XJ[SQPLS_ 5!+
M P04    "  +@PA-K01O[@8"    !@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R.2YX;6R-5.V.FS 0?!7$ YP!.WQ$@-1+5;52*T57]?K;(9N SF!J.^'Z
M]K4-003YJOS!WF5VF%GLS0<NWF0-H+SWEG6R\&NE^BU"LJJAI?*)]]#I-R<N
M6JIT*,Y(]@+HT1:U#$5!$*.6-IU?YC:W%V7.+XHU'>R%)R]M2\7?9V!\*/S0
MOR5>FG.M3 *5>4_/\!/4KWXO=(1FEF/30B<;WGD"3H7_*=SN,H.W@-<&!KG8
M>\;)@?,W$WP[%GY@! &#2AD&JI<K[( Q0Z1E_)DX_?F3IG"YO[%_L=ZUEP.5
ML./L=W-4=>&GOG>$$[TP]<*'KS#YV?C>9/X[7(%IN%&BOU%Q)NW3JRY2\79B
MT5):^CZN36?78>*_E;D+HJD@F@M"\M\"/!7@50$:E5FKGZFB92[XX(GQ9_74
MG(EPBW4S*Y.TO;/OM%NIL]<RRL(<70W1A'D>,=$2<X_8.1";&8*T@%E%Y%01
MV7I\IR)R$V G ;8$Y(X KVR,F,1B.HL)<9R%8;IVXP 2G&1A\($GXI1$')*(
MFV#C)-@\WI3821 _T)01LUEX)2$FZ>H([!PP'),8N^4D3CF)0\X''4V=!.GC
M#<F<!-D##<D<IR1*DB18M\0%S$@4D[4DM+B+9C;^H.+<=-([<*6OM;U\)\X5
M:-+@2;>XUN-X#AB<E-DF>B_&H30&BO?3O$7ST"__ 5!+ P04    "  +@PA-
M'5:@98$"   T"   &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q]EMN.
MVR 0AE_%\@/4G QXE41J7%6MU$JKK=I>LPE)K+6-"R39OGTQ]EI9(+T)!_\S
M\\T0#UY=E7XQ)REM]MJUO5GG)VN'AZ(PNY/LA/F@!MF[)P>E.V'=4A\+,V@I
M]MZH:PL$ "TZT?3Y9N7W'O5FI<ZV;7KYJ#-S[CJA_VYEJZ[K'.9O&T_-\63'
MC6*S&L11_I#VY_"HW:I8O.R;3O:F47VFY6&=?X0/-?0&7O&KD5=S,\_&5)Z5
M>AD77_?K'(Q$LI4[.[H0;KC(6K;MZ,EQ_)F=YDO,T?!V_N;]LT_>)?,LC*Q5
M^[O9V],ZYWFVEP=Q;NV3NGZ1<T)EGLW9?Y,7V3KY2.)B[%1K_&^V.QNKNMF+
M0^G$ZS0VO1^OTQ/*9K.T 9H-T&( R7\-\&R  X-B(O.I?A)6;%9:73,]G=8@
MQC\%?,"NF+MQT]?./W/9&K=[V:"*KHK+Z&C6;"<-NM6\5]0)1;E("@>P4* D
M!?+V^,8>4I1V@),.L'= WJ7!@C0F#?.:?M(X$:]PD$RL([RL" 1I()($(@D@
M'@!-FO(F$"4EXD'YZUB&,*<5P&F>,LE3)GBJ@*>, D&(64F"0M8)'4* ,)8&
MHDD@&@%A  (@F@C$*0\/+)9ASA"]@\.2."R! P,<%L5A&!,0E+&.90C#"MTY
M+I[$X0F<X*7;\CAM0,,:U@D5)OA.;:HD3)6 "<Y@6\5'A4M*23H.!.EF!!*1
M2-B-0!R* \C"8TCHD&-"=U*'=_HCC)&B_@BCCN%>XPI1&"+%P@IC5)&P3,5-
M^Q[OT^]"'YO>9,_*NIO ]^N#4E8ZI^"#R_#DKO!ET<J#':?,S?5TCTT+JX;Y
MCBZ6#X7-/U!+ P04    "  +@PA-B5=%*/8$  "]&P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6R56>UNHS@4?94H#U"PKVV@2B)MVTFGTJY4S6AW
M?]/&;:(A(0NTF7W[Y<.3#9?CA/1'$\BY7^:>XPO,#GGQHUQ;6TU^;K-=.9^N
MJVI_&P3EZ]INT_(FW]M=_<M;7FS3JCXLWH-R7]ATU1IMLT"&H0FVZ68W7<S:
M<\_%8I9_5-EF9Y^+2?FQW:;%OW<VRP_SJ9C^.O%M\[ZNFA/!8K9/W^UW6_VY
M?R[JH^#H9;79VEVYR7>3PK[-I[^)VR<=-08MXJ^-/90GWR=-*2]Y_J,Y>%K-
MIV&3D<WL:]6X2.N/3WMOLZSQ5.?QCW,Z/<9L#$^___*^;(NOBWE)2WN?9W]O
M5M5Z/HVGDY5]2S^RZEM^^&I=07HZ<=7_;C]M5L.;3.H8KWE6MO\GKQ]EE6^=
MESJ5;?JS^]SLVL]#]TN4.#-L()V!/!H(==: G &--5#.0(TUT,Y CS4PSL <
M#:0Y:Q Y@VALA-@9Q/]'H+,&B3-(6(2@NWYM0SRD5;J8%?EA4G0]O4\;ZHC;
MI&ZYU^9DVV'M;W5/E/79SP6%>A9\-HX<YJ[#R![&]#'W"!/U,0]#C.PCO@P1
MAB6SO.CD\;*3K\ )@SRA@N(C)J@7];BR$JZL;!U0ST&"'1!T0*T#=>I A&PU
M$$:P8A%&XD043$0!!\2N;8>)6LRN6U$5R9!?8 "3B=2\K"%,:T,J85=Z"$MD
ME B-B].P. V*4RR=#J-/XIA(F]@3Q\ X!L3A1$,8@X-$,$@$'# 6+J/!H@EI
MB.H%9JL;#:H6FG28A#BC&&84@XQBUCOQ(!#KAR\7$<N+B,=SB%XA"2PD 86P
M?GQ(+A:2#!:?%W(1\7@.T2M$A%CRPV$ITN?"LVN(\>(FL#P*.4+>$$@*3QRL
MHF(H?XG/ Y8_H:XH%HN, "HCF3;>.5"/F1Z)$5ACQ B1N4<@29XX6&;$")VY
M%T.AJ9?-B)"K*P :I8WT%H^51@"ID8JO\5 %=-C^\>P!4(?">#9.@45# -60
MGK(D9JL,QW>?Q&R58L2VX$#\<H6^44%ZIA[$6,\>)C%C)5U1,::L!".+9!7?
M.5!O@ZL'6U(Q7YK+P'Y26 0D$@$6ZPF"?,5C%9"(X%QL'&B,V$@L A*) )]H
M(,C7#IC7$HT0_-9"#NDJR,@P-KY@F+ 2$)8\>R-APM(5A"5,6!I!V <:$M;H
M&J9]Z6+"$B L>39(\MRH7$%8PH2E$81]HB$/8Q,EY.E;PC0DP##RB!QAAI&Y
MHF#,'D+$4/P2#T=P/E!>ABP!1!.=MG4W5YYUU:\),Y4 4XG?*#I0[Q90)\9H
M?J,_ MA/"C.:$*/Y" )!GC@*TUZ!J9K8+=72@9+32W%CV!(] I2Y$9X136$)
M44!"*/*XP,J@KGB"H; R*/3L@7>Y YUK80 12A+OF4>$(RTCCYXIS_,.($:#
M/E;#AP\42TH2WL<C@/VDL&PI)%N\CR'(%P=KFP+3 WD&'86U3457- Z6$H6&
M><DO03S@27032;XF%U#]=+"(**0/GHHTU@=]Q5B@,:<UX/1@41R(E<N%Z!*J
MGP[6!PTF!^79,336!WW%Y* Q634@JQ*\7 3RM(#V/"<$U%(>3=:86OJ*L4%C
M:FDP-JC!XTH$XBH0G+PA:%YL_9$6[YM=.7G)JRK?MJ\$WO*\LK7#\*:N?6W3
MU?$@LV]5\S6JOQ?="Z7NH,KW[F59<'QCM_@/4$L#!!0    (  N#"$VF;Y91
M-0,  )@-   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;(U786^;,!#]
M*X@?$#@#!JHD4I-HVJ1-JCIM^TP3)T$%G(&3=/]^QK@4["/-EX"==_?>'?:3
M/;_R^K4Y,B:<M[*HFH5[%.+TX'G-]LC*K)GQ$ZOD/WM>EYF0P_K@-:>:93L5
M5!8>\7WJE5E>N<NYFGNJEW-^%D5>L:?::<YEF=7_5JS@UX4+[OO$<WXXBG;"
M6\Y/V8']9.+7Z:F6(Z_/LLM+5C4YKYR:[1?N(SQL"&D#%.)WSJ[-X-UI2WGA
M_+4=?-LM7+]5Q JV%6V*3#XN;,V*HLTD=?S52=V>LPT<OK]G_Z**E\6\9 U;
M\^)/OA/'A9NXSH[MLW,AGOGU*],%1:ZCJ__.+JR0\%:)Y-CRHE&_SO;<"%[J
M+%)*F;UUS[Q2SZO._QZ&!Q =0/H R7TK(- !01] Z,V 4 >$'P&*P>M*4;W9
M9");SFM^=>KN\YZR=A7!0RB[OVTG5;/5?[(]C9R]+(.0SKU+FTAC5AV&## T
M'$/6-@3&B V"('Z/\:3(7BG!E*Z(E8 8(CY%;!!$A&L(T&X%*CX8%D$G$H1H
M@E E"$?MCHTR.DRD,)7"I$%"@QCGB5">".%)#)[(XJ%Q1).)>BC*0Q&>U."A
M%L_$=X]1BMBFB'R#(KZ7(D$I$H3"6+_KY%Z*%*5($0IC=:Y2BP(HA $QU_F=
MN(V-N[60P,<-PK>5@]E_%&0Y  8B$V(FW J0-@:F78%5-Z$1(98>&P>R/>G$
M!@#4EAZ!()(L>\1 D:D' ]$),;@_08"D,/U%@])!W=%L\D/@/@:(D46FP6@0
MP(B)!A-,N),!8F61:3%@>]G$[@3<QP Q,FJM\KN=#' K \3+J&DT<+>9 >YF
M@-@9-;U&@\:+(+#6+88"TV<^0XU%X_X(B$%2:V>G%E$\HZDI!T/%$W(([GH$
M\2KKT*-!\=! 0N+3:.I<@YL:04R-&N:PTJ A5YHD81I8AZ [@1L$>%L][G\$
M<2UJGB U:"0J34,PJ;S!L;5D]4%="1IGR\^5NH\,9OMKQZ.Z=7@?\.[.\B.K
M#WG5."]<R,.S.N+N.1=,RO%G<G,=Y36I'Q1L+]K76+[7W5VA&PA^TO<@K[^,
M+?\#4$L#!!0    (  N#"$TZU3A6V@(  &D,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;)57[6[:,!1]E2@/T,0V^0 !4F&:-FF34*=MOUTP$#6)
M,]M ]_:SG9"E\765_FEB<^XY]QJ?R^WRQL6+/#.F@M>JK.4J/"O5+*)([L^L
MHO*!-ZS6GQRYJ*C22W&*9",8/=B@JHQP'*=118LZ7"_MWDZLE_RBRJ)F.Q'(
M2U51\7?#2GY;A2B\;SP5I[,R&]%ZV= 3^\'4SV8G]"KJ60Y%Q6I9\#H0[+@*
M']%BBU,38!&_"G:3@_? E/+,^8M9?#VLPMADQ$JV5X:"ZL>5;5E9&B:=QY^.
M-.PU3>#P_<[^V1:OBWFFDFUY^;LXJ/,JS,/@P([T4JHG?OO"NH*2,.BJ_\:N
MK-1PDXG6V/-2VK_!_B(5KSH6G4I%7]MG4=OGK>._A\$!N O ?0!.W@T@70 9
M!41M9K;43U31]5+P6R#:;ZNAYE*@!=&'N3>;]NSL9[I:J7>O:Y)FR^AJB#K,
MIL7@ 0;UB$BS]Q(8DMA@)QR_%=BZB#2!%0A8!+'QLS=%Y##!#"2860(R)(CG
M,$$"$B1.!C@;5;EQ,23UB*2@2#I!Q,60+(9%,E D T32D8B+(9GG2N2@2 Z(
MY",1".,YKCDH,@>RQ# !BF%SQ-/O!?+X"TWXT@ 0R<C()"!HYDD&=.(CPE.2
M<4$D2\;)0*#4DPQL6N2ZUKUI &AXU;ID(*;,DPS< -!LPHT$0?-Q,N^#WB8#
M-Q,$= IO/7"K0.D';B[<"!#D<N=(()!/!^X%R#4ZR3TM"\%.1_/IU6+8ZCB>
M4"T$RL>W$01Y^@Z&FP8&K)X3#P5L=8P_<"2P03'D/>=( %#NZ4H8]AYV'4-R
MS^\_AAV#DP]4"SL&0[^<3K4 *$_'%P "C>T;#0:TBHF3G65EL.>76IE1:+#;
MS\N/V QXH_V-GJ/;J?<_33N$?Z?B5-0R>.9*CX]VR#MRKIC.,7[0!W;6<W^_
M*-E1F==,OXMV^&T7BC?=8!_U_UVL_P%02P,$%     @ "X,(3:.L@Q4V @
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M:;"MJM98I^S&IKXS^>9\4IAMVQTF]K@>7E,-)VUU=*_@XO-[P.7_4$L#!!0
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M80$*"M!6@ WS(BC(HL/(%E.UF$\DRU*4TC 3 "FQ3&4X!4L R 1-&4Z##%<
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M/X:^JWJ75TWT;*R[,]N;;6N,U4X235S<>_?^NE0*O;6^*%VY[AXA7<6:0__
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M+M6>V\%@#Y)U;N:A8? 6_P!02P,$%     @ "X,(39/.%"$4!@  72$  !D
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MF#=]O9E(5K=WEJ"[.$W_ 5!+ P04    "  +@PA-[/<Y-LP!  "(!   &0
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MY[:#5LRTXE<?@;VWXH/_&$N="B,/>K1X,7N^OH%_B"C)R_?R\NKLT\G-.3Q
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M3.>S;T&#WVR0&+]-5RF*KRS%=>N9-]D:U!$$;4;B4B1O7SP&GCA"Z"2X]0!
M8%PURBB/6U!#%O 8X T,3IHAOH2\GF99%%5(OX(-&<'E.VSLX+$<:MQ<\'[Z
M') ._3Z,M?O- V'DK4XS BW5Y[2\#:HY\,!37C]\PW)W+DM#,S"N_)J5B[QR
M.?1!SZCQVJE0E>_GB_D&M.D )W>,M_= .H;LVCE]V[L%'7Q)T@%<^U8UO.NY
MKG%#U,Y896O!ZYTVV4#H0N-?M6I=Y)DWQ=ZAS[YN1?]-LD!#X=IIR.Y2Q;Z*
MZ.V^R8?M_N3ZS_+]Q>6_[E!-XF2G;D+6P[M5\>3+^:CTHSF$K#VAE8)$263I
M%9JIR@SNRB('(!B!$;[%O\DDN:V8^!PT]%7+3>LD7RG(]RRRI%K&./1"=0GV
MP3V@[1RC[M%BM06Z %IWVQTY6:-E[^^I815:H8"/9%J52*A+I<'O,,L!04?+
MW3%H$?37JP8HR03;!D;/ULLFG0,,O.<;/>$R:YW0L0(&LWX\Y,CW86 .9+?:
MAR8N*UH5F_L>0'<-2FBWO?9J"WIQRGSEL=5"O7<W;2O;MYL[MLSL0?KTF2\3
M<K(7&&VORF*194LU%9RNK!0IVL/INE]\F42@%LZFOF[8&T@"X+_DJ'#=/K="
MINW%O!TC<;PH\'G0B9:[O0IG0((7M.;LUP7;#] A)/EO=0CA:Z<'3XBLS4J8
MB&_DM/NV 3.\P%U#76\?'U=$2X#3+/-J 51K6V9\+IL>C4$,/27J&6+@^_Q7
MM/L284H7L!IE103@K[9+1O^TX4UA>U3#A;)WJ8?+O&T47TW]'42W/3?D4[98
M 3AR4++2AD!MC4IR^TB<9+]4N\L5(^^*TE(A$!284+W@C!>:Z,#6C*>\W5%(
M7 $GU RI\WQ8IVDY@SW*0?=[!Y&8)LJ]#+LNR_MTH]DNXB<:M4AGOT+?$L"N
ME5DS9N-MO2I I,C1KM!I/X_[XK!I7HL;H*RHZ*>;9]'J,X](AEGGM1)/X$&Y
M!3FM)**\2I]H4/A;G *I33?R'&3RS;)"\1%>7:Q O 2QM5?5:'.[S8$(+Q[,
M2,H"#).)30%_ROMLD^%H9?J($GZ6*B$.$2*%4UHB*42"2!(+/$<+@PD%$04\
M)\ \N#IPU^BEIX<<YL,1@1S ?S>%S(B\HE'#3B#2+VF^PIO;EPY,<!-W&,F
M'J"-LURU1CP'F$7 (ZNTQ*GQZN#F"4?PP1)GM4N%2[59;M!,DU;R*5NMX%_Q
MUZP$G"S6>0JCK>":\(M+EMSL,FE'#UG*#C# W5_@9@%*E[!^^F);%LOLGJSQ
MM$&](%EMT>8.DZZ?0<@"Z0+ (M%.4Z8K 3<5%P![/?[?_VN6)(,W)Q?7]%?\
MYE5??,J*)C:=*YWABG6&2Z4SB,N-_) ^RV3&ZDA$2/*V2$NZ$>_@?!9U41+*
M&&R[8.P2Z2,R7P 1OM.8\\9A#9%S@.0[G$:")P/"A%>\1N'>G'O;].Y4@MC.
M'5N"2=#@6_Z0K4@*R%(81_W47#/"*)Z^J43E.//HD/!IRS,ED6H^-&-U]I0'
M 3/1Z.;R]24 4^W/ :9&3+Q!JPPQ*@?L/;^ZC&0%V(2(@T[F ?Y77L.IH'TS
M4/OT.6M;I6"55Y\Y4K&TJ1 "*<R5CSD>]V%TM+G3>!%=0 !N!E(2/'@T&??G
M<IW#<HA#DZ;UJ"0Z>/@.T [NTG*[0(HFB)P\P?7 =Y%O,!.GB)%BO08 X;&S
M@J#7HNFMT*P>X+>M$%>1RV:LPLOK1V""H@''SE-LP12Z5M[A&M1)9?QZV$>?
M=ZGFI.=DA7/VY0G<;/I".!Q//C+Q9=X!QPEOW1G/:*4=II4B:(I*XG[OBJ)&
M 1;P,@6\O\VR#>IG99'JF(!4>T](W[U;P08$(HR625M0#_Z[71'4E92-))LN
M65^T\@MB%]ZZ@%4N\2#PJ#85L*8EV7Y;-X4K%[3R1U3^2J,R(WQ06&&5V;(Z
M0#@8Y!%-]$S35JMG!$OV:"$H/V^(KI*WF19\L@846:0&QW\Z.;DRQ$R> *.S
M 1/F%!BV #HX7T!Z0JE[="#34Y5<9XJNT+L"_L"YTVW]4 #B,K'U5V)6+,V*
M[=:$L[44*0;< ;TAA]=?HQ<*<+*":[\TDIXP5/KZU-Y8&*#US<^/>"3..Y_-
M.XJJ6=]\ZP!T*\S[[T^NWUK60%[(?.T,8;S^U6^!+#A<R8="R()G:X7%?&W'
M\JX=>1WQ>=QNO@&Q:<N\!$_T/3PF,?I27O?^VI=5_FN/7&_P,98?B[X<#H>]
M)!G-X]&K2'!< 6"K*SK!:BM$(77H+)(\$V'8;)5M0S_R3 K,0PZ_+0$-BCM
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M!@5!ZX5*<0T1&S)8>*U>4Q:# >_+O0LJ7@HH&\H\1:LDXT>E"1N5IN4D-P@
M12@*%HI<$4&IZJ+LR#G1H: VB),M^"W!C6)'1%35&F;0%^\QWX,#L#\ #+>E
M$F;>VSP0H'V8([:AR :%NKFV]#UI QX[5N 9<N:CDUJ0S*BB(0 >Y#.G7UUG
M5NK$ ;"^3'Y1H,8.OS/LCI4A-MHL\D>*RU5FD[5=OB19$N4@<]?(D(W).J5<
M%TCPEU_@9<"U8EOI4?G0TMHL69BE,9%SDF.J![UQN&X+%4S.9\*A:88:TXAM
MZV;0 9KCOA&D6CL.IX_HLOH#2Y2A\6YHY,PHY]KG3R04^SD]3N29WH667#6[
M9SJNHEZ D)"-&FB)9^7@VU?)D^M3>0-<9B%GR2"2%J&$BU"$?N],N$4EZ)Y-
MWH@+LES%K^7E+2:MLIJY>=S6UAW\MVU1\TT$FBR8#B,G8J"R*Q.6O:G9]$MW
MC" "] ?#!Y'_<3[Z R.P<,R(*=M24V-.;>+1F\92D]< 85R?9OYPP(QEWCK1
M>.NO,[(B3&'WFN4TR)*<>:@/H$U3?WJ#KKW&_,/7\O.F"( %8'&C"("'P0YK
M--EC5IE&0-A0JNUNVHK="BDTH# 1(F4%M!07]]@ZPRX!4E6MD,"0)VSS+-2;
MU-K5'3&1#XNM$18O#:#4&K4HHLYF*8BQ6ZQ&EP% ;%L2MR&/P>L.TB8_H\7C
MM7A'NC9MQ]H&74N ^S?GFCC?B$;*O3R2<3*,AM.)^Q>=7)R\L7^]8%%>JO!O
MO[!_U6D.1S*))M-Y-!D.VQYT?]^%!7 @0"#@:CXI=[6A;&Q0><EQR_"X1>.X
M60(*TJMQ('VZ%'_Q6KC ,K'WA*KAV^Y>]^1(5C*.QO$HFD['HBWY0AZ/HG@^
MBD:#F7S5F-BW3=LS0?":]Y_P6NMH.N;%+@QOLT6*O(3$Y@UQ4+0'.2G'*F(D
M)4D\6V9\E^5=EI)LK5@EBGHU,V;6103'FJ'6UK!%V>"/L>L:\%8L=%@?':*B
M4/DZ<Y]T)("G%(4-C$(F>8.ETB,#.4NZ;(P"&2%)"G:<Y9K>Z5,B/AC 0IMT
M3>BA"1YQ]Z%4 I:XE8=W8^-I_:=]:<9S?HBCA L-S(8T\Y%!&",NU@]EEK%C
MEX,ZM)M7^.)'U5QC:VV!"%1YE"AUC2":E<YKI-T@B%-63=E66@U_NTH7O_2N
M%P\%VI&L)+TNEL""C-;I2."6.2 9:UZDQD+<19!+I7<'&[?1_11('/>GB?P!
M_IE-Z)_I5/X 5TOIIHX^/!O [^9_["/+'*.D8<^L?P[P/_;757Z7R;E.8!WW
MQ_K/&+CDLWBOCF3;PFOU<5F9G+&(1Q;.TAKXC'&7&*D5R*JWP''37]C(+W3N
MKSIC9S@,22>*SPK'ZKD'0C*Y-;*L%"IND3PRS](8@I2"[NV[?5TB7!=)M"RT
MM^@_&G5T="7=;%1J5@TG8<4^?1U<3$2FWT!JO=_@FN)BG8649(H7.O&GZ0=W
MS,R-<5 ' RWX%O3=$$6C)HZ:RS)FSL'+M9>EY38V5V!O)WE[:[')4-AD_Q-*
M>0MC4K&4H@H4*Q7PC'1'Z+031=]TZ#V?L3Y1SZ@0 %AXR])V)JJ4HZWIN7'K
MNPH':>2D1BHS%3]45.9B<#B'8S!Q%7C8\T-^_T Y\ +(!MG-S-H<U ,5)L!\
MHE0<.J'(;BGJ$*T;3T7M$- '(YZT^D-/]Z6*?\]6SY$RM;2M00>K[5Z#?NJP
M->BG^P*3-2YTM0 _35MP;0&OGH#_!"KK>/&I[@ 0%2*!2%;T.R YL_^0Z%F'
M6<.+)432A,M5E0E$6)E %R1HOP2-3'-!&&5$/+<^SG*KC44JWH7#W'$W;*L&
M!9(J*H@=%14\"%3Y.L>09YS+ YTP8:%49N>QMN$7P#$H+[U&3:PRR+%4>*5=
M/,+NW_'O-M/JG:MLS/'"W;/",NLU;9JI4%XC([XN*D2K%%YBC/'(D4U=$1.[
MJ.:0))=1<0J\]L<8N U7[YGKP,!%A"N]?*61NWXJ>B1U"BI3)C]9Z]*EL2Z)
M$\^8)7<\6FDA'\37[#Y="<]&U6+9=LU9*DMM188FK>@7@LU/!5":OP?* IDD
M*>"J5-3+30U+*[+):'MSF;$AISF+<?BG( NHK!NE[3,A%JST@WQJ643+O2^V
M99"VZ & )3"EZ.M 7/4^\78L/TDN!9:$'7^)M<L[$4A-@#K3VK@YXRO&(S1B
M(#!L@%A>]TS,;FD$-93/^@HA.LR-BE&1@1]M"PQL#E!P]19D5%NLX^#8AK5V
M=(T%.)F@&E60B81('1)A[=XK3#1]\N5()?_D0)4P76WC"CE<72M[VI5+J@]%
MZQBU*#TC-,,<'06W7D2@%\&"O+-R8Y<**WXU0J2,GBRZ#+FU,O<9M9I3H2AW
M4\6(L/=9:'O]OKV!/F,%&_VZ.N5S)^66=2V#*#M&IL0:3MX%>DV!5D1-<(W>
MJHW.X21,F/-C6L26W(KN>+ED1,H;E87T<7@^!L=Q NJ7&PS%<7"-DD%\8E:T
MV0FX7,5$DQ'TM5$70&-C/4+CY_L@8D(X&?\M^8UHIYG.HE$\1_-#$D?)>"0Z
M\Z"GT3!)9#R/AK%KHM"G::PVQ]-Q-(AC^4IPWF85)FX>CZ/A')Z0<1+-)D-W
MF5ZR&"YP-HB&XX%=JO!*9KVS[@O_A\"O0:0'%E'>,X/5ITDGS#2;3J6R"7'$
M@2,)(HP6JXVSO2XBF:T?5\4S:-&*E@OMZW#]L!5LK:0HV-MLD]WEM?&PJS#*
MNB7VM--#8V)$W]B,#\-QV/$?1JAN*"O.#NIF$E7*=T%YTO>L(X"0KN4)#$JA
M^"DGVEFZT<Y5#=O,."]DG6ZVZ)[>*DOOLMS>FP@LK<@VWPSBIRVS>./ZM 2A
M8D]Y2P%BE=*.51QA9Z"V-NT;9P)%YY%D1-ES&BHP\GV9KM&W5WI,WKI:4)MT
M/'V"_3WP6L8%%%2TFKHXUFF28B"G8HH4CJ2DX;P4RL]K,([Q4)K\<@4VQ%.?
MB>I5"4WKC%2,VAZ(XCBL&VRG#5K(/EQ7+N+?(XCJ6:DR<=V5L ^? 4(I--:I
M;#,+_/"M1U7( /5?Y0/L1&>%P^A.9.1 ,LW\K2^N,XZ*<&I)NP$CJ.EC%0L5
M_U4KU1]I_,KU,E1J&/1\/F[+QZ)B"<8^87T$B.ZY#8%5CF^/H"M3@K%&L793
M48@?H$O%Z=LLD8@]54R%GR%S)$?Q,!K-8OQK.(E&0!G5$W^!J99P6/![,IU&
MTT&,?\Y'2309)>((/TSF<13/$B24HV@XG4?Q8+PWEA!8+EL>K$T5$UIT$M[)
M]6?ZI3>81G(\&/> $(/HH[^CM^'2H\#/AHW& !('P)01_+4W@&V_5=$H2/)N
ME?F@DL?*JS<8OXKD*1+,NV?-J[%LUL:ZM84>(9)J=3BP]#^Y?Z>KJO"^4)Y(
M]1'W8 X&OIOLW,2DAX['&Q*/,?CAM"C+;&$Y_?F:LN%,H17>UV0 HW[BY!>^
M=*>**%>"R,+I%K-=*2<"51I>+,_%#@OV?ZY1/7!^Y;T9)4?],NH-YOW6#_@.
M[O<C+K&QWP-RGFAQ"!C1!AC$'Y/LA-2:LM??T\+5^2;#P2L$A'$;T2-F<;$Q
MNN.*C+S2*^YZ2AR@ZA^;I?N-,F0Y@W@G3E]0"+[S!<+@<E$7NX^<'YY$NM3;
M.1Y93Y4;OU%Q!9QAQ^KAI?'1P@1H=L3P=&<DM3GW&] HSU6*\'[4BQ-IT$CX
M:"1]--( !\0#@'\$-E \]:X70,6$AZ$(SRL<@#@OVJN!)?O@3")GV6HIB%0O
M7XB+DA'R4V<28C'>[VGESCCN 5%[^92O)5?)3HVD=68D?RQ6KZ?$X66_ >W!
MUP!;G%-T ).O*QO/X)DE4.2Y,!'Q%@P#2\;HD[G9^HL%%\HG/N,^^)!6K=!3
M6R.;@K<Y]&]]!29=F> 6M%UNL5(D7O93-Y@#7OED6*LF>C^5:$)3+WW,ZE=V
M^=;5YNS _7G_[H CXS5ZG]V6FA>%=TG8(0&G+Z@,@-",9Y2\<B[BJ),@\/PN
M*1>=D#./ZSTU_Z60%\XI[WBDJ_S]64?U7U56M-+9KP".U8["&.V5W(=]T9S'
M?&&RE[0XK\BP]9&R[Q@57O+$JFMGY*77>V6B4ZT(W&"8HV1!'[WCR7P:S>9#
M%(ZBV7@.NN" %"=3((S*>F@E:S(:1\EL N\-9Y-H/A@2EJKT;I"4AM-H/)K"
M7PEPV=%T"J(2"$IQ,HLFLZ$<SJ91,ID*D);N,LJWAZ6\SV#CTR&(:'A"L.!Y
M,K0V"]C29#"0^/-P*FY8OXN'XV@R&1DW.[,(U&GC*8P!8MLXF8+\AFN=PXPH
M^H&"/4Q MAL%)?6Y--I;DOS=G0<UR+Q:,QZ,/BFSXZE3]5$56S,Z1W<AE5%?
M=*U!&$\6WC%=OQU8)Y)#(+=7H.'[N6O8Y@8U-Q;]Z77[^ G%<N!+S3&%/Z8\
MKHM["C'F2ZM"+6DZ&R7/JC&1F<C-WB#:<H_.D4S5-9"%#@(O5)@O83'H<2B>
M":WSJ^(5<(/U-^)$:0'/G7DTSOA:G7LVAF 0!<S@D3>R_\$ZZC\:M\"E6K.I
MZ0R$&;32>S3+7.YI"R#G0\#Y(4:@C/LQZ0_1".[$9#P0/RG(3*: QK,Q/  J
MB0XY61JLUO\"N<"0FN#[]T5YEU$B1/.7RUVM#^)H@JI,DM#2AB.Z&[/9*)H/
M$Z&W*K63J,S6*EM56SQ0 R8_&9K#%80<AXCH"L4Y?BZK5W+>'\R_WRS^SGB&
M67\^%?KH5& (E^EJ.Z88R-AP/@8@3#%:P8;N=(S@SYA,@,0D,;T]07/??,X4
M]"MWZ$RV!XZS?A)_OUG:X#CMSR8<'T9%\AM^$#44&KB,33^(@%%)[[:XN#.)
MHC]3"@XX2D; &08)R7!'20)$>SSPNY'T7[86H6RY:B7O[ )MY06/SNR,9$GZ
MP^0'V8-_1X/V$);Y8$?<R@^-H!6TW&K"0^PUJ BCJ)O9VW&^$6B AG/!0)>>
MG/3C[MQNAE);F4^FBP2? LBW IF>19-LM.-JHBD"BKP7ELJF$84 9EFD&\JS
M 4-Y-OH!_C>9\Z=AW ES.=L)]U;0>TN%6P]SS &F,_77]#>%JP>2&\<M;^XP
M/<S!.^UX;D=[*6MS; 1-ISZ(Z2CX1ZW5L94M&"59#*]3:6!*[!/6-!Z91WV&
MGNK'<6<DRF*F(3F"-O"ZXJFXQ]ED2GV+RLZ5-D,8Q35:HAW'N)LD?\<LDD0V
MJENBR!/Y<M1V%)52E3EX'.? M$]*K9YL)69SY(BG R*O]1'Q$ H-A+\F;NDJ
MEY2I%*Z,JC;93-M52Y,1:1QOI+6B#\$<@UIW.[JB/;%R(*/*5:!?/"L=$ D'
M1,I<'()(ZR,HUE$H@RD+UF^6O8I OA@.@*>.9CL.4>FFP@T#'?]@ IZVJ]5S
M3S??<(,MO$ 5[=]1,;BTVR5E.SUQ #VIF+:2BEP3)^6'LTU>E&ZV4DO9'_(E
MJ--FC[O!=(R<S7I<@.2Z%X=2Z@X$;C@>FS\?J>0+;-.GZ$B,W;QBU-%F('#,
M)K$XY\TMVTBQ/8!X'HWG**$,Q,^J8F_K&\?C$;PT&<I7\G@*XM 41$3T-#I+
MF$T'H";.)!G%!Q-0QZ:#YM*Y+A]Z)&*#AN08H@R['#3HNMAPZ.(ZJVW:KK @
M=OULKALJ.#HG>9 4:PJ1N<>[19YH[X;:=E[2(S9CX%'Q)!&$;UI\:,=4+V!Y
M^(-1P _#5-F!J2S3N+3+]9!7726[O;ADM D?P9',)U$\&/7EB0D;0F#8K&7/
MF=6*TWX5##PE-YK_,7U6?C RV];IKZZ35,68,=UL+UEK?N=%%%7&]0PQO*.;
MKW8,I&-'A1XK/+>P=,TD&HTG48)<#N/ZB0(IT U 17OR81XI$-@#N;?]IX3?
M?\HLM^UZN0*3(QW+9GRX_:5=;G8EJ"[7'ZJ9@]$X&I/- Q%\.IB)[L99&'X
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MN<VX4[$ 'N?H-VIPLP+&?=>H=SOER++HL[<?MI^2<R1'\3 :S;"DXF@XB49
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M?^%&<%6'-Z@S-RAKSY<':*VXT!*74NJ6*(T;CHL%DT&+<7O9$O2@3UW\PS_
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M<C+\8LT([IB^JG#]C&'JQ?TCI5._);CA>O4G99CZ$^%._O-Y_ 902P,$%
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M69,KFK5KXUJ5S5\DGUHO#_59]^-H]@U02P$"% ,4    "  +@PA-'R// \
M   3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M"  +@PA-9O,+8((   "Q    $               @ 'I    9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  N#"$V4DE2S[0   "L"   1
M  "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  N#"$V97)PC
M$ 8  )PG   3              "  ;4"  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ "X,(3<<6DBYD @  %0@  !@              ( !]@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  N#"$VIF_GE
M) 0  # 2   8              "  9 +  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  +@PA-1^L X!4"  #N!0  &
M@ 'J#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ "X,(
M34=F%U^&!   E!,  !@              ( !-1(  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    (  N#"$UC^1DNAP0   \4   8
M      "  ?$6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  +@PA-Y8-:?+T!  #7 P  &               @ &N&P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ "X,(30LB;GX>!@  FQX  !@
M             ( !H1T  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    (  N#"$U$)@E=M0$  -(#   8              "  ?4C  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  +@PA-*MSRR+(!  #2
M P  &               @ '@)0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ "X,(319: *2S 0  T@,  !D              ( !R"<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  +@PA-DF.O
MT;4!  #2 P  &0              @ &R*0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    (  N#"$U?"$9QM0$  -(#   9
M  "  9XK  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M"X,(33J7$ NS 0  T@,  !D              ( !BBT  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  +@PA-C>801;0!  #2 P  &0
M            @ %T+P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    (  N#"$V& C"+M $  -(#   9              "  5\Q  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ "X,(30R536.U 0
MT@,  !D              ( !2C,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  +@PA-.\LJ)W0"  !T"0  &0              @ $V
M-0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  N#"$W>
M06<=ZP$  &8%   9              "  >$W  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ "X,(3;FVU*JW 0  T@,  !D
M     ( ! SH  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M"  +@PA-K@*@UMX!   !!0  &0              @ 'Q.P  >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  N#"$WKQ5;.PP$  #<$   9
M              "  08^  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#%     @ "X,(3;/1;%>V 0  T@,  !D              ( ! $   'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  +@PA-5QS:PSH"
M  #-!@  &0              @ 'M00  >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0    (  N#"$T'8EGT&@(   H'   9              "
M 5Y$  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ "X,(
M3;NEGR Z @  P 8  !D              ( !KT8  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  +@PA-UK.^/R\"  !^!@  &0
M        @ $@20  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   (  N#"$T4R:(L_P$  %(&   9              "  89+  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ "X,(33E3E#=@ @  / <
M !D              ( !O$T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  +@PA-K01O[@8"    !@  &0              @ %34
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  N#"$T=5J!E
M@0(  #0(   9              "  9!2  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ "X,(38E712CV!   O1L  !D
M ( !2%4  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  +
M@PA-IF^6434#  "8#0  &0              @ %U6@  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (  N#"$TZU3A6V@(  &D,   9
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M970S-RYX;6Q02P$"% ,4    "  +@PA-P#+Z75H"  "%!P  &0
M    @ &);0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M  N#"$U@-LOE @(  (0%   9              "  1IP  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ "X,(39/.%"$4!@  72$  !D
M             ( !4W(  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  +@PA-DS9C\:$"  !$"0  &0              @ &>>   >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  N#"$WL]SDVS $
M (@$   9              "  79[  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ "X,(368C]O+?3P  >3L! !0              ( !
M>7T  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ "X,(37WJ%6MI
M @  "PT   T              ( !BLT  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    "  +@PA-Y +NU%D#  #E&P  #P              @ $>T   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ "X,(3>4A,.2P 0   QH  !H
M     ( !I-,  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ "X,(33"4-,&O 0  0!H  !,              ( !C-4  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     #, ,P#7#0  ;-<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>155</ContextCount>
  <ElementCount>234</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED C SHARES AND SHAREHOLDERS' EQUITY (DEFICIT) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Ordinary Shares and Convertible Preferred C Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Ordinary Shares and Convertible Preferred C Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlockTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://meiragtx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationAdditionalInformation</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Company's Financial Instruments Carried at Fair Value Measurements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsCompanysFinancialInstrumentsCarriedAtFairValueMeasurements</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Company's Financial Instruments Carried at Fair Value Measurements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsFairValuesOfWarrantsEstimatedByUsingBlackScholesValuationModel</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Fair Values of Warrants Estimated by Using Black-Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Change in Asset Retirement Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsScheduleOfChangeInAssetRetirementObligations</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Schedule of Change in Asset Retirement Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Non-Current Assets by Geographical Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsSummaryOfNonCurrentAssetsByGeographicalArea</Role>
      <ShortName>Summary of Significant Accounting Policies and Recent Accounting Pronouncements - Summary of Non-Current Assets by Geographical Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Share based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation</Role>
      <ShortName>Share based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Share Based Compensation - Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfCompanysShareOptionActivityRelatedToEmployeesNonEmployeeMembersOfTheBoardOfDirectorsAndNonEmployeeConsultants</Role>
      <ShortName>Share Based Compensation - Summary of Company's Share Option Activity Related to Employees, Non-Employee Members of the Board of Directors and Non-Employee Consultants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Share Based Compensation - Schedule of Grant Date Fair Values of the Stock Option Granted Black Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfGrantDateFairValuesOfTheStockOptionGrantedBlackScholesValuationModel</Role>
      <ShortName>Share Based Compensation - Schedule of Grant Date Fair Values of the Stock Option Granted Black Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Share Based Compensation - Summary of Restricted Ordinary Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationSummaryOfRestrictedOrdinaryShares</Role>
      <ShortName>Share Based Compensation - Summary of Restricted Ordinary Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Share Based Compensation - Schedule of Share Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpense</Role>
      <ShortName>Share Based Compensation - Schedule of Share Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Ordinary Shares and Convertible Preferred C Shares - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureOrdinarySharesAndConvertiblePreferredCSharesAdditionalInformation</Role>
      <ShortName>Ordinary Shares and Convertible Preferred C Shares - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShare</Role>
      <ShortName>Net Loss per Share - Schedule of Basic and Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare</Role>
      <ShortName>Net Loss per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Related Party Transactions - Incurred Charges included in Loss from Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureRelatedPartyTransactionsIncurredChargesIncludedInLossFromOperations</Role>
      <ShortName>Related Party Transactions - Incurred Charges included in Loss from Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgtx-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://meiragtx.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mgtx-20180630.xml</File>
    <File>mgtx-20180630.xsd</File>
    <File>mgtx-20180630_cal.xml</File>
    <File>mgtx-20180630_def.xml</File>
    <File>mgtx-20180630_lab.xml</File>
    <File>mgtx-20180630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>66
<FILENAME>0001193125-18-242784-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-18-242784-xbrl.zip
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MO*JZFZM!J -;/U V#SP4H515S0IP]27/@Y/Y0<2&GI]$<-!**_Y!,/."0=#
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M]IW_M(6@VA %&UHKF\,/%*#K"C'F3;0G03L-.HB>HZ-2V7)_8\Y5-<WL]AW
MC-G#FND:Z&<;%N%TNUU-T7L.U685LE754/;$SJY]-DMW%6B+Z;@(AYLP#&A%
M<;5%I]$<HX:B+;HHEQ!05S<4U[)EJVLY>*-%@8!<T'F.TU-[9L_4NXZP\E70
M":1W@)ZB3\)ZH+NQ=>_I!??!D$7#+]LKK96HW49R;XYV*K)$#W 5MBD^CHC^
M+T'Z5Q^LB.+F^R3HU_9!OU"<Q#Q$[.6F&#D!_?\]!@N N\.;SP$$M\ Z-@?4
M,;*0_#%@;)CVDWB<!]X4\9K;JSI#T7>-0\ :H*YARWW:!911"[O$D+ZL]L'@
M@^.W:\/4HLFC246IZDT@J-B_W=!/TZM1/N(JX:%%Q<":&MP;[(T"!S:$&)C4
MIB8\D=NWFX/QE&\!$Q!%>OH$2*.+U]()5NWZ@B2WBU(V:TB8YQ-UB8U/5;?G
M&9Y,*2^\".:]1513[FH:<;N:JU$3^$0XH[BPHOI:Y^IZB.8B;QBRR-6HN)/I
M!UCR&Y"W90C9"NBW*%?>QR@$.'M[%A"#YEA=V>UZGMQ5+,_N]:D-UMRU:(MH
M:":Q*M$W:T$X513.[SQ6[T.T,^^8^P?A;-1EB]_&E>W:3M)'KXZ;.<&;=QJX
M&I76.-:<WX/\#G+J[-MV#^C1@'.W8\EP!'-DVW%<&0X4JFDZ?=4@><@,&,TV
MO$:OEA18!]1JO5,,^P#+#?SP\_0F# 97(Z#JK9SESX@+[%?'W<*K%--:$+<X
MALZ$VM5(_)T%-R'[R@8P=+LZ!ANB:\/CZ&9BK#B.$CBN:^JFY_4G@3[).?Y
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M0[Y GJ;3-\TND&?? \QX5E]V+4?'ZV^WI[M=DQ!-%,W^WV'VZS"X_]^WV:\
M G[BC;>D-'L,V6\7_:M/W^2O'_Z?]TXBRB3[5>)?])T_/GS\GW?2MV#,4ND3
M^RY]B<=^]*OD7GWI>5_D[M7'C\[GK_#0( Y#?X+E_@8L#-.)CU?I_ 2!GR?^
M<%A\_AX,L[O?+F"[?KJ0;N)DR!+\OKJPI%C59^=W3W:_>,Y_R1\^??W0@Q?Y
M]W$PK(T>2O=^&-Q&OUUD\:2<7X/9\Z]#-LKX$SC\!O]0+_'/MS?%EV^SX9H9
MYZ?)ATV*5?[A?/G]PR?9O?KV[>J/=](,?9OC,Y_BV]5G_OR:I><$)A59!G.
M3"H+K$/U-DMJGW#WCPO-1Z__[9VD_50'SYB46"Q@846NQRA.I.R.21-1.WL"
MP@%8$D9\!SL :&P\2;"JNQ2/<!C,, *RB[\#:;U;@'YC@"A^,;\!Q43^>/+K
M?SPXRB)VGY=]3&-&W]B^B24KF:E.V?GSAO73Q9/4?Q-G63R>O7/U(X?Z_ME>
M7>>.F02J;*SU]+YN*:]R(/F*ZH3V!%KFGEC_; Y)3G,%&R2W-S\K'?C?+Q*9
M9%(:A[#,!?0#70(Q1MPTJE-;32C]?].(S5:A*IW9!]1>&PK;%X..'ALP#%"M
MH(3446(>%B4;4.\F8FDE^4HWMP!Z#++E/[I=S^OWURC@4^@4PL8+(OM7Z9OW
MW]]@X3WO$PR184RQEFX81,' #Z5O20#_Y@[')[3EGD2VY-D?-Y)W^<<$C7W^
M&.W 6;YCV>I&CT?Q]\2?_'8A_GML5CH<E%H'#K<=C2C'@/+8W'%>O%#-O?&C
MH927CSH]0VSWQ"+-&)K>H99Q'GRQ+["THUI&QU:.(@9:]?$$RT3I-,2HL+/C
M$=(AJMG1-?-U< GI4*IT-/,HX+9JI,(3&!EY?MQ K8YAG8DEM2^PJF5VJ'&6
MG'#F^N)S$H]8BNV9X+"![2C.CE%,5>UHBOTZ&(7"X=RF9VE8G15;%+>Y9\<-
MJM(QE*.<3!L(*S"^VBJ-TW/'M\2_9^'9\091]8YA:,UGCOW?/C_#(C)F%T94
M(=K)EMIJF0H?\9)SY\=&EM(AYFLQN(C:T>FS*9G)PP;7<2= XR:,D]]2<;JO
M75$]B"NJ72ZNSVEMIR?NID#>Y+4]MT+:UM0[!=WL>/&%5QAVAQKD/$3_CE#:
M'56E'5L[BIVX)K!)_#__.H]]J^3][Q:[=Y+J"-8>%7$VJQ#!J_E10U5UW=BS
M0,2S5"!9Q- !B^'PWJ*:I5-ZW-ZB*ZM.I9]!5 ^VSWQ>&2=J65K7ZIF.W%,<
M#RO7@6#%_L(F=?I]Q_-,CW17Q8F>+#*PJHS"/)0&_PCP#XXK:88L:88MSM]!
M*>AG434[A0,>(+YQ[GBB_52 E<L<H L>ZK@&IE1*&*\ZG$HAN_5#>#BN_.BG
M:8RM)C$T,LCN>-!D,ILG'DEA'-W*(=#J$ =CDYLLADEN<-P@OHV"?^,OF33R
M@P0E\)1)W^]8) 5%8UN,#1B(FJYB;"I-_"3#A8SR]_$\]H4W74H?(C[ OTE9
M-& X_E_3&(>._>0OAE-,DF# TH[TG4E8^'^,Z4?X2&4U\%0\3<24%=CF$#%-
M$9D?,4FX$FU51([F4V5L<!<%_YKB&X,(X P&=S!/\>84WS6:9E.,,?73.VD4
MQM\7<5Q;@S\KLP_,+0U!4>#.PEBQ(E\: !*#3/;S@GQ2$J1_R:.$ >)@SDND
MACG0:H#EK4["1Q@PB9-,[$",IUMX-*PT=8DCCBB\I48#CR_8]4-,K92^WC%X
M!8^>'3,?%=E0&H+HBFX1AB+.%L"_"](L3C!("MX(X .>\D8CN-KT4OH&NQ.,
M)P WO! >SJ?C"9TX003L,;]72W9J&(Q&+!$XY#/CAO"=%_@?^X](HRD8!,$(
MEA-EE\UD9<0'"GP_>@308-(9-64Q*"' WCB(!%7[0L?E?,.QA. OQQ/P)(YB
M41'F# ( %+&$$W*F+&@MA3G2Z>!N$[3[4;F^V00E(99-96*Q%Q5J7C.W%*0(
M&=939$-DRWLFHK?Y2FMK%XO@8/&6J" L9@0V9ME=S.4-3!*D7#XE0T'OY: \
M1+R@ED&5V%/0N24AXD)$$1^.3!1BU?X#0-MIVF"2$HUB$<RUNXJH3_/H][2-
M?=\R]IUN'_M.UCQSJ.^?[]VO+OK]/WA-?V7W6&]X03^N!'B#4)I]2(.'V8<Q
MV/!WLX]"Y7+[-I'>YE.!L <YMA!%+Y7!\TT,F=\;AZL1^,C\RD\<.W,8VS3$
MO@VL/^9E2V%F@LURPVZ#"$^\J/EG1'X.(?;$M#H:.9/+EUW3""CI4/T$_K=7
M?OU8+3".G!"<:]"+V5$I/0^6V/ORU>ZHY"SCO\Y<?73+PTYQ.#TIF[S@D)#F
M,=G/IMY1R,[77+^T&FA#IO*XAX7[Y-A#[DY(3LU:!Z$8O:/:QR&8Y@%+:,<R
MGDT'G6M(S.P(VK#(BZ,L[/1"OQ%@-W9AK?5W*.=!?MEQ9FX#2^FH^IGD!33/
M-=+JI=<B!]O]:-9^/%$);$FHW!-Q2B*J:<B"=P[\/L0Q_="_/5SXDJNXIMWO
M]F6;=%59HPZ1+=NQ96)874+<GJ-HY)I@7=*1'Z;L;V\7UC(7>%5V*<7VWL-A
MD/%DS<]^,/P0Y8V,5Y3ZCH;> TL&0<KR,M9YK<#CQ?@M+8GH&I2HMDUDW52H
MK#DNE=T^\63#T5U+T37-ULFUKBC6-2'P9@*H 3FN:=76Q4? PH;Q;?TX8< Z
M71[C,A -0D+^R^]^$'W<I=CD/B&35+/<?M>RY*[;=67-,AW9M0PBDYZJJ40W
MJ&6[(BI0UN%(N@%C/ U@'5,N1DBP-.VQ=) $DQS'V)HSO1I]%L%,_/$CU)"T
MU2X%RM!DTM5L65-U8"Y#<V73Z-E]:O=ZI-]K:T@N%&(DYUM#\BJY]:/BDH+7
M $)"0PN\2FKOYN [J]*2):SX!X\-K01L\54V*6"T6/4?+$C\W[\]2/\9ATCL
MJ30)!QW)E\)@'(@FQ'G$633,@ZU"_WLZJX?9]1_AA=('$#;1$*,=4XQ$S,N?
MR6GFWS+I)H@Q(+*<:R@ZK(B8P"B&#](M$Y%K8,<_2EG"?*$E>-"JC]R!+D5T
M+/(;+AC'%R<BN/P!CUOE86:<,\5C/.B2S\EXQ&045V+!9J_ "8INQ9>U(+L
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MC@3R)XC\Y+%808V9KO(?81YNY:8UUD*WE \(Y\0:Y\0JXM81I!^)?@EOF@"
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M\K/V"R*ASC*Y"T/Z6;R].O/G<@MV-A(>ZLH5/\\I_=EU_NK;S&:4&_@8@/8
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MYGV9K:^8LY;:P!>-)WWY'A@>!*_,@P&!6]/9$[7?@3$K/\G?V<U?028C!<C
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MZ!U*2?--E;UL,>-,[D-VC>:P[8Y&GBV9MK6GSFEQK=YNYN+:?6GFXAIF3[U
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MYLN.\ &L52*-XS23_.$]/.[?LGB:%O..>$$23"O.EPT3E N\Y&G-E7SB]*Y
MP, /!].0BX\;7L\ECJJ=AA 8G'79Z@42IRD6U.3(+4K5+%M"!PY3V=SD4CH!
MP3 *!D4-'L:EUJ7T(2IKDG3X"FJ+!^17DZES6(HB-,"^6!)-%!V&L3DU;EH[
M;,*2$99$C@;U\F%2$J1_\4W!U_#:,E.@@^^1- !]&&3\]\52*,^5PIY7'LH;
M2:62\[4K?8LG@&J+*AWI*0;/*7!6J:O"\AVD0YR/SX1TYT\F($(%PK'#^ESZ
M^R7,5-E1',(Y$Y$XV]9.WFD+WHP%X]D#K'^8YA5]AN5"BI3Y?)E)/(V&5>+
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ME@\3L=R>X9ZFO(X7H*<ZME(_^KN?5LNQ<E\53/)C:4_,"GSE#C$<!5,-@Q$
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M>_7=7GVW5]_-<I>U5]]G<F/47GTW]5+LK/B]O?IN/".TX#61R\]<S[=7WV?
M&BUP[=5W>_7]&NZ"VZOOTUY]K[FI..:5PXI;CJM1_M)!7KUKYYN):12(IX(T
MUB@QK__\VKO &YM@[(<I]R3/7UZ85/%H7]5ED]J.K'FZ*EN&T94-2OJ6:_3-
M7L^[)M>J=?&>VI:NDR4XFP=@#LXX8;"777X[.'C\EOA1Z@\03[_[0?0Q3E.7
MC6#,-__AI)!KGF=U';LO.UU'ES7=U66+6EU9[RE]W8'/FF=? X(NWLO$U"QX
M=07TS6&J(^-W%K'$#X%\G.$XB((T2_A-*PKK*&5-1 "!G;=T>+%AS1#P!!QU
MH#]$@WB,N,A_=>'A49"=%%AJP,.J:<BFVE5E3042MWJ6(ENN;FJNK1.B]JXI
M7M)5MGG%PA>@XQ>BO?QB]$/D# ;\OORS_\BOBQK(S\0 LJ8:40V-UN!=#\I3
MD/?R$(R*\&PD]!I KU'%UM?!O@28I^#G;<.$5,B$3&PD^!3 -W1%I]8Z^!>!
M>0K\SPF;^,&P0%S.-2 D^%0-1@C(.%DE)E&5=0C9!+P5DJ\7I(,P1BOB" $(
M&HAQRS2(K/8\1=8<A<A.7U'EKN,:&J&T[QC:J@"$Y[W0)HKRT\HK[&)5.QS'
MBODK]^4A&V7EG>X-_F&*$):;XLN51BB?<7Z:XYWVRG"$U4L7="4!8;%T#HC5
MA[P&QH-^JP0P#H,A!J-AV!_0@^1+DR2^#W@H(X:&!@+D#$$N8D7?_""J:$CB
MS,0#4-+@07Q<50EC%JLB@O]X58OY2,I;;M_PTS,8<_D;_3 LRFPT)_RO6+58
M6#" 13Y*3,31\-K 1:!>I:A' &(X8AC3-2QB)@&O18%A$8*)58(!7O_>#T(N
M(QCW% Y8!_@5L#N)160>3(*XC-@M-P"+DB+\C46L'[QKZ9MXM94AF^!.8>&4
M-7&PQ>JSN-P;*9V.1L$@$$&BHRDO=P.SYT'%G%R&4U[AN"B.,H'_)#A''@\7
M)+-X1/\!0<FR)+B9<LS%,"<B<XH7(__FU6S2H@KS90WWW[$5-("&B(%)"M34
M$%/BCW];K7^#096H0&#1J8A>!/(-HBG#AS&L$TF/KZ42'O7_L_>NS8DC2:/P
M]X[P?U#TF8GHCI"\DA 2=#\[$1CC69_M:?NT/;OO\ZE#0&%K6TB,).SV_OHW
M,ZM**@FP,1<;C'9W=@Q(=<G*ROO%QW HJA0&'_ \5?CB1@2$.4C_!-:)@;$9
MX00N0'SS3X#.,!XO*C=V)()=M:M;"OY3KTF^!;Z#0(D,I1, ^(D(41@%5YBP
M,2A'>!QS<2$2<5Y8\H?1"/Q(=1&[/?S/-,TH>!JC)Y\<CR^&ET]"H&+D61)0
MH1H1&,F#,!%+Q-P<2ZA6325>E1!U[ ^7BGI\C.DOH3HDT]V7GU$I=D I]MRG
MM(?*;JK[YT$&NZS]@M34\& >=9^E5<_?TB4(BE_9R^JX2YZ> [I?PVHVK-DM
MB557MW3'^,WCF"T?WL7C:K__K6FZ9:R<O_KR'K_$T<T7H-)#+L6?//S.XIO$
MG]P&@PXB\[9BA[OVV4GOU#PU6JU>&\T2(.F:K8;1:38:)XU6^Z3=;.Q<[' >
MBBN4A^EX["= YU-:UC(US*(X,D2Z -'0O(J9%$$>@,O+ _!#)/]P"H<6[NNY
M:X;[MIX?[NN^7LSMUJ>N8VZ?&Y"9*YPSDN&<T,RG%>FW 8ME Y$W!H\ZF.51
M1W=)N=D[1[=C-72G9;V*O_?E-]MP=<>MNU6\T)40VOW>W0FX$K;GZ9YY(-<"
M]MMV;-UU5@Y:7_=F['N]\[J30GT>NW<>NR:X[0DM=-N6;K6V0@MW<+^.WO#:
MNF6^6B.F?:?]=:^+^D1V\T2>'8;Z/#-TV83]E0D+-X8?=J3;]CKNQN-Q'%UE
M\,)M' Y9DF*TZF 7K?<4E0;*<-MTVUX!E6?NK J6>Q'$!LK091)'\.> *I&D
M<TN1;# LQW1[5J_;-7JN:QG.6?L$-NV=&,T3M^>UFK!-RWIUV[Z*^*$P<.$?
M ?[QC2HP:07\M#( "8F#G#_,#T)Y#3?%>;5]3=&[YJQS=4(5I4 _[ES]N;3+
M D<P3$^G_>7^BO,Q1JEP:*!#^6L<L?$DC!\8>KVI$)5Q0O$4!1!E>YLT@">Q
MCPJ/TO +*(^H9D]*;_-HC(G_P.>XP1HMO&M.5,S%XU-N8HQQX/VAL;I:,) 5
MRG"CZ72"58.&\'#GJKOTOIMFTVB:Y5UC  '[.8%_\:6G@WA"!8-@8)C;LUK"
MN1Y.ATS+T<D/PP)CYFU/HQ(T-P*<HB\-#"@"-GR,+\?0"AZQD6\WWRSO84WA
M*27@<)#DGX^U#K78ICI0NC:.TTP6P;F9!D-?-!A"*.%6_#2-!X%8"A6DD2/-
M/2)=;!P/4@X=9+QU#L7'EW9'A:U$0YV!".V '2G%IG3-GP">4$0*#*)L[$D0
M'A<78 54+Y\YC[K!>!BQ#02K!K,$V0,_(HJTP+H]O#=0PK(DEKV&M Q#Y/G1
MP7:2V!_<ZAR8O'38>!I2F(S!1B-XI1+N 6/Y%"S#_ 0C/E(1L,)CP/KL)H@H
M$$36%0O2@1]J#_"TGD=N?;"4?I-YCR.CZ&94 :Z/O==%S;-;_XXJI<%4+ )T
MR[*0=S^2!=*&,54D@B&HLA\>X0=;F0]!5IILWE2X4DX:*&"E6BX0X]+R-; 4
MI8D@O65#?L4+S$54(Y09R#@<7M10ZV/=)>S01*<6"*JA "LM0(ECC#*6S"D%
M9?%>8&W:)=6)",9YA!4>J2R[!F/0J.5@J2"5E>**0#51#DJ;Q!FN#:-TX.%!
M5O3TDA#F$(<Q8/_1$, FXY^ ;9->3Y>*7^V4OPZTB8=YP=4<!1$ "2?@05KB
MN@W\]%8;A?$]IR<%Y1GF(3P[$O*'G,V/IG[R(,(7JSQMV4L.!*$XTJ_Q<8E7
M>H9IE3E=3L2+YTX$.L&JX&S[(E8JU3Y<QQ/ MI;9_*AKW=!/@M&#/.!3!B>0
M4W!$<SF*K@@3^12 GBOM1VQA_@[FSH37' D1+5>RY&%YM<4%@CN%%QF(>WZ5
M$/&1R10(?7_+J*1H5F0' =K>YD%RG-_+ #^ZM06# S#"MX!^@*<@57^D!?#@
M"/A>+@1YV<8 -(>P<Y8CHTFQVF Z[>/-PSL*UQ?I*B>!Q="S)01O@ _0]OCZ
M?9GGEF\0_QX188@CE#AYY*THT!C=A!1!B"&B<#1$TV@DJNZ)@T\G^#J(4Z 8
M)',>3#_#RE$FBOEUH7='_%Q$X*!<&M:/1(;%SS3@!+<X^&-Q\U>&=_X%G&E<
M@GXA'Z053)-R%/"A$'A"QGL23J89+1?8"&Y-'LL=-C>,J0\?#RR-;S@6EBM=
M4M]'"G05PA4>3Q%BBP%\6'-VFLEI@!&!G)N*7I)Y&"HVL!9HSH,LJ?3GQ$^R
M8!!,L)N@K+DY"7U@3F.@4G@W6"@DE V!DU^K,CI35TDN.PT1*$7?0\ZY@ ^2
MK($PHRL8 5W-([R?PPJ]95AA>7C.$U6N]DP);?;ZQCEK4!8HPMV' 1=OA"CC
M%^&P0MYZ+/8Z9YI'[W*VJ2L\5N&P>"<+9KHS+%.>' +#57CFLO#FO+4D32]F
MGJYAFT\R3YXCS&/;NC'0(,$?$)&J2B7GIZX)*_^&59V!LI*BT\5+#.0JE7I)
M%T3F> Q:GLKBEMRBRG07;#3?6XEKJC0-#[U*U7(.B=B'!6>Y2,6 1R2!S(],
M@6HG163[0*A&B' L@<LYYJ'N(,;>"$13]"<6( 'Z5);P@6NRM,!CYS/IU-,4
MZW\+E2F)'_R0E@;3@H",T;R$SWB3PQ".A"YL@NB-B1,X0$FJ?W('N/<$"0X*
M#$ I8V":N J0![(@)3U@_OXTGJ8@WU'?0)C Z0<\@ETR,7@4  MR!]QE5(QQ
M *$6<T: DZ1$F:7DQ5GKH@4 68^T 6P<%"_@!P&1"PS#? 8+'+/L^'%<JC#$
M_)-DA0N1B?9$&F?T(.6,"&@#;'N2L+L@GJ:H7OPDF(!B2&26;AO[R63-:,0=
M,F/@ZR"U_ 7G'60\74.5_+5S8(*P/J":/QC>-LO6,%R3CZEE\BX#'I1O<E"Y
MR6*5Q.OY199JC+XR(W0,LWU<Y@3$6F#2(9\82;Y0HU+X6F%[N;*JJ.<E*X6_
M?$SOLNLJ6-X:PA3A3FELD3X&8R[F<*@GSFJ ^B)U<4>9V5?$J HSRS>EV&JO
M!&JEVDE,& ;;0:YW]&ZCNJ)K6*TGV1T%YXUYIA;<UBY"]8ST;:$MV@WS([*W
M%,12JEJ#C\Q3U#Y0DP,L##]-"_- #[C>#6[Z''>6:M=^^@.[30S81]KWZGB&
MF\N_(>M,&>]$57JQ#M&PO%3E/D<AO.P<"B6QGA?7AP$*$]N0I4!R^]S&E!1
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MD065%X[>/<.J3?@C8B(&Q!&"/%MS,4-\EED:*XWR&2H:D)RNRH^X6SV^YT=
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M'G!-*1PE[P_L7@D:H^BKOZ8823R*XTQ$6)#K(M\4QL'FVU(W-4TI3JHT_X=
MG:ZR1W1>SNZRLIS;>)KD+I$"/'G4G #)[$#<;P@+4%= U<IH%<, JZ1PCR<Y
M3H3/LSA52B^_]<.1G%UL2M<F(<8@:MZO%+F%@?8IUHLC#R83[8<!A309%,A;
M&<]'XI: :;8H(@4C@WB:'IT RCL4%.F+%M. [/0'>CTQJY%[<OD>-AHB4A/,
M72>8I[S3-*(2IWT<0Z3/?+EFY%5<S(,!2FTW.5$I(9M,X.+UF82#DF(UL'^Y
MR!S)/6/K-M+<&]1< @_--X:'!7K-''*MYVY/SUVW5ZNW0J]6Y_5ZM6Y]ZI5Z
MM2Z%M<L;&UZS76E!V5;O6)IW9MW%?JP;VJ"WB0VNUJ=K96Q[^7ZKS[%&K=1P
M\ILT&KQDF\E?EJ)8<SJ,M?6&O2>M)5?=8]/6+;>]C3V^\&79^ZMQ*?7F%[T?
MZV-N=819)"ND32JP^WI+7?>2/7.],X!P=<]QW\!=>X.,B6(7ZIOW5F^>9;_:
MO=O7MIDEP7O'NO1N:VTOC]B[LO-=7MN.<;^]YW77<88UZ(5U6!J/:[5LA_;8
M;.NFLY4]'@C+VKW6PEM;W%XQK?I<%MS$.L[J,+W 90Q9)I$R#7YRIS&AS6P%
M).%*/GJWI#-YH2OYZ-W2SN3YKN2C=[4SN78FU\[DVIE<.Y-K9_+;V6#M3-X)
M.\8^.9-MKZF[GO.FK1:XQZ:]E3W6)KY]<"8_'U/G^4B==F,_KLFZ6[6;NNTM
MQ2QW_+J\0=Y2^X/?]-6#FV?6'N$=\>_M\MI>'K5W9>>[O+8=XW][S^WVVR-L
MMS"(=2FE_/4YUXI[;)BN;IJO)BR^ 995>Q[K<]GQ<ZD]PK5'>)-YP6-_R'C-
M\HDH4:9ER.EQHE\LIZFW6AZ]_(LIVHGD1:9US%FO$]0/&A%W+#1A%IL1W0M\
MUBVGH3=,AV,T&J/;CJ776%UC]=$[T=27NEP,IZQ  ^S^MQ@+C^;U%VA8HBM!
MD +AY-C6<BW=Q#=5;.--$1!+14UW7G;^M#3_8UV?!C'<DBBERO.E1C6E'D.;
M;3+S]E#9:KTQ7,83[DN-2W0M3ADU1ZPK<]443QQP49GK8I#%)0IF-W2E#=O"
MVERC>)KPTEQC/\4.+7/*<E')K3^[7ZB1Y33,?!0ROP3C ,@4RI1%+R-_- K"
M@,@7?RD*L%,D_M3%)NZ\CM47('G4%.)#00J[GV&"XN/IYX]*'W(?B*"?L-LX
MQ#);Y2I0V.GB<II@&=:\OX=2A&O!LH_>Y1VDGB\!31)F#$ @P2XK"X2@1%S6
M(]Y:9<B 5\2\XO$TKQ7&2U\5W0:+>F+G$?*"B/]Z]*[HI+*@O)AH\R5[P-S'
MR0^-8L12X(1)49V+=YSC<ME"IN?FLIGH* VSWF#'9VH-S1DL50*3;S8^@USF
MHFS6IE>+[VT0SLQFHRJ@\>Y"V"?F9S#FC:Y!M&MZCFZ:@MDV+ L_Z-4R9#[N
M\(;:4LK&4]BS6N[SF;L\>B=D4'5]QUHOX 72J,#FV'\H"HB5#X%WH[P)[G#F
MAJD-_8=4NT^PMUV$34W@'M5\^Z (,C>RR]L_<_>9+-0OB4"@TEE>&' MZX!V
MSZCJ5_5RM1K%U;(LAU^M$M+7>%KCZ7/Q]-6-!U17LX+K#<^6N [#_&+;=HWM
M!X[M9].,6JWUZ67>\'4Z6[)58W]AH[="?/':GMYP&HL$%K-IZU[;0FH=3V]N
MI0P.F&F;-88=%(;-FIY0\2AP;+%RY6?P^B-D[@G;5 .$YI;7D-3.\YIZ PLR
MEP5N;J0J)7#YO+5=BH962M_A(\#7":H2.0<0<G=NIMJ4D>IG&>GSS_N \\L9
MI'Z^*0Q_Q 5:4[:WG/8W8XC\PX^F(W^0<86[MD;63'#&&GG%)EFU8_-2YLAQ
M";=(+4FF-U15'GTM,R;)XZKM#UE8V?I7# D3R?:RJ6A7/M\I@ZX88=_3,O[X
M,E8[U6Q$WASL1K#8=/2$X0AE"G4WI.LHE>R!AXNFNB0LU +G0=VUUS<T^>FL
M3B0L3([7UIVV4^O<-8*^10M3;ENR=-.Q]:;5JC']D#']2=W_$9FFQ.$?C5-Y
MW!* Z(BV@':K(6*C=,=U=0OP<RE; "K]Y%03US)87NVOT?W00U.^@+P*2%+K
M@C51G-4%_T#^K^B!34[2'E,$(^[>#Z?8-QVC&<+A/79T"P6>S0E-.8%G(Y:F
MNG;YI3LGM"1_H!)C M,)L42;3O 3PW0<# ZY2?PQ-E/CT1-Y>[C!-/03[89%
MI-"!U('1 8/;" !X4^H$AZJ:;)A6UDK5C=_Z0NX9XN03_Z&TFWS:U \9TOAQ
M /_. $'S^%A="T9 P&\#V,50GXG8D)PI'BDVO,;G1ONX59P)C!H&6.L+=.**
MK-.TC]V9!W.HX%2E.(S%+(PSGB1^\$-J+P>C1 QMW[0U'8,FAVP$NQ;!'H-X
M/,:6PGX8_)=P]%CK#(?4.M /*<JW@"*, AP-V1PP*>S 3-H]/ 90RA!-8$LI
M&TQ):\=EC &F\ /QL)G.<_@ '4N8QH^=C8]C@0(>DMVB&'#$6#DZIFER#^0L
M=%V7_P(G%(0"GJ,@23-E^P0@'-#';0RG@XPWME,O04@OYY:&/%H&&\52P%2I
MVR#_!2;!/!K@[*$?C$D,H/R D-WY'&0X5Z5S(#_P2<#)!HX,: 8W@GH0RBL;
MD/D#+S*<@+BS0SE@2G"HM /$82T3F0)(1?-RT\@_\*_>M^OS;N>+T?ER_OO7
M3YI,OA2R/KQ:%O7A="C\S*>VC\):LP1X:TYU2)SJ6J'&0[@.49QQ6J#A-T\J
ML##"/%?R<&ZJ#P\'?'6EML;P@Y?8F0^X6XOIAT[\<H20Q@4>&DOH4<&.&B<.
M!"<*U6W6XB2TMT?<>,3BJ+7S\]E<A-M!&3H,*2UZ/K,3Y89) <&FS(QK@9UO
M/9W+IM2E.9I-B>#FLH:MDWI0Z@E._:AY8V>EDS;(Q(B>_QLG/[C,S:<3F0/4
MR9OW?"8['D:J:PEI>-RXANN@SMXL'?BA##R#MV$#%%@>^3?"WLTP)HB,RO3"
M+5G:'E+1XCK?<6&?4^0+OBB4_J7/4)Y+@EB""Q6+%*OA8_#>U=@P&S5>P!10
M*HO&U7.SXN3I5R/>9D%\K%V@$C^;E>+J2M:G.#W4M<8DN!0=W?.?,?NAXDB%
MA5>,"L(0RB6<.(*=YH<AP%H%]F(]&71>MZ$W34_,VV=HUL54&:R*_36^F^O8
M]G*8+%B:8AJ@+ K8[\(\#A^%4+(D U+G2U44^5\LW7$PKK6-UMTQK(GWA99V
M6:'K@$+-2*65@% LO:0+\;A(^K6P)Z#6!@/P[!N,)R_PR$_IX<)0C/H^R;A
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M:&K'RRHCU(Z7A?<*KI59NUYVP:*^LPM[>:3>B6WO[,)>FZ'M%?O:;]>+W<+
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M'3H"G (>:-- ^^[\<)J#N@/@@.N),4$\BK"LPUV('^%UBO%+2\J<%L#&83U
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MXJH)>4W(:T)>$_(])N3V)]!KD'I+5QC(REQD+U%Q0 $DP24JKA=NO4+DUUA
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M()JQ.Q0U5UZ*IKP]]^^!D*#:H;"^0^$ C<UOL8RI%,:T>RRK.PC]- U& >^
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MZY#/UY3F44ICM=X8J<$3[I.V G\$^,=7N.1?XC0%J2_1+I(A7.[D@7,YPHU
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M;8\H?USB$&2F[,$U'P;E(&8LPK<A"FLOJ8B3.9+4:"6B41IRDQP$FS*15@\
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MRF;LR<IYWR[DPIP$O)Y3_84E!<%2CU66N6#6/T3#@Y=AI.;3GLZ5E*Q+SF(
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M4V.\1]>QUAN-& 8#LP4S$=!@)"20?O2@D=<5@^JB+*951+ MA,_2T4U^A*2
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M([@CL5^K',E&([]7AO]YA(0V0IX.(+\/,BXI"?8MH ]P;W].92BD-IGVPV"
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M%PL\*QD1+.!9&),IP!6]$G*X9- NDMK2/&MKVIQ-1K!NX%]PJV'R/1E-;G-
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M)T;C"3ASX'&M\P0[S@K"7"]6KG*\7HQG27/N!+'7<Z0?$>E#?.,%03GX[9Q
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MC=!N'/RUGXZWXX\T)QJS_5U7X=0> SRA]FVK$K[7'5=Q3GN @OQ8"$=$<(>
M]I3C1KX(?14*UN-VA79-NS#Z_B"]E9Z\8]O'(G0W5?C^Y2BI^0);K/2'DSUN
M&[C0O[/WX#8/)_T=!M_,R>_-N07D%WJ<\OV.?F]3"[!EV9F3IRC!%F (,]?
MI"@$V!EHS]$A1*7"8PQBH2!RB _!4>1&K@P7K+,+[ZFZ!;8CH_^8<+>)C>H+
MGCWWC'X#"EB3M*RO )O*IVZ3J?P6Y_"?9A:8#,'1""9U<OA'.?'@GC"W;7/_
M:W#Q6&^(FKW>F3W/"5^TK>=#["VM&ITT:DI+F$,!#)^OO=+"[!I5+; M2P:
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M3NYSUBDY/KX\IDX[179]BIZ'#IGGNN2T=?C2%$<\%\-,E_.V>M'/\\LL'::
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MO%C3&SF.P2/''PX[*K*1WE)E"?I$Q3J8Q)AZ_>7*\=:$<'"[X?,=63X2!KV
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M\:KEWE-'99!7MD96L8<;]#I:C0==K4RG5I*A3BZM2.240RM!7$MW-B7RM!/
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M]6<4S6-GM2"BV3GH^IKIW -0A60&<.(4>=<O*Q!;4?W-:/XPD#C2RZL\.41
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M*3ES9"A%OAF)63I.P 98I S*&H[K^9+XMLZ3)/:?TH1(.],H\V=R3D;_=0S
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M!,Z'Z+.";@PE[HA1]Z)?06J#BDX?&EL<0L%%I==YD0>-(7K"U5>K+%#9"8I
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M9A;6!*(OZ$7K!25,=$ZYZ\6Z&I)WNSW_YL1>_1NFR^Q]O7Y9(9)V>.63+C[
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MP$W=?@=@\3O</<)$[M/ES]H#!55 A9-G2TZG]87*<J,W&F27IVR7)6PT0TP
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MR,"P11B]GM'"$G1W-Y\/&G\WC?QZXRH[V&=SBG'Z?AD#AB%]@/93AO86('J
M!9ZD!48PR KR$FT=(VT,8PFVSY,$N9;,03V@!@55]+B/&QSD\G10&3064SV4
MJVO")@"+LUH]3Y-]WC#[3 V3^P*O/FH6>L05U CKY0E>L(P<U0)R,Y3R]&#'
M:IT\;3:*\>- B;S^(.S#D.7B>$2EJV\O84)+]?D9G(J^:OM1T\AIM:_$QZLZ
M9BI! $NR")3#3*([7*M#(L0X6!FW'LNX5Y@\QJ.;-V7:AQR["R.Q@48I@(.@
M#OA9SM RE"/2'RJW8/&LK)[YG.FA'4L)Z>O29O/%\I0.\3Y*!\-X ST-MM18
MJ2;( BWI,LA9S/9"I1P8<KU@IY-.4PBK,W)TXV\:).$+ V*R;QGMNH6J*/0)
MT\6TP L66=^61Z1.0$VNK4Y=I[$L+*6D(DRQI15712,;)=9BR\UUB%+1VNP;
M^UUF!W@9_MPWFXL$KL/L9I^EF4_N6C_?X?)MW CH><TH],2ZJ(3C:EY@C\C$
MMW=3J: F=@*H8%O@TVJN5YF+K0VHM7$E%?A<8\WA32Y(FX"3<),5Q/4>Y[1T
M6G/0&<39?%H,.L<^9!EG_E8(C,'Z+['^#S</YQ_!Q^OS]]<?KQ^NK^ZM1KSX
MB*0+)R#K=0RB]7T6!W]_CK=KA+FK?^S#[*W_*[%?LQ/Q3%U4PL@[Z<" '-"C
MDJPC0H=];)A,P,7-I[]>W3U<O_]X!6[OKCY<W=U=78(+</^7\[NK>W#^Z9+^
M\R\W'R^O[N[_!*[^]^?KA_\ /UY>?;B^N'ZP>O6N;!ASX,?WJXN8[*G5(_VZ
M0QA5+T@S\T[F(JQ:K\0SDLDTT_LO UQ1>1XE#UL&<EZEI#]6B@?M@#-O7>&H
MWMFJ"\-)45+'>H<YS![:1>)FRMI /7FQ!;BT(HH#C+H#W(" ?._5?L$J) ;0
M]=SS^-!PJ7\ZS$1Z4/<SZG4^/=132JO%W_KC3@R8 _H.WLI7&)!"%T\))(OJ
M_.V,G">-KWXQU9#>8C=#_S[+U[^H)%"*&G>_('\-3(=%4PL6]:R$Z3#+4S?+
MS"J8$#;5.AC?!YK0BU+*-4HJ)4[:<Y\UCV"V(@H'JT^*LNNE+/ E/T8^]BER
M 8RUF#6U8U8?EK78YC5LLPA>,6IJ\!68;25OC7&-UU>XI@6IWK_]!N.GQ']Y
M#H-S7,CJ =^&U'>EI*(0D_FMDF;R">'\I%SW1BV\V^(FBD+GCV^@:@609L 7
MTI ]S!GQ!P'C_7ZW\Y,WO#KW*8[>-6O.-GV#AIVX4:OI\Z#P;Z34ZA[5TE'_
M[D?[#4K<]PE>).Q/MH7/F^ZP1<I(]P#>TIOEB7=#GO7T6Z-U4VO6B;MOC29Z
M0TTTTK/+P*SLW7N]HJ&'3Y.LUKNCG]H]._H54N1;N-OOF&S0_;N!_KC3J$+7
M<N9-"QP0 9;B_E 3/%D3QHYK;H#@.&9;:2QNPT@<MXV_FXK;>J/R'WWAG>73
MHKD FW%[@ F>K E&XI85(&7<=JRT,:+Z!#-<S9%<0+V&Z_=OGU.XOH[RTF:H
M7RBK57)R= 4!!D=2\EHIQ->T2'&0=$!J8!;R\4CA1]P$"*.?0-G*Z+4^^];<
M1G/#LG!#0$J!UMRP*8WWA<:;&C.I!WA]O*3H0+<1W+/&-T"0DXA67S!;S,[F
M@Y%M?<EP=,]4-7\WV_AK2B^Q9.'<ZMKB<!P, [SU?2P<56F=Q0.Z;I8 ^T!G
M:*4PI%DMY;KNLA57N^[#W=#LNO?4<O0_A>%.=]N"X)9 ,<]Y;J-W6+<M$N0D
MF@=U3LO!J':UV];G&6:WS<*YB]VV! Z& =[5;KNZH'9@M\T28!_H#*V4POA4
M"N#F;M<8V&T?[@9VMUV[LMGE;EL0W!(HYCG/;?0.Z[9%@IQ$LWKG-%^=G@Q&
MM:O=MC[/,+MM%LY=[+8E<# ,\"YTV_3>@H]Q*NB9:\^8A6O5L$K'LII62*02
MP(]8QD_@/,N2\'&?D9U 60QN_?&.CDA@;K!Y7F'>%KUK+2<8K/YR=/4E*G$=
M%%Z-#_#NT4_#@!P(7(?;?0;7EDFLB^D6/[4,MTX]YZ]^N"6[M.*+>+>+H_H)
MN_?8NS(?44**+?KJ5TVA0UT6%108!%>T@]F-M@3J34T :<P!RM#N$4(JY^O_
MW*<(@" 2L(L5),J'.!>KDBZS@^:OYT& RZ2@! =E/A'Z9U"_/4Q\EF&P&*-X
M5M--)7RK-?BOH&H$-%N9E)?JV3X^8,@EI).]@P'9O,SSBEV #XOZ)L('^- *
MQ)$_T+"FFGV,UN4"XG4&=[US ]+OFP2UK%(*">+<RP_\Y,)K,_4X1:R6VTD#
M]L?^([D@/XKP\K(ET>QO47*<!JA/WB<0'TV(XN@=<0\2'J5X!B".+ __52.\
M@6,E-VHY?Y W>9.@86R6_T!2@NLTW:.6X46<9NUAO<J;IL\DR*DE&X?3DY,Y
M&JO-<BC28(L3\(*$5]&78OD@S!L  6[!\,4HHYC=8"!D-98-BI^)=%"(!T2^
MA2,,HQA.;UUL?$^\J(#P'T%",N!KF*'O[F\)#:'?O\(D"_&8Z06A#28)&CY<
M@/391P;CZTBW^S5=E_"#(-FC?^9%1E/@9P B1D=27F 2QE:&_0.8H#PLH>!_
M6QE'7B*!'.P2=&"-QPSG#_6VY?O(Y<G9K'9\\6/M^**]/.  4[R<;T N!/A<
M6TSVYZSX:7?;':MU]<YP][*-WR""493NMYF/<GK^Z4#A\Q9Z8JXR\H?+YJNS
M9=G_%O) 3:"ETX$:K9M:LZZW:]5E8H'L=Z6-@:2-IOJ^7IS5>SRQ6W1#7PKO
M]D&N%AC>ZO3TI$(VN"H"PSJ<!]G1P; ;N!UDBZ?T34P#M!^5MD^.Q1E,;_TW
M/,LNKJ/(>M)HXMEI7F5VM=R"AL6 7,[(M13[$]!#3?(*D_#]#UB,W>R3&TK-
M!)1MM9Z.:(_1=+,AMT>DQ=TM<,UD'MZSQKLECB+23#@]6ZR\O'<BLL#-AEZ%
MDH)*G.$^2H]14QM&]?18>BSS:I;%F^)2%W)KFYW]%%( JKHPD1>T8OD3_/K!
M#W )R3?:F.BC=!^VA>:.)O+QL9J?GK7AC%=*"WDY#.P ^E"[IG;LDL/TH<:U
M0!TAX[9<FXP"FHNB#J+9/M *Z=L$UZO:"9%</F,+P(4""B%PZBT:N,43Y;D4
MTTLLAQG1 FDAQ2(R!QKBL;^&=3BV$=!!8<->&R/#<OOV5;[ZPQG%=)\S."KL
M-*ZP9K_R\G(!U0F%0HJ=[8*'&E,KK5^=-( "DTR-#+FA5!\7LJUW(O)[-OKP
MG[>)A &[6$Z74QXBK._:T65?ZR[- AY6]^'T!IP0)]8/U90:]1ZM83UI R-#
MSD$LI\M%&QV-O>B6<3'8)EK/&KW7.*061VYT&>*C'3SKK<* CIH^[+-] O/Z
M<+?T>M[T<M^^D5WU;1MP$:NDDJ7,O#:$J.P)H-)!4?2OD ]0 Y:!I=5Z K;S
MIZ<$/OD9!!MJ]2ZW.J'[1E\*X_?1&H];FC<_.P%+N1AG0E7"GP[ ]P[ID_>P
MGV!OYL=\QQY4FXJH] ?%.ED7H%AFD0Y. !+K!"P/LI1UKWKC6G4WND!10 H0
MQG"-EDF\FR)!J->=1R/;,()DWS=K%J?W'=.3?'T*24<2&G@7DWZE3/"^=>7
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M(!=I;@R4:LGPA-_BR$GM;Q!7'(?K\U>8^$\P_PN\3<) ^\JT8NO'28 BDY3
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MV!N4QJ&I./.WHQJSQ,8\X&;H!JMV-/YX"3=A$&8_V64O'BDT&8SI"S=8K'<
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M8@,VV!LE*BS7YCZ,)94[ 88S*4WF#OB(I**?T4_H'X]^"M$/_S]02P,$%
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MS?&K![1N-&FV9PS6MF"E7?S:)18>P1&@ZGC&-$ XCEI32)#LU,BVPJUJRUI
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M[AT^O!W#L!NQW?=[>'NED=%$*Q?PTYVF/J3SK5S#IY=?/P(CV[W/!S@]BOH
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M0$]:_KG"*:F%BOS]?XLO?)#P:6"6,S&C.2'9>442?.-K&+!N;JDJ1L80A2X
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M[J1*$:S=KKB/21/#7M'*5]&DI:EXN"GR+OVI;P;R>,O@1 _.CD"!=R_^)4I
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M3X@END/\Q_\"4$L! A0#%     @ "X,(3=$C'/;0^P   QP+ !$
M     ( !     &UG='@M,C Q.# V,S N>&UL4$L! A0#%     @ "X,(3:\J
MTQ$T$@  *[D  !$              ( !__L  &UG='@M,C Q.# V,S N>'-D
M4$L! A0#%     @ "X,(30O[+$,S$   R-(  !4              ( !8@X!
M &UG='@M,C Q.# V,S!?8V%L+GAM;%!+ 0(4 Q0    (  N#"$W'D'OZYR<
M $G" @ 5              "  <@> 0!M9W1X+3(P,3@P-C,P7V1E9BYX;6Q0
M2P$"% ,4    "  +@PA-25-7E>MD  #<R04 %0              @ 'B1@$
M;6=T>"TR,#$X,#8S,%]L86(N>&UL4$L! A0#%     @ "X,(34%!A)9*.
MQUD$ !4              ( ! *P! &UG='@M,C Q.# V,S!?<')E+GAM;%!+
4!08     !@ & (H!  !]Y $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
